Covid 19 Trials

TrialID Last Refre Public title Scientific tiAcronym Primary sp Date registDate regist Export dat Source Reg
NCT04246 3-Feb-20 A Randomize

A Randomized Multicen
Xiangya Hos ### 20200127 6/26/2020 ClinicalTria
NCT04252 17-Feb-20 The Efficac A Randomize

ELACOI Guangzhou ### 20200130 6/26/2020 ClinicalTria
NCT04255 17-Feb-20 2019-nCoVImpact of a Novel Cor Qilu Hospit 2/3/2020 20200203 6/26/2020 ClinicalTria
NCT04260 17-Feb-20 A Survey o A Survey of Psycholog Huazhong U2/3/2020 20200203 6/26/2020 ClinicalTria
NCT04260 17-Feb-20 Clinical S Randomized, Open, Mul

Jieming QU 2/6/2020 20200206 6/26/2020 ClinicalTria
NCT04261 17-Feb-20 The Effica A Randomized, Open-la

Peking Uni 2/6/2020 20200206 6/26/2020 ClinicalTria
NCT04261 17-Feb-20 Evaluating A Randomized, Open-la First Affil 2/6/2020 20200206 6/26/2020 ClinicalTria
ChiCTR200 17-Feb-20 Constructi Construction and Analysis
Zhongnan
of H ### 20200217 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A Medical A Medical Records Based

Emergency
S ### 20200216 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A RandomizA Randomized Controlled

Longhua
Tr Hos ### 20200216 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A randomizA randomized controlled

Longhua
tria Hos ### 20200216 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A Single-b A Single-blind, Randomized

HwaMei Hos ### 20200216 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A Single-a A Single-arm Clinical Trial

HwaMei Hos ### 20200216 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for c Study for constructionWest
and aChina ### 20200216 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A medical Co-infection of novel corona

Zhongnan H ### 20200216 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Evaluate t Evaluate the effectiveness

Affiliated
o ### 20200216 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A comparatA comparative study on Tongji

the Hosp ### 20200216 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Evaluation Evaluation of Rapid Diagnostic
Jiangsu Ins ### 20200215 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A multicentA multicenter, randomiz

Huangshi H ### 20200215 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 The efficac The efficacy and safetyBeijing

of You ### 20200215 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A randomize

A randomized, open and
Thecont
First A ### 20200215 6/26/2020 ChiCTR

A randomized, open-label,
People's
co H ### 20200215 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Study on c Effecacy and safty of conv

The First A ### 20200215 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Applicatio Application of Regulating
TheInt
First A ### 20200215 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 An observaAn observational studyNingbo
on th Firs ### 20200215 6/26/2020 ChiCTR

A randomized controlled
Nanjing
tria Se ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Based on DBased on Delphi Method

Deyang Int ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Ba-Bao-DanStudy for the pharmacodyn

Sir Run Run ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 PsychologicPsychological survey ofGuangdong

fro ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical T Clinical Trial for Integrat
Children's ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical T Clinical Trial for Tanreqing

Shanghai
C Pu ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical S Clinical Study for Anti-agi

Guangzhou ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Development and applicatio

Shenzhen S ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Immunomodu

Optimization of treatment
Wuhan
andJiny
di ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Analysis of Optimization of treatment

Wuhan
andJiny
di ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical Ap Optimization of treatment

Wuhan
andJiny
di ### 20200214 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Clinical study for the inte

Shanghai P ### 20200213 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Randomized

Randomized controlledThe
tri First A ### 20200213 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Traditiona Traditional Chinese medicin

Dongzhimen ### 20200213 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Clinical study for the Zhejiang Pr ### 20200213 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for Study for the key issues Wuxi
of Peopl ### 20200213 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical S Clinical Study for Traditio
Shanghai U ### 20200213 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A multicentA multicenter, randomize

Huangshi H ### 20200213 6/26/2020 ChiCTR

ChiCTR200 17-Feb-20 Babaodan CBabaodan Capsule usedEnze
for Hospi
the ### 20200213 6/26/2020 ChiCTR

A randomized, open, cZhongnan H ### 20200213 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A multicentA multicenter, randomized

The First
c A ### 20200213 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Imaging Fe Imaging Features and Mechanis

West China ### 20200213 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 The efficac Study on Prevention and

China
TreaAcad ### 20200212 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Cohort StudCohort Study of Novel Department
Coronavir ### 20200212 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Clinical study of nebulized

Renmin
X Hos ### 20200212 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for Effect of Novel Coronavirus

West Pn
China ### 20200212 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical S Clinical Study for Tradition

ChiCTR200 17-Feb-20 Effect eva Effect evaluation and prognos

A randomized, parallelTongji
con Hos ### 20200211 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Efficacy of Efficacy of ChloroquineThe

a Fifth A ### 20200211 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A MulticenA Multicenter, Randomized

ChiCTR200 17-Feb-20 Risks of D Risks of Death and Severe

Tongji
case
Hosp ### 20200210 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 EpidemiologEpidemiological investigation
The First P ### 20200210 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Impact of Impact of vitamin D deficiency
ChiCTR200 17-Feb-20 Early Dete Early Detection of Novel

Shenzhen T ### 20200210 6/26/2020 ChiCTR

A randomized, open-label
Wuhan
s Pul 2/9/2020 20200209 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for MMental health and psycho

The Fifth A 2/8/2020 20200208 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 An observaAn observational studyGuangdong

for Xi 2/8/2020 20200208 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Efficacy an Efficacy and safety of aeros

Union Hosp 2/8/2020 20200208 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A clinical Observational study ofGuangdong
Xin-G 2/7/2020 20200207 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Immune Rep

Immune Repertoire (TCR
The&First
B A 2/7/2020 20200207 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Constructi Construction of Early Warnin

The First A 2/7/2020 20200207 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A real wor A real world study for tradit

Shanghai Pu2/7/2020 20200207 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical st Multicenter, randomized,

Ruijin Hosp 2/7/2020 20200207 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A prospectiA prospective, open-label,

The Fifth A 2/6/2020 20200206 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical S Clinical Study for Human

TheMe
First A 2/7/2020 20200207 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A RandomizA Randomized, Open-Labe

ChiCTR200 17-Feb-20 Clinical s Clinical study for communi

Hubei Prov 2/6/2020 20200206 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 CommunityCommunity based prevention

ChiCTR200 17-Feb-20 Clinical st Clinical study on safetyThe

andThird 2/6/2020 20200206 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Chinese meChinese medicine prevention
Zhejianga C 2/5/2020 20200205 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Safety and Safety and efficacy of um

Xiangyang F2/5/2020 20200205 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Safety and Safety and efficacy of uXiangyang 12/4/2020 20200204 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 TherapeutiTherapeutic effect of hydroxyc
Renmin Hos2/4/2020 20200204 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 RecommendaRecommendations of Integr
Hospital of 2/4/2020 20200204 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Randomized,

Randomized, open-label,

The First H 2/3/2020 20200203 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for t A prospective cohort study

Sun Yat sen 2/3/2020 20200203 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A randomise

A randomised, open, contr
Zhongnan H2/3/2020 20200203 6/26/2020 ChiCTR

Tongji
s Hosp2/3/2020 20200203 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Chinese meA prospective randomized

Zhejiang C 2/3/2020 20200203 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Chinese meChinese medicine prevention

Zhejianga C 2/3/2020 20200203 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Traditiona Traditional Chinese Medic

1. Xinhua A 2/2/2020 20200202 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Traditiona Traditional Chinese Medi

1. Xinhua a 2/2/2020 20200202 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical St Clinical Study for Gu-Biao

Wuhan
Ji Hosp2/2/2020 20200202 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A real-worlThe early use of lopinav

Institute 2/2/2020 20200202 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for c Study for clinical characteri

ChiCTR200 17-Feb-20 A RandomizA Randomized Controlled

1. Xinhua
T a 2/2/2020 20200202 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 The effect The effect of shadowboxing

1. Xinhua a 2/2/2020 20200202 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 The effect Pulmonary rehabilitation
1.Xinhua
t af 2/2/2020 20200202 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 CombinatioCombination of traditional

Beijing Hos 2/1/2020 20200201 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A randomizA randomized controlled Beijing

tri hos 2/1/2020 20200201 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A single a A single arm study for Hubei
comb Provi 2/1/2020 20200201 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A single a The evaluation of integrate


Randomized controlledWuhan
trial 1st 2/1/2020 20200201 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A Real WorA Real World Study ForThe

theFirst A 2/1/2020 20200201 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical s Clinical study of type I Affiliated

macr 2/1/2020 20200201 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Study for An epidemiology studyHubei for TCMInte 2/1/2020 20200201 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Chinese HeChinese Herbal medicine

Dongzhimen
for S ### 20200130 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 Clinical Co Study for Traditional Chines

China Acad ### 20200129 6/26/2020 ChiCTR
ChiCTR200 17-Feb-20 A prospect A prospective comparative

The First
st A ### 20200127 6/26/2020 ChiCTR
NCT04268 24-Feb-20 Immunoregu

Immunoregulatory TheSoutheast U2/8/2020 20200208 6/26/2020 ClinicalTria
NCT04269 24-Feb-20 Umbilical Clinical Research Reg ZhiYong Pe 2/7/2020 20200207 6/26/2020 ClinicalTria
ChiCTR200 25-Feb-20 Clinical S Clinical Study on Syndrome

Guangdong
D ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 The Value oThe Value of Critical Care
ChiCTR200 25-Feb-20 ExperimentExperimental study of The

novel
First A ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Key techni Key techniques of umbilica

Hunan yuan ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for s Study for safety and effic

Shanghai Pu ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical T Clinical Trial for Recombina

Renmin Hos ### 20200224 6/26/2020 ChiCTR

Randomized, parallel contr
The 5th Me ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical s Clinical study for ozonated

Tianjin
a Uni ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A cross-se A cross-sectional studyWuhan
of noveJin ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical T Clinical Trial for HumanChinese

Mes PL ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 HumanisticThe Effect of Humanistic TheCaSecond ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 HumanisticThe Therapeutic Efficacy

theoSecond ### 20200224 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A clinical A clinical study for ''Huo-She

Shenzhen na ### 20200223 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A multicentA multicenter, randomize

ChiCTR200 25-Feb-20 Safety and Safety and effectiveness

ChiCTR200 25-Feb-20 A clinical A clinical research for Tongji Hosp ### 20200223 6/26/2020 ChiCTR

Clinical study for safetyThe
a Third ### 20200223 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A multicen A multicenter randomized

Tianjin
co Hu ### 20200223 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for eStudy for establishment

Peking
of Univ ### 20200223 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Effects of Effects of novel coronaviru
Chengdu Un ### 20200223 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for a Study for application oThe Second ### 20200223 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 AssessmentAssessment of cardiac Department
funct ### 20200223 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A Prospect A Prospective RandomizedWest China ### 20200222 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A clinical A randomized, open-label,

Shanghai C ### 20200222 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Umbilical Umbilical cord Wharton's
TheJeSixth ### 20200222 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical st Clinical study for the diagno

Union Hosp ### 20200222 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for t Study for the effects onUnion Hosp ### 20200222 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A multicen A multicenter study forThe First H ### 20200222 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A multicentA multicenter, randomized,

ChiCTR200 25-Feb-20 Study for Study for the effect of Union

earl Hosp ### 20200222 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A prospect An open randomized contro

Zhongshan H ### 20200222 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A single ar A single arm trial to eva

First Peopl ### 20200221 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Shen-Fu injShen-Fu injection in the

Peking
tr Univ ### 20200221 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A single-ar A single-arm, single-center

ChiCTR200 25-Feb-20 Clinical st Clinical study for infusing

Affiliated
c ### 20200221 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Traditiona Traditional Chinese Medicin

Tongde Hos ### 20200221 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A study fo A study for the interventi

ChiCTR200 25-Feb-20 Study on ulStudy on ultrasonographic

Xi'anmChest ### 20200221 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A medical The risk factor and prognosis
Tongji Hosp ### 20200220 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A multi-ce A multi-center study on

The
theFirst A ### 20200221 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Traditiona Traditional Chinese medic
Dongzhimen ### 20200220 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A medical A medical records based
Department
ana ### 20200220 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 The clinica The clinical applicationSecond

and Hos ### 20200220 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 The COVID-1The COVID-19 Mobile Health

Zhongshan
St ### 20200220 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Feature of Feature of Multiple Organs
Department ### 20200220 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Basic and cEfficacy evaluation of iGuangxi me ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for Study for the correlation

Tongji
b Hosp ### 20200220 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Developmen

Development of 2019-nCoV
The First
therape
P ### 20200219 6/26/2020 ChiCTR

A randomized, double-bli
Wuhan Jiny ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Correalati Correalation between The

anxieFifth A ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 MulticenteMulticenter randomized

Thecontr
First A ### 20200219 6/26/2020 ChiCTR

Union
tri Hosp ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Effect of Effect of New Coronavirus
WestPneu
China ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Optimizati Optimization Protocal Hospital

of In of ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical s Clinical study for novelThe

NLRP
First A ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 The efficac The efficacy and safetyHealth

of com ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 An open, coAn open, controlled clin

Nanchang N ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A clinical A clinical study for probio
Shanghai 1 ### 20200219 6/26/2020 ChiCTR

Beijing Cha ### 20200220 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Study on anStudy on anxiety of different

Shanghai Ge ### 20200219 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Liu-Zi-Jue Liu-Zi-Jue Qigong and Acu

Shanghai U ### 20200218 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A prospect An open randomized contro

Zhongshan H ### 20200218 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical t Clinical trials of mesenchyma

Institute o ### 20200218 6/26/2020 ChiCTR

Chinese
T PL ### 20200218 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical S Clinical Study of Chloroquine

ChiCTR200 25-Feb-20 Study for Study on mental healthSichuan

stat Ac ### 20200218 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Study for nStudy for nucleic acid detect


Yueyang
tria Ho ### 20200218 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A prospectiA prospective, multicent

Qingdao Ea ### 20200218 6/26/2020 ChiCTR

Tongji
tri Hos ### 20200217 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 ComparativComparative study forThe
inteFirst A ### 20200217 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Clinical ob Clinical observation of West

the nov
China ### 20200217 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Chinese MeChinese Medicine Promotes Hospital
Reof ### 20200217 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Efficacy an Efficacy and safety of hon

Hubei Hospi ### 20200217 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Early warn Early warning prediction

Enze
of Hospi
p ### 20200215 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 DescriptiveClinical characteristics Union
and Hospi ### 20200215 6/26/2020 ChiCTR

Zhongshan ### 20200215 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A prospectiA prospective, randomize


Union Hospi ### 20200213 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 A multicentA multicenter, randomized,

Union Hospi ### 20200213 6/26/2020 ChiCTR
ChiCTR200 25-Feb-20 Efficacy of Efficacy of therapeuticThe

ef First H ### 20200211 6/26/2020 ChiCTR
NCT04270 2-Mar-20 Clinical Ch A Multicenter ObservatBeijing Chi ### 20200211 6/26/2020 ClinicalTria
NCT04273 2-Mar-20 The Effica The Efficacy and Safe First Affil ### 20200214 6/26/2020 ClinicalTria
NCT04273 2-Mar-20 The Effica The Efficacy and Safe First Affil ### 20200214 6/26/2020 ClinicalTria
NCT04275 2-Mar-20 Clinical S Single Center, Single Tang-Du Ho2/6/2020 20200206 6/26/2020 ClinicalTria
NCT04275 2-Mar-20 The COVID-The COVID-CMHS Chinese Al ### 20200217 6/26/2020 ClinicalTria
NCT04279 2-Mar-20 Treatment A Randomized, PlaceboShuGuang H ### 20200215 6/26/2020 ClinicalTria
NCT04279 2-Mar-20 Clinical Fe Investigation on Clini Third Affil ### 20200215 6/26/2020 ClinicalTria
NCT04279 2-Mar-20 Detection oStudy on Detection of Third Affil ### 20200219 6/26/2020 ClinicalTria
NCT04279 2-Mar-20 The Invest A Multicenter ObservaChildren's ### 20200218 6/26/2020 ClinicalTria
NCT04280 2-Mar-20 FingolimodEfficacy of Fingolimo First Affil ### 20200220 6/26/2020 ClinicalTria
ChiCTR200 2-Mar-20 CombinatioThe therapeutic efficacy

theofSecond 3/2/2020 20200302 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Applicatio The Application of Rehabil

ChiCTR200 2-Mar-20 ApplicationApplication of rehabilitat

ChiCTR200 2-Mar-20 A single-ce A single-center, single-arm
Henanc Provi3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A Clinical A Clinical Trial Study foInstitute o 3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 ApplicationApplication of rehabilitatio

ChiCTR200 2-Mar-20 A randomize

Wuhan Jiny 3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A medical rA medical records based

Lishui
analy
Cent 3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Research a Research and Development

Key Labora
o 3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A Comparati

A Comparative Study for
Hubei
th Prov 3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical ob Clinical observation and

Tongji
res Hosp3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Study for Study for moxibustion Hu'nan

in the puni ### 20200218 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Constructi Construction and applica
Hubei Prov ### 20200217 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Novel CoroNovel Coronavirus Infected

TongjiDHosp ### 20200229 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 microRNA as

microRNA as a markerNanjing
for earlySe ### 20200228 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A randomize A randomized, open-labelTongji

s Hos ### 20200228 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Analysis of Analysis of clinical characteri
The Second ### 20200228 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A survey ofA survey of mental health

Xiangyang C ### 20200228 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Traditiona Traditional Chinese Medicine

ChiCTR200 2-Mar-20 Identifica Identification and Clinical

Xinyang
Tr Cen ### 20200228 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical st A prospective randomized

ChiCTR200 2-Mar-20 Clinical S Clinical Study for Tradition
Affiliated ### 20200228 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Traditiona Traditional Chinese medici

ChiCTR200 2-Mar-20 MultiomicsMultiomics study and eme
Li Caixia ### 20200228 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical o Clinical observation and

Shanghai
resea Pu ### 20200227 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Health relaHealth related quality Xiamen
of Uni ### 20200227 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Correlatio Correlation between imaging

Xianningc Ce ### 20200227 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Study for Clinical research program

ChiCTR200 2-Mar-20 ICU health ICU healthcare personnel
Department
bur ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Investigati Investigation and analysis
Beijing
o Ger ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A study fo A study for the key techno

Wuxi Fifth ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical st Clinical study on novelGanzi

co Hospi ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Evaluation Evaluation Danorevir sodiu

ChiCTR200 2-Mar-20 A multicentA multicenter, randomized,

The Fourth ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 The coagul The coagulation function
Puren
of nov
Hosp ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Efficacy a Efficacy and Safety of Jing-

Shanghai Un ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Exploratio Exploration and Research
Ganzi
forHospi ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 The treatmeThe treatment status and
The Fourth ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Clinical R Clinical Reseach of Acupunctur

Yueyang Ho ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Quality of Quality of life among Chines
NA ### 20200226 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Cancelled du

Study for the Impact ofThe
Novel
Thirte ### 20200225 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Study for Study for evaluation ofFirst

int Teach ### 20200225 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Study of P Study of Pinavir / Ritonavi

Fifth Peopl ### 20200225 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Study for Study for the efficacy of

TheKaFirst A ### 20200225 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A multicentA multicenter, single arm
Central So ### 20200225 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Cancelled bCancelled Cancelled ### 20200224 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A prospect A prospective randomized

A Medical Records Based
Chongqing
Stu L ### 20200221 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A parallel, A parallel, randomizedFirst Affil ### 20200220 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 A prospectiA study on the efficacyChinese

a PL ### 20200219 6/26/2020 ChiCTR

ChiCTR200 2-Mar-20 Single arm Single arm study for explor

The First Ho ### 20200218 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Cancelled dEpidemiological and clinical
Chongqing ### 20200217 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Research f Research for Risks Associa

ChiCTR200 2-Mar-20 Evaluation Evaluation the Efficac Peking Univ ### 20200216 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Evaluation Evaluation the EfficacyPeking Univ ### 20200216 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Cancelled dMedical records basedChongqing
study ### 20200215 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Cancelled due

ChiCTR200 2-Mar-20 Cancelled dMulticenter, randomized,


Thestu
Second ### 20200212 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Retracted dA multicenter, randomiz


A randomized, open, parall
ChiCTR200 2-Mar-20 A RetrospeA Retrospective Study Tongji

for P Hosp ### 20200210 6/26/2020 ChiCTR
ChiCTR200 2-Mar-20 Comparative

Comparative effectivene
ChiCTR200 2-Mar-20 EffectiveneA study on treatment strategies
NCT04276 9-Mar-20 A Pilot Cl A Pilot Clinical Stud Ruijin Hosp ### 20200216 6/26/2020 ClinicalTria
NCT04281 9-Mar-20 A New ScreIdentification of a Ne Affiliated ### 20200220 6/26/2020 ClinicalTria
NCT04282 9-Mar-20 A Study to A Randomized, Open-lab

Huilan Zha ### 20200210 6/26/2020 ClinicalTria
NCT04284 9-Mar-20 CT Scores CT Scores Predict MorShanghai G ### 20200222 6/26/2020 ClinicalTria
NCT04286 9-Mar-20 The Clinic The Efficacy and Safe Beijing Yo ### 20200225 6/26/2020 ClinicalTria
ChiCTR200 9-Mar-20 Study for uStudy on the application
TheofFirst
con A 3/8/2020 20200308 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Novel coronNovel coronavirus pneumonia

ChiCTR200 9-Mar-20 The immediThe immediate psychologica
West China 3/8/2020 20200308 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Risk Facto Risk Factors for Outcomes

Shandong
of No P3/8/2020 20200308 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Clinical P Clinical Prediction and Shandong

Int P3/8/2020 20200308 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Research onResearch on peripheralUnion

immuHosp 3/7/2020 20200307 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Psychologi Psychological Intervention

Tongji
ofHosp3/7/2020
C 20200307 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 A medical rRetrospective study toThe
asseFirst A 3/7/2020 20200307 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 A retrospe A retrospective study on

Thev Third A 3/7/2020 20200307 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Clinical s Clinical study of nano-nose

AnhuiaCanc 3/7/2020 20200307 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Critical ul Critical ultrasound in eval

Tongji Hosp3/7/2020 20200307 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for t Study for the risk factors

Tongji
of Hos 3/6/2020 20200306 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Detection Detection of coronavirus Central
i The 3/6/2020 20200306 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 A clinical A clinical study about tWest China 3/6/2020 20200306 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Novel coro Novel coronavirus pneumonia
Xiamen Med3/6/2020 20200306 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Research f Research for the mechanis

ChiCTR200 9-Mar-20 Multi-Cent Multi-Center Clinical Study

Wuhan Red 3/6/2020 20200306 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Efficacy a Efficacy and safety of Ma-Xin

Affiliated 3/6/2020 20200306 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Zedoary TurZedoary Turmeric Oil for

TheInSecond 3/5/2020 20200305 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 ExtracorporEffecacy and safty of extr

ChiCTR200 9-Mar-20 Survey for Survey for sleep, anxiety

Renmin
a Hos3/4/2020 20200304 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 RetrospectRetrospective studyforTheint First A 3/4/2020 20200304 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 A medical Comparative Study forWestClini China 3/4/2020 20200304 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 To evaluat To evaluate the efficacy

Huo-Shen-S3/4/2020 20200304 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for t Study for the route of ocula
ChiCTR200 9-Mar-20 A single-ce A single-center, single-arm

The First
c A 3/4/2020 20200304 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for t Study for timing of mechan

ChiCTR200 9-Mar-20 HUMSCs and HUMSCs and Exosomes Hubei
Treating
Shiy 3/3/2020 20200303 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 A MulticenSARS-CoV-2 Infection on

Peking
MyocUniv3/3/2020 20200303 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 The clinica The clinical value of cort

Zhongnan H3/3/2020 20200303 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Randomized

Randomized, open, blank
Department3/3/2020 20200303 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for t Study for the Effectiveness

ChiCTR200 9-Mar-20 oXiris Memb

The Effect and Safety of
ChiCTR200 9-Mar-20 Cytosorb inThe Effect and Safety of

ChiCTR200 9-Mar-20 An open and

An open and controlled
Shenyang
cl S 3/3/2020 20200303 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Efficacy an Efficacy and safety of lipo

Maoming Pe3/2/2020 20200302 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 A randomizA randomized parallel Shanghai

contro U 3/2/2020 20200302 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Study for Key techniques of combinati

ChiCTR200 9-Mar-20 A RandomizA Randomized Controlled

Dalian Medi3/2/2020 20200302 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Cancelled bInfluence of nasal high-fo

ChiCTR200 9-Mar-20 Study for t Study for the clinical characte
The Third X 3/2/2020 20200302 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Clinical st Clinical study for the effect
ChiCTR200 9-Mar-20 ApplicationApplication of flash gluc
Shanghai Si 3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Cancelled, dA single-center, open-la

First peopl ### 20200228 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Protective Protective factors of mental

The Third A ### 20200228 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 A Medical The Real World Study to Yueyang
E Hos ### 20200224 6/26/2020 ChiCTR
Effect of early pulmonary
Wuhan
tr Four ### 20200220 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 A pilot st A multicenter, randomiz

ChiCTR200 9-Mar-20 A medical rA medical records based

ChiCTR200 9-Mar-20 Convalescen

Convalescent plasma for
China-Japan
the ### 20200212 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Severe noveSevere novel coronavirus

ChiCTR200 9-Mar-20 The investi The investigation of cytokine

ChiCTR200 9-Mar-20 Recommenda

Recommendations forHospital
Diag of 2/4/2020 20200204 6/26/2020 ChiCTR
ChiCTR200 9-Mar-20 Recommenda
Recommendations of Integrate
Hospital of 2/4/2020 20200204 6/26/2020 ChiCTR

A randomized, controlled
Wuhan
op Jiny ### 20200123 6/26/2020 ChiCTR
NCT04292 ### Clinical Pr Clinical Pr 2019-nCoVFujian Prov ### 20200223 6/26/2020 ClinicalTria
NCT04292 ### Anti-SARS- The Efficacy and Safe Shanghai Pu ### 20200225 6/26/2020 ClinicalTria
NCT04293 ### Efficacy an Randomized, Open, BlaTongji Hosp ### 20200215 6/26/2020 ClinicalTria
NCT04295 ### MulticenterMulticenter Clinical S Jiangxi Qin 3/3/2020 20200303 6/26/2020 ClinicalTria
NCT04296 ### Medical MaMedical Masks Versus McMaster U3/3/2020 20200303 6/26/2020 ClinicalTria
NCT04298 ### Safety Rel Analysis of Safety Re Tongji Hosp ### 20200226 6/26/2020 ClinicalTria
NCT04299 ### Mental HeaMental Health and Its University 3/4/2020 20200304 6/26/2020 ClinicalTria
ChiCTR200 ### Analysis fo Analysis for the mentalJingzhou

h M ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### RetrospectRetrospective analysis Theof eChines ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Evaluation Evaluation on the effect

Theof affilia
C ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Evaluation Evaluation of the effectHwaMei Hos ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Clinical Ap Clinical Application andZhengzhou
Th ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### RetrospectRetrospective and Prospecti

ChiCTR200 ### Favipiravi Favipiravir Combined With

Peking Univ ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Study for eStudy of effects of crisis
Zhengzhou
inte ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Efficacy a Efficacy and Safety of Pi

State Key L ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Clinical r Clinical research and pre

ChiCTR200 ### Open-labelOpen-label, observational

The sFirst H ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### EstablishmeEstablishment of an early

Tongji
warHosp ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Traditiona Clinical study for TCM Xiangyang

Decocti 1 ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Clinical a Clinical and CT imagingJinling

Char Hos ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### CorrelationCorrelation analysis ofTongji

bloo Hosp ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Developmen Development and application

ChiCTR200 ### A medical rInvestigation of dynamic
Tongji
profile
Hosp ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### A medical bAnalysis of influencingWuhan

factors Thir ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Clinical ch Clinical characteristic Hubei Canc ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Clinical st Clinical study for bronchos

ChiCTR200 ### An artifici An artificial intelligenceTongji

as Hosp ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Study for t Study for the effect of Department
ext ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### A clinical A clinical multicenter study
Li Lanjuan
o ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Evaluation Evaluation of the protective

ChiCTR200 ### Factors as Factors associated withBeijing

deathAn ### 20200316 6/26/2020 ChiCTR
ChiCTR200 ### Study for Study for the physical and

The men
First A ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Investigati Investigation on psychologic

Zhengzhou ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Explorator Treatment of Acute Severe

UnionCOVI
hosp ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Preliminar Preliminary screening of
Tongren
Cor Ho ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Development

Development of warning
Zhongnan
sys H ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Novel coro Novel covid-19 pneumonia

Longhua
c Hos ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Clinical s Clinical study on the effic

the First A ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Epidemiolog Epidemiological Characterist

ChiCTR200 ### Clinical va Clinical validation and Tongji
appli Hosp ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Study for Study on the pathogenesis

Tongji
a Hosp ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### The analysiThe analysis of relatedTongji Hosp ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Developmen Development and application
Hwa Meio Ho ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### RetrospectRetrospective analysis Wuhan
of di Thir ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### A medical The value of Lymphocyte Department
subsets ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Nutritional Nutritional risk assessment

Tongjiand
Hosp ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### A medical Ocular dectection of SARS-Co

Tongji hosp ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Study for Study for the virus molec
Shanghai N ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Clinical o Clinical observation anHubei 672 ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### A medical Clinical outcomes and Tongji

follow-up
Hosp
s ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Clinical ch Screening and Identification

ChiCTR200 ### RetrospectiRetrospective study forWuhan

th Thir ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### QuantitativQuantitative CT characteristic
Tongji Hosp
e ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### ExocarpiumExocarpium Citri Grandis Maoming

Re Pe ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Collection Clinical characteristics Union
of seveHospi ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### A retrospecA retrospective study of

Tongji
clinica
Hosp ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Analysis of Analysis of risk factorsThe

af Third ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bStudy on levels of inflamma
ChiCTR200 ### Establishm Establishment and validation

ChiCTR200 ### A medical rClinical characteristics Wuhan

of COVID-1
3rd ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### clinical s clinical study for hemodynamic

Shanghai Fi ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### Clinical c Clinical characteristics The
and Second
treat ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### A multicen A multicenter retrospective

Tongjistud
Hosp ### 20200315 6/26/2020 ChiCTR
ChiCTR200 ### A study forA study for clinical characte

The People ### 20200314 6/26/2020 ChiCTR
ChiCTR200 ### The value The value of CD4 / CD8Cangzhou
cells, C P ### 20200314 6/26/2020 ChiCTR
ChiCTR200 ### A clinical A randomized, open-label,

ChiCTR200 ### A medical rEpidemiologic and Clinical
Ningbo
featur
Firs ### 20200314 6/26/2020 ChiCTR
ChiCTR200 ### Applicatio Application of blood purificat

Huashan Ho ### 20200314 6/26/2020 ChiCTR
ChiCTR200 ### Study for Risk Factors for AnxietyZhongnan
of H ### 20200314 6/26/2020 ChiCTR
ChiCTR200 ### Research f Research for the influence

Xiyuan Hos ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### A Medical Analysis of Risk FactorsShandong

fo P ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### Diagnosis Diagnosis and treatment TheofSecond ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### ContinuousContinuous renal replace Renji Hospi ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### A medical rClinical characteristics Zhejiang
of 20 Ho ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### Study for Study for the therapeutic

TheeFirst A ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### A medical rSedation and AnalgesiaTongji

UsageHosp
i ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### Impact of NImpact of Novel Coronavir

Clinical R ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### Detection Detection of SARS-CoV-2
Shenzhen
in EP H ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### A medical Characteristics, prognosis

Tongji Hos ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### Medical re Accuracy analysis of SARS-CoV-2
ChiCTR200 ### A medical Analysis of the IncidenceShandong

a P ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### A medical rAnalysis of risk factorsShandong
for d P ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### Clinical R Clinical Research for Tradit

ChiCTR200 ### A prospect A prospective cohort stud

ChiCTR200 ### Clinical A Clinical Application of EShandong P ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### CharacterisCharacteristics, prognosis

ChiCTR200 ### ObservatioObservational Study for

Shandong
Pr P ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### Analysis of Analysis of the incidence

Shandong
and P ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### ExplorationExploration of the Clinica
Shandong P ### 20200313 6/26/2020 ChiCTR
ChiCTR200 ### Auscultato Auscultatory characteristics

Shanghaiof Fi ### 20200312 6/26/2020 ChiCTR
ChiCTR200 ### A comparatA comparative study for

Affiliated
t ### 20200312 6/26/2020 ChiCTR
ChiCTR200 ### Prognosis Prognosis InvestigationHubei

a Prov ### 20200311 6/26/2020 ChiCTR
ChiCTR200 ### A retrospe A retrospective cohortWuhan

st Hosp ### 20200311 6/26/2020 ChiCTR
ChiCTR200 ### Randomized
Clinical Study of Chloroquine
Zhongnan
P H ### 20200311 6/26/2020 ChiCTR
ChiCTR200 ### A medical rRisk assessment and treatmen

ChiCTR200 ### Shedding oShedding of SARS-CoV-2 Tongji
in hum
Med ### 20200311 6/26/2020 ChiCTR
ChiCTR200 ### Cross sect Cross sectional study of

West
dial China ### 20200311 6/26/2020 ChiCTR
ChiCTR200 ### RetrospectRetrospective study onGanzi
novelHospi
c ### 20200311 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bApplication of cas13a-mediated

ChiCTR200 ### A randomize

A randomized, blinded,Xiangya
c Hos ### 20200310 6/26/2020 ChiCTR
ChiCTR200 ### Plasma of tConvalescent plasma for

China-Japan
the t ### 20200310 6/26/2020 ChiCTR

A randomized, parallelThe
c Third ### 20200310 6/26/2020 ChiCTR
ChiCTR200 ### Study for An evaluative clinical sUnion Hospi ### 20200310 6/26/2020 ChiCTR
ChiCTR200 ### A multi-cenA multi-center, open-lab

Ningbo Firs ### 20200310 6/26/2020 ChiCTR
ChiCTR200 ### Study for Study on immune cell subsets

The Third
in A ### 20200310 6/26/2020 ChiCTR
ChiCTR200 ### Novel coro COVID-19 infection associated

Department3/9/2020
kid 20200309 6/26/2020 ChiCTR
ChiCTR200 ### The effect The effects of preventio

Peking Univ3/9/2020 20200309 6/26/2020 ChiCTR
ChiCTR200 ### The predic The prediction value ofThe

proSixth A 3/9/2020 20200309 6/26/2020 ChiCTR
ChiCTR200 ### An anaesthAn anaesthesia procedurLiaocheng 3/9/2020 20200309 6/26/2020 ChiCTR
ChiCTR200 ### Cohort studCohort study of Novel Wuhan

Coronavir
Chil 3/9/2020 20200309 6/26/2020 ChiCTR
ChiCTR200 ### A medical Analysis of the characte

ChiCTR200 ### Medical re Medical records basedXiyuan

stud Hos 3/8/2020 20200308 6/26/2020 ChiCTR
ChiCTR200 ### Medical re Study for the correlation

China
be Acad 3/8/2020 20200308 6/26/2020 ChiCTR
ChiCTR200 ### Efficacy a Tozumab combined with
Shanghai
ad G 3/8/2020 20200308 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bEpidemiological research

Guangzhou 3/7/2020 20200307 6/26/2020 ChiCTR
ChiCTR200 ### Efficacy an Efficacy and safety of hon

Hubei Hospi3/6/2020 20200306 6/26/2020 ChiCTR
ChiCTR200 ### Applicatio Application of TCM Nursing
The Second
Sch 3/6/2020 20200306 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical Study of NK Cells

TheinFirst H 3/5/2020 20200305 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bA multicentre, randomized,

The first a 3/3/2020 20200303 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bPositively Controlled Clini

ChiCTR200 ### Study for mStudy for meditation assists

Cancer Inst 3/3/2020 20200303 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled dInvestigation on Mental
Yongchuan
Hea 3/2/2020 20200302 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bEfficacy and safety of chl

Harbin infe 3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 ### Efficacy an Efficacy and safety of Xue-B

Jingzhou Fi 3/1/2020 20200301 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bA randomized, open-labe First peopl ### 20200229 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical trial for umbilicThe Second ### 20200228 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bNovel coronavirus pneumonia

Luohu hosp ### 20200228 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bStudy for sleep status of
Guangzhou
me ### 20200225 6/26/2020 ChiCTR
ChiCTR200 ### Clinical st Efficacy and safety of Lopina

Jingzhou Fi ### 20200224 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bA randomized controlled

ThetriSecond ### 20200224 6/26/2020 ChiCTR
ChiCTR200 ### Lung ultra Lung ultrasound in thePeking
diagn Univ ### 20200223 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bStudy for the false positive
ChiCTR200 ### Cancelled bRandomized controlledThe triaFirst A ### 20200222 6/26/2020 ChiCTR
ChiCTR200 ### MulticenteMulticenter study for the

Thetre
First A ### 20200222 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bA randomized, double-bl

The Sixth A ### 20200221 6/26/2020 ChiCTR
ChiCTR200 ### Nucleic ac Nucleic acid analysis ofTongji

n Hosp ### 20200219 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bStudy on the effect of hum

ChiCTR200 ### Cancelled bAn observational studyThe

of hSecond ### 20200217 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bSingle arm study for the

Guangzhou
effi ### 20200216 6/26/2020 ChiCTR

Jingzhou Ce ### 20200215 6/26/2020 ChiCTR

Jingzhou Ce ### 20200214 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled by
A cox regression analysis
Wuhan
of prAsia ### 20200214 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical Study for Umbilical

ChiCTR200 ### Cancelled bClinical Study of Cord Blo

ChiCTR200 ### Cancelled bClinical Study of Cord Guangzhou

Bloo ### 20200214 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical Study for Umbilical

ChiCTR200 ### Study for Study for epidemiology,Union
diagno
Hosp ### 20200213 6/26/2020 ChiCTR
ChiCTR200 ### Clinical St Clinical Study of Arbidol

Union
H Hosp 2/5/2020 20200205 6/26/2020 ChiCTR
NCT04264 ### Vitamin C Vitamin C Infusion fo ZhiYong Pe 2/4/2020 20200204 6/26/2020 ClinicalTria
NCT04285 ### Critically Critically Ill Patient Chinese Un ### 20200224 6/26/2020 ClinicalTria
NCT04299 ### Safety and Safety and Immunity Ev

Shenzhen G3/5/2020 20200305 6/26/2020 ClinicalTria
NCT04302 ### Novel CoroClinical Study of Nov CAR-T (Shan ### 20200227 6/26/2020 ClinicalTria
NCT04302 ### Accurate C Accurate Classificati Renmin Hos3/7/2020 20200307 6/26/2020 ClinicalTria
NCT04308 ### Influence The COVISTCOVISTRESUniversity ### 20200312 6/26/2020 ClinicalTria

ChiCTR200 ### The relati The correlation betweenTheVita
People ### 20200323 6/26/2020 ChiCTR
ChiCTR200 ### ApplicationApplication of radiology
Hwain tMei Ho ### 20200323 6/26/2020 ChiCTR
ChiCTR200 ### Study for t Study on the impact onUnion
fetusHosp
an ### 20200322 6/26/2020 ChiCTR
ChiCTR200 ### Safety and Safety and Effectiveness

ChiCTR200 ### ProspectiveProspective exploratory
The
cl third x ### 20200322 6/26/2020 ChiCTR
ChiCTR200 ### A medical A medical records basedZhengzhou
stu ### 20200322 6/26/2020 ChiCTR
ChiCTR200 ### Study for Study for metagenomics

TheofFifth
pati A ### 20200322 6/26/2020 ChiCTR
ChiCTR200 ### Psychologi Psychological Support Ningbo

for DiagKan ### 20200322 6/26/2020 ChiCTR
ChiCTR200 ### A medical Clinical Research on Treatmen

ChiCTR200 ### A prognosi The Cohotr of COVID-19Xiangyang 1 ### 20200322 6/26/2020 ChiCTR
ChiCTR200 ### Perioperat Perioperative immuneHu'nan

predi Can ### 20200321 6/26/2020 ChiCTR
ChiCTR200 ### A Study fo Detection of SARS-COV-2

HwaMei
RNA Hos ### 20200321 6/26/2020 ChiCTR
ChiCTR200 ### Effect of A Effect of Auricular point

Xiyuan
pr Hos ### 20200320 6/26/2020 ChiCTR
ChiCTR200 ### A medical rUpper Respiratory Tract

Renmin
Viru Hos ### 20200320 6/26/2020 ChiCTR
ChiCTR200 ### A medical The Diagnosis and prognosis

Changzheng ### 20200320 6/26/2020 ChiCTR
ChiCTR200 ### Internet b Internet based SolutionBeijing

F Nor ### 20200320 6/26/2020 ChiCTR
ChiCTR200 ### A RandomizClinical Trial of Favipirav

ChiCTR200 ### Correlationassociation of T lymphocytes

ChiCTR200 ### Psychologi Psychological Responses

Renmin
of M Hos ### 20200320 6/26/2020 ChiCTR
ChiCTR200 ### A Medical The Retrospective Study

Changzheng
abo ### 20200320 6/26/2020 ChiCTR
ChiCTR200 ### MyocardialMyocardial injury and The

arrythmias
Fifth H ### 20200319 6/26/2020 ChiCTR
ChiCTR200 ### DevelopingDeveloping and evaluating
Tongji
o Hosp ### 20200319 6/26/2020 ChiCTR
ChiCTR200 ### Study for Study for novel coronavirus
ChiCTR200 ### A medical rClinical application of ex

ChiCTR200 ### Effects of Effects of different VTEThe

preFirst A ### 20200319 6/26/2020 ChiCTR
ChiCTR200 ### Clinical s An open, multi-center,The

contSecond ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### Venous ThrVenous Thrombosis Risk

Shandong
of 2019 P ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### Combined dCombined diagnostic value
Shanghai
of noK ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### A medical A medical records based
Hu'nan
stu Prov ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### PreliminaryPreliminary evaluationPLA

of tGenera ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### A Platform A Platform for Rapid Immuno-d

The Fifth A ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### EffectiveneEffectiveness of ''Liu-Zi-The First A ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### CorrelationCorrelation between virolog
Anqing Mun ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### A Medical Clinical Characteristic and
HuiZhou
Ou Mu ### 20200318 6/26/2020 ChiCTR

ChiCTR200 ### ProspectiveProspective, open-label,

Foshan
con Firs ### 20200317 6/26/2020 ChiCTR
ChiCTR200 ### Evaluation Evaluation of the effecHwaMei Hos ### 20200317 6/26/2020 ChiCTR
ChiCTR200 ### An observaAn observational studyXiangya

of Ho ### 20200317 6/26/2020 ChiCTR
ChiCTR200 ### A phase I c A single-center, open and

Jiangsu Pro ### 20200317 6/26/2020 ChiCTR
ChiCTR200 ### Screening aScreening and identification

ChiCTR200 ### Cancelled bClinical guidance of diagnose
ChiCTR200 ### Study for c Study for the effect of Guangzhou

3% 3/6/2020 20200306 6/26/2020 ChiCTR
ChiCTR200 ### Study for t Study for the clinical charac

Guangzhou 3/5/2020 20200305 6/26/2020 ChiCTR
ChiCTR200 ### the Efficac the Efficacy and SafetyZhongnan
of H ### 20200226 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bClinical study of mesenchymal

ChiCTR200 ### Cancelled bA prospective real world

ChiCTR200 ### A medical Optimization and evaluati
ChiCTR200 ### Evaluation Evaluation of myocardial

Westinj China ### 20200217 6/26/2020 ChiCTR
ChiCTR200 ### HydroxychlHydroxychloroquine treating

Ruijin Hosp ### 20200215 6/26/2020 ChiCTR
ChiCTR200 ### A study forA study for the psycholog

The Fifth A ### 20200215 6/26/2020 ChiCTR
ChiCTR200 ### Nasal high-Nasal high-fow preoxygenat

Central The 2/9/2020 20200209 6/26/2020 ChiCTR
ChiCTR200 ### A multicentA multicenter, randomiz


A randomized, open labe
EUCTR2020 ### HydroxychlTreatment of Coronavirus
Fondation
SARS ### 20200310 6/26/2020 EU Clinical
Critical
Care
Research
Group
The
Prince
Charles
JPRN-UMIN ### ExtraCorpoExtraCorporeal Membrane
Hospital
Oxyg 3/6/2020 20200306 6/26/2020 JPRN
NCT04251 ### Washed Mic

Washed Microbiota Tra
The Second ### 20200130 6/26/2020 ClinicalTria
NCT04254 ### A Prospect An Open, Prospective/Tongji Hosp2/2/2020 20200202 6/26/2020 ClinicalTria

NCT04255 ### A Prospect An Open, Prospective/Tongji Hosp2/2/2020 20200202 6/26/2020 ClinicalTria
NCT04261 ### A RandomizA Randomized,Open,Con

Tongji Hosp2/4/2020 20200204 6/26/2020 ClinicalTria
NCT04263 ### The Effica An Open, Prospective/Tongji Hosp2/2/2020 20200202 6/26/2020 ClinicalTria
NCT04264 ### Treatment An Exploratory Clini Wuhan Unio2/8/2020 20200208 6/26/2020 ClinicalTria
NCT04272 ### Prognositc Prognostic Characteri Chongqing ### 20200212 6/26/2020 ClinicalTria
NCT04276 ### Immunity aPhase I/II Multicenter Shenzhen G ### 20200217 6/26/2020 ClinicalTria
NCT04283 ### Study for Study for Clinical Ep Wuhan Unio ### 20200213 6/26/2020 ClinicalTria
NCT04287 ### Recombinan
A Randomized, Open La
The First A ### 20200221 6/26/2020 ClinicalTria
NCT04291 ### The Efficac The Efficacy and Safet Tongji Hosp ### 20200227 6/26/2020 ClinicalTria
NCT04292 ### Prognostic Prognostic Factors of Chongqing 3/1/2020 20200301 6/26/2020 ClinicalTria
NCT04293 ### Therapy fo Human Umbilical CordPuren Hosp ### 20200224 6/26/2020 ClinicalTria
NCT04304 ### A Pilot Stu A Pilot Study of Silde Tongji Hosp ### 20200214 6/26/2020 ClinicalTria
NCT04305 ### Social MedGetting it Right: Tow Jean Liu 3/8/2020 20200308 6/26/2020 ClinicalTria
NCT04306 ### Tocilizuma A RetrospeTACOS Tongji Hosp3/8/2020 20200308 6/26/2020 ClinicalTria

NCT04308 ### Tetrandrin Clinical S TT-NPC Henan Provi3/4/2020 20200304 6/26/2020 ClinicalTria
NCT04312 ### Sequential Sequential SOTSPC Henan Provi ### 20200313 6/26/2020 ClinicalTria
NCT04312 ### MyocardialRetrospective Study Wuhan Unio3/4/2020 20200304 6/26/2020 ClinicalTria
NCT04313 ### Treatment Treatment of COVID-19

Stem Cells ### 20200315 6/26/2020 ClinicalTria
NCT04314 ### Mechanisms

Changes in COVID ME University ### 20200317 6/26/2020 ClinicalTria
NCT04314 ### The ObservThe Observational StuXiangya Hos ### 20200316 6/26/2020 ClinicalTria
NCT04314 ### Adverse EvAdverse EvCovidTox Groupe Hosp ### 20200317 6/26/2020 ClinicalTria
NCT04315 ### Clinical Ch Clinical Ch I-COVID Federico II ### 20200318 6/26/2020 ClinicalTria
NCT04316 ### Clinical Pe Clinical Performance oCentro Stud ### 20200314 6/26/2020 ClinicalTria
NCT04316 ### Mechanisms

Uppsala In UMODCOVIUppsala Un ### 20200313 6/26/2020 ClinicalTria
NCT04318 ### ACE InhibitACE InhibitCODIV-ACENeuromed ### 20200319 6/26/2020 ClinicalTria
ChiCTR200 ### Causes of Causes of fever in outpatie

Chinese PL ### 20200329 6/26/2020 ChiCTR
ChiCTR200 ### To explore Serum and urine proteins
WESTLAKE
and me ### 20200329 6/26/2020 ChiCTR
ChiCTR200 ### RetrospectRetrospective analysis Hubei
o Mate ### 20200328 6/26/2020 ChiCTR
ChiCTR200 ### Study for t Altered brain structureUnion

and fun
Hosp ### 20200328 6/26/2020 ChiCTR
ChiCTR200 ### The relati The relationship betweenShandong E ### 20200328 6/26/2020 ChiCTR
ChiCTR200 ### AI based p AI based prognostic evaluation

ChiCTR200 ### Analysis f Analysis for preventionShandong

an E ### 20200327 6/26/2020 ChiCTR
ChiCTR200 ### Influence oInfluence of COVID-19Guangdong
on dise ### 20200327 6/26/2020 ChiCTR
ChiCTR200 ### The protec The protective effect ofFirst

sl Teach ### 20200327 6/26/2020 ChiCTR
ChiCTR200 ### The investi The investigation on medica
Nanjing Uni ### 20200327 6/26/2020 ChiCTR
ChiCTR200 ### Safety and Safety and Efficacy Study

ChiCTR200 ### A retrospecA retrospective study of
China-Japan
cl ### 20200327 6/26/2020 ChiCTR
ChiCTR200 ### A medical rA medical records basedYichang
stud Cen ### 20200327 6/26/2020 ChiCTR
ChiCTR200 ### EpidemiologEpidemiological study Tongji

of novel
Hosp ### 20200327 6/26/2020 ChiCTR
ChiCTR200 ### The effect The effectiveness of mindf
China Euro ### 20200326 6/26/2020 ChiCTR
ChiCTR200 ### Metabolic Metabolic abnormalities

Theand
Third A ### 20200326 6/26/2020 ChiCTR
ChiCTR200 ### Outcomes aOutcomes and infectivity

Chongqing
of pa ### 20200325 6/26/2020 ChiCTR
ChiCTR200 ### Study on t Study on the mental state
WestofChina ### 20200325 6/26/2020 ChiCTR
ChiCTR200 ### EpidemioloEpidemiological surveySchool

of closof ### 20200325 6/26/2020 ChiCTR
ChiCTR200 ### Epidemiolog
Epidemiologic and Clinical
Renmin
Ch Hos ### 20200325 6/26/2020 ChiCTR
ChiCTR200 ### Shedding vShedding virus and functional

ChiCTR200 ### Clinical fe Clinical features and prRenmin Hos ### 20200325 6/26/2020 ChiCTR
ChiCTR200 ### Clinical st Clinical study on the corre

Wuhan Thir ### 20200324 6/26/2020 ChiCTR
ChiCTR200 ### A multicentA multicenter, single-blin

Beijing you ### 20200324 6/26/2020 ChiCTR
ChiCTR200 ### Study for Study for the effect of Zhengzhou

Mo ### 20200324 6/26/2020 ChiCTR
ChiCTR200 ### A medical rClinical characteristics Nothern
and ri Ji ### 20200323 6/26/2020 ChiCTR
ChiCTR200 ### Efficacy an Clinical efficacy of novel

Diagnosis,
co ### 20200323 6/26/2020 ChiCTR
ChiCTR200 ### A medical A medical records based
Wuhan
retrosThir ### 20200323 6/26/2020 ChiCTR
ChiCTR200 ### Study on h Study on home pharmaceutical
People's h ### 20200323 6/26/2020 ChiCTR
ChiCTR200 ### A RCT for Efficacy and safety of CGuangdong ### 20200320 6/26/2020 ChiCTR
ChiCTR200 ### Clinical ef Clinical efficacy of TCMHospital of ### 20200320 6/26/2020 ChiCTR
ChiCTR200 ### Study for ' Study for ''Bai-Du DuanLonghua

Fan Hos ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### Clinical i Clinical investigation and

First
resea
Teach ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### A randomizGu-Shen Ding-Chuan-Wan

The First
use A ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### A real-worlHospital of Chengdu Univer

Hospital of ### 20200318 6/26/2020 ChiCTR
ChiCTR200 ### The treatmThe treatment and diagnosis

ChiCTR200 ### MulticenterMulticenter clinical study
ChiCTR200 ### ObservatioObservation Of ClinicalThe

Eff First P ### 20200310 6/26/2020 ChiCTR
ChiCTR200 ### Cancelled bthe effects of 6-minuteThe

w First A ### 20200228 6/26/2020 ChiCTR
ChiCTR200 ### Efficacy o Study on Prevention and

China
TreaAcad ### 20200227 6/26/2020 ChiCTR
ChiCTR200 ### EpidemiologEpidemiological and clinical
Daping Hos ### 20200226 6/26/2020 ChiCTR
ChiCTR200 ### Clinical re Effect of pulmonary rehab

ChiCTR200 ### Clinical co Clinical comparative study

WestoChina ### 20200220 6/26/2020 ChiCTR
ChiCTR200 ### Prediction Prediction of prognosisUnion Hosp ### 20200218 6/26/2020 ChiCTR
EUCTR2020 ### Sarilumab An adaptive phase 2/3,Sanofi-ave
ran ### 20200320 6/26/2020 EU Clinical
EUCTR2020 ### Reducing hReducing health care wo
University ### 20200317 6/26/2020 EU Clinical
EUCTR2020 ### a trial of A randomised double-bl
Synairgen ### 20200317 6/26/2020 EU Clinical
NCT04288 6-Apr-20 EculizumabSoliris to SOLID-C19 Hudson Me ### 20200227 6/26/2020 ClinicalTria
NCT04290 6-Apr-20 Nitric Oxi Nitric Oxi NOSARSCOXijing Hosp ### 20200227 6/26/2020 ClinicalTria
NCT04305 6-Apr-20 BevacizumaThe Efficac BEST-RCT Qilu Hospit 3/9/2020 20200309 6/26/2020 ClinicalTria
NCT04316 6-Apr-20 Acute KidneAcute Kidney Injury i Zhenhua Z ### 20200317 6/26/2020 ClinicalTria
NCT04319 6-Apr-20 Effects of Investigati COVID-19 Istanbul U ### 20200320 6/26/2020 ClinicalTria
NCT04319 6-Apr-20 Clinical T Clinical Trial of Fav Beijing Cha ### 20200320 6/26/2020 ClinicalTria
NCT04322 6-Apr-20 Escin in Pa Efficacy an add-on-CO University ### 20200323 6/26/2020 ClinicalTria
NCT04322 6-Apr-20 The Use of The Use of AngiotensinUniversity ### 20200323 6/26/2020 ClinicalTria
NCT04323 6-Apr-20 Traditiona A Retrospective CohorXiyuan Hos 3/8/2020 20200308 6/26/2020 ClinicalTria
NCT04323 6-Apr-20 Use of AscoUse of Ascorbic Acid University ### 20200318 6/26/2020 ClinicalTria
NCT04323 6-Apr-20 HydroxychlHydroxychloroquine foRambam He ### 20200325 6/26/2020 ClinicalTria
NCT04324 6-Apr-20 PrevalencePrevalence and Incide Universita ### 20200324 6/26/2020 ClinicalTria
NCT04324 6-Apr-20 A Phase I/ A Phase I/II Study of Chongqing ### 20200325 6/26/2020 ClinicalTria
NCT04325 6-Apr-20 Cardiac comCardiac comCAPACITY- UMC Utrec ### 20200325 6/26/2020 ClinicalTria
NCT04325 6-Apr-20 CoronaviruComprehensive ClinicaChinese Un ### 20200324 6/26/2020 ClinicalTria
NCT04326 6-Apr-20 Audio DataAudio Data Collection HealthMode ### 20200326 6/26/2020 ClinicalTria
NCT04331 6-Apr-20 COVID-19 PCOVID-19 PC19REG RAD-AID In ### 20200330 6/26/2020 ClinicalTria
ISRCTN149 6-Apr-20 Does point-Evaluating the clinical University ### 20200318 6/26/2020 ISRCTN
ChiCTR200 6-Apr-20 Effects of Effects of a single sessio

Peking Univ4/5/2020 20200405 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Clinical st Clinical study for Celebrex

Guangzhou
in 4/5/2020 20200405 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Study for Study for the Mechanism

N0.2ofPeople4/5/2020 20200405 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Investigat What happens to non-health

RenmincHos4/5/2020 20200405 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 A paired cl A paired clinical study Tongji
of Hosp4/4/2020 20200404 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Study for c Study for clinical effectAffiliated

of 4/3/2020 20200403 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 AssessmentAssessment of mental Ninth

healt Peopl4/3/2020 20200403 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Survey of Survey of psychologicalPeking

stat Uni 4/3/2020 20200403 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 A multi-ce A multi-center telephone

ChiCTR200 6-Apr-20 Applicatio Application of non-invasiv
Shanghai Si 4/3/2020 20200403 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 The efficac The efficacy of convalesce

Eastern th 4/2/2020 20200402 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Impact of Impact of measuring distance

Dermatolog4/2/2020 20200402 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Sleep qualiSleep quality of patients
Shanghai
wi O 4/2/2020 20200402 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Clinical st Clinical study for stem Huangshi

cells Ho4/2/2020 20200402 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Novel coronNovel coronavirus (2019-nCOV)

The First P 4/2/2020 20200402 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Clinical st Clinical study for preventio

Infection p 4/1/2020 20200401 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Efficacy an Efficacy and safety of Tongji Hos 4/1/2020 20200401 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 A medical Clinical experience of 59

Tongji
n Hosp4/1/2020 20200401 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Analysis of Analysis of changes in Affiliated

high 4/1/2020 20200401 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 A single ce A clinical study evaluating

Nanjing
th Uni ### 20200331 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Clinical s Evaluation of the safety

TheanFifth M ### 20200331 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 The Effect The Effects of novel corTongji Hosp ### 20200331 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Clinical ap Clinical application value

Wuhan
of m Asia ### 20200331 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 Novel coronNovel coronavirus infection

The First
( P ### 20200331 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 A medical Safety and effectiveness

Peking
ana Univ ### 20200329 6/26/2020 ChiCTR
ChiCTR200 6-Apr-20 A Medical A Medical Records Based
Xiangya
Retr Ho ### 20200323 6/26/2020 ChiCTR
EUCTR2020 6-Apr-20 HYCOVID - Hydroxychloroquine
HYCOVID - Hydroxychloroquine
versus
CHU Anger
placebo
versus
chez
placebo
###
les patients
20200324
chez les
ayant
6/26/2020
patients
une infection
ayant
EU Clinical
uneCOVID-19
infectionÃ
COVID-1
risque
EUCTR2020 6-Apr-20 Evaluation Evaluation of the concentrat

CHU de Sai ### 20200326 6/26/2020 EU Clinical
EUCTR2020 6-Apr-20 Multi-centrMulti-centre, adaptive,INSERM
rand 3/9/2020 20200309 6/26/2020 EU Clinical
EUCTR2020 6-Apr-20 CounteringCOUNTER-COVID - OralAmsterda

ima ### 20200331 6/26/2020 EU Clinical
EUCTR2020 6-Apr-20 NORWEGIAN
NORWEGIAN CORONAVIRU
Akershus Un ### 20200316 6/26/2020 EU Clinical
EUCTR2020 6-Apr-20 Efficacy of Uno studio randomizzato

Azienda
m UnitÃ
4/2/2020
Sanitaria
20200402
Locale-IRCCS
6/26/2020
di Reggio
EU Emilia
Clinical
ACTRN126 6-Apr-20 ExtraCorpoExtraCorporeal Membrane

The Prince
Oxyge ### 20200330 6/26/2020 ANZCTR
NCT03331 14-Apr-20 Inhaled GasAn Open LaNONTM University ### 20171025 6/26/2020 ClinicalTria
NCT04275 14-Apr-20 BevacizumaA Pilot St BEST-CP Qilu Hospit ### 20200214 6/26/2020 ClinicalTria
NCT04298 14-Apr-20 DAS181 forA Phase II STOP-Flu Ansun Biop ### 20200228 6/26/2020 ClinicalTria
NCT04320 14-Apr-20 Experimenta

An Clinic Trial of Re Shanghai J ### 20200321 6/26/2020 ClinicalTria
NCT04320 14-Apr-20 Risk Facto Risk Factors for Com Oslo Univer ### 20200323 6/26/2020 ClinicalTria
NCT04321 14-Apr-20 Behavior, A PATIENT BEAT19 xCures ### 20200323 6/26/2020 ClinicalTria
NCT04323 14-Apr-20 Early CPAP EC-COVID-PC
EC-COVID- Mario Negri ### 20200325 6/26/2020 ClinicalTria
NCT04324 14-Apr-20 Cohort MulCohort MulCORIMUNOAssistance ### 20200325 6/26/2020 ClinicalTria
NCT04324 14-Apr-20 Cytokine A Cytokine A CYCOV Dr. Alexan ### 20200325 6/26/2020 ClinicalTria
NCT04325 14-Apr-20 Integrated Integrated eCardioCovProfessor ### 20200321 6/26/2020 ClinicalTria
NCT04326 14-Apr-20 Use of cSV Use of cSV GARM-COVHealeon Me ### 20200326 6/26/2020 ClinicalTria
NCT04326 14-Apr-20 Early CPAP EC-COVID-RC

EC-COVID- Mario Negri ### 20200326 6/26/2020 ClinicalTria
NCT04326 14-Apr-20 Treating C The Use of a Bidirect TMC Healt ### 20200325 6/26/2020 ClinicalTria
NCT04327 14-Apr-20 PREdiction PCR-COVID-1

PREDICT University H ### 20200325 6/26/2020 ClinicalTria
NCT04327 14-Apr-20 Investigati Investigating Effect o Mazandaran ### 20200324 6/26/2020 ClinicalTria
NCT04327 14-Apr-20 The Use of The Use of Focused LuUniversity ### 20200327 6/26/2020 ClinicalTria
NCT04328 14-Apr-20 EffectiveneEffectiveneCovid Prof. Dr. ### 20200325 6/26/2020 ClinicalTria
NCT04328 14-Apr-20 Clinical Ch Clinical Characteristi Shanghai 1 ### 20200327 6/26/2020 ClinicalTria
NCT04329 14-Apr-20 Non-invasi Non-invasive DetectioNHS Lothia ### 20200326 6/26/2020 ClinicalTria
NCT04329 14-Apr-20 COVID-19 i Clinical Characteristi Hepatopanc ### 20200329 6/26/2020 ClinicalTria
NCT04330 14-Apr-20 HydroxychlA Study of Hydroxychl Gangnam Se ### 20200330 6/26/2020 ClinicalTria
NCT04330 14-Apr-20 Clinical Ch Clinical C PERN-COVIUniversity ### 20200330 6/26/2020 ClinicalTria
NCT04330 14-Apr-20 Impact of Impact of the CoronavStanford Un ### 20200330 6/26/2020 ClinicalTria
NCT04330 14-Apr-20 A Trial of A Trial of Ciclesonid Korea Univ ### 20200331 6/26/2020 ClinicalTria
NCT04331 14-Apr-20 Renin-AngiPhase IV O SARS-RAS Societa Ita ### 20200330 6/26/2020 ClinicalTria
NCT04331 14-Apr-20 Safety and Safety and Efficacy S Chinese Ac 2/6/2020 20200206 6/26/2020 ClinicalTria
NCT04332 14-Apr-20 COVID-19 BBiological COLCOV19 University ### 20200330 6/26/2020 ClinicalTria
NCT04332 14-Apr-20 Angiotensi Angiotensi ATCO Erasme Uni ### 20200327 6/26/2020 ClinicalTria
NCT04333 14-Apr-20 Study Test Evaluating ConvalesceBaylor Rese ### 20200327 6/26/2020 ClinicalTria
NCT04333 14-Apr-20 Piclidenos Piclidenoson for Trea Can-Fite B 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04333 14-Apr-20 Outcomes oOutcomes oCovid-VAS Vascular In ### 20200331 6/26/2020 ClinicalTria
NCT04333 14-Apr-20 AssessmentAssessmentCovid-19 University 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04335 14-Apr-20 Interest of Interest of eChoVid Assistance 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04335 14-Apr-20 Defibrotid Use of Def DEFI-VID19IRCCS San ### 20200331 6/26/2020 ClinicalTria
ACTRN126 14-Apr-20 Home rehab Home telerehabilitation
Flinders
for M 4/6/2020 20200406 6/26/2020 ANZCTR
ACTRN126 14-Apr-20 COVID-19 RISARIC/WHO Clinical Character

South Metr 4/6/2020 20200406 6/26/2020 ANZCTR
ACTRN126 14-Apr-20 Expressive Expressive Writing To Comba

Deakin Uni 4/6/2020 20200406 6/26/2020 ANZCTR
ACTRN126 14-Apr-20 Use of therUse of therapeutic drug
Royal
moniBris 4/6/2020 20200406 6/26/2020 ANZCTR
ACTRN126 14-Apr-20 Utilizing l Utilizing lung ultrasound

Griffith
in Un 4/6/2020 20200406 6/26/2020 ANZCTR
ACTRN126 14-Apr-20 Maternal aProspective registry ofUniversity
mate 4/6/2020 20200406 6/26/2020 ANZCTR
ACTRN126 14-Apr-20 Can intraveHigh-dose intravenousAustin

zinc ( Hea 4/8/2020 20200408 6/26/2020 ANZCTR
ChiCTR200 13-Apr-20 Study for t Study for the exercise Beijing

reha Spo ### 20200412 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 A Medical Clinical CharacteristicsThe First A ### 20200411 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 A clinical A clinical study for theJiangsu
ef Pro ### 20200411 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 A medical rClinical features and outc
Huanggang ### 20200410 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Investigat The impact of Information

N/A Sour ### 20200410 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 A questionnA questionnaire investigat

The 2nd Xia ### 20200410 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 A randomizA randomized, double-bli

Jiangsu Pro ### 20200410 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Effect of Effect of novel coronavirus
Shandong
pn P ### 20200410 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Impact of Impact of WeChat-basedFujian
pa Prov 4/9/2020 20200409 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 ExperiencePublic health emergencies

Shanghai
of Ji 4/9/2020 20200409 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 A medical rObservational study forthe

myoc
First A 4/9/2020 20200409 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Novel coro Novel coronavirus pneumonia

Wuhan Four4/8/2020
( 20200408 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Clinical st Clinical study for natural

Huzhou Cen4/8/2020 20200408 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Evaluation Evaluation Danorevir sodi

Huoshensha4/8/2020 20200408 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Study for eStudy for early biological

Shanghai
w Ji 4/7/2020 20200407 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 DevelopmenDevelopment and clinical

Chinese
appl PL 4/7/2020 20200407 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Study for Serum, faeces and sputum
Wenzhou
pro Ce4/7/2020 20200407 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 A medical Retrospective analysis Women's
of Ho4/6/2020 20200406 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Developmen

Development and applicatio
Beijing Uni 4/6/2020 20200406 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 A clinical A clinical study for effec

ChiCTR200 13-Apr-20 Early risk Early risk stratification West

of China 3/5/2020 20200305 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Constructi Construction of a Bio inform

the First A ### 20200228 6/26/2020 ChiCTR
ChiCTR200 13-Apr-20 Cancelled bClinical application of inhal
EUCTR202014-Apr-20 Efficacy of Efficacy of Addition of Assistance

Nap ### 20200326 6/26/2020 EU Clinical
EUCTR202014-Apr-20 An open labA pragmatic adaptive open
InflaRx G ### 20200327 6/26/2020 EU Clinical
EUCTR202014-Apr-20 Chemoproph
Chemoprophylaxis of SARS-C
IMMUNO
NCOVID-
20 : A
prospecti
ve,
controlle
d,
randomiz
ed,
multicent
er study
to
compare
the
efficacy
of a
chloroqui
ne analog
(GNS561),
anti PD-1
(nivoluma
b) and
anti-
interleuki
ne-6
receptor
(tocilizum
ab) versus
standard
of care in
advanced
or
metastati
EUCTR202014-Apr-20 Study compa
c can Centre LÃ ### 20200329 6/26/2020 EU Clinical
EUCTR202014-Apr-20 COVID-19 -COVID-19 - ACE inhibitASSISTANC ### 20200329 6/26/2020 EU Clinical

EUCTR202014-Apr-20 COVID-19 -COVID-19 - Epidemiology
GUSTAVE
o ### 20200324 6/26/2020 EU Clinical
Home Home
treatmen treatmen
t of t of
elderly elderly
patients patients
with with
symptom symptom
atic SARS- atic SARS-
CoV-2 CoV-2
infection infection
(COVID- (COVID-
19) : a 19) : a
multiarm, multiarm,
multi- multi-
stage stage
(MAMS) (MAMS)
randomiz randomiz
ed trial to ed trial to
assess the assess the
efficacy efficacy
and and
safety safety
of several of several
experime experime
ntal ntal
treatmen treatmen
ts to ts to
reduce reduce
the risk of the risk of
hospitaliz hospitaliz
ation or ation or
death death
EUCTR202014-Apr-20 (COVE (COVE CENTRE HO 4/1/2020 20200401 6/26/2020 EU Clinical
EUCTR202014-Apr-20 An internatAn international randomised
FIB-HCSC ### 20200326 6/26/2020 EU Clinical
EUCTR202014-Apr-20 Dexamethas
Dexamethasone and oxygen
APHP supp 4/2/2020 20200402 6/26/2020 EU Clinical
EUCTR202014-Apr-20 CLINICAL PRAGMATIC, CONTROLLE
Dr. Xavier 4/3/2020 20200403 6/26/2020 EU Clinical
EUCTR202014-Apr-20 Clinical tr Pilot, randomized, multi

INSTITUT 4/3/2020 20200403 6/26/2020 EU Clinical
EUCTR202014-Apr-20 EPICOS - ExPrevention of SARS-CoV-
Plan Nacio 4/3/2020 20200403 6/26/2020 EU Clinical
EUCTR202014-Apr-20 DEFIBROTI A prospective, multiceFFIS 4/3/2020 20200403 6/26/2020 EU Clinical

EUCTR202014-Apr-20 Dexamethas
Dexamethasone associated
Groupe Hosp4/2/2020 20200402 6/26/2020 EU Clinical
EUCTR202014-Apr-20 Interest in Interest in the administr

HÃ´pital F 4/1/2020 20200401 6/26/2020 EU Clinical
EUCTR202014-Apr-20 Pilot study Pilot study to evaluateFÃ©lix
t Gut 4/7/2020 20200407 6/26/2020 EU Clinical
EUCTR202014-Apr-20 PreventionPRE-EXPOSURE PROPHYLA

ISGlobal 4/7/2020 20200407 6/26/2020 EU Clinical
EUCTR202014-Apr-20 Clinical tr Clinical trial randomizeSociedad E 4/7/2020 20200407 6/26/2020 EU Clinical
EUCTR202014-Apr-20 Randomized
Randomized clinical triInstituto I 4/7/2020 20200407 6/26/2020 EU Clinical
EUCTR202014-Apr-20 Efficacy an Efficacy and Safety of cort

FundaciÃ³n 4/8/2020 20200408 6/26/2020 EU Clinical
EUCTR202014-Apr-20 MANAGEME
EFFICIENCY IN MANA HELLENIC I ### 20200331 6/26/2020 EU Clinical
NCT03680 20-Apr-20 Lessening Lessening LOVIT UniversitÃ ### 20180919 6/26/2020 ClinicalTria
NCT04245 20-Apr-20 Developmen

Development of a SimpBeijing Dit ### 20200126 6/26/2020 ClinicalTria
NCT04252 20-Apr-20 Efficacy an Efficacy an DC-COVID- Shanghai Pu ### 20200129 6/26/2020 ClinicalTria
NCT04261 20-Apr-20 Efficacy a Efficacy and Safety o Shanghai Pu2/6/2020 20200206 6/26/2020 ClinicalTria
NCT04274 20-Apr-20 Identifying Identifying Criticall Peking Univ ### 20200216 6/26/2020 ClinicalTria
NCT04290 20-Apr-20 COVID-19 -MulticenteNOSO-CORHospices Ci ### 20200227 6/26/2020 ClinicalTria
NCT04291 20-Apr-20 Evaluation An Open Clinical Tria The Ninth ### 20200227 6/26/2020 ClinicalTria
NCT04302 20-Apr-20 Expanded AIntermediate-Size Pat U.S. Army 3/2/2020 20200302 6/26/2020 ClinicalTria
NCT04306 20-Apr-20 Blood DonoBlood Donor RecruitmGuangzhou 3/8/2020 20200308 6/26/2020 ClinicalTria
NCT04310 20-Apr-20 Favipiravi Favipiravir Combined Peking Univ3/9/2020 20200309 6/26/2020 ClinicalTria
NCT04315 20-Apr-20 Tocilizuma Tocilizumab (RoActemrUniversitÃ Politecnica
### 20200314
delle Marche
6/26/2020 ClinicalTria
NCT04317 20-Apr-20 Tocilizuma MulticenteTOCIVID-1 National Ca ### 20200319 6/26/2020 ClinicalTria
NCT04319 20-Apr-20 Social MedImpact of Social Med Assiut Univ ### 20200316 6/26/2020 ClinicalTria
NCT04321 20-Apr-20 Outcomes aOutcomes aCOVIP Heinrich-He ### 20200319 6/26/2020 ClinicalTria
NCT04321 20-Apr-20 Impact of SImpact of Swab Site anDr. Deneen ### 20200323 6/26/2020 ClinicalTria
NCT04322 20-Apr-20 Anti-il6 T Effectiven TOCIVID Marius Hen ### 20200324 6/26/2020 ClinicalTria
NCT04324 20-Apr-20 Efficacy a A Phase 2/3, RandomizSwedish Or ### 20200325 6/26/2020 ClinicalTria
NCT04325 20-Apr-20 ConvalesceConvalescent Plasma tMayo Clini ### 20200326 6/26/2020 ClinicalTria
NCT04326 20-Apr-20 Proflaxis Proflaxis for Healthc Istinye Uni ### 20200326 6/26/2020 ClinicalTria
NCT04328 20-Apr-20 COVID MEDComparisonCOVIDMEDBassett He ### 20200327 6/26/2020 ClinicalTria
NCT04329 20-Apr-20 Understan How Immune Responses

University ### 20200329 6/26/2020 ClinicalTria
NCT04330 20-Apr-20 CoronaviruThe CORONA

CORONACI National Un ### 20200330 6/26/2020 ClinicalTria
NCT04330 20-Apr-20 Randomized,

Randomized, Controlled
Instituto ### 20200331 6/26/2020 ClinicalTria
NCT04331 20-Apr-20 Survey of Online-bas CORA Charite Uni ### 20200327 6/26/2020 ClinicalTria
NCT04331 20-Apr-20 Evaluation Evaluation of Efficac Fasa Univer ### 20200330 6/26/2020 ClinicalTria
NCT04331 20-Apr-20 COVID-19 COVID-19 Symptom TrKing's Col ### 20200331 6/26/2020 ClinicalTria
NCT04331 20-Apr-20 Study of thA Single Arm Open-labe

University 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04331 20-Apr-20 Pre-ExposuPre-ExposuPrEP_COVI Barcelona I 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04332 20-Apr-20 Clinical T Pilot, Ran TOCOVID FundaciÃ³ I ### 20200331 6/26/2020 ClinicalTria
NCT04332 20-Apr-20 Efficacy a Efficacy a TOSCA University ### 20200326 6/26/2020 ClinicalTria
NCT04333 20-Apr-20 Preventing Preventing C-19-ACS Imperial C 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04333 20-Apr-20 Telephony Telephony TOVID-49 University 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04333 20-Apr-20 COVID-19 i Prospective Observati University ### 20200331 6/26/2020 ClinicalTria
NCT04334 20-Apr-20 Vitamin D Effect of COVITD-19Universida ### 20200329 6/26/2020 ClinicalTria
NCT04334 20-Apr-20 HydroxychlHydroxychlHyAzOUT Intermounta4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04335 20-Apr-20 COVID-19 RCOVID-19 Registry RhiIHF GmbH - ### 20200331 6/26/2020 ClinicalTria
NCT04335 20-Apr-20 Cardiovasc Cardiovascular ManifeMemorial 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04336 20-Apr-20 Safety and Safety and Efficacy S Renmin Hos ### 20200328 6/26/2020 ClinicalTria
NCT04336 20-Apr-20 Hydrogen-OA Multi-ce COVID-19 Shanghai A ### 20200325 6/26/2020 ClinicalTria
NCT04336 20-Apr-20 Corona-Lik COVID-19-Like Illnes Assiut Univ 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04336 20-Apr-20 Physical AcDetermination Of PhysIstanbul K 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04336 20-Apr-20 Clinical St A Multi-center, Random

Giuliano Ri 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04337 20-Apr-20 Blood Tita Blood Titanium AnalysRoyal Nati 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04337 20-Apr-20 Impact of Impact of PCOVID-ARAUniversity 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04337 20-Apr-20 MavrilimumMavrilimumab to Reduc

Virginia C 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04337 20-Apr-20 Remote Mon

REmote MOn
REMOTE-C Imperial C 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04337 20-Apr-20 Clinical a A Clinical and Radiolo Maastricht 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04337 20-Apr-20 Reduction Reduction in COVID-19Rigshospit 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04337 20-Apr-20 Beat COVID-

A Virtual O JUPITER Beat COVID 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04337 20-Apr-20 Hemodynami

Hemodynami
PiCCOVID Bicetre Hos ### 20200330 6/26/2020 ClinicalTria
NCT04338 20-Apr-20 Point Of CaPoint Of C POCUSCO University ### 20200331 6/26/2020 ClinicalTria
NCT04338 20-Apr-20 Expanded AExpanded Access to CoMayo Clini 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04338 20-Apr-20 HydroxychlPakistan R PROTECT Shehnoor 4/4/2020 20200404 6/26/2020 ClinicalTria
NCT04338 20-Apr-20 Efficacy a Efficacy and Safety o Huilan Zha 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04338 20-Apr-20 CombinatioEvaluation CLOCC Heinrich-He4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04339 20-Apr-20 Characteri Characteri COVID-19 Assiut Univ 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04339 20-Apr-20 COVID-19 RiCOVID-19 Risk Stratifi Brigham an 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04339 20-Apr-20 Max COVIDA Prospective, Longit Max Healthc4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04339 20-Apr-20 Clinical R Clinical Research of Puren Hosp 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04341 20-Apr-20 Breath AnaDevelopment of a BreaMayo Clini 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 20-Apr-20 Clinical Tr Open Rando

TACROVID Hospital Un 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 20-Apr-20 AlloSure G AlloSure G Al-COVE CareDx ### 20200316 6/26/2020 ClinicalTria
NCT04341 20-Apr-20 EpidemioloCOVID 19 - ONCOVID Gustave Ro 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04341 20-Apr-20 The Safety The Safety of ChemothTongji Hosp4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 20-Apr-20 Non-contacEvaluating Non-contacNorthwest 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 20-Apr-20 Psychologi "PsychologBURDENCOAssistance 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 20-Apr-20 Predictive Predictive BIOCOVU University H4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04342 20-Apr-20 NIV and CPA

NIV and CPAP Failure Hospital G 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04342 20-Apr-20 Evaluate t Evaluate the Working Istanbul U 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04342 20-Apr-20 HydroxychlRandomized

COV-HCQ University 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04343 20-Apr-20 PLACE OF STUDY ECMECMO-COVUniversity 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04343 20-Apr-20 Military C Military COVID-19 HydUnited Sta 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 20-Apr-20 Effect of Effect of CYTOCOV- UniversitÃ 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 20-Apr-20 Surgery DuSurgery During Covid- University 4/9/2020 20200409 6/26/2020 ClinicalTria
ACTRN126 20-Apr-20 Effect of Randomised ControlledUNSWTria Syd ### 20200414 6/26/2020 ANZCTR
ACTRN126 20-Apr-20 The design The use of a simplifiedDr
neMichael ### 20200416 6/26/2020 ANZCTR
ACTRN126 20-Apr-20 Adapting thAdapting the Decathlon Dr Simon J ### 20200415 6/26/2020 ANZCTR
ACTRN126 20-Apr-20 Mental heaImpact of Social Isolation

TheoGeorge ### 20200416 6/26/2020 ANZCTR
ACTRN126 20-Apr-20 Virucidal p Virucidal pilot study ofFirebrick

N P ### 20200414 6/26/2020 ANZCTR
ACTRN126 20-Apr-20 Reducing aReducing acute severeThe respira
Univer ### 20200415 6/26/2020 ANZCTR
ACTRN126 20-Apr-20 Airway PresWest Australian AirwaySirPressu

Charles ### 20200415 6/26/2020 ANZCTR
ACTRN126 20-Apr-20 Cord BloodCord Blood Therapy toMonash

preventHe
p ### 20200416 6/26/2020 ANZCTR
ACTRN126 20-Apr-20 Stress-red Stress-reduction UsingUniversity

Pro ### 20200416 6/26/2020 ANZCTR
ChiCTR200 20-Apr-20 Danggui ShClinical study for Danggui

Union
Sh Hosp ### 20200419 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Study for Study for Healthy Behavi
ChiCTR200 20-Apr-20 A medical Observation of the curativ
ChiCTR200 20-Apr-20 The preventThe design of a modifed
The
N95 Fourth
re ### 20200417 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Effecacy a Effecacy and Safety of Sixth

HyperbMedic ### 20200417 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Novel coronNovel coronavirus pneumonia

Union Hosp
( ### 20200417 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Clinical ch Clinical characteristics Renji

and Hospi ### 20200417 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Clinical ob Clinical observation foThe Fifth A ### 20200416 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Study for Study on the prevention

Beijing
of COVI
Uni ### 20200416 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Medical ReMaternal and PerinatalInternation
Outc ### 20200416 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Efficacy o Efficacy of Chinese Herbal
China Acad ### 20200415 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Analysis of Analysis of clinical characte

ChiCTR200 20-Apr-20 Delineate tDelineate the prevalence,The Chines ### 20200414 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 A medical Clinical Research on Treatmen

ChiCTR200 20-Apr-20 Study for A cross-sectional observati

The Chines 4/7/2020 20200407 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 Cancelled bUmbilical cord mesenchyma

Nanjing Se ### 20200228 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 The effect Novel coronavirus pneumonia
Shanghai Un ### 20200218 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 A randomizA randomized, open-label,

Hebei Yilin 2/1/2020 20200201 6/26/2020 ChiCTR
ChiCTR200 20-Apr-20 A randomizA randomized, open-label,

Hebei Yili 2/1/2020 20200201 6/26/2020 ChiCTR
EUCTR202020-Apr-20 Use of a r Use of a respiratory mu

ASSISTANC ### 20200329 6/26/2020 EU Clinical
EUCTR202020-Apr-20 A clinicial A double-blind, placebo
Radboudu ### 20200330 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Efficacy of Efficacy of Hydroxychlor
HÃ´pitaux U ### 20200329 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Efficacy of Randomized clinical trial
FundaciÃ³n
t 4/3/2020 20200403 6/26/2020 EU Clinical
EUCTR201920-Apr-20 Clinical st Phase 1/2 clinical stu Histocell S. ### 20190726 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Tocilizuma A Randomized, ControlMedica Sci ### 20200413 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Clinical tr Randomized, controlled
Instituto de InvestigaciÃ³n
### 20200413
Sanitaria
6/26/2020
FundaciÃ³n
EU Clinical
JimÃ©nez DÃaz
EUCTR202020-Apr-20 Efficacy an Efficacy and safety of sa
Consorci P ### 20200413 6/26/2020 EU Clinical
EUCTR202020-Apr-20 efficacy a Randomized open labelUniversity
tria 4/3/2020 20200403 6/26/2020 EU Clinical
EUCTR202020-Apr-20 CorticoÃ¯des
CorticoÃ¯des
au cours deau
la cours
pneumonie
Hospices
de la pneumonie
virale
Ci 4/3/2020
Covid-19
viraleliÃ©e
20200403
Covid-19
Ã lâ€™infection
liÃ©e
6/26/2020
Ã lâ€™infection
EU
parClinical
le SARS-Cov-2
par le SARS-C
EUCTR202020-Apr-20 COvid-19 aCOvid-19 and Vitamin CHU
D su Anger 4/3/2020 20200403 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Clinical tr Prospective, phase II, Hospital Un ### 20200413 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Efficacy an Phase 2, randomized, open-
FundaciÃ³ ClÃnic per
###a20200413
la Recerca 6/26/2020
BiomÃ¨dicaEU Clinical
EUCTR202020-Apr-20 Random, coRandom, controlled, open,
FundaciÃ³
o H ### 20200413 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Clinical tr Randomized multicenter
FundaciÃ³n
clin ### 20200413 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Preventing Hydroxychloroquine efficacy
Barcelona
i I ### 20200413 6/26/2020 EU Clinical
Randomized open pilotRosario
study GarcÃa de###
VicuÃ±a
20200413 6/26/2020 EU Clinical
EUCTR202020-Apr-20 COLCHICINCOLCHICINA TEST IN THE
MONTREAL
SARS-CO ### 20200413 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Pragmatic cPragmatic clinical tri Institut CatalÃ dâ€™Oncologia
### 20200413 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Preventati ChemoPROphyLaxIs For
Cambridge
covId-19 ### 20200414 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Prevention suPAR-GUIDED ANAKINRA
Hellenic In ### 20200414 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Sedation wSedation with sevoflurane
Instituto
ve d ### 20200414 6/26/2020 EU Clinical
Double-
blind,
placebo-
controlle
d phase
I/II clinical
trial to
evaluate
the safety
and
efficacy
of
allogeneic
mesenchy
mal stem
cells
(MSVÂ®-
allo) in
acute
respirator
y failure
in
patients
with
COVID-19
pneumon
ia.
-
Treatmen
t of
COVID.19
with
allogeneic
EUCTR202020-Apr-20 Treatment me CITOSPIN S ### 20200414 6/26/2020 EU Clinical
Randomized open-blind
FFIS
control ### 20200415 6/26/2020 EU Clinical
EUCTR202020-Apr-20 Clinical tr Two-center, randomized,
FundaciÃ³n ### 20200416 6/26/2020 EU Clinical
Preventin
g
Pulmonar
y
Complica
tions in
Surgical
Patients
at Risk of
COVID-19
-
COVIDSur
gRCT_v1.
0_202003
30
EUCTR202020-Apr-20 Preventing University ### 20200417 6/26/2020 EU Clinical

EUCTR202020-Apr-20 SargramostiA prospective, randomiUniversity ### 20200324 6/26/2020 EU Clinical
IRCT20200 21-Apr-20 ComparisonComparison of The Therapeu
Ahvaz Univ 4/1/2020 20200401 6/26/2020 IRCT
IRCT20151 21-Apr-20 Clinical Tr Clinical Trial of renin Tehran Uni ### 20200329 6/26/2020 IRCT
IRCT20100 21-Apr-20 CombinatioEvaluating efficacy andTehran
safe Uni ### 20200322 6/26/2020 IRCT
IRCT20100 21-Apr-20 Interferon Evaluating efficacy andTehran
safety Uni ### 20200319 6/26/2020 IRCT
IRCT20100 21-Apr-20 Interferon Evaluating efficacy andTehran
safety Uni ### 20200316 6/26/2020 IRCT
IRCT20200 21-Apr-20 Effect of h Formulation of two natura
Iran Univer ### 20200317 6/26/2020 IRCT
IRCT20151 21-Apr-20 Evaluting t Evaluting the therapeutic
Shahid
a Behe ### 20200323 6/26/2020 IRCT
IRCT20170 21-Apr-20 Effect of v evaluation the effect ofTabriz
vitamUniv ### 20200329 6/26/2020 IRCT
IRCT20100 21-Apr-20 ?Effect of Evaluating efficacy andTehran
safety Uni ### 20200319 6/26/2020 IRCT
IRCT20200 21-Apr-20 Effect of Effect of Camostate mesylate
Tabriz Univ 4/3/2020 20200403 6/26/2020 IRCT
IRCT20160 21-Apr-20 The effect The effect of NOSCOVID Qazvin
on pul
Univ ### 20200322 6/26/2020 IRCT
IRCT20120 21-Apr-20 Effect of h Effect of hydroxychloroquin
Tehran Uni 4/5/2020 20200405 6/26/2020 IRCT
IRCT20131 21-Apr-20 Effect of B Effect of Benson Relaxation
Sabzevar
o Un ### 20200330 6/26/2020 IRCT
IRCT20140 21-Apr-20 The effect Evaluation of the efficacy
MOM a resear ### 20200328 6/26/2020 IRCT
IRCT20200 21-Apr-20 Remedy of The effect of geneticalRNAnanoc
biotec ### 20200326 6/26/2020 IRCT
IRCT20190 21-Apr-20 ?Effect of The effect of febuxostatMazandaran
agai 4/5/2020 20200405 6/26/2020 IRCT
IRCT20140 21-Apr-20 Persian MeThe Effect of Persian Medici
Tabriz Univ ### 20200329 6/26/2020 IRCT
IRCT20150 21-Apr-20 ReciGen fo the efficacy of Interferon
Tehran
b Uni 4/3/2020 20200403 6/26/2020 IRCT
IRCT20140 21-Apr-20 The effect Study the effect of intrave
Kerman Uni4/4/2020 20200404 6/26/2020 IRCT
IRCT20160 21-Apr-20 Effect of L Comparison of the Effecti
Artesh Univ ### 20200331 6/26/2020 IRCT
IRCT20151 21-Apr-20 Evaluation Evaluation the EfficacyShahid
and SaBehe ### 20200326 6/26/2020 IRCT
IRCT20160 21-Apr-20 Effect of Effect of metformin in Tabriz
COVID-19
Univ ### 20200327 6/26/2020 IRCT
IRCT20160 21-Apr-20 Study of thStudy of the metforminTabriz
effectUniv
o ### 20200326 6/26/2020 IRCT
IRCT20180 21-Apr-20 The effect The effect of Trachysperm
Arak Univer ### 20200329 6/26/2020 IRCT
IRCT20200 21-Apr-20 ComparisonEvaluation of efficacy Fasa Univer 4/5/2020 20200405 6/26/2020 IRCT
IRCT20200 21-Apr-20 Treatment Sotudy the Efficacy and Tehran
Safet Uni ### 20200331 6/26/2020 IRCT
IRCT20140 21-Apr-20 Evaluation Double blind clinical trial
Iran Univer ### 20200329 6/26/2020 IRCT
IRCT20200 21-Apr-20 Study of thStudy of the effect of Vitamin
Abadan Uni 4/4/2020 20200404 6/26/2020 IRCT
IRCT20200 21-Apr-20 ConvalesceEvaluation of ConvalescentDarmanara
Pla ### 20200330 6/26/2020 IRCT
IRCT20101 21-Apr-20 Evaluation Evaluation of the effe Kerman Uni4/3/2020 20200403 6/26/2020 IRCT
IRCT20200 21-Apr-20 Effect of Effect of Fingolimod for Tabriz
treatme
Univ 4/3/2020 20200403 6/26/2020 IRCT
IRCT20200 21-Apr-20 Mesenchyma Mesenchymal stem cellBagheiat-al
util 4/1/2020 20200401 6/26/2020 IRCT
IRCT20170 21-Apr-20 Investigati Investigating the effecti
Kerman Uni ### 20200331 6/26/2020 IRCT
IRCT20190 21-Apr-20 Effects of Effects of High-dose Vitam
Tehran Uni ### 20200331 6/26/2020 IRCT
IRCT20120 21-Apr-20 Efficacy o Efficacy of different meGorgan Uni 4/2/2020 20200402 6/26/2020 IRCT
IRCT20180 21-Apr-20 Evaluation Evaluation of the effectsTabriz
of LoUniv 4/1/2020 20200401 6/26/2020 IRCT
IRCT20150 21-Apr-20 Hemoperfus To evaluate the effectiveness
Babol Unive4/3/2020 20200403 6/26/2020 IRCT
IRCT20200 21-Apr-20 supplementImpact of vitamin B, A,Tehran
D, Uni 4/4/2020 20200404 6/26/2020 IRCT
JPRN-Japic 20-Apr-20 Phase 3 Cli Multicenter, Adaptive,FUJIFILM
Ra T ### 20200327 6/26/2020 JPRN
JPRN-jRCT 20-Apr-20 Favipiravir A prospective multi-center
TokueopYuta ### 20200227 6/26/2020 JPRN
JPRN-UMIN20-Apr-20 Risk factor Risk factors of death from
Yokohama
co C ### 20200331 6/26/2020 JPRN
JPRN-UMIN20-Apr-20 MulticenteMulticenter prospective
Keio
c Unive ### 20200417 6/26/2020 JPRN
JPRN-UMIN20-Apr-20 ChloroquinChloroquine and hydroYokohama C ### 20200417 6/26/2020 JPRN
NCT03042 27-Apr-20 Repair of Repair of AREALIST Belfast Hea 2/1/2017 20170201 6/26/2020 ClinicalTria
NCT03891 27-Apr-20 A Study to A Phase 1b Double-blinBioCryst P ### 20190315 6/26/2020 ClinicalTria
NCT04092 27-Apr-20 '' The Abdo''Can the Abdominal CrKonya Trai ### 20190913 6/26/2020 ClinicalTria
NCT04252 27-Apr-20 Mesenchyma

Safety and Efficiency Beijing 302 ### 20200127 6/26/2020 ClinicalTria
NCT04252 27-Apr-20 A Trial of A Phase 3 Randomized,Capital Med ### 20200131 6/26/2020 ClinicalTria
NCT04257 27-Apr-20 A Trial of A Phase 3 Randomized,Capital Med ### 20200131 6/26/2020 ClinicalTria
NCT04273 27-Apr-20 Study of H Clinical Study of Hum Wuhan Unio ### 20200214 6/26/2020 ClinicalTria
NCT04276 27-Apr-20 Lopinavir/ An Open-label Randomi

The Univer ### 20200211 6/26/2020 ClinicalTria
NCT04280 27-Apr-20 NK Cells T Clinical Investigation Xinxiang me ### 20200213 6/26/2020 ClinicalTria
NCT04299 27-Apr-20 Stem Cell Clinical Application Tianhe Stem ### 20200228 6/26/2020 ClinicalTria
NCT04304 27-Apr-20 COVID-19 SCOVID-19 SSEROCOV Assistance 3/9/2020 20200309 6/26/2020 ClinicalTria
NCT04315 27-Apr-20 HydroxychlHydroxychlHYDRA National In ### 20200318 6/26/2020 ClinicalTria
NCT04318 27-Apr-20 HydroxychlChemoproph

PHYDRA National In ### 20200319 6/26/2020 ClinicalTria
NCT04320 27-Apr-20 Baricitinib Baricitinib BARI-COVI Hospital of ### 20200320 6/26/2020 ClinicalTria
NCT04320 27-Apr-20 Non-contacNon-contact EndoscopChanghai H ### 20200321 6/26/2020 ClinicalTria
NCT04321 27-Apr-20 COVID-19 RCOVID-19 RCORIPREV- Darrell Tan ### 20200318 6/26/2020 ClinicalTria
NCT04321 27-Apr-20 The Efficac The (Norwegian) NOR Oslo

So Univer ### 20200323 6/26/2020 ClinicalTria
NCT04322 27-Apr-20 Simple, Sa Proposal foLUSCOVID1Catholic Un ### 20200323 6/26/2020 ClinicalTria
NCT04323 27-Apr-20 Efficacy o The Efficacy of Natura Misr Unive ### 20200323 6/26/2020 ClinicalTria
NCT04323 27-Apr-20 Viral Infec Viral Infec COVID-19 Mayo Clini ### 20200324 6/26/2020 ClinicalTria
NCT04324 27-Apr-20 Cohort MulCohort MulCORIMUNOAssistance ### 20200325 6/26/2020 ClinicalTria
NCT04324 27-Apr-20 DIgital Onl Online Sup DISPOSE Gunther Me ### 20200326 6/26/2020 ClinicalTria
NCT04324 27-Apr-20 "COVID-19 "Coronavi CORONAD Nantes Univ ### 20200325 6/26/2020 ClinicalTria
NCT04325 27-Apr-20 Clinical Ev Single-Arm Observation
Cordio Med ### 20200325 6/26/2020 ClinicalTria
NCT04325 27-Apr-20 Efficacy o Efficacy o DEXA-COVIDr. Negrin ### 20200325 6/26/2020 ClinicalTria
NCT04325 27-Apr-20 Efficacy of Efficacy of ENACOVID Assistance ### 20200326 6/26/2020 ClinicalTria
NCT04326 27-Apr-20 ODYSSEY: AODYSSEY: A Randomized,

Vanda Phar ### 20200326 6/26/2020 ClinicalTria
NCT04327 27-Apr-20 A LongitudiA Longitudinal Study Dr. Deneen ### 20200326 6/26/2020 ClinicalTria
NCT04329 27-Apr-20 Efficacy an Phase 2, Randomized, Judit Pich MartÃn###

ez 20200331 6/26/2020 ClinicalTria
NCT04331 27-Apr-20 Protective Protective INHASCO Assistance ### 20200329 6/26/2020 ClinicalTria
NCT04331 27-Apr-20 EpidemioloEpidemioloCOVID CAL Weprom ### 20200330 6/26/2020 ClinicalTria
NCT04333 27-Apr-20 Open-labelA PragmatiPANAMO InflaRx G 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04333 27-Apr-20 ChloroquinChloroquine for Mild HaEmek Med

4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04334 27-Apr-20 Treatment Treatment of Severe Grupo Cooperativo

4/1/2020de 20200401
HemopatÃ6/26/2020
as MalignasClinicalTria
NCT04334 27-Apr-20 TelerehabilInvestigation Of The Kubra Koce 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04335 27-Apr-20 COVID-19 i COVID-19 in Hospitali University 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04336 27-Apr-20 Rutgers COCohort Study of SARS-Rutgers, Th 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04336 27-Apr-20 Impact of Impact of COVID-CH University ### 20200330 6/26/2020 ClinicalTria
NCT04338 27-Apr-20 Screening Accuracy a SCOUT Hasselt Uni 4/4/2020 20200404 6/26/2020 ClinicalTria
NCT04338 27-Apr-20 The ImpactThe Impact of the Cor Sheba Medi4/4/2020 20200404 6/26/2020 ClinicalTria
NCT04339 27-Apr-20 Simulation Simulation of Risk of Tabula Ras 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04340 27-Apr-20 French MulFrench MulFRENCH C Centre Hosp4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 27-Apr-20 Clinical an Clinical and ImmunoloUniversity 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04341 27-Apr-20 CORIMUNO-A
CORIMUNO-A
CORIMUNOAssistance 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04342 27-Apr-20 Safety And Safety And SHARP COVTan Tock S 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04342 27-Apr-20 University Hydroxychloroquine f University 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04342 27-Apr-20 Acquiring Acquiring ConvalescenColumbia U 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04342 27-Apr-20 ChloroquinPhase IIb CloroCOVIDFundaÃ§Ã£o4/4/2020 20200404 6/26/2020 ClinicalTria
NCT04343 27-Apr-20 CoronavirusAspirin, Lo CRASH-19 London Sch 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04343 27-Apr-20 Trial Evalu Cohort MulCORIMUNOAssistance 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04343 27-Apr-20 HyperbaricHyperbaric Oxygen TheOchsner He 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04343 27-Apr-20 Evolution Evolution EPILOGUE University 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04343 27-Apr-20 Mental HeaMental HeaNew Tjhin Wigu 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04343 27-Apr-20 COPING WiEffectiveness of Cris Duke Unive 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04343 27-Apr-20 ConvalescePhase IIa Study Explo Hackensack 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04343 27-Apr-20 Using Biov Using BiovitalsÂ® Sen The Univer ### 20200220 6/26/2020 ClinicalTria
NCT04343 27-Apr-20 Pyridostig Pyridostig PISCO Instituto N 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Prone Posi Prone Posi ProCov ELHARRAR 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 CovidDB: T CovidDB: The Covid-19ClarData ### 20200410 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Impact of Impact of Tele-Interv Federal Uni 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Gargling a A Phase II, RandomizedNYU Lango 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Treatment Treatment RCT LCMC Heal ### 20200410 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 ConvalesceConvalescent Plasma tStony Broo ### 20200410 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Phase I / I Phase I / II Clinical Universida ### 20200410 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Dexamethas

Dexamethas
COVIDICUSAssistance 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Trial Evalu Cohort MulCORIMMU Assistance 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Trial Eval Cohort MulCORIMMUNAssistance 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Impact of Impact of Covid-19 onAssiut Univ ### 20200411 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Covid 19 PaCovid 19 Pandemic. EmAssiut Univ ### 20200410 6/26/2020 ClinicalTria
NCT04344 27-Apr-20 Endoscopy-Endoscopy-related PhoAustin Hea ### 20200410 6/26/2020 ClinicalTria
NCT04345 27-Apr-20 Correlativ Correlativ CORSA Istituto Sc ### 20200410 6/26/2020 ClinicalTria
NCT04345 27-Apr-20 Angiotensi Randomized Trial of A Tanta Unive ### 20200411 6/26/2020 ClinicalTria
NCT04345 27-Apr-20 Study to EvAn Open-label, Randomi

NCT04345 27-Apr-20 Testing fo Testing for COVID-19 German Can ### 20200412 6/26/2020 ClinicalTria
NCT04345 27-Apr-20 ConvalesceMulti-centeConPlas-19Cristina A 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04345 27-Apr-20 ProspectiveProspectiveCovidReg Oslo Univer 4/5/2020 20200405 6/26/2020 ClinicalTria
NCT04345 27-Apr-20 Ayurveda SAyurveda Self-Managem

Aarogyam ### 20200410 6/26/2020 ClinicalTria
NCT04345 27-Apr-20 The SpectruThe Spectrum and ProfInstitute of ### 20200410 6/26/2020 ClinicalTria
NCT04345 27-Apr-20 Spironolac The Effect of Spirono Istanbul U ### 20200410 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 Evaluation Evaluation of Interle Francis Co ### 20200413 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 To Access Strain Stu Strain Ain Shams ### 20200413 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 RetrospectiRetrospect Explore Ain Shams ### 20200413 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 A Study to Tear Fluid miRNA AnalyG. d'Annun ### 20200410 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 COVID-19: COVID-19: Investigati Herlev Hosp ### 20200411 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 CoVid-19 - CoVid-19 - Infection Ludwig Bol ### 20200413 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 Immune Mon
Immune Mon
Chloroqui Universida ### 20200410 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 PRactice o PRactice of VENTilatio Academisch4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 Bone MarroSafety and Efficacy o Guangzhou ### 20200323 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 Burnout AmBurnout Among Caregiv

HÃ´pital 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 TelerehabilInvestigati COVID-19 Yasemin Ã‡ ### 20200413 6/26/2020 ClinicalTria
NCT04346 27-Apr-20 Video-Based

Investigation Of The Istinye Uni ### 20200413 6/26/2020 ClinicalTria
NCT04347 27-Apr-20 ImplementaImplementat
PHYSIO-COUniversity ### 20200410 6/26/2020 ClinicalTria
NCT04347 27-Apr-20 A Retrospea Retrospective Study Xinqiao Ho ### 20200318 6/26/2020 ClinicalTria
NCT04347 27-Apr-20 Establishin Establishi COVIDHLH Technische 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04347 27-Apr-20 A Cohort o A Cohort o COVIDothÃUniversity 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04347 27-Apr-20 Outcome ofOutcome of COVID-19Assiut

C Univ ### 20200414 6/26/2020 ClinicalTria
NCT04347 27-Apr-20 Preventing Prophylactic HydroxycStony Broo ### 20200413 6/26/2020 ClinicalTria
NCT04347 27-Apr-20 Awake PronAwake PronAPPROVE- University 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04347 27-Apr-20 Dexamethas

Dexamethas
DHYSCO Centre Chi 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04348 27-Apr-20 How COVID-

How COVID-19 Virus Ou
HÃ´pital U ### 20200410 6/26/2020 ClinicalTria
NCT04348 27-Apr-20 Defibrotid Phase IIb P DEFACOVI Fundacion p4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04348 27-Apr-20 Clinical an ReportAge-COVID Projec

Istituto Na ### 20200410 6/26/2020 ClinicalTria
NCT04348 27-Apr-20 Evaluating Evaluation COVIDIMMAssaf-Haro ### 20200413 6/26/2020 ClinicalTria

NCT04348 27-Apr-20 ObservatioObservational Study AUSL Roma ### 20200413 6/26/2020 ClinicalTria
NCT04348 27-Apr-20 BAttLe AgaTwo-treatment,Randomiz

Instituto de InvestigaciÃ³n
### 20200410
Sanitaria
6/26/2020
de la FundaciÃ³n
ClinicalTria
JimÃ©nez DÃaz
NCT04348 27-Apr-20 Study of RuRandomized

Ruxo-Sim- FundaciÃ³n ### 20200413 6/26/2020 ClinicalTria
NCT04348 27-Apr-20 COVID-19 An

Assessment of COVID-1Neuroganic ### 20200413 6/26/2020 ClinicalTria
NCT04348 27-Apr-20 Plasma Ric Plasma Ric PRA-001 Ain Shams ### 20200413 6/26/2020 ClinicalTria
NCT04349 27-Apr-20 Efficacy a Efficacy a FAV-001 Ain Shams ### 20200413 6/26/2020 ClinicalTria
NCT04349 27-Apr-20 Saved Fro Chloroquine (CQ) PropColumbia U ### 20200412 6/26/2020 ClinicalTria
NCT04349 27-Apr-20 The FleminThe FleminFMTVDM The Camelo ### 20200411 6/26/2020 ClinicalTria
NCT04349 27-Apr-20 Ultraprote Open LabelVT4COVID Hospices Ci 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04349 27-Apr-20 ICU Trial in ProspectivePOINT-C Medical Uni ### 20200410 6/26/2020 ClinicalTria
NCT04350 27-Apr-20 Use of Dexm

ProspectivePRODEX University ### 20200413 6/26/2020 ClinicalTria
NCT04350 27-Apr-20 Emotional Emotional BEmocovid University ### 20200411 6/26/2020 ClinicalTria
NCT04350 27-Apr-20 Double TheAn Open-label Randomi

The Univer ### 20200413 6/26/2020 ClinicalTria
NCT04350 27-Apr-20 Interferon An InvestigIB1aIC Shahid Behe ### 20200414 6/26/2020 ClinicalTria
NCT04350 27-Apr-20 UmifenovirEfficacy a UAIIC Shahid Behe ### 20200414 6/26/2020 ClinicalTria
NCT04350 27-Apr-20 Applicatio Application of BCG V Ain Shams ### 20200413 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 Efficacy of Clinical Study Evaluat Tanta Unive ### 20200415 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 Impact of Impact of ZnD3-CoVicUniversity H ### 20200414 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 Austrian C Austrian COVID-19 Re Arbeitsgem ### 20200416 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 Ayurveda foAyurveda for Flu-like Aarogyam ### 20200414 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 High-dose High-dose Hydroxychl University ### 20200414 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 Diagnostic Development and AsseSt George's 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 Novel AdopNovel Adoptive Cellul KK Women's ### 20200416 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 Immunologic

Immunologic
ACTICOV-2Centre Hosp ### 20200410 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 Amiodarone

Amiodarone
ReCOVery- Nicolaus C ### 20200414 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 Impact of Impact of PISCA Copenhagen ### 20200411 6/26/2020 ClinicalTria
NCT04351 27-Apr-20 CORonaviruCORonaviruCOR-DLUS University ### 20200416 6/26/2020 ClinicalTria
NCT04352 27-Apr-20 Efficacy o RAndomized

RACONA University 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04352 27-Apr-20 Influence Influence of Physical University ### 20200410 6/26/2020 ClinicalTria
NCT04352 27-Apr-20 COVID-19 aCOVID-19 aVACAT University ### 20200413 6/26/2020 ClinicalTria
NCT04352 27-Apr-20 Adipose MeIV Infusion of Autol Regeneris ### 20200416 6/26/2020 ClinicalTria
NCT04352 27-Apr-20 COVID-19: N

COVID-19: N
BBCovid Claude Ber ### 20200415 6/26/2020 ClinicalTria
NCT04353 27-Apr-20 The RAPID Development and Evalu
Ottawa Hea ### 20200415 6/26/2020 ClinicalTria
NCT04353 27-Apr-20 Efficacay Clinical Study Evaluat Tanta Unive ### 20200415 6/26/2020 ClinicalTria
NCT04354 27-Apr-20 COVID-19 ACOVID-19 AnticoagulatNeil Golde ### 20200413 6/26/2020 ClinicalTria
NCT04354 27-Apr-20 Evaluation Evaluation URGDENTCAssistance ### 20200410 6/26/2020 ClinicalTria
NCT04354 27-Apr-20 Effect of Randomized

HyPreC Sir Mortime ### 20200414 6/26/2020 ClinicalTria
NCT04354 27-Apr-20 French SingEpidemiolog

CovidAmie Centre Hosp4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04354 27-Apr-20 Compartmen
Early and L COV2ICU-DHvidovre Un ### 20200413 6/26/2020 ClinicalTria
NCT04354 27-Apr-20 AiM COVIDAiM COVID for Covid 1Aarogyam ### 20200417 6/26/2020 ClinicalTria
NCT04354 27-Apr-20 QualitativeQualitativeAnosmie-C Centre Hosp ### 20200417 6/26/2020 ClinicalTria
NCT04355 27-Apr-20 Use of Bro Use of Bromhexine anGeneral an ### 20200415 6/26/2020 ClinicalTria
NCT04355 27-Apr-20 Prophylact Prophylactic Corticos Auxilio Mu ### 20200417 6/26/2020 ClinicalTria
NCT04355 27-Apr-20 SOLIRISÂ® SOLIRISÂ® (EculizumabAlexion Ph ### 20200417 6/26/2020 ClinicalTria
NCT04355 27-Apr-20 Evaluation A Phase 2 Randomized,Karyopharm ### 20200417 6/26/2020 ClinicalTria

NCT04355 27-Apr-20 Gut MicrobGut Microbiota, "Spar Universida ### 20200415 6/26/2020 ClinicalTria
NCT04356 27-Apr-20 Long-term Long-term U

TRAPSAH Assistance ### 20200417 6/26/2020 ClinicalTria
NCT04356 27-Apr-20 Non-Invasi Non-Invasive MonitoriMassachuse ### 20200416 6/26/2020 ClinicalTria
NCT04356 27-Apr-20 COVID-19: COVID-19: A Pilot Stu Dr Gerry G ### 20200410 6/26/2020 ClinicalTria
NCT04357 27-Apr-20 The RIsk St The RIsk St RISC-19-IC University ### 20200415 6/26/2020 ClinicalTria
NCT04357 27-Apr-20 COVID-19 PA Study of PsyCOVID Federico II ### 20200416 6/26/2020 ClinicalTria
NCT04357 27-Apr-20 AssessmentAssessmentCovid-Thel University 4/9/2020 20200409 6/26/2020 ClinicalTria
ACTRN126 27-Apr-20 ChloroquinMulti-Site, Randomized,

Australian ### 20200330 6/26/2020 ANZCTR
AUSTRALI
AN
CARDIOV
ASCULAR
COVID-19
REGISTRY
(AUS-
COVID)
AUSTRALI
AN
CARDIOV
ASCULAR
COVID-19
REGISTRY
(AUS-
COVID)
ACTRN126 27-Apr-20 Royal Nort ### 20200417 6/26/2020 ANZCTR
A
Randomis
ed,
Double
Blind,
Placebo-
Controlle
d Trial of
the
Efficacy of
Hydroxyc
hloroquin
e for the
Communi
ty-Based
Treatmen
t of
Adults
With
Diagnose
d COVID-
19
ACTRN126 27-Apr-20 Hydroxychl Medical Re 4/8/2020 20200408 6/26/2020 ANZCTR
ACTRN126 27-Apr-20 A FacebookFeasibility of a Facebook

University
de ### 20200420 6/26/2020 ANZCTR
ACTRN126 27-Apr-20 Impact of hImpact of high intensitJuan P. Fuentes-GarcÃ
### a20200417 6/26/2020 ANZCTR
Retrospec
tive
cohort
study of
COVID-19
infection
among
surgical
patients
after
surgery
ACTRN126 27-Apr-20 Retrospect Anesthesio ### 20200420 6/26/2020 ANZCTR
ACTRN126 27-Apr-20 Study evaluProspective study evalua

Albury Wo ### 20200420 6/26/2020 ANZCTR
ChiCTR200 27-Apr-20 A medical A medical records based

ChiCTR200 27-Apr-20 the efficac the efficacy and safetyRujin

of Hospi ### 20200427 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 A multicen Xiaoyao capsule improves

Xiaogan
C Tr ### 20200427 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 Investigati Investigation on the mental

China-Japa ### 20200426 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 Efficacy of Rqesearch on the Applicatio

Yueyang Int ### 20200426 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 Lingnan Fi Lingnan Fire-Needle Ther

ChiCTR200 27-Apr-20 A randomize

A randomized clinical trial
ChiCTR200 27-Apr-20 Study for eStudy for efficacy and safe
Beijing Uni ### 20200425 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 A multicentA multicenter, randomized,

Mudanjiang ### 20200424 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 A medical Epidemiological characterist
The First P ### 20200423 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 A multicentA multicenter, randomize

Ezhou Hospi ### 20200423 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 Clinical s Clinical study for the potent

Xinhua Hosp ### 20200423 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 Screening A randomized, double-bli

ChiCTR200 27-Apr-20 A medical The impact of wearingthe

m First A ### 20200423 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 A multicen A multicenter randomize

Wuhan Hosp ### 20200423 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 A multicentA multicenter, randomize

ChiCTR200 27-Apr-20 A medical A cohort retrospectiveBayi

studChildr ### 20200421 6/26/2020 ChiCTR
ChiCTR200 27-Apr-20 A retrospecA retrospective study for

Tongji
evoHosp ### 20200421 6/26/2020 ChiCTR
ISRCTN183 27-Apr-20 OccupationPredictive value of biolUniversity ### 20200415 6/26/2020 ISRCTN
ISRCTN512 27-Apr-20 Can the AvaDefining the role of a fert
labormediz ### 20200414 6/26/2020 ISRCTN
ISRCTN143 27-Apr-20 Does takin Protecting frontline heal

University ### 20200414 6/26/2020 ISRCTN
ISRCTN804 27-Apr-20 The impactThe impact of the COVID-19
ISRCTN169 27-Apr-20 RECOVERY IRn adult patients with University 4/6/2020 20200406 6/26/2020 ISRCTN
ISRCTN136 27-Apr-20 Distress anDistress And ResilienceUniversity
of heal 4/1/2020 20200401 6/26/2020 ISRCTN
ISRCTN512 27-Apr-20 Aspergillos Incidence and pathogenesis
St George'
o ### 20191206 6/26/2020 ISRCTN
EUCTR202029-Apr-20 A randomize
A randomized double-blind
Royalpl
Colle ### 20200331 6/26/2020 EU Clinical
EUCTR202029-Apr-20 Therapy witInhaled Nitric Oxide Gas
Massachuss4/3/2020
Th 20200403 6/26/2020 EU Clinical
EUCTR202029-Apr-20 COVID-19: COVID-19: addition of Erasmus

azithromyM 4/6/2020 20200406 6/26/2020 EU Clinical
Investiga
tion of
efficacy
and
Investiga tolerabilit
tion of y of the
efficacy healing
and water
tolerabilit Staatl.
y of the Fachingen
healing STILL in
water patients
Staatl. for
Fachingen symptom
STILL in atic
patients treatmen
for t of
symptom heartburn
atic in
treatmen comparis
t of on to
heartburn placebo
in - Healing
comparis water
on to efficacy in
placebo heartburn
Adaption
due to
EUCTR201729-Apr-20 COVID-19 Fachingen ### 20180719 6/26/2020 EU Clinical
EUCTR202029-Apr-20 A multicentA multicenter, open, Wroclaw Me4/8/2020 20200408 6/26/2020 EU Clinical
EUCTR202029-Apr-20 An internatAn international randomised

AZIENDA O ### 20200420 6/26/2020 EU Clinical
EUCTR202029-Apr-20 Sarilumab Sarilumab Treatment In
ClÃ
cytoKinE
nica Universidad
###de20200420
Navarra/Universidad
6/26/2020 EU
de Clinical
Navarra
EUCTR202029-Apr-20 Study of anPilot study of antithrombin
FundaciÃ³n
a ### 20200420 6/26/2020 EU Clinical
EUCTR202029-Apr-20 Clinical tr Clinical trial of Sarilumab
FundaciÃ³n
in ### 20200420 6/26/2020 EU Clinical
EUCTR202029-Apr-20 OUTPATIENOUTPATIENT TREATMENT

Dra Ana
OF CPu ### 20200420 6/26/2020 EU Clinical
EUCTR202029-Apr-20 Study for t Pilot, double-blind cli FundaciÃ³n ### 20200420 6/26/2020 EU Clinical
EUCTR202029-Apr-20 A SINGLE- A SINGLE-BLINDED RAN

Med. Univ. ### 20200330 6/26/2020 EU Clinical
Ruxolitini
b
Treatmen
t in
Patients
with
Severe
COVID-19
Infection.
A Danish
Safety
and
Efficacy
Study.
-
Ruxolitini
b
Ruxolitini Treatmen
b t in
Treatmen Patients
t in with
Patients Severe
with COVID-19
Severe Infection.
COVID-19 A Danish
Infection. Safety
A Danish and
Safety Efficacy
and Study
Efficacy
Study.
EUCTR202029-Apr-20 Zealand Uni ### 20200414 6/26/2020 EU Clinical
EUCTR202029-Apr-20 An open labAn open label single center
Institute o 4/1/2020 20200401 6/26/2020 EU Clinical
EUCTR202029-Apr-20 Treatment A prospective, randomiUniversity 4/4/2020 20200404 6/26/2020 EU Clinical

NCT04256 4-May-20 Efficacy of Registry St COVID-19 Beijing Ts 2/1/2020 20200201 6/26/2020 ClinicalTria
NCT04313 4-May-20 Artificial The Benefi AI-COVID-XProfessor ### 20200317 6/26/2020 ClinicalTria
NCT04318 4-May-20 HydroxychlHydroxychloroquine PoColumbia U ### 20200320 6/26/2020 ClinicalTria
NCT04319 4-May-20 Clinical Ch Clinical Ch COVID-pre Federico II ### 20200320 6/26/2020 ClinicalTria
NCT04319 4-May-20 MindfulnesMindfulness During C Wake Fores ### 20200320 6/26/2020 ClinicalTria
NCT04320 4-May-20 Joint Use Joint Use JOCOVID Groupe Hosp ### 20200320 6/26/2020 ClinicalTria
NCT04320 4-May-20 Closed-LooAutomated Oxygen TitrLaval Unive ### 20200319 6/26/2020 ClinicalTria
NCT04320 4-May-20 COVID-19 Pandemic Response NDuke Unive ### 20200323 6/26/2020 ClinicalTria
NCT04323 4-May-20 COVID-19 PPRIORITY ( PRIORITY University ### 20200324 6/26/2020 ClinicalTria
NCT04326 4-May-20 SargramostA Prospect SARPAC University ### 20200324 6/26/2020 ClinicalTria
NCT04327 4-May-20 CharacterizCharacterization of C University ### 20200326 6/26/2020 ClinicalTria
NCT04329 4-May-20 Efficacy a Open, Multicentric, N Azidus Bras ### 20200329 6/26/2020 ClinicalTria
NCT04330 4-May-20 Longitudin Longitudin COVIDENCEQueen Mary ### 20200331 6/26/2020 ClinicalTria
NCT04330 4-May-20 Treatment A Prospect COV-AID University ### 20200331 6/26/2020 ClinicalTria
NCT04331 4-May-20 CORIMUNO-1
Cohort MulCORIMUNOAssistance ### 20200331 6/26/2020 ClinicalTria
NCT04332 4-May-20 ConvalesceConvalesceCP-COVID- Universida ### 20200330 6/26/2020 ClinicalTria
NCT04332 4-May-20 Convalescen

Convalescen
CP-COVID- Universida ### 20200331 6/26/2020 ClinicalTria
NCT04333 4-May-20 Corona Vir The Mechanism, ClinicPeking Univ4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04334 4-May-20 Efficacy an Efficacy and Safety o Peking Univ4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04334 4-May-20 InternationInternatio HOPE COVIIVAN J NUÃ 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04334 4-May-20 Evaluating A Phase 1, Randomized,

Symvivo Co ### 20200331 6/26/2020 ClinicalTria
NCT04335 4-May-20 EPA-FFA toA Randomized ControllS.L.A. Pha 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04335 4-May-20 Study of O An Open Label Phase 1University ### 20200331 6/26/2020 ClinicalTria
NCT04337 4-May-20 Renin Angi Renin Angi SRA-COV Assistance 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04338 4-May-20 EliminationThe Random

REPLACECOUniversity 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04339 4-May-20 Personalis Efficiency ESCAPE Hellenic In 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04341 4-May-20 HydroxychlTreatment With Hydrox

Hugo Mend4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04344 4-May-20 Early Infu Early Infusion of Vit Virginia C 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 4-May-20 Early Risk Early Risk CCF French Car 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 4-May-20 Management

Management
OHB10cov Direction 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04345 4-May-20 Mesenchyma

Single Donor Banked BBaylor Col ### 20200410 6/26/2020 ClinicalTria
NCT04345 4-May-20 Anti COVIDAnti COVID-19 Conval Orthosera K ### 20200411 6/26/2020 ClinicalTria
NCT04346 4-May-20 OropharyngOropharyngeal Dysphag

Hospital d ### 20200410 6/26/2020 ClinicalTria
NCT04346 4-May-20 CORIMUNO19

CORIMUNO19
CORIMUNOAssistance 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04347 4-May-20 Study to D COVID-19 SCONEC Medical Un ### 20200412 6/26/2020 ClinicalTria
NCT04347 4-May-20 A Prospect Real World Observati Hackensack ### 20200413 6/26/2020 ClinicalTria
NCT04348 4-May-20 Efficacy a Open Label, MulticentAzidus Bras ### 20200413 6/26/2020 ClinicalTria
NCT04348 4-May-20 Birth Expe Birth Expe CONFINE Central Hos ### 20200410 6/26/2020 ClinicalTria
NCT04349 4-May-20 Beaumont H

Beaumont H
BLAST COVWilliam Be ### 20200413 6/26/2020 ClinicalTria
NCT04350 4-May-20 Polyvalent Value of E ICAR Centre Hosp4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04351 4-May-20 Austrian CoA Multicen ACOVACT Medical Un ### 20200410 6/26/2020 ClinicalTria
NCT04351 4-May-20 Registry f Registry f ReCovER University ### 20200416 6/26/2020 ClinicalTria
NCT04352 4-May-20 Safety and A Randomized, Double-

Sinovac Re ### 20200414 6/26/2020 ClinicalTria
NCT04352 4-May-20 ANTIBODY B

Use of the ANTIBODY Texas Card ### 20200416 6/26/2020 ClinicalTria
NCT04352 4-May-20 HEalth Car Protecting HERO GeoSentine ### 20200416 6/26/2020 ClinicalTria
NCT04353 4-May-20 PATCH 2&3:PATCH 2 & 3: (Preven UnitedHeal 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04353 4-May-20 Clinical Tr A Randomized, Double-b

Cadila Pha ### 20200416 6/26/2020 ClinicalTria
NCT04353 4-May-20 Covid-19 i Covid-19 i covid19 faiUniversity H ### 20200415 6/26/2020 ClinicalTria
NCT04354 4-May-20 COVID-19 Off Label Study to Ev NYU Lango ### 20200416 6/26/2020 ClinicalTria
NCT04355 4-May-20 Open LabelAn Open-LaCOSTA Sheba Medi ### 20200416 6/26/2020 ClinicalTria
NCT04355 4-May-20 PrevalencePrevalenceCOVIPREG Assistance ### 20200417 6/26/2020 ClinicalTria
NCT04355 4-May-20 AssessmentAssessmentAVISA Butantan In ### 20200417 6/26/2020 ClinicalTria
NCT04355 4-May-20 Efficacy o Efficacy of CAPTOCOVAssistance ### 20200417 6/26/2020 ClinicalTria

NCT04355 4-May-20 DisseminatStudy of t ENVIRORE Assistance ### 20200417 6/26/2020 ClinicalTria
NCT04355 4-May-20 Computed TComputed TSTOIC Assistance ### 20200417 6/26/2020 ClinicalTria
NCT04355 4-May-20 Combination

Evaluation COVID-Sca University ### 20200417 6/26/2020 ClinicalTria
NCT04355 4-May-20 Ventil Devi Assesment of Usefulnes

Medical Un ### 20200416 6/26/2020 ClinicalTria
NCT04355 4-May-20 Expanded AAn Open-Label Expande

Incyte Cor ### 20200418 6/26/2020 ClinicalTria
NCT04355 4-May-20 OpportunisOpportunistic Screeni The Univer ### 20200419 6/26/2020 ClinicalTria
NCT04355 4-May-20 Sevofluran Sevoflurane Sedation University ### 20200326 6/26/2020 ClinicalTria
NCT04356 4-May-20 The MentalThe Mental Health StaUniversity ### 20200421 6/26/2020 ClinicalTria
NCT04356 4-May-20 COVID-19 SSARS-CoV-2 SurveillanRigshospit ### 20200413 6/26/2020 ClinicalTria
NCT04356 4-May-20 Immune Res

Immune Response to CSciensano ### 20200417 6/26/2020 ClinicalTria
NCT04356 4-May-20 Study to EvAn Open-Label Study tBausch Hea ### 20200420 6/26/2020 ClinicalTria
NCT04357 4-May-20 COPLA StudCOPLA StudCOPLA Centro de HematologÃ

### 20200414
a y Medicina
6/26/2020
Interna ClinicalTria
NCT04357 4-May-20 Rapid Sali Rapid Salivary Test t UniversitÃ degli Studi
### 20200415
dell'Insubria
NCT04357 4-May-20 suPAR-guidsuPAR-guidSAVE Hellenic In ### 20200420 6/26/2020 ClinicalTria
NCT04357 4-May-20 Psychologi Psychologi ICOS Centre hosp ### 20200416 6/26/2020 ClinicalTria
NCT04357 4-May-20 COVID-19 ECOVID-19 ECOVeR Centogene ### 20200420 6/26/2020 ClinicalTria
NCT04357 4-May-20 Assessing Assessing CORONA-S Duke Unive ### 20200420 6/26/2020 ClinicalTria
NCT04357 4-May-20 IMATINIB I A RANDOMIIMAGE-19 Versailles ### 20200420 6/26/2020 ClinicalTria
NCT04357 4-May-20 AdministraAdministratAVoCaDO Hunter Hol ### 20200417 6/26/2020 ClinicalTria
NCT04357 4-May-20 Efficacy o Randomized

SARCOVID Maria del ### 20200414 6/26/2020 ClinicalTria
NCT04357 4-May-20 WAVE. Wear
Wearable-bWAVE University ### 20200417 6/26/2020 ClinicalTria
NCT04357 4-May-20 Clinical Tr Clinical Tr SARICOR MaimÃ³nide ### 20200420 6/26/2020 ClinicalTria
NCT04357 4-May-20 ComparisonNew Coronavirus AwaIstanbul U ### 20200420 6/26/2020 ClinicalTria
NCT04358 4-May-20 PSYCHIATRIPSYCHIatri PSYCHIC Nantes Univ4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04358 4-May-20 Expanded AConvalescent Plasma Nakhle Sa ### 20200417 6/26/2020 ClinicalTria
NCT04358 4-May-20 Rhu-pGSN fA Phase 2 Randomized,BioAegis Th ### 20200416 6/26/2020 ClinicalTria

NCT04358 4-May-20 COVID-19 M
Mortality Prediction Dascena ### 20200420 6/26/2020 ClinicalTria
NCT04358 4-May-20 Classificat Classification of COV Dascena ### 20200420 6/26/2020 ClinicalTria
NCT04358 4-May-20 Baricitinib Baricitinib Therapy in Fabrizio Ca ### 20200419 6/26/2020 ClinicalTria
NCT04358 4-May-20 Dexmedetom

Impact of COVID-DEXHospital Cl ### 20200415 6/26/2020 ClinicalTria
NCT04358 4-May-20 Anxiety an Anxiety an PSY_CO_C Centre Hosp ### 20200421 6/26/2020 ClinicalTria
NCT04358 4-May-20 Clinical Tr A Randomized, Double-

Cadila Pha ### 20200421 6/26/2020 ClinicalTria
NCT04359 4-May-20 Effectiven Effectiveness and Saf Universida ### 20200415 6/26/2020 ClinicalTria
NCT04359 4-May-20 Different Avoiding High PEEP in Southeast U ### 20200413 6/26/2020 ClinicalTria
NCT04359 4-May-20 Ruxolitini Ruxolitinib RuXoCoil Philipps U ### 20200415 6/26/2020 ClinicalTria
NCT04359 4-May-20 AzithromycEfficacy a AIC Shahid Behe ### 20200418 6/26/2020 ClinicalTria
NCT04359 4-May-20 Estrogen P Phase II Clinical Tria Sharon Na ### 20200421 6/26/2020 ClinicalTria
NCT04359 4-May-20 Nasal EpithNasal CIlia CIPOLLINI University ### 20200420 6/26/2020 ClinicalTria
NCT04359 4-May-20 Favipiravir Efficacy an FIC Shahid Behe ### 20200418 6/26/2020 ClinicalTria
NCT04359 4-May-20 A Study to A Non-Interventional PProgenaBi ### 20200420 6/26/2020 ClinicalTria
NCT04359 4-May-20 SequencingSequencingSTOP COVI Portsmouth ### 20200420 6/26/2020 ClinicalTria
NCT04359 4-May-20 A Phone-caDoes a Sys COVIQuestUniversity ### 20200418 6/26/2020 ClinicalTria
NCT04359 4-May-20 NeurocogniBiomarker-NCoV University ### 20200419 6/26/2020 ClinicalTria
NCT04359 4-May-20 Efficacy of Efficacy of COVID-Agi University ### 20200417 6/26/2020 ClinicalTria
NCT04359 4-May-20 Study of H Study of H THROMBOVUniversity ### 20200416 6/26/2020 ClinicalTria
NCT04360 4-May-20 Inhaled Av Inhaled Av AVINALI NeuroRx, I ### 20200421 6/26/2020 ClinicalTria
NCT04360 4-May-20 Ivermectin Clinical Trial Evalua Tanta Unive ### 20200419 6/26/2020 ClinicalTria
NCT04360 4-May-20 Treatment Expanded Access Prot U.S. Army ### 20200420 6/26/2020 ClinicalTria
NCT04360 4-May-20 Long Term Long Term COVID19 L University ### 20200416 6/26/2020 ClinicalTria
NCT04360 4-May-20 Pilot Clini Randomized, Double-Bli

NCT04360 4-May-20 Precision Precision ImmunologyUniversity ### 20200422 6/26/2020 ClinicalTria
NCT04360 4-May-20 ChloroquinMulti-cent CQOTE University ### 20200422 6/26/2020 ClinicalTria
NCT04360 4-May-20 AssessmentAssessmentCOroFet University ### 20200422 6/26/2020 ClinicalTria
NCT04360 4-May-20 Use of Tel Use of Telehealth Tec University ### 20200421 6/26/2020 ClinicalTria
NCT04360 4-May-20 The ImpactThe Impact of CoronavThe Univer ### 20200422 6/26/2020 ClinicalTria
NCT04360 4-May-20 Targeted S Targeted Steroids for University ### 20200422 6/26/2020 ClinicalTria
NCT04360 4-May-20 Evaluation Evaluation of CommeriWashington ### 20200420 6/26/2020 ClinicalTria
NCT04360 4-May-20 The EffectsEffects of Standard Pr Shahid Behe ### 20200422 6/26/2020 ClinicalTria
NCT04361 4-May-20 Physical A Physical Activity in Basque Cou ### 20200422 6/26/2020 ClinicalTria
NCT04361 4-May-20 HydroxychlClinical Trial Evalua Tanta Unive ### 20200418 6/26/2020 ClinicalTria
NCT04361 4-May-20 Isotretino Evaluation RandomizeTanta Unive ### 20200421 6/26/2020 ClinicalTria
NCT04361 4-May-20 Lung RecruComparison of Two Met

St. Justine' ### 20200412 6/26/2020 ClinicalTria
NCT04361 4-May-20 PerformancComparison of the PerJessa Hospi ### 20200420 6/26/2020 ClinicalTria
NCT04361 4-May-20 Use of HydHydroxychloroquine orApsen Farm ### 20200422 6/26/2020 ClinicalTria
NCT04361 4-May-20 Registry of Registry fo COSA Hannover M ### 20200422 6/26/2020 ClinicalTria
NCT04361 4-May-20 Pilot Study Pilot Stud CytokCOVI Manuel CastellÃ ### 20200421 6/26/2020 ClinicalTria
NCT04361 4-May-20 COVID-19 inCOVID-19 inCOVID19-S Hospital Cl ### 20200422 6/26/2020 ClinicalTria
NCT04361 4-May-20 Clinical Ch Clinical Ch COVIDHIV Assistance ### 20200420 6/26/2020 ClinicalTria
NCT04361 4-May-20 Acral Cuta Acral Cutaneous ThromUniversity ### 20200417 6/26/2020 ClinicalTria
NCT04361 4-May-20 Ruxolitinib COVID-19: RESPIRE Azienda US ### 20200414 6/26/2020 ClinicalTria
NCT04361 4-May-20 Home CareHome CareMon-CovidMario Negri ### 20200414 6/26/2020 ClinicalTria
NCT04361 4-May-20 Influence National C TVP-COVIDSociedad Es ### 20200423 6/26/2020 ClinicalTria
NCT04362 4-May-20 Early Iden Early Identification University ### 20200421 6/26/2020 ClinicalTria
NCT04362 4-May-20 PerformancPerformance Evaluation

Universida
of BCG Vaccination
### in
20200421
Healthcare
6/26/2020
Personnel
ClinicalTria
to Reduce the Severity o
NCT04362 4-May-20 Online CognEfficacy of REST University ### 20200421 6/26/2020 ClinicalTria
NCT04362 4-May-20 Clinical-ep Clinical-ep COVID-AGEComplejo H ### 20200422 6/26/2020 ClinicalTria
NCT04362 4-May-20 Clinical a Clinical and ImmunoloFundacion ### 20200421 6/26/2020 ClinicalTria
NCT04363 4-May-20 Multicentr Multicentr COVID AMBMaison de S ### 20200423 6/26/2020 ClinicalTria
NCT04363 4-May-20 ACCESS A MACCESS (Ame

ACCESS Medable In ### 20200423 6/26/2020 ClinicalTria
NCT04363 4-May-20 A Study fo A Pilot, Multiple Dos 4D pharma ### 20200424 6/26/2020 ClinicalTria
NCT04363 4-May-20 Impact of Impact of PROVID-19Centre Hos ### 20200422 6/26/2020 ClinicalTria
NCT04363 4-May-20 The CEDiD The CEDiD CEDiD King's Col ### 20200423 6/26/2020 ClinicalTria
NCT04363 4-May-20 Incidence Incidence COVIDOP- Versailles ### 20200423 6/26/2020 ClinicalTria
NCT04363 4-May-20 Local Ther Randomized Clinical Instituto N ### 20200423 6/26/2020 ClinicalTria
NCT04363 4-May-20 AdolescentQualitativ AdoPro-Co HÃ´pital C ### 20200421 6/26/2020 ClinicalTria
NCT04363 4-May-20 COVID-19 InDo Respira CRC-COVIDAssistance ### 20200420 6/26/2020 ClinicalTria
NCT04363 4-May-20 Needle SticShould we Use DoubleLazarski Un ### 20200423 6/26/2020 ClinicalTria
NCT04363 4-May-20 The LEAD CO
The LEAD CO
LEAD COVI Louisiana S ### 20200424 6/26/2020 ClinicalTria
NCT04363 4-May-20 A Pilot St A Randomized-ControlOregon Hea ### 20200424 6/26/2020 ClinicalTria
NCT04364 4-May-20 Efficacy o Efficacy o COPEP Calmy Alex ### 20200423 6/26/2020 ClinicalTria
NCT04364 4-May-20 EuRopean SMulti-cent MERMAIDSUMC Utrec ### 20200420 6/26/2020 ClinicalTria
NCT04364 4-May-20 ARB, ACEi, ARB, ACEi, BIRCOV Medical Pra ### 20200423 6/26/2020 ClinicalTria
NCT04365 4-May-20 ProgesteroA Single Center, RandoSara Ghand ### 20200424 6/26/2020 ClinicalTria
NCT04365 4-May-20 ConvalesceConvalescent Plasma fEnos Berna ### 20200418 6/26/2020 ClinicalTria
NCT04365 4-May-20 A Single-ceA Single-center RetrosTongji Hosp ### 20200425 6/26/2020 ClinicalTria
NCT04365 4-May-20 Cardiovasc A Single-center Regis NYU Lango ### 20200425 6/26/2020 ClinicalTria
NCT04365 4-May-20 Pulmonary Pulmonary RehabilitatIstanbul Bi ### 20200426 6/26/2020 ClinicalTria
NCT04365 4-May-20 Loneliness Loneliness During the Modum Ba ### 20200426 6/26/2020 ClinicalTria
NCT04365 4-May-20 The Prone PStudy of thPRON-COVUniversity ### 20200421 6/26/2020 ClinicalTria
NCT04366 4-May-20 Ramipril f A Randomize

RAMIC University ### 20200424 6/26/2020 ClinicalTria
NCT04366 4-May-20 IntermediaIntermediate-size Exp Mesoblast International
### 20200424
SÃ rl 6/26/2020 ClinicalTria
NCT04372 4-May-20 London Amb

London Ambulance SerLondon Amb ### 20200429 6/26/2020 ClinicalTria
ACTRN126 4-May-20 SARS-CoV2SARS-CoV2 in children Gold

preseCoast ### 20200427 6/26/2020 ANZCTR
ACTRN126 4-May-20 Testing a Testing the efficacy of University

a cop ### 20200427 6/26/2020 ANZCTR
ACTRN126 4-May-20 COVID-19: A randomised controlled St Vincent

tr ### 20200427 6/26/2020 ANZCTR
ACTRN126 4-May-20 Neonatal CoNeonatal CoVID-19 StudyHunter
t Ne ### 20200429 6/26/2020 ANZCTR
ISRCTN133 4-May-20 START (Sid The efficacy and safetyEminentla ### 20200424 6/26/2020 ISRCTN
ISRCTN178 4-May-20 Expressive Effectiveness of an expressi
Psychosoci ### 20200423 6/26/2020 ISRCTN
An
internatio
nal
randomiz
ed trial of
additional
treatmen
ts for
COVID-19
in
hospitaliz
ed
patients
who are
all
receiving
the local
standard
of care
ISRCTN839 4-May-20 Public heal World Heal ### 20200325 6/26/2020 ISRCTN
ChiCTR200 4-May-20 The influe The influence of COVID-19
First pandem
Affil 5/4/2020 20200504 6/26/2020 ChiCTR
ChiCTR200 4-May-20 Diagnostic Diagnostic value of chest
Ganzhou
CT Pe5/3/2020 20200503 6/26/2020 ChiCTR
ChiCTR200 4-May-20 A randomize

A randomized, double-blin
State Key L 5/3/2020 20200503 6/26/2020 ChiCTR
ChiCTR200 4-May-20 DevelopingDeveloping and validating

ChiCTR200 4-May-20 Direct evi Direct evidence of rectal
Zhongnan
cance H5/1/2020 20200501 6/26/2020 ChiCTR
ChiCTR200 4-May-20 Study for Study for using sulfateShanghai

in Pu ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 Study on d Study on data management

TCM Data
a C ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 TCM IntervTCM Intervention study

Guang'anme
for ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 Analysis of Analysis of clinical features

Xiangya
of Hos ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 A medical rOutcome analysis of apply

Hospital of ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 Early warn Early warning model and
Thenew
FirstbiA ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 A phase I/I Evaluation of the safetHenan Prov ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 A medical Leukopenia is more commonDepartment
i ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 Applicatio Application of pulmonary

Westr Campu ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 A RandomizA Randomized Controlled

Shanghai
Tr Pu ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 A study forA study for the mentalNingxia

he Nin ### 20200429 6/26/2020 ChiCTR
ChiCTR200 4-May-20 Efficacy an Efficacy and Safety of ulinast

ChiCTR200 4-May-20 Study for t Study for the influenceFujian
of n Prov ### 20200414 6/26/2020 ChiCTR
ChiCTR200 4-May-20 Clinical ch Clinical characteristics Tongji

and deaHosp ### 20200327 6/26/2020 ChiCTR
ChiCTR200 4-May-20 Effectiven Effectiveness and safety
Shanghai
of Pu ### 20200323 6/26/2020 ChiCTR
A
randomiz
ed trial of
efficacy
and
safety of
an early
OUTpatie
nt
treatmen
t of
COVID-19
in
patients
with risk
factor for
poor
outcome :
a strategy
to
prevent
hospitaliz
ation :
OUTCOV
Study
-
OUTCOV
EUCTR20204-May-20 A randomize GROUPE HO4/8/2020 20200408 6/26/2020 EU Clinical

EUCTR20204-May-20 Early Trea Proactive Prophylaxis with
Chronic
A Ob ### 20200321 6/26/2020 EU Clinical
A double-
blind,
randomiz
ed study
versus
placebo
of
avdoralim
ab
(IPH5401)
, an anti-
C5aR
antibody,
in
patients
with
COVID-19
induced
pneumon
ia
- FORCE
(FOR
COVID-19
Eliminatio
n)
EUCTR20204-May-20 A double-b ASSISTANC ### 20200414 6/26/2020 EU Clinical

EUCTR20204-May-20 Evaluation Evaluation of the concent
Randomiz
ed
controlle
Randomiz d trial
ed evaluatin
controlle g the
d trial efficacy
evaluatin of
g the vaccinatio
efficacy n with
of Bacillus
vaccinatio Calmette
n with and
Bacillus GuÃ©rin
Calmette (BCG) in
and the
GuÃ©rin Preventio
(BCG) in n of
the COVID-19
Preventio via the
n of strengthe
COVID-19 ning of
via the innate
strengthe immunity
ning of in Health
innate Care
immunity Workers.
in Health â€
Care COVID-
Workers. BCG
â€ - COVID
COVID- BCG
EUCTR20204-May-20 BCG Assistance ### 20200417 6/26/2020 EU Clinical
EUCTR20204-May-20 Study with Phase I/II clinical trial Red Andalu ### 20200427 6/26/2020 EU Clinical
EUCTR20204-May-20 Plasma tur Plasma turnover in patients
FundaciÃ³ ClÃnic per
###a20200427
la recerca BiomÃ¨dica
6/26/2020 EU Clinical
EUCTR20204-May-20 Efficacy an Double-blind, randomiz
Banc de San ### 20200427 6/26/2020 EU Clinical
EUCTR20204-May-20 PreventionPrevention and treatment
FundaciÃ³n
with ### 20200427 6/26/2020 EU Clinical
EUCTR20204-May-20 Pilot study Pilot study of single-dose
FundaciÃ³n
b ### 20200427 6/26/2020 EU Clinical
EUCTR20204-May-20 Study to evA Phase II, randomizedOryzon Gen ### 20200427 6/26/2020 EU Clinical
EUCTR20204-May-20 Recombinan
Recombinant human angiotens
APEIRON Bi ### 20200323 6/26/2020 EU Clinical
EUCTR20204-May-20 Evaluation A prospective, randomized
UniversitÃ 4/7/2020 20200407 6/26/2020 EU Clinical
EUCTR20204-May-20 CHROLOQUICHROLOQUINE PHOSPHATE
Uni-Pharma
AG ### 20200331 6/26/2020 EU Clinical
EUCTR20204-May-20 A clinical The NOR Solidarity multicen
Oslo Univer ### 20200324 6/26/2020 EU Clinical
EUCTR20204-May-20 Efficacy a Efficacy and safety of Department4/1/2020 20200401 6/26/2020 EU Clinical
NCT04273 ### Evaluating Evaluating the Effica Second Aff ### 20200214 6/26/2020 ClinicalTria
NCT04308 ### Post-exposPost-exposCOVID-19 University ### 20200311 6/26/2020 ClinicalTria

NCT04318 ### HypertensiHypertensiHT-COVID1Zhenhua Z ### 20200320 6/26/2020 ClinicalTria
NCT04321 ### The ImpactThe ImpactCamoCO-1 University ### 20200323 6/26/2020 ClinicalTria
NCT04328 ### Reducing HReducing HBCG-CORO UMC Utrec ### 20200327 6/26/2020 ClinicalTria
NCT04328 ### The ECLA PThe ECLA PCOLCOVID Estudios ClÃnicos ###
Latino
20200330
AmÃ©rica
NCT04329 ### The PATCH The PATCH PATCH Ravi Amara ### 20200330 6/26/2020 ClinicalTria
NCT04334 ### Randomized

PreventionEPICOS Plan Nacion4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04335 ### Tocilizuma CORON-ACTCORON-ACUniversity 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04338 ### Ruxolitini A Phase-II RuxCoFlamUniversity 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04344 ### Cohort of Prospectiv IBD-COVID Nantes Univ4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04344 ### Evaluate t An Open-LaCOVID-19 Perseveran 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04345 ### Preventing Preventing COVID-HEPUniversity 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04347 ### Anti-Interl A Randomized Phase 2Matthew Da4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04348 ### A RandomizA Randomized, Double-

Hope Biosc ### 20200414 6/26/2020 ClinicalTria
NCT04349 ### A Clinical A Phase II, Open LabelHope Biosc 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04351 ### PRophylaxiUse and DoPRECISE Government ### 20200414 6/26/2020 ClinicalTria
NCT04352 ### Efficacy a Treatment of Acute ReAzidus Bras ### 20200415 6/26/2020 ClinicalTria
NCT04353 ### Trial of Hy A RandomizTHICK University ### 20200325 6/26/2020 ClinicalTria
NCT04355 ### EpidemioloCohort Stu COVISEP Assistance ### 20200417 6/26/2020 ClinicalTria
NCT04356 ### Nebulised A Pilot, Op PACA University ### 20200414 6/26/2020 ClinicalTria
NCT04356 ### Analysis o Analysis o COVID-TGTCentre Hosp ### 20200416 6/26/2020 ClinicalTria
NCT04358 ### Prone Posi Evaluation of Prone P University ### 20200416 6/26/2020 ClinicalTria
NCT04359 ### A ComparisA Comparison of 3D a NHS Greate ### 20200416 6/26/2020 ClinicalTria
NCT04359 ### Nebulised A Single-s COVASE University ### 20200421 6/26/2020 ClinicalTria
NCT04359 ### Bacterial Bacterial MICROVID University H ### 20200421 6/26/2020 ClinicalTria
NCT04359 ### COVID-19 Pa

Pragmatic Trial Explo Vanderbilt ### 20200420 6/26/2020 ClinicalTria
NCT04359 ### Plasma TherA Phase 2, RandomizedMax R. O'D ### 20200421 6/26/2020 ClinicalTria
NCT04361 ### Atrium COVA Prospective Study o Michael R ### 20200422 6/26/2020 ClinicalTria
NCT04361 ### Low-dose LDouble-bli GETAFE Hospital Un ### 20200423 6/26/2020 ClinicalTria
NCT04361 ### Cardiovasc Cardiovascular PrevenKlinikum d ### 20200420 6/26/2020 ClinicalTria
NCT04361 ### Treatment Double Bli COVID_MSRed de Ter ### 20200417 6/26/2020 ClinicalTria
NCT04362 ### Passive Imm

A Randomize
PassItOnII Vanderbilt ### 20200421 6/26/2020 ClinicalTria
NCT04362 ### Longitudin Incidence PRECOVIA University H ### 20200423 6/26/2020 ClinicalTria
NCT04362 ### Clinical F Clinical Features and University ### 20200420 6/26/2020 ClinicalTria
NCT04363 ### Arkansas E Arkansas Expanded AcUniversity ### 20200423 6/26/2020 ClinicalTria
NCT04363 ### Immune CelImmune Cells and the University ### 20200420 6/26/2020 ClinicalTria
NCT04363 ### AzithromycAzithromycAziA Nantes Univ ### 20200423 6/26/2020 ClinicalTria
NCT04363 ### HydroxychlHydroxychlHCQPreP Louisiana S ### 20200423 6/26/2020 ClinicalTria
NCT04364 ### NGS DiagnoNGS DiagnoCOVID-19 University ### 20200422 6/26/2020 ClinicalTria
NCT04365 ### HydroxychlEfficacy E HASCOPT Hospital St ### 20200423 6/26/2020 ClinicalTria
NCT04365 ### Protective Protective PEAC Xijing Hosp ### 20200424 6/26/2020 ClinicalTria
NCT04365 ### Become of BPecome of CPOVIDGHPSGroupe Hosp ### 20200426 6/26/2020 ClinicalTria
NCT04365 ### Prehospita Safety and Efficacy o Lazarski Un ### 20200424 6/26/2020 ClinicalTria
NCT04365 ### NutriCovid3Evaluation of the RepeUniversity ### 20200424 6/26/2020 ClinicalTria
NCT04366 ### A Novel NoA Novel Nomogram toXinqiao Ho ### 20200421 6/26/2020 ClinicalTria
NCT04366 ### Mesenchyma

Mesenchymal Stem Cell
Royan Insti ### 20200420 6/26/2020 ClinicalTria
NCT04366 ### Oxygen-OzoOxygen-OzoPROBIOZO Roberto Po ### 20200422 6/26/2020 ClinicalTria

NCT04366 ### Impact of Impact of COVIPACT Centre Fra ### 20200416 6/26/2020 ClinicalTria
NCT04366 ### Patient Re An ObservaCardiacCovBarts & Th ### 20200424 6/26/2020 ClinicalTria
NCT04366 ### Evaluation Multicentric Study to Biosearch S ### 20200427 6/26/2020 ClinicalTria
NCT04366 ### Factors AssFactors Associated WitCentre Hos ### 20200419 6/26/2020 ClinicalTria
NCT04366 ### Intravascu Intraosseous Versus I Lazarski Un ### 20200423 6/26/2020 ClinicalTria
NCT04366 ### RepurposinRepurposinreCoVery Centre Hosp ### 20200424 6/26/2020 ClinicalTria

NCT04366 ### Thrombo Em
Thrombo Em
THROMBOCCentre Hosp ### 20200427 6/26/2020 ClinicalTria
NCT04366 ### PsychologicPsychologi COVMUM Assistance ### 20200420 6/26/2020 ClinicalTria
NCT04366 ### PROne PosiPROne PosiPROVID Assistance ### 20200426 6/26/2020 ClinicalTria
NCT04366 ### Minimal In Increasing MIA-COVIDJessa Hospi ### 20200422 6/26/2020 ClinicalTria
NCT04366 ### PreventionPreventionCOVIDIOL MaimÃ³nide ### 20200425 6/26/2020 ClinicalTria
NCT04366 ### European/EEuropean/EEuroECMOMaastricht ### 20200417 6/26/2020 ClinicalTria

NCT04366 ### Intravascu Comparison of IntraosLazarski Un ### 20200423 6/26/2020 ClinicalTria
NCT04366 ### Internatio InternationIRCEP Pregistry ### 20200423 6/26/2020 ClinicalTria
NCT04367 ### To Study t To Study t SCOPe Max Healthc ### 20200426 6/26/2020 ClinicalTria
NCT04367 ### Electrocar Electrocar ELCOVID University ### 20200416 6/26/2020 ClinicalTria
NCT04367 ### Rapid DeteRapid DeteCOR-DIAL- University H ### 20200427 6/26/2020 ClinicalTria
NCT04367 ### Prospectiv Prospective Registry University ### 20200428 6/26/2020 ClinicalTria
NCT04367 ### Social MedGetting it Right: Tow Jean Liu ### 20200417 6/26/2020 ClinicalTria
NCT04367 ### COST (COviCOST (COviCOST ACTI Azienda Os ### 20200417 6/26/2020 ClinicalTria
NCT04367 ### The Effect The Effect OCAT University ### 20200420 6/26/2020 ClinicalTria
NCT04367 ### Antibody RAntistof R COVCKD Region Mid ### 20200427 6/26/2020 ClinicalTria
NCT04367 ### Cardiac Inj Pathology and PathogeA.O. Osped ### 20200427 6/26/2020 ClinicalTria
NCT04367 ### COVID-19 IImpact of COVID19-CCentre Hosp ### 20200427 6/26/2020 ClinicalTria
NCT04367 ### ARMOR StuSARS-CoV-2 SeroprevaColumbia U ### 20200428 6/26/2020 ClinicalTria
NCT04367 ### COVID-19 COVID-19 OUTBREAK Fondazione ### 20200427 6/26/2020 ClinicalTria
NCT04368 ### Host-pathoHost-pathoCoVUm Johan Nor ### 20200427 6/26/2020 ClinicalTria
NCT04368 ### Registry t Registry to Study Fac Iqvia Pty L ### 20200428 6/26/2020 ClinicalTria
NCT04368 ### COVID-19 COVID-19 IMSEQ Institute o ### 20200427 6/26/2020 ClinicalTria
NCT04368 ### Study Asse A Prospect SAVIOR Carlos Tor ### 20200420 6/26/2020 ClinicalTria
NCT04368 ### Impact of Impact of DEPRECOVPoitiers Un ### 20200428 6/26/2020 ClinicalTria

NCT04368 ### Duke COVIDDuke Shared Data andDuke Unive ### 20200427 6/26/2020 ClinicalTria
NCT04368 ### Clinical V Clinical Validation o University ### 20200424 6/26/2020 ClinicalTria
NCT04368 ### TelemediciUse of Telemedicine f Chinese Un ### 20200425 6/26/2020 ClinicalTria
NCT04368 ### Psychologi Psychological Impairme

NCT04368 ### Lung Ultra Use of Lun COVILUS Centre Hosp ### 20200428 6/26/2020 ClinicalTria
NCT04368 ### Bacterioth Evaluation BACT-ovid University ### 20200427 6/26/2020 ClinicalTria
NCT04368 ### Enhanced PlPlatelet In PIC-19 University ### 20200423 6/26/2020 ClinicalTria
NCT04368 ### NeuroradiolImaging AnCOVID-19BUniversity ### 20200428 6/26/2020 ClinicalTria
NCT04368 ### Breath RegBreath RegBREATH Lawson Hea ### 20200426 6/26/2020 ClinicalTria
NCT04368 ### ObservatioA Prospective, Longit Max Healthc ### 20200429 6/26/2020 ClinicalTria
NCT04368 ### ARDS Caus Main Features and Ve Hospital Cl ### 20200427 6/26/2020 ClinicalTria
NCT04369 ### Repeated MA Repeated Measures Massachuse

T ### 20200423 6/26/2020 ClinicalTria
NCT04369 ### Anxiety An Prevalence Of Anxiet Max Healthc ### 20200428 6/26/2020 ClinicalTria
NCT04369 ### A Single-b A Single-blinded, Ran Prof. Dr. M ### 20200427 6/26/2020 ClinicalTria
NCT04369 ### Effectiven Effectiveness of Usin Lake Erie ### 20200424 6/26/2020 ClinicalTria
NCT04369 ### Efficacy a A Phase 3 Open-label, Alexion Ph ### 20200428 6/26/2020 ClinicalTria
NCT04369 ### The PsychoHow Are YoC19Survey University ### 20200420 6/26/2020 ClinicalTria
NCT04369 ### COVID-19: COVID-19: BATTLE University ### 20200427 6/26/2020 ClinicalTria
NCT04369 ### Mapping OrMapping OrCOVERSCA Perspectum ### 20200422 6/26/2020 ClinicalTria
NCT04369 ### ObservatioObservational Study oOSF Health ### 20200428 6/26/2020 ClinicalTria
NCT04370 ### Covid-19 E Impact of Stroke-CovUniversity ### 20200429 6/26/2020 ClinicalTria
NCT04370 ### ConstructioConstructioVIRUS Nantes Univ ### 20200428 6/26/2020 ClinicalTria
NCT04370 ### Accuracy o Accuracy ofPOCUSars- Ospedale d ### 20200429 6/26/2020 ClinicalTria
NCT04370 ### Provider B Exploring Provider B University ### 20200429 6/26/2020 ClinicalTria
NCT04371 ### Predictors Cardiovasc CARDICoVRIstituto Au ### 20200428 6/26/2020 ClinicalTria
NCT04371 ### Risk FactorRisk Factors, Clinical St. Jude Ch ### 20200424 6/26/2020 ClinicalTria
NCT04371 ### HydroxychlHydroxychlPROVIDE St. Joseph ### 20200428 6/26/2020 ClinicalTria
NCT04371 ### PrevalencePrevalenceEXPOCOVI University H ### 20200428 6/26/2020 ClinicalTria
NCT04372 ### Evaluation Evaluation of the Sle Saint-Josep ### 20200429 6/26/2020 ClinicalTria
NCT04372 ### SEVERITY VALIDATION OF A SEVFondazione ### 20200429 6/26/2020 ClinicalTria
NCT04372 ### ConvalesceConvalescent Plasma fUniversity ### 20200429 6/26/2020 ClinicalTria
ACTRN126 ### Study evaluRetrospective and proAlbury Wo ### 20200420 6/26/2020 ANZCTR
ACTRN126 ### Evaluation ReCOVER (Remote COVID

South Easte ### 20200428 6/26/2020 ANZCTR
ChiCTR200 ### Asymptomat Asymptomatic novel coronavi

A randomized,double blinded
Beijing Dit 5/9/2020 20200509 6/26/2020 ChiCTR
ChiCTR200 ### Correlatio Correlation between novel
The third X 5/9/2020 20200509 6/26/2020 ChiCTR
ChiCTR200 ### A Medical RThe Clinical Efficacy and

Institute o 5/9/2020 20200509 6/26/2020 ChiCTR
ChiCTR200 ### The effecti The effectiveness of dia

ChiCTR200 ### Clinical tr Clinical trial for the wasThe First A 5/8/2020 20200508 6/26/2020 ChiCTR
ChiCTR200 ### Efficacy a Efficacy and safety of hi

Xi'an Inter 5/8/2020 20200508 6/26/2020 ChiCTR
ChiCTR200 ### High dose High dose intravenousRuijin

vit Hosp 5/8/2020 20200508 6/26/2020 ChiCTR
ChiCTR200 ### Study for t Study for the application

Union
of Hosp 5/6/2020 20200506 6/26/2020 ChiCTR
ChiCTR200 ### Follow-up Follow-up study of pregnanc
Union Hosp 5/5/2020 20200505 6/26/2020 ChiCTR
ChiCTR200 ### Study for A randomized, double-bli

ISRCTN680 ### A global r Pregnancy and Neonatal

Imperial C ### 20200430 6/26/2020 ISRCTN
Efficacy of
captopril
nebulizati
on in
Covid-19
patients
suffering
of SARS-
CoV-2
pneumon
ia.
A
randomiz
ed phase
II study
-
CAPTOCO
VID
EUCTR2020 ### Efficacy of ASSISTANC ### 20200411 6/26/2020 EU Clinical

EUCTR2020 ### Evaluation A Phase 2, RandomizedAB Science 4/6/2020 20200406 6/26/2020 EU Clinical
EUCTR2020 ### An open labA pragmatic adaptive open
InflaRx G 4/3/2020 20200403 6/26/2020 EU Clinical
EUCTR2020 ### Losartan anLosartan and spironolactone
ASSISTANC ### 20200415 6/26/2020 EU Clinical
EUCTR2020 ### Study of e Phase 3 multicenter, raNovartis P ### 20200415 6/26/2020 EU Clinical
EUCTR2020 ### Study of e Phase 3 multicenter, raNovartis P ### 20200415 6/26/2020 EU Clinical
EUCTR2020 ### Low-molecuEffectiveness of low CHRU de N ### 20200416 6/26/2020 EU Clinical
"STUDY
OF THE
EFFICIENC
Y OF
NORMAL
HUMAN
IMMUNO
GLOBULI
NS (IVIG)
IN
PATIENTS
AGED 75
YEARS
AND
OVER
COVID-19
WITH
SEVERE
ACUTE
RESPIRAT
ORY
FAILURE"
GERONIM
O 19
-
GERONIM
O19
EUCTR2020 ### "STUDY OF CH Versaill ### 20200416 6/26/2020 EU Clinical

EUCTR2020 ### CurosurfÂ®Preliminary randomized
Centre Hosp ### 20200416 6/26/2020 EU Clinical
EUCTR2020 ### EFFICACY EFFICACY OF INTRAV ASSISTANC ### 20200416 6/26/2020 EU Clinical
EUCTR2020 ### A Randomise
A Randomised Controlled
Chelsea an ### 20200417 6/26/2020 EU Clinical
EUCTR2020 ### Study of in Recombinant InterLeukin-7
RevImmune
( ### 20200415 6/26/2020 EU Clinical
EUCTR2020 ### A Randomize
A Randomized Open label
Ruprecht-Ka ### 20200420 6/26/2020 EU Clinical
EUCTR2020 ### A study of A multi-centre open-label
EUCTR2020 ### Sinus-WashCan a sinus rinse and mouth
Hampshire
w ### 20200427 6/26/2020 EU Clinical
EUCTR2020 ### BCG vaccinREDUCING ABSENCE FROM
National
W Ko ### 20200429 6/26/2020 EU Clinical
EUCTR2020 ### Ruxolitini Ruxolitinib therapy to Avoid
Guyâ€™s an ### 20200430 6/26/2020 EU Clinical
EUCTR2020 ### CLARITHROANTI-INFLAMMATORYHellenic
CLARIT In ### 20200430 6/26/2020 EU Clinical
EUCTR2020 ### DiscontinuaStopping ACE-inhibitors
Medizinisc
in COVID ### 20200326 6/26/2020 EU Clinical
EUCTR2020 ### Control of Control of inflammatory
VALL HEBR 5/5/2020 20200505 6/26/2020 EU Clinical
A
multicent
A er,
multicent randomiz
er, ed, active
randomiz controlle
ed, active d, open
controlle label,
d, open platform
label, trial on
platform the
trial on efficacy
the and
efficacy safety of
and experime
safety of ntal
experime therapeu
ntal tics for
therapeu patients
tics for with
patients COVID-19
with a (caused
lung by
disease infection
caused by with
coronavir severe
us acute
infection respirator
y
ACOVACT syndrome
(Austrian coronavir
CoronaVir us-2)
us
Adaptive ACOVACT
Clinical (Austrian
EUCTR2020 ### Trial) Coron Medical Un 4/9/2020 20200409 6/26/2020 EU Clinical
EUCTR2020 ### Impact of Impact of the use of low
FundaciÃ³
m 5/5/2020 20200505 6/26/2020 EU Clinical
EUCTR2020 ### Anti-il6 tr Effectiveness of InterleThe Parker ### 20200324 6/26/2020 EU Clinical
EUCTR2020 ### CLINICAL CLINICAL TRIAL OF THENAVARRABI5/5/2020
USE 20200505 6/26/2020 EU Clinical
EUCTR2020 ### Clinical tr Single-center, randomized,
FundaciÃ³n 5/5/2020 20200505 6/26/2020 EU Clinical
EARLY
TREATME
NT OF
PNEUMO
NIA
COVID-19
WITH
GLUCOCO
RTICOIDS.
EARLY RANDOM
TREATME IZED
NT OF CONTROL
PNEUMO LED
NIA CLINICAL
COVID-19 TRIAL -
WITH CORTIVID
GLUCOCO
RTICOIDS.
RANDOM
IZED
CONTROL
LED
CLINICAL
EUCTR2020 ### TRIAL NAVARRABI5/5/2020 20200505 6/26/2020 EU Clinical
Low dose
hydrocor
tisone in
patients
with
COVID-19
and
severe
hypoxia
â€“ the
COVID
STEROID
trial
- COVID-
STEROID
trial
EUCTR2020 ### Low dose h Deparment ### 20200330 6/26/2020 EU Clinical

EUCTR2020 ### PRE-EXPOSPRE-EXPOSURE PROPHYLAXIS
NAVARRABI5/7/2020
W 20200507 6/26/2020 EU Clinical
EUCTR2020 ### Ensayo clÃnAico
RANDOMIZATION,
aleatorizado paraMU
IDIVAL
investigar la5/8/2020
eficacia de20200508
la administraciÃ³n
6/26/2020 anticipada
EU Clinical
de la colchicina e
EUCTR2020 ### Early inter Pre-emptive tocilizumab
UMCG
in hyp 4/3/2020 20200403 6/26/2020 EU Clinical
EUCTR2020 ### Study of thRamdomised clinical trial
FundaciÃ³
of iv 5/8/2020 20200508 6/26/2020 EU Clinical
EUCTR2020 ### USE OF CO USE OF CORTICOSTEROID
IDIVAL Inst 5/8/2020 20200508 6/26/2020 EU Clinical
EUCTR2020 ### CLINICAL RANDOMIZED CLINICAL
Tatiana
T Co 5/8/2020 20200508 6/26/2020 EU Clinical
EUCTR2020 ### Pilot study Pilot study to evaluateClÃ
thenica
potUniversidad
5/8/2020de20200508
Navarra/Universidad
6/26/2020 EU
de Clinical
Navarra
EUCTR2020 ### Efficacy an A Multicenter, RandomInstituto Gr 5/8/2020 20200508 6/26/2020 EU Clinical
EUCTR2020 ### Study to EvA Multicenter, Randomiz
Instituto Gr 5/8/2020 20200508 6/26/2020 EU Clinical
NCT04324 ### DAS181 forDAS181 for Severe CORenmin Hos ### 20200325 6/26/2020 ClinicalTria
NCT04333 ### ApplicationApplication of Iron Ch Kermanshah4/1/2020 20200401 6/26/2020 ClinicalTria

NCT04337 ### Distress in Distress During the C Wefight 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04337 ### Ruxolitini Ruxolitinib Managed ANovartis P 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04342 ### A Study on A Study on the ProspeSecond Aff 4/4/2020 20200404 6/26/2020 ClinicalTria
NCT04343 ### An InvestigAn InvestigCOVIFERO Shahid Behe4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04345 ### A Study of A Randomized ControlCalciMedica4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04346 ### Post-ExposUse and DoPEACE Government ### 20200413 6/26/2020 ClinicalTria
NCT04350 ### Trial to St AdministratCOL-COVIDFundacion p ### 20200414 6/26/2020 ClinicalTria
NCT04354 ### HydroxychlA Multicen MOPHYDA King Husse 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04354 ### COVID-19 aThe COVID-CCC19 Vanderbilt ### 20200416 6/26/2020 ClinicalTria
NCT04354 ### COVID-19 :GenerationANTI-COV- Hospices Ci ### 20200417 6/26/2020 ClinicalTria
NCT04358 ### HyperbaricHyperbaricHBOTCOVI Assaf-Haro ### 20200421 6/26/2020 ClinicalTria
NCT04359 ### Increased Increased VTE-COVIDQuovadis A ### 20200421 6/26/2020 ClinicalTria

NCT04359 ### COVID-19 RCOVID-19 Recovered Vo
NCT04360 ### LevamisoleImpact of Levamisole Ain Shams ### 20200415 6/26/2020 ClinicalTria
NCT04361 ### AssessmentAssessmentTRONCHERAbderrahm ### 20200422 6/26/2020 ClinicalTria
NCT04364 ### The UniversEfficacy and Safety o University ### 20200422 6/26/2020 ClinicalTria
NCT04366 ### COVID-19 SCoronaviruCOVIVA University 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04369 ### Blood Bioma

Blood InnatPredictCov Centre Hosp ### 20200427 6/26/2020 ClinicalTria
NCT04369 ### C5a ReceptC5a ReceptC5-COV Assistance ### 20200429 6/26/2020 ClinicalTria
NCT04369 ### Obstetric Obstetric GROCO Assistance ### 20200429 6/26/2020 ClinicalTria
NCT04370 ### Management

Management
TeleCoviDi University ### 20200427 6/26/2020 ClinicalTria
NCT04370 ### Clinical Ap The Clinica Covid-19 Mashhad Un ### 20200429 6/26/2020 ClinicalTria
NCT04371 ### Nursing Pe Nursing Perspective onUniversity ### 20200429 6/26/2020 ClinicalTria
NCT04371 ### AvdoralimaA Double-bFORCE Assistance ### 20200429 6/26/2020 ClinicalTria

NCT04371 ### Efficacy of Efficacy o MG-COVIDAssistance ### 20200429 6/26/2020 ClinicalTria
NCT04371 ### Covid-19 P Covid-19 P STC-19 Groupe Hos ### 20200430 6/26/2020 ClinicalTria
NCT04371 ### Blood BiomBlood Inna PredictCov Centre Hosp ### 20200428 6/26/2020 ClinicalTria
NCT04371 ### Predicting Predicting ICU Admiss Fondazione ### 20200430 6/26/2020 ClinicalTria
NCT04371 ### Safety and Safety and Effectiven Fuzhou Gen ### 20200325 6/26/2020 ClinicalTria
NCT04371 ### Changes in Changes in COVID-HO Hasselt Uni ### 20200430 6/26/2020 ClinicalTria
NCT04371 ### COHIVE: CoCOVID-19 in People Li Kirby Insti ### 20200428 6/26/2020 ClinicalTria
NCT04371 ### Impact of Impact of the COVID- Laval Unive ### 20200422 6/26/2020 ClinicalTria
NCT04371 ### Povidone I Povidone I KILLER Poitiers Un ### 20200429 6/26/2020 ClinicalTria
NCT04371 ### Efficacy an Efficacy and Safety of Rabin Medi ### 20200430 6/26/2020 ClinicalTria
NCT04372 ### Health CareUtilisation US3R UniversitÃ ### 20200422 6/26/2020 ClinicalTria
NCT04372 ### HydroxychlEfficacy o HYdILIC University H ### 20200430 6/26/2020 ClinicalTria
NCT04372 ### SQuISH-COV

SQuISH-COVID: A PilotCytovale, I ### 20200429 6/26/2020 ClinicalTria
NCT04372 ### EpidemioloEpidemiology and OutcSemmelweis ### 20200429 6/26/2020 ClinicalTria
NCT04372 ### Duvelisib A Pilot Study of Duve Washington ### 20200430 6/26/2020 ClinicalTria
NCT04372 ### WeanINg FrWeanINg FrINVICTUS University ### 20200430 6/26/2020 ClinicalTria
NCT04372 ### Unplanned Unplanned (COVID-19)Kasr El Ain ### 20200427 6/26/2020 ClinicalTria
NCT04373 ### Screening A Research Platform t University ### 20200430 6/26/2020 ClinicalTria
NCT04373 ### Stroke Reh Stroke Reh SROCL Jeremia He ### 20200416 6/26/2020 ClinicalTria
NCT04373 ### UnderstandUnderstanding ImmuniStanford Un ### 20200430 6/26/2020 ClinicalTria
NCT04373 ### Evaluation Evaluation of the Flui Erzincan Un ### 20200430 6/26/2020 ClinicalTria
NCT04373 ### Using BCG Using BCG Vaccine to Bandim Hea5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04373 ### Peer ChampPeer Champion Support

Mount Sina ### 20200430 6/26/2020 ClinicalTria
NCT04373 ### Incidence Incidence COVID-APEUniversity ### 20200430 6/26/2020 ClinicalTria

NCT04373 ### A RandomisA RandomisPIONEER Chelsea an 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04373 ### Max IvermeTo Study the Effectiv Max Healthc ### 20200426 6/26/2020 ClinicalTria
NCT04374 ### Less Frequ Reduced Frequency Hem

Dialisis Ma 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04374 ### Early Short Early Short Course CorHenry Ford ### 20200430 6/26/2020 ClinicalTria
NCT04374 ### COVID-19 SCOVID-19 Serologic ScInstituto ### 20200420 6/26/2020 ClinicalTria
NCT04374 ### TherapeutiInterventional Study Prisma Hea ### 20200420 6/26/2020 ClinicalTria
NCT04374 ### COVID-19 PEffect of SARS- COVID Acibadem U ### 20200429 6/26/2020 ClinicalTria
NCT04374 ### Anosmia ReOlfactory Retraining Lawson Hea ### 20200429 6/26/2020 ClinicalTria
NCT04374 ### A Phase II, A Phase II, Open Labe Max Healthc ### 20200429 6/26/2020 ClinicalTria
NCT04374 ### Plasma ExcPlasma ExcREP-COVIDFundacion 5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04374 ### Asymptomat

RCT in Asy ACT Rutgers, Th 5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04374 ### Renin-AngiAssociatio COVHYP Versailles 5/3/2020 20200503 6/26/2020 ClinicalTria

NCT04374 ### HydroxychlHydroxychlCOVID19- King Husse 5/3/2020 20200503 6/26/2020 ClinicalTria
NCT04375 ### MonocytesStudy

a of Immune-media
UniversitÃ degli
5/3/2020
Studi 20200503
dell'Insubria
NCT04375 ### Colchicine Treatment COLVID-19 University ### 20200429 6/26/2020 ClinicalTria
NCT04251 ### Treatment Effects of Traditiona Beijing 302 ### 20200128 6/26/2020 ClinicalTria
NCT04280 ### Adaptive C A Multicenter, AdaptivNational In ### 20200220 6/26/2020 ClinicalTria
NCT04322 ### BiomarkersBiomarkersB-DT-COV2University ### 20200323 6/26/2020 ClinicalTria
NCT04326 ### The GReek TShe GReek G

S RECCO-1 National an ### 20200326 6/26/2020 ClinicalTria
NCT04333 ### HydroxychlA Prospective Clinical Baylor Rese 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04333 ### Safety in Phase 1 Study to Eval Hospital S ### 20200331 6/26/2020 ClinicalTria
NCT04333 ### CROWN COR

An InternatCROWN C Washington ### 20200331 6/26/2020 ClinicalTria
NCT04336 ### Randomized

Randomized Compariso
Rutgers, Th ### 20200331 6/26/2020 ClinicalTria
NCT04336 ### CAPTION AIUse of CaptCAPTION ADuke Unive 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04340 ### Safety and Safety and Efficacy of University 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04341 ### Will Hydro Will Hydro WHIP COVIHenry Ford 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 ### A Clinical A QuadruplGARGLES Aga Khan U 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04341 ### Study of I Efficacy o CORIMUNOAssistance 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04342 ### HealthcareHealthcare Worker Ex Duke Unive 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04343 ### Study of thStudy of thSTOP-COVIBrigham an 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04343 ### A Randomize

A Randomized Placebo-c
NYU Lango 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 ### COvid-19 aCOvid-19 and Vitamin University 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04346 ### Feasibilit Feasibility and Accept Chinese Un 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04348 ### Safety and Safety and Efficacy of University ### 20200413 6/26/2020 ClinicalTria
NCT04349 ### Evaluation A Phase 2 RCoronaviruKaryopharm ### 20200414 6/26/2020 ClinicalTria
NCT04351 ### Low-flow ELow-flow ExtracorporeUniversity 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04353 ### InternationA Prospect ILUSA KU Leuven ### 20200416 6/26/2020 ClinicalTria
NCT04353 ### Renal OutcRenal Outcome in PatiUniversity 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04354 ### CardiovascuPrediction Nancy-Cov Central Hos ### 20200414 6/26/2020 ClinicalTria
NCT04355 ### Inhaled Co Treatment With InhaleSara Varea ### 20200415 6/26/2020 ClinicalTria
NCT04356 ### COVID-19 aImpact of SCHIZOVIDUniversity ### 20200419 6/26/2020 ClinicalTria
NCT04357 ### MyocardialMyocardialMODIF French Car ### 20200419 6/26/2020 ClinicalTria
NCT04357 ### Kerecis Or Use of a M KONS-COVIKerecis Ltd ### 20200420 6/26/2020 ClinicalTria
NCT04359 ### COVID-19 aCOVID-19 and the DevMedical Uni ### 20200421 6/26/2020 ClinicalTria
NCT04359 ### Long-term Long-term CV-COVID- Hospital Cl ### 20200421 6/26/2020 ClinicalTria
NCT04362 ### COVID-EC StClinical Characteristi Hospital Sa ### 20200423 6/26/2020 ClinicalTria
NCT04363 ### COVID 19 BCOVID-19 Inflammatory
NCT04363 ### PharmacoloPharmacologic AscorbiThomas Jef ### 20200423 6/26/2020 ClinicalTria
NCT04363 ### COlchicine COlchicine COMBATCOMaimonides ### 20200423 6/26/2020 ClinicalTria
NCT04363 ### Serology C Serology C ROCOCO Centre Hosp ### 20200424 6/26/2020 ClinicalTria
NCT04365 ### Attention Attention Bias Modifi Tel Aviv Un ### 20200424 6/26/2020 ClinicalTria
NCT04366 ### Study of thStudy of thCOVIDSMEInstitut Pa ### 20200422 6/26/2020 ClinicalTria

NCT04367 ### African Co African Covid-19 Criti University ### 20200427 6/26/2020 ClinicalTria
NCT04368 ### Acute CardAcute CardJoCORE Jordan Col ### 20200426 6/26/2020 ClinicalTria
NCT04370 ### HydroxychlEfficacy and Safety of Services In ### 20200427 6/26/2020 ClinicalTria
NCT04370 ### Changes in Changes in PreferenceRegion Zea ### 20200424 6/26/2020 ClinicalTria
NCT04371 ### Study of R Mental Health ImplicaErasme Uni ### 20200422 6/26/2020 ClinicalTria
NCT04371 ### Sirolimus A Randomize

SirCO-1 Walter K. K ### 20200428 6/26/2020 ClinicalTria
NCT04372 ### ComparisonComparisonCATCH COVTexas Card ### 20200429 6/26/2020 ClinicalTria

NCT04373 ### Home PulseUtilizing Home Pulse Swedish Ho ### 20200430 6/26/2020 ClinicalTria
NCT04373 ### COVID-19 ASARS-COV-2COVHECBESciensano ### 20200413 6/26/2020 ClinicalTria
NCT04374 ### Novel AgentRandomized, Multi-arm

Susanne Ar 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04374 ### Clinical T An Open-label, ProspeBosnalijek ### 20200430 6/26/2020 ClinicalTria
NCT04374 ### Testing fo Testing fo COVIDANS Centre Hosp ### 20200430 6/26/2020 ClinicalTria
NCT04374 ### Level and Level and Predictors University 5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04374 ### Drug Safet Prospectiv COR-CARD Institute o ### 20200422 6/26/2020 ClinicalTria
NCT04374 ### Trial to P A Phase II RECOVER Sidney Kim 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04374 ### SARSCoV2 (Severe Acute Respirat AdventHea 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04374 ### Risk of Ve Risk of Venous ThrombHospital Un 5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04374 ### Effect of Effect of COVID-19 Pa South Egypt5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04374 ### Does HydroProtecting HEROs Megan Lan ### 20200430 6/26/2020 ClinicalTria
NCT04375 ### Correlatio Correlation Between OShahid Behe5/3/2020 20200503 6/26/2020 ClinicalTria
NCT04375 ### Impact of Impact of tCOVIDPRO Hospices Ci 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04375 ### Hospital ReHospital ReMYOCOVIDUniversity ### 20200421 6/26/2020 ClinicalTria
NCT04375 ### Verificatio Verificatio VADER Cliniques u ### 20200417 6/26/2020 ClinicalTria
NCT04376 ### Survey: COSurvey on COVID Cliniques u 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04376 ### HarnessingHOPE Intervention fo University o ### 20200331 6/26/2020 ClinicalTria
NCT04376 ### PET/CT Ima18F-avÃŸ6-binding-pepUniversity 5/3/2020 20200503 6/26/2020 ClinicalTria

NCT04376 ### Surgical T Surgical Telemedicine University 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04376 ### Exchange TExchange TCOVID-19 Ain Shams 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04376 ### CoronaWatc

CoronaWatc
CoronaWatUniversity ### 20200420 6/26/2020 ClinicalTria
NCT04376 ### Extra VascuAssessmentPiCCOVID University ### 20200416 6/26/2020 ClinicalTria
NCT04376 ### Barrier MeaEvaluating EMBELLIE University 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04376 ### Slovenian Slovenian SLO-COVIDUniversity 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04377 ### The Role o The ECHOVID-19 StudyUniversity 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04377 ### Parental S Parenting in a PandemUniversity 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04377 ### Fluoxetine Fluoxetine to Reduce University ### 20200418 6/26/2020 ClinicalTria
NCT04377 ### Risk Facto Risk Facto MindCOVI Zelazna Me 5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04377 ### COVID-19 Pr

COVID-19 PNeuro-Cov Aarhus Univ ### 20200429 6/26/2020 ClinicalTria
NCT04377 ### COVID-19 -COVID-19 - Quality of LChinese Un 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04377 ### COVID-19 PPilot Stud COLOR-19 Azienda Soc5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04377 ### Tocilizuma Comparison of the Eff Hospital S 5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04377 ### Efficacy o CONCOR-KID
CONCOR-K The Hospita ### 20200430 6/26/2020 ClinicalTria
NCT04377 ### COVID-19 HCOVID-19 Health Messa

Milton S. ### 20200430 6/26/2020 ClinicalTria
NCT04377 ### A Study of A Study of COVID-MiliMilitary Ho 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04377 ### The Use of The Use of Tocilizum Hadassah M ### 20200423 6/26/2020 ClinicalTria
NCT04377 ### Developeme

Developeme
SEROCOV Assistance 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04377 ### Safe Retur Safe Return to Regula King Fahad 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04377 ### Finding Ou FORECAST SFORECAST University ### 20200424 6/26/2020 ClinicalTria
NCT04377 ### Safety and A Randomized, Open-La

Massachuse5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04378 ### CORONA: ACORONA: ACORONA Aveni Foun 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04378 ### Efficacy o Efficacy of Therapist Sultan Qab 5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04378 ### AssessmentAssessmentCOM-COVI FundaciÃ³ I ### 20200415 6/26/2020 ClinicalTria
NCT04378 ### Assessing Assessing Pediatric F University 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04378 ### Platelet Co Does the Platelet Cou Konya Trai 5/3/2020 20200503 6/26/2020 ClinicalTria
NCT04378 ### Simulation Simulation of Risk of Tabula Ras 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04379 ### Vagus NervVagus Nerve Stimulati Nemechek 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04379 ### Neurologic Neurologic ManifestatUniversity ### 20200430 6/26/2020 ClinicalTria
NCT04379 ### Analysis of Analysis of VOC-COVI Hopital Fo ### 20200428 6/26/2020 ClinicalTria
NCT04379 ### Surgical Ac Surgical Ac SurgiCovid Hospices Ci 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04379 ### COVID-19 IStudy of thCOVIDHIVPHospices Ci 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04379 ### COvid-19 NCOvid-19 NCON-VINCELuxembourg5/6/2020 20200506 6/26/2020 ClinicalTria

NCT04379 ### BCG VaccinReducing Morbidity anTASK Appli 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04379 ### Geriatric Geriatric GEROCOVI Raffaele An 5/3/2020 20200503 6/26/2020 ClinicalTria
NCT04379 ### Effector anEffector anCovRep Assistance 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04379 ### Clinical Ef AssessmentFUTURE-T National Po 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04379 ### Rintatolim Phase 1/2A Study of RRoswell Par 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04379 ### SUNLIGHT SSUNLIGHT Study: OnlinColumbia U 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04380 ### Study of t An International, Mul R-Pharm In 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04380 ### Describing Describing Chinese HeCenter for 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04380 ### A Pilot Stu A Pilot Study Evaluati Washington5/6/2020 20200506 6/26/2020 ClinicalTria
ISRCTN878 ### Investigat Characterization of oralUniversity
micr 5/5/2020 20200505 6/26/2020 ISRCTN
ISRCTN208 ### Survive andSurvive and Thrive: explorin

University 5/4/2020 20200504 6/26/2020 ISRCTN
ISRCTN970 ### COVID-19 so
Enforced social isolation
University
an 5/4/2020 20200504 6/26/2020 ISRCTN
ISRCTN106 ### The COVID-The COVID-19 Emergency
North
Resp
Brist ### 20200423 6/26/2020 ISRCTN
ChiCTR200 ### Novel coronA safety and immune response

Beijing TIL ### 20200517 6/26/2020 ChiCTR
ChiCTR200 ### A multicentA multicenter, randomize

Wuhan Thir ### 20200515 6/26/2020 ChiCTR

A randomized controllHongqi Hosp ### 20200515 6/26/2020 ChiCTR
ChiCTR200 ### Epidemiolog
Epidemiological, clinical
Fifth
andAffil ### 20200515 6/26/2020 ChiCTR
ChiCTR200 ### The duratioThe duration and influen

ChiCTR200 ### Rapid DeteRapid Detection 2019-nCoV
Southeast
via Su ### 20200513 6/26/2020 ChiCTR
ChiCTR200 ### Clinical st Clinical study of novel Shanghai

coro Pu ### 20200226 6/26/2020 ChiCTR
ChiCTR200 ### A MulticenA Multicenter, Randomized
West China 2/8/2020 20200208 6/26/2020 ChiCTR

ACTRN126 ### Randomised

Randomised controlledUNSW
tria ### 20200511 6/26/2020 ANZCTR
ACTRN126 ### ADAPT - COADAPT - COVID-19 Study

St Vincent
- ### 20200511 6/26/2020 ANZCTR
ACTRN126 ### InternationTherapies to prevent pr

AProf Dr Ka ### 20200511 6/26/2020 ANZCTR
BEAT
COVID-
19: A
Phase III
Bayesian
adaptive
randomis
ation
platform
controlle
d trial to
evaluate
the
efficacy
of drug
interventi
ons for
COVID-19
on
hospital
admission
or death
in the
communi
ty setting
for high
risk older
people
ACTRN126 ### Randomised University ### 20200514 6/26/2020 ANZCTR

IRCT20200 ### Pirfenidin The evaluation of pirfenid
Kermanshah ### 20200420 6/26/2020 IRCT
IRCT20150 ### Tocilizuma Evaluation of the safetyAryogen
and P ### 20200412 6/26/2020 IRCT
IRCT20200 ### Efficacy of Evaluation the efficacyTehran
of Tu Uni ### 20200328 6/26/2020 IRCT
IRCT20190 ### Atorvastat Atorvastatin effect in Cli
Mazandaran ### 20200419 6/26/2020 IRCT
IRCT20171 ### RemdesivirA single-arm multicenter Tehran Uni ### 20200412 6/26/2020 IRCT
IRCT20200 ### ComparisonComparison of the effect Abadan
of Uni ### 20200329 6/26/2020 IRCT
IRCT20200 ### Efficacy e Efficacy evaluation of an
Mashhad Un ### 20200328 6/26/2020 IRCT
IRCT20200 ### UmifenovirEvaluation of the efficacy
Center
a for 4/3/2020 20200403 6/26/2020 IRCT
IRCT20160 ### The effect Assessment of the effectBagheiat-al
of ### 20200420 6/26/2020 IRCT
IRCT20190 ### Interferon Efficacy and safety evaluati
Mazandaran ### 20200411 6/26/2020 IRCT
IRCT20160 ### The effect Evaluation of the effectKerman
of Uni ### 20200416 6/26/2020 IRCT
IRCT20200 ### Effect of Evaluation of Methylpredni
Shiraz Univ 4/8/2020 20200408 6/26/2020 IRCT
IRCT20180 ### Effect of o Formulation and evaluation
Tehrano Uni 4/1/2020 20200401 6/26/2020 IRCT
IRCT20130 ### ComparativComparative assessment Kermanshah
o ### 20200330 6/26/2020 IRCT
IRCT20200 ### The effica Evaluation of the effi Mashhad Un4/2/2020 20200402 6/26/2020 IRCT
IRCT20161 ### Evaluation Study of the Efficacy ofIran
TeicUniver 4/8/2020 20200408 6/26/2020 IRCT
IRCT20151 ### Effect of Effect of Algomed, Menta Semnan Uni4/8/2020 20200408 6/26/2020 IRCT
IRCT20130 ### Evaluation Evaluation the efficacyShahid
and s Behe4/8/2020 20200408 6/26/2020 IRCT
IRCT20180 ### The effect The comparison of effectGhoum Univ4/3/2020 20200403 6/26/2020 IRCT
IRCT20130 ### ComparativComparative assessment
Kermanshah ### 20200422 6/26/2020 IRCT
IRCT20081 ### Effect of Clinical trial of berberine

Mashhad
agains Un4/7/2020 20200407 6/26/2020 IRCT
IRCT20200 ### Effect of h Effects of Viroherb ca Tehran Uni 4/9/2020 20200409 6/26/2020 IRCT
IRCT20200 ### The effecti Evaluation of efficacy Mazandaran ### 20200412 6/26/2020 IRCT
IRCT20131 ### AssessmentAssessment of effect ofShiraz
levamis
Univ 5/4/2020 20200504 6/26/2020 IRCT
IRCT20200 ### Evaluation Evaluation the effect ofMashhad
aq Un ### 20200412 6/26/2020 IRCT
IRCT20200 ### Evaluating Evaluating the therapeutic
Ahvaz e Univ 4/9/2020 20200409 6/26/2020 IRCT
IRCT20080 ### Effect of Evaluation of the effectHomaPhar
o 4/8/2020 20200408 6/26/2020 IRCT
IRCT20200 ### Investigati Investigation of the effect
Deouty
o of ### 20200413 6/26/2020 IRCT
IRCT20200 ### The effect The effect of adding SOVODAK
Mazandaran ### 20200411 6/26/2020 IRCT
IRCT20200 ### ComparisonRandomzied trial of additi
Iranian Mi 4/6/2020 20200406 6/26/2020 IRCT
IRCT20151 ### TherapeuticEvaluation of the therape
Semnan Uni ### 20200410 6/26/2020 IRCT
IRCT20130 ### Post-exposProspective post-exposure
Tabrizhydr
Univ ### 20200412 6/26/2020 IRCT
IRCT20180 ### The ImpactThe effect of family-centere
Torbate-Hei ### 20200410 6/26/2020 IRCT
IRCT20200 ### Effect of Evaluation of the effectMazandaran
o ### 20200420 6/26/2020 IRCT
IRCT20151 ### Evaluation Evaluation the efficacyShahid
an Behe ### 20200410 6/26/2020 IRCT
IRCT20200 ### PreventionEffect of Hydroxychloroquine
Mashhad Un ### 20200414 6/26/2020 IRCT
IRCT20200 ### The effect A comparison of Elderber
Mashhad Un ### 20200412 6/26/2020 IRCT
IRCT20200 ### Efficacy o Evaluating efficacy of Ke
Ardabil Uni 4/8/2020 20200408 6/26/2020 IRCT
IRCT20200 ### evaluation Safety and efficacy o Bagheiat-al 4/8/2020 20200408 6/26/2020 IRCT
IRCT20200 ### Effect of Effect of Bromhexine Hydroch
Tabriz Univ ### 20200414 6/26/2020 IRCT
IRCT20200 ### Efficacy an Randomized, parallel-con
Artesh Univ ### 20200415 6/26/2020 IRCT
IRCT20180 ### Evaluation Comparison of the effectiven
Saveh Univ ### 20200410 6/26/2020 IRCT
IRCT20081 ### Effect of Clinical trial of minocycline
Mashhad
agai Un ### 20200411 6/26/2020 IRCT
IRCT20081 ### Effect of c Clinical trial of the effect
Mashhad Un ### 20200411 6/26/2020 IRCT
IRCT20200 ### Effect of T Evaluation of the EffectBirjand Uni ### 20200414 6/26/2020 IRCT
IRCT20200 ### Dose-Findi Dose-Finding study of Chistasaza
Ivermect ### 20200427 6/26/2020 IRCT
IRCT20180 ### Early trac The comparison between Theearly
Univers ### 20200413 6/26/2020 IRCT
IRCT20200 ### IntravenouTo evaluate the effectivenesTabriz Univ ### 20200411 6/26/2020 IRCT
IRCT20200 ### Treatment Treatment of COVID-19-induced
Tabriz Univc ### 20200419 6/26/2020 IRCT
IRCT20200 ### Evaluating Evaluating the therapeutic Ahvaz efUniv ### 20200413 6/26/2020 IRCT
IRCT20180 ### Evaluation Investigating the effectShahid
of Behe ### 20200410 6/26/2020 IRCT
IRCT20160 ### Evaluation Evaluation of the effectBagheiat-al
of ### 20200430 6/26/2020 IRCT
IRCT20200 ### The effect The effect of IL-6 inhibitor
Tabriz Univ ### 20200414 6/26/2020 IRCT
IRCT20150 ### Efficacy of Evaluation of safety and Ardabil Uni ### 20200411 6/26/2020 IRCT
IRCT20130 ### Effect of i Comparison of interactive Shiraz Univ 5/1/2020 20200501 6/26/2020 IRCT
IRCT20200 ### The effect Evaluation of the role of Iran Univer ### 20200426 6/26/2020 IRCT
IRCT20200 ### Effect of The effect of plasma adminisMashhad Un ### 20200412 6/26/2020 IRCT
IRCT20200 ### Evaluation Evaluation of SinaCurcumin Mashhad Un ### 20200418 6/26/2020 IRCT
IRCT20200 ### Mesenchyma Mesenchymal Stem Cell Iranian
Therapac ### 20200413 6/26/2020 IRCT
IRCT20200 ### Effect of I Evaluation of effectiveness?
Tehran Uni ### 20200414 6/26/2020 IRCT
IRCT20080 ### Investigati Investigating the efficacyCenter
an for ### 20200415 6/26/2020 IRCT
IRCT20200 ### Evaluation Evaluation of the efficacy Artesh
a Univ ### 20200422 6/26/2020 IRCT
IRCT20190 ### The effect Prevention of COVID-19 Iran
dise
Univer ### 20200416 6/26/2020 IRCT
IRCT20200 ### The effect Evaluation of adding melatoni
Mazandaran ### 20200417 6/26/2020 IRCT
IRCT20200 ### Efficacy of Efficacy of convalescent
Tabriz
pla Univ ### 20200422 6/26/2020 IRCT
IRCT20200 ### Evaluation Evaluation the effect ofMashhad
as Un ### 20200415 6/26/2020 IRCT
IRCT20081 ### Effect of l Clinical trial of lithium Mashhad

in i Un ### 20200426 6/26/2020 IRCT
IRCT20200 ### Evaluation Evaluation of the efficaGonabad Un ### 20200429 6/26/2020 IRCT
IRCT20200 ### Effect of A Evaluating the efficacyIslamic
of A Aza 5/4/2020 20200504 6/26/2020 IRCT
IRCT20191 ### Effect of Comparison of the effectivenBagheiat-al ### 20200418 6/26/2020 IRCT
IRCT20200 ### effect of I effect of Interfron-beta1(zif
Zist Daru 5/8/2020 20200508 6/26/2020 IRCT
IRCT20200 ### Placental MPlacental Mesenchymal Execution
Stem ce 5/4/2020 20200504 6/26/2020 IRCT
IRCT20200 ### The effecti The effectiveness of edEsfahan Uni5/7/2020 20200507 6/26/2020 IRCT
IRCT20200 ### Use of Con Experimental Use of COVID-1
Hilton Phar ### 20200428 6/26/2020 IRCT
IRCT20200 ### Effect of p Determining the effectFasa
of s Univer ### 20200421 6/26/2020 IRCT
IRCT20170 ### Effect of The efficacy of inhaledNational
formoteRe ### 20200429 6/26/2020 IRCT
IRCT20200 ### Effect eval Effect evaluation of herJahrom Uni ### 20200421 6/26/2020 IRCT
IRCT20200 ### ComparisonComparison between the Birjand
ef Uni ### 20200417 6/26/2020 IRCT
IRCT20200 ### The effect Effect of Intravenous immu
Gonabad Un5/4/2020 20200504 6/26/2020 IRCT
IRCT20200 ### The effect The effect of herbal drugs
Saveh Univ ### 20200419 6/26/2020 IRCT
IRCT20200 ### The effect Safety and EffectivenessTehran
of a Uni ### 20200420 6/26/2020 IRCT
IRCT20200 ### Effect of The effect of pomegranateShahre-kor
te ### 20200423 6/26/2020 IRCT
IRCT20200 ### Effect of N Evaluating the safety and
Middle
ef Eas ### 20200424 6/26/2020 IRCT
IRCT20200 ### Plasma theUse of convalescent plasma
ShahidinBehe ### 20200421 6/26/2020 IRCT
IRCT20200 ### Evaluation Evaluation of the protecEsfahan Uni5/3/2020 20200503 6/26/2020 IRCT
IRCT20200 ### Stem cell Investigation the adiposeKermanshah5/5/2020 20200505 6/26/2020 IRCT
IRCT20140 ### Effect of n The Effect of a PersianSocial
Natu Dev ### 20200428 6/26/2020 IRCT
IRCT20200 ### TrifluoperaEvaluation of Trifluoperazine
Rasht Unive5/2/2020 20200502 6/26/2020 IRCT
IRCT20080 ### Investigat Investigating the efficacy
Niakofpharm ### 20200422 6/26/2020 IRCT
IRCT20151 ### The prophyThe prophylactic effectArakof Hy
Univer5/4/2020 20200504 6/26/2020 IRCT
IRCT20200 ### ?EvaluationEvaluation the efficacyShahid
and safBehe ### 20200423 6/26/2020 IRCT
IRCT20200 ### Efficacy of Therapeutic Effect of Tenof
Ardabil Uni ### 20200425 6/26/2020 IRCT
IRCT20080 ### Evaluation Evaluation efficacy of Andisheh
a S ### 20200425 6/26/2020 IRCT
IRCT20200 ### Clinical tr Comparison of the Effectiv
Ahvaz Univ ### 20200429 6/26/2020 IRCT
IRCT20200 ### Evaluation Evaluation of colchicine Mashhad Un ### 20200425 6/26/2020 IRCT
IRCT20180 ### Effect of Investigating the effectSanandaj
of D U 5/1/2020 20200501 6/26/2020 IRCT
IRCT20200 ### The effect Evaluation of the effectHamedan
of Un ### 20200428 6/26/2020 IRCT
IRCT20120 ### Effect of p Effect of plasma of patients
Hamedan Un ### 20200427 6/26/2020 IRCT
IRCT20140 ### ComparisonComparison of three metho Sabzevar Un5/4/2020 20200504 6/26/2020 IRCT
IRCT20180 ### The effect The effect of zinc on theEsfahan
trea Uni ### 20200513 6/26/2020 IRCT
IRCT20200 ### Evaluation Efficacy and safety of Isfahan
oral Uni 5/5/2020 20200505 6/26/2020 IRCT
IRCT20121 ### Effect of c Effect of curcumin-pipeEsfahan Uni5/4/2020 20200504 6/26/2020 IRCT
IRCT20200 ### Effect of o The Effect of InhalationShooshtar
o 5/2/2020 20200502 6/26/2020 IRCT
IRCT20080 ### Investigati Investigating the efficacy
Sinaa Darou 5/1/2020 20200501 6/26/2020 IRCT
Sinaa Darou 5/1/2020 20200501 6/26/2020 IRCT
IRCT20200 ### Study the Study of the effectiveness
Kermanshah5/1/2020 20200501 6/26/2020 IRCT
IRCT20150 ### The Effect The Effect of Convalescent
Ardabil
PlaUni 5/9/2020 20200509 6/26/2020 IRCT
IRCT20200 ### effects of Investigation of the effects
Oroumia Un5/4/2020 20200504 6/26/2020 IRCT
IRCT20131 ### The effect Evaluation of the effectMazandaran
of her 5/8/2020 20200508 6/26/2020 IRCT
Bagheiat-al
o 5/5/2020 20200505 6/26/2020 IRCT
IRCT20160 ### The effect The effect of addition ofSabzevar Un5/5/2020 20200505 6/26/2020 IRCT
IRCT20171 ### Evaluation Efficacy of jujube product
Semnan
in a Uni5/7/2020 20200507 6/26/2020 IRCT
IRCT20200 ### effect of p The effect of propolis suppl
Abadan Uni 5/9/2020 20200509 6/26/2020 IRCT
IRCT20200 ### Evaluation Evaluation of the efficacy
Kowsar Bio ### 20200513 6/26/2020 IRCT
IRCT20200 ### RadiotheraAssessment of adding Shahid
low dosBehe ### 20200512 6/26/2020 IRCT
IRCT20120 ### Evaluating Evaluating the effect Hamedan Un ### 20200512 6/26/2020 IRCT
KCT000500 ### Psychiatric Psychiatric Consultation
Daegu
for COVID
Cath ### 20200511 6/26/2020 CRIS
KCT000500 ### Clinical e Treatment effect of Nafamost
Gyeongsang ### 20200511 6/26/2020 CRIS
JPRN-jRCT ### A MulticentA Multicenter, Adaptive Ohmagari ### 20200324 6/26/2020 JPRN
JPRN-UMIN ### COVID-19 RCOVID-19 Registry - COVID-19
NationalRegis
C ### 20200319 6/26/2020 JPRN
JPRN-UMIN ### MulticenterMulticenter observational
Tokyos Univ ### 20200415 6/26/2020 JPRN
Evaluatin
g the
social
function
of people
with
dementia
under the
COVID-19
epidemic
by the
Evaluatin Japanese
g the version of
social the social
function functionin
of people g in
with dementia
dementia scale -
under the Evaluatin
COVID-19 g the
epidemic social
by the function
Japanese of people
version of with
the social dementia
functionin under the
g in COVID-19
dementia epidemic
JPRN-UMIN ### scale Department ### 20200418 6/26/2020 JPRN
JPRN-UMIN ### A MulticentA Multicenter, Retrospective
Kanagawa C ### 20200421 6/26/2020 JPRN
JPRN-UMIN ### Examination Examination of test accuracy
JA Akita Ko ### 20200425 6/26/2020 JPRN
JPRN-UMIN ### Changes of Changes of D-dimer in Nihonpre Univ ### 20200430 6/26/2020 JPRN
JPRN-UMIN ### Had COVID-Had COVID-19 Spread Nagasaki
in Nag U 5/8/2020 20200508 6/26/2020 JPRN
JPRN-UMIN ### Study on r Study on risk perception TheanUniver ### 20200511 6/26/2020 JPRN
JPRN-UMIN ### Simulation Simulation study of trach Tokyo Wome 5/1/2020 20200501 6/26/2020 JPRN
JPRN-UMIN ### Prospectiv Prospective observational Japanese
study R 5/2/2020 20200502 6/26/2020 JPRN
JPRN-UMIN ### Impacts of Impacts of COVID-19 on Takasaki
f Un5/8/2020 20200508 6/26/2020 JPRN
JPRN-UMIN ### A feasibili A feasibility study of r Tokyo Medi ### 20200515 6/26/2020 JPRN
CTRI/2020 ### Hydroxy ChHydroxy Chloroquine, Dr
in Remesh ### 20200331 6/26/2020 CTRI
CTRI/2020 ### Screening Max COVID Study Max Super S4/1/2020 20200401 6/26/2020 CTRI
CTRI/2020 ### Knowledge,Knowledge, attitudes, Kand
M fear
Amran 4/1/2020 20200401 6/26/2020 CTRI
Viral
Infection
and
Respirato
ry illness
Universal
Study:
COVID-19
Registry
and
Validation
of C2D2
(Critical
Care Data
Dictionar
y)
CTRI/2020 ### Viral Infec Discovery 4/3/2020 20200403 6/26/2020 CTRI

CTRI/2020 ### Study of thOpen labelled Randomised
COMMAND
con 4/7/2020 20200407 6/26/2020 CTRI
CTRI/2020 ### AssessmentOutbreak of Respiratory

DACH
Tr Jaipu ### 20200415 6/26/2020 CTRI
CTRI/2020 ### Study of S An open labelled trial to
SSVevPhytop ### 20200415 6/26/2020 CTRI
CTRI/2020 ### COVID-19 DFormulation of a Clinical

CARING
data M ### 20200417 6/26/2020 CTRI
CTRI/2020 ### Study to E Evaluation of Effect of Superinten
Composi ### 20200420 6/26/2020 CTRI
Topical
Chloroqui
ne Nasal
Drops in
Early
Stage
Covid 19-
Impact on
Topical Viral load
Chloroqui and cure
ne Nasal rates
Drops in
Early
Stage
Covid 19-
Impact on
Viral load
and cure
rates
CTRI/2020 ### All India I ### 20200420 6/26/2020 CTRI
CTRI/2020 ### ComparisonA prospective, longitudMax Health ### 20200421 6/26/2020 CTRI
CTRI/2020 ### EFFECTIVE EFFECTIVENESS OF SIMULAT

GSL MEDIC ### 20200421 6/26/2020 CTRI
CTRI/2020 ### Study to asA Phase II, Open Label,Indian
R Cou ### 20200421 6/26/2020 CTRI
An
internatio
nal
randomis
ed trial of
additional
treatmen
ts for
COVID-19
in
hospitalis
ed
patients
who are
all
receiving
the local
standard
of care -
SOLIDARI
TY TRIAL
CTRI/2020 ### A clinical World Heal ### 20200421 6/26/2020 CTRI

CTRI/2020 ### Study to E A Multicenter, Phase ISerum Insti ### 20200421 6/26/2020 CTRI
CTRI/2020 ### Imatinib in Efficacy of Imatinib in mild
All India
SARI ### 20200422 6/26/2020 CTRI
CTRI/2020 ### Evaluation Evaluation of safety and

Internation
effica ### 20200422 6/26/2020 CTRI
CTRI/2020 ### Novel Arti Novel Artificial Intellig Dr Mahesh ### 20200422 6/26/2020 CTRI
PREVALE
NCE OF
SYMPTO
MS OF
ANXIETY
AND
DEPRESSI
ON
DURING
COVID-19
IN INDIA:
A WEB-
BASED
CROSS-
SECTIONA
L STUDY
CTRI/2020 ### ANXIETY A Dr Sameer ### 20200422 6/26/2020 CTRI

CTRI/2020 ### Impact of CImpact of Covid-19 on Department
practice pa ### 20200422 6/26/2020 CTRI
CTRI/2020 ### BCG-Denmar

Effect of BCG-DenmarkDr(Gree
Naraya ### 20200424 6/26/2020 CTRI
CTRI/2020 ### A Clinical A clinical trial to evaluate
Cadila Pha ### 20200424 6/26/2020 CTRI
CTRI/2020 ### Proving th Proving the efficacy ofWelling
Homeopa Hea ### 20200425 6/26/2020 CTRI
CTRI/2020 ### To Study t To Study the Clinical chara

Max Super S ### 20200425 6/26/2020 CTRI
Ã¢??To
study the
effectiven
ess of
Ivermecti
n with
Ã¢??To standard
study the of care
effectiven treatmen
ess of t
Ivermecti versus
n with standard
standard of care
of care treatmen
treatmen t for
t COVID 19
versus cases. A
standard Pilot
of care Study
treatmen
t for
COVID 19
cases. A
Pilot
CTRI/2020 ### Study Max Super S ### 20200425 6/26/2020 CTRI
CTRI/2020 ### A study to Effect of an Ayurvedic Ministry

Formul o ### 20200427 6/26/2020 CTRI
Randomis
ed
Controlle
d Trial to
compare
efficacy
of
hydroxyc
hloroquin
e alone
and in
combinati
on with
azithromy
cin in
treatmen
t of
COVID-19
- HAZES
CTRI/2020 ### Treatment Director G ### 20200428 6/26/2020 CTRI

Randomiz
ed
controlle
d Single
blinded
prospecti
ve multi
centre
clinical
trial to
investigat
e the
safety
and
efficacy
of
ZingiVir-H
as an
adjuvant
therapy in
hospitaliz
ed adults
diagnose
d with
coronavir
us
disease
2019
(COVID-
19)
CTRI/2020 ### Clinical re Pankajakas ### 20200428 6/26/2020 CTRI
CTRI/2020 ### CharacterisEpidemiology and clinical

Dr Sulagna
cha ### 20200429 6/26/2020 CTRI
CTRI/2020 ### A Phase II, A Phase II, Open Label,Max
Ra Super S ### 20200429 6/26/2020 CTRI
CTRI/2020 ### A clinical EFFICACY OF HYDROXYCHLO
Lady Hardi ### 20200430 6/26/2020 CTRI
CTRI/2020 ### A study to EFFICACY OF ORAL NICLOSA
Lady Hardi ### 20200430 6/26/2020 CTRI
CTRI/2020 ### Clinical t Drug Proving & checking
Dr its
Priti
effe
kat ### 20200430 6/26/2020 CTRI
CTRI/2020 ### Clinical tr A Prospective, Open label

MiLab LifeS 5/1/2020 20200501 6/26/2020 CTRI
CTRI/2020 ### Efficacy an A Multi-Centre, Open label,
Biocon Biol 5/1/2020 20200501 6/26/2020 CTRI
Effect of
adjuvant
homoeop
athy with
standard
treatmen
t protocol
in
managem
ent of
covid-19:
a
randomis
ed, open
label,
placebo
controlle
d, parallel
group
study
CTRI/2020 ### Homoeopath Naiminath 5/1/2020 20200501 6/26/2020 CTRI
CTRI/2020 ### The use of Effectiveness of topicalWIN MEDIC 5/1/2020 20200501 6/26/2020 CTRI
CTRI/2020 ### Clinical s Ã¢??Clinical evaluati Dabur Indi 5/2/2020 20200502 6/26/2020 CTRI
CTRI/2020 ### Effects of USAGE OF HYDROXYCHLORO

ALL INDIA 5/2/2020 20200502 6/26/2020 CTRI
Usage of
topical
lignocaine
to
decrease
the gag
reflex
Usage of while
topical sampling
lignocaine for Covid-
to 19: Does
decrease it affect
the gag the yield
reflex of
while
sampling specimen
for Covid- ?
19: Does
it affect
the yield
of
specimen
CTRI/2020 ### ? AIIMS New 5/2/2020 20200502 6/26/2020 CTRI
Effect of
COVID 19
pandemic
on the
teaching
and
training
of
Anaesthe
siology
postgradu
ate
students.
A
questionn
aire
based
survey
CTRI/2020 ### How has th Sanjay Gan 5/3/2020 20200503 6/26/2020 CTRI
CTRI/2020 ### HydroxychlGeneric Protocol on Hydrox
Indian cou 5/4/2020 20200504 6/26/2020 CTRI
CTRI/2020 ### MechanismPutative role of TMPRSS2

Asian
a ser
Heal 5/4/2020 20200504 6/26/2020 CTRI
CTRI/2020 ### HOMOEOPAT
EFFECTIVENESS OF ARSENIC
Central Co 5/4/2020 20200504 6/26/2020 CTRI
CTRI/2020 ### Evaluation Phase 2 Clinical Trial for

Medical
the Ed 5/5/2020 20200505 6/26/2020 CTRI
CTRI/2020 ### Hydroxychlo
An open label randomised
AIIMS Depa 5/5/2020 20200505 6/26/2020 CTRI
CTRI/2020 ### A randomizA randomized controlled

George
trial Inst 5/6/2020 20200506 6/26/2020 CTRI
CTRI/2020 ### RadiographiRadiographic findings and
Maxthei
Super S5/6/2020 20200506 6/26/2020 CTRI
CTRI/2020 ### A CLINICA PROVING THE EFFICACY

SAIOFNIDAN
HOMO5/6/2020 20200506 6/26/2020 CTRI
CTRI/2020 ### Ayurvedic IImpact of Ayurvedic Interven
Central Cou 5/7/2020 20200507 6/26/2020 CTRI
CTRI/2020 ### An ObservaAn Observational studyMAX

to SUPER5/7/2020 20200507 6/26/2020 CTRI
CTRI/2020 ### Can a medicA Phase IIB open label Christian M 5/7/2020 20200507 6/26/2020 CTRI
CTRI/2020 ### Clinical tr Driving pressure guideAll India I 5/8/2020 20200508 6/26/2020 CTRI
CTRI/2020 ### Study of G Observational Study ofcentral cou 5/9/2020 20200509 6/26/2020 CTRI
CTRI/2020 ### Effect of Effect of Hydroxychloroquin

SGPGIMS 5/9/2020 20200509 6/26/2020 CTRI
Observati
onal
Study of
YASHTIM
ADHU
TABLET
intake as
a
preventiv
e
measure
in
pandemic
of COVID-
19 Ã¢??
An open
label,
Randomiz
ed,
Controlle
d,
Prospecti
ve,
interventi
onal,
Communi
ty-based
Cclinical
study on
healthy
subjects
CTRI/2020 ### Study of ef Ministry o ### 20200511 6/26/2020 CTRI
CTRI/2020 ### Outcomes of

Clinical profile and outcomes
Science an ### 20200511 6/26/2020 CTRI
CTRI/2020 ### KnowledgeAwareness and practices
Siddha
re Cent ### 20200511 6/26/2020 CTRI
CTRI/2020 ### A Clinical A Randomized, Open-label

Glenmark P ### 20200512 6/26/2020 CTRI
CTRI/2020 ### Effect of A Evaluation of Efficacy and
Central Cou ### 20200513 6/26/2020 CTRI
CTRI/2020 ### Effect of Effect of alternate nostr
Jawaharlal ### 20200513 6/26/2020 CTRI
CTRI/2020 ### To study t A Randomized and Compar

Ms Shukla ### 20200513 6/26/2020 CTRI
Observati
onal
Study of
ASHWAG
ANDHA
TABLET
intake as
a
preventiv
e
measure
in
pandemic
of COVID-
19 Ã¢??
An open
label,
Randomiz
ed,
Controlle
d,
Prospecti
ve,
Interventi
onal,
Communi
ty-based
Clinical
study on
healthy
subjects
CTRI/2020 ### Study of A Ministry o ### 20200514 6/26/2020 CTRI

CTRI/2020 ### Evaluation Evaluation of the Immun
All India I ### 20200514 6/26/2020 CTRI
CTRI/2020 ### Evaluation Evaluation of Efficacy and

IntasSaPhar ### 20200514 6/26/2020 CTRI
CTRI/2020 ### Ayurveda prEvaluation of the Immuno-s
All India I ### 20200514 6/26/2020 CTRI
NCT04273 ### Efficacy an Efficacy and Safety of Beijing Cha ### 20200215 6/26/2020 ClinicalTria
NCT04278 ### Yinhu Qing Adaptive, Randomized,China Acad ### 20200219 6/26/2020 ClinicalTria
NCT04310 ### Yinhu Qing An Adaptive, RandomizZhong Wan ### 20200315 6/26/2020 ClinicalTria
NCT04322 ### Proactive Proactive ProPAC-COChronic Ob ### 20200323 6/26/2020 ClinicalTria
NCT04334 ### A Study of A RandomizHAZDpaC ProgenaBi 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04335 ### A Study of A RandomizHELPCOVIDProgenaBi 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04340 ### Oncology-pA Prospect ONCOVID University ### 20200331 6/26/2020 ClinicalTria
NCT04340 ### HydroxychlHydroxychlCOMIHY University 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04344 ### COVID-19 PCollection of COVID-1 Thomas Jef 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04346 ### Clinical Tr ProspectiveCovid-19H Hospital Un 4/7/2020 20200407 6/26/2020 ClinicalTria

NCT04346 ### Acalabruti A Phase 2, CALAVI AstraZenec 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04347 ### The Phase The Randomized, Open,

Bukwang P ### 20200414 6/26/2020 ClinicalTria
NCT04353 ### COVID 19-CComparisonCoSigS University ### 20200415 6/26/2020 ClinicalTria
NCT04354 ### DAS181 fo DAS181 for COVID-19:Ansun Biop ### 20200415 6/26/2020 ClinicalTria
NCT04355 ### Characteri Characteri COVID19@Fundacion ### 20200419 6/26/2020 ClinicalTria
NCT04356 ### Etoposide A Phase II Single-Cent Boston Med ### 20200417 6/26/2020 ClinicalTria
NCT04365 ### Study of I Study of I SINK COVI William Be ### 20200426 6/26/2020 ClinicalTria
NCT04366 ### Clinical Tr Phase II Cl MESCEL-COHospital In ### 20200423 6/26/2020 ClinicalTria
NCT04370 ### COVID-19 CCOVID-19 CCHAMPS Villanova U ### 20200427 6/26/2020 ClinicalTria
NCT04372 ### The COVID-A Norwegian Study onOslo Univer ### 20200429 6/26/2020 ClinicalTria
NCT04373 ### UnderstandA Study to UC-COVID University ### 20200430 6/26/2020 ClinicalTria
NCT04375 ### Recombinan

A RandomizBacterial Kafrelsheik 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04375 ### Quality of Health-related Qualit Kantonsspi 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04376 ### Host-pathoHost-pathoHPI-COVID Hospices Ci ### 20200428 6/26/2020 ClinicalTria
NCT04377 ### Thrombo Em

Thrombo Em
THROMBCOCentre Hosp5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04377 ### HaemoglobiAn Important Index onNevsehir Pu5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04378 ### Serologica A Comparative Study oUniversita 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04379 ### A Study to A Prospective, Multi-CImmunic A 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04379 ### Robot Assi Robot Assisted Percut Hospital Is ### 20200427 6/26/2020 ClinicalTria
NCT04379 ### A Study of Single-center, Phase Memorial S 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04379 ### Prognostic Prognostic CLUSCO University 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04380 ### Low-doses Single-centMICOV Federal Sta 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04380 ### Acalabruti A Phase 2, CALAVI US AstraZenec 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04380 ### Changes in Changes in the ConsumUniversity 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04380 ### Almitrine Almitrine and Severe Central Hos ### 20200428 6/26/2020 ClinicalTria
NCT04380 ### Covid-19 P Effects of PanCOVID Fondazione ### 20200421 6/26/2020 ClinicalTria
NCT04380 ### PrevalencePrevalenceBLEEDING Manuel Mo 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04380 ### PrevalencePrevalenceSCREENIN Manuel Mo 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04380 ### ROCO - SelfRandomized

ROCO University 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04380 ### Effectiven Effectiveness and Saf Indonesia U5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04380 ### Luxembourg

Luxembourg
Predi-COVILuxembourg ### 20200430 6/26/2020 ClinicalTria
NCT04381 ### QuarantineThe Impact of QuarantClinical Ex 5/7/2020 20200507 6/26/2020 ClinicalTria

NCT04381 ### Study for t A Randomized Placebo-
Columbia U 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04381 ### Oral Healt Oral Health and Psych Heidelberg 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04381 ### TranspulmoTranspulmoTRANSPUL University ### 20200423 6/26/2020 ClinicalTria
NCT04381 ### Direct and COVID-19 Chez

COVID-OLDUniversity
la Personne Ã¢gÃ©e de ###
Plus de
20200410
70 Ans :6/26/2020
Impact Direct
ClinicalTria
et Indirect Ã 3 Mois.
NCT04381 ### Rehabilita Pulmonary COVID_RE University 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04381 ### Inhalation Inhalation HALT Ola Blenn 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04381 ### Efficacy a A Multi-centre, AdaptiNPO Petro 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04381 ### Norwegian Norwegian SARS-CoV-2Oslo Univer 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04381 ### ConvalesceEfficacy and Safety o Centenario 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04381 ### Potential Phase II ,I GA&COVIDAl-Neelain 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04382 ### Co-infectioCo-infections in COVIDCliniques u 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04382 ### HypertonicHypertonicELVIS COVIUniversity 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04382 ### Impact of The ImpactCOVID-ImpUniversity 5/8/2020 20200508 6/26/2020 ClinicalTria

NCT04382 ### Non-invasi Management
WARd-COVUniversity 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04382 ### Egyptian InEgyptian Initial Exper Alexandria 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04382 ### A Cross-se A Cross-sectional and Peking Univ ### 20200426 6/26/2020 ClinicalTria
NCT04382 ### Coping Str Resting Heart Rate VarUniversity 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04382 ### HydroxychlHydroxychloroquine i Kootenai H ### 20200414 6/26/2020 ClinicalTria
NCT04382 ### Neuromuscu

Effects of NeuromuscuUniversity o5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04382 ### Zilucoplan A Prospect ZILU-COV University 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04382 ### Immunosupr
Effect of SAM-COVI Spanish Net5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04382 ### Novel Regi Novel Treatment Regi Tanta Unive5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04382 ### Safety and A Randomized Open Lab

Algernon P 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04383 ### High Dose IUse of High Dose Inha University 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04383 ### Safety and A Randomized, Double-B

Sinovac Re 5/9/2020 20200509 6/26/2020 ClinicalTria
NCT04383 ### Seropreval Seroprevalence of SARMayo Clini 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04383 ### Fear AmongFear and Practice Mo Cairo Unive ### 20200510 6/26/2020 ClinicalTria
NCT04383 ### Collection Collection COSiN Kirby Insti 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04383 ### Evaluation Evaluation COVER-PR Hospices Ci 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04384 ### The GenevaRetrospective ObservaFranÃ§ois ### 20200420 6/26/2020 ClinicalTria
NCT04384 ### Genetic BasGenetic Factors Influ Mansoura U ### 20200510 6/26/2020 ClinicalTria
NCT04384 ### Efficacy an A Multi-center, RandoTaoyuan Ge4/7/2020 20200407 6/26/2020 ClinicalTria

NCT04384 ### Death Numb
Real or Co DeathPerc University 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04384 ### Covid-19 P Patient Living With T McGill Univ 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04384 ### Efficacy o Randomized

COVID-BCGAssistance 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04384 ### COVID19-Co

Investigat FALP-COVI Fundacion ### 20200429 6/26/2020 ClinicalTria
NCT04385 ### Outcomes iCOVIDAge Study- HospUniversity ### 20200429 6/26/2020 ClinicalTria
NCT04385 ### Taiwan "AeTaiwan "Aerosol Box" V

NCT04278 ### PharmacokiPharmacokiPOPS or P Duke Unive ### 20200218 6/26/2020 ClinicalTria
NCT04307 ### Acute RespiAcute Respiratory Fai University ### 20200310 6/26/2020 ClinicalTria
NCT04311 ### Developmen

Development and VerifHuashan Ho ### 20200314 6/26/2020 ClinicalTria
NCT04323 ### Outcomes oOutcomes oCovidSurg University ### 20200325 6/26/2020 ClinicalTria
NCT04324 ### Prognostic Time of Re NIKE_C19 Catholic Un ### 20200325 6/26/2020 ClinicalTria
NCT04328 ### HydroxychlEfficacy of Hydroxych University ### 20200323 6/26/2020 ClinicalTria
NCT04331 ### An ObservaAn ObservaCOVID-19 Target Pha ### 20200331 6/26/2020 ClinicalTria
NCT04334 ### HealthcareHealthcareHERO-HCQAdrian Her 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04335 ### Sensor BaseSensor BaseHSC19 Lars Wik 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04335 ### Cardiovasc Screening CovCardio Centre Hosp4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04339 ### AssessmentAssessment of Exam FiUniversity 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04340 ### COVID-19 CPilot Study for Use o University 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04340 ### Low-dose HLow-dose HELEVATE Instituto N 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04341 ### Impact of Randomized

SOS-COVIDFondation 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04342 ### CoronaviruCoronaviruCOVIDAtoZThe Clevela 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04344 ### LunG canceObservatioGRAVID Spanish Lu 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 ### AssessmentAssessmentChilblainC Centre Hosp4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04345 ### Associatio Associatio COVCALL Fondation ### 20200410 6/26/2020 ClinicalTria
NCT04347 ### Impact of NImpact of Nasal SalineVanderbilt ### 20200411 6/26/2020 ClinicalTria
NCT04350 ### COVID-19 Remote Monitoring in Vivek Redd ### 20200414 6/26/2020 ClinicalTria
NCT04352 ### Cohort of Cohort of COVIDeF Assistance ### 20200331 6/26/2020 ClinicalTria
NCT04352 ### ExperimentExperimental Use of CHilton Pha ### 20200416 6/26/2020 ClinicalTria
NCT04352 ### PROLIFIC C ChemoPROphyLaxIs For

Cambridge 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04353 ### ConvalesceA Feasibility Study As Noah Meri ### 20200416 6/26/2020 ClinicalTria
NCT04354 ### Interferon Interferon ILIAD University ### 20200416 6/26/2020 ClinicalTria
NCT04354 ### A Study EvaAn Open Label, Phase 2Medical Co ### 20200414 6/26/2020 ClinicalTria
NCT04355 ### Kidney Inv Characteri COVKID Centre Hosp ### 20200417 6/26/2020 ClinicalTria
NCT04357 ### COVID-19 AKnowledge, Attitude, Assiut Univ ### 20200421 6/26/2020 ClinicalTria
NCT04357 ### Efficacy o Efficacy o AIRVM-CO Assistance ### 20200420 6/26/2020 ClinicalTria
NCT04358 ### Cardiac Ar Cardiac Arrhythmias I Vivek Redd ### 20200420 6/26/2020 ClinicalTria
NCT04361 ### Frequency aPrevalence and ClinicaCentre Hosp ### 20200422 6/26/2020 ClinicalTria
NCT04362 ### CoagulopatCoagulopathy of COVIDSt. Michael ### 20200420 6/26/2020 ClinicalTria
NCT04362 ### Cohort of PCohort of PCoCo-NeurAssistance ### 20200424 6/26/2020 ClinicalTria
NCT04363 ### Obstructiv Impact of OSACOVID-KoÃ§ Unive ### 20200419 6/26/2020 ClinicalTria
NCT04364 ### Anakinra f Efficacy a ANACOND University ### 20200417 6/26/2020 ClinicalTria
NCT04364 ### ObservatioObservatioCOVID-RPCAssistance ### 20200424 6/26/2020 ClinicalTria
NCT04364 ### COVID-19: P ovidone-IoPIIPPI Alexandra ### 20200425 6/26/2020 ClinicalTria
NCT04365 ### Study of Cl Study of Cl REACOVIMDirection ### 20200419 6/26/2020 ClinicalTria
NCT04365 ### Prazosin t Alpha-1 AdPREVENT Johns Hopk ### 20200424 6/26/2020 ClinicalTria
NCT04365 ### Stress Bio Stress Bio AUTONOMIDirection ### 20200424 6/26/2020 ClinicalTria
NCT04365 ### The Effect The Effect SIDIACO University ### 20200414 6/26/2020 ClinicalTria
NCT04365 ### MulticenterMulticenterREMDECO-Assistance ### 20200425 6/26/2020 ClinicalTria
NCT04367 ### MultiStem A Phase 2/ MACoVIA Athersys, I ### 20200427 6/26/2020 ClinicalTria
NCT04368 ### CharacterizCharacterizMY-CO-VIDRennes Uni ### 20200424 6/26/2020 ClinicalTria
NCT04378 ### Hydrogen/O

Effects of Hydrogen/OGuangzhou ### 20200429 6/26/2020 ClinicalTria
NCT04378 ### Immunophen

A Prospect IMPACC National In 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04378 ### A Study of A Study of LEAF-4L67 Institut d 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04379 ### InterLeuki A Multicen ILIAD-7-UK Revimmun 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04379 ### Analysis of Epidemiological AnalysHospital Un ### 20200422 6/26/2020 ClinicalTria
NCT04380 ### COVID-19 SCOVID-19 SCo-Stars Great Ormo5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04381 ### A Study of A Phase II RandomizedMemorial S 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04382 ### Study Asse A Prospect SAVIORII Allegheny S ### 20200414 6/26/2020 ClinicalTria
NCT04383 ### Collaborat Collaborat COH-FIT University ### 20200427 6/26/2020 ClinicalTria
NCT04384 ### Malaysian Olfactory and GustatorHospital S ### 20200510 6/26/2020 ClinicalTria
NCT04384 ### Predicting Predicting POCUS Stanford Un5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04384 ### Covid-19 InCovid-19 InCONNAITR Direction 5/9/2020 20200509 6/26/2020 ClinicalTria
NCT04384 ### CurosurfÂ®Randomized

Caards-1 Dr Christo 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04384 ### "Investiga ''(COVID-19) and Anx Kanuni Sul ### 20200511 6/26/2020 ClinicalTria
NCT04384 ### Accelerate Accelerate PROVENT- Nordsjaell ### 20200511 6/26/2020 ClinicalTria
NCT04384 ### Outcomes oOutcomes oCovidSurg- University ### 20200511 6/26/2020 ClinicalTria
NCT04385 ### Role of In Role of In CoVInnate Centre Hosp ### 20200510 6/26/2020 ClinicalTria
NCT04385 ### Hyperimmun

Efficacy a COV2-CP University 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04385 ### COVID-19 HCOVID-19 HCOV-HI University ### 20200420 6/26/2020 ClinicalTria
NCT04385 ### Trial of In A Randomised Double-b

Synairgen ### 20200424 6/26/2020 ClinicalTria
NCT04385 ### Predictive Identifica COVIDBioT University 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04385 ### PsychologicPsychologicFamilles-C University ### 20200416 6/26/2020 ClinicalTria
NCT04385 ### ConvalesceThe Use of ConvalesceHenry Ford 5/9/2020 20200509 6/26/2020 ClinicalTria
NCT04385 ### #StayHome:#StayHome:#StayHom Center for ### 20200421 6/26/2020 ClinicalTria
NCT04385 ### Cytokine A Cytokine A CYCOV-II Dr. Alexan ### 20200419 6/26/2020 ClinicalTria
NCT04385 ### Cognitive Cognitive CONNECT FundaciÃ³n 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04385 ### Use of Hig Use of High Flow NasaHÃ´pital L ### 20200511 6/26/2020 ClinicalTria
NCT04385 ### Demographi

Demographics and OutAtlantic H ### 20200511 6/26/2020 ClinicalTria
NCT04386 ### Investigati Investigating the Role Tameside G ### 20200510 6/26/2020 ClinicalTria
NCT04386 ### Preventing Preventing PROTECT-SUniversity ### 20200430 6/26/2020 ClinicalTria

NCT04386 ### Neurologic COVID-19 OCORONA University 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04386 ### Neonatal CNeonatal ComplicationUniversity ### 20200415 6/26/2020 ClinicalTria
NCT04386 ### Study on t Pilot Study on the UseASST Fateb 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04386 ### Immune Cha

Whole Blood
COVIDIMMCentral Hos 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04386 ### Covid-19 a Covid-19 and PreventiCentre Hosp ### 20200512 6/26/2020 ClinicalTria
NCT04386 ### Clinical E Ã‰pidÃ©mio

LymphoCo Versailles ### 20200512 6/26/2020 ClinicalTria
NCT04386 ### Detection oEvaluation SALICOV Centre Hosp ### 20200511 6/26/2020 ClinicalTria
NCT04386 ### Kidney Inj Prospective Parallel- I.M. Seche ### 20200511 6/26/2020 ClinicalTria
NCT04386 ### COVID-19 ICOVID-19 IHOP-COVI Assistance ### 20200430 6/26/2020 ClinicalTria
NCT04386 ### Study to E A Phase 3, Randomized,

Sorrento Th5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04387 ### The ImpactThe Effect of Patient Keimyung U ### 20200512 6/26/2020 ClinicalTria
NCT04387 ### Ocular SequOcular SequSOCOVID Fondation ### 20200512 6/26/2020 ClinicalTria
NCT04387 ### Protecting Protecting Health Car Aarogyam ### 20200513 6/26/2020 ClinicalTria
NCT04387 ### Dornase AlNebulized DACOVID Feinstein I ### 20200511 6/26/2020 ClinicalTria
NCT04387 ### Detection Observational Cohort Istituto Cl ### 20200513 6/26/2020 ClinicalTria
NCT04387 ### Analysis o Analysis of ACROVID Poitiers Un ### 20200429 6/26/2020 ClinicalTria
NCT04387 ### Epidemiolog

Epidemiolog
COVIDOR Raphael Se ### 20200512 6/26/2020 ClinicalTria
NCT04388 ### Safety and Phase 2b/3EPCOvid-1 Instituto N ### 20200512 6/26/2020 ClinicalTria
NCT04388 ### Screening PPRAISE@COVI

PRAISE@C University ### 20200512 6/26/2020 ClinicalTria
NCT04388 ### Assessing Assessing ASPIRE University 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04388 ### Survey of SDepartment of ChineseTaipei City ### 20200512 6/26/2020 ClinicalTria
NCT04388 ### COVID-19, Study of t CLOT Ramsay GÃ ### 20200513 6/26/2020 ClinicalTria
NCT04388 ### Epidemiolog

Epidemiolog
2019nCoV_Policlinico ### 20200512 6/26/2020 ClinicalTria
NCT04389 ### HSS Covid- Hospital for Special Hospital fo 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04389 ### AntimalariaAntimalarial and CovidAssiut Univ ### 20200511 6/26/2020 ClinicalTria
NCT04389 ### PROphylaxisPROphylaxisPROTECT Cambridge ### 20200512 6/26/2020 ClinicalTria
NCT04389 ### The Safety A Multicenter, Single- Windtree T ### 20200513 6/26/2020 ClinicalTria
NCT04390 ### Efficacy a A ProspectiCOVIDMESBanc de San5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04390 ### Malaysian Olfactory and GustatorHospital S ### 20200510 6/26/2020 ClinicalTria
NCT04390 ### ConvalescePlasma From Individu Joakim Dill ### 20200410 6/26/2020 ClinicalTria
NCT04390 ### Early CPAP Early Cont PAP-COVIDIcahn Scho ### 20200512 6/26/2020 ClinicalTria
NCT04394 ### Post-PandeEffects of COVID-19-R National Un ### 20200513 6/26/2020 ClinicalTria
To
compare
the
effectiven
ess of two
drugs
(hydroxyc
hloroquin
e and
lopinavir/
ritonavir
alone or
combined
in
treating
hospitaliz
ed
patients
with
confirme
d COVID-
19
compared
to
standard
of care
ACTRN126 ### Australasian COVID-19University 4/6/2020 20200406 6/26/2020 ANZCTR
ACTRN126 ### Tocilizuma Tocilizumab for the treatment

QIMR Bergh ### 20200519 6/26/2020 ANZCTR
ACTRN126 ### The safety The safety and efficacyGrand

of STCMedi ### 20200521 6/26/2020 ANZCTR
ACTRN126 ### Evaluation Evaluation of Shift, a sma

UNSW Sydne ### 20200515 6/26/2020 ANZCTR
ACTRN126 ### Prevalence Loss of SMELL as an earlY

Royal
marker
Nort ### 20200518 6/26/2020 ANZCTR
ACTRN126 ### In a simul Simulation time taken Mackay
am Hos ### 20200519 6/26/2020 ANZCTR
ACTRN126 ### PsychologicPsychological impact ofThe
COVI
Royal ### 20200521 6/26/2020 ANZCTR
ISRCTN405 ### Which treaA randomised phase IIUniversity

pro ### 20200515 6/26/2020 ISRCTN
ISRCTN852 ### Using bloo Investigating the use ofUniversida ### 20200511 6/26/2020 ISRCTN
ISRCTN441 ### School opeThe School Opening inNorwegian
the Ag I5/4/2020 20200504 6/26/2020 ISRCTN
ChiCTR200 ### The real-w The real-world study for

Thet Fifth M ### 20200523 6/26/2020 ChiCTR
ChiCTR200 ### Status of Status of managementBeijing
of surgery
Fri ### 20200523 6/26/2020 ChiCTR
ChiCTR200 ### Investigati Investigation of MentalBeijing

Statu Can ### 20200523 6/26/2020 ChiCTR
ChiCTR200 ### The resear The research Of novel The
coronav
First H ### 20200523 6/26/2020 ChiCTR
ChiCTR200 ### A follow-u A follow-up study about

Theclinic
First A ### 20200523 6/26/2020 ChiCTR

ChiCTR200 ### AssociationAssociations between Southern

subopti M ### 20200521 6/26/2020 ChiCTR
ChiCTR200 ### Clinical ch Clinical characteristics Department

and ### 20200521 6/26/2020 ChiCTR
ChiCTR200 ### Follow up Follow up study of convalescen

ChiCTR200 ### Clinical st Clinical study for rapidThe

detec
Third P ### 20200521 6/26/2020 ChiCTR

Thet First H ### 20200519 6/26/2020 ChiCTR
ChiCTR200 ### ConvalesceConvalescent Plasma inGuizhou

the treat
Pro ### 20200519 6/26/2020 ChiCTR
ChiCTR200 ### Novel coro Novel coronavirus pneumonia

ChiCTR200 ### The investi The investigation of psychos
Wuhan Ment ### 20200519 6/26/2020 ChiCTR
ChiCTR200 ### Efficacy of Efficacy of Early Prone Union

Po Hosp ### 20200519 6/26/2020 ChiCTR
ChiCTR200 ### Acute CareAcute Care Surgery during Oscar Cano ### 20200519 6/26/2020 ChiCTR
ChiCTR200 ### Effect of Effect of high dose intrav

Ruijin Hosp ### 20200518 6/26/2020 ChiCTR
ChiCTR200 ### A clinical A clinical study for theHongqi Hosp ### 20200518 6/26/2020 ChiCTR
ChiCTR200 ### An open, prAn open, prospective, Beijing

mult hos 2/5/2020 20200205 6/26/2020 ChiCTR
NL8536 ### NeurologicaNeurological Manifestations
Zuyderlan
of ### 20200415 6/26/2020 Netherlands
The use
of ACE2
receptor
increasing
medicatio
n at
hospital
The use admission
of ACE2 and
receptor mortality
increasing rates in
medicatio COVID-19
n at patiÃ«nts
hospital
admission
and
mortality
rates in
COVID-19
patiÃ«nts
NL8512 ### nonen 4/2/2020 20200402 6/26/2020 Netherlands
NL8551 ### Covid High Outcomes of patients with
Zuyderland
CO ### 20200423 6/26/2020 Netherlands
NL8501 ### Using eHeaUsing eHealth to support Interactive
CO 4/1/2020 20200401 6/26/2020 Netherlands
NL8522 ### The Digita The Digital Doc in the Emerge
none ### 20200412 6/26/2020 Netherlands
NL8523 ### Volatile An Volatile agents for sedation
University ### 20200413 6/26/2020 Netherlands
NL8562 ### Bioelectric Bioelectric ImpedanceNone
Analysis
(inves ### 20200421 6/26/2020 Netherlands
NL8563 ### Patientâ€™Patientâ€™s knowledge None
And beh ### 20200422 6/26/2020 Netherlands
NL8570 ### COVID-19 i Nosocomial COVID-19 Franciscus
infections in ### 20200429 6/26/2020 Netherlands
NL8529 ### General pr Monitoring patient flow MCCat gene
Omnes ### 20200414 6/26/2020 Netherlands
NL8572 ### PrevalencePrevalence of asymptomatic
UMCG deep ### 20200430 6/26/2020 Netherlands
NL8576 ### Effect van Effects of COVID-19 onStichting
quality oO ### 20200420 6/26/2020 Netherlands
NL8521 ### ContinuousContinuous positive airway
Raad prvan B ### 20200413 6/26/2020 Netherlands
NL8580 ### Metabolic Metabolic syndrome And NoneSeverity of ### 20200428 6/26/2020 Netherlands
NL8578 ### Alkaline phAlkaline phosphatase forRode Kruis 5/2/2020 20200502 6/26/2020 Netherlands
NL8577 ### Digital Car Randomized controlledAcademic
trial H5/6/2020 20200506 6/26/2020 Netherlands
NL8587 ### Quality of Quality of life in COVID-19
Boards of di 5/6/2020 20200506 6/26/2020 Netherlands
NL8589 ### Biomarker-Biomarker-based EarlyProf.Anti-infl
Dr. L. 5/7/2020 20200507 6/26/2020 Netherlands
NL8528 ### Control of Control of COVID-19 inUMChospita
Utrec ### 20200415 6/26/2020 Netherlands
NL8535 ### Functional Functional status and health
Board ofst D ### 20200415 6/26/2020 Netherlands
NL8538 ### Sleep positSleep position related None.
to hospi ### 20200417 6/26/2020 Netherlands
NL8513 ### COVID-19 i COVID-19 in rheumaticReade
patients:
Resea 4/7/2020 20200407 6/26/2020 Netherlands
NL8609 ### Enhancing Enhancing the BCG-inducedRadboudu ### 20200511 6/26/2020 Netherlands
NL8613 ### Serial mea Serial measurements inNone.
CO Inves ### 20200512 6/26/2020 Netherlands
NL8543 ### COVID19 ulCOVID19 ultrasound triageNone ### 20200418 6/26/2020 Netherlands
NL8625 ### Hocus POCUS Hocus POCUS: a tool forUMCincrUtrec ### 20200515 6/26/2020 Netherlands
NL8547 ### REDUCING REDUCING HOSPITAL ADMI Radboudu ### 20200422 6/26/2020 Netherlands
NL8627 ### Associatio Association of BMI with none
COVID-19 ### 20200518 6/26/2020 Netherlands
NL8526 ### NeuroinvasSARS-CoV-2 presence in Zuyderland
the ce ### 20200414 6/26/2020 Netherlands
NL8460 ### BiomarkersBiomarkers for prognosis nonein cri ### 20200316 6/26/2020 Netherlands
NL8473 ### Immunity aThird population-basedNational
immuneIn ### 20200323 6/26/2020 Netherlands
NL8483 ### A weapon aThe use of (social) mediaFred Found ### 20200326 6/26/2020 Netherlands
NL8485 ### COVID-19 dCOVID-19 during pregnancy:
MÃ¡xima a pro ### 20200327 6/26/2020 Netherlands
An open
label
randomiz
ed
controlle
An open d trial of
label chloroqui
randomiz ne,
ed hydroxyc
controlle hloroquin
d trial of e or only
chloroqui supportiv
ne, e care in
hydroxyc patients
hloroquin admitted
e or only with
supportiv moderate
e care in to severe
patients COVID-19
admitted
with
moderate
to severe
COVID-19
NL8490 ### UMC Utrec ### 20200331 6/26/2020 Netherlands
NL8491 ### CounteringCountering Lung Damage Amsterda
in COVID- ### 20200331 6/26/2020 Netherlands
NL8497 ### Lung ultra A prospective observational
Radboudu ### 20200331 6/26/2020 Netherlands
NL8498 ### Lung ultrasLung ultrasound (LUS) Radboudu
as a tool ### 20200331 6/26/2020 Netherlands
NL8504 ### Pre-emptivePre-emptive tocilizumab
UMCG,
in hypo
Roc 4/3/2020 20200403 6/26/2020 Netherlands
EUCTR2020 ### A randomise
A randomised double-blind
EUCTR2020 ### IMU-838 anProspective, RandomizUniversity 5/7/2020 20200507 6/26/2020 EU Clinical

EUCTR2020 ### A Clinical A clinical trial of nebulize
EUCTR2020 ### Covid-19: ACovid-19: A randomized,
UZLeuven
o 4/6/2020 20200406 6/26/2020 EU Clinical
EUCTR2020 ### An internatAn international randomised

World Heal ### 20200417 6/26/2020 EU Clinical
EUCTR2020 ### ExperimentCOVID 19: Experimental
CHUuseAMBRO
of ### 20200415 6/26/2020 EU Clinical
EUCTR2020 ### BCG vaccinUsing BCG vaccine to enha
EUCTR2020 ### Clinical tr A multicentre, open-label
FundaciÃ³ ### 20200521 6/26/2020 EU Clinical
EUCTR2020 ### A phase I/I A phase I/II study to University ### 20200319 6/26/2020 EU Clinical
EUCTR2020 ### Evaluation Usefulness of vitamin D
FundaciÃ³n
on ### 20200521 6/26/2020 EU Clinical
EUCTR2020 ### Controlled Controlled and randomi
IDIVAL Inst ### 20200521 6/26/2020 EU Clinical
EUCTR2020 ### TD-0903 foA Phase 2, Randomized,
Theravance ### 20200429 6/26/2020 EU Clinical
NCT04275 ### Xiyanping Retrospective Cohort Jiangxi Qin ### 20200217 6/26/2020 ClinicalTria
NCT04313 ### Phase I Cli A Single-ceCTCOVID-1CanSino Bio ### 20200315 6/26/2020 ClinicalTria
NCT04321 ### Treatment Treatment of Moderate
Lisa Barret ### 20200324 6/26/2020 ClinicalTria
NCT04322 ### Colchicine Colchicine ColCOVID- Azienda Os ### 20200324 6/26/2020 ClinicalTria
NCT04325 ### HydroxychlHydroxychlHYCOVID University ### 20200325 6/26/2020 ClinicalTria
NCT04326 ### Evaluation Evaluation COVIDx CCTU- Can ### 20200326 6/26/2020 ClinicalTria
NCT04328 ### Household Household EPI-COVID-Institut Pa ### 20200323 6/26/2020 ClinicalTria
NCT04334 ### Descriptiv Descriptive Study Reg Jessa Hospi 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04338 ### COVID-19 COVID-19 and Deep VeJessa Hospi 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04340 ### The Role o The Role of Adaptive Barts & Th 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04341 ### A Phase II A RandomizCTII-nCoV Insitute of 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 ### Effects of Effects of DPP4 Inhib University 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04342 ### ConvalesceConvalesceConCoVid- Erasmus Me ### 20200331 6/26/2020 ClinicalTria
NCT04352 ### Outcomes of

Outcomes of naÃ¯ve Pat
Centre Hosp ### 20200414 6/26/2020 ClinicalTria
NCT04352 ### EchocardioCardiac Structural an RenJi Hospi ### 20200416 6/26/2020 ClinicalTria
NCT04358 ### ConvalescePhase II, COP-COVIDHospital Un ### 20200421 6/26/2020 ClinicalTria

NCT04359 ### Efficacy o ComparativCHEER Shaheed Zul ### 20200420 6/26/2020 ClinicalTria
NCT04361 ### Evaluation A Prospect (ESCAPE) Brigham an ### 20200423 6/26/2020 ClinicalTria
NCT04363 ### Study of F Study of FT516 Safety Masonic Ca ### 20200423 6/26/2020 ClinicalTria
NCT04363 ### Use of the A Randomized Placebo-c

Johns Hopk ### 20200423 6/26/2020 ClinicalTria
NCT04366 ### ComparisonEnoxaparinX-Covid 19 Niguarda H ### 20200424 6/26/2020 ClinicalTria
NCT04367 ### IntermediaIntermediaIMPROVE Columbia U ### 20200427 6/26/2020 ClinicalTria
NCT04370 ### HydroxychlA Randomized Study Ev

St. Francis ### 20200426 6/26/2020 ClinicalTria
NCT04370 ### VITACOV: VVITACOV: VVITACOV University ### 20200426 6/26/2020 ClinicalTria
NCT04371 ### DYNAMIC StDoxycyclineDYNAMIC Nantes Univ ### 20200427 6/26/2020 ClinicalTria
NCT04372 ### Efficacy of Evaluation PLASCOSS Direction ### 20200424 6/26/2020 ClinicalTria
NCT04374 ### CommunitySURVEY of RETAIL P Damanhour 5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04375 ### Treatment Evaluation of the Pos Kanuni Sul 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04377 ### Prediction Prediction COVID-CTPCentre Hosp5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04377 ### Spread andLongitudin CoV-ETH Goldhahn 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04377 ### Effect of The Possible Effect o Kanuni Sul 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04388 ### Post Covid Cardiopulmcovid-19 Mansoura U ### 20200511 6/26/2020 ClinicalTria
NCT04388 ### Detection Detection COVID-19 Tongji Hosp ### 20200512 6/26/2020 ClinicalTria
NCT04388 ### Inhaled NitPrevention NO-COVID-Tufts Medi ### 20200513 6/26/2020 ClinicalTria
NCT04389 ### Feasibilit Feasibility of Non-co Changhai H 5/9/2020 20200509 6/26/2020 ClinicalTria
NCT04389 ### Effectiven Feasibilit ChroMig-S Fondazione 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04389 ### COVID-19 SAerosol Inhalation of TC Erciyes ### 20200512 6/26/2020 ClinicalTria
NCT04389 ### Patient Ou Patient Outcome of CaNantes Univ ### 20200514 6/26/2020 ClinicalTria
NCT04389 ### Interferon Interferon Gamma Induc

MeMed Diag ### 20200513 6/26/2020 ClinicalTria
NCT04389 ### ContagiousRetrospect CONDITIO Igenomix ### 20200514 6/26/2020 ClinicalTria

NCT04389 ### Clinical a Clinical a COVIDICA Poitiers Un ### 20200514 6/26/2020 ClinicalTria
NCT04389 ### ConvalesceConvalescent Plasma fThomas Jef ### 20200427 6/26/2020 ClinicalTria
NCT04389 ### Use of Des The Use of Desferal a Hesham Al- ### 20200513 6/26/2020 ClinicalTria
NCT04389 ### AmotosalenAmotosalen-UltravioleUniversity ### 20200512 6/26/2020 ClinicalTria
NCT04390 ### TOFAcitini TOFAcitini TOFACoV-2UniversitÃ Politecnica

### 20200513
delle Marche
NCT04390 ### Safety and Safety and Efficacy o BioXcellera ### 20200512 6/26/2020 ClinicalTria
NCT04390 ### LB1148 for A Phase 2 Study to E Leading Bio ### 20200513 6/26/2020 ClinicalTria
NCT04390 ### Immunogene

Various Molecular MarMansoura U ### 20200512 6/26/2020 ClinicalTria
NCT04390 ### Low Dose RAssessment of Adding Shahid Behe ### 20200513 6/26/2020 ClinicalTria
NCT04390 ### mulTi-Arm mulTi-Arm TACTIC-R Cambridge 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04390 ### Study to EvThe Intestinal Microbi Bioithas SL 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04390 ### ConvalesceA Phase 2 Randomized,Columbia U ### 20200514 6/26/2020 ClinicalTria

NCT04390 ### The Global COVID-19 i PCHF-COVIUniversity 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04391 ### The Use of The Use of Peripheral Invivoscribe ### 20200514 6/26/2020 ClinicalTria
NCT04391 ### Resting En Resting En RECOVERY Centre Hosp ### 20200515 6/26/2020 ClinicalTria
NCT04391 ### Cold Laser Multiwave Locked SystLowell Gen 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04391 ### Detection Detection COVIDSPE Universitai ### 20200513 6/26/2020 ClinicalTria
NCT04391 ### Oral ManifeOral Manifestation o Cairo Unive ### 20200514 6/26/2020 ClinicalTria
NCT04391 ### Registry o Registry o CTC REGIS CytoSorben ### 20200512 6/26/2020 ClinicalTria
NCT04391 ### ObservatorNational P COVID19_ French Inn ### 20200513 6/26/2020 ClinicalTria
NCT04392 ### Effects of Effects of NIRS-COV Hvidovre Un ### 20200514 6/26/2020 ClinicalTria
NCT04392 ### Colchicine Application of Colchi Kermanshah ### 20200515 6/26/2020 ClinicalTria
NCT04392 ### ProctologicA WorldwidPROCTOLOSocieta Ita ### 20200515 6/26/2020 ClinicalTria

NCT04392 ### Incidence oIncidence of COVID-19Northwell ### 20200515 6/26/2020 ClinicalTria
NCT04392 ### Health, PerHealth, PerSAPRIS-SE Institut N ### 20200515 6/26/2020 ClinicalTria
NCT04392 ### COVID-19 -Study of thRICO Hospices Ci ### 20200513 6/26/2020 ClinicalTria
NCT04392 ### New AntiviEffect of a CombinatioMansoura U ### 20200512 6/26/2020 ClinicalTria
NCT04392 ### Upper LimbUpper Limb Robotic Reh

Fondazione ### 20200515 6/26/2020 ClinicalTria
NCT04392 ### Efficacy of Efficacy of Ivermectin Combined M5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04392 ### Clinical Us What is the Effect of SBÃœ Dr. S ### 20200425 6/26/2020 ClinicalTria
NCT04393 ### Ulinastatin A Multi-Center, Random

Stanford Un ### 20200515 6/26/2020 ClinicalTria
NCT04393 ### At-Home CO

At-Home COVID-19 AntProofPilot ### 20200424 6/26/2020 ClinicalTria
NCT04394 ### Impact of Impact of Implementati

Jessa Hospi ### 20200516 6/26/2020 ClinicalTria
NCT04394 ### Imaging Fe COVID-19 ICOVID19IF Francesco ### 20200515 6/26/2020 ClinicalTria
NCT04394 ### Early Care Early Care, PAIN-COVI Hospital Cl ### 20200513 6/26/2020 ClinicalTria
NCT04394 ### Ultra Low Low Doses ULTRA-COVFundacion ### 20200515 6/26/2020 ClinicalTria
NCT04394 ### sFlt1: a Bi sFlt1: a Bi COVIDsFlt1CHU de Re ### 20200516 6/26/2020 ClinicalTria
NCT04394 ### Silymarin Trial of S SCOPE Cairo Unive ### 20200515 6/26/2020 ClinicalTria
NCT04395 ### National SuEmerging HECHO University ### 20200515 6/26/2020 ClinicalTria
NCT04259 1-Jun-20 Viral Excre Viral Excre Cov-CONT Institut N 2/5/2020 20200205 6/26/2020 ClinicalTria
NCT04306 1-Jun-20 Nitric Oxi Nitric Oxi NOSARSCOMassachuse ### 20200310 6/26/2020 ClinicalTria
NCT04318 1-Jun-20 COVID-19: COVID-19: COVID19- University ### 20200317 6/26/2020 ClinicalTria
NCT04336 1-Jun-20 PrevalencePrevalenceINCOVPED University H4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04337 1-Jun-20 Evaluation Endometriosis PatientKanuni Sul 4/5/2020 20200405 6/26/2020 ClinicalTria
NCT04338 1-Jun-20 Nitric Oxid Nitric Oxi NO COV-E Massachuse4/5/2020 20200405 6/26/2020 ClinicalTria
NCT04338 1-Jun-20 Impact of PImpact of Pandemic COV

Ospedale P 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 1-Jun-20 Sirolimus Sirolimus SCOPE University 4/5/2020 20200405 6/26/2020 ClinicalTria
NCT04342 1-Jun-20 COVID-19 GastrointesCOVID-19 Al-Azhar Un4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04342 1-Jun-20 A Double-blA Double-blSTOP COVI Washington4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04345 1-Jun-20 Efficacy o Cohort MulCORIPLAS Assistance ### 20200410 6/26/2020 ClinicalTria
NCT04346 1-Jun-20 Safety and BHV3500-203: Double-B

Biohaven P 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04347 1-Jun-20 Potential A National Collaborati King Fahad 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04347 1-Jun-20 Respirator Respirator PHYSIO-COUniversity H4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04348 1-Jun-20 TransmissibTransmissibility and V National In ### 20200415 6/26/2020 ClinicalTria

NCT04350 1-Jun-20 First in H A Phase 1, Double-bli Theravanc ### 20200414 6/26/2020 ClinicalTria
NCT04351 1-Jun-20 Psychologi Psychologi PRPsyCOVIUniversity H ### 20200414 6/26/2020 ClinicalTria
NCT04351 1-Jun-20 Psychologi Psychologi OsPsyCOVIUniversity H ### 20200415 6/26/2020 ClinicalTria
NCT04353 1-Jun-20 Psychologi Psychologi DolPsyCOVUniversity H ### 20200415 6/26/2020 ClinicalTria
NCT04354 1-Jun-20 Ruxolitini A Pilot Study of Ruxo Washington ### 20200416 6/26/2020 ClinicalTria
NCT04355 1-Jun-20 Colchicine Randomized

COLHEART-University ### 20200414 6/26/2020 ClinicalTria
NCT04355 1-Jun-20 Immunity ASeropreval PED-COVIDAssistance ### 20200417 6/26/2020 ClinicalTria
NCT04355 1-Jun-20 CoVID-19 PConvalescent CoVID-19The Christ ### 20200415 6/26/2020 ClinicalTria
NCT04358 1-Jun-20 HydroxychlA Multi-center, RandoNovartis P 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04360 1-Jun-20 PEEP Increm

PEEP Incremental and Szeged Uni ### 20200422 6/26/2020 ClinicalTria
NCT04361 1-Jun-20 LeflunomidLeflunomide for the T University ### 20200422 6/26/2020 ClinicalTria
NCT04361 1-Jun-20 Neurodegen

Neurodegen
MARNEVO-Centre Hos ### 20200416 6/26/2020 ClinicalTria
NCT04362 1-Jun-20 Efficacy a A Randomized, PlaceboHope Biosc ### 20200421 6/26/2020 ClinicalTria
NCT04365 1-Jun-20 Canakinuma

Canakinumab to Reduce
The Clevela ### 20200424 6/26/2020 ClinicalTria
NCT04365 1-Jun-20 The PsychoExploring the Psychol The Univer ### 20200425 6/26/2020 ClinicalTria
NCT04365 1-Jun-20 The PsychoExploring the Psychol The Univer ### 20200425 6/26/2020 ClinicalTria
NCT04365 1-Jun-20 Effect of Effect of Treatments Groupe Hosp ### 20200425 6/26/2020 ClinicalTria
NCT04368 1-Jun-20 Prone Posi Prone Posi PAPR University ### 20200424 6/26/2020 ClinicalTria
NCT04368 1-Jun-20 TelerehabilA Telereha ATHLOS Clinical Ex ### 20200420 6/26/2020 ClinicalTria
NCT04372 1-Jun-20 Trial of E Trial of E TREAT NO Vanderbilt ### 20200430 6/26/2020 ClinicalTria
NCT04373 1-Jun-20 Enhanced HDevelopment of a Nove

NCT04374 1-Jun-20 PrevalencePrevalence of SARS-CoJohns Hopk 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04375 1-Jun-20 A Study of The Effects of CoronavBarts & Th 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04376 1-Jun-20 Use of the Incidence and Implica Tiva Group ### 20200430 6/26/2020 ClinicalTria
NCT04380 1-Jun-20 Atorvastat Prospectiv STATCO19 Mount Aubu5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04383 1-Jun-20 Outcome ofOutcome of COVID-19Helsinki
P Un 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04384 1-Jun-20 COVID-19 OAssessmentHandicall University ### 20200510 6/26/2020 ClinicalTria
NCT04384 1-Jun-20 Organicell A Phase I/II RandomizeOrganicell 5/9/2020 20200509 6/26/2020 ClinicalTria
NCT04385 1-Jun-20 Advanced The Status of AdvanceAl-Azhar Un ### 20200511 6/26/2020 ClinicalTria
NCT04386 1-Jun-20 CompassionThe Compassionate UsSerenaGrou ### 20200511 6/26/2020 ClinicalTria
NCT04386 1-Jun-20 Phase II RCPhase II, MOsCOVID1 Azienda Os ### 20200512 6/26/2020 ClinicalTria
NCT04387 1-Jun-20 Evaluating Evaluating the Effica Princess N ### 20200512 6/26/2020 ClinicalTria
NCT04388 1-Jun-20 Investigati Investigating Anosmia Princess N ### 20200513 6/26/2020 ClinicalTria
NCT04390 1-Jun-20 Sars-CoV-2Pilot Study SAINT Clinica Un 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04390 1-Jun-20 COVID-19 inCOVID-19 in the Swedis

Uppsala Un ### 20200514 6/26/2020 ClinicalTria
NCT04391 1-Jun-20 ConvalesceEfficacy of Convalesce Hospital S 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04391 1-Jun-20 Associatio Relationsh BMI-SARS- University H ### 20200514 6/26/2020 ClinicalTria
NCT04392 1-Jun-20 Study Eval Randomised
HYACINTH Institut d ### 20200515 6/26/2020 ClinicalTria
NCT04392 1-Jun-20 COVID-19 FiA Randomized, Double-

Ridgeback ### 20200429 6/26/2020 ClinicalTria
NCT04392 1-Jun-20 A Study of A Phase 2 Study of COTriHealth I ### 20200515 6/26/2020 ClinicalTria
NCT04392 1-Jun-20 Clinical Tr Open, Controlled, RandInstituto de 5/3/2020

InvestigaciÃ³n
20200503
Sanitaria
6/26/2020
de la FundaciÃ³n
ClinicalTria
JimÃ©nez DÃaz
NCT04393 1-Jun-20 ABX464 in A Phase 2/ Mir-Age Abivax S.A. ### 20200518 6/26/2020 ClinicalTria
NCT04393 1-Jun-20 Baricitini BARICIVID-1BARICIVID-Azienda Osp ### 20200516 6/26/2020 ClinicalTria
NCT04393 1-Jun-20 Longitudin Inflammatory, Pulmona

NCT04393 1-Jun-20 Lung UltrasLung UltrasLUS-COVIDCentre Hosp ### 20200515 6/26/2020 ClinicalTria
NCT04393 1-Jun-20 Urinary Bi Urinary Bi COVID-AKI University ### 20200514 6/26/2020 ClinicalTria
NCT04393 1-Jun-20 Wearable SWearable Sensor to MShirley Rya ### 20200516 6/26/2020 ClinicalTria
NCT04393 1-Jun-20 Transfusio Transfusio TSUNAMI Azienda Osp ### 20200516 6/26/2020 ClinicalTria
NCT04393 1-Jun-20 SINUS WASH

Can a Sinus Rinse and Hampshire ### 20200518 6/26/2020 ClinicalTria
NCT04393 1-Jun-20 Heparins f Heparins f HETHICO Quovadis A ### 20200516 6/26/2020 ClinicalTria
NCT04393 1-Jun-20 Mobile PhoA Double-bPsyCovid_ FundaciÃ³ d'investigaciÃ³

### 20200518
SanitÃ ria
6/26/2020
de les Illes
ClinicalTria
Balears
NCT04393 1-Jun-20 COVID-19 aOnCovid: NOnCovid Imperial C ### 20200518 6/26/2020 ClinicalTria
NCT04394 1-Jun-20 A Web-BaseA Web-Based Gentle Bo

Monash Uni ### 20200518 6/26/2020 ClinicalTria
NCT04394 1-Jun-20 Do VitaminDo VitaminCOVIDVIT Bursa City ### 20200518 6/26/2020 ClinicalTria
NCT04394 1-Jun-20 Pilot Inte Pilot Inter CoronaStreHebrew Uni ### 20200513 6/26/2020 ClinicalTria
NCT04394 1-Jun-20 EndotracheAnalysis of TubeObs-CUniversity ### 20200518 6/26/2020 ClinicalTria
NCT04394 1-Jun-20 HydroxychlUse of HydroxychloroqSamah Lutf ### 20200517 6/26/2020 ClinicalTria
NCT04395 1-Jun-20 COVid-19: Randomized

COVAYDE HÃ´pital d ### 20200515 6/26/2020 ClinicalTria
NCT04395 1-Jun-20 A Phase 2 A Phase 2 CSAVE Amyndas Ph ### 20200519 6/26/2020 ClinicalTria
NCT04395 1-Jun-20 ArrhythmiaThe ACOVIDACOVID Herlev and ### 20200519 6/26/2020 ClinicalTria
NCT04395 1-Jun-20 1,3,7-Trime1,3,7-TrimeTMX COVI Poitiers Un ### 20200514 6/26/2020 ClinicalTria
NCT04395 1-Jun-20 Impact of Impact of COVID-19 PaOspedale P ### 20200519 6/26/2020 ClinicalTria
NCT04395 1-Jun-20 Internatio Therapies to Prevent National In ### 20200518 6/26/2020 ClinicalTria
NCT04395 1-Jun-20 SARS-CoV-2SARS-CoV-2Disguise Meshalkin R ### 20200519 6/26/2020 ClinicalTria

NCT04395 1-Jun-20 Sexual Fun Sexual Function AmonAssiut Univ ### 20200519 6/26/2020 ClinicalTria
NCT04395 1-Jun-20 Safety and A Multi-Center Pilot S SeaStar Me ### 20200517 6/26/2020 ClinicalTria
NCT04395 1-Jun-20 Ayurveda aEffect of Ayurveda as British Ayu ### 20200519 6/26/2020 ClinicalTria
NCT04396 1-Jun-20 Safety and A Phase 2 Randomized,Atea Pharma ### 20200516 6/26/2020 ClinicalTria
NCT04396 1-Jun-20 Physical AcPhysical Activity Leve University ### 20200517 6/26/2020 ClinicalTria
NCT04396 1-Jun-20 Patients P Patients Perspectives University ### 20200518 6/26/2020 ClinicalTria
NCT04396 1-Jun-20 Effectiven Effectiven BATEP Universitat ### 20200515 6/26/2020 ClinicalTria
NCT04396 1-Jun-20 The ProfessThe Profes PPRI University ### 20200423 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 Intensive Characterization of A University ### 20200520 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 PrevalencePrevalenceEuro-COVI PitiÃ©-Salp ### 20200519 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 COVID-19 PE

Safety and Efficacy o Lawson Hea ### 20200513 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 COVID-19 TCOVID-19 Re

COVID3T NHS Greate ### 20200516 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 Efficacy a Use of COVID-19 ConvaInstitute ### 20200520 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 ExtracorpoExtracorpoECMO-SARRennes Uni ### 20200519 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 Mobile HeaMobile Health Study aUniversity ### 20200520 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 RT-PCR on RT-PCR on P20/09 Versailles ### 20200520 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 Remote Mon

Remote Mon
RECAP The Christ ### 20200520 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 COVID-19: Study of I CO-QUETT University ### 20200519 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 Psychologi Psychologi PSYCOV-CVUniversity ### 20200421 6/26/2020 ClinicalTria
NCT04397 1-Jun-20 Mental HeaHearing and Supporti University ### 20200519 6/26/2020 ClinicalTria
NCT04398 1-Jun-20 Characteri Characteri CCOVID-PRInova Heal ### 20200520 6/26/2020 ClinicalTria
NCT04398 1-Jun-20 A Daily Co A Daily Coping Toolki Kent State ### 20200520 6/26/2020 ClinicalTria
NCT04398 1-Jun-20 iNOPulse f Randomized

NO-COVER Roger Alva ### 20200520 6/26/2020 ClinicalTria
NCT04398 1-Jun-20 ACT-20 in A Phase 1/2 Randomize

Aspire Hea ### 20200520 6/26/2020 ClinicalTria
NCT04399 1-Jun-20 Ivermectin A Pilot St IvAzCol Instituto d ### 20200519 6/26/2020 ClinicalTria
NCT04400 1-Jun-20 Cellular I Cellular I CIRCA-19 Ottawa Hos ### 20200427 6/26/2020 ClinicalTria
NCT04404 1-Jun-20 ConvalesceConvalescent Plasma TYale Univer ### 20200522 6/26/2020 ClinicalTria
ACTRN126 1-Jun-20 Post-IntensPost-Intensive Care Nutrition

The Austra
Sta ### 20200525 6/26/2020 ANZCTR
ACTRN126 1-Jun-20 Multi-site Airway Interventions inSt.S Vincent ### 20200527 6/26/2020 ANZCTR
ACTRN126 1-Jun-20 Has the th Has the threat of SARSProfessor

COVID-1 J ### 20200522 6/26/2020 ANZCTR
ACTRN126 1-Jun-20 Covid-19 B Covid-19 Biobank: a clAlfred Hea ### 20200525 6/26/2020 ANZCTR
ACTRN126 1-Jun-20 The MEND A

(Mpilot, open-label, random
Cynata The ### 20200525 6/26/2020 ANZCTR
ChiCTR200 1-Jun-20 Study for The Effect of Internet-bInternation ### 20200531 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 Efficacy a Efficacy and safety of lefl
Shandong U ### 20200529 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 A correlati A correlation study between

Shaanxif Tr ### 20200529 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 Epidemiolog Epidemiological and Clinical
ChiCTR200 1-Jun-20 Erythrocyt Erythrocyte Sedimentation
Affiliated
Rate ### 20200528 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 Study for t Study for the effect of The

Tradaffilia ### 20200528 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 The compreThe comprehensive evaluation

Children's ### 20200528 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 Severe Rel Severe Reluctant COVID-19
none Pati ### 20200528 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 Study for Study for Traditional Chinese

ChiCTR200 1-Jun-20 A follow upA follow up research ofThe

exer
First A ### 20200527 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 Efficacy of Rqesearch on the Applicatio

Yueyang Int ### 20200527 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 Psychiatri Psychiatric admissionsnil
during the ### 20200527 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 A Randomize

A Randomized, Double-bli
Xiangyang ### 20200526 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 Study for Study for the improvement

ChiCTR200 1-Jun-20 Usefulness Usefulness of abdominal

Jiangsu
m Peo ### 20200525 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 A Medical A Medical Records Based

Wuhan Wome
4/3/2020 20200403 6/26/2020 ChiCTR
ChiCTR200 1-Jun-20 Research f Use of Herbal Medicines Hospital

t of 2/2/2020 20200202 6/26/2020 ChiCTR
ISRCTN152 1-Jun-20 Online pareOnline parent training Heim
for rePÃ¡l ### 20200523 6/26/2020 ISRCTN
ISRCTN134 1-Jun-20 A pilot stu A pilot study of virucidRoyal Surr ### 20200522 6/26/2020 ISRCTN
ISRCTN647 1-Jun-20 Investigati An observational studyOxford
to e Uni ### 20200522 6/26/2020 ISRCTN
ISRCTN305 1-Jun-20 STOP-COVID1

A randomised double-blind
University
pla ### 20200520 6/26/2020 ISRCTN
ISRCTN502 1-Jun-20 How effectiA Phase III prospectiv University ### 20200520 6/26/2020 ISRCTN
ISRCTN443 1-Jun-20 The symptoLongitudinal study of COVID-19:
ISRCTN111 1-Jun-20 A therapeumulTi-Arm TherapeuticCambridge

study i ### 20200515 6/26/2020 ISRCTN
ISRCTN880 1-Jun-20 PreventativPROphylaxis for paTiEnts
Cambridge
at risk ### 20200514 6/26/2020 ISRCTN
ISRCTN100 1-Jun-20 ComparisonEVALUATION: Extravascular
Klinikum d 4/7/2020 20200407 6/26/2020 ISRCTN
EUCTR2020 2-Jun-20 A Phase 2 RA Phase 2 RandomizedAcerta

Stud Pha ### 20200411 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 Recombinan
Recombinant InterLeukin-7
RevImmun
(C ### 20200414 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 An open prAn open prospective rand

Assistance ### 20200417 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 Interleukin Interleukin-1 (IL-1) andCentre Hos ### 20200420 6/26/2020 EU Clinical
Prophylax
is of
COVID-19
infection
with
hydroxyc
hloroquin
e in
Prophylax healthcar
is of e
COVID-19 personnel
infection with high
with risk of
hydroxyc infection.
hloroquin
e in
healthcar
e
personnel
with high
risk of
EUCTR2020 2-Jun-20 infection. HOSPITAL ### 20200420 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 Phase 2/3 sA phase 2/3, randomize
ABIVAX ### 20200417 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 An internatAn international randomised

Vilnius Uni 4/7/2020 20200407 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 ravulizumaA Phase 3 Open-label, Alexion Pha ### 20200428 6/26/2020 EU Clinical
A
randomiz
ed, open-
label,
adaptive,
proof-of-
A concept
randomiz clinical
ed, open-trial of
label, modulati
adaptive,on of host
proof-of-thromboi
concept nflammat
clinical ory
trial of response
modulati in
on of host
patients
thromboi with
nflammat COVID-
ory 19.
response
in - DAWN
patients AntiCo
with
COVID-
19.
EUCTR2020 2-Jun-20 UZLeuven ### 20200410 6/26/2020 EU Clinical

Phase 2,
randomiz
ed,
controlle
d, open
label
multi-
center
study to
assess
efficacy
and
safety of
DFV890
for the
Study to treatmen
assess t of SARS-
efficacy CoV-2
and infected
safety of patients
DFV890 in with
patients COVID-19
with pneumon
COVID-19 ia and
pneumon impaired
ia and respirator
impaired y function
respirator
y function
EUCTR2020 2-Jun-20 Novartis P 5/5/2020 20200505 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 TriiodothyrTriiodothyronine for the
Uni-Pharma
tre ### 20200422 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 A study to A Prospective, Multi-CImmunic A ### 20200512 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 BCG VACCI A RANDOMIZED CLINICAL
Hellenic In ### 20200520 6/26/2020 EU Clinical
Preventio
n of
COVID19
infection
with
hydroxyc
hloroquin
e in
institutio
nalized
older
people
and
nursing
home
staff. An
open,
randomiz
ed
controlle
d
stepped-
wedge
clinical
trial by
clusters.
PREVICHA
RM Study
-
PREVICHA
RM
EUCTR2020 2-Jun-20 COVID 19 p FIMABIS ### 20200525 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 Efficacy a Efficacy and safety of AN

CHRU de T ### 20200415 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 MulticenterMulticenter, randomized,
Cristina A ### 20200526 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 Efficacy o Efficacy of vitamin D tre

Investigati ### 20200526 6/26/2020 EU Clinical
Colchicine
for the
Treatmen
t of
Hyperinfl
ammatio
n
associate
Colchicine d with
for the Pneumoni
Treatmen a due to
t of COVID-19
Hyperinfl
ammatio
n
associate
d with
Pneumoni
a due to
COVID-19
EUCTR2020 2-Jun-20 Sociedad EspaÃ±ola
###de20200526
CardiologÃ
6/26/2020
a EU Clinical
A pilot,
open
label,
phase II
clinical
trial of
nebulised
recombin
ant
tissue-
Plasmino
gen
Activator
(rtPA)in
patients
with
COVID-19
ARDS:
The
Plasmino
gen
Activator
COVID-19
ARDS
(PACA)
trial
-
Nebulised
rtPA for
ARDS due
to COVID-
19 â€“
The PACA
EUCTR2020 2-Jun-20 A clinical trial University 4/9/2020 20200409 6/26/2020 EU Clinical
Senicapoc
in COVID-
19
Patients
with
Severe
Respirato
ry
Insufficie
ncy
â€“ A
Randomiz
ed, Open-
Label,
Phase II
Trial -
COVIPOC
EUCTR2020 2-Jun-20 Senicapoc t Aarhus Uni 4/1/2020 20200401 6/26/2020 EU Clinical

EUCTR2020 2-Jun-20 A clinical CATALYST - A randomise
EUCTR2020 2-Jun-20 A Phase 2 RA Phase 2 RandomizedKaryopharm4/3/2020
Singl 20200403 6/26/2020 EU Clinical
Ruxolitini
b for
treatmen
t of
Covid-19
induced
lung
injury
ARDS
(RuXoCoil
)
A single-
arm,
Ruxolitini open-
b for label,
treatmen proof of
t of concept
Covid-19 study
Patienten
with
acute
respirator
y
distress
EUCTR2020 2-Jun-20 syndrome Philipps-U ### 20200427 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 Efficacy an Efficacy and safety of 7Section fo 4/3/2020 20200403 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 EffectiveneEffectiveness of the comb

Basque Hea ### 20200531 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 Clinical tr Clinical trial, PHASE Miguel Cer ### 20200531 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 A clinical A multi-center, open-labe

Staidson (B ### 20200531 6/26/2020 EU Clinical
EUCTR2020 2-Jun-20 Investigati A randomized, double-blin
GlaxoSmith ### 20200513 6/26/2020 EU Clinical
NCT03648 4-Jun-20 A Study to An Open Label, Dose-EMillennium ### 20180824 6/26/2020 ClinicalTria
NCT04061 4-Jun-20 Sero-epide Serum TestSTORY University ### 20190730 6/26/2020 ClinicalTria
NCT04305 4-Jun-20 Nitric Oxi Nitric Oxi NoCovid Massachuse3/9/2020 20200309 6/26/2020 ClinicalTria
NCT04320 4-Jun-20 Beaumont Q
COVID CT, Beaumont Qu
William Be ### 20200323 6/26/2020 ClinicalTria
NCT04321 4-Jun-20 Safety and Evaluation of the Safe Hospital Is ### 20200323 6/26/2020 ClinicalTria
NCT04331 4-Jun-20 ChloroquineMulticenter, RandomizWroclaw Me ### 20200330 6/26/2020 ClinicalTria
NCT04332 4-Jun-20 AzithromycAzithromycACTION Thomas M. ### 20200330 6/26/2020 ClinicalTria
NCT04336 4-Jun-20 Covid-19 P Covid-19 P PANDOR Centre Hos ### 20200330 6/26/2020 ClinicalTria
NCT04338 4-Jun-20 CAP-1002 iA Randomized, Double-

Capricor In ### 20200331 6/26/2020 ClinicalTria
NCT04341 4-Jun-20 Evolution oProspective DescriptivCentre Hos 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04343 4-Jun-20 DeterminatiDetermination of the Genesis Fo 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04346 4-Jun-20 An Open RaAn Open Randomized St

Burnasyan 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04348 4-Jun-20 BCG VaccinBacillus C BADAS Texas A&M ### 20200330 6/26/2020 ClinicalTria
NCT04350 4-Jun-20 HydroxychlHydroxychloroquine TrMontefiore ### 20200414 6/26/2020 ClinicalTria
NCT04352 4-Jun-20 The Covid- The ImpactHEROES University 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04362 4-Jun-20 St. Jude Tr SJTRC-St. Jude Tracki St. Jude Ch ### 20200422 6/26/2020 ClinicalTria
NCT04363 4-Jun-20 Clinical I A Prospective, Open-l Inmunotek ### 20200419 6/26/2020 ClinicalTria
NCT04373 4-Jun-20 One-Year Qu

Quality of COVENTRY Groupe Hosp ### 20200426 6/26/2020 ClinicalTria
NCT04374 4-Jun-20 Home-based

Home-based Treatment
Mansoura U5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04375 4-Jun-20 COVID-19: Human EpidHEROS National In ### 20200430 6/26/2020 ClinicalTria
NCT04376 4-Jun-20 Quality of Assessment of Health-Hospital M 5/4/2020 20200504 6/26/2020 ClinicalTria

NCT04377 4-Jun-20 Incidence oIncidence oCOVIDECO Fondation 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04379 4-Jun-20 Nudges to Using Behavioral NudgMedical Co 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04380 4-Jun-20 Tableted C Clinical Tr COVID-19 Immunitor ### 20200429 6/26/2020 ClinicalTria
NCT04381 4-Jun-20 Noncoding The Role o MiRCOVID Heinrich-He5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04381 4-Jun-20 Ivermectin A Pilot, Proof of Conc Laboratorio 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04389 4-Jun-20 COVID-19 PCOVID-19 PCOPICADS Odense Uni ### 20200512 6/26/2020 ClinicalTria
NCT04390 4-Jun-20 Efficacy a MulticentreSEN-CoV-F Institut Pa ### 20200514 6/26/2020 ClinicalTria
NCT04392 4-Jun-20 The EffectsTesting th CRAFTftiugUniversida 5/9/2020 20200509 6/26/2020 ClinicalTria
NCT04393 4-Jun-20 Using PRP the Effect of PRP and Aljazeera H ### 20200515 6/26/2020 ClinicalTria
NCT04395 4-Jun-20 Dexamethas

Dexamethasone Versus
Centro de EducaciÃ³n
### Medica
20200516
e Investigaciones
ClÃnicas Norberto Qu
NCT04395 4-Jun-20 Lung CT Sc Lung CT Sc TAC-COVIDUniversity ### 20200518 6/26/2020 ClinicalTria
NCT04395 4-Jun-20 Pediatric A Pediatric A PACCOVRAKK Women's ### 20200518 6/26/2020 ClinicalTria
NCT04395 4-Jun-20 Psychiatric Psychiatric Consultati Daegu Cath 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04397 4-Jun-20 MavrilimumA RandomizCOMBAT-1Ospedale S ### 20200520 6/26/2020 ClinicalTria
NCT04397 4-Jun-20 The GCO-00Cohorte NoCACOVID-1Federation ### 20200513 6/26/2020 ClinicalTria
NCT04398 4-Jun-20 Anti-infla Anti-infla ACHIEVE Hellenic In ### 20200517 6/26/2020 ClinicalTria
NCT04398 4-Jun-20 Phase I/II A Randomized, Observer

CanSino Bio ### 20200518 6/26/2020 ClinicalTria
NCT04399 4-Jun-20 The Effica The Efficacy ComparinThe First A ### 20200519 6/26/2020 ClinicalTria
NCT04399 4-Jun-20 Evaluation ReCOVER (RReCOVER Dr Sze-Yua ### 20200521 6/26/2020 ClinicalTria
NCT04399 4-Jun-20 Effect of A Randomized Trial of Duke Unive ### 20200519 6/26/2020 ClinicalTria
NCT04399 4-Jun-20 Flow ContrFlow Controlled Venti Hamad Medi ### 20200518 6/26/2020 ClinicalTria
NCT04399 4-Jun-20 NiclosamidNiclosamide for Patie Tufts Medi ### 20200519 6/26/2020 ClinicalTria
NCT04399 4-Jun-20 Mechanisms

Multi-organ Failure i Imperial C ### 20200519 6/26/2020 ClinicalTria
NCT04399 4-Jun-20 The Utilit The Utility of Bedsid Kanuni Sul ### 20200521 6/26/2020 ClinicalTria
NCT04399 4-Jun-20 Baricitinib A proof-of BREATH IRCCS Polic ### 20200513 6/26/2020 ClinicalTria
NCT04400 4-Jun-20 Ozone TherThe Effectiveness of Marmara Un ### 20200521 6/26/2020 ClinicalTria
NCT04400 4-Jun-20 OCTAGAM E1FFICACY AND SAFET Octapharm ### 20200521 6/26/2020 ClinicalTria
NCT04400 4-Jun-20 "Increasing"IncreasingCOVID-19 University ### 20200521 6/26/2020 ClinicalTria
NCT04400 4-Jun-20 Short-termShort-term Physical F Fundacion p ### 20200520 6/26/2020 ClinicalTria
NCT04400 4-Jun-20 EnoxaparinEnoxaparin for Primar University ### 20200515 6/26/2020 ClinicalTria
NCT04400 4-Jun-20 Attitude a Attitude and Percepti Zagazig Uni ### 20200520 6/26/2020 ClinicalTria
NCT04400 4-Jun-20 Investigat A Phase 2/3 Study to University ### 20200512 6/26/2020 ClinicalTria
NCT04400 4-Jun-20 Randomized
Randomized Double-BliMarvin Mc ### 20200522 6/26/2020 ClinicalTria
NCT04400 4-Jun-20 Using GM-CUsing GM-CSF as a Host

Singapore 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 Attitude o Survey Studying the C Damanhour ### 20200522 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 Changing OSurvey Of Egyptian P Damanhour ### 20200522 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 One-year OMultiparamCO-Qo-ICUCentre Hosp ### 20200522 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 Status of A Descriptive Study o Beijing Fri ### 20200522 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 Lessening Lessening LOVIT-COVUniversitÃ ### 20200521 6/26/2020 ClinicalTria

NCT04401 4-Jun-20 Nigella Sat Effects of Nigella Sat King Abdula ### 20200521 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 Predictive Development and ValidClinique Sa ### 20200521 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 How RoutinAccuracy o MONACOVCentre Hosp ### 20200518 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 Recovery ofThe COVID-COVID-Rec Australian 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 Distance L Assessment of Dental Cairo Unive ### 20200521 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 Anti-SARS CBAT IT: Ba BAT IT Baylor Col ### 20200521 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 TXA COVID-1

Randomized ControlledColumbia U ### 20200521 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 Treatment Treatment of Lung Inj Hope Pharm ### 20200521 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 CharacterisClinical and Epidemio Recep Tayy ### 20200522 6/26/2020 ClinicalTria
NCT04401 4-Jun-20 COVID-19: Laser Inter COLIDE Somerset N ### 20200515 6/26/2020 ClinicalTria
NCT04402 4-Jun-20 Study on SaStudy on Safety and EfBangladesh ### 20200519 6/26/2020 ClinicalTria
NCT04402 4-Jun-20 Psychologi Psychologi StudentCo Versailles ### 20200521 6/26/2020 ClinicalTria
NCT04402 4-Jun-20 IgG/IgM AnEvaluation and Correl Fadi Hadda ### 20200522 6/26/2020 ClinicalTria
NCT04402 4-Jun-20 Stellate G Stellate Ganglion Blo West Virgin ### 20200522 6/26/2020 ClinicalTria
NCT04402 4-Jun-20 The Effecti The Effectiveness of T Istanbul Me ### 20200522 6/26/2020 ClinicalTria
NCT04403 4-Jun-20 The Clinica The Clinical Differen The First A ### 20200421 6/26/2020 ClinicalTria
NCT04403 4-Jun-20 ComparisonComparison of the ID Ascension ### 20200521 6/26/2020 ClinicalTria
NCT04403 4-Jun-20 NORMAL HU

"STUDY OFGERONIMOVersailles ### 20200518 6/26/2020 ClinicalTria
NCT04403 4-Jun-20 Familial M Pain, Sleep, Fatigue, Istanbul Un ### 20200523 6/26/2020 ClinicalTria
NCT04403 4-Jun-20 ConvalesceConvalescent Plasma TBangabandh ### 20200520 6/26/2020 ClinicalTria
NCT04403 4-Jun-20 Ivermectin The Efficacy of Iverm Tanta Unive ### 20200523 6/26/2020 ClinicalTria
NCT04403 4-Jun-20 Egyptian D Cross-sectional Descr Ain Shams ### 20200519 6/26/2020 ClinicalTria
NCT04403 4-Jun-20 Somerset aEvaluation SOCRATES Somerset N ### 20200521 6/26/2020 ClinicalTria
NCT04404 4-Jun-20 PH94B in t A Phase 2a Open-labelVistaGen Th ### 20200521 6/26/2020 ClinicalTria
NCT04404 4-Jun-20 The AÃ§aÃRandomized

Berry COVID-19
ACAI
Clinical
Anti-Inflammation
Trial
University
of AÃ§aÃPalm
Trial###
Berry
20200524
Extract as6/26/2020
an Intervention
ClinicalTria
in Patients Diagnos
NCT04307 8-Jun-20 ComparisonRandomized ControlledAsan Medic ### 20200310 6/26/2020 ClinicalTria
NCT04317 8-Jun-20 CD24Fc as A Randomize

SAC-COVIDOncoImmun ### 20200319 6/26/2020 ClinicalTria
NCT04321 8-Jun-20 Hyperimmun

Plasma FroCOV19-PL Foundation ### 20200323 6/26/2020 ClinicalTria
NCT04327 8-Jun-20 BCG VaccinBCG VaccinBRACE Murdoch Ch ### 20200325 6/26/2020 ClinicalTria
NCT04327 8-Jun-20 In-depth I In-depth C COntAGIouUniversita ### 20200326 6/26/2020 ClinicalTria
NCT04328 8-Jun-20 Pre-exposuPre-exposure ProphylaUniversity ### 20200327 6/26/2020 ClinicalTria
NCT04328 8-Jun-20 The Vietna A Multi Ce VICO Oxford Univ ### 20200327 6/26/2020 ClinicalTria
NCT04334 8-Jun-20 LIBERATE TLipid Ibup LIBERATE King's Col 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04334 8-Jun-20 Use of a R Use of a R MultiCov Assistance 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04341 8-Jun-20 ASC TherapAllogeneic ASC COVIDRigshospit 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04341 8-Jun-20 Efficiency Efficiency and Satisf Pierre and 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04345 8-Jun-20 Efficacy a Efficacy a CCAP Thomas Ben ### 20200410 6/26/2020 ClinicalTria
NCT04351 8-Jun-20 Test and T Randomized

COVID65pl University ### 20200415 6/26/2020 ClinicalTria
NCT04354 8-Jun-20 Treatment Efficacy of Novel Age University ### 20200416 6/26/2020 ClinicalTria
NCT04359 8-Jun-20 Direct Inc Direct Inc DISTANSE St. Michael ### 20200416 6/26/2020 ClinicalTria
NCT04359 8-Jun-20 Impact of CImpact of SCOVAPID University H ### 20200421 6/26/2020 ClinicalTria
NCT04362 8-Jun-20 A Clinical A Clinical COVSurf University ### 20200420 6/26/2020 ClinicalTria
NCT04362 8-Jun-20 Long-term Long-term LIINC University ### 20200423 6/26/2020 ClinicalTria
NCT04364 8-Jun-20 COVID-19 Se

Severe AcuCOVID-T Fondazione ### 20200422 6/26/2020 ClinicalTria
NCT04366 8-Jun-20 Evaluating A RandomizAVM0703 AVM Biotec ### 20200426 6/26/2020 ClinicalTria
NCT04366 8-Jun-20 COVID-19 (The Impact of a Barri University ### 20200424 6/26/2020 ClinicalTria
NCT04367 8-Jun-20 Health BehHealth Behavior Chan University ### 20200428 6/26/2020 ClinicalTria
NCT04368 8-Jun-20 Evaluation A 2-Part, Phase 1/2, Novavax ### 20200424 6/26/2020 ClinicalTria
NCT04372 8-Jun-20 A Study to A Randomized, Double-

Genentech, ### 20200429 6/26/2020 ClinicalTria
NCT04373 8-Jun-20 Human Ab Human Ab HARMONICRennes Uni ### 20200422 6/26/2020 ClinicalTria
NCT04374 8-Jun-20 Early trans Early trans LIFESAVER Fondazione 5/2/2020 20200502 6/26/2020 ClinicalTria
NCT04376 8-Jun-20 Predicting Predicting the Need f Central Hos 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04377 8-Jun-20 TocilizumabA Phase II Study of IL Memorial S 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04378 8-Jun-20 Characteri Characteri EpiCoV-BrazUniversity 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04378 8-Jun-20 MindfulnessMindfulness Training University 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04378 8-Jun-20 COVID-19 aImpact of SCOVID-BM University H5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04379 8-Jun-20 COVID-19 PCOVID-19 PCOPING Jon Bailey 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04382 8-Jun-20 ProspectiveCharacteristics and OuRegion VÃ 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04382 8-Jun-20 Treatment Treatment of Covid-1 Institute o 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04384 8-Jun-20 ConvalesceConvalescent Plasma fJoakim Dill 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04385 8-Jun-20 Clinical, CharacterizPR-Covid-1University 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04386 8-Jun-20 MeditationMeditation and Yoga fResearch F ### 20200511 6/26/2020 ClinicalTria
NCT04386 8-Jun-20 Measuremen
Measuremen
POVA-TIE University ### 20200511 6/26/2020 ClinicalTria
NCT04387 8-Jun-20 Serologic Serologic Surveillance Hospital It ### 20200513 6/26/2020 ClinicalTria
NCT04388 8-Jun-20 COVID-19 CAn Open-Label, Single University 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04393 8-Jun-20 The Critic The Critic Tetrix Hospital Sa ### 20200517 6/26/2020 ClinicalTria
NCT04393 8-Jun-20 Lung Irrad Pilot Study of Low-Do Brigham an ### 20200515 6/26/2020 ClinicalTria
NCT04394 8-Jun-20 COVID-19 W

COVID-19 Health and Rutgers, Th ### 20200515 6/26/2020 ClinicalTria
NCT04395 8-Jun-20 Home UsabiUsability Study of Ho Exact Scie ### 20200519 6/26/2020 ClinicalTria
NCT04397 8-Jun-20 Inhaled NOInhaled NO for the Tr Beyond Air ### 20200519 6/26/2020 ClinicalTria
NCT04400 8-Jun-20 AcceptanceAcceptance of Telemed

FundaciÃ³n ### 20200514 6/26/2020 ClinicalTria
NCT04401 8-Jun-20 COVID-19 an

COVID-19 EP
COVID-TR Institut Pa ### 20200522 6/26/2020 ClinicalTria
NCT04402 8-Jun-20 TD-0903 foA Phase 2, RandomizedTheravanc ### 20200522 6/26/2020 ClinicalTria
NCT04402 8-Jun-20 COVID-19: SARS-CoV-2MEMO-CO Assistance ### 20200519 6/26/2020 ClinicalTria
NCT04402 8-Jun-20 ObservatioObservatioCOVID-PSL Centre de R ### 20200520 6/26/2020 ClinicalTria

NCT04402 8-Jun-20 Study of Vi Study of Vi TRANSCOVCentre Hosp ### 20200518 6/26/2020 ClinicalTria
NCT04403 8-Jun-20 Th1/Th2/ThTh1/Th2/ThResistir Asociacion ### 20200523 6/26/2020 ClinicalTria
NCT04403 8-Jun-20 COLchicineCOLchicineCOLORIT Lomonosov ### 20200520 6/26/2020 ClinicalTria
NCT04403 8-Jun-20 Tannin SpecEfficacy of TaCOVID Hospital de Clinicas

###JosÃ©
20200522
de San6/26/2020
MartÃn ClinicalTria
NCT04403 8-Jun-20 PerformancPerformance EvaluatioBangladesh ### 20200524 6/26/2020 ClinicalTria
NCT04403 8-Jun-20 Safety and Safety and TOCIBRAS BeneficÃªn ### 20200524 6/26/2020 ClinicalTria
NCT04404 8-Jun-20 Validation Validation of a Memb Richmond P ### 20200522 6/26/2020 ClinicalTria
NCT04404 8-Jun-20 Setting up Setting up a COVID-19 Services In ### 20200524 6/26/2020 ClinicalTria
NCT04404 8-Jun-20 Extraordin Extraordin PedCan-COFatma Soli ### 20200525 6/26/2020 ClinicalTria
NCT04404 8-Jun-20 CACOLAC : CACOLAC : CRACOLAC Rennes Uni ### 20200522 6/26/2020 ClinicalTria
NCT04405 8-Jun-20 COVID-19 OEfficacy a COZI FranÃ§ois ### 20200526 6/26/2020 ClinicalTria
NCT04405 8-Jun-20 TAF/FTC foRandomized, Double-blHospital It ### 20200526 6/26/2020 ClinicalTria

NCT04405 8-Jun-20 ConvalescePlasma FroCPC-SARS Grupo Mexi ### 20200526 6/26/2020 ClinicalTria
NCT04405 8-Jun-20 ConsequencConsequencQUARCOPSUniversity H ### 20200518 6/26/2020 ClinicalTria
NCT04405 8-Jun-20 Evaluation Evaluation ERap-COV Assistance ### 20200519 6/26/2020 ClinicalTria
NCT04405 8-Jun-20 Efficacy of Randomized, Placebo CCentro de Estudios###

en InfectogÃ
20200523a6/26/2020
Pediatrica ClinicalTria
NCT04405 8-Jun-20 Thromboemb

Incidence COVICLOT University ### 20200525 6/26/2020 ClinicalTria
NCT04405 8-Jun-20 PreventionPrevention of Infecti Federal Sta ### 20200518 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 Study of thA Population-Based SeEuropean Un ### 20200526 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 Viral Speci Viral Specific T-cells Children's ### 20200526 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 EndovasculEndovasculET-COVID- University ### 20200526 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 Muscle MasMuscle Mass and StrenUniversity ### 20200523 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 PreventionPrevention of CoronavMaterno-Per ### 20200524 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 COVID-19: COVID-19: PCo-SURVIV University ### 20200513 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 AnticoagulaInterMediatIMPACT Weill Medic ### 20200526 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 MonitoringMonitoring of Lung Fl Hillel Yaff ### 20200523 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 Home-Based

Home Based Covid-19 Albert
Re Eins ### 20200522 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 ReorganizaReorganizaCAPANCOVCHU de Re ### 20200527 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 Prediction Prediction of Acute K University ### 20200518 6/26/2020 ClinicalTria
NCT04406 8-Jun-20 An ObservaAn Observational StudMax Healthc ### 20200525 6/26/2020 ClinicalTria
NCT04407 8-Jun-20 COVID-19 RCOVID-19 RCORONA Vastra Got 5/3/2020 20200503 6/26/2020 ClinicalTria
NCT04407 8-Jun-20 STATIN TH STATIN TH STACOV Institut Inv ### 20200527 6/26/2020 ClinicalTria
NCT04407 8-Jun-20 Vitamin D Vitamin D Testing and Arizona Sta ### 20200519 6/26/2020 ClinicalTria
NCT04407 8-Jun-20 COVID-19 IImpact of COVID-19 PaCairo Unive ### 20200523 6/26/2020 ClinicalTria
NCT04407 8-Jun-20 Vienna VerVienna VerVIVI Medical Un ### 20200527 6/26/2020 ClinicalTria
NCT04407 8-Jun-20 Awake PronAwake PronAPRONOX Hospital Ge ### 20200527 6/26/2020 ClinicalTria
NCT04407 8-Jun-20 Efficacy, S MulticenterSILVERBUL Investigaci ### 20200527 6/26/2020 ClinicalTria
NCT04407 8-Jun-20 Dietary In Dietary In COVIDiet McGill Univ ### 20200527 6/26/2020 ClinicalTria
NCT04407 8-Jun-20 COPD in th Cross-Sectional Obser University ### 20200527 6/26/2020 ClinicalTria
NCT04408 8-Jun-20 SeroepidemSeroepidemiological S Butantan In ### 20200522 6/26/2020 ClinicalTria
NCT04408 8-Jun-20 Mental HeaMental Health SupportThe Hospita ### 20200526 6/26/2020 ClinicalTria
NCT04408 8-Jun-20 Use of Con Use of Convalescent PNorthside H ### 20200515 6/26/2020 ClinicalTria
NCT04408 8-Jun-20 Awake PronAwake Proning in Pati Columbia U ### 20200525 6/26/2020 ClinicalTria
NCT04408 8-Jun-20 High Versu Randomised

COVID-19 Azienda Os ### 20200526 6/26/2020 ClinicalTria
NCT04408 8-Jun-20 Endothelia Endothelial Function, Guy's and ### 20200527 6/26/2020 ClinicalTria
NCT04408 8-Jun-20 Brain MRI Descriptiv ANOSIRM Centre Hosp ### 20200526 6/26/2020 ClinicalTria
ACTRN126 8-Jun-20 A phase II, A phase II, open label University 6/1/2020 20200601 6/26/2020 ANZCTR
ACTRN126 8-Jun-20 Open label Open label, prospectivSouth West ### 20200529 6/26/2020 ANZCTR
ACTRN126 8-Jun-20 VentricularVentricular Arrhythmias
The
in Univers6/1/2020
Im 20200601 6/26/2020 ANZCTR
ACTRN126 8-Jun-20 COACHING COACHING

F FOR COVID-19:
SouthA West
Pi ### 20200529 6/26/2020 ANZCTR
ACTRN126 8-Jun-20 Testing an Testing an Online Coping

TheSkUniver ### 20200529 6/26/2020 ANZCTR
ACTRN126 8-Jun-20 AngiotensinAngiotensin II InfusionRinaldo

in CO Be ### 20200528 6/26/2020 ANZCTR
ChiCTR200 8-Jun-20 In vivo use In vivo use of ivermectin

Rayak
(IV Hosp 6/7/2020 20200607 6/26/2020 ChiCTR
ChiCTR200 8-Jun-20 A medical A medical records based Yichang
r Cen6/7/2020 20200607 6/26/2020 ChiCTR
ChiCTR200 8-Jun-20 Analysis of Characteristics of recurre

yunnan CD 6/6/2020 20200606 6/26/2020 ChiCTR
ChiCTR200 8-Jun-20 Effectiven Effectiveness of day care

None 6/3/2020 20200603 6/26/2020 ChiCTR
ChiCTR200 8-Jun-20 A Survey A A Survey Among Collage
Xiangya Hos6/3/2020 20200603 6/26/2020 ChiCTR
ChiCTR200 8-Jun-20 Oral Favipi The Single Oral Favipiravir

Wuhanfor Huo6/2/2020 20200602 6/26/2020 ChiCTR
ISRCTN992 8-Jun-20 Peer suppoPeer support training forUniversity
ado ### 20200529 6/26/2020 ISRCTN
ISRCTN155 8-Jun-20 Investigati Investigating the impact
University
of C ### 20200528 6/26/2020 ISRCTN
ISRCTN121 8-Jun-20 SupportingAn acceptance-based program

ISRCTN113 8-Jun-20 A collaboraMonitoring the introduPoliclinic ### 20200526 6/26/2020 ISRCTN
ISRCTN104 8-Jun-20 Survival of Survival of patients suffering
FundaciÃ³n ### 20200521 6/26/2020 ISRCTN
ISRCTN439 8-Jun-20 Testing an Testing an early onlineNorthumbri4/8/2020

inte 20200408 6/26/2020 ISRCTN
ISRCTN773 8-Jun-20 Cohort studPredicting hospitalization
ISRCTN501 8-Jun-20 A randomise

Randomized evaluation
University
of COVID-19
4/2/2020 20200402 6/26/2020 ISRCTN
EUCTR2020 8-Jun-20 A study to A pilot, multiple dose stu
4D pharma 4/9/2020 20200409 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 A First-in- A First-in-Human Studyargenx

i BV 4/9/2020 20200409 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 Study eval A multi-centre, randomUniversity ### 20200429 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 A study co Glasgow Early Treatment

NHSArGreate ### 20200430 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 Study of i Multicenter, randomized
HUVEPHAR 5/5/2020 20200505 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 HydroxychlHydroxychloroquine for

UniversitÃ
the treat 4/1/2020 20200401 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 A study to A phase III, randomizeVakzine P ### 20200417 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 Treatment Aerosolized DNase I forRegion

the Sk ### 20200428 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 A study to A Prospective, Multi-CImmunic A 5/7/2020 20200507 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 Amiodarone
Amiodarone or Verapamil
Uniwersyte
in C ### 20200429 6/26/2020 EU Clinical
EUCTR2015 8-Jun-20 Adaptive t Randomized, Embedded,
University
Mult ### 20150713 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 Study to in A Multi-site Phase I/I BioNTech ### 20200414 6/26/2020 EU Clinical
EUCTR2020 8-Jun-20 ZilucoplanÂA prospective, randomiUniversity 5/6/2020 20200506 6/26/2020 EU Clinical

EUCTR2020 8-Jun-20 Clinical St A randomized, prospectiv
DRK-Blusp ### 20200331 6/26/2020 EU Clinical
NCT04283 11-Jun-20 Safety and Phase I, Open-Label, National In ### 20200221 6/26/2020 ClinicalTria
NCT04292 11-Jun-20 Study to E A Phase 3 RandomizedGilead Sci ### 20200228 6/26/2020 ClinicalTria
NCT04292 11-Jun-20 Study to EvA Phase 3 RandomizedGilead Sci ### 20200228 6/26/2020 ClinicalTria
NCT04320 11-Jun-20 A Study to A RandomizCOVACTA Hoffmann- ### 20200323 6/26/2020 ClinicalTria
NCT04322 11-Jun-20 Safety and An Open-laCoalition-I Hospital d ### 20200324 6/26/2020 ClinicalTria
NCT04322 11-Jun-20 An ObservaAn ObservaSISCO A.O. Osped ### 20200324 6/26/2020 ClinicalTria
NCT04323 11-Jun-20 Anti-infla Anti-infla ONSCOVID King Saud U ### 20200323 6/26/2020 ClinicalTria
NCT04329 11-Jun-20 HydroxychlHydroxychlHAHPS Intermounta ### 20200330 6/26/2020 ClinicalTria
NCT04334 11-Jun-20 HydroxychlRandomized Study to EProvidence 4/2/2020 20200402 6/26/2020 ClinicalTria

NCT04335 11-Jun-20 COVID-19 ICOVID-19 Infection in Salome Kri 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04336 11-Jun-20 Outcomes oOutcomes oMexCOVIDInstituto N 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04337 11-Jun-20 GerontologGerontologCOVIDeHP University 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04344 11-Jun-20 Microbial EMicrobial Etiology of Poitiers Un ### 20200410 6/26/2020 ClinicalTria
NCT04344 11-Jun-20 Peginterfe Peginterfe PROTECT Johns Hopk ### 20200410 6/26/2020 ClinicalTria
NCT04344 11-Jun-20 ChloroquinChloroquinHOPE Uni-Pharma4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04347 11-Jun-20 ObservatioObservatioRegCOVID1Instituto 4/3/2020 20200403 6/26/2020 ClinicalTria

NCT04348 11-Jun-20 Screening Screening SARAH Ain Shams ### 20200413 6/26/2020 ClinicalTria
NCT04348 11-Jun-20 TriiodothyrTriiodothyrThy-SupporUni-Pharma4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04351 11-Jun-20 A Study to A Multi-Center, Adapt Kinevant S ### 20200415 6/26/2020 ClinicalTria
NCT04355 11-Jun-20 Efficacy a Efficacy a COVIDORNFondation ### 20200415 6/26/2020 ClinicalTria
NCT04355 11-Jun-20 Evolution Evolution Traumax University ### 20200416 6/26/2020 ClinicalTria
NCT04357 11-Jun-20 The Effect Efficacy of Pulmonary Tehran Uni ### 20200413 6/26/2020 ClinicalTria
NCT04359 11-Jun-20 Prone PositThe Effect COVID-19_Walid HAB ### 20200420 6/26/2020 ClinicalTria
NCT04363 11-Jun-20 A Study to A Phase-II MARIPOSAHoffmann- ### 20200421 6/26/2020 ClinicalTria
NCT04363 11-Jun-20 Protect: S PROTECT: APROTECT Istituto Sc ### 20200424 6/26/2020 ClinicalTria
NCT04365 11-Jun-20 Study of S Ã‰tude Des

COV-CREMCentre Hosp ### 20200425 6/26/2020 ClinicalTria
NCT04370 11-Jun-20 Sleep Qual Sleep QualiCONFIDODCentre Hos ### 20200429 6/26/2020 ClinicalTria
NCT04370 11-Jun-20 XPro1595 fA Multicenter, DoubleInmune Bio, ### 20200429 6/26/2020 ClinicalTria
NCT04370 11-Jun-20 Recruit Bl Recruit Blood Donors Guangzhou ### 20200428 6/26/2020 ClinicalTria
NCT04373 11-Jun-20 Baricitini A Phase II RandomizedUniversity ### 20200417 6/26/2020 ClinicalTria

NCT04374 11-Jun-20 A Study of Phase II Study of N-aceMemorial S 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04377 11-Jun-20 Human Conv

Safety and PharmacokiJohns Hopk 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04384 11-Jun-20 Accelerate A Novel and Practical Centre for 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04385 11-Jun-20 InactivatedInactivated ConvalesceNational B 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04385 11-Jun-20 Study of t Phase 1b, Randomized,ImmunityBi 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04389 11-Jun-20 D-dimer LeAssessment of D-dimeKanuni Sul ### 20200514 6/26/2020 ClinicalTria
NCT04391 11-Jun-20 DipyridamoDipyridamoDICER Yogendra K ### 20200515 6/26/2020 ClinicalTria

NCT04393 11-Jun-20 Drug ManagDrug ManagRHUMACOVUniversity ### 20200422 6/26/2020 ClinicalTria
NCT04396 11-Jun-20 Combination

Combination
Antibodies Kafrelsheik ### 20200518 6/26/2020 ClinicalTria
NCT04397 11-Jun-20 COVID-19 CAn Open-Label, ControUniversity ### 20200519 6/26/2020 ClinicalTria
NCT04397 11-Jun-20 Study of t Phase 1b Randomized,NantKwest, ### 20200518 6/26/2020 ClinicalTria
NCT04401 11-Jun-20 COVID-19: Herd Immun

SARSCoV2CInstitute o ### 20200521 6/26/2020 ClinicalTria
NCT04401 11-Jun-20 A RandomizA Randomized, Double-

Edesa Biote ### 20200521 6/26/2020 ClinicalTria
NCT04402 11-Jun-20 Different Difference CoVEX Asociacion ### 20200523 6/26/2020 ClinicalTria
NCT04402 11-Jun-20 CORONA (CO
A Prospect CORONA University ### 20200522 6/26/2020 ClinicalTria
NCT04403 11-Jun-20 Increased RCohort Stu COVIT-D Hospital Sa ### 20200524 6/26/2020 ClinicalTria
NCT04405 11-Jun-20 DeterminatDetermination of AcutState Budge ### 20200526 6/26/2020 ClinicalTria
NCT04405 11-Jun-20 Clinical S Clinical Scores for O Dr. Alexan ### 20200525 6/26/2020 ClinicalTria
NCT04405 11-Jun-20 Exploring Exploring BRAINCOV University 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04406 11-Jun-20 Psychologi Effect on the COVID-1 Universitai ### 20200428 6/26/2020 ClinicalTria
NCT04406 11-Jun-20 MicrovasculInvestigation of Syste National In ### 20200523 6/26/2020 ClinicalTria

NCT04407 11-Jun-20 Study of t Study of A SOLID FundaciÃ³ ### 20200525 6/26/2020 ClinicalTria
NCT04407 11-Jun-20 Prevalence Evaluation CRITICoVidCentral Hos ### 20200414 6/26/2020 ClinicalTria
NCT04407 11-Jun-20 Safety and Safety and Efficacy o Catalysis S ### 20200525 6/26/2020 ClinicalTria
NCT04407 11-Jun-20 COVID-19 aMental Health Outco Northeaste ### 20200527 6/26/2020 ClinicalTria
NCT04407 11-Jun-20 ConvalesceConvalescent Plasma Biofarma ### 20200516 6/26/2020 ClinicalTria
NCT04407 11-Jun-20 The Use of The Use of Oxygen HooNorthwell ### 20200527 6/26/2020 ClinicalTria
NCT04407 11-Jun-20 Effects of Effects of NR-COVID1University ### 20200522 6/26/2020 ClinicalTria

NCT04407 11-Jun-20 Diagnostic Diagnostic COVID-OLFUniversity ### 20200527 6/26/2020 ClinicalTria
NCT04407 11-Jun-20 COVID-SEroImpact of COVID-SERUniversity ### 20200527 6/26/2020 ClinicalTria
NCT04407 11-Jun-20 Outpatient Outpatient Clinic in O University ### 20200527 6/26/2020 ClinicalTria
NCT04407 11-Jun-20 Drug ManagDrug ManagRHUMAJIC University ### 20200528 6/26/2020 ClinicalTria
NCT04408 11-Jun-20 Morbi-mortMorbi-mortCOVIDHome

Assistance ### 20200528 6/26/2020 ClinicalTria
NCT04408 11-Jun-20 A ResearchA ResearchSWitCh King's Col ### 20200526 6/26/2020 ClinicalTria
NCT04408 11-Jun-20 Facilitatin Facilitatin FALCON-C1Manchester ### 20200526 6/26/2020 ClinicalTria
NCT04408 11-Jun-20 QoL and thEffects of Social Dist Fondazione ### 20200521 6/26/2020 ClinicalTria
NCT04408 11-Jun-20 ConvalesceConvalescent Plasma fo

National an ### 20200525 6/26/2020 ClinicalTria
NCT04408 11-Jun-20 Improving Improving Activity E Lawson Hea ### 20200520 6/26/2020 ClinicalTria
NCT04408 11-Jun-20 Change in Retrospective Change Gaziosmanp ### 20200527 6/26/2020 ClinicalTria
NCT04408 11-Jun-20 Efficacy o Efficacy of PEP-Q Postgradua ### 20200524 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Whole BlooEvaluation of Whole BMedical Co ### 20200528 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Evaluation Evaluation CO-RNPC University ### 20200518 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Phase 3 St Randomized Double BliRestorbio I ### 20200528 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Evaluation Evaluation TRASCOV Epicentre ### 20200528 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Treatment A Phase 2, Multicente CSL Behrin ### 20200528 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Evaluation Evaluation of Therape Mohammad ### 20200528 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Effects of Effects of the COVID- University ### 20200511 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Brief Tele Harnessing TelehealthStanford Un ### 20200528 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Tele-based COVID-19 CCO-CarES Rigshospit ### 20200522 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 COVID-19 BCOVID-19 BOBELIX NHS Greate ### 20200522 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Antiseptic Effect of AMPoL University ### 20200528 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 The Utilit The Utility UroCovid Fundacio P ### 20200526 6/26/2020 ClinicalTria
NCT04409 11-Jun-20 Pharmacy EImpact of Covid-19 onDamanhour ### 20200522 6/26/2020 ClinicalTria
NCT04410 11-Jun-20 Lung FunctiShort and Long Term AFederal Uni ### 20200525 6/26/2020 ClinicalTria
NCT04410 11-Jun-20 MicrobiotaMicrobiotaMICRO-CO University ### 20200518 6/26/2020 ClinicalTria

NCT04410 11-Jun-20 Aggrenox TA RandomizATTAC-19 Rutgers, Th ### 20200528 6/26/2020 ClinicalTria
NCT04410 11-Jun-20 Humoral ImDevelopment and PersMagdalena ### 20200529 6/26/2020 ClinicalTria
NCT04410 11-Jun-20 P2Et Extra Study of the P2Et Ext Hospital Un ### 20200527 6/26/2020 ClinicalTria
NCT04410 11-Jun-20 Home Detox

Home-withd
MOHC Fondazione ### 20200525 6/26/2020 ClinicalTria
NCT04410 11-Jun-20 Pulmonary Optical Coherence To IRCCS San ### 20200521 6/26/2020 ClinicalTria
NCT04410 11-Jun-20 HydroxychlHydroxychlCOVID-Pre Barcelona I ### 20200526 6/26/2020 ClinicalTria

NCT04410 11-Jun-20 Can the Pr Can the Prediction MaNational Un ### 20200527 6/26/2020 ClinicalTria
NCT04410 11-Jun-20 Glycaemia Glycaemia GLYCOVID-Steno Diab 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04410 11-Jun-20 COVID-19 PCOVID-19 PCR Test ResIstanbul Me ### 20200522 6/26/2020 ClinicalTria
NCT04411 11-Jun-20 Efficacy a An Open-Label, MulticMinistry of ### 20200523 6/26/2020 ClinicalTria
NCT04411 11-Jun-20 COVID-19, O

The InfluenCOLC Maastricht ### 20200520 6/26/2020 ClinicalTria
NCT04411 11-Jun-20 Epigenetic The Effect of miRNA anBakirkoy Dr ### 20200525 6/26/2020 ClinicalTria
NCT04411 11-Jun-20 Feasibilit Convalescent Plasma tAscension ### 20200522 6/26/2020 ClinicalTria
NCT04411 11-Jun-20 Study of S A Phase 2 iLeukPulm Partner The ### 20200529 6/26/2020 ClinicalTria
NCT04412 11-Jun-20 Effect of U Effect of Using Barrie Derince Tr ### 20200531 6/26/2020 ClinicalTria
NCT04412 11-Jun-20 To Assess tTo Assess the Efficie Health Sci ### 20200530 6/26/2020 ClinicalTria
NCT04412 11-Jun-20 The Senior The Senior SCOPE University ### 20200529 6/26/2020 ClinicalTria
NCT04412 11-Jun-20 Multi-modaMulti-modaMIIC-MI University ### 20200527 6/26/2020 ClinicalTria

NCT04412 11-Jun-20 Covid-19: PCovid-19: PNETSINCOVAzienda Os ### 20200526 6/26/2020 ClinicalTria
NCT04412 11-Jun-20 Clinical As Clinical A COVID-19_National R ### 20200515 6/26/2020 ClinicalTria
NCT04412 11-Jun-20 EchocardioEchocardiography in PUniversity ### 20200520 6/26/2020 ClinicalTria
NCT04412 11-Jun-20 COVID-19 Re

COVID-19 RCRASH University ### 20200527 6/26/2020 ClinicalTria
NCT04412 11-Jun-20 COVID-19 CAn Open Label Trial o Gailen D. M ### 20200528 6/26/2020 ClinicalTria
NCT04413 11-Jun-20 Menstrual CMenstrual Cycle Charac

Haydarpasa ### 20200527 6/26/2020 ClinicalTria
NCT04413 11-Jun-20 ImplementaImplementaICOPE University ### 20200525 6/26/2020 ClinicalTria
NCT04306 15-Jun-20 TCM Differ Clinical Tr TDATPOC Jiangsu Fa 3/1/2020 20200301 6/26/2020 ClinicalTria
NCT04311 15-Jun-20 IntravenousIntravenousCOVID-AIV NeuroRx, I ### 20200314 6/26/2020 ClinicalTria
NCT04315 15-Jun-20 Trial of Tr Multi-centrDisCoVeRy Institut N ### 20200313 6/26/2020 ClinicalTria
NCT04326 15-Jun-20 EffectiveneEffectiveness and SafeUniversida ### 20200326 6/26/2020 ClinicalTria
NCT04327 15-Jun-20 COVID-19-aCOVID-19-aCoDEX Hospital Si ### 20200326 6/26/2020 ClinicalTria

NCT04327 15-Jun-20 Safety and A Randomize
COVID-19- Karolinska ### 20200325 6/26/2020 ClinicalTria
NCT04327 15-Jun-20 Evaluation Evaluation of Covid 1 Kanuni Sul ### 20200327 6/26/2020 ClinicalTria
NCT04332 15-Jun-20 HyperbaricOpen Label Single-CenNYU Lango ### 20200330 6/26/2020 ClinicalTria
NCT04333 15-Jun-20 HydroxychlA Phase 1b, RandomizeSanofi 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04336 15-Jun-20 Safety, To Phase 1 Open-label St Inovio Pha 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04339 15-Jun-20 AzithromycAzithromycAZIQUINE- Frantisek 4/6/2020 20200406 6/26/2020 ClinicalTria

NCT04340 15-Jun-20 The Use of The Use of UltrasoundUniversity 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04341 15-Jun-20 AssessmentAssessmentCOVID-SERHospices Ci 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04343 15-Jun-20 Efficacy of Efficacy of Ivermecti University 4/5/2020 20200405 6/26/2020 ClinicalTria
NCT04343 15-Jun-20 Trial to Ev A Randomized, Double-B

Romark Lab4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04345 15-Jun-20 Efficacy a An Open Clinical Tria Huoshensha ### 20200410 6/26/2020 ClinicalTria
NCT04345 15-Jun-20 A Randomize

A Randomize
OAHU-COVQueen's Me4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04347 15-Jun-20 EVALUATIOEVALUATIOTEACHCOVUniversity ### 20200411 6/26/2020 ClinicalTria

NCT04347 15-Jun-20 IMPACT: IMIMPACT RAP
IMPACT University ### 20200413 6/26/2020 ClinicalTria
NCT04347 15-Jun-20 Predict Ad Covid-19 Associated Ne

NCT04348 15-Jun-20 ClazakizumA Phase II Trial to Ev Cedars-Sin ### 20200413 6/26/2020 ClinicalTria
NCT04352 15-Jun-20 Evaluating Evaluating the Use of Spectral Di ### 20200415 6/26/2020 ClinicalTria
NCT04355 15-Jun-20 Telmisarta Telmisartan for Treat Laboratorio ### 20200417 6/26/2020 ClinicalTria
NCT04356 15-Jun-20 CONVALESCDETERMINACOPLASCO Instituto d ### 20200417 6/26/2020 ClinicalTria

NCT04358 15-Jun-20 Plasma AdsPlasma Adsorption in Marker The ### 20200420 6/26/2020 ClinicalTria
NCT04359 15-Jun-20 Efficacy a Efficacy a CORTICOV University ### 20200420 6/26/2020 ClinicalTria
NCT04359 15-Jun-20 Trial to Ev A Randomized, Double-B

Romark Lab ### 20200420 6/26/2020 ClinicalTria
NCT04359 15-Jun-20 Sarilumab Sarilumab for Patient Westyn Bra ### 20200420 6/26/2020 ClinicalTria
NCT04361 15-Jun-20 The COVID-Impact of Multi-DenomKansas Cit ### 20200416 6/26/2020 ClinicalTria
NCT04367 15-Jun-20 COVID-19 DCOVID-19 SEVIDENCE UNICANCE ### 20200428 6/26/2020 ClinicalTria
NCT04371 15-Jun-20 Prophylact Prophylact PREVENT Texas Card ### 20200429 6/26/2020 ClinicalTria
NCT04372 15-Jun-20 AntithrombAntithrombotic TherapUniversity ### 20200424 6/26/2020 ClinicalTria
NCT04374 15-Jun-20 MoxibustioMoxibustion Plus CuppGuang'anme ### 20200420 6/26/2020 ClinicalTria
NCT04374 15-Jun-20 Effects of Effects of a Mobile A University 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04382 15-Jun-20 A Phase II, A Phase II, Controlled MGC Pharma

5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04382 15-Jun-20 Proof of CoMulticenterAPLICOV-P PharmaMa 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04382 15-Jun-20 CombinatioCombination of Recomb

Kafrelsheik 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04384 15-Jun-20 COVID-19 PCOVID-19 Prophylaxis Nucleo De 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04385 15-Jun-20 Internatio An Interna ICOS University 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04385 15-Jun-20 Long Term Long Term Functional University 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04385 15-Jun-20 Vitamin D Improving Vitamin D University 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04389 15-Jun-20 FamotidineFamotidine Use in NonNorthwell ### 20200513 6/26/2020 ClinicalTria
NCT04389 15-Jun-20 CombinatioCombinatioCombinati Kafrelsheik ### 20200512 6/26/2020 ClinicalTria

NCT04392 15-Jun-20 Hyperimmun
Randomized, Open Labe
Federal Res ### 20200513 6/26/2020 ClinicalTria
NCT04393 15-Jun-20 mulTi-Arm mulTi-Arm TherapeuticCambridge ### 20200516 6/26/2020 ClinicalTria
NCT04394 15-Jun-20 Trial of Im Randomized Double-BliUniversity 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04395 15-Jun-20 An ExpandeAn Expanded Access, SGenentech, ### 20200515 6/26/2020 ClinicalTria
NCT04395 15-Jun-20 Maternal-f Maternal-FTMF-COVIDCentre Hos ### 20200519 6/26/2020 ClinicalTria
NCT04400 15-Jun-20 The COVID-COvid-19 PCOPE University ### 20200521 6/26/2020 ClinicalTria
NCT04403 15-Jun-20 Cardiac Im Cardiovasc CISCO-19 NHS Greate ### 20200520 6/26/2020 ClinicalTria
NCT04408 15-Jun-20 COVID-19: Specimen CCAPTURE LumiraDx U ### 20200430 6/26/2020 ClinicalTria
NCT04408 15-Jun-20 GLS-1200ToEfficacy, Safety, and GeneOne Lif ### 20200522 6/26/2020 ClinicalTria
NCT04408 15-Jun-20 Efficacy an Efficacy an ACES Guy's and ### 20200527 6/26/2020 ClinicalTria
NCT04409 15-Jun-20 Chat-basedChat-based Instant MeThe Univer ### 20200526 6/26/2020 ClinicalTria
NCT04409 15-Jun-20 COVID 19 VCOVID19 Viral ClearanAssiut Univ ### 20200528 6/26/2020 ClinicalTria
NCT04409 15-Jun-20 Prevention A MulticentCOVID-PACThe TIMI S ### 20200528 6/26/2020 ClinicalTria
NCT04410 15-Jun-20 PREPARE-IBPREPARE-IBPREPARE I Hull Univer ### 20200529 6/26/2020 ClinicalTria
NCT04411 15-Jun-20 Cholecalci Randomized

CARED Vitamin D ### 20200526 6/26/2020 ClinicalTria
NCT04411 15-Jun-20 Risk Facto Risk Factors for Prol Azienda Us ### 20200529 6/26/2020 ClinicalTria
NCT04411 15-Jun-20 Current an Studies on Current an Karolinska ### 20200526 6/26/2020 ClinicalTria
NCT04411 15-Jun-20 Study of S Randomized Open Label

George Sak ### 20200529 6/26/2020 ClinicalTria
NCT04411 15-Jun-20 PROTECT-AS
PROTECT-AS
PROTECT- Hull Univer ### 20200529 6/26/2020 ClinicalTria
NCT04412 15-Jun-20 An Investi An Investigation on t Canadian M ### 20200529 6/26/2020 ClinicalTria
NCT04412 15-Jun-20 Prediction Bayesian NePredictCov Hospices Ci ### 20200529 6/26/2020 ClinicalTria
NCT04412 15-Jun-20 A Study in A Single-center, Rand Jon Lampa 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04412 15-Jun-20 Safety and A Randomized, Double-b

Chinese Ac ### 20200521 6/26/2020 ClinicalTria
NCT04412 15-Jun-20 Lung Ultra Lung Ultrasound for A Dalarna Co 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04412 15-Jun-20 Covid-19 anPrevalence COVIDIAB- Laboratoir 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04412 15-Jun-20 A RCT - Saf A Randomize

ARCHITECTQueen's Me6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04412 15-Jun-20 Cyclospori Phase I Trial for the University 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04413 15-Jun-20 Self-compaA Self-compassion GroUniversity ### 20200521 6/26/2020 ClinicalTria
NCT04413 15-Jun-20 Novel COVIPrevalence and ClinicaAssiut Univ 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04413 15-Jun-20 Efficiency Study of thNIVISCO Hospices Ci 6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04413 15-Jun-20 Immunomodu

Immunomodu
DEXDO-CO Assistance ### 20200421 6/26/2020 ClinicalTria
NCT04413 15-Jun-20 Registry o SeraphÂ®-100 Microbin
Children's ### 20200519 6/26/2020 ClinicalTria
NCT04413 15-Jun-20 COVID-19 IContaminatCOVIDOCR Assistance 6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04414 15-Jun-20 Protein Ele ComplicatioCOVELEC Elsan 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04414 15-Jun-20 Ruxolitinib Safety and Efficacy S Marcelo Ia ### 20200529 6/26/2020 ClinicalTria
NCT04414 15-Jun-20 A Clinical A Randomized, Open La

Kaleido Bi 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04414 15-Jun-20 Tools for Tools for Wellbeing C Rutgers, Th ### 20200531 6/26/2020 ClinicalTria
NCT04414 15-Jun-20 EchocardiogEchocardiogECHO-COV Hospital A ### 20200527 6/26/2020 ClinicalTria
NCT04414 15-Jun-20 Conestat AlRecombinant Human C1

NCT04414 15-Jun-20 DetermininDetermining the ReproImperial C ### 20200529 6/26/2020 ClinicalTria
NCT04415 15-Jun-20 A Phase 2 A Phase 2, RandomizedSyndax Pha ### 20200529 6/26/2020 ClinicalTria
NCT04415 15-Jun-20 Tofacitini Investigat I-TOMIC Yale Univer 6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 Extracellu the Determination of Gaziosmanp6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 Effect of Effect of COVID-PRECharite Uni 6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 The Role o The Role o COVID-19 Hong Kong 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 Development

Development
CovILD Medical Un ### 20200526 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 Photodynam

Photobiomodulation an
Cairo Unive ### 20200524 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 Mesenchyma

Mesenchyma
COVID-19 Instituto N ### 20200530 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 COVID-19 ConsequencCOVID Paris Trans ### 20200529 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 COVID 19 : COVID 19 : AntiCoV-H Rennes Uni ### 20200527 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 Autism SpecClinical E CLIECO University ### 20200519 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 COVID-19 COVID-19 aCOVID&PR Universida ### 20200529 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 COVID-19 EObservatioCOVIM French Inn 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04416 15-Jun-20 AssessmentA Proposed Alternativ University ### 20200513 6/26/2020 ClinicalTria
NCT04417 15-Jun-20 Reliability Reliability of the Fre Northwell 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04417 15-Jun-20 Reducing CReducing Hospital AdmRadboud Un ### 20200525 6/26/2020 ClinicalTria
NCT04418 15-Jun-20 Vocal Feat Testing of Soniphi Vo Soniphi LL 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04418 15-Jun-20 Project Re Comparison of the Eff University ### 20200529 6/26/2020 ClinicalTria
NCT04419 15-Jun-20 Efficacy o Determination of Effi Cambridge 6/3/2020 20200603 6/26/2020 ClinicalTria
ISRCTN144 15-Jun-20 COVID-19 i Understanding SARS-CoV-2

University
inf 6/5/2020 20200605 6/26/2020 ISRCTN
ISRCTN590 15-Jun-20 SulodexideEndothelium restoration
CLINEDEM
and the 6/4/2020 20200604 6/26/2020 ISRCTN
ISRCTN558 15-Jun-20 Investigat TRACK-COVID: a population-base

ISRCTN153 15-Jun-20 A study to A cohort study to evaluate
SingHealth 6/1/2020 20200601 6/26/2020 ISRCTN
ISRCTN119 15-Jun-20 Whatâ€™s St ero-epidemiological survey
University
of En 6/1/2020 20200601 6/26/2020 ISRCTN
ChiCTR200 15-Jun-20 Serum protSerum protein marker Chongqing
in patient ### 20200615 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 Developmen

Development and Applicat
Shengjing H ### 20200614 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 The effica The efficacy and safetyTongji

of Hosp ### 20200612 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 A medical Retrospective cohort study
Department
of n ### 20200612 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 A medical Study on predictors of Department
novel co ### 20200612 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 A medical Analysis of Tongue Features

Evidence-Ba
of ### 20200612 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 Evaluating Evaluating the EfficacyChildren's

and ### 20200611 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 Clinical st Clinical study on the efMaoming Pe ### 20200611 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 A study fo A study for long-term prognosi
ChiCTR200 15-Jun-20 Clinical ob Clinical observation of Dongguan P ### 20200610 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 Hip FracturHip Fracture in elderly Hospital
peopl Ra ### 20200610 6/26/2020 ChiCTR
ChiCTR200 15-Jun-20 A medical rPreliminary efficacy ofXijing

Tocil Hosp ### 20200610 6/26/2020 ChiCTR
The
Danish
Pre-HCQ
Dialysis
Study:
Hydroxyc
hloroquin
e for
preventio
n of
COVID-19
in
dialysis-
treated
patients
with end-
stage
renal
disease -
A
multicent
er
parallel-
group
open
randomiz
ed clinical
trial
- The
Danish
Pre-HCQ
COVID19
Dialysis
EUCTR202015-Jun-20 Hydroxychlo
Study Rigshospita ### 20200326 6/26/2020 EU Clinical
Low dose
of IL-2 In
Acute
respirator
y DistrEss
syndrome
related to
COVID-19
LILIADE-
COVID
- LILIADE-
COVID
EUCTR202015-Jun-20 Low dose of Assistance 4/7/2020 20200407 6/26/2020 EU Clinical

EUCTR202015-Jun-20 MedicationCOVID-19 Prophylaxis Odense
with Uni ### 20200417 6/26/2020 EU Clinical
EUCTR202015-Jun-20 Hydroxychlo
An adaptive Phase 2/3,sanofi-ave
ra ### 20200330 6/26/2020 EU Clinical
EUCTR202015-Jun-20 Phase 3 ranPhase 3 randomized, doub
Novartis P ### 20200415 6/26/2020 EU Clinical
EUCTR202015-Jun-20 A study to A phase III, double-bl Vakzine P 4/6/2020 20200406 6/26/2020 EU Clinical
EUCTR202015-Jun-20 Low Dose Or
A Phase 2 RandomizedKaryopharm4/6/2020
Si 20200406 6/26/2020 EU Clinical
EUCTR202015-Jun-20 Testing theAdaptive design phaseBiophytis S 5/3/2020 20200503 6/26/2020 EU Clinical
EUCTR202015-Jun-20 A study to A Prospective, Multi-CImmunic A ### 20200514 6/26/2020 EU Clinical
EUCTR201815-Jun-20 STOP PIV - A Phase III RandomizeAnsun Biop ### 20191121 6/26/2020 EU Clinical
A single-
site,
randomis
ed,
controlle
d, parallel
design,
open-
label
investiga
tion of an
approved
nebulised
recombin
The ant
COVASE human
study: DNase
Investiga enzyme
tion of an (dornase
approved alfa) to
nebulised reduce
human hyperinfla
Dnase mmation
enzyme in
(Pulmozy hospitalis
me) to ed
reduce participan
hyperinfla ts with
mmation COVID-19
in (The
hospitalis COVASE
ed people trial)
with - Dornase
EUCTR202015-Jun-20 COVID-19 al University 6/8/2020 20200608 6/26/2020 EU Clinical
EUCTR202015-Jun-20 COVID-19: ECOVID-19: Efficacy of solna
Department ### 20200331 6/26/2020 EU Clinical
DRKS0002115-Jun-20 COVID-19 aCOVID-19 associated brainstem
Klinik fÃ¼ e ### 20200420 6/26/2020 German Clin
DRKS0002115-Jun-20 Feasibility Feasibility and usabilityUniversitÃ
of ### 20200428 6/26/2020 German Clin
DRKS0002115-Jun-20 CytoResc - CytoResc - CytoSorb RescueCharitÃ©for CC ### 20200427 6/26/2020 German Clin
DRKS0002115-Jun-20 SARS-CoV-2SARS-CoV-2 in tears inKlinikpatients
fÃ¼wi ### 20200430 6/26/2020 German Clin
DRKS0002115-Jun-20 ObservationObservational clinical tria
Klinikum r ### 20200416 6/26/2020 German Clin
DRKS0002115-Jun-20 Explorativ Explorative Study of the German
As Can ### 20200612 6/26/2020 German Clin
DRKS0002115-Jun-20 LimitationsLimitations of social lifeCarl von O 5/4/2020 20200504 6/26/2020 German Clin
DRKS0002115-Jun-20 Exploring Exploring immunological Institut
control
fÃ 6/4/2020 20200604 6/26/2020 German Clin
DRKS0002115-Jun-20 ProspectiveProspective gas chromat Klinik fÃ¼ ### 20200420 6/26/2020 German Clin
DRKS0002115-Jun-20 The effect The effects of the COVID-19
UniversitÃ
pand ### 20200417 6/26/2020 German Clin
DRKS0002115-Jun-20 Dysosmia aDysosmia and Dysgeusia Kantonsspi
in COVID-19 ### 20200422 6/26/2020 German Clin
DRKS0002115-Jun-20 PrevalencePrevalence of COVID-19 Zentrum
in Chil fÃ ### 20200422 6/26/2020 German Clin
DRKS0002115-Jun-20 The influenThe influence of proton UniversitÃ¤
pump i ### 20200427 6/26/2020 German Clin
DRKS0002115-Jun-20 Local and sLocal and systemic markersUniversitÃ¤ ### 20200422 6/26/2020 German Clin
DRKS0002115-Jun-20 Evaluation Evaluation of online suppo
UniversitÃ¤ ### 20200424 6/26/2020 German Clin
DRKS0002115-Jun-20 Registry of Registry of hospitalizedUniversitÃ
pediat ### 20200422 6/26/2020 German Clin
DRKS0002115-Jun-20 Database f Database for diagnosisInstitut
and thera
f ### 20200424 6/26/2020 German Clin
DRKS0002115-Jun-20 Investigati Investigation of the predict
Klinikum d ### 20200519 6/26/2020 German Clin
DRKS0002115-Jun-20 Impact of Impact of pantoprazoleUniversitÃ
on ab ### 20200427 6/26/2020 German Clin
DRKS0002115-Jun-20 Covid-19 HO Covid-19 HOspitalized UniversitÃ¤
patients Re ### 20200429 6/26/2020 German Clin
DRKS0002115-Jun-20 Validation Validation of new detection
UniversitÃ¤
met ### 20200428 6/26/2020 German Clin
DRKS0002115-Jun-20 Long term ALong term Analysis andKlinikum

Eva St ### 20200430 6/26/2020 German Clin
DRKS0002115-Jun-20 Lung Ultra Lung Ultrasound in Covid-19
VivantesPneum
H ### 20200429 6/26/2020 German Clin
DRKS0002115-Jun-20 Naturalisti Naturalistic evaluationUniversitÃ¤
o 5/4/2020 20200504 6/26/2020 German Clin
DRKS0002115-Jun-20 AlterationsAlterations in inflammatory
Klinikuman d ### 20200427 6/26/2020 German Clin
DRKS0002115-Jun-20 A short, a A short, animated video Heidelberg
to ### 20200512 6/26/2020 German Clin
DRKS0002115-Jun-20 Identificat Identification of predictive
Bundeswehr
bio ### 20200427 6/26/2020 German Clin
DRKS0002115-Jun-20 COVID-19 RCOVID-19 Registry FreiburgUniversitÃ
- COVID ### 20200330 6/26/2020 German Clin
DRKS0002115-Jun-20 COVID-19 rCOVID-19 related obstetricVorstand
and d ### 20200331 6/26/2020 German Clin
DRKS0002115-Jun-20 Improvemen Improvement of the nutrition
Klinik fÃ¼r 4/1/2020 20200401 6/26/2020 German Clin
DRKS0002115-Jun-20 Point-of-caPoint-of-care coagulationPrivate
testiUn ### 20200428 6/26/2020 German Clin
DRKS0002115-Jun-20 Investigati Investigation of the influ
Leiter der 4/3/2020 20200403 6/26/2020 German Clin
DRKS0002115-Jun-20 PROTEGO: P ROTEGO: PRospectiveUniversitÃ 5/4/2020 20200504 6/26/2020 German Clin

DRKS0002115-Jun-20 COVID-19 RCOVID-19 Registry of theKlinikum
LMU Hos
d 4/1/2020 20200401 6/26/2020 German Clin
DRKS0002115-Jun-20 Evaluation Evaluation of the performanc
UniversitÃ 4/1/2020 20200401 6/26/2020 German Clin
DRKS0002115-Jun-20 AccompanyiAccompanying monitoring Paracelsus
of pr 4/2/2020 20200402 6/26/2020 German Clin
DRKS0002115-Jun-20 Developmen Development of a testInstitut
to measufÃ ### 20200327 6/26/2020 German Clin
DRKS0002115-Jun-20 DemographicDemographic and epidemiologi
Abteilung 4/7/2020 20200407 6/26/2020 German Clin
DRKS0002115-Jun-20 Psychologi Psychological distress of
Klinik
the fÃ¼ ### 20200327 6/26/2020 German Clin
Lean
European
Open
Survey on
SARS-
CoV-2
(COVID-
19) -
LEOSS
Lean
European
Open
Survey on
SARS-
CoV-2
(COVID-
DRKS0002115-Jun-20 19) Deutsches 4/8/2020 20200408 6/26/2020 German Clin
DRKS0002115-Jun-20 COVID-19 CCOVID-19 Contact Study Medizinisc
- Immu 4/7/2020 20200407 6/26/2020 German Clin
DRKS0002115-Jun-20 get.calm anget.calm and move.onLeuphana
â€“ tac U4/6/2020 20200406 6/26/2020 German Clin
DRKS0002115-Jun-20 prospectiv prospective observationa KKH Bergst ### 20200326 6/26/2020 German Clin
DRKS0002115-Jun-20 An e-MentaAn e-Mental Health Interventi
Klinik fÃ¼ ### 20200416 6/26/2020 German Clin
DRKS0002115-Jun-20 Cytokine a Cytokine adsorption inUniversitÃ
sever 4/8/2020 20200408 6/26/2020 German Clin
DRKS0002115-Jun-20 Covid-19 C Covid-19 Case-Cluster-Study
Institut fÃ ### 20200414 6/26/2020 German Clin
DRKS0002115-Jun-20 Study on S Study on SARS-CoV-2-Serology
Performa(CO N ### 20200414 6/26/2020 German Clin
DRKS0002115-Jun-20 Clinical ch Clinical characteristics Nierenzent
of renal 5/4/2020 20200504 6/26/2020 German Clin
DRKS0002115-Jun-20 Clinical an Clinical and immunological
Nierenzent 5/4/2020 20200504 6/26/2020 German Clin
DRKS0002115-Jun-20 VOICE: Onl VOICE: Online-Survey on UniversitÃ
dist 4/9/2020 20200409 6/26/2020 German Clin
DRKS0002115-Jun-20 Dynamics oDynamics of regional lung UniversitÃ
ae 4/6/2020 20200406 6/26/2020 German Clin
DRKS0002115-Jun-20 ProspectiveProspective molecularKrankenhaus
bio ### 20200415 6/26/2020 German Clin
DRKS0002115-Jun-20 Effects of Effects of digital homeGoethe-Uni ### 20200420 6/26/2020 German Clin
DRKS0002115-Jun-20 Identificat Identification of host cell
Klinik fÃ¼r ### 20200319 6/26/2020 German Clin
DRKS0002215-Jun-20 TraumatoloTraumatological emergency BG Unfallk consu6/5/2020 20200605 6/26/2020 German Clin
DRKS0002215-Jun-20 CovidCare 1CovidCare 1 â€“ Surveillanc
UniversitÃ 6/2/2020 20200602 6/26/2020 German Clin
DRKS0002215-Jun-20 An intensi An intensive longitudinal MSB st Medica ### 20200612 6/26/2020 German Clin
DRKS0002215-Jun-20 PsychosociaPsychosocial functioning UniversitÃ¤ ### 20200529 6/26/2020 German Clin
DRKS0002215-Jun-20 Evaluation Evaluation of three co Landesklin 6/9/2020 20200609 6/26/2020 German Clin
DRKS0002215-Jun-20 PrevalencePrevalence of SARS-CoV-2 UniversitÃ¤
(COV 6/3/2020 20200603 6/26/2020 German Clin
DRKS0002115-Jun-20 Investigati Investigation of the immun
KassenÃ¤rz 6/5/2020 20200605 6/26/2020 German Clin
DRKS0002115-Jun-20 Survival an Survival and risk factorsKlinik
in Cov fÃ¼ ### 20200528 6/26/2020 German Clin
DRKS0002115-Jun-20 The role o The role of immune-reactions
UniversitÃ in ### 20200527 6/26/2020 German Clin
DRKS0002115-Jun-20 COVID-19 inCOVID-19 in an academic Klinikum
te Ko ### 20200428 6/26/2020 German Clin
DRKS0002115-Jun-20 Hypernatrem Hypernatremia in critically
Ortenauklin
ill pa ### 20200512 6/26/2020 German Clin
DRKS0002115-Jun-20 CORRECT: CO CORRECT: COvid (Covid-19)Klinikum Regisr ### 20200430 6/26/2020 German Clin
DRKS0002115-Jun-20 RetrospectRetrospective analysis Schwerpunk
of ### 20200511 6/26/2020 German Clin
Retrospec
tive
examinati
on of the
course of
a Covid-
19
infection
Retrospec in
tive patients
examinati with
on of the inflamma
course of tory
a Covid- bowel
19 disease
infection
in
patients
with
inflamma
tory
bowel
DRKS0002115-Jun-20 disease Gesellschaf 6/5/2020 20200605 6/26/2020 German Clin
DRKS0002115-Jun-20 Detection Detection of a delayedUKSH 5/6/2020 20200506 6/26/2020 German Clin
DRKS0002115-Jun-20 Analysis o Analysis of the Pathophysiolo
CharitÃ© C ### 20200513 6/26/2020 German Clin
DRKS0002115-Jun-20 Quality ass Quality assurance of cochlear
UniversitÃ¤ ### 20200512 6/26/2020 German Clin
DRKS0002115-Jun-20 lnfluence lnfluence of the COVID-19-pandem
Klinik fÃ¼r ### 20200511 6/26/2020 German Clin
DRKS0002115-Jun-20 Prospectiv Prospective COVID-19 Abteilung
Cohort Munic ### 20200519 6/26/2020 German Clin
DRKS0002115-Jun-20 Incidence aIncidence and risk factors
UniversitÃ
for ac 5/5/2020 20200505 6/26/2020 German Clin
DRKS0002115-Jun-20 Influence Influence of COVID-19HNO Infection
Univer ### 20200514 6/26/2020 German Clin
DRKS0002115-Jun-20 Sorting th Sorting the wheat formUniversitÃ
the ch 5/8/2020 20200508 6/26/2020 German Clin
DRKS0002115-Jun-20 COVID-19 aCOVID-19 associated neuropathy
Klinik fÃ¼ ### 20200511 6/26/2020 German Clin
DRKS0002115-Jun-20 Communicat Communication in times Klinik
of the
III c 5/8/2020 20200508 6/26/2020 German Clin
DRKS0002115-Jun-20 Neuroendoc Neuroendocrine mechanisms
Institut SofÃ 5/6/2020 20200506 6/26/2020 German Clin
DRKS0002115-Jun-20 Incidence aIncidence and long-term UniversitÃ
co ### 20200512 6/26/2020 German Clin
DRKS0002115-Jun-20 A prospectiA prospective trial on the
Helios Uni ### 20200525 6/26/2020 German Clin
DRKS0002115-Jun-20 Treatment Toreatment of Sars-CoV2 Klinikum
infec S ### 20200610 6/26/2020 German Clin
DRKS0002115-Jun-20 Evaluation Evaluation of online suppUniversitÃ¤ ### 20200515 6/26/2020 German Clin
DRKS0002115-Jun-20 Serial cros Serial cross-sectional sUniversita ### 20200518 6/26/2020 German Clin
DRKS0002115-Jun-20 Impact of Impact of the COVID-19 Lehrstuhl
Pandemf ### 20200519 6/26/2020 German Clin
DRKS0002115-Jun-20 Influence oInfluence of the Corona UniversitÃ
regula ### 20200529 6/26/2020 German Clin
DRKS0002115-Jun-20 Covid-19 r Covid-19 related Obstetric
UniversitÃ
Ana ### 20200518 6/26/2020 German Clin
DRKS0002115-Jun-20 COVID-19 tCOVID-19 treatment outcomes
AbteilungatI ### 20200610 6/26/2020 German Clin
DRKS0002115-Jun-20 CoViD-19 i CoViD-19 imaging registerKlinikstudy
fÃ¼rA ### 20200515 6/26/2020 German Clin
DRKS0002115-Jun-20 Study plat Study platform ArcHIVMUC - SubResea ### 20200528 6/26/2020 German Clin
DRKS0002115-Jun-20 The ImpactThe Impact of quarantine UniversitÃ
and ### 20200528 6/26/2020 German Clin
SLCTR/202 15-Jun-20 HydroxychlHydroxychloroquine for
Department
Post 5/4/2020 20200504 6/26/2020 SLCTR
IRCT20200 15-Jun-20 Study to EvA prospective randomized
Digestive D ### 20200314 6/26/2020 IRCT
IRCT20200 15-Jun-20 treatment Assessment of vitaminGhoum

A eff Univ ### 20200612 6/26/2020 IRCT
IRCT20200 15-Jun-20 The effect The effect of naproxenAbadan
on the he
Uni ### 20200330 6/26/2020 IRCT
IRCT20180 15-Jun-20 Efficacy of Efficacy of the myrtle (Myrt
Kerman Uni ### 20200328 6/26/2020 IRCT
IRCT20180 15-Jun-20 Efficacy of Efficacy of the barley-based
Kerman Uni ### 20200328 6/26/2020 IRCT
IRCT20200 15-Jun-20 ComparisonComparison of vitaminAbadanD3 and Uni ### 20200329 6/26/2020 IRCT
IRCT20200 15-Jun-20 ComparisonEvaluation of safety a Bagheiat-al 4/1/2020 20200401 6/26/2020 IRCT
IRCT20190 15-Jun-20 Effect of c Investigation of the efficac
Yazd Univer ### 20200518 6/26/2020 IRCT
IRCT20200 15-Jun-20 Evaluation The efficacy of oral 25-hydr
Tehran Uni 4/9/2020 20200409 6/26/2020 IRCT
IRCT20180 15-Jun-20 Effect of A Evaluation of the effectIran
of Ar
Univer ### 20200418 6/26/2020 IRCT
IRCT20200 15-Jun-20 Effect of Study of Methylprednisolone
Tehran Uni ### 20200415 6/26/2020 IRCT
IRCT20151 15-Jun-20 A study on A study on melatonin and
Semnan
Vi Uni4/9/2020 20200409 6/26/2020 IRCT
IRCT20081 15-Jun-20 Effect of Study of Prednisolone Tehran
effec Uni 6/1/2020 20200601 6/26/2020 IRCT
IRCT20091 15-Jun-20 The effect The effect of surfactantShahid
on cl Behe6/1/2020 20200601 6/26/2020 IRCT
IRCT20200 15-Jun-20 Evaluation Investigating preventive
Tehran
ef Uni ### 20200411 6/26/2020 IRCT
IRCT20200 15-Jun-20 Mesenchyma Mesenchymal Stem Cell Iranian
Therap
ac ### 20200413 6/26/2020 IRCT
IRCT20200 15-Jun-20 The effect Evaluating efficacy andMazandaran ### 20200531 6/26/2020 IRCT
IRCT20190 15-Jun-20 ANIF1 effe Evaluation of ANIF1 antiviral
Mazandaran
d ### 20200612 6/26/2020 IRCT
IRCT20200 15-Jun-20 web- basedThe effect of the web- Shahroud
ba U ### 20200530 6/26/2020 IRCT
IRCT20081 15-Jun-20 Clinical tr Evaluation of the effectMashhad
of tr Un ### 20200517 6/26/2020 IRCT
IRCT20091 15-Jun-20 Effect of i Effect of intratracheal Tabriz
In Univ ### 20200518 6/26/2020 IRCT
IRCT20200 15-Jun-20 effects of evaluation of the eff Mashhad Un ### 20200426 6/26/2020 IRCT
IRCT20190 15-Jun-20 Effect of s Investigating the effectivenes
Deputy Dea ### 20200517 6/26/2020 IRCT
IRCT20200 15-Jun-20 Effect of Investigating the EffectProfessor
of A ### 20200518 6/26/2020 IRCT
IRCT20150 15-Jun-20 PembrolizuThe evaluation of safetyCinnaGen
and ### 20200527 6/26/2020 IRCT
IRCT20080 15-Jun-20 Investigat Investigating the efficacy
Niwasha
a c ### 20200527 6/26/2020 IRCT
IRCT20200 15-Jun-20 Effect of Comparison effect of N-C Shahid Behe6/7/2020 20200607 6/26/2020 IRCT
IRCT20200 15-Jun-20 Evaluation Evaluation of the efficien
Quality Im ### 20200516 6/26/2020 IRCT
IRCT20200 15-Jun-20 IVIG and C Intravenous immunoglubolin
Oroumia( Un ### 20200517 6/26/2020 IRCT
IRCT20200 15-Jun-20 Effects of Effects of a Persian diet"no
Semnan Uni ### 20200521 6/26/2020 IRCT
IRCT20131 15-Jun-20 The effect The effect of cupping (Persian
Mazandaran ### 20200520 6/26/2020 IRCT
IRCT20150 15-Jun-20 Prone positProne position effectiveness
Shahid Behe ### 20200613 6/26/2020 IRCT
IRCT20200 15-Jun-20 Evaluation Evaluation of the effectSemnan
of G Uni ### 20200516 6/26/2020 IRCT
IRCT20200 15-Jun-20 Effect of Effect of Laris-Teucrium Tabriz Univ 6/2/2020 20200602 6/26/2020 IRCT
IRCT20200 15-Jun-20 Evaluation Evaluation of the therapeuti
Ardabil Uni ### 20200514 6/26/2020 IRCT
IRCT20200 15-Jun-20 Vitamin A The effect of supplementatIran Univer ### 20200611 6/26/2020 IRCT
IRCT20170 15-Jun-20 Low dose wEvaluation of low doseTehranwhole Uni
l ### 20200525 6/26/2020 IRCT
IRCT20081 15-Jun-20 Efficacy o Comparison Efficacy of Yasouj Univ ### 20200517 6/26/2020 IRCT
IRCT20200 15-Jun-20 Stem cell Assessment of safety, DEY Compa ### 20200514 6/26/2020 IRCT
IRCT20180 15-Jun-20 The efficac Investigating the effectShahid
o Behe ### 20200611 6/26/2020 IRCT
IRCT20200 15-Jun-20 The effect The effect of cognitive-bTehran Uni ### 20200516 6/26/2020 IRCT
IRCT20140 15-Jun-20 Polio Vacc Short-term Protection Petroleum
for COVID-1 ### 20200523 6/26/2020 IRCT
IRCT20200 15-Jun-20 Effects of Evaluation of the effectsBandare-ab
o ### 20200531 6/26/2020 IRCT
IRCT20200 15-Jun-20 Evaluation Evaluation effects of DINVL
Health heMed ### 20200523 6/26/2020 IRCT
IRCT20151 15-Jun-20 Evaluating Evaluation the efficacyShahid
and Behe ### 20200518 6/26/2020 IRCT
IRCT20150 15-Jun-20 sex hormonThe use of sex hormones Mashhad
in the cUn ### 20200529 6/26/2020 IRCT
IRCT20200 15-Jun-20 Evaluation Evaluation of the effectArakof Univer ### 20200515 6/26/2020 IRCT
IRCT20120 15-Jun-20 Evaluating Evaluating the effect oHamedan Un ### 20200518 6/26/2020 IRCT
IRCT20200 15-Jun-20 Efficacy ev Efficacy evaluation of inha
CinnaGen ### 20200516 6/26/2020 IRCT
IRCT20170 15-Jun-20 Effect of Effect of the combination Shahid Beh ### 20200612 6/26/2020 IRCT
IRCT20090 15-Jun-20 AssessmentAssessment of boron-cont Tabriz Univ ### 20200517 6/26/2020 IRCT
IRCT20080 15-Jun-20 Investigati Investigating the efficacy
Bagheiat-al ### 20200523 6/26/2020 IRCT
Bagheiat-al
a ### 20200514 6/26/2020 IRCT
IRCT20200 15-Jun-20 HydroxychlEvaluation of the efficie
Quality Im ### 20200610 6/26/2020 IRCT
Bagheiat-al
of ### 20200528 6/26/2020 IRCT
IRCT20200 15-Jun-20 The effect The effects of Ginger on Bandare-ab
c ### 20200523 6/26/2020 IRCT
IRCT20080 15-Jun-20 Evaluation Evaluation efficacy of "Curcu
Bagheiat-al ### 20200523 6/26/2020 IRCT
IRCT20200 15-Jun-20 Efficacy o Evaluating efficacy of Ke
Ardabil Uni ### 20200519 6/26/2020 IRCT
IRCT20200 15-Jun-20 Interventi The effect of methanolicKashan Uni ### 20200517 6/26/2020 IRCT
IRCT20151 15-Jun-20 Evolution Evolution of the efficacyShahid Behe ### 20200531 6/26/2020 IRCT
IRCT20200 15-Jun-20 Investigati Interventional study ofShahid
in Behe ### 20200519 6/26/2020 IRCT
IRCT20150 15-Jun-20 Plasmaphere Plasmapheresis and plasma
Shahidexcha
Behe ### 20200531 6/26/2020 IRCT
IRCT20160 15-Jun-20 stem cell t Evolution of Allogenic Mashhad
Mesen Un ### 20200530 6/26/2020 IRCT
IRCT20151 15-Jun-20 The effect The effect of omega-3 Sabzevar
suppl Un ### 20200520 6/26/2020 IRCT
IRCT20180 15-Jun-20 Effect of A The effect of Auriculotherapy
Yazd Univer
on ### 20200613 6/26/2020 IRCT
IRCT20200 15-Jun-20 ComparisonEvaluation of the effic Arak Univer ### 20200529 6/26/2020 IRCT
IRCT20150 15-Jun-20 Cyclospori Cyclosporin for the Prevention
Shahid Behe
a ### 20200525 6/26/2020 IRCT
IRCT20200 15-Jun-20 Effect of L Effect of Laris - HyssopTabriz
c Univ ### 20200521 6/26/2020 IRCT
IRCT20200 15-Jun-20 Evaluation Evaluation the anti-inflammato
Ahvaz Univ ### 20200528 6/26/2020 IRCT
IRCT20151 15-Jun-20 PentaglobinThe effect of pentaglobinShahid
in thBehe ### 20200610 6/26/2020 IRCT
IRCT20161 15-Jun-20 Using inte Evaluation and comparisonMashhad
of Un6/2/2020 20200602 6/26/2020 IRCT
Bagheiat-al
an ### 20200527 6/26/2020 IRCT
IRCT20160 15-Jun-20 Investigati Investigation of the effe
Khoram-Aba6/8/2020 20200608 6/26/2020 IRCT
IRCT20200 15-Jun-20 Clinical tr A randomized clinical tr
Ahvaz Univ ### 20200530 6/26/2020 IRCT
IRCT20200 15-Jun-20 Treatment Immediate uses of convalesc
High Educa ### 20200614 6/26/2020 IRCT
IRCT20200 15-Jun-20 Effect of U Evaluating effectiveness
Tehran
a Uni 6/6/2020 20200606 6/26/2020 IRCT
IRCT20150 15-Jun-20 Evaluation Evaluation the effects of
Vice
Oxyc
chance6/8/2020 20200608 6/26/2020 IRCT
IRCT20200 15-Jun-20 Effect of D Effect of Dinvl medicinal
Zahravi
h Ph 6/6/2020 20200606 6/26/2020 IRCT
IRCT20120 15-Jun-20 effect of a ?Evaluation of Safety and
Persisgen
effi ### 20200613 6/26/2020 IRCT
IRCT20200 15-Jun-20 Evaluation Evaluation the effect ofJahrom
ra Uni ### 20200611 6/26/2020 IRCT
KCT00051015-Jun-20 A Trial of A Trial of Ciclesonide inKoera
Adults
Univ
w ### 20200610 6/26/2020 CRIS
LBCTR202015-Jun-20 The effect The effect of confinement

HotelonDieu ### 20200416 6/26/2020 LBCTR
LBCTR202015-Jun-20 An internatAn international randomise
WHO ### 20200423 6/26/2020 LBCTR
JPRN-Japic 15-Jun-20 A Study to A Study to Evaluate theChugai
Safet Phar ### 20200423 6/26/2020 JPRN
JPRN-jRCT 15-Jun-20 new SARS-CClinical evaluation of the
Watanabe
SARS- Y5/1/2020 20200501 6/26/2020 JPRN
JPRN-jRCT 15-Jun-20 A MulticentA Multicenter, Adaptive Ohmagari ### 20200520 6/26/2020 JPRN
JPRN-jRCT 15-Jun-20 Triple com A prospective multi-cente
Tokue Yuta ### 20200227 6/26/2020 JPRN
JPRN-jRCT 15-Jun-20 A multicentA multicenter, open-label
Sugiyama H ### 20200327 6/26/2020 JPRN
JPRN-jRCT 15-Jun-20 CombinatioMulticenter, Single blindKyoji Mori 5/1/2020 20200501 6/26/2020 JPRN
JPRN-jRCT 15-Jun-20 Clinical sa Clinical safety and usefulness
Wakabayash
o 6/3/2020 20200603 6/26/2020 JPRN
JPRN-jRCT 15-Jun-20 Favipiravir Multicenter, open-label,
Doir Yohei 3/2/2020 20200302 6/26/2020 JPRN
JPRN-jRCT 15-Jun-20 Teprenone Randomized controlledICHIHARA
trial of E ### 20200520 6/26/2020 JPRN
Preventio
n of
COVID-19
infection
in a
medical
institutio
n
and
maintena
nce of
medical
system -
Preventio
n of
COVID-19
infection
Preventio in a
n of medical
COVID-19 institutio
infection n
in a and
medical maintena
institutio nce of Jichi
n medical Medical
and system University
maintena Division
nce of of
medical Gastroent
JPRN-UMIN15-Jun-20 system erology 4/1/2020 20200401 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 A prospectiA prospective cohort study
Yokohama C ### 20200422 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 Fact-findin Fact-finding survey on Kanagawa
sub P5/8/2020 20200508 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 ImmunologiImmunological efficacyAdministra
of Qi 5/9/2020 20200509 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 ExaminatioEndoscopy is an aerosol Oita
genSan-a ### 20200511 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 InternationInternational survey toJapanese
invest S ### 20200518 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 ImmunologiImmunological efficacyAdministra
of J ### 20200515 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 COVID 19 - COVID 19 - What FamiliesSt. Marian ### 20200520 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 Corona viruLong-term follow-up ofDaini Osaka ### 20200525 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 Immunologic Immunological efficacyAdministra
of lac ### 20200522 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 Usefulness Usefulness of PCR testinChiba Unive ### 20200526 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 ExaminatioEndoscopy is an aerosol Oita
genSan-a ### 20200526 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 Prospectiv Prospective observation Juntendo U ### 20200528 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 The analysiThe analysis of COVID-19Yokohama
in C6/1/2020 20200601 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 Clinical Ou Clinical Outcomes of COVID-
Toho Unive 6/1/2020 20200601 6/26/2020 JPRN
Homeopa
thy for
Covid-19
in
primary
care:
randomiz
ed,
parallel-
group,
double-
blind,
placebo-
controlle
d, clinical
trial -
Homeopa
thy for
Covid-19
in
primary
care:
randomiz
ed,
parallel-
group,
double-
blind,
placebo-
controlle
d, clinical
trial
(Covid-
JPRN-UMIN15-Jun-20 Homeopathy Simile st Sao Carlos 6/1/2020 20200601 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 A retrospecA retrospective study on
Japanese
the t R 6/1/2020 20200601 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 RetrospectiRetrospective study onJapanese
clinical R 6/1/2020 20200601 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 A retrospecA retrospective study on
Japanese
serum R 6/1/2020 20200601 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 prospectiveprospective cohort study
Gunma pref6/9/2020 20200609 6/26/2020 JPRN
JPRN-UMIN15-Jun-20 Longitudin Longitudinal study on wor
Keio Unive 6/8/2020 20200608 6/26/2020 JPRN
Kinki
Health
Administr
ation
Center,
Mie
Health
Checkup
JPRN-UMIN15-Jun-20 SUrveillan SUrveillance of SARS-CoV-2
Clinic Vir 6/9/2020 20200609 6/26/2020 JPRN
Lagos
COVID-19
Chloroqui
ne
Treatmen
t Trial
(LACCTT)
PACTR202015-Jun-20 A Single-Center, Random
LAGOS ST 4/2/2020 20200402 6/26/2020 PACTR
PACTR202015-Jun-20 Effectiven Effectiveness of Measles
Misr
Vac
Unive ### 20200412 6/26/2020 PACTR
PACTR202015-Jun-20 Efficacy an Efficacy and safety of IInternatio ### 20200413 6/26/2020 PACTR
PACTR202015-Jun-20 Folic acid The host Epigenetic methylati

Faculty of ### 20200416 6/26/2020 PACTR
PACTR202015-Jun-20 Preventing PROTECT-Surg Dr Birgit ### 20200421 6/26/2020 PACTR
PACTR202015-Jun-20 A study to A phase Ib/II single-bliUniversity ### 20200426 6/26/2020 PACTR
PACTR202015-Jun-20 HydroxychlEfficacy and safety of Hy

Faculty of ### 20200514 6/26/2020 PACTR
PACTR202015-Jun-20 Effect of Efficacy of Interferential

AWOLOLA
T ### 20200525 6/26/2020 PACTR
PACTR202015-Jun-20 Efficacy o Randomized clinical trial,

Malagasy ### 20200529 6/26/2020 PACTR
RBR-6m69f15-Jun-20 TherapeuticTherapeutic PulmonaryUniversidad4/2/2020

Teler 20200402 6/26/2020 REBEC
RBR-9pgwf 15-Jun-20 PsychologicPsychological effects ofHospital
preventUn 4/9/2020 20200409 6/26/2020 REBEC
RBR-8969z 15-Jun-20 Treatment Clinical Trial using N-acetylcy
Universidad ### 20200413 6/26/2020 REBEC
Evaluatio
n of
patients
treated
by
telemedic
ine in the
Covid-19
pandemic
in Brazil
in a
Telemedi medical
cine in clinic in
the the
Covid-19 suppleme
pandemic ntary
in Brazil health
in a sector in
medical SÃ£o
clinic in Paulo,
the Brazil - :
suppleme MAZZEI
ntary MEDICAL
health CENTER
sector in
SÃ£o
Paulo,
RBR-658k 15-Jun-20 Brazil Centro Medi ### 20200422 6/26/2020 REBEC
RBR-6w5tb 15-Jun-20 Effects of Effectiveness of a protoHospital UniversitÃ¡rio
### 20200429
de BrasÃlia6/26/2020
- BrasÃlia,REBEC
DF, Brazil
Evaluatio
n of the
use of
Hydroxyc
hlorochin
e in
Chinese
flu
RBR-3k4wx15-Jun-20 Evaluation of the use of
Hospital
Hydr Sa 5/5/2020 20200505 6/26/2020 REBEC
RBR-3rdhg 15-Jun-20 The role of The role of early acuteDepartamento
renal de###
ClÃn20200514
ica MÃ©dica 6/26/2020
da Faculdade
REBECde Medicina de Bot
RBR-4vm3y15-Jun-20 Effect of c Use of convalescent plasma
Instituto
s E ### 20200515 6/26/2020 REBEC
RBR-62y3h 15-Jun-20 Acute impaiAcute Kidney Injury in Faculdade
Infecti d ### 20200518 6/26/2020 REBEC
RBR-9y32y 15-Jun-20 Acute and cAcute and chronic cardioUniversidad ### 20200524 6/26/2020 REBEC
RBR-9d8z6 15-Jun-20 Safety and Open and controlled tria

Hospital do ### 20200327 6/26/2020 REBEC
RBR-2dxyx 15-Jun-20 MechanicalMechanical ventilator Hospital
for use i Un 6/2/2020 20200602 6/26/2020 REBEC
RBR-43hbk 15-Jun-20 Evaluation Evaluation with point-of-ca
Disciplina 6/3/2020 20200603 6/26/2020 REBEC
RBR-949z6 15-Jun-20 Full versus Full versus prophylacticFaculdade
h d5/6/2020 20200506 6/26/2020 REBEC
RBR-876qb 15-Jun-20 Treatment Eculizumab for the treatment

Hospitalofdas6/8/2020
ClÃnicas da
20200608
Faculdade
6/26/2020
de Medicina
REBEC
de RibeirÃ£o Preto da
RBR-4qjzh 15-Jun-20 Study of vaA prospective observational
Disciplina
st 6/8/2020 20200608 6/26/2020 REBEC
RPCEC000015-Jun-20 CIGB 2020 Randomized control clinical
Centert for ### 20200413 6/26/2020 RPCEC
RPCEC000015-Jun-20 ESPERANZAEvaluation of the effectCenter
an for ### 20200414 6/26/2020 RPCEC
RPCEC000015-Jun-20 Pharmacody Pharmacodynamics and Center
safetyfor 5/3/2020 20200503 6/26/2020 RPCEC
RPCEC000015-Jun-20 Therapy fo Evaluation of the effectCancerology5/5/2020
o 20200505 6/26/2020 RPCEC
RPCEC000015-Jun-20 BiomodulinaEvaluation of the safetyCentro Nac 5/5/2020 20200505 6/26/2020 RPCEC
RPCEC000015-Jun-20 Treatment Treatment of patients Center
with of ### 20200512 6/26/2020 RPCEC
RPCEC000015-Jun-20 PrevengHo-Homeoprophylaxis safety Department ### 20200513 6/26/2020 RPCEC
RPCEC000015-Jun-20 CIGB-258 aAdministration of the CIGB-25
Center for ### 20200514 6/26/2020 RPCEC
RPCEC000015-Jun-20 VA-MENGOC- Population impact of iFinlay Vacc ### 20200522 6/26/2020 RPCEC
RPCEC000015-Jun-20 Evaluation Evaluation of the syneFinlay Vacc ### 20200522 6/26/2020 RPCEC
RPCEC000015-Jun-20 Explorator Evaluation of the effecCentro Nac ### 20200528 6/26/2020 RPCEC
RPCEC000015-Jun-20 ATENEA-CoApplication of the CIGBCenter
300 a for ### 20200528 6/26/2020 RPCEC
RPCEC000015-Jun-20 Heberon AlUse of Heberon(R) AlfaNational
R in B ### 20200529 6/26/2020 RPCEC
RPCEC000015-Jun-20 BiomodulinaEvaluation of the efficaCentro Nac ### 20200529 6/26/2020 RPCEC
RPCEC000015-Jun-20 Rectal Ozo EXPLORATORY STUDY National
OF TH Ce 6/5/2020 20200605 6/26/2020 RPCEC
TCTR2020015-Jun-20 A RandomizA Randomized Controlle

Self-spons ### 20200528 6/26/2020 TCTR
TCTR2020015-Jun-20 Endotoxin Endotoxin and circulating
Excellence
bacter ### 20200522 6/26/2020 TCTR
TCTR2020015-Jun-20 An InvestigAn Investigation of theFaculty

Ef of ### 20200512 6/26/2020 TCTR
TCTR2020015-Jun-20 Chula Covi Chula Covid-19 Rapid Test

Chulalongk
for Pand ### 20200424 6/26/2020 TCTR
TCTR2020015-Jun-20 Mental HeaMental Health Circumstance
Pharmacoep ### 20200425 6/26/2020 TCTR
TCTR2020015-Jun-20 Efficacy of Efficacy of HA330 Hemoperfusion

Excellence 4/3/2020 20200403 6/26/2020 TCTR
TCTR2020015-Jun-20 Use of CoviUse of Covid-19 Rapid Liver
Test for
Resea
Ho 4/5/2020 20200405 6/26/2020 TCTR
TCTR2020015-Jun-20 ComparativComparative effectiveness

Health
of Syst ### 20200331 6/26/2020 TCTR
TCTR2020015-Jun-20 Social, eth Social, ethical and behavioural

Wellcome T ### 20200331 6/26/2020 TCTR
TCTR2020015-Jun-20 Covid-19 p Preparedness and Responsive
Study Grou ### 20200321 6/26/2020 TCTR
TCTR2020015-Jun-20 ED ResponsResponse adjustment of

Study
emerg
Grou ### 20200320 6/26/2020 TCTR
PER-010-2 15-Jun-20 SOLIDARIT SOLIDARITY: AN INTERNAT

OMS/OPS, ### 20200416 6/26/2020 REPEC
NCT04315 18-Jun-20 Evaluation An Adaptive Phase 2/3Regeneron ### 20200315 6/26/2020 ClinicalTria
NCT04316 18-Jun-20 Norwegian Norwegian NO COVID-University ### 20200313 6/26/2020 ClinicalTria
NCT04321 18-Jun-20 Personaliz Personaliz PROACTIVEUniversity ### 20200320 6/26/2020 ClinicalTria
NCT04335 18-Jun-20 Evaluation A Partiall SPIN-CHAT Lady Davis 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04335 18-Jun-20 CheckpointA RandomizCOPERNIC MedSIR ### 20200331 6/26/2020 ClinicalTria
NCT04335 18-Jun-20 Video-Based

Effectiveness of Vide Biruni Univ 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04339 18-Jun-20 AtovaquoneOpen-Label, Non-Rando
HonorHealt 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04345 18-Jun-20 HydroxychlFeasibility, Safety an Hackensack 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04346 18-Jun-20 Impact of Impact of the Double- Cliniques u 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04346 18-Jun-20 Convalescen

A Pilot Study to Explo A.O. Osped 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04347 18-Jun-20 Honey & Nig

The Role o HNS-COVIDSohaib Ash ### 20200411 6/26/2020 ClinicalTria
NCT04348 18-Jun-20 CONvalesceA RandomizCONCOR-1 Hamilton H ### 20200413 6/26/2020 ClinicalTria

NCT04348 18-Jun-20 A COVID-19COVID-19 Study - A Pr ObvioHeal ### 20200413 6/26/2020 ClinicalTria
NCT04350 18-Jun-20 Longitudin Longitudinal Energy E Duke Unive ### 20200414 6/26/2020 ClinicalTria
NCT04351 18-Jun-20 Impact of Impact of COVID-GY Hospices Ci ### 20200415 6/26/2020 ClinicalTria
NCT04351 18-Jun-20 Effects of Effects of RASCOVID-University ### 20200414 6/26/2020 ClinicalTria
NCT04355 18-Jun-20 Covid-19 inManifestations Relate University ### 20200417 6/26/2020 ClinicalTria
NCT04357 18-Jun-20 COVID-19 Su

Effects of CoVS Clinical Nu ### 20200417 6/26/2020 ClinicalTria
NCT04357 18-Jun-20 Low Dose oLow Dose oLILIADE-COAssistance ### 20200410 6/26/2020 ClinicalTria
NCT04359 18-Jun-20 Serum IL-6 Prognostic UHID-COVIUniversity ### 20200416 6/26/2020 ClinicalTria
NCT04366 18-Jun-20 Clinical Tr Phase I / II Clinical Andalusian ### 20200422 6/26/2020 ClinicalTria
NCT04367 18-Jun-20 Developmen

Developmen
MolCOVID University ### 20200427 6/26/2020 ClinicalTria
NCT04367 18-Jun-20 Study of t Study of t COVID'HE University ### 20200416 6/26/2020 ClinicalTria
NCT04368 18-Jun-20 Study to DeA PHASE 1/2, PLACEB Biontech S ### 20200427 6/26/2020 ClinicalTria
NCT04370 18-Jun-20 Ozone Aut A Trial of COVID-OZ Institut d' ### 20200427 6/26/2020 ClinicalTria
NCT04371 18-Jun-20 EmergencyEmergencyRECOP University ### 20200429 6/26/2020 ClinicalTria
NCT04371 18-Jun-20 QT-Logs : AQT-Logs : aQT-Logs Assistance ### 20200430 6/26/2020 ClinicalTria
NCT04372 18-Jun-20 HydroxychlRandomized, Double-BlSanford He ### 20200425 6/26/2020 ClinicalTria
NCT04374 18-Jun-20 ConvalesceEfficacy and Safety of University ### 20200427 6/26/2020 ClinicalTria
NCT04379 18-Jun-20 Evaluation Evaluation Covid-19 Nisantasi U 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04381 18-Jun-20 COVIDNOCHE

High Flow COVIDNOCUniversity 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04381 18-Jun-20 A MulticenA Multi-ce ATOMIC2 University 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04382 18-Jun-20 The ImpactThe Impact of COVID-1El Zaitoun 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04387 18-Jun-20 Study of thStudy of thSEROSARS Direction ### 20200513 6/26/2020 ClinicalTria
NCT04389 18-Jun-20 DociparstatA Phase 2/3 Study to EChimerix ### 20200513 6/26/2020 ClinicalTria
NCT04393 18-Jun-20 Digital Car Randomized

DCC Academisch ### 20200511 6/26/2020 ClinicalTria
NCT04395 18-Jun-20 Helmet CPAHelmet ConCOVID HEL Lund Unive ### 20200518 6/26/2020 ClinicalTria
NCT04397 18-Jun-20 Nebulized Nebulized Heparin vs. Frederick ### 20200519 6/26/2020 ClinicalTria
NCT04401 18-Jun-20 Full Dose HSystemic AnticoagulatNorthwell ### 20200520 6/26/2020 ClinicalTria
NCT04401 18-Jun-20 COVID-19 ACOVID-19 Associated National In ### 20200522 6/26/2020 ClinicalTria
NCT04402 18-Jun-20 A Study of A Randomized, Double-

Apellis Pha ### 20200522 6/26/2020 ClinicalTria
NCT04403 18-Jun-20 HydroxychlHydroxychloroquine anCardresear ### 20200523 6/26/2020 ClinicalTria
NCT04403 18-Jun-20 Impact of Impact of COVID-19 onFayoum Uni ### 20200524 6/26/2020 ClinicalTria
NCT04404 18-Jun-20 Study of SAStudy of SAEpiCovCrei Direction ### 20200525 6/26/2020 ClinicalTria
NCT04407 18-Jun-20 Efficacy an Ivermectin and DoxycyInternation ### 20200517 6/26/2020 ClinicalTria
NCT04408 18-Jun-20 Study of K Study of K IMMUNO-CDirection ### 20200528 6/26/2020 ClinicalTria
NCT04412 18-Jun-20 Frailty in RelationshiFRA-COVIDUniversity ### 20200530 6/26/2020 ClinicalTria
NCT04412 18-Jun-20 Timing of Timing of TTTCOV19 Sahlgrensk ### 20200524 6/26/2020 ClinicalTria
NCT04413 18-Jun-20 Yoga PranaYoga- Base YOCO Health Rice ### 20200529 6/26/2020 ClinicalTria
NCT04415 18-Jun-20 Treatment Treatment COOPCOVI University 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04415 18-Jun-20 Effects of Effects of a N95 Respi The Clevela 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04416 18-Jun-20 STerOids i Use of HighSTOIC University 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04417 18-Jun-20 Caracteris Caracteris HoCoPsy University 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 Clinical E Treatment Effect of N Gyeongsang6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 Patient Pr TherapeutiPPT-COVIDCentre Hosp6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 Validating Validating EliSpot Centre Hosp ### 20200518 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 CT Biomarke
Identificat COVID 19-ICentre Hosp6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 EstablishmeIdentifica COVID-HO Assistance 6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 Vielight R A RandomizCOVIDLightVielight Inc 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 A Trial of CONCOR-1:CONCOR-1 Weill Medic6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 ConvalesceA Pilot Study to Expl Piero Luigi 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 COVID-19 aCOVID-19 aCOVIDOB University 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04418 18-Jun-20 Neuro-COVINeuro-COVINeuro-COVEmanuela K ### 20200528 6/26/2020 ClinicalTria
NCT04419 18-Jun-20 Peri-Opera Peri-Operative NeutroBarking, H 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04419 18-Jun-20 A Study of A Phase 1/2, Double-BTelios Phar 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 COVID-19 VCOVID-19 Virtual Car Lawson Hea ### 20200529 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 Primary PreScheme of Primary

PI-Covid-1
Prevention
Unidad de
of Infection
###by20200525
COVID-19,6/26/2020
in Health Providers:
ClinicalTriaPhase II Contro
NCT04420 18-Jun-20 Targeted MTargeted MTMD Northweste6/3/2020 20200603 6/26/2020 ClinicalTria

NCT04420 18-Jun-20 Study of t Study of t FRENCH IC Centre Hosp6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 Cohort ComIncidence COVID-EP Groupe Hosp6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 MaintenancMaintenance Versus Re

Brigham an 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 Low Dose RLow Dose RLOWRAD-CHospital Sa ### 20200514 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 Mental HeadePressionPANDEMICInstituto M 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 Descriptiv Descriptiv HEART-COVAssistance 6/5/2020 20200605 6/26/2020 ClinicalTria

NCT04420 18-Jun-20 Impact of Impact of RetroCov Medical Uni6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 Synbiotic Synbiotic SynCov Medical Uni6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 Effects of Effects of Three Mont University 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04420 18-Jun-20 Investigati Investigational COVID-Rutgers, Th 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04421 18-Jun-20 QuadraMune

Phase II Study of Qua Therapeutic6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04421 18-Jun-20 A Study to A Randomized, Double-

Belleropho 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04421 18-Jun-20 Utility of Efficacy and Safety of Cairo Unive 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04421 18-Jun-20 Patients a Patients anPAPESCO-1Institut Ca ### 20200518 6/26/2020 ClinicalTria
NCT04421 18-Jun-20 PreemptivePreemptive Therapy f McGill Univ 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04422 18-Jun-20 COVID-19 an

COVID-19 and Liver InjMax Healthc6/7/2020 20200607 6/26/2020 ClinicalTria
NCT04422 18-Jun-20 Impact of Multi-Center ProspectKhalifa Uni 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04422 18-Jun-20 Effects on ObservationQT-COVID- Matilde Za 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04422 18-Jun-20 UltrasonogBruk av UltCOVIDUS- St. Olavs H 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04422 18-Jun-20 Needs of PeTracking Needs of Per Washington6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04423 18-Jun-20 TocilizumabA Nested InterventionUniversity 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04423 18-Jun-20 ThrombosisThrombosisCovid-19 Nisantasi U 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04423 18-Jun-20 KnowledgeKnowledge About Covid

Aljazeera H 6/7/2020 20200607 6/26/2020 ClinicalTria
NCT04424 18-Jun-20 BromhexIneOpen LabelBISCUIT Lomonosov ### 20200527 6/26/2020 ClinicalTria
NCT04425 18-Jun-20 SafeFit Tri SafeFit Trial: Virtual University 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT03376 22-Jun-20 Pilot RCT Pilot RandoCHILL-pilot University ### 20171207 6/26/2020 ClinicalTria
NCT04193 22-Jun-20 ARrest RES ARrest RE ARREST Stanford Un ### 20191203 6/26/2020 ClinicalTria
NCT04303 22-Jun-20 ChloroquinChloroquinCOPCOV University 3/6/2020 20200306 6/26/2020 ClinicalTria
NCT04315 22-Jun-20 NestaCellÂ Explorator HOPE Azidus Bras ### 20200318 6/26/2020 ClinicalTria
NCT04322 22-Jun-20 Colchicine Colchicine COVID-19 Montreal He ### 20200323 6/26/2020 ClinicalTria
NCT04325 22-Jun-20 Early PP W Early Prone Position Rush Unive ### 20200326 6/26/2020 ClinicalTria
NCT04331 22-Jun-20 TocilizumabEarly Insti COVIDOSE University 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04334 22-Jun-20 Safety and Phase 2, Randomized, Blade Ther 4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04335 22-Jun-20 Valsartan PRAETORIAN-COVID: ARadboud

D Un4/2/2020 20200402 6/26/2020 ClinicalTria
NCT04337 22-Jun-20 Maternal AMaternal And NeonataKanuni Sul 4/5/2020 20200405 6/26/2020 ClinicalTria
NCT04337 22-Jun-20 Nitric Oxi Multi-CenteNOCOVID Sanotize R 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04337 22-Jun-20 Dynamic EvDynamic EvTRODVID-1Tourcoing 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04338 22-Jun-20 TXA and CoExplorator TCOutpatieUniversity 4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04341 22-Jun-20 Study of T A Phase 1b/2, RandomiI-Mab Biop 4/4/2020 20200404 6/26/2020 ClinicalTria
NCT04341 22-Jun-20 A Online-d Evaluation of a Brief Karolinska 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04342 22-Jun-20 COVID-19 CA Multicenter, Prospe Wake Fores4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04343 22-Jun-20 Study to E A Phase 2, RandomizedCytoDyn, In ### 20200331 6/26/2020 ClinicalTria
NCT04344 22-Jun-20 ExhaustionBurnout, Emotional DiUniversitÃ 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 22-Jun-20 Corticoste Corticoste CORTI-CoviHospices Ci ### 20200410 6/26/2020 ClinicalTria
NCT04344 22-Jun-20 Non InvasivNon-invasive Positive Lawson Hea4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04344 22-Jun-20 Collection A Pilot St NIAID National In ### 20200413 6/26/2020 ClinicalTria
NCT04345 22-Jun-20 HydroxychlRandomized

COVIDOC University 4/5/2020 20200405 6/26/2020 ClinicalTria
NCT04346 22-Jun-20 Non-COVIDNon-COVID
P PSI
P RECOR Nantes Univ ### 20200410 6/26/2020 ClinicalTria
NCT04346 22-Jun-20 Oral Favip A Phase 2 Randomized,Stanford Un ### 20200410 6/26/2020 ClinicalTria
NCT04347 22-Jun-20 A Clinical A Clinical Trial to Ev Cadila Pha ### 20200331 6/26/2020 ClinicalTria
NCT04347 22-Jun-20 Study to EvA Phase 2b/3, Randomiz

CytoDyn, In ### 20200413 6/26/2020 ClinicalTria
NCT04348 22-Jun-20 Efficacy a Proof of Concept, MultAzidus Bras 4/3/2020 20200403 6/26/2020 ClinicalTria
NCT04348 22-Jun-20 Non-COVIDNon-COVID

P PSI
P RECOR Nantes Univ ### 20200413 6/26/2020 ClinicalTria
NCT04351 22-Jun-20 Phase 3 St A Phase 3 Randomized,Humanigen, ### 20200415 6/26/2020 ClinicalTria
NCT04351 22-Jun-20 A Systems A Systems Approach toUniversity ### 20200415 6/26/2020 ClinicalTria
NCT04353 22-Jun-20 Stopping A Stopping A ACEI-COVI Medical Un ### 20200414 6/26/2020 ClinicalTria
NCT04355 22-Jun-20 Study of I Study of I CovImmunCentre Hosp ### 20200417 6/26/2020 ClinicalTria
NCT04355 22-Jun-20 ConvalesceConvalescent Plasma tStanford Un ### 20200417 6/26/2020 ClinicalTria
NCT04356 22-Jun-20 TreatmentsOutpatientCOVERAGEUniversity ### 20200411 6/26/2020 ClinicalTria
NCT04358 22-Jun-20 Pulsed Inh Expanded Access: PulsBelleropho ### 20200421 6/26/2020 ClinicalTria
NCT04360 22-Jun-20 Plasma Col Plasma Collection Fr National In ### 20200422 6/26/2020 ClinicalTria
NCT04361 22-Jun-20 Trial Eval A RandomizCOVIDORL Fondation ### 20200422 6/26/2020 ClinicalTria
NCT04362 22-Jun-20 Study of E Phase 3 MuCAN-COVI Novartis P ### 20200424 6/26/2020 ClinicalTria
NCT04363 22-Jun-20 Chronic FatChronic FatFatCovid-1 Centre Hosp ### 20200424 6/26/2020 ClinicalTria
NCT04365 22-Jun-20 SARS-CoV-2Recovery in Patients University ### 20200424 6/26/2020 ClinicalTria
NCT04366 22-Jun-20 Efficacy o Interleukin JAKINKOV Centre Hos ### 20200427 6/26/2020 ClinicalTria
NCT04366 22-Jun-20 Clinical T Phase I / II Multicen Andalusian ### 20200422 6/26/2020 ClinicalTria
NCT04368 22-Jun-20 RadiographRadiographic Findings Max Healthc ### 20200429 6/26/2020 ClinicalTria
NCT04369 22-Jun-20 Trans Thor Trans Thoracic ManipuEmory Univ ### 20200428 6/26/2020 ClinicalTria
NCT04373 22-Jun-20 C-reactive Triage Strategies Bas Henning Bl 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04375 22-Jun-20 Efficacy an Efficacy and Safety of Pontificia 5/3/2020 20200503 6/26/2020 ClinicalTria
NCT04375 22-Jun-20 London's E Phase I/II LESSCOVIDLawson Hea ### 20200422 6/26/2020 ClinicalTria
NCT04377 22-Jun-20 A Study of A Phase 3, Multicente Covis Pharma

5/5/2020
S.Ã .r.l. 20200505 6/26/2020 ClinicalTria
NCT04379 22-Jun-20 LDCT in COLow-dose CLDCTiP Research a ### 20200430 6/26/2020 ClinicalTria
NCT04380 22-Jun-20 A Study to Phase 2, Randomized, Janssen Ph 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04381 22-Jun-20 EmergencyEmergency Ventilator Stanford Un5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04382 22-Jun-20 Inhaled Ib Extended CCÃ³rdobaTrQuÃmica Luar

5/6/2020
SRL 20200506 6/26/2020 ClinicalTria
NCT04383 22-Jun-20 Role of Ib Role of Ib RISC University 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04385 22-Jun-20 Myeloproli Myeloproli MPN-COVI Fondazione ### 20200511 6/26/2020 ClinicalTria
NCT04386 22-Jun-20 Photobiomo

Is PhotobiomodulationUniversity 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04386 22-Jun-20 Oral 25-hy Preventive and TherapTehran Uni ### 20200511 6/26/2020 ClinicalTria
NCT04388 22-Jun-20 Predictors Predictors PRESCO Verily Life 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04389 22-Jun-20 Double-BlinA Randomized, Double-B

Pluristem L ### 20200514 6/26/2020 ClinicalTria
NCT04389 22-Jun-20 PostpartumEvaluation of Pregna Kanuni Sul ### 20200514 6/26/2020 ClinicalTria
NCT04389 22-Jun-20 PostoperatEvaluation of Pregnan Kanuni Sul ### 20200514 6/26/2020 ClinicalTria
NCT04390 22-Jun-20 Respirator Prediction READY Dascena ### 20200514 6/26/2020 ClinicalTria
NCT04391 22-Jun-20 HydroxychlEfficacy and Safety of Centenario ### 20200512 6/26/2020 ClinicalTria
NCT04391 22-Jun-20 Validity o Validity of at Home V Vanderbilt ### 20200515 6/26/2020 ClinicalTria
NCT04393 22-Jun-20 Serologic Observational Trial E Hospital Un ### 20200426 6/26/2020 ClinicalTria
NCT04394 22-Jun-20 Impact of Impact of COVID-19 PaOkan Unive ### 20200518 6/26/2020 ClinicalTria
NCT04394 22-Jun-20 Full Antic Randomized

ACTION Brazilian C 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04395 22-Jun-20 ConvalesceA Multicenter RandomiLifefactors ### 20200515 6/26/2020 ClinicalTria
NCT04399 22-Jun-20 MavrilimumMavrilimumab to Reduc

The Clevela ### 20200521 6/26/2020 ClinicalTria
NCT04400 22-Jun-20 PrevalencePrevalence and Sever University ### 20200522 6/26/2020 ClinicalTria
NCT04403 22-Jun-20 Characteri Characterizing SARS-C HIV Vaccin ### 20200522 6/26/2020 ClinicalTria
NCT04405 22-Jun-20 A Study to A Prospective, EpidemMiltenyi Bi ### 20200519 6/26/2020 ClinicalTria
NCT04407 22-Jun-20 Role of Ch Role of Children in Jonsson Co ### 20200527 6/26/2020 ClinicalTria
NCT04409 22-Jun-20 Prognosis Prognostic Factors i Kanuni Sul ### 20200528 6/26/2020 ClinicalTria
NCT04409 22-Jun-20 HyperbaricThe Applic HBOT Maimonides ### 20200527 6/26/2020 ClinicalTria
NCT04410 22-Jun-20 Evaluation Evaluation COVID-WELUniversity ### 20200522 6/26/2020 ClinicalTria

NCT04410 22-Jun-20 Povidone-IoA Pilot, Op GARGLES Universiti ### 20200527 6/26/2020 ClinicalTria
NCT04410 22-Jun-20 Psychologi Psychological Impact Medical Uni ### 20200514 6/26/2020 ClinicalTria
NCT04412 22-Jun-20 Safety and A MULTICENTER, RAN Pfizer ### 20200530 6/26/2020 ClinicalTria
NCT04412 22-Jun-20 Impact of Impact of COVID-19 Pan

Okan Unive ### 20200530 6/26/2020 ClinicalTria
NCT04412 22-Jun-20 Primary AnInternatio ISACS-STE UniversitÃ degli

6/1/2020
Studi 20200601
del Piemonte
6/26/2020
Orientale
ClinicalTria
"Amedeo Avogadro"
NCT04414 22-Jun-20 Low Dose PPhase II St COVRTE-19Hospital Pr 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04414 22-Jun-20 A Study of Opaganib, COVID-19 RedHill Bi ### 20200526 6/26/2020 ClinicalTria
NCT04415 22-Jun-20 SedAting WiSedAting WiSAVE-ICU Sunnybrook6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04415 22-Jun-20 Evaluation Evaluation AMPCOVIDUniversity ### 20200529 6/26/2020 ClinicalTria
NCT04416 22-Jun-20 PREEMPTIVPREEMPTIVCOLCHI-COInstituto 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04420 22-Jun-20 Clinical Tr A Randomized, Single-b

FundaciÃ³n 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04422 22-Jun-20 Video DancThe ImpactPTT-OnlineFederal Uni 6/7/2020 20200607 6/26/2020 ClinicalTria
NCT04422 22-Jun-20 LanadelumaLanadelumaCOVID_LA Radboud Un6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04422 22-Jun-20 FibromyalgPrevalence of FibromyAl-Azhar Un6/7/2020 20200607 6/26/2020 ClinicalTria
NCT04422 22-Jun-20 COVID 19 SCOVID 19 SPneumoserUniversity 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04422 22-Jun-20 Evaluation Evaluation EPRICOD University 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04422 22-Jun-20 Characteri Characteri PULCO-19 University 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04422 22-Jun-20 Data Analy Data Colle CYTOAID University 6/6/2020 20200606 6/26/2020 ClinicalTria
NCT04422 22-Jun-20 The Safety Imatinib for the Trea Alexandria 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04422 22-Jun-20 The ImpactThe Impact of CoronaviUniversity 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04423 22-Jun-20 EndoscopicImpact of the COVID-1University 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04423 22-Jun-20 Telematic COVID Follow-App: TelHospital Un 6/6/2020 20200606 6/26/2020 ClinicalTria
NCT04423 22-Jun-20 Analysis o The Analysis of the I Coordinaci ### 20200527 6/26/2020 ClinicalTria
NCT04423 22-Jun-20 COVID-19 RCOVID-19 Related HealAmerican D 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04423 22-Jun-20 Efficacy an Proof of Concept, MultAzidus Bras 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04423 22-Jun-20 Identifica Identifica IDENTIFY Dascena 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04424 22-Jun-20 MURDOCK MURDOCK

Ca C3PI
Ca Duke Unive 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04424 22-Jun-20 Sero-prevaSero-prevalence of CoEgyptian C 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04424 22-Jun-20 External D Influence of External Karolinska 6/7/2020 20200607 6/26/2020 ClinicalTria
NCT04424 22-Jun-20 Post-traumPTSD in Health Worke Ospedale P 6/7/2020 20200607 6/26/2020 ClinicalTria
NCT04424 22-Jun-20 Prone Posi Prone Positioning on Poudre Val 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04424 22-Jun-20 Thorax ComInitial Thoracic CT F Tepecik Tr 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04424 22-Jun-20 Trial of Op A RandomizTOLD UConn Hea ### 20200529 6/26/2020 ClinicalTria
NCT04424 22-Jun-20 The NaturalObservatioSTORM University 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 Home-based

Effect of Home-based University 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 AiM Covid Efficacy of AiM Covid Aarogyam 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 Detection Detection COVID_OF CRG UZ Bru ### 20200527 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 Darunavir/ Efficacy a DOLCI Hamad Medi ### 20200521 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 A Multi-ce A Multi-center, Random

Zhejiang H ### 20200528 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 A GamifiedA Gamified Network foUniversit 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 A Phase 2 TA Phase 2 Trial of Inf Tufts Medi 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 Safety, Tol A Master Protocol AssRegeneron 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 Ivermectin The Use of Ivermectin Ministry of 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 MK-5475 inA Study to Assess the Merck Sha 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 A Clinical A Randomized,DoubleHeNan

B Sinc 5/9/2020 20200509 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 EffectiveneEffectiveness and Saf FundaciÃ³n ### 20200529 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 COVID-19 APrevalence of SARS-C Hospital Un 6/6/2020 20200606 6/26/2020 ClinicalTria
NCT04425 22-Jun-20 Efficacy o Efficacy of Convalesc Institute of 6/7/2020 20200607 6/26/2020 ClinicalTria
NCT04426 22-Jun-20 Serologica Serologica PRO-SERO Institut B 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04426 22-Jun-20 The ImpactCOVID-19 and Disabili Lawson Hea ### 20200528 6/26/2020 ClinicalTria
NCT04426 22-Jun-20 Cardiovasc Cardiovascular Diseas Karolinska 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04426 22-Jun-20 InterLeuki A Multicen ILIAD-7-US Revimmun 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04426 22-Jun-20 Identificat Identification of Gen Szeged Uni 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04426 22-Jun-20 MorbimortaMorbimortaCORhum University H6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04426 22-Jun-20 SARS-COV-2SARS-COV-2COVEMUZ Universitai 6/8/2020 20200608 6/26/2020 ClinicalTria

NCT04426 22-Jun-20 CommunityCommunity Health Work
NCT04426 22-Jun-20 COVID-19 aCOVID-19 aCAHMP-EDUniversity 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04426 22-Jun-20 Core WarmiCore Warming of COVID

Washington6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04426 22-Jun-20 Safety, Tol A Master Protocol AsseRegeneron 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04427 22-Jun-20 Evaluation Evaluation Masq-AuteCentre Hosp ### 20200610 6/26/2020 ClinicalTria
NCT04427 22-Jun-20 Cancer: Ra Cancer: Ra CARDS Royal Mars ### 20200521 6/26/2020 ClinicalTria
NCT04427 22-Jun-20 Smell and Smell and COVID-19 University ### 20200610 6/26/2020 ClinicalTria
NCT04427 22-Jun-20 Predictive Predictive MI-COVID University 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04427 22-Jun-20 RT-PCR SARRT-PCR SARCOVID-19 University ### 20200610 6/26/2020 ClinicalTria
NCT04427 22-Jun-20 Exploring I Exploring I BIG-C Cambridges6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04427 22-Jun-20 Effect of C Effect of Covid-19 Ep Beijing Fri 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04428 22-Jun-20 Standard oEffectiven PLACO-COVAzienda Ospedaliera

6/7/2020CittÃ
20200607
della Salute
6/26/2020
e della
ClinicalTria
Scienza di Torino
NCT04428 22-Jun-20 TherapeutiA Phase I Trial of a T GeneCure B6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04428 22-Jun-20 Healthy Li Effectiveness of a He University 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04428 22-Jun-20 AutologousClinical Study for th Celltex Th 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04429 22-Jun-20 Cerebral C Assessment of Cerebr University 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04429 22-Jun-20 Safety of Phase 1 First-in-Huma Tychan Pte 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04429 22-Jun-20 Safety and Safety and CELMA Trustem ### 20200610 6/26/2020 ClinicalTria
NCT04429 22-Jun-20 Donated AnA RandomizDAWN-Pla Universita 6/9/2020 20200609 6/26/2020 ClinicalTria
ACTRN126 22-Jun-20 COVID-19 pEffectiveness of Prophylac

Walter and ### 20200422 6/26/2020 ANZCTR
ACTRN126 22-Jun-20 A reusable A reusable personalised
Western He ### 20200422 6/26/2020 ANZCTR
ACTRN126 22-Jun-20 An intervenA Phase 1 Randomised,University ### 20200612 6/26/2020 ANZCTR
Comparin
g the user
seal
check and
fit test
between
two types
of N95
respirator
s - the
Halyard
N95
Particulat
e Filter
Respirato
rs and the
ProShield
Â® N-95
masks
ACTRN126 22-Jun-20 Comparing the user seal
The Royal ### 20200619 6/26/2020 ANZCTR
ACTRN126 22-Jun-20 Amnion cellAllogeneic Amniotic Epitheli

Monash He ### 20200615 6/26/2020 ANZCTR
ACTRN126 22-Jun-20 Atrial Fibr Atrial Fibrillation in patie
The Univers ### 20200622 6/26/2020 ANZCTR
ISRCTN123 22-Jun-20 DIAMONDS-S

Diagnosis and management
Imperial
of fe
C ### 20200622 6/26/2020 ISRCTN
ISRCTN604 22-Jun-20 Evaluation Panbioâ„¢ COVID-19 IgAbbott (Ge ### 20200622 6/26/2020 ISRCTN
ISRCTN134 22-Jun-20 Management Management of patientsCambridge

wit ### 20200617 6/26/2020 ISRCTN
ISRCTN549 22-Jun-20 Could proneAwake prone positioningUppsala
with hi
Co ### 20200615 6/26/2020 ISRCTN
ISRCTN899 22-Jun-20 A phase III A phase III randomizedUniversity
cont ### 20200611 6/26/2020 ISRCTN
ISRCTN932 22-Jun-20 Studying t COVID-19 infection in pregn

Queen Mary ### 20200611 6/26/2020 ISRCTN
ISRCTN154 22-Jun-20 A Saudi AraSaudi Arabia study for King
t Saud ### 20200610 6/26/2020 ISRCTN
ISRCTN940 22-Jun-20 BehaviouralBehavioural ActivationTees, Esk 6/9/2020 20200609 6/26/2020 ISRCTN
ISRCTN170 22-Jun-20 Clinical tr A first-in-human clinicaImperial C 6/4/2020 20200604 6/26/2020 ISRCTN

ISRCTN335 22-Jun-20 To study t Rationale and investigatio
Kimera Lab 6/2/2020 20200602 6/26/2020 ISRCTN
ISRCTN695 22-Jun-20 Best avail Best available treatment Imperial
study C 6/2/2020 20200602 6/26/2020 ISRCTN
ISRCTN403 22-Jun-20 Does ivermA double-blind clinical Lagos
trial Unive ### 20200526 6/26/2020 ISRCTN
ISRCTN999 22-Jun-20 CROWN CORO An international, multiUniversity ### 20200526 6/26/2020 ISRCTN
ISRCTN213 22-Jun-20 TherapeuticA pilot randomized clinical
King tSaud ### 20200518 6/26/2020 ISRCTN
ISRCTN283 22-Jun-20 Evaluation The PRIEST study: Pandemic
Sheffield
Resp 5/4/2020 20200504 6/26/2020 ISRCTN
ISRCTN400 22-Jun-20 UKOSS: PanMaternal and perinatalUniversity
outcomes 4/1/2020 20200401 6/26/2020 ISRCTN
ISRCTN865 22-Jun-20 PRINCIPLE:Platform Randomised trial
University
of I ### 20200322 6/26/2020 ISRCTN
ISRCTN375 22-Jun-20 Enhanced coAcceptability and feasibil
Central No ### 20200131 6/26/2020 ISRCTN
ISRCTN164 22-Jun-20 Inhale workThe impact of using fi University 8/5/2019 20190805 6/26/2020 ISRCTN
ISRCTN182 22-Jun-20 UnderstandRates, Risks and RoutesAcademic
to Reduce a ### 20190729 6/26/2020 ISRCTN
ISRCTN552 22-Jun-20 B-cells in Understanding stroke-induced
Salford RoB ### 20180924 6/26/2020 ISRCTN
ChiCTR200 22-Jun-20 A follow-u A follow-up study of novel

The Second
co ### 20200619 6/26/2020 ChiCTR
ChiCTR200 22-Jun-20 A multicen A multicenter clinical stMaternal a ### 20200619 6/26/2020 ChiCTR
ChiCTR200 22-Jun-20 Psychologi Psychological Preparedness
nil to ### 20200617 6/26/2020 ChiCTR
ChiCTR200 22-Jun-20 A medical The influence of novelTianjin

coronaMed ### 20200617 6/26/2020 ChiCTR
ChiCTR200 22-Jun-20 Impact of CImpact of COVID-19 onNone
Labor ### 20200616 6/26/2020 ChiCTR
ChiCTR200 22-Jun-20 Study for Study for sleep qualityShanghai

of O 4/7/2020 20200407 6/26/2020 ChiCTR
EUCTR202022-Jun-20 Covid-19: ACovid-19: A randomized,
UZLeuven
op ### 20200327 6/26/2020 EU Clinical
EUCTR202022-Jun-20 A Phase 2 RA Phase 2 RandomizedKaryopharm4/1/2020

Singl 20200401 6/26/2020 EU Clinical
EUCTR202022-Jun-20 Systematic Randomized controlledUniversitÃ
tria ### 20200324 6/26/2020 EU Clinical
EUCTR202022-Jun-20 Does subcuSubcutaneous and Intraveno
University 5/4/2020 20200504 6/26/2020 EU Clinical
EUCTR202022-Jun-20 Treatment Front line treatment with
Friedrich-S
Rux ### 20200416 6/26/2020 EU Clinical
Resolving
inflamma
tory
storm in
COVID-19
patients
by
Omega-3
Treatmen polyunsat
t with urated
Omega-3 fatty
polyunsat acids.
urated
fatty - A single-
acids in blind,
COVID-19 randomiz
patients. ed,
placebo-
A single- controlle
blind, d
randomiz feasibility
ed, study
placebo-
controlle
d
feasibility
EUCTR202022-Jun-20 study. Karolinska ### 20200513 6/26/2020 EU Clinical
EUCTR202022-Jun-20 A clinical The NOR-SWE Solidarity
Karolinska
multi ### 20200420 6/26/2020 EU Clinical
EUCTR202022-Jun-20 Treating COUse of inhaled corticoster

EUCTR202022-Jun-20 An open-laAn open-label, adaptivThirty Resp 6/8/2020 20200608 6/26/2020 EU Clinical
EUCTR202022-Jun-20 A Phase 2, A Phase 2, Open-Label,Acerta
R Pha 5/8/2020 20200508 6/26/2020 EU Clinical
EUCTR202022-Jun-20 A study to A randomized, single bli
CharitÃ© R ### 20200513 6/26/2020 EU Clinical
EUCTR202022-Jun-20 Treatment Iwnhalation of Ciclesonide

Capio
for S:t ### 20200424 6/26/2020 EU Clinical
A clinical
study to
evaluate
the
efficacy
of
different
anti-viral
drugs in
SARS-
CoV-2
infected
patients
(COVID-
EUCTR202022-Jun-20 19) WHO SOLIDARITY Finland:
University
Th ### 20200417 6/26/2020 EU Clinical
COVID-19
A Phase 3
Open-
label,
Randomiz
ed,
Controlle
d Study to
Evaluate
the
Efficacy
and
Safety of
Intraveno
usly
Administe
red
Ravulizu
mab
Compare
d with
Best
Supportiv
e Care in
Patients
with
COVID-19
Severe
Pneumoni
a, Acute
Lung
Injury, or
Acute
Respirato
EUCTR202022-Jun-20 ravulizuma r Alexion Pha ### 20200427 6/26/2020 EU Clinical
EUCTR202022-Jun-20 Investigat A phase 2/3 study to det
CTRG ### 20200421 6/26/2020 EU Clinical
EUCTR202022-Jun-20 A Phase 2 SACCORD 2: A MulticentUniversity ### 20200423 6/26/2020 EU Clinical
NCT02765 25-Jun-20 MR-EvaluatiMR-EvaluatiMERSEP Uppsala Un 5/2/2016 20160502 6/26/2020 ClinicalTria
NCT03963 25-Jun-20 Careful Ve Careful Ve CAVIARDS-St. Michael 5/6/2019 20190506 6/26/2020 ClinicalTria
NCT04244 25-Jun-20 GlucocorticGlucocorticoid TherapyPeking Uni ### 20200123 6/26/2020 ClinicalTria
NCT04285 25-Jun-20 The Effect A Clinical Study to In Tasly Pharm ### 20200219 6/26/2020 ClinicalTria
NCT04288 25-Jun-20 Treatment A Phase II, Multicent Beijing 302 ### 20200224 6/26/2020 ClinicalTria
NCT04303 25-Jun-20 Various Com

A 6 Week PTHDMS-CORajavithi H ### 20200224 6/26/2020 ClinicalTria
NCT04304 25-Jun-20 Treatment Treatment HCQ4COV1Fundacio Ll 3/5/2020 20200305 6/26/2020 ClinicalTria
NCT04311 25-Jun-20 Losartan foRandomized ControlledUniversity ### 20200313 6/26/2020 ClinicalTria
NCT04312 25-Jun-20 Losartan foRandomized ControlledUniversity ### 20200313 6/26/2020 ClinicalTria

NCT04312 25-Jun-20 NO PreventNitric Oxid NOpreventMassachuse ### 20200315 6/26/2020 ClinicalTria
NCT04312 25-Jun-20 The Use of A Phase 2 Multiple DosPulmotect, ### 20200316 6/26/2020 ClinicalTria
NCT04313 25-Jun-20 The Use PUA Phase 2 Multiple DoPulmotect, ### 20200316 6/26/2020 ClinicalTria
NCT04318 25-Jun-20 COVID-19 PStudy to ChCOVID-Bio UniversitÃ Vita-Salute

### 20200319
San Raffaele
NCT04320 25-Jun-20 Acute Encep

Outcomes iNeuroCOVIIctal Group ### 20200322 6/26/2020 ClinicalTria
NCT04323 25-Jun-20 MethylpredProlonged MP-C19 University ### 20200319 6/26/2020 ClinicalTria
NCT04323 25-Jun-20 Expanded AExpanded Access TreatGilead Sci ### 20200324 6/26/2020 ClinicalTria
NCT04323 25-Jun-20 ConvalesceConvalesceCSSC-001 Johns Hopk ### 20200324 6/26/2020 ClinicalTria
NCT04324 25-Jun-20 Anti-CoronAnti-CoronACT COVIDPopulation ### 20200325 6/26/2020 ClinicalTria
NCT04325 25-Jun-20 Sero-epide Sero-epidem

CORSER Institut Pa ### 20200326 6/26/2020 ClinicalTria
NCT04327 25-Jun-20 Sarilumab An Adaptive Phase 3, Sanofi ### 20200326 6/26/2020 ClinicalTria
NCT04328 25-Jun-20 Chemoproph

Chemoproph
COVIDAXISCentre Hosp ### 20200325 6/26/2020 ClinicalTria
NCT04329 25-Jun-20 Effects of Effects of a Mobile M University ### 20200326 6/26/2020 ClinicalTria
NCT04329 25-Jun-20 ALBERTA HO

A Randomized, Double-b
Dr. Michael ### 20200329 6/26/2020 ClinicalTria
NCT04330 25-Jun-20 TreatmentsA Multi-cenCATCO Sunnybrook ### 20200323 6/26/2020 ClinicalTria
NCT04331 25-Jun-20 Bidirectio GO2 PEEP SGO2 PEEP Emory Univ ### 20200331 6/26/2020 ClinicalTria
NCT04331 25-Jun-20 Single-Bli A Phase 2 COVID-LamStanford Un ### 20200327 6/26/2020 ClinicalTria
NCT04332 25-Jun-20 Outcomes ROutcomes RORCHID Massachuse ### 20200331 6/26/2020 ClinicalTria
NCT04333 25-Jun-20 Prospectiv A Prospect IMMUNONCentre Leo 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04335 25-Jun-20 Recombinan

Recombinan
APN01-COVApeiron Bio 4/1/2020 20200401 6/26/2020 ClinicalTria
NCT04339 25-Jun-20 Mental HeaMental Health Impact National In 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04340 25-Jun-20 Safety and Safety and Effective Peking Uni 3/3/2020 20200303 6/26/2020 ClinicalTria
NCT04341 25-Jun-20 Early Vers Early Vers ECMO-VID University ### 20200330 6/26/2020 ClinicalTria
NCT04342 25-Jun-20 The Role ofThe Role of Resistant Yale Univer 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04342 25-Jun-20 A Study of A Randomized, Double-

Eli Lilly a ### 20200410 6/26/2020 ClinicalTria
NCT04343 25-Jun-20 ConvalesceConvalescent Plasma Saint Franc 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04343 25-Jun-20 MethylpredEfficacy of MetCOVID FundaÃ§Ã£o4/9/2020 20200409 6/26/2020 ClinicalTria

NCT04343 25-Jun-20 National S National S COVID19P University 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04343 25-Jun-20 Pegylated A Randomized ControllRaymond C 4/9/2020 20200409 6/26/2020 ClinicalTria
NCT04344 25-Jun-20 Incline Po UPright In UPSAT Johns Hopk ### 20200410 6/26/2020 ClinicalTria
NCT04344 25-Jun-20 Awake PronAwake PronAPPEX-19 Boston Uni 4/8/2020 20200408 6/26/2020 ClinicalTria
NCT04345 25-Jun-20 A Real-lif The Results of COVID Tanta Unive ### 20200411 6/26/2020 ClinicalTria
NCT04346 25-Jun-20 CompassionCompassionate Use OpImplicit Bi ### 20200413 6/26/2020 ClinicalTria
NCT04346 25-Jun-20 Efficacy of An Open-label Randomi

Azienda UnitÃ Sanitaria
### 20200412
Locale Reggio
6/26/2020
EmiliaClinicalTria
NCT04346 25-Jun-20 Efficacy of Efficacy of Convalesce Institute of ### 20200414 6/26/2020 ClinicalTria
NCT04347 25-Jun-20 Seropreval Seroprevalence of SARQueen's Uni4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04347 25-Jun-20 PVP-I Nasa Effect of PVP-I Nasal Stanford Un ### 20200413 6/26/2020 ClinicalTria
NCT04348 25-Jun-20 Hydrocorti Low-dose HCOVID STE Scandinavia ### 20200411 6/26/2020 ClinicalTria
NCT04350 25-Jun-20 DapagliflozAn InternatDARE-19 Saint Luke ### 20200414 6/26/2020 ClinicalTria
NCT04351 25-Jun-20 The Effica Clinical Study Evaluat Tanta Unive ### 20200415 6/26/2020 ClinicalTria
NCT04352 25-Jun-20 An Online An Online Survey to U Institute of ### 20200414 6/26/2020 ClinicalTria
NCT04353 25-Jun-20 Efficacy o MulticenterMeCOVID Instituto d ### 20200416 6/26/2020 ClinicalTria
NCT04353 25-Jun-20 AssessmentIsotretino Isotretinoi Kafrelsheik ### 20200410 6/26/2020 ClinicalTria
NCT04353 25-Jun-20 Camostat MThe Effect of CamostatYale Univer ### 20200416 6/26/2020 ClinicalTria
NCT04353 25-Jun-20 ModulationNovel Extracorporeal Lawson Hea4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04354 25-Jun-20 The UnitedThe UK MS UKMSRCV1Swansea Un4/6/2020 20200406 6/26/2020 ClinicalTria
NCT04354 25-Jun-20 Asymptomat

Asymptomatic SARS- Co
Kasr El Ain ### 20200416 6/26/2020 ClinicalTria
NCT04354 25-Jun-20 AdministraAdministration of Chl Cairo Unive ### 20200417 6/26/2020 ClinicalTria
NCT04354 25-Jun-20 CoronaviruCoronaviruCORIA Kirby Insti ### 20200416 6/26/2020 ClinicalTria
NCT04355 25-Jun-20 Use of UC- Umbilical Cord-derive Camillo Ric ### 20200413 6/26/2020 ClinicalTria

Use of Convalescent PRoyal Colle ### 20200415 6/26/2020 ClinicalTria
NCT04356 25-Jun-20 Efficacy o Tocilizumab to PreventMassachuse ### 20200419 6/26/2020 ClinicalTria
NCT04357 25-Jun-20 Measles VaEffectiven MV-COVID Kasr El Ain ### 20200419 6/26/2020 ClinicalTria
NCT04357 25-Jun-20 Prognosis Prognosis of SARS-CovHakeam Ab ### 20200419 6/26/2020 ClinicalTria

NCT04357 25-Jun-20 Impact of LProspective DescriptioCentre Hos ### 20200420 6/26/2020 ClinicalTria
NCT04357 25-Jun-20 Fibrinolyti Fibrinolytic Therapy t Denver Hea ### 20200418 6/26/2020 ClinicalTria
NCT04358 25-Jun-20 Evaluating A Randomized, Double-

National In ### 20200420 6/26/2020 ClinicalTria
NCT04358 25-Jun-20 Liver Injur Liver Injury in Hospit Austral Uni ### 20200418 6/26/2020 ClinicalTria
NCT04358 25-Jun-20 Study of thOpen Label, Randomize

Fujifilm Ph ### 20200416 6/26/2020 ClinicalTria
NCT04358 25-Jun-20 Keto-diet f Keto-diet KICC-COVI Johns Hopk ### 20200416 6/26/2020 ClinicalTria
NCT04359 25-Jun-20 A RandomizA Randomized Trial of NYU Lango ### 20200420 6/26/2020 ClinicalTria
NCT04360 25-Jun-20 Covid-19 A COVID-19-associated CUniversity ### 20200413 6/26/2020 ClinicalTria
NCT04361 25-Jun-20 AssessmentAssessmentLAPTRANS Centre Hos ### 20200422 6/26/2020 ClinicalTria
NCT04361 25-Jun-20 Tocilizuma Tociluzumab for Cyto Emory Univ 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04362 25-Jun-20 Phase 3 Ra Phase 3 Ra RUXCOVID Novartis P ### 20200422 6/26/2020 ClinicalTria
NCT04362 25-Jun-20 Burnout anBurnout and Medical Er

NCT04362 25-Jun-20 ChloroquinAn Open LaARCHAIC UMC Utrec ### 20200420 6/26/2020 ClinicalTria
NCT04362 25-Jun-20 Investigat Investigation of the National Ca ### 20200424 6/26/2020 ClinicalTria
NCT04363 25-Jun-20 VA RemoteVA RemoteVA-REACH Salomeh K ### 20200423 6/26/2020 ClinicalTria
NCT04363 25-Jun-20 Collection Cohort of Patients WitCentre Hos ### 20200421 6/26/2020 ClinicalTria
NCT04363 25-Jun-20 Tocilizuma Treatment of Serious Instituto ### 20200417 6/26/2020 ClinicalTria
NCT04364 25-Jun-20 ConvalesceConvalescent Plasma tNYU Lango ### 20200422 6/26/2020 ClinicalTria
NCT04364 25-Jun-20 A Study to A Phase 2, RandomizedRenibus The ### 20200420 6/26/2020 ClinicalTria
NCT04364 25-Jun-20 Angiotensi SuspensionBRACE-CO D'Or Instit 4/7/2020 20200407 6/26/2020 ClinicalTria
NCT04365 25-Jun-20 Natural Ki A Phase I/I CYNK001C Celularity ### 20200422 6/26/2020 ClinicalTria
NCT04365 25-Jun-20 OUTpatientA Randomize

OUTCOV Groupe Hosp ### 20200423 6/26/2020 ClinicalTria
NCT04366 25-Jun-20 ThrombosisEvaluation COVBIO Hospices Ci ### 20200423 6/26/2020 ClinicalTria
NCT04366 25-Jun-20 Radiation The RESCUERESCUE 1- Emory Univ ### 20200424 6/26/2020 ClinicalTria
NCT04367 25-Jun-20 ScreenNC, ScreenNC: A Study to University ### 20200427 6/26/2020 ClinicalTria
NCT04368 25-Jun-20 In-vitro Di In-vitro Diagnostic Te Applied Bio ### 20200427 6/26/2020 ClinicalTria
NCT04368 25-Jun-20 Management

Management of Covid-Cairo Unive ### 20200424 6/26/2020 ClinicalTria
NCT04369 25-Jun-20 COVID-19 StCOVID-19 StCurie-O-SAInstitut Cur ### 20200427 6/26/2020 ClinicalTria
NCT04369 25-Jun-20 Treating C Treating COVID-19 WitNYU Lango ### 20200425 6/26/2020 ClinicalTria
NCT04370 25-Jun-20 Multi-site A Multi-site, RandomizNorthwell ### 20200427 6/26/2020 ClinicalTria
NCT04370 25-Jun-20 Tocilizuma Tocilizumab in Hospit National Ca ### 20200430 6/26/2020 ClinicalTria
NCT04371 25-Jun-20 Impact of NImpact of NCOVISLEEP University ### 20200428 6/26/2020 ClinicalTria
NCT04371 25-Jun-20 Outcomes oOutcomes After Implem
Fundacion ### 20200428 6/26/2020 ClinicalTria
NCT04371 25-Jun-20 MSCs in C Mesenchymal Stem CelIcahn Scho ### 20200428 6/26/2020 ClinicalTria
NCT04371 25-Jun-20 COVID-19 HCOVID-19 Health MessNational B ### 20200428 6/26/2020 ClinicalTria
NCT04371 25-Jun-20 Genetics o Genetics of COVID-19 National H ### 20200429 6/26/2020 ClinicalTria
NCT04371 25-Jun-20 Efficacy of Efficacy o SnPPIX Kafrelsheik ### 20200429 6/26/2020 ClinicalTria
NCT04373 25-Jun-20 ConvalesceComparisonCSSC-004 Johns Hopk ### 20200430 6/26/2020 ClinicalTria
NCT04373 25-Jun-20 Weight-AdjEffectiven COVI-DOSECentral Hos 5/1/2020 20200501 6/26/2020 ClinicalTria
NCT04373 25-Jun-20 Cardiac Ar Cardiac Ar ACICOVID Centre Hos ### 20200430 6/26/2020 ClinicalTria
NCT04374 25-Jun-20 Descriptiv Descriptiv PsyConf University ### 20200430 6/26/2020 ClinicalTria
NCT04375 25-Jun-20 Study of OrIbrutiNib i iNSPIRE AbbVie 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04376 25-Jun-20 Investigat A RandomizOSCAR GlaxoSmith 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04376 25-Jun-20 AssessmentAssessmentCOWAIT University 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04376 25-Jun-20 Favipiravi The Regimen of FavipiBaqiyatalla 5/3/2020 20200503 6/26/2020 ClinicalTria
NCT04377 25-Jun-20 Impact on Impact on Anxiety andNational In 5/5/2020 20200505 6/26/2020 ClinicalTria
Prospective Phase II University ### 20200416 6/26/2020 ClinicalTria
NCT04377 25-Jun-20 AssessmentA Phase 3, RandomizedIncyte Cor 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04377 25-Jun-20 ObservationObservational Study t IRCCS San 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04380 25-Jun-20 Low Dose ALow Dose Anti-inflammGrupo de InvestigaciÃ³n

5/4/2020 20200504
ClÃnica en
6/26/2020
OncologÃ
ClinicalTria
a Radioterapia
NCT04382 25-Jun-20 Study of E Phase 2, Randomized, Novartis P 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04382 25-Jun-20 Covid-19 InA Phase 2, RandomizedBeiGene 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04382 25-Jun-20 Study of E A Phase 2, MAS-COVI Novartis P 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04382 25-Jun-20 Sitagliptin Sitagliptin SIDIACO-R University 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04383 25-Jun-20 Surveillan Surveillance of Indiv National In 5/9/2020 20200509 6/26/2020 ClinicalTria
NCT04383 25-Jun-20 Covid-19 T Covid-19 Triage Using Vastra Got 5/4/2020 20200504 6/26/2020 ClinicalTria
NCT04383 25-Jun-20 ConvalesceRandomized

PLASM-AR Hospital It 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04383 25-Jun-20 Prone Posi Prone Posi COVID-PR St. Michael 5/5/2020 20200505 6/26/2020 ClinicalTria
NCT04383 25-Jun-20 Inhaled Se Inhaled Se ISCA University 5/8/2020 20200508 6/26/2020 ClinicalTria
NCT04385 25-Jun-20 Health andHealth and Wellbeing Pregistry ### 20200510 6/26/2020 ClinicalTria
NCT04386 25-Jun-20 Phase Ib-II Adaptive Phase IB-II Aivita Biom ### 20200511 6/26/2020 ClinicalTria
NCT04386 25-Jun-20 Evaluation Evaluation APRV-COVICentral Hos ### 20200414 6/26/2020 ClinicalTria
NCT04386 25-Jun-20 A Study to A Phase II COVASTIL Genentech, ### 20200511 6/26/2020 ClinicalTria
NCT04387 25-Jun-20 COVID-19 PThe Impact of COVID- South Valle ### 20200512 6/26/2020 ClinicalTria
NCT04387 25-Jun-20 Study to A A Phase III, Double-b Vakzine P ### 20200511 6/26/2020 ClinicalTria
NCT04387 25-Jun-20 NCI COVID-NCI COVID-19 in CanceNational Ca ### 20200513 6/26/2020 ClinicalTria
NCT04387 25-Jun-20 Favipiravi Treatment of Covid-19Royal Colle 5/9/2020 20200509 6/26/2020 ClinicalTria
NCT04387 25-Jun-20 DeterminanMajor DeteMC-19 Catholic Un ### 20200513 6/26/2020 ClinicalTria
NCT04388 25-Jun-20 Interferon A Randomized Phase 2Icahn Scho ### 20200512 6/26/2020 ClinicalTria
NCT04388 25-Jun-20 COVID-19 TRandomized, Placebo-C

Veru Inc. ### 20200513 6/26/2020 ClinicalTria
NCT04389 25-Jun-20 The COvid-RepurposinCOSMO McGill Univ ### 20200513 6/26/2020 ClinicalTria
NCT04389 25-Jun-20 The ImpactThe Impact and CopingKaohsiung K ### 20200514 6/26/2020 ClinicalTria
NCT04390 25-Jun-20 COVID-19 RCOVID-19 RCLEO-CD Centre Hosp ### 20200514 6/26/2020 ClinicalTria
NCT04391 25-Jun-20 Prone Posi Effectiveness of Pron Hospital Un ### 20200510 6/26/2020 ClinicalTria
NCT04391 25-Jun-20 IC14 (Anti Phase 2, Randomized, Implicit Bi ### 20200514 6/26/2020 ClinicalTria
NCT04391 25-Jun-20 COVID-19 PCOVID-19 Pandemic Imp

National I ### 20200515 6/26/2020 ClinicalTria
NCT04392 25-Jun-20 FAvipiravi A Trial of FACCT King Abdul ### 20200510 6/26/2020 ClinicalTria
NCT04394 25-Jun-20 Controlled Controlled CLARITY The George ### 20200518 6/26/2020 ClinicalTria
NCT04394 25-Jun-20 Brief Cogn Effect of Brief Cognit Universida 5/3/2020 20200503 6/26/2020 ClinicalTria
NCT04394 25-Jun-20 Low Dose RLow Dose Radiation ThAll India I ### 20200517 6/26/2020 ClinicalTria
NCT04394 25-Jun-20 PathogenesPathogenesis of BTK- National In ### 20200519 6/26/2020 ClinicalTria
NCT04395 25-Jun-20 Sleep Qual Sleep Quality and Eff Assiut Univ ### 20200519 6/26/2020 ClinicalTria
NCT04395 25-Jun-20 A Study of A Phase I Study of Re ProgenaBi ### 20200519 6/26/2020 ClinicalTria
NCT04395 25-Jun-20 Collateral Collateral COVIDIV Fondation ### 20200518 6/26/2020 ClinicalTria
NCT04396 25-Jun-20 EXercise T The ImpactWHO University ### 20200518 6/26/2020 ClinicalTria
NCT04397 25-Jun-20 A Clinical A MulticentCORONA Biocad ### 20200519 6/26/2020 ClinicalTria
NCT04397 25-Jun-20 Hormonal IHormonal In

HITCH VA Office ### 20200514 6/26/2020 ClinicalTria
NCT04397 25-Jun-20 Blood Coll A Blood Collection St TScan Thera ### 20200519 6/26/2020 ClinicalTria
NCT04397 25-Jun-20 MyocardialAssociation of Early Icahn Scho ### 20200519 6/26/2020 ClinicalTria
NCT04399 25-Jun-20 EMPOWER EMPOWER

- - BAME vs COV
Future Gen ### 20200521 6/26/2020 ClinicalTria
NCT04399 25-Jun-20 hCT-MSCs Pilot Study of Safety Joanne Kur ### 20200521 6/26/2020 ClinicalTria
NCT04399 25-Jun-20 COVID-19 BBuilding C QTW2020 The Univer ### 20200519 6/26/2020 ClinicalTria
NCT04401 25-Jun-20 CardiopulmCardiopulmonary InflaNational In ### 20200522 6/26/2020 ClinicalTria
NCT04401 25-Jun-20 Adaptive C A Multicenter, AdaptivNational In ### 20200522 6/26/2020 ClinicalTria

NCT04402 25-Jun-20 PulmozymePulmozyme to ImprovBoston Chi ### 20200512 6/26/2020 ClinicalTria
NCT04402 25-Jun-20 LSALT PeptMulticenter, RandomizArch Biopar ### 20200512 6/26/2020 ClinicalTria
NCT04403 25-Jun-20 Prospectiv A Prospective Natural National In ### 20200523 6/26/2020 ClinicalTria
NCT04404 25-Jun-20 PRE-VENT SA Phase 3 Randomized,CTI BioPha ### 20200522 6/26/2020 ClinicalTria
NCT04405 25-Jun-20 Dose-ConfiA Phase 2a, RandomizeModernaTX, ### 20200513 6/26/2020 ClinicalTria
NCT04405 25-Jun-20 A Safety, T A Phase IIa Randomized

Ridgeback ### 20200526 6/26/2020 ClinicalTria
NCT04405 25-Jun-20 The Effect The Safety of EIDD-28 Ridgeback ### 20200526 6/26/2020 ClinicalTria
NCT04405 25-Jun-20 SCB-2019 aA Phase 1, RandomizedClover Bio ### 20200525 6/26/2020 ClinicalTria
NCT04405 25-Jun-20 HydroxychlHydroxychlPACTT Centre HÃ´ ### 20200526 6/26/2020 ClinicalTria
NCT04405 25-Jun-20 COG-UK ProA Phase II COG-UK HOUniversity 5/7/2020 20200507 6/26/2020 ClinicalTria
NCT04407 25-Jun-20 Appendicit Change in the Inciden Claus Ande ### 20200527 6/26/2020 ClinicalTria
NCT04407 25-Jun-20 Evaluation Zinc Vitamin D and b1 Kanuni Sul ### 20200527 6/26/2020 ClinicalTria
NCT04407 25-Jun-20 Testing theValidation of Machine King's Col ### 20200527 6/26/2020 ClinicalTria
NCT04407 25-Jun-20 InterLeuki A Multicen ILIAD-7-FR Revimmun ### 20200527 6/26/2020 ClinicalTria
NCT04408 25-Jun-20 AKI BiomarAKI Biomarkers for PreGuy's and ### 20200527 6/26/2020 ClinicalTria
NCT04408 25-Jun-20 COVID-19 inCOVID-19 DCOVIDHEL UniversitÃ ### 20200519 6/26/2020 ClinicalTria
NCT04409 25-Jun-20 A Study to A Phase II REMDACTAHoffmann- ### 20200528 6/26/2020 ClinicalTria
NCT04409 25-Jun-20 DISmantlinPhase I Pil DISCONNECExactis Inn ### 20200513 6/26/2020 ClinicalTria
NCT04410 25-Jun-20 Study of MA Phase 2, RandomizedViralClear ### 20200428 6/26/2020 ClinicalTria
NCT04411 25-Jun-20 A Longitud A Longitudinal Study National In ### 20200530 6/26/2020 ClinicalTria
NCT04411 25-Jun-20 A Study of A Randomized, PlaceboEli Lilly a ### 20200529 6/26/2020 ClinicalTria
NCT04412 25-Jun-20 Clinical T A Randomized, Double-
Aevi Genom ### 20200529 6/26/2020 ClinicalTria
NCT04412 25-Jun-20 AnticoagulaPatient Characteristi Karolinska ### 20200530 6/26/2020 ClinicalTria
NCT04412 25-Jun-20 Use of PCR National ObVIGIL Centre Hos ### 20200530 6/26/2020 ClinicalTria
NCT04412 25-Jun-20 Optimizing Optimizing OPTIMAL University ### 20200512 6/26/2020 ClinicalTria
NCT04412 25-Jun-20 Study to E A Randomized Double-b

aTyr Pharm 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04413 25-Jun-20 Cardiac COCardiac In CCC AORTICA G ### 20200523 6/26/2020 ClinicalTria
NCT04413 25-Jun-20 Clinical Ch Clinical Characteristi Nevsehir Pu ### 20200525 6/26/2020 ClinicalTria
NCT04414 25-Jun-20 Bacillus C A RandomizACTIVATEIIHellenic In 6/1/2020 20200601 6/26/2020 ClinicalTria
NCT04416 25-Jun-20 COVID19 ClCOVID-19, Clinical Pre St George' 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04416 25-Jun-20 Quality of Quality of Life and L Universida 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04417 25-Jun-20 Study of L RESOLUTION:

RESOLUTI Laurent Ph ### 20200528 6/26/2020 ClinicalTria
NCT04417 25-Jun-20 Living WithA Longitudinal Survey National H 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04418 25-Jun-20 Online Lea Evaluation of the Onl South Valle 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04419 25-Jun-20 RAS and CoInvestigating the Rel Imperial C ### 20200416 6/26/2020 ClinicalTria
NCT04420 25-Jun-20 Efficacy o Multicentric Pragmati Centro de 6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04420 25-Jun-20 SeroCOVIDiSeroCOVIDiSeroCOVIDiAssistance 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04420 25-Jun-20 Infusion of Efficacy a COMBAT-CPÃ¤r Johan 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04421 25-Jun-20 A Study of A Randomize

COV-BARRIEli Lilly a 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04421 25-Jun-20 Effects of A RandomizCAPRI Priscilla H 6/3/2020 20200603 6/26/2020 ClinicalTria

NCT04422 25-Jun-20 Senior-COVA MulticentSeniorCOV Hospices Ci 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04422 25-Jun-20 Registry o ObservatioCHRONOS1National R 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04422 25-Jun-20 Prophylact Use of Ivermectin as Zagazig Uni 6/6/2020 20200606 6/26/2020 ClinicalTria
NCT04423 25-Jun-20 ImplicationImplications of Covid- Azienda UnitÃ

6/8/2020
Sanitaria
20200608
Locale Reggio
6/26/2020
EmiliaClinicalTria
NCT04424 25-Jun-20 Magnetic RPossibilities of Ches Research a 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04424 25-Jun-20 Saliva/Nar Evaluation of Saliva/N National In 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04424 25-Jun-20 HFNC Trea the Effect of HFNC Tr Sisli Hamid 6/7/2020 20200607 6/26/2020 ClinicalTria
NCT04424 25-Jun-20 COVID-19 LTOMEKAÂ®MD

P University ### 20200520 6/26/2020 ClinicalTria
NCT04425 25-Jun-20 Handling OHandling OxHOT-COVI Aalborg Uni6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04425 25-Jun-20 Obesity andObesity as COV-OB-IC Central Hos ### 20200528 6/26/2020 ClinicalTria
NCT04425 25-Jun-20 Safety and The CRISIS CRISIS Clear Creek 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04425 25-Jun-20 Use of RemUse of RemRPM Montefiore 6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04425 25-Jun-20 PrevalencePrevalenceSERO-MARHospital d 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04425 25-Jun-20 USEFULNESS

USEFULNESS
IVERCAR Eurnekian P6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04425 25-Jun-20 IVERMECTIN

EVALUATION of IvermeEurnekian P6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04426 25-Jun-20 Psychologi Psychological Effects Szeged Uni 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04427 25-Jun-20 EnoxaparinIntermediaINHIXACOVAzienda Osp ### 20200529 6/26/2020 ClinicalTria
NCT04427 25-Jun-20 Accelerate A Novel and Practical Centre for ### 20200610 6/26/2020 ClinicalTria
NCT04427 25-Jun-20 AssessmentAssessment of ThermalFederal Sta ### 20200610 6/26/2020 ClinicalTria
NCT04427 25-Jun-20 A Study of A RandomizBLAZE-1 Eli Lilly a 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04427 25-Jun-20 Low Dose W

Vented COVVENTED Ohio State 6/5/2020 20200605 6/26/2020 ClinicalTria
NCT04427 25-Jun-20 Utility of Efficacy of Lactoferr Cairo Unive ### 20200610 6/26/2020 ClinicalTria
NCT04427 25-Jun-20 Is Adipose Is Adipose TA/SARS-C Centre Hosp ### 20200610 6/26/2020 ClinicalTria
NCT04428 25-Jun-20 Thymosin AlA Pilot Tri Ta1 Inova Heal 6/7/2020 20200607 6/26/2020 ClinicalTria
NCT04428 25-Jun-20 ChloroquinPhase II, Randomized, Hospital Un ### 20200426 6/26/2020 ClinicalTria
NCT04429 25-Jun-20 Safety, Tol Exploratory Study of Inotrem ### 20200529 6/26/2020 ClinicalTria
NCT04429 25-Jun-20 Efficacy, S A Randomized, Double-B

MediciNov 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04429 25-Jun-20 Ivermectin Ivermectin vs. Placeb Sheba Medi ### 20200524 6/26/2020 ClinicalTria
NCT04429 25-Jun-20 Health Pro Health Pro SERODRONTourcoing ### 20200610 6/26/2020 ClinicalTria
NCT04429 25-Jun-20 Impact of Impact of MAGIC Central Hos ### 20200611 6/26/2020 ClinicalTria
NCT04429 25-Jun-20 COVID-19 PPoWerS StuPoWerS University ### 20200611 6/26/2020 ClinicalTria
NCT04429 25-Jun-20 Hydroxychlo
Hydroxychloroquine UsWellStar H ### 20200610 6/26/2020 ClinicalTria
NCT04430 25-Jun-20 Impact of CImpact of tHAD-Covid University ### 20200610 6/26/2020 ClinicalTria
NCT04430 25-Jun-20 Short-termShort-term Outcome ofAzienda Soc ### 20200611 6/26/2020 ClinicalTria
NCT04430 25-Jun-20 Covid-19 atCoronavirusCOMETE-1 Centre Hos ### 20200611 6/26/2020 ClinicalTria
NCT04430 25-Jun-20 Registry f Qatar Cardiovascular Hamad Medi ### 20200611 6/26/2020 ClinicalTria
NCT04430 25-Jun-20 Remote ConRemote GluCGM-ISO Nordsjaell ### 20200526 6/26/2020 ClinicalTria
NCT04431 25-Jun-20 Impact of Impact of CIO Hospices Ci ### 20200610 6/26/2020 ClinicalTria
NCT04431 25-Jun-20 Virtual Mi The Impact of Virtual Icahn Scho ### 20200612 6/26/2020 ClinicalTria
NCT04431 25-Jun-20 SeroconverSeroconversion AmongNordsjaell ### 20200511 6/26/2020 ClinicalTria
NCT04431 25-Jun-20 A Study of A Prospect CoVPN 500COVID-19 P 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04431 25-Jun-20 Study to EvA Phase 2/3CARAVAN Gilead Sci 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04431 25-Jun-20 A Study to Phase 2 Cli IFORS Universida ### 20200610 6/26/2020 ClinicalTria
NCT04431 25-Jun-20 CO-PARENT:

CO-PARENT:
Co-PARENTUniversity ### 20200612 6/26/2020 ClinicalTria
NCT04431 25-Jun-20 In-Utero V In-Utero Vascular Acc University ### 20200611 6/26/2020 ClinicalTria
NCT04431 25-Jun-20 Validation Validation of a Rapid Yale Univer ### 20200612 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 The Use of The Significance of L Gaziosmanp ### 20200611 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 Treatment Treatment of Severe Centro Me ### 20200612 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 ANTIBODY-ANTIBODY-ABACCuS William Be ### 20200612 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 Study of t Randomized, Double-BlFibroGen ### 20200612 6/26/2020 ClinicalTria

NCT04432 25-Jun-20 Study to EvA Multicenter, RandomInstituto Gr ### 20200612 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 A Phase 1 A Phase 1, Multi-Cent Bio-Thera ### 20200612 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 Impact of Impact of ELIKYA CO Centre Hosp ### 20200615 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 Descriptiv Descriptiv LUSCOVID Assistance ### 20200615 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 Patients' Patients' Preferences Massachuse ### 20200612 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 PerceptionsPerceptions, RepresentCentre Hos ### 20200615 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 Maternal PMaternal PsychologicaGeneral an ### 20200614 6/26/2020 ClinicalTria

NCT04432 25-Jun-20 Natural LanA Database and AnalytCambridge ### 20200615 6/26/2020 ClinicalTria
NCT04432 25-Jun-20 Dornase AlDetermination of DornAcibadem U ### 20200615 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 Reliability ComparisonUSCovid University ### 20200612 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 A RandomizA Randomized ControllNanyang Te ### 20200614 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 BNP, SerumB-natriuretic Peptide Assiut Univ ### 20200614 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 COVID19 VeCOVID-19 Versus H1N1Alexandria ### 20200614 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 RepurpoSinRepurpoSinSTORM Temple Uni ### 20200610 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 COVID19 anImmediate CoPE-HCP Queen Mary6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 COVID-19 -COVID-19 -SURG-SAT-Mansoura U ### 20200610 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 Impact of Impact of Cancellatio Mansoura U ### 20200610 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 COVID-19 Cr

COVID-19 Cr
TOCCIP Rennes Uni ### 20200612 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 COPE - COVCOPE - COVCOPE Sahlgrensk ### 20200615 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 PB1046, a A Randomize

VANGARD PhaseBio P ### 20200528 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 The DeveloPancreatic Injury in Usak Unive ### 20200612 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 COVID-19 i National S PEDONCOVUniversity ### 20200424 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 A Clinical A RandomizCAPSID Deutsches 5/6/2020 20200506 6/26/2020 ClinicalTria
NCT04433 25-Jun-20 Best SuppoRadiation RESCUE1-1Emory Univ ### 20200612 6/26/2020 ClinicalTria
NCT04434 25-Jun-20 HydroxychlHydroxychloroquine Ma

Sadat City ### 20200613 6/26/2020 ClinicalTria
NCT04434 25-Jun-20 Treatment Open, Non-comparative

NCT04434 25-Jun-20 Associatio Association of the Ne Hospital Re ### 20200612 6/26/2020 ClinicalTria
NCT04434 25-Jun-20 An AdaptivAn Adaptive, MulticentChromis LL ### 20200613 6/26/2020 ClinicalTria
NCT04434 25-Jun-20 OncologicalOncologicalASTANA Instituto B ### 20200615 6/26/2020 ClinicalTria
NCT04434 25-Jun-20 Validation Clinical V I-GLOBAL European I 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 The Utilit The Utility of Camost Yale Univer ### 20200616 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Ketotifen: Ketotifen: Novel Use Horus Univ ### 20200615 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Remote-by-Remote-by-Default CarUniversity ### 20200616 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Physical RePhysical Rehabilitatio KoÃ§ Unive ### 20200615 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 CompassionCompassionate Use ofShaare Zed ### 20200526 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Covid-19 a COvid-19 eCOVIT-EHPUniversity ### 20200612 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Crizanlizu Crizanlizu CRITICAL Johns Hopk ### 20200616 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Lipid Meta Lipid Meta COVIDOLIPCentre Hosp ### 20200616 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Virtual Ass Development of an AutUniversity 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Efficacy an Prospective, RandomizAzidus Bras 6/8/2020 20200608 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Lung DamaSequelaeCoSequelaeC University ### 20200612 6/26/2020 ClinicalTria

NCT04435 25-Jun-20 AssessmentAssessment of the Eff Astana Med ### 20200614 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Study to A A Phase III, RandomizeVakzine P ### 20200616 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Cardiovasc Uncovering the CardiaUniversity 6/2/2020 20200602 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Ivermectin ComparativIDRA-COVI Mahidol Un ### 20200615 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Efficacy o Unicenter, COVITOZ-0Hospital Un ### 20200611 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Inhaled Ci Ciclesonide Clinical T McGill Univ ### 20200616 6/26/2020 ClinicalTria
NCT04435 25-Jun-20 Efficacy of Off Label Study to Ev University 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04436 25-Jun-20 A Study of A RandomizCOVID-19 Janssen Va ### 20200615 6/26/2020 ClinicalTria
NCT04436 25-Jun-20 NiclosamidPhase 2, Multicentre, First Wave ### 20200616 6/26/2020 ClinicalTria
NCT04436 25-Jun-20 An Open StAn Open Study of the Gamaleya R ### 20200616 6/26/2020 ClinicalTria
NCT04436 25-Jun-20 Immune Bi Immune Dys

IBOC University ### 20200612 6/26/2020 ClinicalTria
NCT04437 25-Jun-20 Dietary an Dietary an COV-EAT University ### 20200615 6/26/2020 ClinicalTria
NCT04437 25-Jun-20 PostpartumPostpartum Depression

General an ### 20200615 6/26/2020 ClinicalTria
NCT04437 25-Jun-20 Post Expos Post Expos HCQ-COVI Hamad Medi ### 20200617 6/26/2020 ClinicalTria
NCT04437 25-Jun-20 Network-TaNetwork-TaSnowball Duke Unive ### 20200617 6/26/2020 ClinicalTria
NCT04437 25-Jun-20 ProspectiveLongitudinaOBVIONCOGroupe Hosp ### 20200617 6/26/2020 ClinicalTria
NCT04437 25-Jun-20 Efficacy of Efficacy of Intravenou Jinnah Hosp ### 20200617 6/26/2020 ClinicalTria
NCT04437 25-Jun-20 An Open StAn Open Study of the SGamaleya R ### 20200616 6/26/2020 ClinicalTria
NCT04437 25-Jun-20 COVIDAR - COVIDAR - COVIDAR Hospital Cl ### 20200528 6/26/2020 ClinicalTria
NCT04437 25-Jun-20 Evaluation Evaluation of Vaginal FAcibadem U ### 20200617 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 Evaluating Evaluating the Effica Metro Infe ### 20200617 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 COVID ScreCOVID Screening StratSt. Joseph ### 20200617 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 Rehabilita Rehabilita REACT Azienda UnitÃ Sanitaria

### 20200610
Locale Reggio
6/26/2020
EmiliaClinicalTria
NCT04438 25-Jun-20 Evaluation Evaluation IMMUNOVAzienda Os ### 20200616 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 Use of Con Use of Con CP IN COV Cairo Unive ### 20200616 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 HydroxychlHydroxychloroquine PoRambam He ### 20200618 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 COVidIVERm

Randomized,
COVER IRCCS Sacr ### 20200410 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 Daily HomeA Descriptive Pilot S Sheba Medi ### 20200617 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 Contributi Contributi COVID-PR University ### 20200617 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 Investigati Investigation of Fatig Ankara Yild ### 20200617 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 Brain Heal Brain Health in the T Miro Healt ### 20200615 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 Glucocorti Treatment CORTIVID Fundacion ### 20200618 6/26/2020 ClinicalTria
NCT04438 25-Jun-20 The COVID-An ObservaCOVICARE NHS Lanark ### 20200618 6/26/2020 ClinicalTria
NCT04439 25-Jun-20 Ibrutinib f Randomized Double-BliJennifer W ### 20200617 6/26/2020 ClinicalTria
NCT04439 25-Jun-20 Efficacy a A RandomizCOBRA University 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04439 25-Jun-20 A Study to Evaluation FITE19 PTC Therap ### 20200617 6/26/2020 ClinicalTria
NCT04439 25-Jun-20 COVID-19 inCOVID-19 inCOLD Stanford Un ### 20200617 6/26/2020 ClinicalTria
NCT04440 25-Jun-20 Study of thA Phase 2, SOC Sorrento Th ### 20200617 6/26/2020 ClinicalTria
NCT04440 25-Jun-20 Isolated D Isolated During COVIDUniversity ### 20200618 6/26/2020 ClinicalTria
NCT04441 25-Jun-20 Study to EvBicentric, MARACOVIHospital Un ### 20200618 6/26/2020 ClinicalTria
NCT04441 25-Jun-20 Efficacy a Prospective, RandomizAzidus Bras ### 20200618 6/26/2020 ClinicalTria

The Therapeutic Potent
Alkarkh He ### 20200612 6/26/2020 ClinicalTria
NCT04441 25-Jun-20 AssessmentAssessment of Lung I Centre Hosp ### 20200616 6/26/2020 ClinicalTria
NCT04441 25-Jun-20 Identifica Identificat COVID_OMIRCCS Polic ### 20200612 6/26/2020 ClinicalTria
NCT04441 25-Jun-20 Effect of P The ImpactTEAM-ICU Cedars-Sin ### 20200618 6/26/2020 ClinicalTria
NCT04441 25-Jun-20 Seropreval Study of thSeroCoV-H University ### 20200520 6/26/2020 ClinicalTria
NCT04441 25-Jun-20 FOUND - AnFrequency FOUND Fondazione ### 20200618 6/26/2020 ClinicalTria
NCT04441 25-Jun-20 Tolerabili A Randomized, Double-b

Shanghai Ju6/6/2020 20200606 6/26/2020 ClinicalTria
NCT04441 25-Jun-20 TherapeutiTherapeutic Plasma ExEmory Univ ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 ImmunizatiCOV-IMMUNO

COV-IMM Canadian C ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 Impact of Phone Survey for UndePromundo, ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 Characteri Characteri AfriCoVER Institute o ### 20200616 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 InterLeukinA Multicen ILIAD-7-US-Revimmun ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 ConvalesceInfusion of Convalesc University ### 20200511 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 Predictors Predictors and Mecha University ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 Factors As Factors Associated Wi University ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 NasoVAX inPhase 2, Double-blind Altimmune, ### 20200617 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 PTSD SymptPTSD Symptoms Among

NCT04442 25-Jun-20 Difficulti Difficulties in Emoti University ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 Parental S Parental Stress After University ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 The ImpactThe Impact of Inform University ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 Parental B Parental Burnout Duri University ### 20200619 6/26/2020 ClinicalTria
NCT04442 25-Jun-20 Effectiven Effectiveness of Conv Bagcilar Tr ### 20200617 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 AlterationsAlterationsAGMFMSS First Affil 6/3/2020 20200603 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 PreeclampsEvaluation of COVID-1Zeynep Kam ### 20200621 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 Brain ImagiBrain Imag BIBS King's Col ### 20200619 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 ChloroquinEfficacy of Chloroquin CMN "20 d ### 20200617 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 Insomnia AInsomnia After the C University ### 20200619 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 Glycine Su Controlled and Randomi

Instituto ### 20200618 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 Predictors Predictors of Mental University ### 20200619 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 Efficacy a Efficacy and Safety o Cairo Unive ### 20200620 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 Status and Status and Predictor University ### 20200619 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 Characteri Characterizing the Pe Randy Loft ### 20200619 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 Nitric Oxid Multi-Center, Double- Sanotize R ### 20200620 6/26/2020 ClinicalTria
NCT04443 25-Jun-20 Clinical T Clinical Tr ANA-COVIDFundacion ### 20200618 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 Loneliness Loneliness During the Modum Ba ### 20200620 6/26/2020 ClinicalTria

Prospective, RandomizArmed Forc ### 20200527 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 Antibody RAntibody Responses inAssiut Univ ### 20200619 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 Informatio Information Sources aUniversity ### 20200621 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 Registry o InterNaTional rEgistr European I ### 20200622 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 Clinical I Identification of Fac Institut d' ### 20200622 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 Effect of Effect of COST-HD Sisli Hamid ### 20200621 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 Conjunctiv Conjunctival Swab vs Medical Un ### 20200618 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 PROSAIC-19PROSAIC-19PROSAIC-1 Imperial C ### 20200616 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 Effects of Effects of COVID-19 I University ### 20200619 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 COVID-19 VAn Adaptive Phase I/I University ### 20200615 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 COVID 19: Is SARS-Co LapCoVIDS University ### 20200615 6/26/2020 ClinicalTria
NCT04444 25-Jun-20 A Pragmati UtilizaÃ§Ã£o
RAPID-BRAUniversity
da Enoxaparina em Dose Anticoagulante
### 20200622em6/26/2020
PacientesClinicalTria
Hospitalizados Com sÃn
NCT04444 25-Jun-20 Do NetworkCentrality in the Cro Modum Ba ### 20200620 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Phase I Cli A Multi-center, DoubleAnhui Zhif ### 20200616 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 ExperimentExperimental ExpandeJonathan G ### 20200620 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 A Study of A Multi-center, RandoSentien Bio ### 20200622 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 COVID-19 HThe COVID-CO-HOST University ### 20200622 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Inhaled Ilo Inhaled Ilo ILOCOVID Hamad Medi6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Study of thStudy of the TreatmentGuy's and ### 20200527 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Clinical Tr A Multicentre, Open-l Fundacion ### 20200613 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Phase 2 TriDouble Bli DAMPEN CJon Simmo ### 20200622 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Ivermectin Use of Ivermectin as Zagazig Uni ### 20200619 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Effects of Effects of Online and Centre de ### 20200622 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Stellate Ga Stellate Ganglion Bloc University 6/9/2020 20200609 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Effect of P Effect of Physical Th Government ### 20200622 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Safety and A Phase 1/2a, Multi-c Genexine, I ### 20200619 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Pediatrics Retrospective and ProColumbia U ### 20200622 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Diagnostic Diagnostic Value of N Assiut Univ ### 20200618 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 OPV as PotOral Polio Vaccine as Bandim Hea ### 20200622 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 An ObservaAn ObservaCHLORAZ Centre Mu ### 20200622 6/26/2020 ClinicalTria

Mesenchymal StromalUniversity
C ### 20200619 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 An AdaptiveAn AdaptiveVIRCO Bayside He ### 20200622 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 EPISODE-PSEPISODE-PSEPISODE-P MindRhythm ### 20200618 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Short TermThe Effect of the Shor The Miriam ### 20200619 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Unraveling Unraveling the MechanUniversita ### 20200622 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Measles VaMeasles Vaccine: Is T Ain Shams ### 20200623 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Prasugrel Prasugrel PARTISAN Azienda Os 6/4/2020 20200604 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Dramatic CDramatic CONCOCARECHU de Re ### 20200623 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Anticoagul Anticoagulation in PatHamad Medi ### 20200623 6/26/2020 ClinicalTria
NCT04445 25-Jun-20 Respirator Respirator COVID-VENI.M. Seche ### 20200622 6/26/2020 ClinicalTria
NCT04446 25-Jun-20 Protection A Multicen HERD MELISA Ins ### 20200623 6/26/2020 ClinicalTria
NCT04446 25-Jun-20 A Preventi A Randomized Open-lab

National Un ### 20200511 6/26/2020 ClinicalTria
NCT04446 25-Jun-20 COVID-19 (COVID-19 (SARS-CoV-2)

NCT04446 25-Jun-20 Bicentric Bicentric ECMO-SL-CUniversity ### 20200623 6/26/2020 ClinicalTria
NCT04446 25-Jun-20 Immune StaImmune StaCovidImmuUniversity ### 20200622 6/26/2020 ClinicalTria
NCT04446 25-Jun-20 A Study of A Phase II RandomizedAI Therapeu ### 20200623 6/26/2020 ClinicalTria
NCT04446 25-Jun-20 Anti-AndroAnti-Androgen TreatmApplied Bio ### 20200622 6/26/2020 ClinicalTria
web addre Recruitmenother reco Inclusion Inclusion Inclusion Date enrol Target size Study type Study desi
https://cl Not recruitNo N/A N/A All 25-Jan-20 500 InterventioAllocation:
https://cl Recruiting No 18 Years 80 Years All 28-Jan-20 125 InterventioAllocation
https://cl Recruiting No N/A N/A All 20-Jan-20 12000 Observational
https://cl Recruiting No N/A N/A All 3-Feb-20 30000 Observational
https://cl Not recruitNo 18 Years 75 Years All 7-Feb-20 380 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All 10-Feb-20 80 InterventioAllocation

http://wwwNot Recrui No Both 2/1/2020 survival gr ObservatioFactorial
http://wwwNot Recrui No 18 Both ### Case seriesObservatioSequential
http://wwwNot Recrui No 18 75 Both 3/1/2020 experimentInterventioParallel
http://wwwRecruiting No Both ### ConventionInterventioParallel
http://wwwRecruiting No Both 2/6/2020 Case seriesInterventioSingle arm

http://wwwNot Recrui No 0 100 Both ### Case seriesObservatioSequential
http://wwwRecruiting No Both ### Case seriesObservatioFactorial
http://wwwRecruiting No Both ### Case seriesObservatioSequential
http://wwwNot Recrui No 18 75 Both ### Target condDiagnostic Sequential

http://wwwRecruiting No Both ### Target condDiagnostic Sequential
http://wwwNot Recrui No 18 80 Both ### experimentInterventioParallel
http://wwwRecruiting No 18 75 Both ### ExperimentInterventioParallel
http://wwwRecruiting No 18 75 Both ### Chinese traInterventioParallel
http://wwwRecruiting No 18 Both ### ExperimentInterventioParallel
http://wwwRecruiting No 16 99 Male ### experimentInterventioNon random

http://wwwRecruiting No 18 75 Both 2/1/2020 ExperimentInterventioParallel
http://wwwRecruiting No 18 Both ### Case seriesObservatioSequential
http://wwwNot Recrui No 3 85 Both ### ObservatioPreventionNon random
http://wwwRecruiting No 18 90 Both ### ExperimentInterventioNon random
http://wwwRecruiting No 18 75 Both 2/1/2020 Case seriesObservatioSequential

http://wwwRecruiting No 0 18 Both ### control gr InterventioNon random
http://wwwNot Recrui No 18 Both ### ExperimentInterventioParallel
http://wwwRecruiting No 1 100 Both ### Target condDiagnostic Factorial
http://wwwRecruiting No 18 Both ### Thymosin tInterventioParallel
http://wwwRecruiting No Both ### case series ObservatioSequential
http://wwwRecruiting No Both ### Case seriesPrognosis Cohort stu
http://wwwRecruiting No 18 80 Both ### Control gr InterventioParallel
http://wwwNot Recrui No 18 80 Both 3/1/2020 Control groInterventioParallel

http://wwwRecruiting No Both ### Target condDiagnostic Factorial
http://wwwRecruiting No 15 85 Both ### TCM Group:InterventioNon random
http://wwwRecruiting No 18 80 Both 2/5/2020 experimentInterventioParallel
http://wwwRecruiting No Both ### experimentInterventioParallel

http://wwwNot Recrui No 18 80 Both ### ExperimentInterventioParallel
http://wwwRecruiting No 18 75 Both ### experimentInterventioParallel
http://wwwRecruiting No 18 85 Both ### control gr InterventioParallel
http://wwwNot Recrui No Both ### case series ObservatioSequential

http://wwwRecruiting No Both 2/3/2020 Case seriesObservatioSequential
http://wwwRecruiting No Both ### Epilepsy g ObservatioFactorial
http://wwwRecruiting No Both 2/1/2020 Suspected ObservatioNon random

http://wwwRecruiting No 18 70 Both ### General paInterventioParallel
http://wwwRecruiting No Both ### non-severeObservatioFactorial

http://wwwNot Recrui No Both ### Vitamin D ObservatioFactorial
http://wwwNot Recrui No 1 100 Both 3/1/2020 Target condDiagnostic Sequential
http://wwwNot Recrui No 18 Both ### control gr InterventioParallel
http://wwwRecruiting No 14 ?? Both ### doctors gr InterventioFactorial
http://wwwNot Recrui No Both 2/7/2020 ExperimentObservatioSequential
http://wwwRecruiting No 18 Both 2/9/2020 Case seriesInterventioSingle arm

http://wwwNot Recrui No Both 2/7/2020 ExperimentObservatioNon random
http://wwwNot Recrui No 18 90 Both ### Normal groBasic ScienFactorial
http://wwwNot Recrui No Both 2/8/2020 Case seriesObservatioSequential
http://wwwRecruiting No 18 Both 2/7/2020 ExperimentInterventioParallel
http://wwwNot Recrui No 18 80 Both ### mild-moderInterventioNon random
http://wwwRecruiting No 18 65 Both 2/1/2020 Control gr InterventioParallel
http://wwwRecruiting No 16 75 Both ### Group A:30InterventioNon random

http://wwwRecruiting No Both 2/6/2020 Treatment InterventioSingle arm
http://wwwRecruiting No 18 Both 2/5/2020 control gr InterventioParallel

http://wwwNot Recrui No 18 Both 2/5/2020 control gr InterventioParallel
http://wwwRecruiting No Both ### single arm InterventioSingle arm
http://wwwNot Recrui No 18 75 Both 2/4/2020 A:10;B:10; InterventioParallel
http://wwwNot Recrui No 18 75 Both 2/4/2020 ExperimentInterventioParallel
http://wwwRecruiting No 18 80 Both 2/3/2020 ExperimentInterventioNon random
http://wwwNot Recrui No 18 65 Both ### DRV/c grouInterventioParallel
http://wwwRecruiting No 18 Both 2/4/2020 experimentInterventioParallel
http://wwwRecruiting No 14 80 Both 2/4/2020 (ordinary) InterventioParallel
http://wwwRecruiting No 14 80 Both 2/4/2020 treament gInterventioParallel
http://wwwNot Recrui No 18 70 Both 2/3/2020 experimenta

InterventioParallel
http://wwwNot Recrui No Both ### ExperimentPreventionCase-Contr
http://wwwNot Recrui No 18 80 Both 2/1/2020 experimenta

InterventioNon random
http://wwwNot Recrui No 18 90 Both 2/1/2020 Case seriesObservatioSequential

http://wwwNot Recrui No Both 2/2/2020 control gr InterventioParallel
http://wwwNot Recrui No Both 2/4/2020 control gr InterventioParallel

http://wwwNot Recrui No Both 2/3/2020 Case seriesObservatioSingle arm
http://wwwNot Recrui No Both 2/1/2020 Group 1:50InterventioNon random
http://wwwNot Recrui No 18 60 Both 2/1/2020 CommunityInterventioParallel
http://wwwNot Recrui No Both 2/1/2020 Case seriesInterventioSequential
http://wwwRecruiting No Both ### A:15;B:15; InterventioParallel

http://wwwRecruiting No 18 Both ### Group A:20InterventioNon random
http://wwwNot Recrui No 18 75 Both ### Group 1:20InterventioNon random
https://cl Not recruitNo 18 Years N/A All 10-Feb-20 120 InterventioAllocation:
https://cl Recruiting No 18 Years 75 Years All 6-Feb-20 10 InterventioInterventi

http://wwwRecruiting No 50 100 Both ### severe NCPInterventioFactorial
http://wwwNot Recrui No 18 Both ### Control groInterventioParallel
http://wwwRecruiting No 18 80 Both ### control groInterventioFactorial

http://wwwNot Recrui No Both ### Case seriesObservatioSequential
http://wwwNot Recrui No 16 75 Male ### ExperimentInterventioParallel

http://wwwNot Recrui No 15 60 Both ### Case seriesObservatioSingle arm
http://wwwNot Recrui No 0 90 Both ### HumanisticInterventioNon random
http://wwwNot Recrui No Both ### ExperimentInterventioParallel
http://wwwRecruiting No 18 70 Both ### CombinatioInterventioParallel
http://wwwRecruiting No 18 75 Both 2/1/2020 Two groupsInterventioDose comp
http://wwwNot Recrui No 18 Both ### Case seriesObservatioSingle arm

http://wwwNot Recrui No 16 50 Female 3/1/2020 AdolescentObservatioFactorial
http://wwwNot Recrui No 18 65 Both 3/1/2020 1:30;2:30; InterventioNon random
http://wwwRecruiting No Both ### Severe gro ObservatioFactorial
http://wwwNot Recrui No 15 35 Both ### Exercise p InterventioParallel

http://wwwRecruiting No Both ### Light grou ObservatioFactorial

http://wwwRecruiting No Both ### general aneObservatioFactorial
http://wwwRecruiting No 18 75 Both ### Psychologi InterventioParallel
http://wwwNot Recrui No Both ### case series ObservatioSequential
http://wwwNot Recrui No 18 75 Both ### HydroxychlInterventioParallel
http://wwwRecruiting No 18 80 Both 2/7/2020 Case seriesInterventioSingle arm
http://wwwNot Recrui No 18 Both ### Case seriesInterventioSingle arm
http://wwwNot Recrui No 18 80 Both ### Interventi InterventioParallel
http://wwwRecruiting No 1 90 Both ### Case seriesObservatioSequential

http://wwwNot Recrui No 18 75 Both ### Case seriesInterventioSingle arm

http://wwwRecruiting No 18 Both ### Case seriesInterventioSingle arm
http://wwwRecruiting No 18 70 Both 2/6/2020 Case seriesInterventioSequential
http://wwwNot Recrui No 18 90 Both ### Training:1 ObservatioFactorial

http://wwwRecruiting No Both ### Severe gro ObservatioFactorial
http://wwwRecruiting No 18 80 Both 2/4/2020 1:30;2:30; InterventioParallel
http://wwwRecruiting No Female ### Case seriesBasic ScienSequential
http://wwwNot Recrui No 18 60 Both ### Case seriesTreatment Sequential
http://wwwRecruiting No Both ### ExperimentInterventioParallel

http://wwwNot Recrui No 16 30 Both ### college st ObservatioSequential
http://wwwNot Recrui No Both ### Group 1:12InterventioParallel
http://wwwRecruiting No 18 75 Both ### Ganovo / r InterventioNon random

http://wwwNot Recrui No 18 100 Both ### Mild GroupInterventioFactorial
http://wwwRecruiting No 18 Both ### Low-dose gInterventioParallel
http://wwwRecruiting No Male ### pneumoniaObservatioFactorial
http://wwwNot Recrui No 18 80 Both ### Control gr InterventioParallel
http://wwwNot Recrui No 18 75 Both ### ChloroquinInterventioParallel
http://wwwNot Recrui No 60 Both ### experimentInterventioParallel
http://wwwRecruiting No 18 Female ### Target condDiagnostic Sequential

http://wwwNot Recrui No Both ### Control gr InterventioNon random
http://wwwRecruiting No 0 1 Both ### COVID-19 pObservatioFactorial

http://wwwRecruiting No Both ### Control gr InterventioParallel

http://wwwRecruiting No Both ### common gro
ObservatioFactorial
http://wwwNot Recrui No 18 60 Both ### A1:80;A2:8InterventioParallel
http://wwwRecruiting No 18 Both ### experimentInterventioParallel
http://wwwRecruiting No 16 99 Both ### hydroxychlInterventioParallel
https://cl Not recruitNo N/A 18 Years All 15-Feb-20 500 Observational

https://cl Recruiting No 18 Years 90 Years All 14-Feb-20 450 Observational
https://cl Recruiting No 18 Years 65 Years All 15-Feb-20 136 InterventioAllocation:
https://cl Recruiting No N/A 28 Days All 1-Feb-20 100 Observational
https://cl Recruiting No 18 Years 80 Years All 22-Feb-20 30 InterventioAllocation
http://wwwNot Recrui No 20 90 Male 3/5/2020 Case seriesInterventioNon random
http://wwwNot Recrui No Both 3/1/2020 one group:InterventioSingle arm
http://wwwNot Recrui No 20 45 Both 3/2/2020 Case seriesInterventioParallel

http://wwwNot Recrui No 18 Both 3/2/2020 Case seriesInterventioSingle arm
http://wwwNot Recrui No Both 3/1/2020 Control gr InterventioParallel
http://wwwRecruiting No 18 80 Male 3/1/2020 Group 1:40InterventioParallel
http://wwwRecruiting No Both 1/1/2020 Target condDiagnostic Sequential
http://wwwRecruiting No 18 Both ### Exposure gObservatioNon random
http://wwwRecruiting No Both 3/1/2020 Mild groupObservatioFactorial
http://wwwNot Recrui No 0 0 Both 3/1/2020 Case seriesInterventioSequential

http://wwwRecruiting No 18 65 Both 3/1/2020 Case seriesObservatioSingle arm
http://wwwRecruiting No 0 18 Both ### Monitor caObservatioSequential
http://wwwRecruiting No 18 Both 3/4/2020 Pirfenidon InterventioParallel

http://wwwNot Recrui No Both ### Interventi ObservatioSequential
http://wwwNot Recrui No Both ### Two groupsInterventioNon random
http://wwwRecruiting No 18 90 Both 2/1/2020 Light and ObservatioFactorial
http://wwwNot Recrui No 18 79 Both 3/1/2020 The experi InterventioParallel

http://wwwRecruiting No 18 Both 1/1/2020 Case seriesObservatioSequential

http://wwwNot Recrui No 18 90 Both 3/9/2020 Case seriesObservatioSingle arm

http://wwwRecruiting No Both ### case series ObservatioSingle arm
http://wwwNot Recrui No Both ### High infla InterventioParallel

http://wwwNot Recrui No 18 Both ### Burnout poObservatioSequential
http://wwwNot Recrui No Both ### Case seriesEpidemilogSequential
http://wwwNot Recrui No Both 3/1/2020 Exocrine g InterventioParallel
http://wwwNot Recrui No 18 70 Both ### ExperimentTreatment Single arm

http://wwwNot Recrui No 18 75 Both 3/1/2020 Routine tr InterventioParallel

http://wwwNot Recrui No Both ### Target condDiagnostic Cross-secti

http://wwwRecruiting No 18 100 Both ### General poHealth servSequential
http://wwwNot Recrui No 60 Both ### the elderly ObservatioSequential
http://wwwRecruiting No 8 91 Both ### Case seriesInterventioSequential

http://wwwNot Recrui No Both ### Case seriesInterventioSingle arm
http://wwwNot Recrui No Both 3/1/2020 InterventioParallel
http://wwwNot Recrui No Both ### ExperimentInterventioNon random
http://wwwRecruiting No 18 75 Both ### Kesuting s InterventioParallel
http://wwwNot Recrui No 18 Both ### ExperimentInterventioSingle arm

http://wwwRecruiting No 18 Both ### hydroxychlInterventioParallel
http://wwwRecruiting No 18 75 Both ### hydroxychlInterventioParallel

http://wwwRecruiting No 18 80 Both ### Low-dose gInterventioParallel
http://wwwNot Recrui No 18 80 Both ### control gr InterventioParallel
http://wwwRecruiting No 18 65 Both ### arm A:36;aInterventioParallel

https://cl Not recruitNo 18 Years 75 Years All 15-Feb-20 30 InterventioInterventi
https://cl Not recruitNo N/A N/A All Feb-20 230 InterventioInterventi
https://cl Recruiting No 18 Years N/A All 4-Feb-20 294 InterventioAllocation
https://cl Not recruitNo N/A N/A All 31-Jan-20 39 Observational

http://wwwRecruiting No Both 2/1/2020 ExperimentInterventioParallel
http://wwwNot Recrui No 18 100 Both ### Case seriesObservatioSingle arm

http://wwwNot Recrui No Both 3/7/2020 ExperimentInterventioParallel
http://wwwRecruiting No 18 90 Both 3/8/2020 case series ObservatioSequential
http://wwwRecruiting No 0 18 Both ### monitor ca ObservatioSequential

http://wwwNot Recrui No 18 - Both ### Target condDiagnostic Sequential

http://wwwRecruiting No Both 3/9/2020 Patients w ObservatioFactorial

http://wwwNot Recrui No 16 30 Both 3/6/2020 Medical st ObservatioSequential
http://wwwNot Recrui No 18 90 Both 3/8/2020 CRRT groupInterventioParallel
http://wwwRecruiting No 18 Both ### ExperimentInterventioNon random
http://wwwNot Recrui No 18 65 Both 3/4/2020 cross-secti ObservatioSequential

http://wwwNot Recrui No Both 3/4/2020 Control gr ObservatioNon random
http://wwwRecruiting No Both 3/3/2020 Patients i ObservatioCross-secti

http://wwwRecruiting No 18 70 Both 2/1/2020 COVID-2019EpidemilogSequential
http://wwwRecruiting No 18 Both 3/4/2020 Azvudine PInterventioSingle arm
http://wwwNot Recrui No 14 90 Both 3/3/2020 Group 2:50ObservatioFactorial

http://wwwNot Recrui No Both 2/2/2020 treatment InterventioParallel
http://wwwRecruiting No 18 Both 3/1/2020 Early corti InterventioParallel
http://wwwRecruiting No 18 110 Both 3/3/2020 Interferon InterventioParallel
http://wwwRecruiting No 18 75 Both 3/2/2020 Lipoic acid InterventioParallel
http://wwwRecruiting No Both ### PRE-GROUPObservatioNon random
http://wwwNot Recrui No Both 3/1/2020 Control gr InterventioParallel
http://wwwNot Recrui No 18 90 Both 3/2/2020 Group 2:35InterventioParallel

http://wwwRecruiting No Both 3/3/2020 Case seriesEpidemilogSequential
http://wwwNot Recrui No Both 3/2/2020 ACEIs/ARBsObservatioSequential
http://wwwNot Recrui No 18 80 Both 3/6/2020 Case seriesObservatioSingle arm

http://wwwRecruiting No 18 Both ### group A:20InterventioParallel
http://wwwNot Recrui No 18 99 Both ### patient gr ObservatioFactorial
http://wwwRecruiting No 18 - Both ### ExperimentInterventioParallel
http://wwwRecruiting No Both ### ExperimentInterventioFactorial

http://wwwRecruiting No Both 2/3/2020 ExperimentInterventioParallel
http://wwwRecruiting No 18 Both ### interventi InterventioParallel
https://cl Not recruitNo 18 Years 75 Years All 1-Jan-20 400 Observational

https://cl Not recruitNo 18 Years N/A All 1-Mar-20 328 InterventioAllocation
https://cl Not recruitNo 18 Years 100 Years All ### 80 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All 1-Apr-20 576 InterventioAllocation
https://cl Not recruitNo 18 Years 90 Years All 7-Mar-20 120 Observational
https://cl Not recruitNo 10 Years 19 Years All 15-Oct-20 3428 Observational

http://wwwRecruiting No 18 80 Both ### Population ObservatioSequential
http://wwwRecruiting No Both ### Control gr InterventioParallel

http://wwwNot Recrui No Male ### Case seriesObservatioSequential
http://wwwRecruiting No 18 65 Both 3/1/2020 Group 1:90InterventioParallel

http://wwwNot Recrui No 18 70 Both ### ObservatioObservatioSingle arm
http://wwwRecruiting No 18 85 Both 2/1/2020 MSC groupObservatioSingle arm
http://wwwRecruiting No Male 2/1/2020 Case seriesObservatioSequential
http://wwwRecruiting No Both 2/1/2020 Case seriesInterventioNon random
http://wwwNot Recrui No 0 99 Both ### Ordinary C ObservatioSequential
http://wwwRecruiting No 18 85 Both ### Case seriesHealth servSequential

http://wwwRecruiting No 18 85 Male ### Case seriesObservatioSequential
http://wwwNot Recrui No Both 3/1/2020 Group 1:70ObservatioFactorial
http://wwwRecruiting No 20 88 Both ### Target condDiagnostic Sequential

http://wwwNot Recrui No Male 2/1/2020 Case seriesInterventioSequential
http://wwwNot Recrui No Both ### The triple ObservatioCohort stu
http://wwwNot Recrui No 18 Both 2/1/2020 Case seriesInterventioSequential
http://wwwNot Recrui No 18 ?? Both ### ObservatioObservatioFactorial
http://wwwNot Recrui No 7 70 Both ### Case seriesInterventioSequential

http://wwwNot Recrui No 12 85 Both 3/1/2020 Case seriesScreening Sequential
http://wwwNot Recrui No 18 80 Both 2/1/2020 Group 2:15InterventioNon random
http://wwwRecruiting No 16 75 Both ### High dose InterventioSingle arm

http://wwwNot Recrui No Male ### Target condDiagnostic Sequential
http://wwwNot Recrui No Both ### Group 1:20InterventioParallel

http://wwwNot Recrui No 1 100 Male 3/1/2020 Case seriesObservatioSequential
http://wwwNot Recrui No 0 86 Both ### Case serie ObservatioSequential

http://wwwRecruiting No 18 100 Both ### Case seriesObservatioCohort stu
http://wwwRecruiting No 18 Both ### ExperimentInterventioCross-secti
http://wwwRecruiting No 23 94 Both ### non-cancerObservatioFactorial
http://wwwRecruiting No 18 75 Both 2/1/2020 experimentObservatioSequential

http://wwwRecruiting No 18 75 Both 2/1/2020 ExocarpiumInterventioParallel

http://wwwRecruiting No 18 Both ### severe patiObservatioSequential
http://wwwNot Recrui No Both ### Case seriesObservatioCase study
http://wwwRecruiting No 65 100 Both ### discharge ObservatioCase study

http://wwwNot Recrui No Both ### Target condDiagnostic Sequential

http://wwwNot Recrui No 12 Both ### Case seriesObservatioFactorial

http://wwwRecruiting No 2 89 Both 2/1/2020 Case seriesObservatioCase-Contr

http://wwwRecruiting No 18 80 Both ### Case seriesInterventioCohort stu

http://wwwRecruiting No Both 2/1/2020 Case seriesEpidemilogSequential
http://wwwRecruiting No 18 Both 3/7/2020 4 groups:2 ObservatioFactorial

http://wwwNot Recrui No 1 99 Both ### Case seriesEpidemilogSingle arm
http://wwwNot Recrui No 16 Both ### Case seriesInterventioSingle arm
http://wwwNot Recrui No 18 74 Both ### two groupsObservatioCase-Contr
http://wwwNot Recrui No Both ### control gr InterventioParallel
http://wwwNot Recrui No 14 90 Both ### NIV group: ObservatioFactorial

http://wwwRecruiting No 20 80 Male ### Case seriesObservatioSequential

http://www.chictr.or No 14 90 Both 2/1/2020 case series ObservatioSequential

http://wwwRecruiting No Both ### Control gr ObservatioNon random
http://wwwRecruiting No 14 90 Both 2/1/2020 ECMO group

InterventioNon random
http://wwwRecruiting No 14 90 Both 2/1/2020 transnasal ObservatioSequential

http://wwwRecruiting No 14 90 Both 2/1/2020 case series ObservatioCase study
http://wwwNot Recrui No 18 Both 3/9/2020 Case seriesObservatioSequential
http://wwwRecruiting No 18 65 Both 3/1/2020 Group 2:60InterventioParallel
http://wwwRecruiting No Both 3/1/2020 Integrated ObservatioCohort stu

http://wwwNot Recrui No 14 90 Both 4/1/2020 Exposed grObservatioFactorial

http://wwwRecruiting No 22 55 Male 3/5/2020 in hospita ObservatioSequential

http://wwwRecruiting No 1 100 Both 2/9/2020 Target condDiagnostic Sequential
http://wwwRecruiting No 18 - Both ### eperimentaInterventioParallel
http://wwwNot Recrui No 18 Both ### experimentInterventioParallel
http://wwwNot Recrui No 18 Both 3/9/2020 experimentInterventioParallel
http://wwwNot Recrui No 18 96 Both ### Case seriesObservatioNon random
http://wwwRecruiting No 18 80 Both ### Two groupsBasic ScienFactorial
http://wwwNot Recrui No 0 18 Both 2/1/2020 Infection wBasic ScienFactorial
http://wwwRecruiting No 18 Both 3/3/2020 tumor pati ObservatioSequential

http://wwwNot Recrui No 2 65 Both ### Group A:60InterventioParallel
http://wwwRecruiting No 0 18 Both ### case series ObservatioSequential
http://wwwNot Recrui No 18 ND Both 3/9/2020 Chinese meObservatioFactorial
http://wwwNot Recrui No 18 ND Both 3/9/2020 Case seriesObservatioSequential

http://www.chictr.or No 1 80 Both 3/7/2020 1:132;2:13 EpidemilogSequential
http://wwwRecruiting No 18 75 Both 2/4/2020 Control gr InterventioParallel

http://wwwNot Recrui No 18 Male 3/6/2020 Group 1:30ObservatioNon random
http://wwwNot Recrui No 18 80 Both ### experimentInterventioParallel
http://wwwNot Recrui No Both 3/1/2020 treatment InterventioParallel
http://wwwNot Recrui No 18 75 Both ### Positive d InterventioParallel
http://wwwRecruiting No 14 70 Both 3/3/2020 1:100;2:10 InterventioParallel

http://www.chictr.or No 18 55 Both ### Case seriesObservatioSequential
http://www.chictr.or No 18 65 Both 3/1/2020 ExperimentInterventioParallel

http://wwwNot Recrui No 18 65 Both 3/5/2020 Control gr InterventioParallel
http://www.chictr.or No 18 60 Both ### Case seriesObservatioSequential

http://wwwRecruiting No 18 60 Both ### Case seriesHealth servSequential

http://wwwNot Recrui No 18 Both ### Target condDiagnostic Sequential
http://www.chictr.or No 12 Both ### Target condDiagnostic Factorial
http://www.chictr.or No 18 80 Both ### experimentInterventioParallel
http://wwwRecruiting No 18 70 Both ### Routine tr Prognosis Parallel
http://www.chictr.or No 18 65 Both ### PhosphoricInterventioParallel
http://wwwNot Recrui No Both 3/1/2020 ExperimentInterventioParallel
http://wwwRecruiting No 18 Both ### Case seriesInterventioSingle arm
http://wwwNot Recrui No 18 65 Both ### PhosphoricInterventioParallel
http://wwwNot Recrui No 18 75 Both ### PhosphoricInterventioParallel

http://www.chictr.or No 1 90 Both 2/1/2020 Case seriesObservatioSequential
http://wwwNot Recrui No 18 Both ### High dose InterventioParallel

http://wwwNot Recrui No 18 65 Both 2/7/2020 Two cohortObservatioFactorial

https://cl Recruiting No 18 Years N/A All 14-Feb-20 140 InterventioAllocation:
https://cl Not recruitNo 18 Years N/A All 14-Feb-20 8 Observational
https://cl Recruiting No 6 Months 80 Years All 15-Feb-20 100 InterventioInterventi
https://cl Not recruitNo 18 Years 75 Years All 5-Mar-20 24 InterventioInterventi
https://cl Not recruitNo N/A N/A All ### 669 Observational
https://cl Not recruitNo N/A N/A All ### 50000 Observational [Patient Registry]
http://wwwNot Recrui No 0.1 85 Male ### Case seriesObservatioSequential
http://wwwRecruiting No Both 4/1/2020 Case seriesHealth servSequential
http://wwwRecruiting No 20 50 Female 2/1/2020 Case seriesObservatioSequential
http://wwwRecruiting No 18 80 Both ### Case seriesInterventioSequential

http://wwwRecruiting No Both ### Pirfenidon InterventioParallel
http://wwwRecruiting No 0 90 Both 2/5/2020 Diagnosed ObservatioSequential
http://wwwNot Recrui No 18 65 Both ### Group 1:30InterventioParallel
http://wwwNot Recrui No 18 80 Both ### experimentInterventioNon random

http://wwwRecruiting No 0 100 Both 2/9/2020 COVID-19 ObservatioCohort stu
http://wwwRecruiting No Both ### Group 2:16InterventioHistorical
http://wwwNot Recrui No Both ### SARS-COV-2ObservatioFactorial
http://wwwNot Recrui No 11 18 Both ### SFBT groupInterventioParallel
http://wwwRecruiting No 18 75 Male 3/5/2020 ExperimentInterventioParallel
http://wwwRecruiting No Both ### Critical gr ObservatioFactorial

http://wwwRecruiting No Both ### the patien Basic ScienSequential
http://wwwRecruiting No 38 70 Male ### Case seriesObservatioCohort stu
http://wwwRecruiting No 18 80 Both ### 1:80;2:40; InterventioNon random

http://wwwRecruiting No 14 Both ### Case seriesInterventioNon random

http://wwwRecruiting No 16 90 Both 2/1/2020 COVID-19 pObservatioSequential
http://wwwNot Recrui No Both ### COVID-19 pObservatioSequential
http://wwwRecruiting No 18 65 Both ### A:15;B:15; InterventioParallel
http://wwwRecruiting No Both ### TricholomaInterventioParallel
http://wwwNot Recrui No 18 - Both ### observatio ObservatioSingle arm
http://wwwRecruiting No 18 60 Both ### 1:36;2:36;3PreventionNon random

http://wwwNot Recrui No 1 99 Both ### EpidemilogSequential
http://wwwNot Recrui No 18 85 Both 3/6/2020 control gr InterventioCase-Contr

http://wwwNot Recrui No 18 100 Both ### 1 the criti InterventioParallel
http://wwwNot Recrui No 18 ?? Both ### ExperimentObservatioNon random

http://wwwNot Recrui No Both 3/1/2020 Target condDiagnostic Sequential
http://wwwNot Recrui No Both ### tumor pati ObservatioFactorial
http://www.chictr.or No 18 80 Both ### experimentInterventioParallel
http://wwwRecruiting No Both 2/6/2020 Mild Type InterventioParallel
http://wwwRecruiting No 18 70 Both ### InterventioInterventioParallel

Controlle
d: no
Randomis
ed: no
Open: no
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
https://wwAuthorisedNo Female3/5/2020 25 Interventio
https://up Recruiting No 1years-old 100years-oMale and 2/1/2020 500 ObservatioNot select
https://cl Not recruitNo 14 Years 70 Years All 5-Feb-20 0 InterventioAllocation:

https://cl Not recruitNo 18 Years N/A All ### 10 InterventioAllocation
https://cl Recruiting No 6 Months 80 Years All ### 100 InterventioInterventi

https://cl Not recruitNo 18 Years 80 Years All Feb-20 0 InterventioAllocation
https://cl Not recruitNo 18 Years 75 Years All 1-Apr-20 550 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All 1-Mar-20 201 Observational
https://cl Not recruitNo 18 Years 75 Years All 24-Feb-20 0 InterventioAllocation:
https://cl Recruiting No 18 Years N/A All 9-Feb-20 10 InterventioInterventi
https://cl Recruiting No 21 Years N/A All 8-Mar-20 5000 Observational

https://cl Recruiting No 18 Years 75 Years All 5-Mar-20 60 InterventioAllocation
https://cl Recruiting No 18 Years N/A All 1-Jan-20 500 Observational
https://cl Recruiting No 18 Years N/A All ### 5 InterventioInterventi
https://cl Not recruitNo 18 Years N/A All ### 200 Observational
https://cl Recruiting No 18 Years N/A All ### 80 Observational [Patient

https://cl Recruiting No N/A N/A All ### 1000 Observational
https://cl Recruiting No 18 Years 50 Years Female 1-Jan-20 20 Observational [Patient
https://cl Not recruitNo 18 Years N/A All Mar-20 200 InterventioInterventi
https://cl Recruiting No 18 Years N/A All ### 100 Observational

http://wwwRecruiting No 1 80 Both ### Target condDiagnostic Sequential
http://wwwNot Recrui No 18 50 Female ### Cesarean s ObservatioSequential
http://wwwNot Recrui No 18 80 Both ### mild recov ObservatioFactorial


http://wwwRecruiting No 18 Both ### Group M:30InterventioParallel

http://wwwNot Recrui No 18 65 Both 4/1/2020 hDPSCs groInterventioParallel

http://wwwNot Recrui No 18 98 Both ### Survival an ObservatioSequential

http://wwwNot Recrui No 22 47 Both ### mindfulnesInterventioQuasi-rand
http://wwwNot Recrui No Both ### Case seriesObservatioCohort stu


http://wwwNot Recrui No 0 100 Both ### Case seriesObservatioCase-Contr
http://wwwRecruiting No 18 75 Both ### 1:14;2:14; InterventioParallel

http://wwwRecruiting No 16 85 Both ### treatment InterventioNon random

http://wwwNot Recrui No 7 101 Both ### Case seriesEpidemilogCase-Contr
http://wwwRecruiting No 45 80 Both ### Homeopathi ObservatioSequential
http://wwwNot Recrui No Both 3/1/2020 Case seriesObservatioSingle arm
http://wwwNot Recrui No 18 80 Both 2/1/2020 ExperimentInterventioNon random
http://wwwRecruiting No 18 ?? Both ### confirmed ObservatioFactorial
http://wwwRecruiting No 18 75 Both ### CM group: Treatment Quasi-rand
http://wwwRecruiting No 0 ?? Both ### Suspected InterventioParallel

http://wwwRecruiting No Both ### Light grou ObservatioFactorial
http://www.chictr.or No 7 90 Both ### ExperimentInterventioCross-over
http://www.chictr.or No 18 Both ### Case seriesObservatioSequential

http://wwwNot Recrui No Both 2/1/2020 Case seriesEpidemilogSequential
http://wwwNot Recrui No Both ### experimentInterventioParallel
http://wwwRecruiting No Both ### COVID-19 gObservatioFactorial

Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
3
https://wwAuthorisedYes Female ### 460 Interventio
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
https://wwAuthorisedNo Female ### 1000 Interventio
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
https://cl Not recruitNo 18 Years N/A All 25-Feb-20 Expanded Access
https://cl Not recruitNo 18 Years N/A All ### 0 InterventioAllocation:

https://cl Recruiting No 18 Years 80 Years All ### 140 InterventioAllocation:
https://cl Not recruitNo 18 Years 55 Years All ### 200 Observational
https://cl Recruiting No 18 Years 75 Years All 5-Mar-20 150 InterventioAllocation:
https://cl Not recruitNo 18 Years N/A All 1-Jan-98 1302508 Observational

https://cl Not recruitNo N/A 85 Years All Mar-20 50 InterventioAllocation
https://cl Recruiting No N/A N/A All ### 500 InterventioInterventi
https://cl Not recruitNo 18 Years N/A All Mar-20 1116 InterventioAllocation
https://cl Not recruitNo 18 Years 75 Years All 1-Apr-20 300 Observational
https://cl Recruiting No 18 Years N/A All ### 90 InterventioAllocation:

https://cl Recruiting No 18 Years N/A All 24-Feb-20 170 Observational
https://cl Recruiting No 18 Years 100 Years All ### 500000 Observational [Patient Registry]
http://isr Recruiting No Both ### 500 InterventioProspectiv
http://wwwNot Recrui No 10 85 Both ### Control gr Basic ScienFactorial

http://wwwRecruiting No 18 100 Both ### ordinary grObservatioFactorial
http://wwwRecruiting No 18 80 Both 2/5/2020 ExperimentInterventioCase-Contr
http://wwwNot Recrui No 20 65 Both 4/3/2020 Medical peHealth Ser Sequential
http://wwwNot Recrui No 18 80 Both ### Case seriesHealth Ser Sequential
http://wwwNot Recrui No 18 N/A Both ### Rheumatic ObservatioFactorial

http://wwwNot Recrui No 18 80 Both 4/1/2020 Control:50 InterventioParallel
http://wwwNot Recrui No 18 85 Both ### Group 1:10InterventioNon random
http://wwwNot Recrui No 20 30 Both 3/5/2020 experimentHealth Ser Diagnostic

http://wwwNot Recrui No Both ### eye patch ObservatioFactorial
http://wwwRecruiting No 18 90 Both 2/1/2020 ExperimentInterventioSingle arm
http://wwwNot Recrui No / / Both ### Target condDiagnostic Sequential
http://wwwNot Recrui No 18 70 Both 4/1/2020 NintedanibInterventioParallel
http://wwwNot Recrui No 30 90 Male ### ObservatioSequential
http://wwwNot Recrui No 18 70 Both 5/1/2020 Different d Basic ScienDose comp
http://wwwRecruiting No 18 80 Both ### ExperimentInterventioCase-Contr
http://wwwNot Recrui No 13 N/A Both 4/1/2020 COVID-19 wi

ObservatioFactorial
http://wwwNot Recrui No / / Both ### Target condDiagnostic Sequential
http://wwwRecruiting No 18 ? Both ### Mild:400;s ObservatioFactorial

https://wwAuthorisedNo Female ### 1300 InterventioControlled

https://wwAuthorisedNo Female3/9/2020 3100 InterventioControlled

https://wwAuthorisedNo Female ### InterventioControlled
https://an Recruiting No No limit No limit Both males 3/5/2020 400 ObservatioPurpose: Na

https://cl Not recruitNo 14 Years N/A All 24-Oct-17 20 InterventioInterventi
https://cl Not recruitNo 18 Years N/A All Apr-20 280 InterventioAllocation:
https://cl Recruiting No 18 Years N/A All ### 100000 Observational [Patient Registry]
https://cl Not recruitNo 18 Years N/A All 6-Apr-20 3000 Observational [Patient Registry]
https://cl Recruiting Yes 18 Years N/A All ### 1000 Observational
https://cl Recruiting No 18 Years 100 Years All ### 30 InterventioAllocation

https://cl Recruiting No 30 Years 70 Years All ### 30 InterventioInterventi
https://cl Not recruitNo 18 Years 50 Years All ### 75 InterventioAllocation:

https://cl Recruiting No N/A 18 Years All ### 12500 Observational
https://cl Not recruitNo 18 Years 99 Years All Apr-20 50 Observational

https://cl Recruiting No 18 Years 120 Years All ### 2000 Observational [Patient
https://cl Recruiting No 18 Years 70 Years All 27-Jan-20 9 InterventioInterventi
https://cl Recruiting No N/A 100 Years All 2-Apr-20 2000 Observational

https://cl Not recruitNo 18 Years N/A All Apr-20 300 Observational
https://cl Not recruitNo 18 Years N/A All 6-Apr-20 50 InterventioInterventi

https://an Not Recrui No 18 Years No limit Both males 5/1/2020 58 InterventioPurpose: Tr
https://an Not Recrui No 18 Years No limit Both males 4/7/2020 100000 ObservatioPurpose: Na
https://an Recruiting No 18 Years No limit Both males ### 150 InterventioPurpose: T
https://an Not Recrui No 18 Years 80 Years Both males ### 60 ObservatioPurpose: Na

https://an Not Recrui No 18 Years 60 Years Females ### 200 ObservatioPurpose: Na
http://wwwNot Recrui No 18 80 Both ### interventi ObservatioNon random
http://wwwNot Recrui No 18 88 Both ### mild, modeObservatioSequential

http://wwwNot Recrui No Both ### Patients w ObservatioFactorial
http://wwwNot Recrui No 18 Both 4/9/2020 1:250;2:12 InterventioParallel

http://wwwNot Recrui No 18 80 Male 1/1/2020 1:50; ObservatioSequential
http://wwwNot Recrui No 29 91 Both 1/1/2020 survival g ObservatioFactorial
http://wwwRecruiting No 18 45 Both 4/1/2020 Case groupObservatioFactorial
http://wwwNot Recrui No Both 3/1/2020 NK cell gr InterventioParallel
http://wwwRecruiting No 18 75 Both ### Case seriesInterventioSingle arm
http://wwwRecruiting No 14 75 Both ### Case seriesObservatioFactorial

http://wwwNot Recrui No 25 65 Both 3/1/2020 common typ

InterventioParallel
http://wwwNot Recrui No 18 100 Both 3/1/2020 Novel coro ObservatioSequential
http://wwwRecruiting No 0 120 Both 2/1/2020 Case seriesEpidemilogSequential

http://wwwNot Recrui No 18 Both 3/2/2020 ExperimentInterventioSequential

https://wwAuthorisedYes Female4/7/2020 1200 InterventioControlled



https://wwAuthorisedYes Female ### 84 InterventioControlled





https://cl Recruiting Yes 18 Years N/A All 8-Nov-18 800 InterventioAllocation:
https://cl Recruiting No 1 Year 90 Years All 1-Jan-20 50 Observational
https://cl Recruiting No N/A N/A All 30-Jan-20 30 InterventioAllocation

https://cl Recruiting No N/A N/A All 9-Mar-20 300 Observational
https://cl Not recruitNo N/A N/A All Apr-20 Expanded Access
https://cl Recruiting No 18 Years 65 Years All 8-Mar-20 150 InterventioAllocation

https://cl Not recruitNo 18 Years 90 Years All ### 38 InterventioInterventi
https://cl Recruiting No 25 Years 65 Years All ### 400 Observational
https://cl Not recruitNo N/A N/A All 9-Mar-20 533 Observational
https://cl Recruiting No 18 Years N/A All 5-Apr-20 200 InterventioAllocation

https://cl Recruiting No 30 Years 79 Years All 2-Apr-20 54 InterventioAllocation
https://cl Recruiting No 18 Years N/A All 6-Apr-20 4000 InterventioAllocation:
https://cl Recruiting No 60 Years N/A All ### 2414 InterventioAllocation
https://cl Not recruitNo 18 Years 75 Years All 6-Apr-20 800 InterventioAllocation:


https://cl Recruiting No 18 Years N/A All 1-Apr-20 30 Observational
https://cl Recruiting No N/A N/A All 1-Apr-20 500 Observational [Patient Registry]
https://cl Recruiting No N/A N/A All 6-Apr-20 4000 Observational

https://cl Recruiting No 18 Years 65 Years All 6-Apr-20 20 InterventioAllocation:
https://cl Recruiting No 8 Years 80 Years All Apr-20 100 Observational
https://cl Not recruitNo 18 Years 45 Years Female 12-Apr-20 100 Observational
https://cl Recruiting No N/A N/A All Apr-20 100 Observational

https://cl Not recruitNo 18 Years N/A All May-20 10 InterventioInterventi
https://cl Recruiting No 18 Years 110 Years All 6-Apr-20 100000 Observational
https://cl Not recruitNo N/A N/A All 15-Apr-20 200 Observational

https://cl Not recruitNo 18 Years N/A All 6-Apr-20 300 Observational
https://cl Not recruitNo 18 Years N/A All 10-Jan-19 Expanded Access
https://cl Not recruitNo 18 Years N/A All 1-Jun-20 334 InterventioAllocation:
https://cl Not recruitNo N/A N/A All 1-May-20 200 Observational

https://cl Recruiting No 18 Years N/A All 10-Sep-19 120 Observational



https://an Not Recrui No 18 Years No limit Both males ### 140 InterventioPurpose: Tr
https://an Not Recrui No 35 Years 45 Years Males ### 1 InterventioPurpose: T
https://an Not Recrui No 18 Years No limit Both males ### 100 InterventioPurpose: T
https://an Not Recrui No 18 Years No limit Both males 5/1/2020 3000 ObservatioPurpose: Ps
https://an Not Recrui No 18 Years 65 Years Both males ### 20 InterventioPurpose: Pr

https://an Not Recrui No 18 Years No limit Both males 6/1/2020 1000 InterventioPurpose: Pr
https://an Not Recrui No 18 Years No limit Both males ### 100 ObservatioPurpose: Na
https://an Not Recrui No 18 Years 70 Years Both males 6/1/2020 507 InterventioPurpose: Pr
http://wwwRecruiting No Both ### Case seriesInterventioSingle arm

http://wwwRecruiting No 7 25 Both ### Group 1:65ObservatioNon random
http://wwwNot Recrui No 25 33 Both 2/2/2020 Two groupsInterventioCross-over
http://wwwNot Recrui No 18 Both ### 1.5ATA:15;InterventioParallel
http://wwwNot Recrui No 18 90 Both 5/1/2020 Target condDiagnostic Diagnostic
http://wwwNot Recrui No 18 90 Both 2/8/2020 Case seriesObservatioCohort stu
http://wwwRecruiting No 18 70 Both 4/1/2020 control gr InterventioCohort stu

http://wwwRecruiting No Female ### Case seriesObservatioCohort stu
http://wwwNot Recrui No Both ### Case seriesObservatioCase study

http://wwwNot Recrui No 0 100 Male 6/1/2020 Case seriesObservatioCross-secti
http://wwwRecruiting No 0 100 Both 4/1/2020 Patient:30;ObservatioSequential
http://wwwRecruiting No 18 75 Both ### Case seriesInterventioNon random

http://wwwRecruiting No 25 65 Both ### In-hospital InterventioNon random
http://wwwNot Recrui No 18 Both 2/1/2020 Routine tr InterventioParallel
http://wwwNot Recrui No 18 Both 2/1/2020 Routine tr InterventioParallel
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Conventio
https://wwAuthorisedYes Female4/9/2020 194 Interventional stra
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: yes
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n:
Adaptive
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
https://wwAuthorisedNo Female ### 1600 InterventioOther
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
3
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
current
practice
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: No
comparat
or
https://wwAuthorisedNo Female ### 165 InterventioNum
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
4
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
6
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n: Low-
level
interventi
on trial
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
https://wwAuthorisedNo Female4/9/2020 30 InterventioPlacebo
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: no
Randomis
ed: no
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
1
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Other
specify
the
comparat
or: The
same
https://wwAuthorisedNo Female ### 1000 Interventiomedicina
Controlle
d: no
Randomis
ed: no
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
1
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: yes
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Control
https://wwAuthorisedNo Female ### 6400 Interventio(normal p
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
standard
of care
Randomiz
ation:
Randomiz
ed,
Blinding:
Single
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: simple
randomiz
ation with
a random
digit
table,
Blinding
descriptio
n: _
Participan
ts are
blinded to
the
http://en.i Not Recrui No 20 years 45 years Both ### 45 interventiodetails of
Randomiz
ation:
Randomiz
ed,
Blinding:
Triple
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Preventio
n,
Randomiz
ation
descriptio
n:
Patients
consumin
g renin-
angiotens
in-
aldostero
ne system
inhibitors
are
recruited
in the
study
using
computer
http://en.i Recruiting No 18 years no limit Both 4/5/2020 60 interventioized-
http://en.i Recruiting No no limit no limit Both ### 50 interventioRandomizat
http://en.i Not Recrui No 18 years 75 years Both ### 30 interventioRandomizat
http://en.i Recruiting No 18 years 65 years Both ### 30 interventioRandomizati
http://en.i Recruiting No 18 years 65 years Both ### 150 interventioRandomizat
http://en.i Not Recrui No 18 years no limit Both 3/3/2020 20 interventioRandomizat
http://en.i Recruiting No 18 years no limit Both 4/3/2020 30 interventioRandomizat
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Randomiz
ation will
be done
according
to the
blocks
randomiz
ation
method.
Regarding
to the
sample
size, 5
patients
http://en.i Recruiting No 18 years 75 years Both ### 50 interventiowil
http://en.i Recruiting No 18 years 80 years Both 4/8/2020 40 interventioRandomizat
Randomiz
ation: Not
randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t, Blinding
descriptio
n: In this
study
patients,
nurse ,
superviso
r and
researche
r don't
know
which
group of
patients
will use
the
http://en.i Not Recrui No 2 years no limit Both ### 125 interventiomedici
http://en.i Not Recrui No 18 years 95 years Both ### 10 interventioRandomizati
http://en.i Not Recrui No no limit no limit Both ### 30 interventioRandomizat
http://en.i Not Recrui No 18 years no limit Both ### 60 interventioRandomizat
http://en.i Not Recrui No 18 years 85 years Both 4/3/2020 60 interventioRandomizat
http://en.i Recruiting No 18 years no limit Both ### 40 interventioRandomizat
http://en.i Not Recrui No no limit no limit Both ### 374 interventioRandomizati
http://en.i Not Recrui No no limit no limit Both 4/1/2020 30 interventioRandomizati
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Firstly
patients
are
divided
into
moderate
and
severe
groups to
match
the
severity
of the
disease
then
according
http://en.i Recruiting No no limit no limit Both 4/3/2020 60 interventioto co
http://en.i Recruiting No 18 years 80 years Both 4/8/2020 40 interventioRandomizati
https://www Recruiting No 20 74 BOTH ### 96 INTERVENTMulticente
https://jrc Recruiting No >= 20age oNot applic Both ### 50 Interventiosingle arm
https://up Not Recrui No Not applic Not applic Male and ### Others,metNot select
https://up Recruiting No Not applic Not applic Male and ### 600 ObservatioNot select
https://up Not Recrui No Not applic Not applic Male and ### Others,metNot select
https://cl Recruiting Yes 16 Years N/A All 7-Jan-19 75 InterventioAllocation:
https://cl Not recruitNo 18 Years N/A All 23-Oct-19 100 Observational [Patient Registry]


https://cl Not recruitNo 18 Years 80 Years All ### 5 InterventioInterventi
https://cl Recruiting No 18 Months N/A All 17-Apr-20 1220 InterventioAllocation


https://cl Not recruitNo 18 Years N/A All Apr-20 5000 Observational [Patient Registry]

https://cl Not recruitNo 18 Years N/A All Apr-20 210 InterventioAllocation
https://cl Recruiting No 18 Years N/A All 15-Apr-20 20 InterventioInterventi
https://cl Not recruitNo 65 Years N/A All 20-Apr-20 30 InterventioAllocation:
https://cl Recruiting No N/A 18 Years All 3-Apr-20 350 Observational [Patient Registry]
https://cl Recruiting No 18 Years N/A All 3-Apr-20 220 Observational [Patient Registry]
https://cl Not recruitNo N/A N/A All Apr-20 160 Observational

https://cl Not recruitNo 18 Years 80 Years All Apr-20 1200 InterventioAllocation




https://cl Not recruitNo N/A N/A All May-20 300 Observational
https://cl Not recruitNo N/A N/A All 15-Apr-20 60 InterventioAllocation

https://cl Recruiting No N/A N/A All ### 400 Observational [Patient Registry]

https://cl Recruiting No N/A N/A All ### 200 InterventioAllocation
https://cl Recruiting No 1 Year 80 Years All 14-Apr-20 500 Observational

https://cl Not recruitNo 18 Years 75 Years All Apr-20 20 InterventioAllocation:

https://cl Recruiting No 18 Years 80 Years All 17-Jan-20 1000 Observational

https://cl Recruiting No 18 Years 80 Years All Apr-20 122 InterventioAllocation:
https://cl Not recruitNo N/A N/A All 1-Jan-19 120 Observational [Patient Registry]

https://cl Not recruitNo 18 Years 80 Years All 20-Apr-20 20 InterventioInterventi
https://cl Recruiting No 18 Years N/A All Apr-20 350 InterventioAllocation:

https://cl Recruiting No N/A N/A All 11-Apr-20 500 InterventioAllocation:

https://cl Not recruitNo 18 Years 60 Years All 6-Mar-20 32 InterventioAllocation:
https://cl Recruiting No 18 Years N/A All Apr-20 20 InterventioInterventi
https://cl Recruiting No 21 Years 65 Years All Apr-20 8 Observational


https://cl Not recruitNo N/A 18 Years All ### 38 InterventioInterventi
https://cl Not recruitNo 18 Years 50 Years Female May-20 600 InterventioAllocation:

https://cl Not recruitNo 18 Years N/A All 17-Apr-20 Expanded Access


https://an Recruiting No 18 Years 64 Years Both males ### 680 InterventioPurpose: Pr
https://an Not Recrui No 18 Years 75 Years Both males ### 70 InterventioPurpose: Tr

https://an Recruiting No 18 Years No limit Both males 4/7/2020 50 ObservatioPurpose: Sc
http://wwwNot Recrui No 0 100 Both ### Control gr ObservatioNon random
http://wwwRecruiting No 18 ? Both 1/1/2020 HDIVC grouInterventioCohort stu
http://wwwRecruiting No 18 70 Both ### Control g InterventioParallel
http://wwwNot Recrui No 26 55 Male ### ExperimentHealth Ser Non random
http://wwwRecruiting No 18 80 Both ### Group 2:93InterventioParallel
http://wwwRecruiting No 18 65 Both ### Interventi InterventioParallel
http://wwwRecruiting No Both 3/1/2020 Group 2:12InterventioParallel


http://wwwRecruiting No 18 100 Both ### Group A:68ObservatioFactorial
http://wwwNot Recrui No 18 80 Both ### COVID-19 crObservatioFactorial
http://wwwRecruiting No 18 100 Both ### Case seriesObservatioCohort stu
http://wwwNot Recrui No Both ### Control Gr InterventioParallel
http://wwwNot Recrui No 0 100 Both ### ECMO group

ObservatioCohort stu

http://isr Not Recrui No Both ### 80 ObservatioObservation
http://isr Recruiting No Both ### 2170 ObservatioSingle-cent
http://isr Recruiting No Both ### 988 InterventioMulticentr

http://isr Recruiting No Both 4/9/2020 200 ObservatioObservation
http://isr Recruiting No Both 4/6/2020 4002 InterventioAdaptive (g
http://isr Recruiting No Both 4/2/2020 400 ObservatioMixed-meth
http://isr Recruiting No Both ### 70 ObservatioObservation






https://cl Recruiting No N/A N/A Female 1-Jan-20 200 Observational [Patient Registry]

https://cl Recruiting No 13 Years N/A Female ### 2000 Observational [Patient Registry]
https://cl Not recruitNo 16 Years N/A All 5-May-20 12000 Observational
https://cl Recruiting No 18 Years N/A All Apr-20 342 InterventioAllocation

https://cl Not recruitNo 18 Years 60 Years All 1-May-20 10 InterventioInterventi
https://cl Not recruitNo 18 Years 60 Years All 1-May-20 80 InterventioAllocation

https://cl Not recruitNo 18 Years N/A All Jun-20 200 InterventioAllocation:


https://cl Recruiting No 18 Years N/A Female 16-Apr-20 600 InterventioAllocation


https://cl Not recruitNo 18 Years N/A Female 24-Apr-20 2200 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All 5-May-20 230 InterventioAllocation


https://cl Recruiting No 18 Years 70 Years All 30-Apr-20 300 Observational [Patient Registry]
https://cl Recruiting No N/A N/A All 16-Apr-20 100 InterventioAllocation


https://cl Not recruitNo 18 Years 120 Years All 1-May-20 100 Observational
https://cl Not recruitNo 15 Years N/A All May-20 1000 Observational
https://cl Not recruitNo 18 Years N/A All 1-May-20 Expanded Access
https://cl Not recruitNo 18 Years N/A All Jun-20 60 InterventioAllocation


https://cl Not recruitNo 18 Years 80 Years All 5-Mar-20 20 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All Jun-20 150 Observational

https://cl Recruiting No 7 Years N/A All May-20 500 Observational

https://cl Not recruitNo 18 Years 75 Years All 1-Jun-20 144 InterventioAllocation:
https://cl Not recruitNo 18 Years 65 Years All May-20 100 InterventioAllocation:
https://cl Not recruitNo N/A N/A All Jun-20 Expanded Access
https://cl Not recruitNo 18 Years N/A All 1-Jul-20 40 InterventioAllocation:

https://cl Recruiting No 18 Years N/A Female 17-Apr-20 3600 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All 1-May-20 90 InterventioAllocation:

https://cl Not recruitNo N/A N/A All 1-May-20 50 InterventioAllocation

https://cl Not recruitNo N/A N/A All 20-Apr-20 30 InterventioInterventi
https://cl Recruiting No N/A N/A All 1-Mar-20 200 Observational [Patient Registry]

https://cl Not recruitNo N/A N/A All Apr-20 50 Observational [Patient Registry]

https://cl Not recruitNo N/A N/A Female 1-May-20 200 Observational
https://cl Recruiting No N/A 99 Years All 1-Mar-20 1000 Observational
https://cl Not recruitNo 18 Years N/A All May-20 90 InterventioAllocation:
https://cl Not recruitNo 18 Years 85 Years All May-20 400 InterventioAllocation

https://cl Not recruitNo N/A N/A All Apr-20 298 InterventioAllocation
https://cl Not recruitNo N/A N/A All 28-Feb-20 300 Observational

https://cl Not recruitNo 18 Years N/A All May-20 1080 InterventioAllocation
https://cl Recruiting No 18 Years N/A Male 27-Apr-20 40 InterventioAllocation


https://cl Not recruitNo 18 Years N/A All Apr-20 Expanded Access
https://an Not Recrui No Years 16 Years Both males ### 400 ObservatioPurpose: Na
https://an Not Recrui No 16 Years 30 Years Both males 6/2/2020 90 InterventioPurpose: Ed
https://an Not Recrui No Days 45 Years Both males 5/1/2020 1000 ObservatioPurpose: Na
http://isr Recruiting No Both ### 116 InterventioA Multicen
http://isr Recruiting No Both 4/7/2020 150 InterventioBetween-sub
http://isr Recruiting No Both ### 10000 InterventioOpen-label

http://wwwRecruiting No 18 90 Both ### Case seriesInterventioHistorical
http://wwwNot Recrui No Both 1/1/2020 Target condDiagnostic Sequential
http://wwwNot Recrui No 18 80 Both 5/2/2020 Control:60 InterventioParallel
http://wwwNot Recrui No 18 90 Both 5/1/2020 non-critic ObservatioFactorial

http://wwwNot Recrui No 35 80 Both 5/5/2020 Case seriesBasic ScienSequential

http://wwwRecruiting No 3 Both ### Phase I A1:InterventioParallel

http://wwwNot Recrui No 7 16 Both ### Confirmed ObservatioFactorial
http://wwwNot Recrui No 18 70 Both 5/1/2020 experimentObservatioNon random
http://wwwRecruiting No 10 80 Both ### COVID-19 co

InterventioFactorial
http://wwwNot Recrui No 18 75 Both ### ExperimentaInterventioParallel


Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: Each
IMP
https://wwAuthorisedNo Female ### 640 Interventiotested w
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
4
Controlle
d: no
Randomis
ed: no
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
1
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: yes
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Treatmen
https://wwAuthorisedNo Female ### 26 Interventiot accordin
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n: Nested
in a
prospecti
ve cohort
observati
onal
study
If
controlle
d, specify
comparat
or, Other
https://wwAuthorisedNo Female ### 30 InterventioMedicinia
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: Best
available
https://wwAuthorisedNo Female ### 1008 Interventiotr
Controlle
d: no
Randomis
ed: no
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n: Pilot
study
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Controlle
d: no
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
https://wwAuthorisedYes Female4/3/2020 200 Interventio
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: no
Randomis
ed: no
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n:
Prospecti
ve,
multicent
er, open,
phase 2
study,
one arm-
non
randomiz
ed
If
controlle
d, specify
comparat
https://wwAuthorisedNo Female4/2/2020 60 Interventioor,
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Standard
of care
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n: Multi-
stage,
adaptive
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
https://wwAuthorisedYes Female ### 1500 InterventioOt



https://cl Recruiting No N/A N/A All 7-May-20 56 InterventioAllocation

https://cl Not recruitNo 1 Year 95 Years All 30-Jun-20 80 InterventioAllocation:
https://cl Recruiting No 18 Years N/A All Apr-20 450000 Observational

https://cl Recruiting No 18 Years N/A All Apr-20 24 InterventioAllocation:
https://cl Not recruitNo 18 Years N/A All ### Expanded Access

https://cl Not recruitNo 18 Years N/A Female Apr-20 50 InterventioAllocation


https://cl Not recruitNo 18 Years N/A All 12-Jan-20 41 InterventioAllocation

https://cl Not recruitNo 18 Years N/A Female Apr-20 120 InterventioAllocation
https://cl Recruiting No N/A N/A All 14-Apr-20 45 InterventioAllocation

https://cl Not recruitNo 18 Years N/A Female 1-May-20 25000 Observational [Patient Registry]
https://cl Not recruitNo N/A N/A All May-20 200 Observational
https://cl Recruiting No 18 Years N/A All Apr-20 50 Observational

https://cl Not recruitNo 18 Years 50 Years Female May-20 900 Observational

https://cl Recruiting No N/A N/A All 5-May-20 100000 Observational [Patient Registry]
https://cl Recruiting No N/A 99 Years All 24-Apr-20 40 InterventioAllocation

https://cl Not recruitNo 18 Years 90 Years All 24-Apr-20 1000 Observational [Patient Registry]


https://cl Not recruitNo 18 Years N/A All 19-Jun-19 Expanded Access
https://an Not Recrui No 18 Years No limit Both males ### 2000 InterventioPurpose: T
http://wwwNot Recrui No 2 80 Both ### asymptomat
ObservatioFactorial

http://wwwNot Recrui No 25 65 Female 1/1/2020 Case seriesObservatioSequential
http://wwwNot Recrui No 18 Both 5/9/2020 Case seriesObservatioSequential
http://wwwNot Recrui No 18 65 Both 5/8/2020 Routine tr InterventioParallel
http://wwwNot Recrui No Both 2/5/2020 severe grouInterventioCase study
http://wwwNot Recrui No Both 5/4/2020 Single pati ObservatioSequential


Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Standard
https://wwAuthorisedNo Female5/6/2020 230 Interventioof care
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
https://wwAuthorisedNo Female5/4/2020 Interventio
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: Best
Supportiv
https://wwAuthorisedNo Female ### 130 Interventioe C
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: group
control
https://wwAuthorisedNo Female ### 90 InterventioNum
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: no
Randomis
ed: no
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: yes
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: arm
without
IMP
https://wwAuthorisedNo Female5/4/2020 20 InterventioNu
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
https://wwAuthorisedYes Female: yes M 212 Interventio
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Current
https://wwAuthorisedYes Female ### 450 InterventioUK standa
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: no
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: yes
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
3
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: no
Randomis
ed: no
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Controlle
d: no
Randomis
ed: no
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Continua
https://wwAuthorisedYes Female ### 798 Interventiotion of p
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
3
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
4
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Another
regimen
https://wwAuthorisedNo Female5/4/2020 140 InterventioN
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: Usual
care
https://wwAuthorisedNo Female4/3/2020 200 InterventioNumber
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
WITHOUT
ANAKINR
A
https://wwAuthorisedNo Female ### 180 InterventioN
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Routine/s
https://wwAuthorisedNo Female5/4/2020 78 Interventiotandard
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: WITH
OUT
TREATME
https://wwAuthorisedNo Female ### 200 InterventioN
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: no
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other: no
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group: no
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n:
Compreh
ensive
cohort
design
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
https://wwAuthorisedNo Female5/7/2020 200 Intervention
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
yes
Placebo:
no
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Standard
https://wwAuthorisedNo Female5/8/2020 100 InterventioMedical
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Standartd
https://wwAuthorisedNo Female5/8/2020 100 InterventioMedical
https://cl Recruiting No 3 Years 99 Years All Apr-20 50 InterventioAllocation:




https://cl Recruiting No 18 Years N/A Female 23-Apr-20 1300 Observational



https://cl Not recruitNo 18 Years N/A All 30-Jun-20 25 InterventioAllocation



https://cl Not recruitNo 18 Years N/A Female 10-Apr-20 58 Observational

https://cl Recruiting Yes 18 Years 99 Years All 21-Feb-20 800 InterventioAllocation:
https://cl Recruiting Yes 18 Years N/A All 3-Apr-20 180 InterventioAllocation

https://cl Recruiting No 18 Years N/A All May-20 500 InterventioAllocation
https://cl Not recruitNo 18 Years 89 Years All Jun-20 80 InterventioAllocation

https://cl Not recruitNo 18 Years 65 Years All 1-Jul-20 50 InterventioAllocation:

https://cl Recruiting No 18 Years N/A All 3-May-20 20 InterventioAllocation
https://cl Recruiting No N/A N/A Female 28-Apr-20 1850 Observational

https://cl Recruiting No 18 Years N/A All 1-May-20 81 InterventioAllocation:

https://cl Recruiting No 18 Years N/A All 4-May-20 24 Observational

https://cl Not recruitNo 18 Years N/A All 1-May-20 2000 Observational [Patient Registry]
https://cl Recruiting No 18 Years 100 Years All 3-May-20 50 Observational
https://cl Recruiting No 18 Years 65 Years All May-20 40 InterventioAllocation:

https://cl Recruiting No 18 Years 99 Years All 1-May-20 240 InterventioAllocation
https://cl Recruiting No 18 Years N/A All 5-May-20 1000 Observational [Patient Registry]
https://cl Not recruitNo 6 Years 99 Years All ### Expanded Access

https://cl Recruiting No 18 Years 60 Years All May-20 10 InterventioAllocation

https://cl Not recruitNo 31 Days 18 Years All 1-Jun-20 100 Observational

https://cl Recruiting No 18 Years N/A Female 1-May-20 8500 Observational

https://cl Not recruitNo N/A 18 Years All 1-May-20 100 InterventioAllocation
https://cl Not recruitNo 18 Years 65 Years All 4-May-20 660 InterventioAllocation:

https://cl Not recruitNo 18 Years 100 Years All 12-Jun-20 18 InterventioAllocation

https://cl Not recruitNo 60 Years N/A All Jul-20 50 InterventioAllocation

https://cl Not recruitNo 18 Years 75 Years All May-20 60 Observational


http://isr Recruiting No Both ### 20 ObservatioObservatio
http://isr Recruiting No Both 5/1/2020 350 ObservatioMixed meth

http://isr Recruiting No Both ### 6000 ObservatioProspective
http://wwwNot Recrui No 18 60 Both 6/1/2020 DC injectio PreventionSingle arm


http://wwwRecruiting No 18 70 Both ### Group 1:30InterventioQuasi-rand

http://wwwRecruiting No 18 Both ### Treatment InterventioParallel
http://wwwRecruiting No 18 Both 2/6/2020 Low dose gInterventioParallel
http://en.i Not Recrui No 18 years no limit Both ### 40 interventioRandomizati
http://en.i Not Recrui No 20 years 50 years Both 4/5/2020 100 interventioRandomizati
http://en.i Recruiting No 18 years no limit Both ### 120 interventioRandomizati
http://en.i Not Recrui No no limit 70 years Both ### 60 interventioRandomizati
http://en.i Recruiting No 18 years no limit Both 4/8/2020 80 interventioRandomizati
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Randomiz
ation in
three
stages:
1-
Random
sequence
generatio
n: this
step
simple or
limited
randomiz
ation will
http://en.i Recruiting No 18 years 65 years Both ### 40 interventiobe done b
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Randomiz
ation in
three
stages: 1-
Generatio
n simple
or limited
randomiz
ation will
be done
based on
a table of
http://en.i Recruiting No 18 years 65 years Both ### 40 interventiorandom
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Patients
are
divided
into two
Therapeu
tic groups
by
random
method
and used
6 blocks
method.
Individual
s are the
http://en.i Recruiting No 18 years no limit Both 4/9/2020 60 interventiorandom
http://en.i Recruiting No no limit no limit Both 4/8/2020 60 interventioRandomizati
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Given
that this
study is
part of
the
SOLIDARI
TY Trial
by the
World
Health
Organizati
on, the
randomiz
ation
method is
http://en.i Recruiting No 18 years no limit Both 4/8/2020 3000 interventioo
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Randomiz
ation
happens
at three
stages:
1-
Random
sequence
generatio
n: Simple
or limited
randomiz
ation will
be
http://en.i Recruiting No 18 years 65 years Both ### 40 interventioperform
http://en.i Not Recrui No 1 year 75 years Both 4/7/2020 140 interventioRandomizati
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Randomiz
ation in
three
stages: 1-
Random
sequence
generatio
n: this
step
simple or
limited
randomiz
ation will
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Randomiz
ation in
three
stages: 1-
Random
sequence
generatio
n: this
step
simple or
limited
randomiz
ation will
http://en.i Recruiting Yes 18 years 65 years Both 4/5/2020 60 interventioRandomizati
http://en.i Recruiting No no limit no limit Both ### 82 interventioRandomizati
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Randomiz
ation in
three
stages: 1-
Random
sequence
generatio
n: this
step
simple or
limited
randomiz
ation will
http://en.i Recruiting No 18 years 65 years Both 5/2/2020 40 interventiobe done b
Randomiz
ation:
Randomiz
ed,
Blinding:
Triple
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Supportiv
e,
Randomiz
ation
descriptio
n: In this
study, to
allocate
members
to control
and
interventi
on
groups,
first a
cluster of
four
sections
http://en.i Recruiting No 23 years 65 years Both 5/4/2020 60 interventioof a sect
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Supportiv
e,
Randomiz
ation
descriptio
n:
Randomiz
ation
method:
Simple
randomiz
ation
Randomiz
ation
unit:
individual
Randomiz
ation
tool: from
random
number
http://en.i Recruiting No 18 years no limit Both 5/4/2020 10 interventiotabl
Randomiz
ation:
Randomiz
ed,
Blinding:
Single
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: In this
study, we
will use
the
Restricted
randomiz
ation
method
of block
randomiz
ation.
Blockage
is usually
http://en.i Recruiting No 18 years no limit Both ### 60 interventioused to
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
method is
used to
randomiz
ed the
patients.
In this
method,
the
number
of people
assigned
http://en.i Recruiting No 18 years no limit Both 5/1/2020 80 interventioto each
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
method is
used to
randomiz
ed the
patients.
In this
method,
the
number
of people
assigned
http://en.i Recruiting No 18 years no limit Both 5/1/2020 80 interventioto each
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
method is
used to
randomiz
ed the
patients.
In this
method,
the
number
of people
assigned
http://en.i Recruiting No 18 years 85 years Both ### 50 interventioto each
Randomiz
ation:
Randomiz
ed,
Blinding:
Single
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
Using
four
blocks,
we
randomly
arrange
the
patients
using the
rand
section of
the
software
http://en.i Recruiting No 18 years 75 years Both 5/9/2020 68 interventioand
http://en.i Not Recrui Yes 60 years no limit Both ### 5 interventioRandomizat
http://cris Not Recrui No No Limit No Limit Both ### 54 ObservatioObservation
http://cris Not Recrui No 18(Year) No Limit Both ### 84 InterventioPrimary Pur
https://jrc Not Recrui No >= 20age oNot applic Both ### 100 Interventiorandomized
https://up Recruiting No 20years-ol Not applic Male and ### 1000 ObservatioNot select
https://up Not Recrui No 20years-ol Not applic Male and ### 300 ObservatioNot select
https://up Recruiting No Not applic Not applic Male and 5/1/2020 500 ObservatioNot select
https://up Recruiting No 5years-old 99years-ol Male and ### 20 InterventioSingle arm
https://up Not Recrui No 20years-ol 100years-oMale and 5/8/2020 100 ObservatioNot select
https://up Not Recrui No 20years-ol Not applic Male and 6/1/2020 182 ObservatioNot select
https://up Not Recrui No 18years-ol 60years-ol Male and ### 1980 InterventioParallel R
https://up Recruiting No 20years-ol Not applic Male and 2/1/2020 100 ObservatioNot select
https://up Recruiting No Not applic Not applic Male and ### 100 InterventioSingle arm
Randomiz
ed,
Parallel
Group,
Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Stratified
block
randomiz
ation
Method
of
allocation
concealm
ent:Seque
ntially
numbere
d, sealed,
opaque
envelopes
Blinding
and
masking:
Open
http://www.
Not Recrui No 4/8/2020 500 InterventioLabel
Other
Method
of
generatin
g
randomiz
ation
sequence
: Method
of
allocation
concealm
ent:
Blinding
and
http://www.
Not Recrui No 4/8/2020 5000 Observatio masking:
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.ctri.nic.in No 4/9/2020 1000 Observatio e
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Not Recrui No ### 50000 Observatio e
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:An
Open list
of
random
numbers
Blinding
and
masking:
Open
http://www.
Not Recrui No ### 32 InterventioLabel
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Not Recrui No 5/1/2020 1000 Observatio e
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Not Recrui No ### 30 Interventioe
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Open
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:
Open
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
: Method
of
allocation
concealm
ent:
Blinding
and
http://www.
Not Recrui No ### 90 Observatio masking:
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:P
articipant
and
Outcome
Assessor
http://www.
Not Recrui No 5/1/2020 26 InterventioBlinded
Randomiz
ed,
Parallel
Group,
Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Stratified
randomiz
ation
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group,
Multiple
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:
Open
http://www.
Recruiting No 5/1/2020 7000 InterventioLabel
Randomiz
ed,
Parallel
Group,
Placebo
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:P
articipant,
Investigat
or,
Outcome
Assessor
and Date-
http://www.
Not Recrui No ### 5946 Interventioen
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:
Open
http://www.
Recruiting No ### 100 InterventioLabel
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Non-
randomiz
ed,
Multiple
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Recruiting No ### 1650 Interventioe
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group,
Placebo
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Stratified
block
randomiz
ation
Method
of
allocation
concealm
ent:Seque
ntially
numbere
d, sealed,
opaque
envelopes
Blinding
and
masking:P
articipant,
http://www.
Not Recrui No 5/1/2020 1826 InterventioInvestig
Randomiz
ed,
Parallel
Group,
Placebo
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:P
articipant,
Investigat
or and
Outcome
Assessor
http://www.
Recruiting No ### 40 InterventioBlinded
Cluster
Randomiz
ed Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Phar
macy-
controlle
d
Randomiz
ation
Blinding
and
masking:
Open
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
: Method
of
allocation
concealm
ent:
Blinding
and
http://www.
Not Recrui No ### 1000 Observatio masking:
Non-
randomiz
ed, Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:
Blinding
and
masking:
Open
http://www.
Non-
randomiz
ed, Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Other
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:An
Open list
of
random
numbers
Blinding
and
masking:P
articipant
and
Outcome
Assessor
http://www.
Not Recrui No ### 300 InterventioBlinded
Other
Method
of
generatin
g
randomiz
ation
sequence
:Other
Method
of
allocation
concealm
ent:An
Open list
of
random
numbers
Blinding
and
masking:
Outcome
Assessor
http://www.
Recruiting No ### 112 InterventioBlinded
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:On-
site
computer
system
Blinding
and
masking:
Open
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Coin
toss,
Lottery,
toss of
dice,
shuffling
cards etc
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Coin
toss,
Lottery,
toss of
dice,
shuffling
cards etc
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group,
Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Other
Blinding
and
masking:
Not
Applicabl
http://www.
Not Recrui No 5/8/2020 100 Interventioe
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group,
Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Open
http://www.
Recruiting No 5/1/2020 30 InterventioLabel
Randomiz
ed,
Parallel
Group,
Placebo
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Open
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Other
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Open
http://www.
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Non-
randomiz
ed, Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Other
Method
of
allocation
concealm
ent:On-
site
computer
system
Blinding
and
masking:P
articipant
http://www.
Not Recrui No 5/6/2020 60 InterventioBlinded
Other
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:On-
site
computer
system
Blinding
and
masking:
Open
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:
Open
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Cluster
Randomiz
ed Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:
Open
http://www.
Single
Arm Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Open
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
: Method
of
allocation
concealm
ent:
Blinding
and
http://www.
Not Recrui No 5/9/2020 150 Observatio masking:
Randomiz
ed,
Parallel
Group,
Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Open
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:Seque
ntially
numbere
d, sealed,
opaque
envelopes
Blinding
and
masking:P
articipant
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
: Method
of
allocation
concealm
ent:
Blinding
and
http://www.
Recruiting No ### 50 Observatio masking:
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Other
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Stratified
randomiz
ation
Method
of
allocation
concealm
ent:Centr
alized
Blinding
and
masking:
Open
http://www.
Randomiz
ed,
Parallel
Group,
Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:An
Open list
of
random
numbers
Blinding
and
masking:
Open
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Stratified
randomiz
ation
Method
of
allocation
concealm
ent:Other
Blinding
and
masking:
Not
Applicabl
http://www.
Randomiz
ed,
Parallel
Group,
Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Other
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:P
articipant
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Open
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:An
Open list
of
random
numbers
Blinding
and
masking:
Open
http://www.
Non-
randomiz
ed, Active
Controlle
d Trial
Method
of
generatin
g
randomiz
ation
sequence
:Not
Applicabl
e
Method
of
allocation
concealm
ent:Not
Applicabl
e
Blinding
and
masking:
Open
http://www.
Randomiz
ed,
Parallel
Group
Trial
Method
of
generatin
g
randomiz
ation
sequence
:Compute
r
generate
d
randomiz
ation
Method
of
allocation
concealm
ent:An
Open list
of
random
numbers
Blinding
and
masking:
Open
http://www.
https://cl Not recruitNo 18 Years N/A All Nov-20 116 InterventioAllocation:



https://cl Not recruitNo 18 Years 80 Years All Aug-20 24 InterventioAllocation

https://cl Recruiting No N/A 70 Years All 5-May-20 450 InterventioAllocation
https://cl Recruiting No N/A N/A All 1-May-20 200 Observational

https://cl Not recruitNo 18 Years N/A All ### 17 Observational [Patient Registry]
https://cl Recruiting No 18 Years N/A All 1-Jan-19 700 Observational [Patient Registry]




https://cl Recruiting No 18 Years N/A All May-20 500 Observational


https://cl Recruiting No 1 Year N/A All 29-Apr-20 384 Observational

https://cl Recruiting No N/A 20 Years All 5-Mar-20 5000 Observational
https://cl Recruiting Yes N/A N/A All 1-Jan-20 1000 Observational






https://cl Not recruitNo 18 Years 75 Years All 21-Jan-20 90 InterventioAllocation

https://cl Not recruitNo 18 Years 99 Years All ### 650 Observational [Patient Registry]



https://cl Not recruitNo 18 Years 50 Years Female May-20 200 Observational
https://cl Not recruitNo 18 Years N/A All 1-Jun-20 1000 Observational

https://cl Recruiting No N/A 29 Days All 1-Apr-20 500 Observational

https://cl Recruiting No 18 Years N/A All Jun-20 100 InterventioAllocation
https://cl Not recruitNo 18 Years 60 Years All 1-Mar-20 52 Observational

https://cl Recruiting No 18 Years 90 Years All 4-May-20 6000 Observational [Patient Registry]
https://cl Not recruitNo 18 Years 65 Years All 18-Jun-20 700 Observational

https://cl Recruiting No 18 Years N/A Female 21-Apr-20 11000 Observational [Patient Registry]


https://cl Not recruitNo 21 Years 75 Years All 1-Jun-20 34 InterventioInterventi
https://an Recruiting No 18 Years No limit Both males ### 2500 InterventioPurpose: Tr
https://an Not Recrui No 18 Years No limit Both males ### 75 InterventioPurpose: P

https://an Not Recrui No 18 Years No limit Both males ### 10 InterventioPurpose: Ed
https://an Not Recrui No 18 Years No limit Both males 6/1/2020 90 ObservatioPurpose: Ps
http://isr Recruiting No Both ### 588 InterventioOpen-label

http://isr Recruiting No Both ### 200 InterventioThis is a t
http://isr Not Recrui No Both ### 116750 InterventioInterventi
http://wwwRecruiting No 18 90 Both 1/1/2020 Case serie ObservatioSequential

http://wwwRecruiting No 0 100 Both ### Case seriesObservatioCross-secti
http://wwwNot Recrui No 18 Both ### Case seriesObservatioCross-secti

http://wwwNot Recrui No 17 71 Both 3/1/2020 A?B?C:60; ObservatioCase-Contr
http://wwwRecruiting No Both 2/1/2020 COVID-19 pObservatioSequential
http://wwwRecruiting No 0 100 Both ### Health:200ObservatioFactorial
http://wwwRecruiting No 18 70 Both ### recovered ObservatioFactorial
http://wwwRecruiting No Both ### Group A:80InterventioParallel
http://wwwNot Recrui No Both ### symptomatiObservatioFactorial

http://wwwNot Recrui No 18 80 Both 2/1/2020 prone posi ObservatioFactorial

http://wwwNot Recrui No 18 90 Both ### Control:25 ObservatioCohort stu
http://wwwRecruiting No 18 Both 5/4/2020 ExperimentObservatioNon random
http://wwwRecruiting No 18 65 Both ### Case seriesInterventioSingle arm
http://wwwRecruiting No Both 2/6/2020 control gr InterventioNon random

https://tri Recruiting No ### 285 Observatio 

https://tri Recruiting No 4/8/2020 50 Observatio 
https://tri Not Recrui No ### 20 Interventio 
https://tri Not Recrui No 4/1/2020 50 Observatio 
https://tri Not Recrui No ### 300 Observatio 
https://tri Not Recrui No 5/8/2020 13 Interventio 
https://tri Recruiting No ### 100 Unknown 
https://tri Recruiting No 5/7/2020 500 Observatio 
https://tri Recruiting No ### 1600 Interventio 

https://tri Recruiting No 4/6/2020 354 Interventio 


https://cl Not recruitNo N/A 100 Years All ### 426 Observational


https://cl Not recruitNo 18 Years N/A All 21-Jan-20 51 Observational

https://cl Recruiting No 18 Years 60 Years All 1-May-20 200 InterventioAllocation:
https://cl Recruiting No 12 Months N/A All 30-Apr-20 220 InterventioAllocation:


https://cl Not recruitNo N/A N/A All ### 100 Observational [Patient Registry]
https://cl Recruiting No 18 Years 60 Years Male ### 200 Observational [Patient Registry]


https://cl Not recruitNo N/A N/A All 1-Jun-20 200 InterventioAllocation:
https://cl Not recruitNo 18 Years 80 Years All Jun-20 40 InterventioAllocation:

https://cl Recruiting Yes 18 Years N/A All 8-May-20 1167 InterventioAllocation

https://cl Not recruitNo N/A N/A All 1-Jun-20 500 Observational
https://cl Not recruitNo 18 Years N/A All 1-Jun-20 90 Observational [Patient Registry]
https://cl Not recruitNo 18 Years 50 Years Male ### 20 InterventioAllocation

https://cl Not recruitNo 18 Years N/A All May-20 1000 Observational [Patient Registry]



https://cl Not recruitNo N/A 18 Years All 7-Apr-20 2500 Observational
https://cl Recruiting Yes 18 Years 99 Years All ### 200 InterventioAllocation:

https://cl Not recruitNo 18 Years 45 Years Female 5-Apr-20 80 Observational [Patient Registry]



https://cl Not recruitNo N/A 17 Years All Jun-20 1920 InterventioAllocation

https://cl Not recruitNo N/A N/A All ### 100 InterventioAllocation:





https://cl Recruiting No 18 Years 100 Years All 1-Mar-20 100 Observational

https://cl Recruiting No N/A N/A All 1-May-20 100 Observational [Patient Registry]

https://cl Not recruitNo 18 Years N/A All Jul-20 144 InterventioAllocation:
https://cl Not recruitNo 18 Years N/A Female 1-Apr-20 503 Observational

https://cl Not recruitNo 18 Years N/A All 1-Sep-20 54 InterventioAllocation


https://cl Not recruitNo 18 Years N/A Female ### 100 Observational [Patient Registry]

https://an Recruiting No 23 Years No limit Both males ### 100 Observational
https://an Not Recrui No 16 Years 50 Years Females 8/1/2020 100 ObservatioPurpose: Na
https://an Recruiting No 18 Years No limit Both males ### 250 ObservatioPurpose: Na
http://wwwNot Recrui No Female ### ExperimentInterventioParallel

http://wwwNot Recrui No 43 70 Both ### ExperimentInterventioNon random
http://wwwRecruiting No 20 50 Both ### PLC-C =38 ObservatioFactorial

http://wwwNot Recrui No 2?? 84 Both ### Case seriesObservatioSequential
http://wwwNot Recrui No 6 87 Both ### faster ver ObservatioFactorial

http://wwwRecruiting No Both ### Control:15 InterventioParallel

http://wwwNot Recrui No 18 70 Both ### interventi InterventioParallel
http://wwwNot Recrui No 18 80 Both ### ARBs GroupObservatioFactorial

http://isr Recruiting No Both ### 300 InterventioInterventi
http://isr Recruiting No Both 6/1/2020 25 InterventioSingle-arm
http://isr Recruiting No Both 3/1/2020 1000 ObservatioObservatio
http://isr Recruiting No Both ### 300 InterventioMulti-centr

http://isr Recruiting No Both 6/1/2020 2000 InterventioPhase III p
http://isr Recruiting No Both ### 135 ObservatioLongitudina
http://isr Recruiting No Both 5/7/2020 375 InterventioRandomised

http://isr Recruiting No Both ### 500 Interventio 
http://isr Not Recrui No Both ### 25 ObservatioObservatio


https://wwNot Recrui No Female ### 300 InterventioControlled


https://wwAuthorisedNo Female ### 200 InterventioControlled:






https://cl Recruiting No 18 Years N/A All 1-Oct-18 80 InterventioAllocation
https://cl Recruiting Yes N/A 24 Years All 15-Oct-19 3500 Observational

https://cl Recruiting No 18 Years N/A All Jun-20 25 Observational
https://cl Not recruitNo 18 Years N/A All 21-Jul-20 Expanded Access




https://cl Not recruitNo 18 Years N/A All 23-Oct-19 75 InterventioAllocation:
https://cl Not recruitNo N/A 21 Years All ### 2000 Observational [Patient Registry]

https://cl Not recruitNo 1 Year N/A All ### 1000 InterventioAllocation:



https://cl Not recruitNo 18 Years N/A All 30-Jul-20 20 InterventioAllocation

https://cl Recruiting No N/A 28 Days All 1-May-20 90 Observational [Patient Registry]
https://cl Recruiting No 18 Years 65 Years All May-20 50 InterventioAllocation:


https://cl Not recruitNo N/A N/A All 1-Jun-20 40 InterventioAllocation
https://cl Not recruitNo 18 Years 75 Years All Nov-20 30 InterventioAllocation



https://cl Not recruitYes 18 Years N/A All 27-Jun-20 24 InterventioAllocation






https://cl Recruiting No 18 Years N/A Female ### 160 InterventioAllocation

https://cl Recruiting No N/A 18 Years All 1-Jan-20 100 Observational
https://cl Not recruitNo 18 Years 75 Years All 6-Jul-20 48 InterventioAllocation


https://cl Not recruitNo N/A N/A All Jun-20 100 InterventioAllocation



https://cl Not recruitNo 6 Months 100 Years All 1-Jun-20 18901 Observational

https://an Not Recrui No 18 Years No limit Both males 6/8/2020 200 InterventioPurpose: T
https://an Not Recrui No 18 Years No limit Both males 6/5/2020 50 InterventioPurpose: P

https://an Not Recrui No 5 Years No limit Both males 6/3/2020 6000 ObservatioPurpose: Na
https://an Not Recrui No 18 Years No limit Both males 6/8/2020 46 InterventioPurpose: Ed
https://an Not Recrui No 18 Years No limit Both males ### 315 ObservatioPurpose: N
http://wwwNot Recrui No Both ### 1:30;2:30; InterventioParallel

http://wwwNot Recrui No 29 83 Both 5/7/2020 1:49;2:157 ObservatioFactorial
http://wwwNot Recrui No 1 92 Both ### Case seriesObservatioCohort stu
http://wwwNot Recrui No 60 100 Both 6/5/2020 Case seriesObservatioCross-secti

http://wwwRecruiting No Both ### Case serie ObservatioSequential
http://wwwNot Recrui No Both ### Case seriesInterventioSequential

http://isr Recruiting No Both ### 100 InterventioPilot rando
http://isr Recruiting No Both 5/5/2020 2000 ObservatioLongitudina
http://isr Recruiting No Both 6/8/2020 360 InterventioPragmatic r

http://isr Recruiting No Both 4/1/2020 300 InterventioMulticentre
http://isr Not Recrui No Both 5/4/2020 75 InterventioInterventio

http://isr Not Recrui No Both 4/8/2020 2000 ObservatioSingle-cent
http://isr Recruiting Yes Both ### 12000 InterventioRandomised





https://wwAuthorisedYes Female ### 200 InterventioControlled:
https://wwAuthorisedYes Female ### 196 InterventioControlled:

https://cl Not recruitNo 12 Years N/A All 6-Mar-20 6000 InterventioAllocation

https://cl Not recruitYes 18 Years N/A All 3-Apr-20 450 InterventioAllocation:

https://cl Not recruitNo 18 Years 100 Years All Jun-20 10000 Observational
https://cl Recruiting No 1 Year 100 Years All 22-Apr-20 1000 Observational [Patient Registry]


https://cl Recruiting No 1 Month 18 Years All ### 30 InterventioAllocation
https://cl Not recruitNo 18 Years 45 Years Female ### 300 Observational [Patient Registry]

https://cl Not recruitNo 18 Years N/A All Aug-20 865 InterventioAllocation:
https://cl Recruiting No 18 Years 65 Years All 1-Jun-20 60 Observational


https://cl Recruiting No 70 Years N/A All 1-Jun-20 100 InterventioAllocation:


https://cl Recruiting No 18 Years N/A All 1-Mar-20 200 InterventioAllocation

https://cl Recruiting No 65 Years N/A All May-20 550 InterventioAllocation:
https://cl Recruiting No 18 Years N/A All Jun-20 100 InterventioAllocation:


https://cl Recruiting No N/A N/A Female ### 714 InterventioAllocation:

https://cl Not recruitNo N/A N/A Female 10-Apr-20 179 Observational

https://cl Recruiting No 18 Years N/A All 1-Jun-20 100 InterventioAllocation
https://cl Recruiting No 18 Years 47 Years Female 10-Apr-20 200 Observational

https://cl Not recruitNo 65 Years N/A All Oct-20 600 Observational [Patient Registry]

https://cl Recruiting Yes 18 Years 90 Years All 3-Jun-20 200 InterventioAllocation

https://cl Not recruitNo N/A N/A All Jun-20 20 Observational [Patient Registry]

https://cl Recruiting No 18 Years N/A All Sep-20 500 Observational [Patient Registry]

https://cl Recruiting No 18 Years 110 Years All 1-Jun-20 1000 InterventioAllocation:

https://cl Not recruitNo 18 Months 85 Years All Jun-20 0 InterventioAllocation:
https://cl Not recruitNo 18 Years 60 Years All Jul-20 24 InterventioAllocation


https://cl Not recruitYes 18 Years N/A All 15-Jun-20 1407 InterventioAllocation
https://cl Not recruitNo 18 Years N/A All Jun-20 Expanded Access
https://cl Recruiting No 18 Years 48 Years Female 5-May-20 50 Observational

https://cl Recruiting No 18 Years N/A All 1-Jun-20 50 Observational


https://cl Recruiting No 18 Years 75 Years All Jun-20 100 InterventioAllocation


https://cl Not recruitNo 1 Month N/A All 2-Jun-20 600 InterventioAllocation

https://cl Not recruitNo 18 Years 50 Years Male 10-Jun-20 100 Observational
https://cl Recruiting No 18 Years 80 Years All 5-Jul-20 52 Observational [Patient Registry]

https://cl Not recruitNo N/A N/A All Aug-20 60 InterventioAllocation:

https://cl Recruiting No 16 Years 55 Years Female ### 300 Observational
https://cl Recruiting No 18 Years N/A All Jun-20 400 Observational

https://cl Not recruitNo N/A N/A All Jun-20 10000 InterventioAllocation:
http://isr Recruiting No Both 6/3/2020 11000 ObservatioNon-random

http://isr Recruiting No Both ### 600 InterventioProspectiv
http://isr Recruiting No Both ### 90000 ObservatioLongitudina

http://isr Not Recrui No Both 4/6/2020 40 ObservatioObservatio
http://wwwNot Recrui No Both ### Heart Fail ObservatioFactorial
http://wwwNot Recrui No 18 99 Male ### convalesceObservatioFactorial



http://wwwNot Recrui No 70 98 Both ### Case seriesObservatioCase study
http://wwwNot Recrui No 18 110 Male ### Tocilizuma ObservatioFactorial
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: No
treatmen
t
https://wwNot Recrui No Female ### 568 InterventioNumb
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: Lack
of
treatmen
https://wwNot Recrui No Female ### 206 Interventiot
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or:
Standard
of care
https://wwNot Recrui Yes Female4/2/2020 350 Interventio
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: yes
Double
blind: no
Parallel
group: no
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n:
enrollme
nt
stratified
by: Use of
concomit
ant
therapies
and High
Risk
Comorbid
ities
If
controlle
https://wwAuthorisedYes Female ### 300 Interventiod, spec
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n:
placebo-
controlle
d, group
sequentia
l and
adaptive
If
controlle
d, specify
comparat
or, Other
Medicinia
https://wwAuthorisedNo Female ### 310 Interventiol
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other:
yes
Other
trial
design
descriptio
n:
Optional
two part-
study:
Part 1:
Proof of
concept,
Part 2:
Expansion
If
controlle
d, specify
comparat
https://wwAuthorisedNo Female ### 200 Interventioo
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group: no
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
Controlle
d: yes
Randomis
ed: yes
Open: yes
Single
blind: no
Double
blind: no
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
no
Other:
yes
Other
specify
the
comparat
or: Best
Available
https://wwAuthorisedNo Female ### 40 InterventioCa
Controlle
d: yes
Randomis
ed: yes
Open: no
Single
blind: no
Double
blind: yes
Parallel
group:
yes
Cross
over: no
Other: no
If
controlle
d, specify
comparat
or, Other
Medicinia
l Product:
no
Placebo:
yes
Other: no
Number
of
treatmen
t arms in
the trial:
2
http://ww Recruiting No 18 Years no maximuBoth, male ### 70 observatio Allocation:
http://ww Not Recrui No 18 Years 80 Years Both, male 5/1/2020 100 interventioAllocation:
http://ww Recruiting No no minimu no maximuBoth, male ### 30 observatio Allocation:
http://ww Recruiting No 18 Years 70 Years Both, male 4/1/2020 30 interventioAllocation:
http://ww Not Recrui No 18 Years no maximuBoth, male 4/2/2020 360 observatio Allocation:
http://ww Recruiting No 1 Years 99 Years Both, male ### 450 observatio Allocation:
http://ww Not Recrui No 18 Years 80 Years Both, male ### 60 observatio Allocation:
http://ww Not Recrui No 18 Years no maximuBoth, male ### 100 interventioAllocation:
http://ww Recruiting No no minimu 18 Years Both, male ### 1000 observatio Allocation:
http://ww Recruiting No 18 Years no maximuBoth, male 4/8/2020 1000 observatio Allocation:
http://ww Recruiting No 18 Years 60 Years Both, male ### 24 interventioAllocation:
http://ww Not Recrui No no minimu no maximuBoth, male 5/3/2020 750 observatio Allocation:

http://ww Recruiting No 18 Years no maximuBoth, male ### 220 interventioAllocation:
http://ww Recruiting No 18 Years no maximuBoth, male 5/8/2020 1000 interventioAllocation:
http://ww Not Recrui No 18 Years 59 Years Both, male ### 20000 interventioAllocation:
http://ww Recruiting No no minimu no maximuBoth, male 4/3/2020 100 observatio Allocation:
http://ww Recruiting No 18 Years no maximuBoth, male 4/2/2020 1500 observatio Allocation
http://ww Not Recrui No 18 Years no maximuBoth, male 4/5/2020 2000 observatio Allocation: Other;. Ma
http://ww Not Recrui No 18 Years 99 Years Both, male ### 15 observatio Allocation: Other;. M
http://ww Not Recrui No 18 Years no maximuBoth, male 6/4/2020 90 interventioAllocation:
http://ww Recruiting Yes 18 Years 100 Years Both, male ### 30 interventioAllocation:
http://ww Not Recrui No no minimu no maximuBoth, male ### 1400 observatio Allocation:
http://ww Not Recrui No 18 Years no maximuBoth, male ### 2000 observatio Allocation:
http://ww Recruiting No 18 Years no maximuBoth, male 6/2/2020 2550 observatio Allocation: Single arm
http://ww Recruiting No 18 Years 100 Years Both, male ### 500 observatio Allocation
http://ww Not Recrui No 65 Years no maximuBoth, male ### 1276 observatio Allocation: Single arm
http://ww Not Recrui No 18 Years 100 Years Both, male 3/1/2020 100 observatio Allocation:
http://ww Not Recrui No 18 Years no maximuBoth, male 7/1/2020 200 observatio Allocation: Non-rando
http://ww Recruiting No 18 Years no maximuBoth, male 4/3/2020 200 observatio Allocation: Single arm
http://ww Recruiting No no minimu no maximuFemale ### observatio Allocation:
http://ww Recruiting No 18 Years no maximuBoth, male 4/5/2020 100 observatio Allocation: Other;. M
http://ww Recruiting Yes 18 Years no maximuBoth, male ### 500 observatio Allocation:
http://ww Not Recrui No 18 Years 120 Years Both, male 4/8/2020 observatio Allocation:
https://slc Not Recrui No 5/4/2020 400 (200 i InterventioRandomized
Randomiz
ation:
Randomiz
ed,
Blinding:
Triple
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: In this
study,
100
patients
with
covid 19
will be
randomly
divided
into two
groups.
The
selection
http://en.i Not Recrui No 1 year no limit Both 5/4/2020 94 interventioof
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Factorial,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: This
study will
be a
randomiz
ed,
double-
blind,
phase 3
clinical
trials on
100
patients.
Randomiz
http://en.i Recruiting No 18 years no limit Both 6/6/2020 100 interventioatio
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: In this
clinical
trial, 260
patients
with
positive
COVID-19
will be
recruited.
Patients
will be
http://en.i Recruiting Yes 18 years 75 years Both ### 260 interventiorando
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Method:
Simple
randomiz
ation.
Unit:
Individual
.
Tools:
Random
http://en.i Recruiting No 18 years no limit Both ### 100 interventioblocks
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
randomiz
ation;
Individual
; Random
Number
Tables.
Randomiz
ed
permutati
http://en.i Not Recrui No no limit 65 years Both 4/7/2020 30 interventioon blocks
Randomiz
ation:
Randomiz
ed,
Blinding:
Single
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t, Other
design
features:
This study
will be
carried
out on 60
hospitaliz
ed ?
COVID-19
patients.
Patients
randomly
divided
http://en.i Recruiting No 18 years no limit Both ### 60 interventiointo
Randomiz
ation:
Randomiz
ed,
Blinding:
Triple
blinded,
Placebo:
Not used,
Assignme
nt:
Factorial,
Purpose:
Treatmen
t, Other
design
features:
COVID-19
treatmen
t study,
Randomiz
ation
descriptio
n: After
the
participan
t enters
the study,
http://en.i Recruiting No 18 years 99 years Both ### 60 interventioi.e. af
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Preventio
n,
Randomiz
ation
descriptio
n: in this
study, the
random
allocation
for
interventi
on and
placebo
groups is
based on
a
"Random
http://en.i Recruiting No 18 years 75 years Both ### 540 interventioAlloc
Randomiz
ation:
Randomiz
ed,
Blinding:
Single
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Supportiv
e,
Randomiz
ation
descriptio
n: The
sequence
of
random
allocation
and the
list of
blocks
will be
obtained
by the
statistical
http://en.i Recruiting No no limit no limit Both ### 74 interventiocon
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n:
Initially,
the blocks
(n=4)
with
different
arrangem
ents of A
and B will
be
defined.
Consideri
http://en.i Not Recrui No 18 years 70 years Both 5/5/2019 30 interventiong the d
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Preventio
n,
Randomiz
ation
descriptio
n: In this
study,
block
randomiz
ation will
be used
and the
size of
the blocks
will be
selected
http://en.i Recruiting No 18 years no limit Both 6/4/2020 500 interventiorandomly
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
method is
used to
randomiz
ed the
patients.
For
randomiz
http://en.i Recruiting No 18 years no limit Both ### 80 interventioation, we
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: -Simple
randomiz
ation
-Individua
l
rabdomiz
ation
-By using
http://en.i Recruiting No 18 years 90 years Both ### 60 interventiotable of r
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
randomiz
ation;
Individual
; Random
Number
Tables.
Randomiz
ed
permutati
http://en.i Recruiting No no limit no limit Both ### 10 interventioon blocks
http://en.i Not Recrui No 60 years no limit Male ### 10 interventioRandomizati
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
method is
used to
randomiz
ed the
patients.
In this
method,
http://en.i Recruiting No 18 years no limit Both ### 72 interventiothe n
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
method is
used to
randomiz
ed the
patients.
In this
method,
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Simple
randomiz
ation,
Random
Number
Table
The
numbers
will be
assigned
to the
http://en.i Recruiting No 16 years 100 years Both ### 40 interventiopartici
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
method is
used to
randomiz
ed the
patients.
For
randomiz
http://en.i Recruiting No 18 years 65 years Both ### 30 interventioation, we
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
method is
used to
randomiz
ed the
patients.
In this
method,
http://en.i Not Recrui No 18 years no limit Both 4/8/2020 50 interventioRandomizati
Randomiz
ation:
Randomiz
ed,
Blinding:
Double
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Simple
randomiz
ation.
Eligible
patients
randomly
and
without
consideri
ng a
http://en.i Recruiting No 18 years 70 years Both ### 20 interventiospecif
http://en.i Not Recrui No no limit no limit Both ### 108 interventioRandomizati
Randomiz
ation:
Randomiz
ed,
Blinding:
Not
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: Block
Randomiz
ation
method is
used to
randomiz
ed the
patients.
In this
method,
Randomiz
ation:
Randomiz
ed,
Blinding:
Single
blinded,
Placebo:
Used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: In this
study, we
will use
the
Restricted
randomiz
ation
method
of block
randomiz
ation.
Blockage
http://en.i Recruiting No 18 years no limit Both ### 60 interventiois us
Randomiz
ation:
Randomiz
ed,
Blinding:
Single
blinded,
Placebo:
Not used,
Assignme
nt:
Parallel,
Purpose:
Treatmen
t,
Randomiz
ation
descriptio
n: A
random
number
table and
block
randomiz
ation
method is
used. In
this
method
60 eligible
http://en.i Not Recrui No 18 years no limit Both ### 60 interventiopatients
http://cris Recruiting No 19(Year) 100(Year) Both 4/8/2020 141 InterventioPrimary Pur
https://lbc Not Recrui No 18 85 Both ### 500 ObservatioAllocation

https://lbc Not Recrui No 18 99 Both ### 1000 InterventioAllocation
https://www Recruiting No 18 BOTH ### 10 INTERVENTOpen-label,
https://jrc Recruiting No Not applic Not applic Both 5/1/2020 50 Observational
https://jrc Not Recrui No >= 20age oNot applic Both ### 35 Interventiorandomized
https://jrc Not Recrui No >= 20age oNot applic Both 4/1/2020 50 Interventiosingle arm
https://jrc Recruiting No >= 20age oNot applic Both 4/3/2020 90 Interventiorandomized
https://jrc Recruiting No >= 20age o< 75age ol Both 5/1/2020 160 Interventiorandomized
https://jrc Recruiting No >= 18age oNot applic Both 6/3/2020 10 Interventiosingle arm
https://jrc Not Recrui No >= 16age oNot applic Both 3/2/2020 86 Interventiorandomized
https://jrc Recruiting No >= 20age oNot applic Both ### 100 Interventiorandomized
https://up Not Recrui No 20years-ol 70years-ol Male and 5/9/2020 15 InterventioSingle arm
https://up Not Recrui No 18years-ol 95years-ol Male and ### 90 ObservatioNot select
https://up Not Recrui No 1years-old 100years-oMale and ### 200 ObservatioNot select
https://up Not Recrui No 20years-ol 70years-ol Male and ### 15 InterventioSingle arm
https://up Not Recrui No 1years-old 18years-ol Male and ### 500 Others,metNot select
https://up Recruiting No 20years-ol 70years-ol Male and ### 30 InterventioSingle arm
https://up Recruiting No 20years-ol 100years-oMale and ### 200 ObservatioNot select
https://up Not Recrui No 18years-ol 90years-ol Male and ### 90 ObservatioNot select
https://up Recruiting No 20years-ol Not applic Male and ### 20 ObservatioNot select
https://up Not Recrui No 18years-ol Not applic Male and ### 100 InterventioParallel R
https://up Not Recrui No Not applic Not applic Male and 6/8/2020 50 ObservatioNot select
https://up Not Recrui No 20years-ol 60years-ol Male and 6/8/2020 2000 ObservatioNot select
https://up Not Recrui No 20years-ol Not applic Male and ### 1000 InterventioSingle arm
https://pacNot Recrui No 19 Year(s) 44 Year(s) Both ### 600 InterventioFactorial:

https://pacNot Recrui No 19 Year(s) 44 Year(s) Both 5/1/2020 72 InterventioParallel:
https://pacNot Recrui No 19 Year(s) 44 Year(s) Both ### 60 InterventioParallel: d
https://pacNot Recrui No 19 Year(s) 44 Year(s) Both ### 400 InterventioParallel:
https://pacNot Recrui No 19 Year(s) 44 Year(s) Both 6/1/2020 384 InterventioParallel:
https://pacNot Recrui No 13 Year(s) 18 Year(s) Both ### 48 InterventioParallel: d
http://wwwRecruiting No 18Y 75Y - 4/1/2020 99 Interventi double-blin

http://wwwRecruiting No 18Y 90Y - 4/7/2020 2300 ObservatioRetrospecti
http://wwwNot Recrui No 18Y 0- ### 200 Interventi Clinical tr
http://wwwRecruiting No 0 0- 4/1/2020 90 Interventi Non-randomi
http://wwwNot Recrui No 18Y 60Y - ### 250 Interventi Prevention
http://wwwNot Recrui No 18Y 0 - 5/1/2020 45 Interventi Randomized,

http://wwwRecruiting No 18 0 - 5/1/2020 118 Interventi Trial, rand
http://wwwRecruiting No 18Y 0 - ### 20 Interventi Non-randomi
http://wwwRecruiting No 18 0 - 5/1/2020 1000 ObservatioRetrospecti
http://wwwNot Recrui No 18Y 0 - 7/1/2020 100 Interventi Clinical tr
http://wwwNot Recrui No 18Y 0- ### 630 Interventi Randomized,

http://wwwNot Recrui No 18 0- 6/4/2020 5 Interventi Treatment c
http://wwwRecruiting No 0 130Y - ### 50 ObservatioA prospecti
http://wwwRecruiting No 18Y 85 - ### 30 Interventi Clinical tr
http://wwwRecruiting No 18Y 80Y - ### 10 Interventi Clinical tr

http://wwwNot Recrui No 0 0- ### 50 ObservatioProspective
https://rp Recruiting No 60 years None Male/Fema ### 80 InterventioRandomizati
https://rp Recruiting No 19 years None Male/Fema ### 120 InterventioRandomizati
https://rp Not Recrui No 19 years 60 years Male 5/4/2020 30 InterventioRandomizati
https://rp Not Recrui No 18 years. 65 years. Male/Fema ### 50 InterventioAllocation:
https://rp Recruiting No 60 years none Male/Fema 4/3/2020 Inclusion ObservatioAllocation:
https://rp Recruiting No 18 years ol none Male/Fema ### 80 InterventioAllocation
https://rp Recruiting No 18 years 64 years Male/Fema ### 180 ObservatioAllocation:
https://rp Not Recrui No 19 years None Male/Fema ### 16 InterventioAllocation
https://rp Recruiting No 19 years None Male/Fema ### 115000 InterventioAllocation:
https://rp Recruiting No 60 years None Male/Fema ### 60 InterventioAllocation:
https://rp Not Recrui No 18 years None Male/Fema 6/1/2020 20 InterventioAllocation:
https://rp Not Recrui No 19 years None Male/Fema 6/1/2020 20 InterventioAllocation:
https://rp Recruiting No None None Male/Fema ### All patient ObservatioAllocation
https://rp Not Recrui No 60 years None Male/Fema ### 160 ObservatioAllocation:
https://rp Not Recrui No 19 years 80 years Male/Fema 6/8/2020 32 InterventioAllocation:
http://wwwRecruiting No 18 Years 60 Years Both 6/1/2020 110 InterventioRandomized

http://wwwNot Recrui No 18 Years 0 N/A (No lBoth ### 19 ObservatioNon-rando
http://wwwNot Recrui No 18 Years 74 Years Both 6/1/2020 96 InterventioRandomized
http://wwwRecruiting No 0 N/A (No l0 N/A (No lBoth ### 200 ObservatioNon-rando

http://wwwRecruiting No 18 Years 100 Years Both ### 2500 ObservatioN/A
http://wwwNot Recrui No 18 Years 0 N/A (No lBoth 5/1/2020 206 InterventioRandomized

http://wwwRecruiting No 18 Years 0 N/A (No lBoth ### 40 ObservatioNon-rando
http://wwwNot Recrui No 18 Years 100 Years Both ### 400 InterventioRandomized
http://wwwRecruiting No 18 Years 0 N/A (No lBoth 5/1/2020 2640 ObservatioN/A

http://wwwNot Recrui No 30 Years 70 Years Both ### 650 ObservatioN/A
http://wwwNot Recrui No 18 Years 95 Years Both ### 5000 ObservatioN/A
https://wwRecruiting No 4/3/2020 1000 InterventioThe novel c

https://cl Recruiting No 18 Years 80 Years All 1-Jul-20 24 InterventioAllocation


https://cl Recruiting No 18 Years N/A Female 6-May-20 400 Observational







https://cl Recruiting No 18 Years 50 Years Female 28-Apr-20 200 Observational [Patient Registry]
https://cl Not recruitNo 18 Years 60 Years All Jul-20 300 InterventioAllocation:
https://cl Not recruitNo 18 Years N/A Female 15-Jun-20 1000 InterventioAllocation:

https://cl Not recruitNo N/A 17 Years All Jun-20 20 Observational

https://cl Not recruitNo 48 Years 60 Years Female ### 21 InterventioAllocation
https://cl Recruiting No 18 Years 120 Years All 8-Jun-20 500 InterventioAllocation

https://cl Not recruitNo 17 Years N/A All 1-Jul-20 200 Observational

https://cl Recruiting No 18 Years 42 Years Female 1-Apr-20 300 Observational

https://cl Not recruitYes 16 Years N/A All 29-Apr-20 40000 InterventioAllocation:

https://cl Not recruitNo N/A 15 MinutesAll ### 40 Observational



https://cl Recruiting No 65 Years N/A All 1-Jul-20 1057 InterventioAllocation
https://cl Not recruitNo 18 Years 95 Years All 17-Apr-20 Expanded Access


https://cl Recruiting No 18 Years N/A All Jul-20 24 InterventioAllocation

https://cl Recruiting No N/A N/A All 30-Sep-20 200 Observational


https://cl Recruiting No 1 Year N/A All 5-May-20 92 Observational [Patient Registry]

https://cl Not recruitNo 18 Years 45 Years Female ### 150 Observational




https://cl Not recruitNo N/A N/A All 1-Mar-20 10 Observational [Patient Registry]

https://cl Not recruitNo N/A N/A All ### 290 InterventioAllocation
https://cl Recruiting No N/A N/A All 7-Jun-20 40 InterventioAllocation


https://cl Not recruitNo N/A 45 Years Female 15-Jun-20 20 InterventioAllocation


https://cl Not recruitNo 18 Years N/A All 1-Mar-20 22784 Observational [Patient Registry]
https://cl Not recruitNo 18 Years N/A All Aug-20 1500 Observational



https://cl Recruiting No 18 Years N/A All 13-Jan-20 186 InterventioAllocation
https://cl Recruiting No 1 Year N/A All 1-May-20 50 Observational [Patient Registry]
https://an Recruiting No 18 Years 70 Years Both males ### 2250 InterventioPurpose: Pr

https://an Not Recrui No 18 Years No limit Both males 5/1/2020 20 InterventioPurpose: P



http://isr Recruiting No Both ### 240 InterventioMulticentr
http://isr Recruiting No Both ### 2000 InterventioSingle-blin
http://isr Recruiting No Female ### 200 ObservatioProspectiv

http://isr Recruiting No Both ### 1000 ObservatioRetrospecti
http://isr Recruiting No Both ### 100 InterventioA multicent

http://isr Recruiting No Both 6/1/2020 64 InterventioInterventio
http://isr Recruiting No Both ### 45 InterventioRandomised
http://isr Recruiting No Both 6/1/2020 30000 InterventioInternation

http://isr Recruiting No Both 5/1/2020 80 InterventioPilot interven
http://isr Recruiting No Both ### 20000 ObservatioBoth; Desig
http://isr Recruiting No Female ### 500 ObservatioObservatio
http://isr Recruiting Yes Both ### 3000 InterventioPragmatic,
http://isr Recruiting No Both 9/4/2017 70 InterventioSingle-cent
http://isr Not Recrui No Both 8/6/2018 130 ObservatioSingle-cent
http://wwwNot Recrui No 8 82 Both ### Case seriesObservatioCohort stu
http://wwwRecruiting No 0 50 Both ### Confirmed ObservatioFactorial

http://wwwRecruiting No 18 120 Both ### Case seriesPreventionSequential
http://wwwRecruiting No 20 65 Both ### Have unde ObservatioCase-Contr

http://wwwNot Recrui No 20 65 Both 6/4/2020 Laboratory Health Ser Sequential
http://wwwRecruiting No 28 54 Male 3/1/2020 For the mi ObservatioCross-secti






https://cl Not recruitNo 18 Years N/A All 26-Jan-20 80 InterventioAllocation
https://cl Not recruitNo 18 Years 75 Years All 5-Mar-20 100 InterventioAllocation:


https://cl Recruiting No 18 Years 99 Years Female 13-Apr-20 150 InterventioAllocation


https://cl Not recruitNo 18 Years N/A All 1-Aug-20 200 InterventioAllocation

https://cl Recruiting No N/A N/A All 16-Jun-20 120 InterventioAllocation:
https://cl Not recruitNo 18 Years 70 Years All ### Expanded Access

https://cl Not recruitYes 18 Years N/A All 20-Apr-20 29 InterventioAllocation



https://cl Not recruitNo 18 Years 80 Years All 1-Sep-20 15 InterventioAllocation

https://cl Recruiting No 18 Years N/A All Jul-20 40 InterventioAllocation

https://cl Not recruitNo 216 MonthN/A All 30-Apr-20 300 InterventioAllocation


https://cl Recruiting No 18 Years N/A Male 1-May-20 200 Observational

https://cl Not recruitNo 18 Years 80 Years All Aug-20 56 InterventioAllocation

https://cl Not recruitNo 18 Years N/A All Aug-20 40 InterventioAllocation

https://cl Recruiting No 18 Years N/A All 15-Jun-20 500 Observational [Patient Registry]
https://cl Not recruitNo 18 Years N/A Female ### 7000 Observational


https://cl Not recruitNo 18 Years N/A All Sep-20 66 InterventioAllocation


https://cl Recruiting No N/A N/A All 4-Jun-20 1061 Observational
https://cl Not recruitNo 18 Years 85 Years Male 1-Jul-20 198 InterventioAllocation:



https://cl Not recruitNo N/A N/A All Jul-20 2000 InterventioInterventi


https://cl Recruiting No N/A 14 Years All 3-Jun-20 600 Observational [Patient Registry]




https://cl Not recruitNo 15 Years 75 Years All 1-Sep-20 800 Observational [Patient Registry]
https://cl Not recruitNo 18 Years N/A All 1-Aug-20 780 InterventioAllocation



https://cl Not recruitNo N/A N/A All 13-Jun-20 45 InterventioAllocation

https://cl Recruiting No N/A N/A All 2-Jun-20 100 Observational [Patient Registry]

https://cl Not recruitNo N/A 18 Years All Jun-20 52 InterventioAllocation

https://cl Not recruitNo 18 Years N/A All Jul-20 200 Observational [Patient Registry]

https://cl Not recruitNo N/A N/A All 20-Jul-20 174 InterventioAllocation:
https://cl Recruiting No 18 Years N/A Female 15-Jun-20 160 InterventioAllocation
https://cl Recruiting No 18 Years N/A Female ### 200 Observational

https://cl Not recruitNo 18 Years 100 Years All Jul-20 200 Observational
https://cl Not recruitNo N/A N/A All 1-Jul-20 90 Observational

https://cl Not recruitNo N/A N/A All 1-Jul-20 10000 Observational [Patient Registry]
https://cl Recruiting No 18 Years N/A Female 2-Jun-20 1200 Observational [Patient Registry]

https://cl Recruiting No 1 Month 30 Years All 27-Apr-20 300 Observational [Patient Registry]

https://cl Not recruitNo 18 Years N/A All 1-Aug-20 200 InterventioAllocation:
https://cl Not recruitNo 30 Years 60 Years Female 14-Jan-19 111 Observational
https://cl Not recruitNo N/A N/A All 1-Jun-20 1 Observational [Patient Registry]


https://cl Not recruitNo 18 Years 80 Years All Jun-20 70 Observational [Patient Registry]

https://cl Not recruitNo 24 Months 18 Years All 30-Apr-20 397 Observational
https://cl Not recruitNo 18 Years N/A Female Jun-20 300 Observational

https://cl Not recruitNo N/A N/A All Jun-20 10000 Observational [Patient Registry]
https://cl Recruiting No 18 Years 70 Years Female 15-Jun-20 35 Observational

https://cl Not recruitNo 18 Years 85 Years All 1-Sep-20 90 Observational

https://cl Not recruitNo 18 Years N/A All Aug-20 80 InterventioAllocation


https://cl Recruiting No 50 Years 75 Years All 23-Jul-19 960 Observational


https://cl Recruiting No 18 Years 40 Years Female ### 100 Observational [Patient Registry]

https://cl Not recruitNo 18 Years 120 Years All 1-Jul-20 9 Observational
https://cl Not recruitNo 18 Years N/A All Sep-20 300 InterventioAllocation:

https://cl Not recruitNo 18 Years 80 Years All 15-Jun-20 100 Observational [Patient Registry]

https://cl Not recruitNo 74 Years 95 Years Male 10-Jun-20 21 Observational
https://cl Not recruitNo 18 Years N/A All Aug-20 20 Observational

https://cl Recruiting No 1 Year N/A All 29-Apr-20 400 Observational



https://cl Not recruitNo 18 Years N/A All Jul-20 250 Observational
https://cl Recruiting No N/A 70 Years All 7-May-20 8 InterventioAllocation


https://cl Recruiting No 21 Years 60 Years Male ### 5000 InterventioAllocation
https://cl Recruiting No 18 Years 80 Years Male 12-Jul-20 50 Observational

https://cl Not recruitNo 50 Years N/A Male 26-Jun-20 254 InterventioAllocation:
Phase Countries Contact Fi Contact La Contact AdContact EmContact Te Contact AffInclusion C Exclusion C
 Inclusion Criteria:

 
 Patients diagnosed with RT-
 
 Exclusion Criteria:
 
 Patients infected with othe
Phase 4 Pinhua Pan, Medical pinhuapan +86 13574810968 

 
 - In sputum, throat swab,
 the nucleic acid of the no
Phase 4 China ; Yueping Li, MD, Mastelipipi007@ 020- 36052117; 

 
 - Patients visiting emergen
 
 
 -
China Panpan Hao, MD panda.how86-18560086593 

 
 - can use mobil phone or c
 
 - volunteer to take part in
 
 
 - can not use phone or com
 
N/A China ; Yuhong Dai;Yuhong Daeier_dai@ +86 13476229575;+8 

 
 1. Sign the informed conse
 
 2. Age =18 years, regardles
 
 3. Subjects with pneumon
Phase 4 
 - Adult aged >=18years old
 
 - Laboratory (RT-PCR) con
 lower respiratory tract sa
 
Phase 2/Phase 3 Taisheng Li litsh@263. 010-69155086 
 
 - 1. Aged between 18 and
 
 - 2. Laboratory (RT-PCR) a
N/A ; Yunqing Qiu, Master;X;xxw69@1 ;+86 1360 First Affil according
N/A China Yan Zhao 169 Donghudoctoryan +86 13995 EmergencyInclusion c Exclusion c
Inclusion criteria: 1. Aged >=18 years
 2. Diagnosed of 2019-nCoV infec
RetrospectChina Yan, Zhao 169 Donghudoctoryan +86 13995 Emergency 3. Failed Exclusion
by c
Inclusion criteria:
Exclusion1. Meet
criteria:
the1.diagno
Patie
N/A China LU Zhenhui 725 Wanpintcmdoctor +86 13817 Longhua Hos 2. The 2.
acute stage
Pregnant,
is complicate
preparin
Inclusion criteria:
Exclusion1. Meet
criteria:
the1.diagno
Patie
N/A China LU Zhenhui 725 Wanpintcmdoctor +86 13817 Longhua Hos 2. Meet 2.
the TCM
Pregnant,
diagnostic
preparin
crite
Exclusion criteria: 1. Fema
 2. Patients with know
 3. Patients with haem
Inclusion criteria:
 4. Patients
Patients aged
with chro
18 o
N/A China Ting Cai 41 Xibei St caiting@uc+86 13738 HwaMei Hos Criteria 5.
for diagnosis
Patients(meet
with arrh
all th
 3. Patients with haem
 4. Patients
Inclusion criteria: Patients aged
with chro
18 o
N/A China Ting Cai 41 Xibei St caiting@uc+86 13738 HwaMei Hos Criteria 5.
for diagnosis
Patients(meet
with arrh
all th
0 China Yao, Rong 37 Guoxue 10370705 +86 18980 West ChinaInclusion c Exclusion c
Inclusion criteria:
Exclusion1. Influenza
criteria: 1.patien
Patie
N/A China Zhao Yan 169 Donghudoctoryan +86 13995 Zhongnan H 2. From 2.
December
Clinical1, data
2019istoseri
Fe
Inclusion criteria:
Exclusion1. Suspected,
criteria: 1. mild,
Unab
N/A China Wang Tan 1478 GongnWangtan21+86 13756 Affiliated 2. The 2.
expert Cases
team ofwhere
consultati
comp
Inclusion criteria:
ExclusionConfirmed
criteria: or
1. suspe
Patie
 1. Aged 2.
<= 75Those
years;with severe
 2. Patients
 3. with
Inability
newlyto diagnose
unders
0 China Xu Shuyun 1095 Jiefa sxu@hust. +86 13517 Tongji Hosp 3 4. Invasive ve
0 China Cao Jun 117 Meiyuacaojuncn@+86 0510- Jiangsu Ins Inclusion Exclusion c
Inclusion criteria:
Exclusion1. patients
criteria: with
1. Preg
no
 2. Fever,
 2.
respiratory
People tract
with allergi
and o
 3. Aged 3.
18 to Severe
80 years;Primary dis
4 China Tingrong Huang, Bangj6 Guangchafangbji@1 +86 0714- Huangshi H 4. Signed 4.
informed
Obstructive
cons pneum
Inclusion criteria: 1. Subjects have sig
 2. AgedExclusion
>= 18 and criteria:
<= 75 years.
1. Patie
4 China Ronghua Jin 8 Xitoutou,dinghuigu +86 13811 Beijing You 3. Met 2.
th Patients who have
Exclusion criteria: 1) pneu
 2) 1)
Inclusion criteria: daily treatment
common type of
pn
 2) aged 3)
18 to patients
75 years with
old; confi
N/A China Wu Guolin 4)signing
79 Qingchuwuguolin2 +86 13136 The First A 3) voluntary those allergi
of written in
Inclusion criteria:
Exclusion(1) criteria:
aged >=18 (1)year
kno
0 China Pei Guangzhong 222 Zhengd50381850 +86 13839 People's H (2) real-time
 (2)fluorescence
patients with rt-pcr
mal
Inclusion criteria: 1. Laboratory confi
 2. Aged > 18 years;
 3. Written informed
Exclusion consent
criteria: giv
1. Hype
0 China Xiaowei Xu 79 Qingchuxxw69@12+86 13605 The First A 4. Clinical
 2.deterioration despite
Have immunoglob
0 China Huaqi Wang 1 Jianshe wanghuaq +86 15890 The First A Inclusion c Exclusion c
Inclusion criteria: 1. Aged >= 18 year
 2. Laboratory (RT-PCR) confirme
 3. Pneumonia confirmed with ch
 4. <= 8Exclusion
days sincecriteria:
illness 1.onset
Prega
4 China Chao Cao 59 Liuting caocdocto +86 574-8 Ningbo Firs 5. Willing
 2.
to Patients with seve
Exclusion criteria: (1) Tho
 (2) mentally ill subjec
 (3) those who are pre
 (4)1.those
Inclusion criteria: Age iswho notuselimite ot
0 Yongxiang Yi (5)
1 Kangfu Roian0126@1+86 13338 Nanjing Se 2. Clinical thoseis in accorda
diagnosis
Inclusion criteria:
Exclusion
1. Non
criteria:
suspected
1. Suspc
 2. Participate
 2. Patients
in novel with
coronavirseve
N/A China Qiu Jun 159 Tiansha97300753 +86 13881 Deyang inte 3. Novel 3.
coronavirus
People who pneumonia
could
Inclusion criteria:
Exclusion
1. Aged
criteria:
>=18 1. years
Preg
 2. A novel
 2.
coronavirus
The patients infection
had m
4 China Ying Kejing 3 Qingchunyingsrrsh +86 13588 Sir Run Run 3. According
 3.toPotential
novel coronaviru
violation
Inclusion criteria:
Exclusion
1. Aged>
criteria:181.years
Staffo
 2. Working
 2.time
Regulatory
in the frontstuden line
N/A China Zhan Jie 111 Dade Rzhanjie34 +86 15818 Guangdong 3. The 3.
workingThose
department
who refused is th
0 China Zhai Xiaowen 399 Wanyua zhaixiaow +86 64931 Children's Inclusion c Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
Those who (1) mee
Imm
 (2) Those
 (2)
who Preparing
have beenpregna diagno
0 China Hongzhou Lu, Xiaoron 2901 Caolanluhongzho +86 18930 Shanghai Pu (3) Inpatients
 (3)aged
Patients
18 to with
75 alle
yea
Exclusion criteria: 1. Extre
Inclusion criteria:
 2. 1.
Pregnant
Patientsorwith lactatico
0 Chao Xu 1 Fourth N 16497276 +86 15018720816 2. Voluntarily
 3. Insign
thewritten
opinion inform
of th
Inclusion criteria: Pneumonia cases w
0 China Weiren Huang 3002 Sungapony8980 +86 13923 Shenzhen S A comprehensive
Exclusion c analysis was c
Exclusion criteria: 1. Aged
 2. Pregnant or lactati
 3. Allergic to the test
Inclusion criteria:
 4. 1.
The2019underlying
adult patie dis
N/A China Xia Jiaan 1 Yintan R 31318629 +86 13871 Wuhan Jiny 2. The 5.
absolu CO
Inclusion criteria: (1) Patients diagno
N/A China Wu Wenjuan 1 Yintan R 88071718 +86 13397 Wuhan Jiny (2) Patients admitted
Exclusion c to the ICU
Exclusion criteria: 1. Age>
Inclusion criteria:
 2. 1.
After
Patients
CPR. who me
RetrospectChina Wu Wenjuan 1 Yintan R 13468014 +86 13397 Wuhan Jiny 2. ECMO-treated
 3. Accompanied
patients with by o
Inclusion criteria:
Exclusion
(1) criteria:
Comply with (1) Imp th
 (2) Aged (2)
18-80Those
years.with severe
N/A China Lixin Wang 507 Zhengm wlx1126@h+86 18917 Shanghai P (3) Those (3)
who Pregnant
voluntarily women
partic
Exclusion criteria: 1. Patie
 3. 1.
Inclusion criteria: Patients with activ
General/severe/
 4.
 2. Patients Patients
whose viralwith
nucleic tumo a
0 China Li Jiansheng 156 Jinshu li_js8@16 +86 371-6 He'nan Uni 3. Patients
 5.who
Patients
are characterize
wi
Exclusion criteria: 1. Peop
Inclusion criteria:
 2. 1.
Combined
Meet thewith diagno oth
 2. Pneumonia
 3. Patients
SeveritywithIndex hem(PS
N/A China Yaosheng Zhang, Jia 5 Hai-Yun-Czysjsgzs@ +86 18134 Dongzhimen 3. Aged 4.
18- Combined with sev
Exclusion criteria: 1. Rest
 2. Staff with respirato
N/A China Yongshi Jia 158 Shangtjiayongsh +86 13605 Zhejiang PrInclusion c 3. Staff who need the
0 China Xiangming Fang 299 Qingyanxiangming +86 13861 Wuxi PeoplInclusion c Exclusion c
Exclusion criteria: 1. Preg
 2. Combined with ca
0 China Wei Zhang Pulmonary zhangw119+86 13601 Shuguang Ho Inclusion c 3. Those with observ
Inclusion criteria: 1. Hospitalized pati
 2. Meet any one of the criteria f
 1) Respiratory
Exclusiondistress:
criteria:RP1. >=
Preg30
 2) At rest, thePeople
 2. oxygenwith saturation
allergi
0 China Tingrong Huang, Bangj6 Guangchafangbji@1 +86 0714- Huangshi H< 3. Patients with serio
Inclusion criteria:
Exclusion1. Patients
criteria: with
1. Seveco
 2. Above 2.
18 years
Estimated
old (inclusive)
Time of
4 China Xiaoyin Huang Nanbaixianzjwzhxy@1+86 13819 The First A 3. Voluntarily
 3. There
sign written
is clearinform
evid
0 China Lv Dongqing 1 Tongyanglvdq@enz +86 13867 Enze HospiInclusion c Exclusion c
Inclusion criteria: 1. Aged 18-75 year
 2. BodyExclusion
weight 40-100
criteria:kg1.and
InfecBM
 3. Been 2.
Confirmed
Used with
non-steroida
commo
 4. With 3.
fever,Have
respiratory
severetract
liver ad
0 China Jun Lin 169 Donghuwdznyy@1+86 13971 Zhongnan H 4. Those who are kno
Inclusion criteria:
 3. 1. ALTThe/ AST>
patients
5 ULN,wh
 2. Aged 4.
18 to Definite
85 years;diagnosis
4 China Xiaoling Xu 17 Lujiang xxlahh08@+86 18963 The First A 3. IL-6 2. Underwent
Exclusion chest
criteria:
CT scan
1. CT durim
0 China Bin Song 37 Guoxue songlab_r 86 28 854 West China 3. Able 2.to complete
Pregnant theand
study.lacta
Exclusion criteria: (1) Pati
Inclusion criteria:
 (2)(1) Patients
Complywho withhav th
N/A China Huang Luqi; Li Zhiqian 16 Nanxiaohuangluqi +86 010-6 China Acad (2) Agree 2. 1.
Inclusion criteria: Long-term
18 years applica
old <= a
0 China Zhan Zhang 3. Based
99 Zhangzhdoctorzha +86 18062 Renmin Hos 2. Pharyngeal swabs,on the resea
alveolar la
N/A China Chen Lei 37 Guoxuexleilei_25@ +86 18980 West ChinaInclusion c 2. Patients and healt
Inclusion criteria:
 2. 1. pregnant
Patientsordiagnos
lactati
 2. Be between
 3. Patients
18-85 years
with of menag
N/A China Mao Wei 54 Youdianmaoweilw +86 0571- The First A 3. Informed 4.consent
Those who and are
signedpar
0 China Nianzhi Zhang 117 Meisha13505615 +86 13505 The First A Inclusion c Exclusion c
Inclusion criteria:
Exclusion1. Aged
criteria:
>=181. to
Preg70
 2. Diagnosed
 2. 2019-nCoV
Those who are infecte
alle
4 China Qin Ning, Meifang Ha 1095 Jiefa 31531955 +86 27 83 Tongji Hosp 3. Understand 3. Severe
an cardiovascu
Inclusion criteria:
Exclusion(Allcriteria:
the following
(Subjec c
 1. Aged 1.
>= 18Patients
years; with a his
 2. Meet 2.
all thePatients
following with
criteria
hem
4 China Xia Jinyu 52 Meihua xRiajinyu@m+86 13823 The Fifth A (1) Epidemiological
 3. Patients hist
Inclusion criteria: Subjects participati
N/A China Nanshan Zhong, Zegu 151 Yanjingzheng862 +86 18928 The First A 1. General- Exclusion
severe c hospitalized p
Inclusion criteria: SARI
 1. An ARI with history of fever o
N/A China Min Xie 1095 Jiefa xie_m@12 +86 18602 Tongji Hosp 2. Surveillan
Exclusion c
N/A China Chengfeng Qiu 144 Jinxi R qiuchengf +86 14786 The First P Inclusion c Exclusion c
 2. Supplementation w
Inclusion criteria:
 3. 1.
Patients
Aged >= with
18 seve
year
0 China Jun Guo 37 Guoxue guojun@wc+86 15388 West China 2. Patients 4.
whoMalignant
meet thetumors;
diagno
Inclusion criteria: Suspected cases of
0 China Deng Guofang 29 Bulan R jxxk1035@+86 13530 Pulmonary Comprehensive
Exclusion analysis based o
Exclusion criteria: 1. Know
Inclusion criteria:
 2. 1.
Hormone
Adults (defined
therapy a
 2. Patients
 3.
with
Patients
new typewithofdiab
cor
0 China Ronghui Du 28 Baofengbluesearh +86 15337 Wuhan Pul 3. The 4.
time interval
Knownbetween
co sym
Inclusion criteria: 1) Medical staff inv
 2) 2019-nCoV infection suspecte
 3) Voluntarily participate in this
0 China Wen Shenglin, Xia Jin 52 Meihua wenshl@mai +86 13312 Department 4) A Exclusion cr
Exclusion criteria: ?Allerg
0 China Zhang Zhongde 111 Dade Rdoctorzzd +86 13903 GuangdongInclusion c ?Patients who do no
Exclusion criteria: 1) Know
 2) Confirmed hepatiti
Inclusion criteria:
 3) 1)
Acute
Agedrespiratory
>=18 years
0 China Hu bo, Li wei 1277 Jiefa hubo@mail+86 13707 Union Hosp 2) Patients 4)
with
According
new coronaviru
to the ju
0 China Zhang Zhongde 111 Dade Rdoctorzzd +86 13903 GuangdongInclusion c Exclusion c
Inclusion criteria: 1. Patients with no
0 China Fang Xueling 79 Qingchu13588867 +86 13588 The First A Exclusion c
Inclusion criteria: 1. Patients with no
0 China Cai Hongliu 79 Qingchucaiicu@16 +86 13505 The First A Exclusion c
Inclusion criteria: 1. Suspected case:
N/A China Lu Hongzhou 2901 CaolanLuhongzho+86 18930 Shanghai Pu Patients Exclusion
in observation
c period o
Inclusion criteria:
Exclusion
1. Sign
criteria:
the informe
1. Critic
 2. Aged (1)
>=18 years;
Respiratory failur
 3. Subjects
 (2)
diagnosed
Shock occurred;
as 2019-n
 (1) Detection
 (3)ofPatients
2019-nCoV
with nucl
othe
4 China Qu Jieming 197 Secondjmqu0906 +86 21 64 Ruijin Hosp (2) The 2 virus gene s
Inclusion criteria:
 2. 1.
Documented
Aged >=18 yearsallerg
 2. Patients
 3.
hasDocumented
been diagnosed histow
4 China Hong Shan 52 Meihua shanhong@+86 0756 The Fifth A 4. Documented histo
Inclusion criteria:
 2. 1.
There
Diagnosed
are comorbi
as no
0 China Lanjuan Li /Xiaowei Xu79 Qingchuljli@zju.ed +86 0571- The First A 1) Basis 3.
of diagnostic
The investigator
criteria: "Nbe
0 China Qiu Yunqing 79 Qingchuqiuyq@zju.+86 13588 The First A 2. Patients with novel
Exclusion c coronavir
Inclusion criteria:
Exclusion
1. Conforming
criteria: 1. Seve
to th
 2. Aged 2.
between
Clear18evidence
and 65 yearof b
0 China Xiaolin Tong 856 Luoyu Xiaolinton +86 13910 Hubei Prov 3. Signing 3.
thePatients
generalized
withinform
seve
Inclusion criteria: 1. Suspected and c
18-65 years old; 1. Clear
criteria:
0 China Tong Xiaolin 856 Luoyu 25241708 +86 18908 Hubei Prov 3. Signing theSerious
 2. generalprimary
informed di
Inclusion criteria:
Exclusion
1. 16
criteria:
to 75 years
1. Anyos
 2. Respiratory
 2. Patient
or blood refuses
samplesto
0 China Liu Yingxia 29 Bulan R yingxialiu +86 755 6 The Third 3. Within 3.
7 days
Pregnant
of onset:
or lactati
Onset
0 China Chengping Wen 548 Binwenwengcp@1+86 571 8 Zhejiang C Inclusion c Exclusion c
Exclusion criteria: 1. Have
0 China Pei Bei 15 Jiefang xyxzyxzh@ +86 18995 Xiangyang FInclusion c 2. Other circu
0 China Pei Bin 15 Jiefang xyxzyxzh@ +86 18995 Xiangyang 1Inclusion c Exclusion c
4 China Zhang Zhan 238 Jiefan doctorzha +86 18962 Renmin HosInclusion c Exclusion c
0 China Xie Chunguang 39 Shi-Er-Qxcg718@al+86 18980 Hospital of Inclusion Exclusion c
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. 75
Hype
ye
 2. Tested
 2.
positive
Bodyforweight
novel<40coro k
0 China Yunqing Qiu 79 Qingchuqiuyq@zju.+86 13588 The First A reaction 3.
(RT-PCR)-based
Considereddiagnoas seve
Exclusion criteria: 1. Aller
 2. 1.
Inclusion criteria: Body weight
18 to <40ok
75 years
0 China Qiu Yunqing 79 Qingchuqiuyq@zju.+86 13588 The First H 2. Tested 3. Considered
positive for novel ascoro
seve
Exclusion criteria: 1. preg
 2. Documented allerg
Inclusion criteria:
 3. 1.
Documented
Aged >=18 yearshisto
 2. Patients
 4.
hasDocumented
been diagnosed histow
4 China Jiang Shanping 102 Yanjia shanpingj +86 13922 Sun Yat sen * WHO. Clinical
 5. management
Documented of
histo
Inclusion criteria:
 2. 1.
ALT/AST
Aged 18-65
>5 UNL year
o
 2. been 3.
Confirmed
Severely
withill2019-nC
patient
 3. Sign 4.
the ICF;
Contraindication o
N/A China Wang Xinghuan/Ke He169 Donghuwangxingh +86 18971 Zhongnan H 4. no more 5.than
Pregnancy
10 days testing
from th
Exclusion criteria: 1) Any
 2) patients who have
 3) 1.
Inclusion criteria: noAdult
clinical
agedor chest
>= 18
0 China Jianping Zhao 4)
1095 Jiefa zhaojp@tjh+86 13507 Tongji Hosp 2. Patients In unexplained
with the state of no o
vira
Exclusion criteria: (1) The
0 China Wen Chengping 548 Binwenwengcp@1+86 13906 Zhejiang C Inclusion c (2) It is not suitable f
 (2) Patients have oth
0 China Chengping Wen 548 Binwenwengcp@1+86 13601 Zhejiang C Inclusion c (3) Patients allergy o
Inclusion criteria: 1. patients diagnos
 2. virus turned negative after tre
 3. agedExclusion
18-70 years old; 1. Patie
criteria:
 4. patients with
 2. clear consciousn
Pregnant or lactati
0 China Min Huang 11 Lingjiao 10258233 +86 13307 1. Xinhua a 5. Signing thePatients
 3. informedwho conhave
 3. Patients
Exclusion
diagnosed
criteria:
with
1. pulm
Patie
 4. aged 2.
18-70Pregnant
years old;or lactati
0 China Jixian Zhang 11 Lingjiao jxzhang16 +86 13377 1. Xinhua a 5. patients
 3.
with
Patients
cle who have
Inclusion criteria: Healthy children be
 (1) MainExclusion
features:criteria:
moderate
1. Clinic
bod
N/A China Su Wen 215 Zhongs78440452 +86 13659 Wuhan Hosp (2) Common
 2.manifestations:
Those who haveSym re
Exclusion criteria: 1. ARDS
 2. 1.
Inclusion criteria: suffering
diagnosisfrom HBV
of 201
N/A China Jiang Hua 32 Second cdjianghu +86 028 8 Sichuan Ac 2. adult 3.
patients
severe
agedheart,
18-80liver
yea
Inclusion criteria: 1. Patients with pn
N/A China Li Jiansheng 156 Jinshu li_js8@16 +86 371 6 The First A 2. To sign
Exclusion
informedc consent.
18-70 years
criteria:
old; 1. Patie
 3. patients with
 2. clear consciousn
Pregnant or lactati
0 China Wenguang Xia 11 Lingjiao docxwg@1+86 13377 1. Xinhua a 4. Signing thePatients
 3. informedwho consent
have
18-70 years
criteria:
old; 1. Patie
 4. patients
 2.
with
Pregnant
clear consciousn
or lactati
0 China Chanjuan Zheng 11 Lingjiao chanjuanz +86 18971 1. Xinhua a 5. Signing
 3.
thePatients
informedwho have
consent
18-70 yearscriteria:
old; 1. Patie
 4. patients
 2. with
Pregnant
clear consciousn
or lactati
0 China Wenguang Xia 11 Lingjiao docxwg@1+86 13377 1.Xinhua af 5. Signing 3.thePatients
informedwith consen
men
Exclusion criteria: 1) Preg
 2) 1)
Inclusion criteria: Severe basic
patients disea
diagnos
 2) The 3) Other problems
classification was judged th
0 China WANG YUGUANG, LI X23 Back StrZJHTCM@F+86 13902 Beijing Hos 3) Informed 4)consent.
Patients have diffi
Inclusion criteria: 1) Pneumonia patie
 2) The Exclusion
type of pneumonia
criteria: 1)waspatie
ju
4 China LIU QINGQUAN, MIAO23 Back StrZJHTCM@F+86 13902 Beijing Hos 3) Informed 2)consent.
patients were not
N/A China Xia Wenguang, An Cha11 Lingjiao DOCXWG@+86 13902 Hubei inte Inclusion c Exclusion c
 2. pregnant and lacta
Inclusion criteria:
 3. 1.Patients
patients complicat
with 20
0 China Li Jiansheng, Li Suyun 19 Renmin lisuyun20 +86 371 6 The First H 2. Sign 4.
informedClinica
consent.
 2. 1.
Inclusion criteria: Previous
aged 18serious
to 60 ye ch
 2. to be 3. Previous
confirmed withallergy
a expos to
0 China Wei Li 215 Zhongswhsdyyykj +86 13163 Wuhan 1st 3. with 4.fever, Newly
positivediagnosed
results of2
 2. Patients with seve
4 China Zhongqi Yang, Minyo 16 Jichang yang_zhon +86 13688 The First A Inclusion c 3. Patients who have
Inclusion criteria:
Exclusion1. 2019-nCoV
criteria: 1. Thos
infec
 2. nCoV 2.
nucleic
Patients
acid positive;
with a his
 3. Aged 3.
>=18 History
years; of hip or kn
0 China Dewei Zhao 6 Jiefang S zhaodewei +86 0411- Affiliated 4. 
N/A China ZHANG ZHONGDE, ZH 10 Poyang LZJHTCM@F+86 13902 Tianjin Uni Inclusion Exclusion c
Inclusion criteria: 1) Aged >= 18 yea
 2) Meet the diagnostic
Exclusion criteria:criteria
1) Seveo
0 China Tengxiao Liang, Tong 5 Haiyuncanshanghong+86 010 8 Dongzhimen 3) The 2)
informed consent form.
Obstruct
Exclusion criteria: 1) Patie
 2) Patients whose ini
Inclusion criteria:
 3) 1) Patients
Complywith withseve
the
0 China Huang Luqi 16 Nanxiaohuangluqi +86 010-6 China Acad 2) Agree 4)
to participate
It is difficult
in tto adm
Inclusion criteria:
Exclusion1. New
criteria:
coronavirus
1. Preg
 2. Meet 2.
the diagnostic
People with criteria
allergi
fo
4 China Zhong Nanshan / Song151 Yanjia ylsong70@+86 020 3 The First A 3. Pneumonia 3. Severe
Severitybasic
Indexdisea
(PS

 
 1. Adult SARI patients with
 
 2. Absolute value of lymph
 
Phase 2 3. Severe respiratory failur

 
 - 18-75 years old ,no gend
 
 - According to Diagnosis a
Phase 2 China ;; XingHuan Wang, profe;znyylcsy@;18971387 Wuhan Univ infection(Trial Version 4)
Inclusion criteria:
Exclusion
(1) criteria:
Comply with
(1) It th
is
N/A China Donghui Huang 53 Jidajin 13600001 +86 0756- Guangdong (2) Agree (2)
to paPregnant women
0 China Wanhong Yin 37 Guoxue doctorwhy +86 13518 DepartmentInclusion c Exclusion c
Inclusion criteria:
Exclusion
1) The
criteria:
confirmed
1) Anyp
 2) aged 2)
18 to Allergic
65 years;constitutio
New Treatm
China Le Aiping 17 Yongwaileaiping@ +86 13707 The First A 3) Real-time
 3)fluorescent
Being too old RT-PCRwith
Exclusion criteria: 1. Histo
Inclusion criteria:
 2. 1.Vascular
Aged 18-60embolismyear
 3.
 2. Patients Suspected
with or estab
clinical symptom
0 China Xue Zhigang 102 South xuezg@tong 4. Female
+86 15000 Hu'nan Yua 3. Voluntarily sign thepatients
informed of
Exclusion criteria: Exclusio
 1. Have a history of d
Inclusion criteria:
 2. (1)
female
Inpatients
patients agedwh
0 China Lu Hongzhou 2901 Caolan luhongzho +86 18930 Shanghai Pu (2) Persons
 3.diagnosed
People with 2019
Inclusion criteria:
Exclusion
(1) criteria:
Those who (1) mee
Imm
 (2) Inpatients
 (2)aged
Preparing
18 to pregna
75 yea
0 China Qianxue Chen 99 Jiefang chenqx666+86 027-8 Renmin Hos (3) Voluntarily
 (3) Patients
receive treatmen
with alle
Inclusion criteria:
Exclusion
Inclusion
criteria:of1.case
Thecrp
 1. Common
 2.type
Accompanied
patient: with by fe
c
0 China Yanling Zhao 100 West Fo zhaoyl285 +86 13681 The 5th Me 2. Severe 3.
pat have
Inclusion criteria:
 2) (1)
G-6PD
Confirmed
defect (Favpatie
 (2) Aged 3)
fromPregnancy,
18 to 80 years,especi m
0 China Yu Hongzhi 890 Jin'gu ykb@tju.ed+86 22 58 Haihe hospi (3) Patients
 4)with
Patients
positive
who detecti
conti
N/A China You Shang 1277 Jiefa you_shang +86 15972 Union HospInclusion c Exclusion c
Inclusion criteria:
Exclusion
Subjects
criteria:
who Subject
met
 1. Male 1.
or female
pregnant
patients
or lactati
aged
 2. willing
 2.
to sign
Malignant
informed tumors,
conse
2 China Jian Bo and Chuanzhu 28 Fuxing Rboj301@si +86 13801 Chinese PL 3. Based 3.
on theThose
criteria
whofor havesuspr
0 China Gong Shouping 157 West 5tshpingg@1+86 13709 The SecondInclusion c Exclusion c
Exclusion criteria: Patient
0 China Gong Shouping 157 West 5tshpingg@1+86 13709 the SecondInclusion c Investigator consider
Inclusion criteria: (1) All patients wer
 (2) Clear
Exclusion
mind, cooperation
criteria: (1) with
and
 (3) Men (2)
and women
Pregnantaged and 18lact
an
0 China Yuan Yongming Room 18A 064699629 +86 18664 Shenzhen na (4) informed
 (3)consent
Personshas who beenare sp
4 China Hongzhou Lu 9th Floor, luhongzho +86 21-37 Jiangxi Qin 2. Meet Exclusion
the diagnostic
c criteria fo
Exclusion criteria: 1) ARDS
 2) ARDS caused by ot
 3) Patients
Inclusion criteria: WHO grade III or I
are eligibl
 1) Aged 4)
18-75Patients
years; with mali
N/A China Zhang Wei 17 Yongwaizhangweil +86 13707 The First A 2) The <patient meets the ARDS d
Inclusion criteria:
Exclusion
1. Aged
criteria:
>=18 1. years
Patie
 2. Severed
 2.COVID-19
Patientspatients,
who have m
 RR>=30 3.
times/min;
Patients with shoc
N/A China Wang Shaogang 1095 Jiefa lingqing1 +86 15827 Tongji Hosp Rest 4. Patients combined
Inclusion criteria:
Exclusion
1. 16
criteria:
to 75 years
1. Anyos
 2. Respiratory
 2. Patient
or blood refuses
samples to
0 Liu Yingxia 29 Bulan R yingxialiu +86 755 6 Shenzhen t 3. A novel
 3.
coronavirus
Pregnant nucleic
or lactatiac
 2. Within 1 weekcriteria:
Exclusion of onset; 1. Any s
 3. Meet the diagnostic
 2. The patient criteria
may bo
0 China Xiaoguang Tong 6 Jizhao RoTongxg@y +86 13820 Tianjin Hu 3. Those who have co
Inclusion criteria: 1. COVID-19 diagno
 2. Excess specimens for clinical t
N/A China Hong Zhao 8 Xi-Shi-Ku zhaohong_+86 13810 Peking Univ 3. SignExclusion c consent f
the informed
Inclusion criteria:
Exclusion
1. aged
criteria:
between
1. preg1
 2. no history
 2.of history
gynecological
of psychiat di
N/A China Hua Lu 37 Shi-Er-Q19242380 +86 18980 Chengdu Un 3. willing 3.
to join
takethis
sedatives
researchinan t
N/A China Tian Feng 382 Wuyi Rotflook@16 +86 13934 The SecondInclusion c Exclusion c
0 China Mingxing Xie 1277 Jiefa xiemx@hus+86 13607 Union HospInclusion Exclusion c
N/A China XIONG YAN 363 Furongluyibingli +86 18328 West ChinaInclusion c Exclusion c
Inclusion criteria:
 3. Subjects
ALT / AST> who5 ULN,
meet
 1. Will 4.
sign written
Expectedinformed
survivalconi
4 China Huji Xu 415 Fengyaxuhuji@sm+86 13671 Shanghai C 2. Ch 5. Patients diagn
0 China Lianru Gao 6 Fucheng Rlianru666 +86 18600 The Sixth Inclusion c Exclusion c
Exclusion criteria: 1. Prev
0 China Mingxing Xie 1277 Jiefa xiemx@hus+86 13607 Union HospInclusion c 2. Previous severe em
RetrospectChina Haifa Xia, Xiangdong 1277 Jiefanxiangdong +86 15071 Union HospInclusion c Exclusion c
Exclusion criteria: 1. In th
Inclusion criteria:
 2. 1. Age between
Patients with psyc 18
0 China Xu Yong 85 Jiefang xuyongsmu+86 18234 The First H 2. The patient under isolation ob
Inclusion criteria: 1. aged 18-70 year
 2. 2019 new coronavirus nucleic
 3. meetExclusion
the national
criteria:
diagnosis
1. sevec
 4. subjects
 2.onset
pregnant
withinand8 days
nurs(
3 China Ke Hu 99 Zhangzhhukejx@16+86 18971 Renmin Hos 5. subjects 3.or subjects
a received l
Inclusion criteria: 1. In line with the d
N/A China Qingping Wu 1277 Jiefanwqp1968@+86 13971 Union Hosp< Exclusion c
 2. RT-PCR
Exclusion
positivecriteria:
for 2019-nCo
1. Inves
0 China Yin Zhenyu Room 507, Yinzy@xmu+86 13950 Zhongshan 3.
H The 2.
clinicalAssymptoms
judged by areinves
slig
Inclusion criteria:
Exclusion
1. Inpatients
criteria: 1.aged
Prev
 2. Confirmed
 2. patient
Patientsdiagnosed
diagnosed
0 China Bende Liu 1 Culture Aliubende9 +86 13907 First Peopl Cl 3. Patients diagnosed
Inclusion criteria: 1. Confirmed and s
 2. Meet the diagnostic
Exclusion criteria:criteria
1. Pregfo
 3. Clinical classification
 2. People with is "heavy
allergi
4 China Ma Penglin 49 North Humapenglin +86 13810 Peking Univ 4. Aged 3.
18 to Severe
75 years basic disea
Inclusion criteria: (1) Aged >=18 year
 (2) novel
Exclusion
coronavirus
criteria:
nucleic
(1) Itaci
is
 (3) The (2)
clinicalLight
typesorwere
severecommpa
N/A China Cheng Zhenshun 169 Donghuchzs1990@+86 02767 Zhongnan H (4) Informed (3)consent
Patientshas with
b dysa
Inclusion criteria: 1. The diagnosis co
 2. Clinical classification
Exclusion criteria:is1.norma
High
N/A China Xuebing Yan 9 Kunpeng yRxbxuzhou +86 15205 Affiliated 3. Subject aged
 2. The>=18
doctor believe
Exclusion criteria: (1) Diag
N/A China Kequn Chai 234 Gucui Rckqmzygzs +86 13906 Tongde HosInclusion c (2) Diagnosed with m
Inclusion criteria: 1. Aged 18 to 80 ye
 2. People
Exclusion
who had criteria:
ineffective
1. Theprp
New Treatm
Chinese Feng WANG 151 Yanjia 41247573 +86 13710 The First A 1) living,
 2.
studying,
People working
who have togea
Inclusion criteria: 1. novel coronaviru
 (1) 1 days beforecriteria:
Exclusion onset, 14 had
1. Exclu
0 China Huang Yi Xi'an Chesthuang-yi- +86 13319 Xi'an Chest (2) during
 2.
theExclude
14 daysthose
beforewho on
RetrospectChina Gang Xu 1095 Jiefa xugang@tjh+86 13507 Tongji HospInclusion c Exclusion c
Exclusion criteria: 1. Hype
Inclusion criteria:
 2. 1.Body
Aged weight
18 to<40
75 ye k
0 China Shentu Jianzhong?Wu 79 Qingchustjz@zju.e 1.4E+10 The First A 2. Patients 3.with
Considered
novel coronavir
as seve
Inclusion criteria: 1. Meet the diagno
N/A China Yao-sheng Zhang/Ting-5 Hai-Yun-Cysz3129@1+86 18610 Dongzhimen 2. Meet Exclusion
the diagnostic
c criteria fo
RetrospectChina Zhou Min 1095 Jiefa minzhou@t+86 15002 DepartmentInclusion c Exclusion
Exclusion criteria: (1) Sub
 (2)(1)
Inclusion criteria: Female patients
Age 18-70 o
years
 (3)
 (2) Clinical Highly allergic
symptoms, con
signs, and
N/A China Luo Zhigang 35 Jiefang 70688539 +86 13907 Second Hos (3) Clinical (4) Coagulation disor
symptoms,
 2. With risk factor of COVID-19;
 3. Access to nCapp platform;
N/A China Chunxue Bai 180 Fenglinbai.chunxu+86 18621 Zhongshan 4. to beExclusion
able to complete
c a 1 ye
0 China Qing Zhou 238 Jiefan qingzhou. +86 13971 Renmin HosInclusion Exclusion c
 2. Patients with a his
4 China Chaoqian Li 6 Shuangyo25347766 +86 13807 DepartmentInclusion c 3. The researchers ju
Inclusion criteria: 1. Female of after m
0 China Shixuan Wang 1095 Jiefa sxwang@tj+86 027-8 Tongji Hos 2. Meet Exclusion
the pneumonia
c diagnos
Inclusion criteria: 1)2019-nCoV-cured
0 China XiaoWang Qu 102 Luo-Jiaquxiaowan+86 15526 The First P 2)Sign Exclusion
informed cconsent.
Exclusion criteria: 1. The c
 1) Respiratory failure
Inclusion criteria:
 2) 1.Shock
Agedoccurs;
18 to 70 ye
N/A China Zhang Dingyu 1 Yintan R 18138863 +86 13507 Wuhan Jiny 2. Patients 3)
withCombined
severe novelfailure
coo
Inclusion criteria:
Exclusion
1. Volunteer
criteria: 1.toPlan
par
 2. Aged 2.
18-65Hospitalized
years, male for or fem
ot
 3. Weight
 5.
>= 40kg
Combined
and <=100kg,
with ser
N/A China Jing Liu 52 Meihua liujing25@ +86 13844 The Fifth A 4. Medical 6.
staff
Hasduring
fever,the
runnnove
Exclusion criteria: 1. Com
 2. Malignant tumor o
 3. pregnant or lactati
 4. suffer from severe
0 China Nanshan Zhong 151 Yanjia linling@gir +86 13902 The First A Inclusion c 5. H
Exclusion criteria: (1) Hyp
 (2) Favism;
 (3) Pregnancy;
 (4) Abnormal coagula
Inclusion criteria:
 (5)(1)People
In linewith
withmedi
ethi
 (2) Patients
 (6)
withSevere
positive
anemia;
detecti
 (3) Chest
 (7)
CT confirmed
Hypocalcemia;
pulmona
N/A China Chen Xiangdong 1277 Jiefa xiangdong +86 15071 Union Hosp (4) Hospitalized patients with fe
N/A China Tao Li 28 South Dixuntao26@+86 18980 West ChinaInclusion c Exclusion c
Inclusion criteria: (1) Patients with m
 (2) Aged more than 18 years old
N/A China Tang Jianyuan 39 Shi-Er-Qtangjiany +86 13910 Affiliated (3) Informed
Exclusion
consent
c of the pati
 3. 1.
Inclusion criteria: ALTThe/ AST> 5 ULN,
patients wh
 2. Aged 4.
18 to Expected
85 years; life<1 we
4 China Hongliang He 17 Lujiang 44271370 +86 15956 The First A 3. IL-1ÃŸ 5.
elevated
Definite
(using
diagnosis
Elisa m
Inclusion criteria:
Exclusion
(1) criteria:
Adult aged (1) >=1
The
 (2) Laboratory-confirmed
 (2) Patients with 2019-n
seri
3 China Baofeng Yang 194 Xuefu Ryangbf@em+86 133 04Heilongjian (3) Chest (3)
imagingPatients
(CT) confirmed
wi
4 China Hongyi Chen 167 HongduChenhongy+86 13807 Nanchang N 2. Pneumonia Exclusion patients
c with new
Inclusion criteria: 1. aged >=18 years
 2. Gender
Exclusion
limitation;
criteria: 1. patie
 3. Patients
 2.must
Patients
be able with
to auto
sign
0 China Peng Hu 301 Yancha189176831+86 18917 Shanghai 10 4. Be willing
 3.toH provide stool and
Inclusion criteria: 1. Voluntarily sign
 2. MaleExclusion
or female aged 18
criteria: 1. and
Fema o
2 China Zhaohui Tong 8 Workers 13910930 +86 13910 Beijing Cha 3. According
 2.to Males
the "Diagnosis
or femalesaw
 2. Patients with men
N/A China Jiang Hong 650 Xinsongjhong.pku +86 15301 Shanghai Ge Inclusion c 3. Minors
Inclusion criteria: (1) Meet NCP critic
 (2) Volunteer
Exclusionto criteria:
participate
1. Patie
in th
 (3) The 2.
selectedPregnant
patients orwere
lactatib
0 China Fang Lei 1200 Cailu fanglei58 +86 021-5 Faculty of (4) No 3.
seriousPa ment
Inclusion criteria:
Exclusion
1. The
criteria:
age at
1.the
In thti
4 China Yin Zhenyu 201-209 HuYinzy@xmu+86 13950 Zhongshan 2.
H The 2.
changeAccord
of typical viral pn
Inclusion criteria: 1. Male or female,
 2. 2019 new coronavirus nucleic
 3. Diagnosed
Exclusionas moderate
criteria: 1.toMalig
sev
1-Feb China Robert Chunhua Zhao 5 Shantiao zhaochunh+86 010-6 institute o 4. Wi 2. The clinical predicti
Exclusion criteria: 1. critic
Inclusion criteria:
 2. 1.Patients
Aged >=60with years
eye d
 3.
 2. Patients Severe liver
confirmed withdiseas
nove
4 China Feng Cao 28 Fuxing Rfengcao88 +86 13911 Chinese PL 3. Those 4. Patients
without broad
Inclusion criteria: 1) Male and female
 2) Severe
Exclusion
patients
criteria:
(in any1)case:
Caser
 3) Within
 2)
12 days
Pregnant
after illness
and lactaon
4 China Zhao Yan 169 Donghudoctoryan +86 13995 Zhongnan H 4 3) The subjects recei
Inclusion criteria: (1) nurses with wo
 (2) registered
Exclusionnurses
criteria:
who(1)areadva
qu
N/A China Caixia Xie 32 West Se8999578@+86 13699 Sichuan Ac (3) nurses (2)
whonurses
volunteered
during tothep
 2. A history of fertility or sexual
0 China Shixuan Wang 1095 Jiefa sxwang@tj+86 02783 Tongji Hos 3. Meet Exclusion
the pneumonia
c diagnos
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. 60
Patie
ye
 2. Inpatients
 2.whoPregnant
meetor thelactati
diag
0 China Fang Min 110 Ganhe fangmin19 +86 18930 Tuina Insti 3. Understand
 3. Paand agree to
Exclusion criteria: 1. The s
Inclusion criteria:
 2. 1.Those
Patients
withorsevere
his/h
0 China Dong Liang 1377 Jiao- dl5506@12+86 18560 Qilu Hospit 2. Those < diagnosed with mild or
Exclusion criteria: (1) Posi
 (2) Respiratory failur
Inclusion criteria:
 (3)(1)People
Aged with
18-65metayea
 (2) Virus
 (4)
nucleic
active
acid tuberculosi
test is posi
N/A China Chen Hong 1095 Jiefa chenhong1+86 13296 Tongji Hosp (3) Lung (5)
CT showed
Massivemultiple
pulmona pat
0 China CHEN Xinyu 95 Shaoshachenxinyu +86 13807 The First A Inclusion c Exclusion c
Inclusion criteria: 1. The neonates de
N/A China Jun Tang 20 Third S tj1234753 +86 18180 West China 2. The Exclusion c
newborn,whose mother h
N/A China Tang Jianyuan 39 Shi-Er-Qtangjiany +86 13910 Hospital of Inclusion c Exclusion c
Inclusion criteria: 1. Diagnosed Nove
 2. Aged 18 to 65 years;
4 China Yang Yi 4 Garden H15326774 +86 18971 Hubei Hospi 3. The Exclusion
time interval
c between sym
Inclusion criteria: 1. Aged >18 years;
 2. Laboratory (RT-PCR) confirme
RetrospectChina Lyu Dongqing 1 Tongyanglvdq@enz +86 13867 Enze Hospi 3. LungExclusion
involvement confirmed
N/A China Peng Yudong 1277 Jiefa am-penicil +86 13886 Union HospiInclusion c 2. Patients with syste
Exclusion criteria: 1. Invol
Inclusion criteria:
 2. 1.Pregnant
Severe patients
or breastf
 2. Aged 3. Presence
35 years old to of
74other
years
 4.
 3. Patients or Expected
authorized life is les
family
4 China Junbo Ge 180 Fenglinjbge@zs-ho-64041925 Zhongshan 5. Allergy to ALA or d
Exclusion criteria: 1. The p
Inclusion criteria:
 2. 1.People
18 years
witholdheart
<= a
0 China Zhan Zhang 99 Zhangzhdoctorzha +86 18062 Renmin Hos 2. Who 3. are in Peo
close contact with
Exclusion criteria: 1)One o
Inclusion criteria:
 Respiratory
1) Aged >=distress,
18 year
 2) In line
 At
with rest,
the diagnostic
oxygen satur crit
4 China Xin Zheng 1277 Jiefa Xin11@hot+86 18602 Union Hospi 3) Severe Atrial
pneumoniaarterial
indexoxygen
(PSI
Exclusion criteria: 1)One o
 Respiratory
Inclusion criteria: 1) Aged >=distress,
18 year
 At
 2) In line with rest, oxygen satur
the diagnostic crit
4 China Xin Zheng 1277 Jiefa Xin11@hot+86 18602 Union Hospi 3) Severe Artial
pneumoniaarterial
indexoxygen
(PSI
 who had diagnosed a
4 China Zhuoli Zhang 8 Xishiku S zhuoli.zh +86 13901 The First h Inclusion c who was allergic to 4
 1. For the 2019-nCoV infecti

 
 
 Diagnosed with 2019-nC
 
China ;;;; Kunling Shen, MD,Ph ;;;xubaop ;;;8610596 Beijing Chi 1. Respiratory or blood

 
 1. Age =18 years;
 
 2. Laboratory (RT-PCR) dia
Phase 2 ; Jinglin Xia, MD;Jinglin ;xiajingli ;0577-555 First Affil fifth edition of the Chine

 
 
 2. The laboratory (RT-PCR)
Phase 2 ; Jinglin Xia, MD;Jinglin ;xiajingli ;0577-555 First Affil CoVID-19 (refer to the fift

 
 - Men and women aged 1
 
 - In line with the new coro
Phase 1/PhChina ; Jianqi Lian, MD;Sicao Lliangjq@f +86-13571892829;+86 (trial version 4) issued by
 
 - High risk of COVID-19
 
 - RT-PCR test result of SAR
 
 
 - Not available for RT-PCR
N/A China ;; Chunxue Bai;Chunxue ;bai.chunx ;+8618621 Shanghai Re 

 
 - Patients with pulmonary
 
 - Age 18-65
 
Phase 2 China ; Chenghai Liu, PhD;Chechenghaili 8621-20256521; - 2019-nCoV nucleic acid n

 
 1. Epidemiological history
 Hubei province or exposu
 
China ;; Liang Peng, Doctor;We;xwx1983@;+8613760 Third Affil 2. Sympto

 
 1. Epidemiological history
 Hubei province or exposu
 
China ;; Liang Peng, Doctor;We;xwx1983@;+8613760 Third Affil 2. Sympto

 
 - The neonates with COVID
 
 
 - The neonates with majo
N/A China 

 
 - The patients who were d
 factors) and severe cases
 
 - Aged 18 to 85 years;
Phase 2 China ; Ying Fu;Wan-Jin Chen fuying199 +86;+1386061359 <
Exclusion criteria: Allergy
0 Ma Xiaorong 157 West 5tmaxr0910 +86 13992 the SecondInclusion c Pregnancy
Inclusion criteria:
Exclusion
1. aged
criteria:
between
1. Hear
1
 2. clinical
 2.
dignosied
New myocardial
2019-nCovisp
 3. Cured 3.
within
Severe
one month
liver and
of di
ki
1 China Nijun 20 Chazhong
nijun1000 +86 19890 The First A 4. consious,em
 4. Oxygen saturation
Inclusion criteria: (1) Aged 20-45 yea
0 China RongJin Lin 20 Chazhong
nplrj@126 +86 13809 The First A (2) Understand
Exclusionandc willing to pa
Exclusion criteria: (1) kno
Inclusion criteria:
 (2)(1)women
aged >=18
who year
are b
0 China Shao Fengmin 7 Weiwu Roguyuesunn+86 15037 He'nan Prov (2) positive
 (3)
COVID-19
partic nucleic ac
Inclusion criteria:
Exclusion
1) confirmed
criteria: 1)or patie
sus
 2) be able
 2)
to understand
patients with themen
con
N/A China Dong Shang 9 West Sectshangdong+86 18098 Institute o 3) voluntarily
 3) patients
participatewithin serio
this
Exclusion criteria: 1. Hear
Inclusion criteria:
 2. 1.New
Agedonset
18-80
of myo
year
 2. Meet 3.
the diagnostic
Blood pressure:
criteriamo
 3. Blood 4.
pressure
Body90-150
temperature
/ 60-1
N/A China Ni Jun 20 Chazhonnijun1000 +86 19890 The First A 4. Extrem
 5. Blood o
Exclusion criteria: 1. Cann
Inclusion criteria:
 2. 1.Those
Agedwho 18 to
are 75alle
ye
 2. Inpatients
 3.with
Critical
novel
patients
coronav m
N/A China Zhang Dingyu 1 Yintan R 18138863 +86 13507 Wuhan Jiny 3. Agree (1)
and sign
Respira
the informed c
Exclusion criteria: 1. Pneu
RetrospectChina Chuxiao Shao 289 Kuocang scx1818@1+86 0578 Lishui CentInclusion c 2. Not receiving antiv
Inclusion criteria: 1. confirmed clinica
 2. inpatients have confirmed clin
RetrospectChina Kunlun He 28 Fuxing Rhekl301@a+86 010 6 Key Labora 3. the CTExclusion
imagescare complete, t
Exclusion criteria: 1. Othe
 2. Known to be allerg
0 China Jianzhong Liu 4 Garden Hljzwd@163+86 13307 Hubei ProvInclusion c 3. Women during lac
RetrospectChina Ziqiang Zhang 389 Xincunzzq1419@1+86 18721 Tongji HospInclusion c 3. Cancer patients.
Inclusion criteria: Moxibustion interv
 Participants
Exclusion
inclusion
criteria:
criteria:
(1) Pati
 1. Aged (2)
18 to 75Those
yearswith
old;malign
 2. Those (3)
that meet
Persons
onewith
or more
a me
0 China Xiaorong Chang Hanpu Sciexrchang19 +86 0731 Hu'nan Uni (1)In the (4)
pa preg
0 China Zhongyu Zhou 4 Huayuan 22094479 +86 18672 Hubei ProvInclusion c Exclusion c
Inclusion criteria:
Exclusion
Thiscriteria:
study intends
(1) Excl
N/A China Yan Hao; Xiaoping Luo1095 Jiefa haoyaner@+86 13971 Tongji Hosp 1. Epidemi
 (2) Exclude pneumon
Inclusion criteria: 1. Age is not limite
0 China Yongxiang Yi 1 Kangfu Roian0126@1+86 13338 Nanjing Se 2. Confirmed
Exclusiongroup:clinical
c diag
Exclusion criteria: 1. AST a
 2. bilirubin> 1.5 x ULN
Inclusion criteria:
 3. 1.AtFirst
visit diagnosis
1, calculate o
0 China Huilan Zhang 1095 Jiefa huillanz_ +86 15391 Tongji Hos 2. Epidemiological
 4. Patientshistory
withTrave
pote
RetrospectChina Zhenhua Zhang 678 Furongzzh1974cn +86 13215 The SecondInclusion c Exclusion c
Inclusion criteria: 1. Front line medic
 2. Participate in the prevention
 3. Voluntary to finish
Exclusion psychologi
criteria: 1. refus
N/A China Ming Chen 136 Jingzh 55815147 +86 13797 Xiangyang C 4. without psychological
 2. with mentalhistory
disord
Inclusion criteria: 1. Confirmed or cli
>= 2 years;
criteria: 1. With
0 China Ming Chen 136 Jingzho55815147 +86 13797 Xiangyang C 3. Volunteers.
 2. Patients who refus
0 China Lu Yibin 1 Siyi Road luyb6810@+86 13937 Xinyang CenInclusion c 2. Pregnant or lactati
 2. With trachea dysfu
 3. pregnant women,
N/A China Hu Bing 37 Guoxue hubingnj@+86 18980 West ChinaInclusion c 4. Patients with diffic
Inclusion criteria:
Exclusion1. Suspected,
criteria: (1)mild,
Kno
 2. Aged (2)
>= 18 years;
Unwilling to coop
0 China Wang Tan 1478 GongnWangtan21+86 13756 Affiliated 3. Patients (3)whoPatients
voluntarily
withparti
men
Inclusion criteria: 1. Confirmed or cli
> 1 year;criteria: 1.With
0 Rui Pan 136 Jingzh 55815147 +86 13986 Xiangyang C 3. Volunteers.
 2.refuse to traditiona
0 China Li Caixia N1 Shangchli_caixia@z+86 15268 The Fourth Inclusion c Exclusion c
Inclusion criteria: 1. be over 18 years
 2. 2019-nCoV infected patients c
RetrospectChina Feng Li 2901 Caolan dr_lif08@ +86 18121 Shanghai Pu 3. Subjects
Exclusion
and their
c families (or
N/A China Jiemin Zhu Room 222, jieminzhu +86 15960 Xiamen UniInclusion c Exclusion
 2. Underwent
Exclusion chest
criteria:
CT scan
1. CT dur
im
RetrospectChina Kaihu Yu 228 Jingui 20662556 +86 13508 Xianning Ce 3. Able 2.
to complete
Pregnant theand
study.
lacta
 2. It conforms
Exclusion tocriteria:
the diagnostic
1. Serio
0 China Kaijiang Yu 23 Youzheng drkaijian +86 13303 The First A 3. Sign 2.
the informed
Obstrucconsent for
N/A China WANG Jing 169 Donghuwangjing9 +86 18186 DepartmentInclusion c Exclusion c
N/A China Jihui Lyu 118 Wenquan lvjihui@13 +86 010 6 Beijing GerInclusion c Exclusion c
Exclusion criteria: (1) Age
 (2) Patients with seve
0 China Meiping Chu 1215 Guangchump198 +86 15052 Wuxi Fifth Inclusion c (3) Pregnant and lact
Exclusion criteria: 1. No m
Inclusion criteria:
 2. 1.Patients
novel coronaviru
who had r
 2. enteral
 3.nutrition
patientssupport
with hypetrea
0 China Lijia Deng 94 West Str27216302 +86 17723 Ganzi Hospi 3. No use 4.
of Fat
patients
emulsion
withtaboo
seve
N/A China Junxue Wang 415 Fengyadocd1@sin+86 18917 Shanghai C 2. PneumoniaExclusion patients
c with new
Inclusion criteria: (1) Adults aged >=1
 (2) a novel coronavirus infection
0 China Wei Yang 37 Yiyuan Shydyangw +86 13845 The Fourth (3) Hospitalized
Exclusion patients
c with fe
RetrospectChina Li Jiangping 1 Benxi Str 10784044 +86 18602 Puren HospInclusion Exclusion c
Inclusion criteria: 1. Patients with co
 2. TCM syndrome differentiation
 3. Aged between 18-75 years ol
4 China Liu Hua/Wang Qian 1200 Cailu yyliuhua@ +86 18930 Shanghai Un 4. V Exclusion c
1 China Lijia Deng 94 West Str27216302 +86 17723 Ganzi HospiInclusion c Exclusion c
RetrospectChina Zhenjie Hu 12 Jiankangsyicu@vip. +86 13933 The Fourth Inclusion c Exclusion c
Inclusion criteria:
Exclusion1. Aged
criteria:
18 to1. 80
Patieye
0 China Zhou Jia 110 Ganhe pdzhoujia +86 18017 Yueyang Ho 2. Patients 2. with
Patients
novel coronavir
wh
N/A China Daisy Dexing Zhang 4/F, Schoolzhangdxda +852 2252 JC School Inclusion c Exclusion c
N/A China Bin Zhan 16 Railway 40630252 +86 13678 The Thirte Inclusion c 2. Patients and healt
Inclusion criteria: 1) Any age;
 2) Meet Exclusion
the diagnostic
criteria:standard
1) Liver
 3) Voluntarily
 2) Psychosis,
accept TCM orsyndr
cogn
New Treatm
China Bi Ying-fei 88 Changlinyingfei19 +86 13920 First Teach 4) Agree 3) Those
to sign who aconse
informed
Inclusion criteria: (1) Aged >=18 year
 (2) Novel
Exclusion
coronavirus
criteria:
pneumon
(1) Mee
N/A China Xie Liangdong Chizhuling 25904100 +86 13707 Fifth Peopl (3) The (2)
patientSevere
himselfprimary
participa di
Inclusion criteria:
Exclusion1) The
criteria:
confirmed
1) Anyp
 2) aged 2)
18 to Allergic
65 years;constitutio
0 China Shao Yi 17 Yongwaifreebee99 +86 13576 The First A 3) The 3)
time interval
Severebetween
basic disea th
Inclusion criteria:
Exclusion
1. Patients
criteria: volunte
1. Peop
2 china Zhiyong Peng 169 DonghuPengzy5@h+86 18672 Central So 2. Patients 2.
whoHaving
werereceived
diagnosed Va
0 Cancelled Cancelled wdxjy@wh 123 Cancelled Inclusion c Exclusion c
N/A China XIONG YAN 363 Furongluyibingli +86 18328 West ChinaInclusion c Exclusion c
Exclusion criteria: 1) Child
RetrospectChina Chen Hao 116 North S10418633 +86 023 6 Chongqing Inclusion c 2) lack of important c
Inclusion criteria:
Exclusion
(1) criteria:
Age 18 to (1)80Pati
ye
 (2) Respiratory
 (2) Patients
specimen withwereknop
4 China Liangdan Sun 218 Jixi Ro ahmusld@ +86 13856 First Affil (3) Clinical
 (3)
classification
Patients withis mild
seveo
 2. Non-suspected
Exclusion criteria:
and non-confi
1. Susp
 3. Front-line
 2.medical
Patientsstaffs
with in seve
de
4 China Feng Cao 28 Fuxing Rfengcao88 +86 13911 Chinese PL 4. Participate
 3. People
voluntarily
whoandcould sig
Inclusion criteria: 1. Patients withmil
 2. Patient cough criteria:
Exclusion score > 1;1. Expe
4 China Wei Zhang 17 Yongwaizhangweil +86 0791- The First A 3. Aged 2. Patients with asthm
 2. Patients with seve
4 China Hua Shucheng 71 Xinmin Sshuchengh +86 13756 The First HoInclusion c 3. Severe liver diseas
RetrospectChina Kaihu Xiao 165 Xinchexiaokh1@1+86 19923 Chongqing Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Hospital
criteria: workers
1. Patie
RetrospectChina Yu Jia 99 Zhang-Zyogaqq116+86 18062 Renmin Hos 2. Aged 2. >=18 Patients
years old.who are n
 2. Patients with confirmed
Exclusion criteria: 1. cases
Patie
 (1) Epidemiology
 2. Patientshistory;
with serve
4 China Shen Ning 49 Huayuanshenning1 +86 15611 Peking Univ (2) Clinical manifestations
 3. Patients with(epide iden
Inclusion criteria:
Exclusion
1. Age
criteria:
18 to1 75
Patien
Ye
 2. Diagnosed
 2 Patients
with COVID-19,ac
with serve
4 China Shen Ning 49 Huayuanshenning1 +86 15611 Peking Univ 3. Sever 3
COVID-19,
Patientsexcept
with identi
shoc
RetrospectChina Wang Hailong 165 Xinchewangjinlo +86 15923 Three GorgInclusion c Exclusion c
Inclusion criteria:
 1. Subjects
Patients whowith meet
prev
 1. Sign 2.
writtenPatients
informed withconsen
prev
4 China Wenxiang Huang 1 Youyi Roawenxiang_ +86 13883 The First A 2. Chinese
 3. Patients with s
 1. Subjects
Inclusion criteria: Patients whowith meet
prev
 1. Sign 2.
writtenPatients
informed with prev
consen
4 China Wenxiang Huang 1 Youyi Ro wenxiang_ +86 13883 The First A 2. Chinese
 3. Patients with s
Inclusion criteria:
 2. 1.
Severe
Informed
renalconsen
impa
 2. Confirmed
 3. infection
Severe liver withdiseas
201
4 China Huawei Mao 136 Secondmaohwei@+86 13928 Chongqing 3. Compliance with the interven
 4. Pre-exist
Exclusion criteria: 1. Seve
Inclusion criteria:
 2. 1.
The Aged
patients
18- 80wereyea
0 China Peng Hu 74 Lingjian hp_cq@16 +86 13608 The Second 2. Pneumonia
 3. Patients
patientswith
withcontnew
 2. Death is expected
4 China Liu Dong 1095 Jiefa ld_2069@1+86 13507 Institution Inclusion c 3. There is clear evid
Exclusion criteria: 1. Mee
Inclusion criteria:
 2. 1.
Meets
Staff any
of tongji
contraiho
RetrospectChina Liu Dong 1095 Jiefa ld_2069@1+86 13507 Tongji Hosp 2. Aged 3.
>=18 Pregnant
years. women,
Inclusion criteria: (1) 18â€“65 years o
 (2) Diagnosed
Exclusion ascriteria:
mild to modera
(1) Pati
 (3) Be willing
 (2)toPatients
sign informed
are pregn co
N/A China Yaokai Chen 109 Baoyu yaokaiche +86 023-6 Chongqing (4) The (3)
clinicalPatients
assessmenthaveand aspc
Inclusion criteria: 1. Male or female o
 2. NovelExclusion
coronavirus
criteria:
infection
1. Patie
is
 3. The 2.
diagnosis
Pregnancy
of severeorcoron
lacta
N/A China Yaokai Chen 109 Baoyu yaokaiche +86 13638 Chongqing (1) Re 3. Researchers believ

 
 1.Willingness of study parti
 consent; 2.Male or female,
Phase 1 ; Jie-ming Qu, MD.,PhD.;jmqu0906 ;+86-21-6 Ruijin Hosp confirm

 
 - Who agree to participate
 
 
 - Confirmed NCIP patients
N/A China ;; Yan Liu;Xiaotian Sun;Y;xiaotian ;+86-0106 The Fifth M 

 
 (1) Age = 18 years. (2) Clinic
 pneumonia include: on the
Phase 3 China ; Huilan Zhang, PD;Huil huilanz_7 15391532171; following

 
 - all patients suspected of
 
 
 - patients' data are not av
N/A China 

 
 1. Subjects or their legal re
 agree not to participate i
Phase 4 ; Ronghua Jin;Huiguo D ;dinghuig ;+86-1391 Beijing You a
0 China Guojun Zhang 1 Jianshe zlgj-001@ +86 13673 The First A Inclusion c Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
Aged >=18 (1) year
Pati
 (2) novel
 (2)
coronavirus
Pregnant pneumoni
or lacta
RetrospectChina Xiaoyang Lu 79 Qingchuluxiaoyang +86 13605 The First A (3) Patient
 (3) Patients whose G
N/A China Yunxia Zuo 37 Guoxue zuoyunxia +86 18980 DepartmentInclusion c Exclusion c
Inclusion criteria: 1. Patients who we
RetrospectChina Jiang Shujuan , Jinan, S docjiangs +86 15168 Department 2. Patients
Exclusion c
who agreed to enroll
Exclusion criteria: (1) Chro
Inclusion criteria:
 (2)Patients
Cardiorenal
with insuffi
new
N/A China Liu Yi 324 Jing-Wu15168888 +86 18660 Shandong P (3) Pregnant women
18 to 90criteria:
years; 1. Preg
0 China Mei Heng 1277 Jiefa hmei@hust+86 13886 Union Hosp 3. Sign 2.
the written
Patients
informed
with mencon
Inclusion criteria:
Exclusion
Thiscriteria:
study intends
(1) Excl
N/A China Yan Hao; Xiaoping Luo1095 Jiefa haoyaner@+86 13971 Tongji Hosp 1. Epidem (2) Exclude pneumon
 2) Patients with prev
RetrospectChina Zhang Huafen 79 Qingchuzhanghuaf +86 13757 The First A Inclusion c 3) The investigator b
Exclusion criteria: 1) < 18
 2) pregnant and lacta
N/A China Wang Hongyang 225 Changhhywangk@v+86 13801 The Third AInclusion c 3) patients with men
Inclusion criteria: COVID-19 group:
 1. Age>Exclusion
= 18 years criteria:
old, noCOVID-
gende
 2. Patients
 1. withPatients
covid-19 without
determ s
0 China Hu Liu 107 Huanhudrliuhu@g +86 13866 Anhui Canc 3. Total 2. Patients
bilirubin <=1.5who
UNL,usedasp
Inclusion criteria: 1. Aged > 18 years;
 2. COVID-19
Exclusion coronavirus
criteria: 1.
nucleic
Child
 3. Chest 2.
imaging Serious
has clear
cardiopulm
viral p
0 China Li Shusheng 1095 Jiefa shushengl +86 13971 Department 4. Respirat
 3.
Exclusion criteria: 1) <14 y
 2) 1.
Inclusion criteria: pregnant
Have any women;
of the
 3)
 (1) travel ICUor
history hospital
residencestayhi<
RetrospectChina Minghao Fang 1095 Jiefa Fangmh@tj+86 15071 Emergency (2) close 4)
contac The necessary clin
N/A China Chen Xiao 627 Wuluo cxfn817@1+86 13986 Central TheInclusion c Exclusion c
Inclusion criteria: Patients diagnosed
 Mild group
RetrospectChina Ying binwu 37 Guoxue binwuying +86 18980 West China Diagnosed Exclusion
patientsc classified as
N/A China Ye Wan 1999 Guank41743383 +86 13806 Xiamen Med Inclusion c Exclusion c
Inclusion criteria: 1. Adult patients co
 2. Patients
Exclusion
with clear
criteria:
manifestati
1. Patie
0 China Li Shusheng 1095 Jiefa shushengl +86 13971 Tongji Hosp 3. Patients
 2. requiring
Pregnant oxygen
women. the
Exclusion criteria: (1) Com
 (2)1.Combined
Inclusion criteria: Aged 18 to with m
75 ye
 (3)
 2. Real-time Pregnant orRT-PC
fluorescence lacta
4 China Xu Zhihua Mianyang C11217338 +86 18508 Mianyang C 3. Sequencing
 (4) Suffer
of virus genes in r
Inclusion criteria: 1. Laboratory confi
 2. Clinical classification is mild o
 3. LungExclusion
involvement criteria:
confirmed
1. Patie
0 China Chuantao Zhang 39 Shi-Er- 10357887 +86 13880 Affiliated 4. Hospitalised
 2. Pawith: Fever: axill
Inclusion criteria: (1) Aged 18 years o
 (2) Real-time
Exclusion fluorescent
criteria: (1)
RT-PCR
Kno
 (3) Clinical
 (2)classification
Mild and severe
is comm p
0 China Yuanrong Dai 109 Xueyua13968888 +86 13857 the Second (4) Signed (3)
informed
Combinedc with se
 2. 1.
Inclusion criteria: blood
agedpurification
>=18 years
 3. conformed
 2. laboratory patients hadSARS-C
other
0 China Xiaowei XU 4.
79 Qingchuxxw69@12+86 13605 The First A 3. critically allergic
ill and to dimethy
require intens
Exclusion criteria: (1)Peop
Inclusion criteria:
 (2)(1) people
Chinesewho residen
can't
 (2) People
 (3)people
aged between who18 can't
and
N/A China Zhongyuan Xia 238 Jiefan wenqin-19 +86 13808 Renmin Hos (3) People have electronic
 (4)people socia
who can't
RetrospectChina CHEN Xinyu 95 Shaoshachenxinyu +86 13807 The First A Inclusion c Exclusion c
0 China Kang Yan 37 Guoxue Kangyan@s+86 18980 West ChinaInclusion Exclusion c
Inclusion criteria: Must meet all of th
 1. aged 18 to 75 years male or fe
 2. BodyExclusion
Weight 40-100kg,
criteria: 1.andaccoB
0 Wang Hao Zhiyin Avenwanghaohh+86 13901 Huo-Shen-S 3. to meet Note:
the diagnostic
those who criteria
com
Exclusion criteria: 1. COVI
 (1) Those who refuse
Inclusion criteria:
 (2)1.Pregnant
COVID-19 women
suspe
 1.1 Diagnostic
 (3)Patients
criteria for
withsuspec
men
 1.1.1 History
 2. ofnon-COVID
Epidemiology:
health
0 China Xufang Sun 1095 Jiefa s_186277 +86 18627 Department (1) Those who refuse
Exclusion criteria: (1) kno
Inclusion criteria:
 (2)(1)women
aged >=18
who year
are b
0 China Li Suyun 19 Renmin 38797527 1.39E+10 The First A (2) positive
 (3)COVID-19
partic nucleic ac
Exclusion criteria: 1. Age <
 2. Pregnant;
Inclusion criteria:
 3. 1.Patient
Meetsis2019
irritable
nov
RetrospectChina Shusheng Li 1095 Jiefa shushengl +86 13971 Eergency / 2. Under 4.
non-invasive
Intubation-mechan
ventilatio
N/A China Jie Luo 32 Renmin 18219024 +86 0719 Shiyan TaihInclusion c Exclusion c
Inclusion criteria: (1) All confirmed a
N/A China Yong Huo No.8 Xishikdrhuoyon +86 13901 Peking Univ (2) Voluntarily
Exclusionagree
c to enter th
 2. Patients who are d
4 China Chen Zhenshun 169 Donghuchzs1990@+86 13627 Zhongnan HInclusion c 3. Severe immunosup
Exclusion criteria: 1. Any s
Inclusion criteria:
 2. 1.Patients
Aged >=18
who years
have
 2. Clinically
 3. diagnosed
No clinicalpatients
manifesw
4 China Huilan Zhang 4.fluorescent
1095 Jiefa huilanz_7 +86 15391 Department (1) real-time Known allergy or h
RT-PCR
Inclusion criteria: 1) Confirmed or cli
 2) Those who have been identifi
 3) Inpatients
Exclusionagedcriteria:
18 to 75
1) Patie
year
0 China Zhijun Fang 100 Cross fangzjnj@h+86 13372 Affiliated 4) Vo 2) According to the r
Inclusion criteria: 1. Written informe
over 18 years;
criteria: 1. Resp
 3. Fullfill
 2.
the diagnostic
Comorbidities
criteria
inclu
o
0 China Xuemei Li 1 Shuai-Fu-lixmpumc +86 13911 Peking Uni 2019-nCoV 3. diagnosis
Concurrentconfirmed
use of
Inclusion criteria: 1. Written informe
over 18 criteria: 1. Resp
 3. Fullfill the diagnostic
 2. criteria
Comorbidities o
inclu
0 China Xuemei Li 1 Shuai-Fu-lixmpumc +86 13911 Peking Uni 2019-nCoV 3. diagnosis
Concurrentconfirmed
use of
N/A China Ye Gu 85 Heping Ssylykjk@1 +86 18502 Shenyang S 2. Pneumonia
Exclusion c
patients with new
Exclusion criteria: (1) Fem
Inclusion criteria:
 (2)(1)Patients
Patientsallergic
aged frt
4 China Chen Chunbo 101 Weimi gghicu@16+86 13922 Maoming Pe (2) Mild (3)
patients
Patients
with confirmed
who are
 2. 1.
Inclusion criteria: Acute respiratory
Real-time fluored
0 China Xiuming Song 528 ZhanghXiumingso +86 13817 Shuguang Ho 2. Confirmed
 3. asPatients
a novel with
coronav
diab
Inclusion criteria: 1. Criteria for inclu
 (1) Comply
Exclusion
with criteria:
the diagnostic
(1) Patic
 (2) Above
 (2)
2 years
Complicated
old; liver
N/A China Zhang Wei 42 Wenhuazhagnweij
R +86 13505 Affiliated 2 (3) Have other seriou
Inclusion criteria:
Exclusion1) confirmed
criteria: 1)orpatie
sus
 2) be able
 2)to understand
patients with themen
con
N/A China Wei Yao 9 West Sect41148433 +86 17709 Dalian Medi 3) voluntarily
 3) patients
participatewithin serio
this
Inclusion criteria: 1. Eligible patients
 2. Were identified as laboratory
N/A China Wu Caineng 16 Jichang wucaineng +86 13580 The First A 3. ThoseExclusion
who need c intubation in
Retrospective study Chengxian Guo 138 Tongzi gchxyy@16+86 0731- The Third XInclusion Exclusion c
RetrospectChina Yanling Shi Departmentakidney_d +86 0577 The First A Inclusion c Exclusion c
Inclusion criteria: 1. patient with nov
 2. patients with type 2 diabetes;
betweencriteria:
18-80 years
1.diabe
ol
N/A China ZHOU JIAN 600 Yishan zhoujian@s+86 18930 Shanghai Si 4. With 2.previous
effective flash history
glucoseofm
 1) 1.
Inclusion criteria: Respiratory
Aged 18 tofailure
70 ye
 2)
 2. Patients with Shock occurs; infe
pneumonia
N/A China Bende Liu 1 Culture Aliubende9 +86 13907 First People 3. Confirmed
 3) cas Combined failure o
Inclusion criteria: (1) registered nurs
 (2) to combat the new coronavir
0 China Pang Yong-li 600 Tianhepangi88@1+86 15626 The Third A (3) volunteer
Exclusion to participate
c in th
N/A China Bin Li 110 Ganhe 18930568 +86 18930 Yueyang Hos Inclusion c Exclusion c
0 China CAI YU 473 Hanzhecaiy_kf@1 +86 18702 Wuhan Four Inclusion c Exclusion c
Inclusion criteria:
Exclusion 1. Aged>=
criteria:18,
1. Critic
male
 2. Fever,
 
axillary
i. Patients
temperature
with respi >
 3. Consistent
 ii. with
Patients
the clinical
with shocdi
0 China Ye Feng/ Yang Zifeng/ 151 Yanjia yefeng@gir+86 13710 The First A 4. Patients
 whoiii. Patients
sign informed
with oth co
Inclusion criteria: 1. Confirmed and s
 2. Medical staff of
Exclusion anesthesiolog
criteria: 1. Gene
RetrospectChina Zongze Zhang 169 Donghuzhangzz@w+86 13971 Zhongnan H 3. Voluntary 2.participation
Medical staffinwith the
Inclusion criteria: 1. The patient sign
 2.The age of the patient is 18 or
 3. COVID-19 patients diagnosed
0 China Cao Bin Cherry Bloscaobin_be 1.39E+10 China-Japan 4. NucleicExclusion
acid posic
Inclusion criteria:
Exclusion 1. Aged
criteria:
>= 181. Patie
year
 2. Patients
 2.clinically
Severediagnosed
cardiovascu a
0 China Jianfeng Zhou 1095 Jiefa zhougene@+86 027 8 Department 3. Severe/critical
 3. Patients pat with clinic
Inclusion criteria: 1.No age restrictio
 2. Clinically confirmed
Exclusion 2019-nCo
criteria: 1. Patie
0 China Jianfeng Zhou 1095 Jiefa zhougene@+86 027-8 Department 3. Patients 2.withPatients
willingness
not provid
and
Inclusion criteria: 1. Conform to the w
 2. Conform to the diagnostic crit
N/A China Xie Chunguang 39 Shi-Er-Qxcg718@al+86 18980 Hospital of 3. OverExclusion
18 years cold
N/A China Xie Chunguang 39 Shi-Er-Qxcg718@al+86 18980 Hospital of Inclusion Exclusion c
Inclusion criteria:
Exclusion 1. Adult
criteria:
aged1. >=18
Any s
 2. Patients
 2.infected
Knownwith allergy
neworcoh
N/A China Zhang Dingyu 1 Yintan R 18138863 1.35E+10 Wuhan Jiny 3. In the 3.
stateIncrease
of no oxygen
in alanine
at re
 Inclusion criteria.

 
 1. 2019-nCov (SARA-Cov-2
 
 2. Older than 18 years old
 
China Xiuling Shang Fujian Prov 3. Meet the diagnostic crit

 
 - The participants were di
 
 - Participants received anti
 
 - Written the informed co
 
China ;; Hongzhou Lu, Ph.D;Ho;luhongzh ;+86-021- Shanghai Pu 
 
 1. Age = 18 years;
 
 2. Clinically diagnosed pati
Early Phase 1 Jianping Zhao, Ph.D. Zhaojp88@ 1.35E+10 accordance with the crite

 
 1. Aged >=18 years;
 
 2. Novel coronavirus pneu
 
N/A 3. The patient himself parti

 
 - Nurses who work > 37 ho
 
 
 - Nurses with one or more
 
N/A ; Mark B Loeb;Mark Lo ;loebm@mc;90533400 McMaster U
 - Nurses

 
 - Wuhan residents;
 
 - novel coronavirus pneum
N/A Laboratory tests revealed

 
 1. age range: 10-19;
 
 2. full-time students in the
 
 3. nationality: China;
 
 4. exposure context: COVID
 
N/A 2. residence in Jingzhou for mor
 3. Aged 16-65 years;
N/A China Deng Xiaopeng 47 Taqiao R49637569 +86 13872 Jingzhou M 4. self-volunteered.
Exclusion c
RetrospectChina Prof. Christopher CK L Departmentchris.kcla +852 3505 The ChinesInclusion c Exclusion c
Exclusion criteria: 1. A pre
N/A China Wang Tan 1478 GongnWangtan21+86 13756 Affiliated Inclusion c 2. With other major d
Exclusion criteria: 1. Gest
 2. Patients with othe
N/A China Honghua Ye 41 Xibei St yehonghua+86 13505 HwaMei HosInclusion c 4. Patients wi
Inclusion criteria:
 2. 1.pregnant
Pneumonitis
and lacta
pati
 2. Meet 3.
the standard
Combining of TCM
severe sy
0 China Wang Dazhong 33 Huanghe13803818 +86 13803 Zhengzhou 3. Sign 4. the informed
Clinical consent.
researcher
Exclusion criteria: 1. The p
 2. Patients
Inclusion criteria: The patients were
of stomato
 1. The 3.
visitingThe
datapatients was cu
of patients
1 China Jingzhi Ma 1095 Jiefa majingzhi +86 13871 Tongji Hosp 2. The 4.
pati The patients was u
Inclusion criteria: 1. Male and female
 2. Clinically diagnosed with Coro
 3. Increased
Exclusion
interleukin-6;
criteria: 1. Case
 4. Sign 2. Allergicconsent;
the informed to Favipira
 3.
 5. Subjects whoPregnant
can take and lacta
medici
4 China Guiqiang Wang 8 Xishiku S john13121 +86 13911 Peking Univ 6. Agree 4.
to collect
Subjects
cl received
N/A China Wang He 33 HuangheWH9400@1+86 15937 Zhengzhou Inclusion c Exclusion c
Inclusion criteria: 1. Patients aged fro
 2. conformed
Exclusion to criteria:
epidemic1.histor
peop
 3. fever 2.
and respiratory symptom
the researchers ju
 4. normal or decreased
 3. those wholeukocyt
cannot
0 China Qun Luo 151 Yanjia luoqunx@1+86 13710 State Key L 5. conformed
 4. anyto imagi
significant clin
Exclusion criteria: (1) pati
 (2) infants and young
 (3) patients with unc
N/A China Yang Si-Jin 182 Chunhulykyk3160 +86 15228 Affiliated Inclusion c (4
Exclusion criteria: (1) Past
Inclusion criteria:
 (2)1.Patients
Patientsinfected
diagnos
0 China Xie yuanlin 311 Yingpan12867794 +86 13975 The First H According (3)
to the
Patients
"New with
Coronavmal
Inclusion criteria: All patients who m
 Epidemiological history:
RetrospectChina Luo Xiaoping 1095 Jiefa xpluo@tjh.+86 027-8 Tongji Hos 1. travel Exclusion
or residence
c history of
Exclusion criteria: 1. not q
Inclusion criteria:
 2. 1.Pregnant
novel coronaviru
or lactati
N/A China Zhu Bo 3 Yunxing R27477014 +86 13995 Xiangyang 1 2. age 3.
unlimited, malewith
Patients and fema
seve
Inclusion criteria:
Exclusion1. Suspected
criteria: 1.COVID
CT im
RetrospectChina Lu Guangming 305 East Z cjr.luguan +86 13951 Jinling Hos 2. Patients
 2.confirmed
Incomplete withetiolog
etiolo
Exclusion criteria: (1) befo
 (2) malignancies;
 (3) the presence of s
RetrospectChina Feng Gao 1095 Jiefa 13971587 +86 13971 Tongji HospInclusion c (4) 7 days before adm
Inclusion criteria: Stage I and ii healt
 Stage 3:
 1. Clinical manifestations:
 (1) Fever;
Exclusion criteria: Stage 1
 (2) normal
 Stage
or decreased
3: white b
 (3) CT pulmonary
 1. Patientsexudation;
who cann Or
0 Shiyue Li 151 Yanjia lishiyue@ +86 13902 The First A 2. I
0 China Zhang Sheng 1095 Jiefa aloof3737 +86 18971 Tongji HospInclusion c Exclusion c
Inclusion criteria:
Exclusion1) Comply
criteria:with
(1) Pati
the
N/A Chian Guoqin Sun 241 Peng-L70798689 +86 18971 Wuhan Thir (2) Complete (2)clinical
Patientsdata
whose
of patida
Inclusion criteria: The mild cases wer
N/A China Tiejun Wang 116 Zhuodatiejunwan +86 13277 Department 1) respiratory
Exclusion failure
c requiring m
Inclusion criteria:
Exclusion1. Critical
criteria:patients
1. Preg
 2. airway
 2.
intubation
Combined withwith
mecha sev
RetrospectChina Shusheng Li 1095 Jiefa Shushengl +86 13971 Tongji Hosp 3. voluntarily
 3. Patients
joined thiswithstudy
lungw
Inclusion criteria: 1. COVID-19 patien
0 China Liming Xia 1095 Jiefa Lmxia@tjh.+86 13607 Tongji Hosp 2. ViralExclusion
pneumonia c manifestatio
 2. Endotracheal intubation patie
1 Wen Jianli 98 Fenghuazywenjian +86 15186 The Third A 3. PatientsExclusion
with off-line
c extubati
N/A China Li Lanjuan 79 Qingchuljli@zju.ed +86 13906 The First A Inclusion c Exclusion c
Inclusion criteria:
Exclusion 1. Aged
criteria:
>=181. years
Preg
 2. Symptoms
 2. Patients
of novel coronavir
with adva
0 Wen Jianli 98 Fenghuazywenjian +86 15186 The Third A 3. Positive 3.
nucleic
Suspected
acid test
cases.
of no
Inclusion criteria: 1. positiveness of n
 2. newly-onset pneumonia in a C
 3. typical symptoms of pneumon
RetrospectChina Jiang Xie 2 Anzhen Rofrank7820 +86 13161 Beijing Anz 4. live in
Exclusion
Wuhan cin the past
Inclusion criteria:
Exclusion 1. Aged
criteria:
18-65
1. Med
year
 2. Meical
 2.
workersOccupation
normal isworki
not
N/A China Fengbin Liu 16 Jichang liufb163@ +86 020-3 the First 3. Auqired 3.theMedical
informed consen
Inclusion criteria:
Exclusion 1. Above
criteria:
7 years
1. Toooly
 2. Meet 2.
the diagnostic
Non-neoplastic
criteriacoo
 3. Clear 3.
consciousness
Impaired andconsciou
stabl
0 China Yibin Hao 33 Huanghehaoyibin0 +86 15903 Zhengzhou 4. V 4. Those who cannot
Inclusion criteria: 1. Volunteers who
>=18 years; criteria: 1. Viral
 3. Patients
 2.diagnosed
Patients with
are not
acutesu
 (1) Laboratory
 3. Participation
(RT-PCR) confirm
in oth
0 China Xiang Cheng 1277 Jiefa nathancx@+86 15972 Union hosp (2) Lung 4.
in Other circumstanc
0 China Peng Sun 1111 XianxSP2082@sh+86 18121 Tongren HoInclusion c Exclusion c
Inclusion criteria:
Exclusion (1) criteria:
Patients(1)diagno
CT r
N/A China Xu Haibo 169 Donghuxuhaibo11 +86 13545 Wuhan Univ (2) There (2)
are CT Incomplete
image examina
clinica
Inclusion criteria: 1. patients with no
 2. Fever, respiratory
Exclusion tract1)and
criteria: o
Ordin
 3. Aged 2)
18 to Patients
80 years;with aller
4 China Bangjiang Fang 725 Wanpinfangbji@1 +86 18917 Longhua Hos 4. Signed
 3)
informed
Patientscons
with mali
Inclusion criteria:
 2. 1. Patients
Male orwith
female
maligp
 2. Willing
 3.
to signPatients
informed
who conse
have
New Treatm
China Dou Qifeng 88 Jiankan douqifeng +86 13503 the First A 3. novel 4.
coronavirus
There wasnovelevidenc
coron
Exclusion criteria: 1. Exclu
 2. Exclude medical st
N/A China Yan Hao, Xiaoping Luo1095 Jiefa haoyaner@+86 13971 Tongji HospInclusion c 3. Exclude if the med
0 China Ning Qin 1095 Jiefa qning@vip.+86 027-8 Tongji HospInclusion c Exclusion c
Inclusion criteria: 1. Intervention gro
 (1) Aged 18 to 50 years;
 (2) Diagnosed
Exclusion ascriteria:
a depression
(1) otheo
 2. Non-intervention
 (2) complicatinggroup: with
0 Yuan Yang 1095 Jiefa yuanyang7 +86 13995 Tongji Hos (1 (3) taking antidepres
Inclusion criteria:
patients(1)who Agew
RetrospectChina Ye Tu 1095 Jiefa whtuye@1+86 18986 Tongji Hosp (2) patients (2) who pneumonia
received with
patien i
N/A China Jingfeng Zhang Room 711, jBingfengz +86 15706 Hwa Mei HoInclusion c Exclusion c
N/A China Xia Tian 241 Peng-Lhcwy100@+86 13871 Wuhan ThirInclusion c Exclusion c
N/A China Zhengrong Mao 19 Renmin mR aozheng +86 18695 The First A Inclusion c Exclusion c
Exclusion criteria: 1) Aged
Inclusion criteria:
 2) 1) Pregnant;
Meets COVID-19
 2) Critically
 3) ill COVID-19 as patients
an co
RetrospectChina Yi Bian 1095 Jiefa bianyi252 +86 15102 Eergency / 3) length of stay
 4) in ICU >=24
Insufficient hou
medica
Inclusion criteria:
Subjects(1)mustInfeu
N/A China Junming Wang 1095 Jiefa eyedrwjm +86 13886 Tongji hosp (2) Fever (2)
and/or Patients
respiratory
with mycsym
N/A China Xu Jie 280 Mohe Rdr.xu@ali +86 13501 Shanghai N 2. Clinical
Exclusion
diagnosis
c of 2019 - nC
Inclusion criteria:
Exclusion
(1) criteria:
mild / general
(1) Patip
 (2) Aged (2)
>=18 Patients
years; more tha
1 China Li Xugui 279 Luoyu spine672@+86 13807 Hubei 672 (3) Obtain (3)
patients'
Patients
informed
with seveco
Exclusion criteria: 1. Disch
N/A China Xu Shuyun 1095 Jiefa sxu@hust. +86 13517 Tongji HospInclusion c 2. Discharge cases w
Inclusion criteria:
Exclusion
1. tumor
criteria:
group:
(1) Tho
 (1) Aged (2)
>=18 Complicated
years; with
 (2) Diagnosed
 (3) as
Patients
a malignant
duringtumpe
RetrospectChina Zhihua Wang, Xiangli 1095 Jiefa zhwang_hu+86 13607 Tongji Hos (3) The (4)
diagnosis
Immune
and treatment
dysf
 2. Patients who are c
1 China JIAN PENG 216 Guansh13758526 +86 13907 Wuhan thirInclusion 3. Patients with prev
Retrospective study Liang Wang 1095 Jiefa wang6@tjh+86 13971 Tongji HospInclusion c Exclusion c
Exclusion criteria: (1) Fem
Inclusion criteria:
 (2)(1)
Patients
aged between
with alle1
4 China Hu Linhui 101 Weimi hulinhui@l+86 13580 Maoming Pe (2) Common
 (3)type
Pa patients with
Retrospective study Xin Li 1277 Jiefa 31444082 +86 13797 Union HospiInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Those
criteria:
who 1. meet
Incom
RetrospectChina LIU DONG 1095 Jiefa ld_2069@1+86 13507 Tongji Hosp 2. In-patients
 2. Those
admitted
whichin design
the re
Exclusion criteria: 1. Tran
1 China Peng Jian 241 Peng-L54116340 +86 18627 The Third Inclusion 2. Patient with only o
0 China Wu Kaifeng 98 Fenghuakiphoonw +86 13788 The Third AInclusion c Exclusion c
Exclusion criteria: 1. Prev
RetrospectChina TAO WANG 1095 Jiefa wt7636@1+86 13971 Tongji HospInclusion c 2. The patients' med
Inclusion criteria: 1. Confirmed case:
 (1) epidemiological history:
1 China Wang Hua-bing 241 Peng-L27322554 +86 15377 Wuhan 3rd 1) travel history or
Exclusion cr residence his
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to1. 80
Patie
yr
N/A China Yingjia Xu 801 Heqingxuyingjia@+86 18017 Shanghai Fi 2. Diagnosed
 2. as
Patients
COVID-19
participati
pneu
Retrospective study Yuan Yadong 215 Hepingyuanyd11 +86 15833 The SecondInclusion c Exclusion c
Inclusion criteria:
Exclusion
Patients
criteria:
must Patient
mee
 1. Patients
 1.
admitted
The clinical
to hospital
data ar
RetrospectChina Lingli Dong 1095 Jiefa tjhdongll +86 18672 Tongji Hosp 2. Patients
 2.
identified
The ageas ofany
the rheu
pati
N/A China Guo Zhang 6 Taoyuan zhangguog +86 13978 The PeopleInclusion c 2. Patients developed
N/A Lihui Wang 13 North Q84961499 +86 13832 Cangzhou PInclusion c Exclusion
Exclusion criteria: 1. With
Inclusion criteria:
 3. 1.
Patients
Aged between
taking oth 1
4 China Zhaofen Lin,Wansheng415 Fengyalinzhaofen +86 13601 Shanghai C 2. In accordance
 4. Notwithsuitable
NCP tocriter
par
RetrospectChina Qian Guoqing 59 Liuting guoqing.q +86 15888 Ningbo FirsInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to1. 80
Rena
ye
 2. Diagnosed
 2. as
Relative
COVID-19
/ absolute
pneu
N/A China Jing Chen 12 Wulumuq money_09 +86 13816 Huashan Ho 3. ad 3. Pregnant women,
N/A China Xiong Chen 169 Donghuzn_chenxi +86 13995 Zhongnan HInclusion c Exclusion c
Inclusion criteria: (1) Aged >18 years
RetrospectChina Xia Hong 1 Xiyuan Pl97023653 +86 13699 Xiyuan Hos (2) canExclusion
completecthe wechat qu
Inclusion criteria:
Exclusion
1. Patients
criteria: who
1. Age<
we
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 2. ARDS 2.
patients
Accompanied
according to byth
o
RetrospectChina GuoLin Song 32 Feishan ant000999 +86 13985 The SecondInclusion Exclusion c
Inclusion criteria:
 2. 1.
Patients
Patients with
who hem
ag
 2. Aged 3.
>16 years
Withold;
severe coagu
 3. Patients
 4.
with
WithCRPactive
morebleedithan
N/A China Qin Wang 1630 Dongfqinwang_ +86 13621 Renji Hospi 4. The 5.
severe Pregnant
or critial patients w
RetrospectChina Hong Wang 1229 Gudunhongwang +86 0571 Zhejiang HoInclusion c Exclusion c
Inclusion criteria: (1) Patients with N
 (2) Inpatients
Exclusionaged >18 years
criteria: (1) Deaold
0 China Jing-Guo Cheng Wenzhou Me wzwsjcjg@+86 13857 WenZhou Me (3) Patients Know
 (2) the
Basic inform suc
diseases
Exclusion criteria: 1) Age
Inclusion criteria:
 2) 1)Pregnant
The diagnosis
women; m
RetrospectChina Zhigang He 1095 Jiefa 10976858 +86 18827 Eergency / 2) Patients
 3)
receiving
Incomplete
NIV or inform
MV
Inclusion criteria: (1) Currently partic
N/A China Zhang Yue 1120 Lianhzyzy1933@+86 18823 Clinical R (2) Voluntarily
Exclusionparticipate
c in this
0 China Qingyou Zheng 1333 Xinhuzhengqing +86 18601 Shenzhen HInclusion Exclusion c
Inclusion criteria: 1. confirmed with C
 2 olderer than 65criteria:
Exclusion years; 1. decla
RetrospectChina Cuntai Zhang 1095 Jiefa ctzhang04 +86 15927 Department 3. meet 2.
the critically
important ill criteria
data mia
RetrospectChina Zhanlian Huang 600 Tianhezhanlianh +86 13580 The Third AInclusion c Exclusion c
 2. ARDS patients according to th
RetrospectChina Fenglin Liu 12 Lieshishxkyylfl@1 +86 13953 Shandong P 3. Patients
Exclusion
in ICUc met the VAP c
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong PInclusion c Exclusion c
Exclusion criteria: (1) Oth
Inclusion criteria:
 (2)(1)Serious
novel mental
coronavir ill
N/A China Burenbatu 1742 Huoli nmbrbt89 +86 18804 Affilated H (2) According
 (3)to the diagnostic s
Sus
Inclusion criteria:
Exclusion
(1) criteria:
Corresponding
1. With
0 China Li Xiaodong 856 Luoyu lixiaodon +86 13908 Hubei Prov (2) Imaging
 2.manifestations
Severe primary Fibro
dis
Inclusion criteria:
Exclusion
1. Patients
criteria: who
1. Agedwe
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 2. Severe
 2.
ARDSAccompanied
patients accordi by o
Exclusion criteria: 1. youn
Inclusion criteria:
 2. 1.
doconfirmed
not fulfill thewithcrC
 2. ICU admission;
 3. declared clinical de
RetrospectChina Hongyu Gao 1095 Jiefa hygao@tjh.+86 13886 Department 3. meet 4.
the critically
important ill criteria
data mia
14 years criteria:
or more;1. Hem
0 China Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 3. diagnosis
 2.ofIntracranial
ARDS accordingpressu
Inclusion criteria:
 2. 1.
Pneumothorax;
Patients who we
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong P 2. ARDS patients
 3. are asthma
Severe defined or Ac
RetrospectChina Fenglin Liu 12 East Lie xkyylfl@1 +86 13953 Shandong PInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. over
criteria:
18 years
1. Invesold
 2. Patients
 2.
diagnosed
Not suitablewithfor Covid
in
N/A China Zhi Zhang 100 Hainin 16683890 +86 13621 Shanghai Fi 3. Have 3.
64-rowPatients
high-resolution
who cannC
0 China Huanqin Han 57 South R huanqinha +86 13828 Affiliated 2. Patients with COVID-19
Exclusion c confir
Inclusion criteria: 1. Conforming to th
 2. Aged between 18 and 65 year
0 China Xiaodong Li 856 Luoyu lixiaodon +86 13908 Hubei Prov 3. Signing
Exclusion
the generalized
c inform
Inclusion criteria:
Exclusion
(1) criteria:
Comply with(1) Patith
RetrospectChina Wei Li 215 Zhongs78440452 +86 18995 Wuhan Hosp (2) Complete
 (2)clinical
Patientsdatawhose
of pati
da
Inclusion criteria: 1. Male and female
 2. Patients with confirmed COVI
 3. Need to continue the antiviru
 4. AgreeExclusion
to sign the
criteria:
informed
1. Caseco
 5. Able 2.
to ingest,
Pregnant
absorband andlacta
tol
4 China Zhao Yan 169 Donghudoctoryan +86 13995 Zhongnan H 3. The subjects partic
Inclusion criteria:
Exclusion1. confirmed
criteria: 1.critica
If the
 2. grouping
 2.criteria:
aged <meet14 years;
the cli
RetrospectChina Minghao Fang 1095 Jiefa fangmh@tj+86 15071 Department (1) the2. Patients without th
RetrospectChina Lijia Demi 94 West Str27216302 +86 17723 Ganzi HospiInclusion c Exclusion c
Inclusion criteria:
ExclusionPneumonia
criteria: 1.
cases
Suspw
0 China Guangtao huang 149 Dalian haitao314 +86 18085 Affiliated A comprehensive
 2. Pneumonia
analysiscaused
was c
Inclusion criteria:
Exclusion1. Aged
criteria:
18 to
1. 75
Critic
ye
0 China Pinhua Pan, Yehong K 87 Xiangya pinhuapan +86 13574 Xiangya Hos 2. The 2.
diagnosisKnown
of new-type
allergiesco
Inclusion criteria: 1. The patient sign
 2. patient aged >=18 years old;
 3. COVID-19 patients diagnosed
0 China Cao Bin 2 Yinghua Scaobin_be +86 13911 China-Japa 4. Nucleic
Exclusion
acid positive
c within 72
Inclusion criteria: 1. Those who agree
 2. Adult aged >=18years
Exclusion criteria: old, ma
1. Parti
0 China Cai Qingxian 29 Bulan R 41180423 +86 13760 The Third 3. The 2.
inpatients
Lowwithbodymild or cop
weight
Inclusion criteria: 1. Those who agree
 2. Adults
Exclusion
aged >=18years
criteria: 1.old,
Parti
m
0 China Zhang Yu 1277 Jiefa whxhzy@1+86 13971 Union Hospi 3. The 2.
inpatients
Withwithbleeding
mild ororcob
Exclusion criteria: 1. Thos
 2. 1.
Inclusion criteria: Researchers
Medical staff who ofa
RetrospectChina Zhongze Lou 3.
59 Liuting lorenzo_8 +86 0574- Ningbo Firs 2. Patients Thenew-coronary
with investigator isp
Exclusion criteria: 1) < 18
 2) pregnant and lacta
N/A China Wang Hongyang 225 Changhhywangk@v+86 13801 The Third AInclusion c 3) patients with seve
Exclusion criteria: 1. Exclu
Inclusion criteria:
 2. 1.Dead
COVID-19
children;
infecti
0 China Wang Xiaowen 100 Hongkob5477@16+86 15907 Department 2. Children 3. with
Signkidney
to reject
injury:
thisHp
 2. aged 18 or above;
N/A China Baoshan Cao 49 North Gacaobaosha +86 15611 Peking Univ 3. informed
Exclusion
consent
c and ability
Inclusion criteria:
Exclusion1. From
criteria:
January
1. Pneu1,
RetrospectChina Chen Lei 26 Yuancunchenlei0n +86 13570 The Sixth A 2. From 2.
JanuarPatients with incom
0 China Zunyuan Liu 67 Dongchaly29.love +86 18263 Liaocheng Inclusion c Exclusion c
Inclusion criteria: 1. Children aged 0-
 2. Agreed to participant in the s
N/A China Liu Zhisheng 100 Hongkoliuzsc@12 +86 027-8 Wuhan Chil 3. Can Exclusion
cooperatecrwith the later
 (2) Patients with acti
 (3) Organ transplant
RetrospectChina Qingping Shi 287 Changhsir_shi@1 +86 13855 The First A Inclusion c (4) Patients with men
Exclusion criteria: 1. Case
Inclusion criteria:
 2. 1. Compliance
A case with
of a pregna
RetrospectChina Miao Qing 1 Xiyuan Plmiaoqing5 +86 13910 Xiyuan Hos 2. Aged 3.
>=18 Incomplete
years. case.
 2. 1.
Inclusion criteria: A case of a pregna
Compliance with
RetrospectChina Miao Qing 1 Xiyuan Plmiaoqing5 +86 13910 Xiyuan Hos 2. Aged 3.
>=18 Incomplete
years. case.
Exclusion criteria: (1) preg
Inclusion criteria:
 (2)(1)ALT/AST
aged 18-80
> 5 times
yea
 (2) severe
 (3)
(including
definitecritical
diagnosis
risk
4 China Min Zhang NO.85 Wujimaggie_zh +86 18121 Shanghai G (3) blood (4)
CRP andpatien
ESR were mor
Inclusion criteria: Epidemiological his
 1. History of residence or travel
 2. Exposure history to resident o
RetrospectChina Hanwei Chen 8 Fuyu Roadocterwei +86 18922 Guangzhou< Exclusion c
 2. Aged 18 to 65 years;
4 China? Yang Yi 4 Garden H15326774 +86 18971 Hubei Hospi 3. The Exclusion
time interval
c between sym
N/A China Meizhen Lin 111 Dade Rlmzmay@1+86 18922 The SecondInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Male
criteria:
or female
1. Sevea
 2. Patients
 2.
with
Multiple
confirmed
organ nove
fail
 3. Diagnosed
 3. as
Pregnant
moderate or lactati
cases
0 China Kaijiang Yu 23 Youzhengdrkaijian +86 0451- The First H 4. Volunta
 4. Cases with maligna
Exclusion criteria: (1) asth
 (2)(1)
Inclusion criteria: patients withyear
age: 18-75 seve
1 China He jing 16 Jichang sakeonel@+86 13760 The First A (2) compliance
 (3) thewith
risk
thestratificati
pneumo
Inclusion criteria: 1) Confirmed or cli
 2) Those who have been identifi
 3) Inpatients
Exclusion
agedcriteria:
18 to 751) Patie
year
0 China Haibin Ni 100 Cross nhb_2002 +86 15312 Affiliated 4) Vo 2) According to the r
Inclusion criteria:
Exclusion
(1) criteria:
diagnosed (1)as
patia
 (2) aged (2)
14 to patients
70 years whose
old; su
0 China Jia Lijun 725 Wanpinljjia@shut +86 13585 Cancer Inst (3) (3) endotracheal intu
N/A China Song Ying 439 Xuanhu16473805 +86 13668 YongchuanInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to1. 65
Patieye
0 China Jing Xu Room 319, 1l 8604501 +86 18604 Harbin Peiy 2. The 2.
eligiblePatients
subjectswith
(maleblooan
Inclusion criteria:
 2. 1.
Pregnant
The patient
or lactati
sign
 2. Aged 3.
18-80Serious
years; basic disea
0 China xiao wei 8 Hangkong99xw@sina+86 071 6 Jingzhou Fi 3. the novel
 4.coronavirus
Expected death novelwi c
Inclusion criteria:
 1) 1.Respiratory
Aged 18 tofailure
70 ye
 2. Patients
 2)
withShock
pneumonia
occurs; infe
N/A China Bende Liu 1 Wenhua Aliubende9 +86 13907 First peopl 3. Confirmed
 3) cas
Combined failure o
0 China Gao Jun 167 Fangdon13816012 +86 13816 The SecondInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Upon
criteria:
the1.judgm
The s
0 China Bi Xiaohui 33 Zhongyu52471295 +86 15618 Luohu hosp 2. According 2.toThethesubject
new typesuffers
of
0 Zhu Haibing 8 East Fuy zhb-ck@16+86 13826 Central HosInclusion c Exclusion c
 3. ALT / AST > 2-fold
Inclusion criteria:
 4. 1. Sign thesurvival
Expected writtenti
 2. Aged 5.
18-80With
yearsserious
old; liver d
0 China Wei Xiao 8 Hangkong99xw@sina+86 18972 Jingzhou Fi 3. Meet the diagnostic
 6. criteriao fo
Patients taking
 2. Cardiogenic dyspn
 3. Life expectancy<24
Inclusion criteria:
 4. 1.
Pregnant
Aged>=18 and/or
yearsla
 2. Diagnosed
 5. as
There
severe
is a and
statecritic
of
N/A China Gao Dengfeng 157 Xiwu Rogaomedic +86 15091 The Second 3. Being 6.
treated
Previously
in the ICU.complic
0 China Zhu Fengxue 11 Xizhimenfxzhu72@1+86 13911 Peking UnivInclusion c Exclusion
Inclusion criteria: 1. Common inpatie
 2. Patients who are older than 1
0 China Zairong Wei 149 Dalian 18811699 +86 15208 Affiliated 3. Consenting
Exclusionorcthe guardian of
4 China Hong tao 17 Yongwaiht2000@vi+86 13803 The First A Inclusion c Exclusion c
 2. Pregnant and lacta
 3. People with allergi
4 China Qingling Zhang 151 Yanjia zqling68@ +86 13609 The First A Inclusion c 4. Severe basic disea
Inclusion criteria:
Exclusion
1. Meet
criteria:
the1.require
Serio
 2. Aged 2.
18 to With
65 years
pneumonia
male or in f
4 China Ying Deng 22 Second surewin00 +86 13500 The Sixth A 3. The 3.
intervalWith
fromone theofonset
followo
Inclusion criteria:
Exclusion
Confirmed
criteria: or1. suspe
Patie
 1. Aged 2.
between
Those 18-85
withyears
severeol
 2. Patients
 3.
with
Inability
newlyto diagnose
unders
N/A China Jingzhi Ma 1095 Jiefa majingzhi +86 13871 Tongji Hosp 3. 4. Invasive ve
 2. 1.
Inclusion criteria: Pregnant
Patientsorwith lactati
co
0 Wei Wei 1 Fourth N wwei@chin+86 13729 Guangzhou 2. Voluntarily
 3. Insign
thewritten
opinion inform
of th
 2. Cardiogenic dyspn
 3. Life expectancy<24
Inclusion criteria:
 4. 1. Aged>=18
Pregnant and/oryearsla
 2. Diagnosed
 5. as severe
There is a and
statecritic
of
N/A China Gao Dengfeng 157 Xiwu Ro gaomedic +86 15091 The Second 3. Being 6.
treated
Previously
in the ICU.
complic
Inclusion criteria:
Exclusion
(1)Aged
criteria:
>=18 (1)years
Kno
 (2) Novel
 (2)
coronavirus
Mild or nucleic
critical paac
 (3) Clinical
 (3)
classification
Severe liver is ordin
disea
1-Feb China Weiping Cai 627 Dongfegz8hcwp@+86 020-8 Guangzhou (4) I <
Inclusion criteria:
Exclusion
Subjects
criteria:
who 1. meet
Serio
 1. Meet 2.
the requirements
With pneumonia of thein
4 China Jinghua Mao 60 Jingjing hbjzyyywl +86 071 6 Jingzhou Ce 2. Aged 3.
18 With one of follow
Inclusion criteria:
Exclusion
1. Patients
criteria: who
If subje
me
 2. Aged 1.
18-75Be years
dysphagia
male orand fem
 3. Serious
 2.
patient
Complicated
meet onewith of t
4 China Jinghua Mao 60 Jingjing hbjzyyywl +86 071 6 Jingzhou Ce 3. Alle
N/A China Huang Keqiang 300 Taizih hkq12312 +86 15287 Wuhan AsiaInclusion c Exclusion c
 2. 1.
co
0 Chao Xu 3. In
1 Fourth N 16497276 +86 15018 Guangzhou 2. Voluntarily thewritten
sign opinion of th
inform
Inclusion criteria:
 2. 1.
Pregnant
co
0 Chao Xu 1 Fourth N 16497276 +86 15018 Guangzhou 2. Voluntarily
 3. Insign
thewritten
opinion inform
of th
 2. 1.
co
0 Chao Xu 3. In
85 Kefeng 16497276 +86 15018 Guangzhou 2. Voluntarily thewritten
sign opinion of th
inform
Inclusion criteria:
 2. 1.
Pregnant
co
0 Chao Xu 1 Fourth N 16497276 +86 15018 Guangzhou 2. Voluntarily
 3. Insign
thewritten
opinion inform
of th
N/A China Jin Yang 1277 Jiefa whuhjy@si+86 13554 Union HospInclusion c Exclusion c
4 China Xin Zheng 1277 Jiefa xin11@hot+86 027 8 Union HospInclusion c 2. People with high-r
 
 1. = 18 years old;
 
 2. Diagnosed as serious or
 Clinical management of 2
 
Phase 2 China ;; Zhiyong Peng, profess ;pengzy5@;+8618672 Wuhan Univ<

 
 - admission to ICU
 
 - adult (=18 years old)
 
 - confirmed case of 2019-
N/A Hong Kong polymerase chain rea

 
 - Healthy and Covid-19-po
 
 - The interval between the
Phase 1 China ;; Lung-Ji Chang;Lung-Ji ;c@szgimi. ;+86(755)8 Shenzhen G patients. The onset of sy

 
 - 1. Age = 18, age = 75, ge
 
 - 2. novel coronavirus diag
Early Phase 1 ; Liwei cheng, doctor;X ;xiaoyang ;18986033 Research o plan. (severe patients me

 
 - Patients with novel coro
 swab test of viral nucleic
 
 
N/A China Qiong Gong, MD. Renmin Hos - Patien

 
 - Anyone volunteer to par
 
 
 - Anyone non-voluntary to
onal [Patient Registry] France ;; FrÃ©deric DUTHEIL;Lis;promo_int;04737549 University 
N/A China Kun Ye 6 Taoyuan yezi5729@+86 18978 The PeopleInclusion c Exclusion c
N/A China Jie Lin 41 Xibei St linjie1992 +86 15258 Hwa Mei HoInclusion c Exclusion c
0 China CHEN Hui 58 Shenlonchenhhust +86 13437 Union HospInclusion Exclusion c
 2. Patients diagnosed with nove
 3. Patients >=21 criteria:
Exclusion days since the fi
1. Patie
0 China Zhang Dingyu 1 Yintan Ro18138863 +86 13507 Wuhan Jiny 4. The 2.
diagnosis of pulmonary
Patients with recefi
 (2) The investigator j
Inclusion criteria:
 (3)(1)Patients
Patientswithagedseve
1
 (2) Clear
 (4)
diagnosis
pregnant
of patients
and lact w
0 China Meng Jie 138 Tong-Zimengjie@c+86 13607 The Third X (3) Voluntarily
 (5) Those
join thewho
trialhave
ands
0 China Jiao Xianfa 33 Huanghe27835378 +86 13674 Zhengzhou Inclusion c Exclusion c
Inclusion criteria: (1) Fever patients;
 (2) peoples
Exclusion
who criteria:
need to (1)screen
limi
 (3) patients
 (2)forLack
possible
of sample
infectioinf
 (4) Age (3)
and gender
unableareornot limitt
failure
N/A China Pengfei Pang 52 Meihua pangpf@mai +86 18902 The Fifth A ( (4) Abnormal results
 2. Weakness affects p
 3. Communication ba
 4. Already participate
N/A China Haihang Yu Zhuangyu Ryuhaihang 8.61E+12 Ningbo KanInclusion c 5. Take psychotropic
Inclusion criteria: 1. Patients who ha
betweencriteria:
18 to 801.years
Patie
N/A China Luping Lin 627 Dongfe13533550 +86 13533 Guangzhou 3. the subjects
 2. The compliancethe
participating of
RetrospectChina Pei Bin 15 Jiefang xyxzyxzx@ +86 18995 Xiangyang 1Inclusion c Exclusion c
Inclusion criteria: (1) aged 18-60 yea
 (2) BMI in the normal range (1+/
 (3) diagnosis
Exclusion
of lung
criteria:
cancer,
(1) had
bre
 (4) ASA (2)
grade I-II;
used albumin and
N/A China Yang Jinfeng 283 Tongzi 31597770 +86 13875 Hu'nan Can (5) no (3) had a history of c
Inclusion criteria: 1. Aged >14years o
RetrospectChina Rengbin Ji 41 Xibei St rengbinji +86 13989 HwaMei Hos 2. The Exclusion
diagnosis cconforms to the
Inclusion criteria:
Exclusion
(1) criteria:
Patients(1) withPati
m
 (2) Those
 (2)
who Patients
meet thewith diagnos
neo
0 China Jing Li 1 Xiyuan Plxyyylijing +86 15901 Nursing De (3) Those (3)
who Patients
meet thewith diagnos
men
 (2) Maternal patients
 (3) Pediatric patients
 (4)Meet
Inclusion criteria: Suicide
thedeath
criteria casfo
RetrospectChina Binru Wang 241 Pengli wanbr2000+86 13554 Wuhan Thir 1. clinical (5) Transferred to ho
manifestations:
Inclusion criteria:
Exclusion
(1) criteria:
To include 1) Patie
confi
Retrospective study Fan Li 415 Fengyafanli0930 +86 13564 Department (2) Among 2)theChildren,
patie pregnant
Exclusion criteria: 1) Have
Inclusion criteria:
 2) 1.Have
Aged suicidal
11-18 idea
year
 2. GAD-7 3)
scoreNot
above
willing
10;to let t
 3. willing
 4)
to participate
Currently this
taking stud
ps
N/A China Shitao Chen 19 Xin-Jie- kittychen +86 15967 Mental Heal 4. Have 5
stable internet and quie
 2. Pregnant and lacta
 3. 1.
Inclusion criteria: Lopinavir/ridonavi
Male and female
2-Mar China Zhaohui Tong 4.
8 Worker Stongzhaoh +86 13910 Beijing Cha 2. Patients Cases of diagnosed
previously r
RetrospectChina GAO Hong 29 Bulan R 13603035 +86 13603 Shenzhen T 2. AgedExclusion
older than 18 years.
Inclusion criteria: (1) Medical staff in
 (2) People aged between 18 and
N/A China Zhongyuan Xia 238 Jiefan wenqin-19 +86 13808 Renmin Hos (3) People Exclusion
have electronic
c socia
Inclusion criteria: (1) Patients with no
 (2) Patients with novel coronavi
Retrospective study Tang Hao 415 Fengyatanghao_0 +86 13816 Department (3) Patients meetc the clinical sus
Exclusion
Inclusion criteria: 1. Diagnosed COVI
RetrospectChina Chen Jian 52 Meihua chenjn@mai +86 13926 The Fifth H 2. Suspending
Exclusion COVID-19
c patient
Exclusion criteria: (1) Ree
Inclusion criteria:
 (2)(1) The
TheCTpatients
image can wi
RetrospectChina Wei Wang 1095 Jiefa wwang@vip+86 13871 Tongji Hosp (2) CT was (3)
positive
Patients
for the
withfirst
pleu
ti
0 China Liujie 37 Guoxue liudr@out +86 18980 West ChinaInclusion Exclusion c
Exclusion criteria: 1. aged
 2. 1.
Inclusion criteria: after cardiopulmon
patients who me
N/A China Zhaohui Tong 8 Worker Stongzhaoh +86 13910 Beijing Ch 2. patients 3. accompanied
with s by o
 2. Severe liver functio
 3. Severe renal impa
4 China Chunli Liu 151 Yanjia chunli@gir +86 13560 The First A Inclusion c 4. Have any coexistin
Exclusion criteria: 1. sNCP
 2. WHO grade III or IV
Inclusion criteria:
 3. 1.Malignant
Patients tumor
are eligi
1 China Ye Xiaoqun 1 Minde Ro51120166 +86 0791 The Second 2. The 4. patients Lactating
met thewomen
diagnoso
0 China Jiang Shujuan 324 Jing-Wudocjiangs +86 15168 Shandong P 2. PatientsExclusion
who agreed
c to enroll
RetrospectChina MINGLI LIU 480 Shuang39595618 +86 13761 Shanghai KInclusion c Exclusion c
N/A China YY Chen 61 West Ji chenyinyi +86 13637 Hu'nan ProvInclusion Exclusion c
Exclusion criteria: (1) thos
 (2) pregnant and lact
Inclusion criteria:
 (3)(1) severe
all patients
basic disea
with
0 China Gang Sun 28 Fuxing Rsunok301 +86 13501 PLA Genera (2) aged >=18 years,
 (4) seriousapproved
renal dam b
Exclusion criteria: Exclusio
Inclusion criteria:
 (1)1.There
novelwascoronaviru
no rap
RetrospectChina Tian Lin 52 Meihua tianlin@ma+86 0756 The Fifth A 2. Willing (2)
to participate
Subjects whoin rapid
cou
0 China Feng Zhen 17 Yongwaifengzhenl +86 13970 The First A Inclusion c Exclusion c
RetrospectChina Changqing Hu 352 Renmin13966906 +86 13966 DepartmentInclusion c Exclusion c
RetrospectChina Huang Hui 41 Erling 39340681 +86 13825 HuiZhou Mu Inclusion c Exclusion c
Exclusion criteria: The clin
 1) Respiratory failure
Inclusion criteria:
 2) 1. Shock
Agedoccurs;
18 to 70 ye
N/A China Binghong Zhang 99 Zhang-Zzbhong62 +86 13886 Renmin Hos 2. Patients 3)withCombined
severe COVID-1
failure o
Inclusion criteria:
Aged 18(1) to 65
Femy
N/A China Bin Zhang/Yinong Ye 81 Lingnan FSYYN001 +86 18038 Department (2) Patients (2)withALTmild
is higher
or normal
than
Inclusion criteria:
Exclusion1. Aged
criteria:
>=18 1. years
Gest
 2. The 2.
person,Patients
who is diagnosed
with aller
N/A China Ting Cai 41 Xibei St caiting@uc+86 13738 HwaMei Hos 3. Patients with othe
Inclusion criteria: 1) > 18 years of age
 2) identify the patients infected
 3) the patient
Exclusion completes
criteria: 1.CTthose
exa
N/A China Zhang Lina 87 Xiangya zln7095@1+86 15874 Intensive C 4) sign 2.
the informed
the patient
consent.
or his g
Inclusion criteria:
Exclusion1. Aged
criteria:
between
1. Fami 1
 2. Able 2.
to understand
Subject allergic
the conteto
1 China Zhu Fengcai 172 Jiangsuiszfc@sina +86 025 8 Jiangsu Pro 3. Able 3.
and willing
Woman to complete
who is prea
Inclusion criteria:
criteria: with
1. Patie
CO
0 China Qianjin Lu 139 Renminqianlu586 +86 731-8 The 2nd Xi 2. Age- 2.and sex-matched
Those who refusenorma
RetrospectChina GuoLin Song 32 Feishan ant000999 +86 13985 The SecondInclusion Exclusion c
Inclusion criteria: 1. Pharyngeal swab
 2. AgesExclusion
betweencriteria:
18 to 851.years
Patie
0 China Fan Zhong 8 Huaying gz8hzf@12+86 18122 Guangzhou 3. Su 2. Patients judged by
Inclusion criteria:
Exclusion1. Pharyngeal
criteria: 1. Patie
swab
 2. Males 2.
and females
Patients aged
with 18
men to
0 China Chuo Li 8 Huaying gz8hlc@12+86 15989 Guangzhou 3. Participant (2) ALT/AST increase
Inclusion criteria:
 (3)(1)Severe
Aged patients
18 yearswo
 (2) Voluntarily
 (4) Pregnancy;
signed informed
0 China Xinghuan Wang 169 Donghuwangxingh +86 027 6 Zhongnan H (3) Hospitalized
 (5) HIV patients
positive
diagno
 2. 1.
Female and lacta
patients
 3.Have
 2. SARS-CoV-2 malignant
nucleic acid testtum
p
N/A China Chengyun Liu 1277 Jiefa chengyunl +86 18007 Union Hosp 3. Lung<CT exam
Inclusion criteria:
Exclusion
1) Those
criteria:
who1) have
Acco
 2) Be over
 2)
18 Those
years old
who(includin
are alle
N/A China Dawei Wang 100 Shizhi cleverwd +86 025-5 Affiliated 3) Voluntarily
 3) Pregnant
sign written
or la
inform
0 China Wei Zhang 17 Yongwaizhangweil +86 13707 The First A Inclusion crExclusion c
Inclusion criteria: 1. novel coronaviru
 2. No contraindications
Exclusion criteria:for1. Patie
MR e
0 China Ying-kun Guo 20 South R gykpanda +86 18180 West China 3. understand
 2. Contraindications
the potential risks
 2. Other serious med
 3. 1.
Inclusion criteria: Not suitable
Aged for ga
18 years ol
4 China Guochao Shi 197 Secondshi_guoch +86 13918 Ruijin Hosp 2. Meet 4.
the novel
Preg coronavirus p
 2. Stay in hospital for 3 days or m
18 or above;
criteria: 1. Confi
0 China Hongmei Tao 52 Meihua 13926946 +86 13926 The Fifth A 4. Info 2. KPS > 30 points.
Inclusion criteria:
Exclusion
1. Eligible
criteria:patients
1. Intub
 2. Were 2.
identified
Pregnancy,
as laboratory
severe
N/A China Li Bixi 627 Wuluo bxlee@soh+86 13397 Central The 3. Those 3.
who Those
need intubation
patients hasin
Inclusion criteria:
Exclusion
o becriteria:
enrolled,
Youallcan
th
 1) the confirmed
 1) anypatient
situation
(orthat
lega
 2) Aged 2)
18-65allergic
years, gender
constitutio
not
4 China Li Lanjuan 79 Qingchuljli@zju.ed +86 13906 The First A 3) the time
 3)intpatients w
Exclusion criteria: (1) any
Inclusion criteria:
 (2)(1)allergic
aged 18
constitutio
to 70 y
4 China Gong Guozhong 139 Renmingongguozh+86 13873 The Second (2) Light and heavy
 (3) patients
serious with
basic dise
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory - Exclusion criteria: - P
(Phase -Child less than 12 ye
III): yes -Known hypersensitiv
Therapeu -Feeding
tic use -Retinopathy
(Phase Inclusion criteria:
 -Known
 - Women
deficit inand
G6P
IV): no - Teenager
 -Refusal
girls and to
boys
participat
aged m
France IHU MÃ©diterranÃ©e19-21 Boul line.medd 00334 13 7Fondation - Persons
 -Patient
who have given their f
Not applic Japan,Asia Keibun Liu Takebayashkeiliu040 028-626-5 Saiseikai Inclusion crExclusion c

 
 1. 14-70 years old
 
 2. 2019 novel coronavirus
 
 3. Subjects voluntarily parti
 
N/A China Faming Zhang, MD; PHD The Second 
 1)2019-nCoV nucleic acid te
 of viral pneumonia.
 
 
Phase 4 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 1. Patients who meet any
 
 1. 2019-nCoV nucleic acid
 
 2. CT of the lung conforme
 
 
Phase 4 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 1. Patients wh

 
 1. Age:18~55 years old, un
 
 2. Laboratory (RT-PCR) con
 manifestations.
 
Phase 3 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 3.

 
 1.Meet the definition of sev
 
 1. Shortness of breath,RR=
 
 2. In a resting state:SPO2=
 
Phase 4 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 3. P

 
 1. Volunteers who have un
 
 2. Age =18 years, gender u
 
 3. Patients diagnosed with
N/A China <

 
 
 - Diagnosed with 2019-nC
N/A China 2019-nCoV infection; CT

 
 lower respiratory tract sa
 
Phase 1/PhChina ;; Lung-Ji Chang, PhD;Lu ;c@szgimi. ;+86(755)8 Shenzhen G - The interval between the

 
 - Patients confirmed with
 "Pneumonitis Diagnosis a
N/A China ; Yang Jin;Yang Jin whunjy@1 13554361146;135543 
 
 1. Laboratory diagnosis:
 
 - Respiratory specimen
 
N/A China Yimin Li, PhD, MD The First A - The viral gene sequen

 
 1. Aged between 18 and 7
 
Phase 2/Phase 3 Lin Chen chenlin_t 8.61E+12 guideline "Pneumo

 
 
 - Diagnosed with CONVID1
N/A China SARS-Cov-2 infection; CT

 
 1. Male or female, 18 year
 
 2. CT image is characteristi
 
N/A China 3. Laboratory confirmation

 
 1. Patients diagnosed as CO
 
 1. mild patient: fever,re
 pneumonia can be see
 
Phase 3 China ; Qing Ning, Professor;Qqning@vip.+8613971521450; 

 
 - At least 21 years
 
 - Has stayed in Singapore
 
 
 - Below 21 years
 
Singapore ; ; Jean Liu, PhD;Jean Liu ;jeanliu@y ;66013694;Yale-NUS C - Has stayed in Singa

 
 1. Agrees to the collection
 
 2. Male or non-pregnant fe
 
China ;; SHAOXIAN HU, M.D;YI;yuyikai@1;+1 (484) Tongji Hosp 
 
 - Patients with mild and se
 pneumonia according to
 
Phase 4 China - Plan for New C

 
 - Patients diagnosed with
 
 - Aged between 18-75
 
 - Willing to sign the i
 
N/A China ;; Xiaoju Zhang, PhD;Ziq ;13781919 ;+86-1378 Henan Provi Exclusion Crite

 
 - (1) Age =18 years. (2) Lab
 Lung involvement confirm
 
 
N/A China 

 
 COVID-19 positive accordin
 
 
 - Participants in other clin
 
Phase 1 Jordan ; Adeeb M AlZoubi, Ph. adeebalzou+962795337575;+962 -

 
 - All patients >18 years of
 inclusion.
 
 - Healty age-matched volu
 
 1. age >18 years old
 
 2. identify the patients infe
 
 3. the patient completed C
 
N/A China ;; Zhang Li Na, MD;Zhao ;56212264 ;+8613667 Xiangya Hos 4. sign the info
 
 - all patients treated for C
 
 
 - Chronology not compati
France ;; Joe-Elie Salem, MD, ;nguyen.le ;00331584 Clinical In 

 
 - pregnant women with la
N/A Italy Gabriele Saccone, MD gabriele.s 8.17E+08 

 
 - Adults healthcare worke
 
 - Chronic patients with at
 
 
N/A Italy ;; Maurizio Cipolla, MD; ;antonio.g ;+3939200 Medical di - People that have been in

 
 - Admitted to intensive ca
 
 - suspected or verified CO
 
 
 - Pregnancy or breastfeed
 
Sweden ;; Robert Frithiof, MD. P ;robert.fri ;07365634 Uppsala Uni - Preexisting

 
 Patients hospitalized for CO
 
 
 none
Italy ;; Augusto Di Castelnuo ;dicastel@n;32890356 IRCCS Neu 
Inclusion criteria:
Exclusion
(1) criteria:
Outpatient
(1) you
and
RetrospectChina Kun Xiao 28 Fuxing R45595789 +86 13716608331 (2) The (2)
body temperature
refuse to signhighe
info
0 China Haixiao Chen 150 Ximen cShenhx@e +86 13706 Taizhou HosInclusion c Exclusion
RetrospectChina Shen Chan 745 Wuluo sunnyabs1 +86 18986 Maternal aInclusion Exclusion c
Inclusion criteria:
Exclusion
1) About
criteria:
one1) mont
POSI
N/A China Wenliang Fan 1277 Jiefa fwl@hust. +86 027 8 Union Hosp 2) No other
 2)neurological
Those who disease
cannot
N/A China Xianli Du 5 Yan-Er-D lilibestev +86 15192 Shandong EInclusion Exclusion c
Inclusion criteria:
Exclusion
1) Positive;
criteria: 1) Thos
N/A China Fan Yang 1277 Jiefa fyang@vip +86 027 8 Union Hosp 2) There 2)
is a CT
Patients
examination
who are in uo
Inclusion criteria: 1. Myopia teenage
N/A China Xianli Du 5 Yan-Er-D lilibestev +86 15192 Shandong E 2.The cornea
Exclusionis c
 2. age < 18 years;
 3. Participating in an
 4. refuse to sign the i
N/A Tianwang Li 466 Xinganlitian-wa +86 13710 GuangdongInclusion c 5. individuals who su
N/A China Yuan-hao Wu 314 West An doctor.wu +86 022 2 First Teach Inclusion c 2. Combining system
N/A Wei Min 321 Zhongsh 82464790 +86 15850 Nanjing UniInclusion c Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
Aged 18-65
(1) Rec
yea
 (2) Voluntarily
 (2) Severe
participate
liver in
disea
this
N/A China Prof. Qingsong Ye; Dr 238 Jiefan 20215851 +86 027 8 Center for (3) Diagnosed
 (3) with
Patients
severe
withpneu
kno
RetrospectChina Daoyuan Si 126 Xiantaisidaoyuan +86 13578 China-JapanInclusion Exclusion c
RetrospectChina Zhang Rong 183 Yiling 13972046 +86 13972 Yichang CenInclusion c Exclusion c
N/A China Yan Hao, Xiaoping Luo1095 Jiefa haoyaner@+86 13971679960, 13 Inclusion c 2. The guardian does
N/A China Zheng Xue 699 Hongfezhengxue. +86 17717 China Euro Inclusion Exclusion
Exclusion criteria: (1) Basi
0 China Zhuang-Gui Chen 600 Tianhechenzhuan +86 13600 DepartmentInclusion c (2) Not willing to par
Inclusion criteria: (1) Have a clear his
 (2) TwoExclusion
consecutive
criteria:
positive
(1) Pati
nuc
 (3) No (2)
clinicallyPatients
relevanthave
symptono
N/A China Qiuling Shi 1 Yi-Xue-Y qshi@cqmu+86 023-6 Department (4) Patient (3) Patients with unc
voluntary.
N/A Xiandong Meng 28 Dianxin wchmhcmx+86 18980 West ChinaInclusion c Exclusion c
Inclusion criteria: 1. History of conta
 2. During the 14-day clinical obs
 3. Nucleic
Exclusion
acid test
criteria:
positive
1. Have
twic
 4. Without
 2.any
Patients
clinically
norelevan
willing
N/A China Xiaojun Tang 1 Yi-Xue-Y tangxiaoj +86 13668 School of 3. Patients with cons
RetrospectChina Zhongyuan Xia 99 Zhangzhwanzimili +86 17762 Renmin HosInclusion Exclusion cr
Inclusion criteria: Patients with Covid
 (1) clinical and inpatient data ar
N/A China Wei Wang 1095 Jiefa wwang@vip+86 13871 Tongji Hosp Must include:
Exclusionblood
c routine on a
 2. 1.
Inclusion criteria: Patients with seve
The diagnosis of
Retrospective study Qingta Meng 238 Jiefan mengqt201+86 13995 Department 2. Patients 3.
with
Patients
invasive
whose
mechan co
Inclusion criteria: (1) a patient who m
 (2) stable
Exclusion
condition,
criteria:
normal
(1) pati
cog
0 China GAO Tian-lin 349 Hangzh22356581 +86 18930 The First R (2) patients combine
Inclusion criteria: 1. male and female
 2. positive result of test for 2019
 3. Clinical
Exclusion
diagnosed
criteria:
with1.pneum
seve
 4. onset 2.
withinpregnant
7 days (severe
and nurs ca
2 China Jin Ronghua 8 Xi-Tou-Ti jin_eagle@+86 13901 Beijing You 5. the info
 3. subjects received l
 2. Those who cannot
 3. 1.
Inclusion criteria: Suicide-prone
Those who meet by t
0 China Fu Liran 33 Huanghefuliran@1 +86 15837 Zhengzhou 2. The 4.
patientpregnant women,
was conscious, w
RetrospectChina Jun Shao 98 Nantongsjun1982@+86 18051 Nothern Ji Inclusion c Exclusion c
 2. patients with malig
Inclusion criteria:
 3. 1.
patients
patientswith
aged
seve 16
 2. they 4.
were willing
recentto orsign
participa
the i
RetrospectChina Zhe Xu 100 West 4txuzhe302 +86 15001 Diagnosis, 3. The 5.
novel coronavirus
evid nucleic
Inclusion criteria: (1) Inpatients in ou
 (2) AgeExclusion
and gender criteria:
are not
(1)limit
Pati
 (3) The (2)
PT-PCRPatients
test is positive
with inco or
RetrospectChina Pengcheng Luo 241 Peng-Lpluo@whu.+86 13507 Wuhan Thir (4) There (3)
is a complete
There aremedical
patient
N/A China Zhang Yi 33 Huanghenicole861 +86 13837 People's h Inclusion c Exclusion c
Inclusion criteria:
Meet the(1)diagn
Criti
 (2) Aged (2)
18-85TCM years;diagnosis of
N/A China Zhongde Zhang 111 Dade Rdoctorzzd +86 13903 Guangdong (3) To agree (3) toPatients
participate
whoincannthe
Inclusion criteria:
criteria: with
1. Thossev
 2. Aged 2.
>=18 Patients
years, bothwithmenallera
N/A China Peiyang Gao 39 Shi-Er- gaopy930 +86 18980 Hospital of 3. Agree 3.
to participate
Cases where comp
Inclusion criteria: 1. patients with no
 2. Fever,
Exclusion
respiratorycriteria:
tract1)and
nove o
 3. Aged 2)
18 to The
80 years;
age is less tha
N/A China Wei Lu 725 Wanpinicuwei@16+86 18917 Longhua Hos 4. Signed
 3)
informed
Patientsconswith aller
 2. Without the inform
0 China Sun Hongyuan 88 Changlinsunhongy +86 18222 First Teach Inclusion c 3. Unable to coopera
Inclusion criteria:
Aged >=18 (1) year
Kno
 (2) 2019-nCoV
 (2) Acute
pneumonia
infection
is diaof
4 China Li Shi-yue 151 Yanjia lishiyue@ +86 13902 the First A (3) Patient's
 (3) condition
The function
has reach
of liv
 2. Non-fever non-new
Inclusion criteria:
 3. 1.Fever
During
caused
the outbr
by ot
N/A China Peiyang Gao 39 Shi-er- gaopy930 +86 18980 Hospital of 2. Comply 4.
wi Patients with tube
Inclusion criteria: 1. Novel coronaviru
 (1) there were travel
Exclusion history
criteria: or r
1. Havin
0 China Lei Genping Plus 2 Wei leigenpin +86 13609 Affiliated (2) During theMycoplasma
 2. 14 days before pneu on
0 China Mingxing Xie 1277 Jiefa xiemx@hus+86 13607 Union HospInclusion Exclusion c
 2. previous arrhythm
 3. previous chronic re
Inclusion criteria:
 4. 1.hemodynamic
Novel coronaviruinst
4 China Hu Xingxing 100 Shizi S huxingxin +86 17327 Jiangsu Pro 2. Respiratory
 5. se rate in calm state
Inclusion criteria:
Exclusion1. Normal
criteria:and
1. Pneu
seve
 2. Viral 2.
nucleicHaveacidcontraindica
test is negati
 3. Aged 3.
>= 18Mental
years; disorders,
N/A China Ming Wu 17 Lujiang ahslyywm +86 18655 The First A 4. Patients
 4.with
Patients
c wit
Inclusion criteria:
Comply with
(1) Criti
th
 (2) Aged (2)
>= 18Patients
years; who can
N/A China Huang Luqi; Ruan Lia 16 Nanxiaohuangluqi +86 010-6 China Acad (3) Agree (3)
to participate
Patients with
in thesevetr
RetrospectChina Cao Guoqiang 10 Changji cgq1963@ +86 023 6 Daping HosInclusion c Exclusion c
Inclusion criteria:
criteria: discharg
1. Pneu
 2. Adults
 2.
overHave
18 years
contraindica
of age w
0 China Chengqi He 37 Guoxue hxkfhcq@1+86 18980 West China 3. Study 3.
participants
Mental are disorders,
willing
Inclusion criteria: (1) RT-PCR detectio
 (2) GeneExclusion
sequence criteria:
of the(1)
virus
Subi
0 China Yan Kang 37 Guoxue kangyan_h +86 18980 West China (3) (2) Subjects who rece
Exclusion criteria: 1. A com
 2. 1.
Inclusion criteria: The estimated
Patients surv
confirm
0 China Jin Yang 1277 Jiefa whuhjy@si+86 13554 Union Hosp 2. Those 3. The broad-spectru
without patient's med
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France;CanDirection des OpÃ©rat1 avenue PiPublic-Registry-MA-F Sanofi-avenInclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
NetherlandMarc J. M. Bonten HeidelbergM.J.M.Bon 00318875 5University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Jody Brookes Mailpoint jody.broo 2.38E+09 Synairgen Inclusion c Exclusion c

 
 - Age 18 or older.
 
 - Confirmed Covid-19 infe
 
 - ARDS
 
 - ICU patient
 
 
Phase 2 Thomas C Pitts, M.D. Drpitts@h 6.47E+09 - Active Neiss

 
 1. Age =18 years
 
 
 3. PaO2/FiO2 < 300 or SpO
 
Phase 2 ; Chong Lei, MD, PhD;L ; ; Fourth Mil Exclusion Crit
 
 1. Age: 18-80 years old, ma
 
 2. Covid-19 confirmed case
 
 3. Comply with any of the
 
 - Dyspnea, RR = 30 time
N/A China ;;; Yihai Cao, Dr;Yuguo Ch;;jiaojiao ;;1856008 Qilu Hospit

 
 - COVID-19 pneumonia pa
 
 
 - Patients who were youn
 
China - Patients who had underg

 
 - Being between the ages
 
 - To continue their active
 period.
 
Turkey ;; Ipek Yeldan, Prof.;Eren;erenavcil ;+9005320 Istanbul Un - Spending time at ho

 
 - Male and female, 18-75
 
 - Patients previously diagn
Phase 2/PhChina ; Shumin Wang, Phd.;S shuminwa +86 13488760399;+8 is no more than 14 days;

 
 - Aged between 18 and 75
 
 - Positivity to covid-19 scr
 
Phase 2/PhItaly ; LUCA GALLELLI;LUCA Ggallelli@uni3339245656;3339245 - In escin group: Low resp

 
 - We identify individuals a
 care practice for at least
 
 
 - We
 Key Inclusion Criteria:
 
 1. Patients were diagnosed
 (COVID-19) Treatment G
 
Phase 3 China ;; Hao Li, Professor;Hao L;xyhpliha ;+0086-13 Xiyuan Hos 2. Patients received a com

 
 - In case of doubt of inters
 
 - Positive swab test of SAR
 
 - Interstitial pneumonia
 
N/A Italy ; Salvatore Corrao, MD;s.corrao@ti+390916662717;+390 - Sig

 
 - Adult patients (>18 years
 
 - Confirmed COVID-19 infe
 within 48 hours of testin
 
Early Phase 1 ; Paul;Paul ;M_paul@r;+972-50- Rambam M -
 Group 1
 
 
 - Aged 18 to 75 years old
 
 - Individuals with a clinica
Paolo Gisondi paolo.giso +39 0458122547 confirmed by the Investig

 
 1. Sign written informed co
 
 
 3. Conforms to the NCP Cr
Phase 1/PhChina ;; Min Liu, A.B;Min Liu, ;gwzxlium ;13668072 Chongqing Diagnosis

 
 - Highly suspected/confirm
 
 
 - Patients that opt-out
N/A Netherland ; Folkert W. Asselbergs f.w.asselb +31 (0) 88 755 5555;+ 
 
 - Case are adults age = 18
 COVID-19
 
 - Controls are patients adm
 
N/A Hong Kong ; Paul CHAN; paulkscha +852 35053339;+852 <

 
 Cohort 1:
 
 - Females and males over
 
 - Willing to share demogra
 
United Sta ; Daniel R Karlin, MD, ; +1 (201) 212-6643; - Willing to follow app use

 
 - 18 years or older
 
 - Suspected or known Cov
 
onal [Patient Registry] United Sta ; ; Daniel Mollura, MD; ;dgebow@ ;415-244-1Rad-AID; - Image procedure perform
Not Applic United Kingdom Inclusion c Exclusion cr
Exclusion criteria: 1. Anot
 2. Another sleep diso
Inclusion criteria:
 3. 1.
Current
Insomnia
usingdiagno
hypn
N/A China Hongqiang Sun 51 Huayuansunhq@bjm+86 10 82 Peking Univ 2. Insomnia
 4.happened
Individuals after
wh the
Inclusion criteria:
Exclusion
1. The
criteria:
nucleic
1. Have
acid
 2. The 2.
patientSerious
has fevernausea,
or / and
vo
0 China Hong wenxin 627 Dongfewinsonho +86 13729 Guangzhou 3. Aged 3. >=18 Taking
years old.
drugs that m
Inclusion criteria:
Exclusion
Healthy
criteria:
group:
Uninfec
hea
 normal normal
group: diagnosed
group: patien
those
0 China Xiuyong Li 1088 Yinghlxy7111@1+86 13505 2nd People' severe severe
group: diagnosed
group: patient
those w
Inclusion criteria:
Exclusion
1. People
criteria:aged
1. a bet
his
N/A China Zhongyuan Xia 238 Jiefan wenqin-19 +86 27 88 Wuhan Univ 2. People 2.
havemedical-care
electronic social
work
0 China Xiaomei Guo 1095 Jiefa xmguo@tjh+86 13971 Tongji HospInclusion c Exclusion c
Exclusion criteria: 1. Hear
Inclusion criteria:
 2. 1.
Blood
Patients
pressure
with <9
ne
 2. Aged 3.
>=18 Blood
years; oxygen satu
1 China Jiang ZhiXia 149 Dalian jzxhl@126 +86 19385 Affiliated 3. The 4.
limbs function
Respiratory
is soun
freque
Inclusion criteria:
Exclusion
1. Informed
criteria: 1.consen
Neve
 2. Aged 2.
20-65Having
years; a history of
N/A China Yaqin Zhu 500 Quxi R zyq1590@ +86 13817 Ninth Peopl 3. Dental 3.
emergency
Drug abusers.
medical sta
Inclusion criteria:
Exclusion
1. Chinese
criteria:emerge
1. Have
 2. Aged 2.
>= 18Taking
years; antipsychoti
N/A China Xuezhong Yu 1 Shuai-Fu-yxzpumch +86 13601 Peking Uni 3. Meet 3.
ethical
Participating
standards and in clin
b
Exclusion criteria: 1. uncle
 2. participants are no
Inclusion criteria:
 3. 1.
malignancy;
Rheumatic disea
 2. Residents
 4.inpregnancy
Hubei province;
or abor
RetrospectChina Lingli Dong 1095 Jiefa 39317673 +86 02783 Tongji Hosp 3. > 18 5. breast-feeding.
years old.
Inclusion criteria:
 (2)(1)combined
patients with
with ade
 (2) patients
 (3)
agedintolerance
18-80 years to carold
N/A China Shen Chengxing 600 Yishan shencx@sjt+86 18501 Shanghai Si (3) patients
 (4)
who regular
signed f informe
 (2)(1)
severe or or critica
lacta
 (3)
 (2) 18-85 yearsALT
old;/ AST > 5-fold
0 China Weiqin Li 305 Zhongsliweiqindr +86 13951 Eastern the (3) Obtaining
 (4)informed
The diagnosis
consent;of r
Inclusion criteria: 1. aged between 2
 2. generally well;
0 China LI HANG 8 Cao-Lan-Zdrlihang@ +86 13693 Peking Univ 3. ableExclusion
to understand
c and sign a
RetrospectChina Li Chen 150 Jimo R leetangba +86 13585 Shanghai OInclusion Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
Aged 181. toWith
90 y
 (2) Patients
 2.with
witha malignant
definite diagn tum
 (3) Expected
 3.survival
Participated
time in > 10othd
1 China Feng Ganzhu 12 Guangchzhu16352 +86 18951 Huangshi H (4) Serology:
 4. HIV
Severe
antibody
allergicnegati
hist
 (2) Sample size less t
 (3) Samples with sev
0 China Xiang Changgang 1 Wenhua A18971327 +86 18971 The First P Inclusion c (4) The researchers b
Inclusion criteria:
Exclusion
1. Aged
criteria:
18 to
1. 75in pr
ye
 2. mild 2.
or normal
to determine
patients; the h
 3. not using
 Patients
chloroquine
suffering
phosph fro
0 China Xiao Fei 52 Meihua xiaof35@sy+86 13380 The Fifth A 4. under 3.
the gastroscope,
patients suffering
there
Inclusion criteria:
Exclusion
1) Aged
criteria:
18 to
1) 70Prevye
4 China Xianglin Yuan 1095 Jiefa yuanxiangl +86 13667 Tongji Hos 2) Infection
 2)with
Combining
new coronaviru
with ot
Exclusion criteria: ???????
N/A Li Wan 1095 Jiefa wanli0604 +86 13638 Tongji HospInclusion Incomplete medical h
Inclusion criteria:
Exclusion
(1) criteria:
Aged 18-70-yea
(1) Pati
 (2) Non-medical
 (2) Patients
staff andwithstaff
sevew
N/A China Ou Cehua 25 Taiping oucehua@s+86 15608 Affiliated (3) Patients
 (3)
withPatients
non-new whocoronare
Inclusion criteria:
Exclusion
1. Healthy
criteria:male
1. Patieor
1 China Chenyu Zhang 163 Xianlincyzhang@n+86 13913 Nanjing Uni 2. Male 2.
body Patients
weight 50kg,
who femaoften
Exclusion criteria: 1) Preg
Inclusion criteria:
 2) 1)High-resolution
Male or female CTp
 2) Willing
 3)
to sign
Acute
informed
interstitial
conslu
2 China Fu-Sheng Wang 100 West Fofswang30 +86 010-6 The Fifth M 3) Confirmed
 4) cases who meet "N
Inclusion criteria:
Exclusion
1. Hospitalized
criteria: 1. Miss bet
RetrospectChina Lingli Dong 1095 Jiefa 39317673 +86 027-8 Tongji Hosp 2. Diagnosed
 2. with
< 12 years
COVID-19.
old.
Inclusion criteria: 1. Clinical manifest
 2. Pulmonary CT results indicate
RetrospectChina Zejin Liu 300 Taizi zejinliu@1 +86 18963 Wuhan Asia 3. Apparently
Exclusionhealthy
c physical e
 (2) Sample size less t
 (3) Samples with sev
0 China Xiang Changgang 1 Wenhua A18971327 +86 18971 the First P Inclusion c (4) The researchers b
 2. Patients with confirmed cases
 (1) Epidemiology history;1. Patie
Exclusion criteria:
N/A China Dongyang Liu 49 North Huliudongyan+86 18610 Peking Univ (2) Clinical manifestations
 Patients (epide
with identifi
RetrospectChina Fan Rong 87 Xiangya fanrong34 +86 13808 DepartmentInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
Exclusion
 -
criteria:
Patient -
majeR
IV): no - Infection
 -COVID-19
Saturation
confirmÃ©
capillaire
France chef de projets 4 rue Larre DRCI-Promo2.41E+08 CHU Anger - Diagnostic
 - por
DÃ©faillance dâ€™
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
France project manager URCIP - Ba carine.lab 33(0)4771 URCIP- CHUInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France;Bel Christelle DELMAS 8 rue de la rqrc.siege 3.32E+10 INSERM Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
NetherlandJurjan Aman De Boelela j.aman@am3.16E+10 Amsterda Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase Exclusion criteria: 1.
III): no 2. History of psoria
Therapeu Inclusion criteria:
 3. 1.
Tinnitus,
Hospitali
reduce
tic use 2. Adults
 4.18 year
Visual
or older
impairme
(Phase 3. Moderately
 5. Known
severeadverse
disease r
IV): yes 4. SARS-CoV-2
 6. Pregnancy
positive nasoph
Norway Department of Infecti Sykehusveijan.erik.b 4.77E+09 Akershus Un
 5. Signed
 7.informed
Prolonged
consent
QT in
m
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Italy Trial Information SuppGrenzacherglobal.rochegenentec F. HoffmanInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. criteria: 1.
 2. Admission
 2. to Patients
an intensive
treatedc
Not Applic Australia;Hong Kong;Taiwan, Province Of China;Indonesia;Korea, Republic Of 
 
 - Written informed consen
 
 - Has been previously diag
 Corona-like viral infectio
 
Phase 2 Canada Jeremy D Road, MD Professor 1

 
 1. Age 18 to 80.
 
 2. Confirmed COVID-19 dia
 
Phase 2/PhChina;Italy ; Yuguo Chen, Dr;Jiaoji ;jiaojiaop ;(086)053 Qilu Hospit 3. Accord with any of the f
 Inclusion criteria of Cohort

 community acquired pneum
 
 Cohort 1:
 
Phase 2 China ; Jennifer Ho, MD, PhD;;ifan@ans ;+86 186 2 Ansun Biop Subjects must meet all of th

 
 - Formally serving medica
 
 
 - pregnant women;
 
Phase 3 China ; Zhongji Meng;Zhongji zhongji.m 18971905757;+86-18 - severe chronic diseases w

 
 - Norwegian adult
 
 
 - Unable to consent
N/A Norway ; Arne SÃ¸raas, MD, Ph Arne.Vasli +4790652904;+47906 

 
 - People who are feeling s
 
 - People who are feeling s
 
onal [Patient Registry] United Sta ; ; Mark Shapiro;BEAT19.;info@beat;(415) 754 xCures; - People who are not f
 
 All the ED patients positive
 following symptoms:
 
 - fever
 
 - cough/dyspnea
 
onal [Patient Registry] ; Guido Bertolini, MD;G;Guido.ber ;+39 035 4 Istituto di 

 
 - Laboratory-confirmed SA
 public health assay in an
France Olivier HERMINE, MD ohermine@6.04E+08 

 
 - SARS-CoV-2-infection wi
 
 - vv-ECMO therapy
 
 
 - pregnancy, breastfeedin
N/A Germany ;; Alexander Supady, Dr ;alexander ;+4976127 University 

 
 - all known cardiovascular
 
 1. all spectrum of coron
N/A Romania ;; Alexandru Burlacu, MD;;alexandr ;;0040744 University angiopl

 
 - Must have confirmed an
 involvement of lung tissu
 
Early PhaseUnited Sta Robert W Alexander, MD Global All - Must be clear of any vira

 
 ED patients positive to or su
 following symptoms:
 
 - fever
 
 - cough/dyspnea
 
N/A ; Guido Bertolini, MD;G;guido.bert;+39 035 4 Istituto di - res
 
 - Oxygen saturation <93%
 
 - Able to provide informed
 
 - Not currently requiring in
 
 - Receiving oxygen by face
 
N/A United States 

 
 - All patient admitted in IC
 Biological Risk" (REB) bef
 
N/A France ;; Julien Poissy, MD,PhD ;julien.pois;03204444 University H - Clinical i

 
 Recipient:
 
 1. COVID-19 Patients
 
 2. Consent to attend the st
 
 3. Age 30 to 70 years
 
 4. Don't be intubated
 
N/A Iran, Islam Majid Saeedi, Ph.D. Vice-Chanc 5.

 
 - Clinical suspicion of COV
 
 
 - Age less than 18 years
 
N/A Denmark ; SÃ¸ren H Skaarup;SÃ¸ ;soeska@r ;28911869 Aarhus Univ - Previous enrollment in th

 
 - Confirmed cases of Covid
 
 - Mild to severe clinical pr
Phase 3 Pakistan ;; Umar Farooq, PhD;Um;dean@ayu;00923219 Khyber Med National Ea

 
 Laboratory (RT-PCR) con
China Ming Li, M.D. mlid163@1 8.61E+12 
 
 - =18 years old with clinica
 to SARS-CoV-2 AND
 
Michael Eddleston m.eddlest 0131 242 3867 - presenting to the Roy

 
 - 1) Aged 18 or above;
 
 - 2) Laboratory-confirmed
 
 - 3) Pre-existing liver cirrh
 
N/A China ; ; ; ; ; ; ; ; Mingkai Chen, MD;Xia;;;;;;;;;;;; ;;;;;;;;;;;; Renmin Hos 

 
 - A contact person from co
 
 - Medical staff exposed fro
 
Phase 3 ; Yong Goo Song, Profes;imfell@yu ;82-2-2019Gangnam Se
 - Persons exposed

 
 1. < 18 years-old, and
 
 2. Present to a participatin
 
 3. Undergo SARS-CoV-2 te
 
 
Canada ;; Stephen Freedman, ;stephen. ;40395577 University 1) Refusal

 
 1. The patients must be 18
 
 2. Patients who opt in to c
 
 3. Patients must have the
<

 
 - Patients with mild COVID
 
 - Patient within 7 days fro
Phase 2 Joon Young Song, MD infection@82-2-2626-3052 diagnosis (SARS-CoV-2 R
 
 Patients affected by COVID1
 
 
 -
N/A Italy ; ; ; ; ; ; ; ; Guido Iaccarino, MD; ;;;;;;;guia ;;;;;;;+390 Federico II University;Inversity
 of Milan, BICOCC
 Inclusion criteria:

 
 1. Chinese patients, aged 1
 
 2. Diagnosis of COVID-19, a
 
Phase 1/PhChina ; Zhou Qi, Doctor;Wang;wangliu@i;+86-0106 Institute o 3. According to the diagno

 
 - Patients / caregivers trea
 symptomatic infection by
 
N/A France ; Isabelle PELLEGRIN;Is isabelle.p 05 57 82 11 50;05 57 - men and women, adults

 
 - Age > 18 years old
 
 - Expected ICU stay of > 48
 
 - Bilateral Viral Pneumoni
 
 - Orotracheal intubation f
 
Phase 2/Phase 3 ;; Filippo Annoni, MD;R ;;filippo. ;;0032(0)4 Erasme hosp
 
 Inclusion Criteria Donor:

 
 
 - must have been hospital
Phase 1 COVID-19 SARS-CoV-2 RT

 
 1. Female and male patien
 
 2. Confirmed COVID-19 inf
 
 3. Hospitalized at Hasharo
 
Phase 2 Israel ; Zivit Harpaz;Zivit Harp;Zivit@canf;+972-3-9 Can-Fite B 4. Di
 
 - Adults (age =18 years) un
 theatre, this includes obs
 
onal [Patient Registry] Spain ; Enrique M San Norberesannorbe 0034686754618;0034 - Either before or after sur

 
 - Healthcare workers of th
 
 - Patients of the Departme
 
N/A Switzerlan ; ; Guido Beldi, Prof. Dr. ;Guido.Bel ;03163282 University - Written informed consen
 Inclusion criteria :

 
 - > 18 years old
 
 - Suspected of COVID-19 i
 
 Exclusion criteria :
 
; Mehdi BENCHOUFI, M;mehdi.ben;+33(0) 6 3 Assistance - Patients on whom the ul

 
 - Documented COVID-19 p
 (nasopharyngeal swab (N
Phase 2 Fabio Ciceri, MD ciceri.clini +39 02 2643 at co
Not Applic Australia Inclusion c Exclusion c
Exclusion criteria: Confirm
 
 Refusal by participan
 
Not Applic Australia Inclusion c Any o
Inclusion criteria: Diagnosis of IBD: C
Not Applic Australia Exclusion c
 Distress:
Inclusion criteria: Positive for COVID
Not Applic Australia Admission
Exclusion
or being
c considered f
Not Applic Australia Inclusion c Exclusion
Exclusion criteria: â€¢
 â€¢ Allergy to Zn
 â€¢ Severe hepatic im
 â€¢
Inclusion criteria: â€¢eGFR equal to ad
Consenting or
Phase 1 / Australia â€¢ Hospitalized wit
Inclusion criteria:
Exclusion
(1) criteria:
patients(1)
diagno
bod
 (2) patients
 (2)
after
heart
discharge;
rate at rest>
 (3) patients
 (3)
aged
continuous
18 to 80 oxyge
years
0 China Jinghua Qian 48 Xinxi Roydkfedu@1+86 18600 Beijing Spo (4) patients
 (4)
voluntarily
patien agree to
Inclusion criteria: Laboratory confirm
RetrospectChina Jinzhi Lu 8 Hangkongjinzhilu2 +86 18163 The First A all COVID-19
Exclusion
p c
Inclusion criteria: 1. Discharged patie
 2. WithExclusion
dyspnea criteria:
symptom 1. (mM
Dysp
 3. Aged 2.
18~75Resting
years old;
heart rate>
 4. Have 3.
and can
Adjusting
use smartdosage
phono
N/A China Li Jianan 300 Guangzlijianan@n +86 13705 Jiangsu Pro 5. Obtain 4.
the Combined
consent of uncontr
the sub
N/A China Liping Jia 11 Kaopeng41025513 +86 15171 HuanggangInclusion Exclusion c
Inclusion criteria:
Exclusion
1. Students
criteria: 1.
cursing
Staff
N/A Bolivia DIANA MARIA CESPEDSuit 29, U dicespede +86 15549 Wuhan Univ 2. Students
 2.currently
Incomplete registered
inform
Inclusion criteria: 1. Patients with clin
RetrospectChina Qianjin Lu 139 Renminqianlu586 +86 13797 The Second 2. HaveExclusion
exposurec to people with
Inclusion criteria:
Exclusion
1. Aged
criteria:
above
1. Fami
18 y
 2. Able 2.
to understand
Subject allergic
the conte
to
2 China Zhu Fengcai 172 Jiangsujszfc@sina-83759357 Jiangsu Pro 3. Able 3.
and willing
Woman to complete
who is prea
Retrospect?? Shengtian Zhao 324 Jing-W39813984 +86 15153 Shandong PInclusion c Exclusion c
0 Guihua Liu 18 Daoshanlgh198706 1.84E+10 Inclusion c Exclusion c
Inclusion criteria: 1. suspicion of COV
N/A China Sanlian Hu 600 Yishan liuliu902 +86 18930 Shanghai Ji 2. agedExclusion
>16 years. c
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Patie
Co
RetrospectChina Yun Liu 300 Guangzyanggang2 +86 18601 the First A 2. Patients
 2.
diagnosed
The medical withrecord
Coro
Exclusion criteria: 1. Parti
Inclusion criteria:
 2. 1.
Patients
Aged 18-45
with hype
year
 2. Inpatients;
 3. People with other
N/A China zhu pengfei 473 Hanzhehappyzhup 8.61E+12 Wuhan Four 3. According
 4.toPatients
the novelwithcorona
othe
Exclusion criteria: 1) left h
 2) pregnancy and lac
 3) 1.
Inclusion criteria: liver
Agedfailure MELDol
18 years
 4) with
 2. diagnosed a history
viral of deep v
pneumon
0 China Enhai Cui 198 Hongqikjkceh@12+86 13857 Huzhou Cen 3. voluntary 5)informed
cases that consent
the
N/A China Junxue Wang Zhiyinhu A docd1@sin 1.89E+10 Huoshensha 2. Pneumonia
Exclusion c
patients with new
 2. Previous history of
Inclusion criteria:
 3. 1.
Inability
Patients toaged
commu 14
 2. Real-time
 4.fluorescence
Patients withrt-pcracqu
N/A China Ying Fan 600 Yishan fanyingsh +86 13918 Shanghai Ji 3. The 5.
respiratory
Patients
tractwith
specime
malig
Exclusion criteria: (1)Uncl
 (2)Insufficient
Inclusion criteria: (1)Completesample samp
N/A China Zhang Chunyan 28 Fuxing Rrebrcca@1+86 18810 Chinese PL (2)New (3)Contaminated
coronavirus-infectedsam pn
0 China Tangshaohua Kang-Le-Fatsh006@16+86 13858 Wenzhou Ce Inclusion c Exclusion c
RetrospectChina Bai Xiaoxia 1 Xueshi R baixiaoxia +86 13957 Women's Ho Inclusion c Exclusion c
Inclusion criteria: 1. Meet the history
 2. Meet Exclusion
the discharge
criteria:
standards
1. Patie
0 China Yingshuai Li 11 Beisanhuliyingshu +86 13681 Beijing Uni 3. Meet 2.
the diagnosis
Patients standar
who have
Inclusion criteria: 1. Confirmed cases
25-65 years;
criteria: 1. With
 3. Asexual
 2.
difference;
Patients with malig
 4. Clinical
 3.
stage
Pregnant
(light, common
women;
1-Feb China Zhenlin Zhao Floor 10, B zhaozl200 +86 13828 Shenzhen R 5. Immunology
 4. HIV standard:
positive.periph
Inclusion criteria:
Exclusion
1. Aged
criteria:
>181.years
Patieo
RetrospectChina Rui Zeng 37 Guoxue zengrui_0 +86 028-8 West China 2. patients 2.
diagnosed
Give up treatment
COVID-19
N/A China Weng Jianping 17 Lujiang wengjp@us+86 0551- the First A Inclusion c 2. Patients developed
Inclusion criteria: (1) Comply with th
 (2) Patients
Exclusion
=18 years
criteria:
of 1.Serio
age wit
4 China Yun Lin 1277 Jiefanfrank0130 +86 13986 Union Hosp (3) Agree
 2.Obstructi
to participate in the
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu Exclusion criteria: â€
tic use Inclusion criteria:
 â€¢ â€¢
Pregnancy
COVID-19
(Phase â€¢ Age 
18 years
â€¢ Prisoners
or older
IV): no â€¢ Presence
 â€¢ ofNaproxen
pneumonia allerg
France Eldoie SOLER DRCI, 1 av elodie.sol +3301 44 8Assistance â€¢ PaO2/FiO2
 â€¢ Severe
< 300 mmrenal
Hgfailu
or
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
Exclusion
 1.
criteria:
At least
 1.
18 y
IV): no 2. Clinically
 2.evident
Intubated
or otherwise
> 48h at
NetherlandClinical Research an Winzerlaer korinna.pil +4989414 InflaRX G â€¢ Chest
 3.
X-ray
Patients
or CT-scan
who dem
or M
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Project manager URCIP - Ba arnauld.ga 33(0)4771 CHU Saint Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III):
Therapeu
tic use
Exclusion
 I1.
criteria:
Age E1
18 or o
IV): no I2. Histologically
 E2. Fororcohort
cytologically
2 only
France Julien GAUTIER 28 rue Lae julien.gaut +33426 55 Centre LÃ I3. E3. Contraindication
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use Exclusion criteria: Su
 1. Subjects
Shock requiring
meeti
IV): no 1. Age 2.
= 18 year/old
Acute respirator
France Carla VANDENABELE DRCI HÃ´pitcarla.vand +33140 27 ASSISTANC 2. Chronically
 3. Circulatory
treated withassi
RA
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Inclusion criteria: â€¢ All types
tic use â€¢ Male/female participants
(Phase â€¢ Age>18
Exclusion
y.o. criteria: â€
IV): no â€¢ Signed
 â€¢
informed
Patients
consent
with kn
fo
France â€¢ No â€¢
restriction
Patients
on Eastern
current
Co
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France REC 12 rue dub patrick.ca 3.31E+10 CENTRE HOInclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain SCREN-UICEC profesor mafibucicec. 3.49E+14 FIB-HCSC Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu Exclusion criteria: 1.
 2. 1.Age
Grossesse =ou18allait
yea
(Phase 2.Admitted
 3.toCorticothÃ©rapie
ICU within 48 hou
IV): no 3.Confirmed
 4.orInfection
highly suspected
bactÃ©r
France DRCI 1, Avenuesfadila.amerali@aphp.fAPHP 4.Acute 5.
hypoxemic
Absencerespiratory
de consen f
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Xavier Solanich More Feixa Llarg xsolanich@b3.49E+10 Dr. Xavier Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain UICEC Sant Pau Sant QuintÃ
epenag@sa
77-79 3.49E+10 INSTITUT Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Clinical Trials Depart PÂº Castellana 127-1 3.49E+10 Effice Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain LOLA SERNA GUIRAO LUIS FONT lola.serna@carm.es FFIS Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Clinical research proj 133 Avenuel.lamrani@ 3.31E+10 Groupe Hosp
Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Clinical Research Dire 29 rue Manpvachey@fo3.31E+10 HÃ´pital F Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Unidad de EnfermedadCamino de gutierrez_ 3.5E+10 FISABIO Inclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Jose MuÃ±oz GutiÃ©rCalle Ross jose.munoz 3.49E+14 ISGlobal Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Emilio Garcia Cabrera Calle Casti secretaria@delosclini Delos Clini Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Epidemiologist Plaza de Creunate.ara 3.49E+10 Eunate AranInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Anabel SÃ¡nchez Carretera anabelsan 3.49E+10 FundaciÃ³nInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Greece President of the Boar 88 Michalainsepsis@o 3.02E+11 HELLENIC I Inclusion Exclusion c

 
 1. Admitted to the intensiv
 diagnosis;
 
Phase 3 Canada ;;; FranÃ§ois Lamontagn ;;marie-he ;;819-346- UniversitÃ 2. Currently treated with a

 
 - 1. Suspected cases (form
 
 Meet the following 2 at the
 
N/A China ;; Yao Xie, Doctor;Yao Xi;xieyao00 ;8610-843 Department Epidemiological history The

 
 printing and distributing
Phase 3 China Hongzhou Lu, Ph.D luhongzho-37990268 cor
 
 printing and distributing
Phase 3 China cor

 
 - Admitted to intensive ca
 
 - Adult (aged over 18 year
 
China - Anticipate a length of ICU

 
 1 ) Any adult or child or me
 who presents an infectious
 
France ; Philippe VANHEMS, M;philippe. ;04 72 11 Service Hy 2) Suspect Ca

 
 - Aged 18-75 years old;
 
 - Pneumonia patients with
Phase 4 China Yahong Chen, MD Ascletis Ph RT-PCR and clinical mani

 
 - DoD-affiliated personnel
 emergency-essential civi
Phase 1 Sandi K Parriott sandi.k.par301-619-6824 Armed Forces w

 
 - Blood donors whose last
 
 
N/A China - Blood donors whose blo

 
 1. Clinically diagnosed with
 
 2. Increased interleukin-6
 
 3. Sign the informed conse
 
N/A China ; Guiqiang Wang;Guiqi ;john1312 ;13911405 Peking Univ 4. Subjects who can take m
 
 - SARS-CoV2 Infection diag
 
 - CT-scan confirmed multi
 
 - Need of oxygen therapy
 
Phase 2 Italy -

 
 1. Any gender
 
 2. No age limit
 
 3. Informed consent for pa
Phase 2 Italy ; Francesco Perrone, M ;f.perrone@;+3908159 Istituto Na consent cannot be expre

 
 - Medical Physicians in Mi
 
 
 - none
N/A Egypt ;; Aliae Mohamed-Hussei;aliaehuss ;01222302 Assiut Univ 

 
 1. Age > 70 years
 
 2. ICU-Admission
 
 3. Infection or suspected in
 
 
 1. Age <70 years
N/A Denmark;F Christian Jung, MD contact@vi 2.12E+09 

 
 - Able to consent and agre
 
 - Coming to The Everett C
 
United Sta Ethan Berke, MD UnitedHeal - Ev

 
 - SARS-CoV-2 infection con
 
 - Positive imaging: consoli
Phase 2 Denmark ; Lars Erik Kristensen, ;lars.erik. ;0045 381 The Parker infiltration either by CT-s
 
 1. Signed informed consen
 authorized representativ
 
Phase 2/PhItaly ; Emanuele Nicastri, M ;sobi.imm ;+46 8 697 Direttore D 2. Documented presence o

 
 - Patients must be 18 year
 
 - Hospitalized with COVID
Phase 2 United Sta Michael Joyner, MD Mayo Clini SARS-CoV-2 RT-PCR testi

 
 1. person who are working
 case
 
 2. Their first degree relativ
 
Turkey ; Mahir M Ozmen, Profes
ozmenmm@g
+905324246838;+905 
 Inclusion criteria

 
 1. Hospitalized patient
 
 2. Laboratory confirmation
 
 3. Randomization within 7
 
Phase 2/PhUnited Sta ; ; Daniel Freilich, MD;Je ;jennifer.v ;60754769 Bassett Me<

 
 The following persons may
 
 - A patient of any age mee
N/A Switzerlan ; ; Claire-Anne Siegrist, ;claire-ann ;+4179553 Professor o confirmed case definition

 
 - Men and non-pregnant w
 
 - Known diagnosis of hype
 
 - Current use of ACEi or AR
 
Phase 4 Ireland ;; John William McEvoy ;johnwilli ;+353 9 15 National Un -

 
 1. Patients who meet the r
 respiratory infection sym
 
Phase 4 Javier Crespo, MDPhDjaviercre 9.42E+08 2. Aged =
 
 - informed consent was gi
 
 - age = 18
 
 - able to complete the que
 
 - country of residence: Ge
 
Germany ;;; Andreas StrÃ¶hle, Pro;;antonia. ;;+4930450CharitÃ©-U Exclus

 
 Definitely positive COVID-19
 
 
 Patients with acute respirat
 
 1. Spo2<60%
 
Phase 2/PhIran, Islam ; ; Siamack Afazeli;Siamac;Dr.afazel ;+9891213 Fasa Univer 

 
 - Adults of 18 years and ab
 been approved for down
N/A United Sta ; Tim D Spector;Victori ;victoria.v ;02071886 King's Coll 

 
 - COVID-19 infection diagn
 
 - Need for supplemental o
 
 - 12 years of age or older
 
N/A Canada ;;; Steven Chan, M.D.;Vik;;steven.c ;;416-946- Princess M 

 
 - Age = 18 years
 
 - Negative PCR and negati
 
 - Healthcare worker at Ho
 
Phase 3 Spain ; Jose MuÃ±oz GutiÃ©rr;jose.muno;60877407 Barcelona I - Female participants: neg

 
 - Subject (or authorized le
 before beginning any stu
 
Phase 2 Spain ; Pere Domingo, MD, P pdomingo@; - Understand and agree to
 
 - All gender patients aged
 
 - Patients with SARS-CoV-
Italy ; Roberto Giacomelli, roberto.gi 0039 0862 434742;08 involvement, hospitalize

 
 
 2. Age =/>40 or diabetes o
 
 3. Requires hospital admis
N/A United Ki ;; Prapa Kanagaratnam, ;alena.mar ;07776 22 Imperial C 
 - Hospitalisation in the acu
 in St Nicolas during the is
 
France Cedric ANNWEILER, Mceannweile(+33)241354725 Ex

 
 - HIV disease
 
 (PCR) or other commerci
 
onal [Patient Registry] United Sta Dima Dandachi, MD dandachid@
573-884-8728 

 
 - Non-severe symptomatic
 gastrointestinal symptom
N/A Spain ; Manuel J Castillo, MD ;mcgarzon ;+34 6494 Universida respiratory i

 
 - Adult, Age>44 years, com
 
 - Confirmed COVID-19, via
 days
 
Phase 3 United Sta ; Brandon Webb, MD;Va;Valerie.A ;80150746 Intermounta
 Excl

 
 - In-patients fulfilling the f
 
 SARS-CoV-2 infection In-pati
 observational study
 
Germany ;; Anselm Gitt, MD;Anse ;gitta@klil ;+49 621 5 Stiftung IH 
 
 - Patients admitted to the
 congestion and/or dyspn
 
United Sta ; Efstratios KoutroumpaEfstratios 4123203161;412-320- Exclusion

 
 1. Aged 18-65 years;
 
 2. Voluntarily participate in
 
Phase 1/PhChina ;; Prof. Qingsong Ye, P ;qingsongy ;+8615858 Center for 3. Diagnosed with severe p

 
 All subjects participating in
 
 1. According to the Diagno
N/A China ; Zhang Ze Guang, doct zheng862018928868242;86-20- 

 
 - All subject except exclud
 
 
 - subject diagnosed as CO
N/A Egypt ; Aliae Mohamed-Hussealiaehusse 01222302352;+20122 

 
 - Volunteer to participate
 
 - Being pregnant
 
 - Aged between 18 - 45
 
 - To understand Turkish
 
N/A Turkey ; Ayse Zengin AlpÃ¶zgenazengin@is(212) 866 37 00 43144 - Spend most of th

 
 1. Voluntarily participating
 informed of the study an
Phase 3 Italy Giuliano Rizzardini, Md ASST Fateb 

 
 - Patients that have been
 
 
 - Patients that do not have
N/A United Ki Harry Hothi, PhD harry.hoth +44 (0) 20 8909 5847? 
 
 - admission to the intensiv
 
 - with a proven COVID infe
 
 - agree with participation
 
N/A France ;; Pierre Asfar, MD, PhD;;piasfar@c ;+3324135 CHU Angers<

 
 - Documented COVID19 p
 infiltrates on chest x-ray
Phase 2 United Sta Antonio Abbate, MD, PhD Virginia C wi

 
 - Aged 18 years or over.
 
 - Able to provide written c
 
 
 - Any participants that wit
 
N/A ; Ara Darzi, Prof;Fahad ;f.iqbal@im;07588550 Institute o 

 
 - confirmed COVID-19 pati
 reverse-transcriptase po
N/A China pharyngeal swab sp

 
 - Older than 18 years of ag
 previously tested positiv
 
N/A Denmark ;;;;; Henrik Ullum, Prof., ;;;;hennin ;;;;+4526 Rigshospita - Participant is outside the

 
 1. Adults residing in the Un
 understanding and readi
United Sta Rama Jager, M.D. rjager@bea(708) 620-4608 against

 
 - Confirmed or suspected
 
 - Patients admitted to ICU
 vasopressors.
 
France Xavier Monnet, MD.P xavier.mo +33 01 45 21 35 39 - Monitored by
 
 - Patient with COVID-19 co
 in-charge physician,
 
 - =18 years old,
 
; ; ; ; ; ; ; ; ; Philippe LE CONTE, P ;;;;;;;;;Fr ;;;;;;;;;33 University - Not requiring respi

 
 - Age at least 18 years
 
 - Laboratory confirmed di
 
N/A United Sta ; Michael Joyner, MD;M;USCOVIDp;507-255-4Mayo Clinic - Admitted to an acute car

 
 1. Confirmed SARS-CoV-2 (
 
 2. Either gender
 
 3. Symptomatic for examp
 
Phase 3 ; Javed Akram, FRCP;S ;shehnoor ;+92 321 4 University 

 
 1. 18-70 years old (includin
 
 2. Infection with new coro
Phase 2 Huilan Zhang, PD Huilanz_7 1.54E+10 test. P

 
 - Participants =18 years of
 randomization
 
 - Willing and able to provi
 
Phase 4 

 
 - Patients with diagnosis o
 
 
 - Patients refuse to partici
N/A 
 
 - Positive reverse transcrip
 syndrome coronavirus 2
 
 - Age 18 and older
 
United Sta ; David Levine, MD;Da dmlevine@617-732-7063;617-73 Exclusion Criteria

 
 - Indian males and female
 
 - All the employees of Ma
 
 
India ;; Sujeet Jha, MRCP (U.K;sujeet.j ;+9199106 Max Health 

 
 1. Male or female, 18 year
 
 
Phase 1/PhChina ; Yan Liu, MD;Yan Liu, 44782285 +8613387517458;+86 3. Laboratory confirmation

 
 
 
 - None
N/A United Sta ; ; Tushar Patel;Robert ;brannock ;904-953-2Mayo Clinic 

 
 - COVID-19 infection confi
 
 - New onset radiological in
 
 - Respiratory failure (PaO2
 
Phase 3 Spain ;; Xavier Corbella, MD, ;xsolanich@;0034 932 Hospital Un - PCR

 
 - Liver, Heart, Lung or Kidn
 diagnosis of COVID-19
 
Alana Burns aburns@ca415.287.2420 
 
 - All types of locally advan
 
 - Male/female participant
 
 - Age>18 y.o.
 
Phase 2 France ; Lisa DEROSA, MD;Lis lisa.deros 0142114211;0142114 - Signed informed consen

 
 - Patient is 18 to 80 years
 
 - Patient must have histol
 
N/A China ; Qinglei Gao, Dr.;Qingl qingleigao +86-13871127473;+8 - Chemotherapy must be

 
 - Any employee of Lake Fo
 
 - Age greater than 18 year
 
 
Andrew Gostine, MD andrew.go (312) 695-0061 - Age less than 18 years-

 
 - Patients:
 
 - Age>18y
 
 - Admission to the parti
France ;; Elie AZOULAY, MD Ph ;nancy.ken ;14249999 APHP; during the COVID-19 p

 
 - Clinical criteria for suspic
 respiratory infection (rhi
N/A ; Delphine Garrigue, M ;Delphine.g;03 20 44 University H s

 
 - Patients with acute resp
 based on assistant clinici
 
 
N/A Spain ;;; Miguel Guia;Antonio E;;miguelg ;;0035191 Hospital G -
 
 - between the ages of 18-
 
 - works from home
 
 - works in the office befor
 
 
Ayse Zengin AlpÃ¶zgeazengin@is 9.06E+11 - have any systemic

 
 
 - Age above 18 years
 
 - Women of childbearing a
Phase 3 Germany ;; Benjamin MordmÃ¼ller
;diane.egg ;+4970712 University contraception for t

 
 - Patient over the age of 1
 
 - Diagnostic COVID-19 by
 
 - Hospitalisation in resusc
N/A France ;; Pierre-Emmanuel FAL ;pierre-em ;33 3 69 55Service de 

 
 All mission critical personne
 Flight Medicine Clinic unabl
Phase 2 United Sta ; ; ; ; ; Angela Phillips, PhD; ;;;;usaf.p ;;;;703-69 11 MDG;NM
 

 
 - confirmed COVID-19 dise
 
 - refractory shock with ne
 
 - IL6 = 500 ng/l
 
N/A Germany ;; Stefan Kluge, MD;Dom;d.jarczak ;+49 40 74 University - Indication

 
 general surgeon
 
 
 other speciality
Italy 
Inclusion criteria:
Exclusion
Inclusion
criteria:
Criteria:
Exclusio
 â€¢ Score
 â€¢
of greater
Currentthanpsychos
or equ
 â€¢ Aged â€¢
at least
Imminent
18 yearssuicid
 â€¢ Sufficient
 â€¢English
Current language
substan
 â€¢ Access
 Noto teleconferencing
access to internet
Not Applic Australia 
Not Applic Australia Inclusion Exclusion
Not Applic Australia;China;United States of America;Italy;Germany;Spain Inclusion c 
 â€¢ Previously diagn
Inclusion criteria:
 â€¢ Adult
Previously
(18+ yearsdiagnol
 (a) confirmed
 â€¢COVID-19
Known tosympto
be pre
Phase 0 Australia (b) symptom
 onset within the pa
Phase 3 Australia Inclusion c Exclusion c
Inclusion criteria: Mechanically venti
 COVID-19 positive
Not Applic Australia AdmittedExclusion
to Intensive
c Care Unit
Exclusion criteria: 1)
Inclusion criteria:
 2) Hospitalised
Patients with patien
kn
 1) Expected
 3) toReceiving
remain an invasiv
in-pa
Not Applic Australia 2) Features
 4) consistent with un
Patients with vir
Exclusion criteria: 1. Alrea
Not Applic New Zealand Inclusion cr 2. Taking immune su
Exclusion criteria: 1. not q
 3. 1.
Inclusion criteria: There
novelare factors i
coronaviru
N/A China Yang shenglan 1277 Jiefa yangsheng +86 13995 Union Hosp 2. age 4. Those
unlimited, who
male anddofema
not
0 China Xun Liu 600 Tianhenaturesty +86 18922 The Third AInclusion c Exclusion c
RetrospectChina Zhang Yuanli 57 Renmin zhangyuan +86 13828 Affiliated Inclusion c Exclusion c
0 China Chuanan Shen 51 Fuchengshenchuan +86 010 6 The FourthInclusion c Exclusion c
 2. having a history of
Inclusion criteria:
 3. 1.coagulation
Aged >=18disordyears
 4.
 2. Patients explicit history
suspected of havingof t
0 China Shuyi Pan 5. fluorescent
6 Fucheng Rpsy99920 +86 18600 Sixth Medic (1) Real-time having a history
RT-PCRof
Inclusion criteria:
Exclusion
1) Positive;
criteria: 1) Thos
Diagnostic China Fan Yang 1277 Jiefa fyang@vip +86 027 8 Union Hosp 2) CT examination.
 2) Patients who are u
Inclusion criteria: 1. at least 18 years
 2. Confirmed COVID-19 patients
RetrospectChina Xiong Ma 160 Pujian maxiongm +86 13636 Renji Hospi 3. pre-existing
Exclusionchronic
c liver dise
Inclusion criteria: 1. At the time of si
 2. Covid-19 convalescent
Exclusion criteria: 1.patien
The r
4 China Huang Mingxing 52 Meihua huangmx5@ +86 15989 The Fifth A 2. Known allergic rea
 (2) positive nucleic ac
Inclusion criteria:
 (3)(1)positive
novel coronavir
IgM of SA
 (2) the (4)
co workedpositive
personnel
IgG ofwe SA
0 The PeopleLingru Li 11 North ThLilingru9 +86 13426 Beijing Uni (3) the (5)
detectionpregnant or prepa
RetrospectChina He-Feng Huang 910 Hengshhuanghefg +86 021 6 InternationInclusion Exclusion c
Exclusion criteria: (1) Peo
Inclusion criteria:
 (2)(1)People
Both male
with pulm
and
 (2) The (3)
territoryCombined
is limitedwith
to wum
N/A China Lu Cheng 16 Nanxiaolv_cheng0 +86 010-64093264 (3) Voluntarily
 (4) Pregnant
participatewomen
in the
Inclusion criteria: 1. Age is not limite
RetrospectChina Chen Miao 149 Dalian 76459095 +86 13595 Affiliated 2. The Exclusion
diagnosis cis in accordance
N/A China Prof. KS Chan Paul Departmentpaulkscha +852 3505 The ChinesInclusion c Exclusion c
Inclusion criteria: 1. Patients who ha
betweencriteria:
18 to 801.years
Patie
N/A China Luping Lin 627 Dongfe13533550 +86 13533 Guangzhou 3. the subjects
 2. The participating
compliancethe of
Inclusion criteria: 1. Adult >= 18 year
 2. Laboratory confirmed COVID-
N/A Christopher KC Lai 1/F Lui Chechris.kcla +852 5569 Chinese Un 3. Provide
Exclusion
directcclinical care to
Inclusion criteria:
Exclusion
1. Upon
criteria:
the1.judgm
The s
1 China Yongxiang Yi 1-1 Zhongfuhcm20070 +86 13584 Nanjing Se 2. According
 2.toThethesubject
new type
suffers
of
0 China Shan Chunlei 1200 Cailu shanclhap +86 18616 Shanghai UnInclusion c Exclusion c
Inclusion criteria: 1. Patients with co
 2. Above 18 years old (inclusive)
 3. At the time of enrollment, the
4 China Zhong Nanshan/Zhang385 Xinshi jiactm@16 +86 0311 Hebei Yilin 4. Voluntarily
Exclusionsign
c written i
Inclusion criteria: 1. Those who meet
 2. Over 18 years old (including 1
4 China Zhong Nanshan/Zhang385 North Xjiactm@16 +86 0311- Shijiazhuan 3. At the
Exclusion
time ofcenrollment, the
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
France PÃ´le Promotion - DRCHÃ´pital St aurelie.zin 3.31E+10 ASSISTANCEInclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
NetherlandCardiology Research Geert Grooteplein Zui 3.16E+10 Radboudu Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
Exclusion
 -
criteria:
Subject Pa
Male
IV): no - Subject
 -
infected
Patients
with
with
COVID
COVID
19
France Eric DEMONSANT 1 place de dpidrci@ch 3.34E+10 HÃ´pitaux U - Clinical
 -
manifestation
Patient on Sartan
of COVID
(T
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Alberto Borobia Paseo de laa.borobia 3.49E+10 Servicio de Inclusion
FarmacologÃ
Exclusion
a ClÃnica.
c Unidad de En
Human
pharmaco
logy
(Phase I):
yes
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain BegoÃ±a Castro Parque Tecbcastro@hi 3.49E+10 Histocell S. Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Clinical Trial Unit Torre GlÃ²rregulatory 3.49E+10 Medica Sci Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain CLINICAL RESEARCH UAvenida reymireia.arc 3.49E+14 FUNDACION
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Ana Aldea IMIM. Dr Aaaldea@im 3.49E+10 Consorci Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes Exclusion criteria: --
Therapeu Inclusion criteria:
 - contraindication
 Written informto
tic use Adult under
 Oxygen
75 yearssaturation
old ra
(Phase - documented
 - <90%infection
in ambient
with SA
air
IV): no - COVID-19
 -symptoms
<94% withoccurring
oxygen t
France Claire CHAUVETON 191 avenuedepotAC@ch3.31E+11 University - need for oxygen ther
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
France Regulatory Project M 3 QUAI DESdrci_promo472406829Hospices CiInclusion criteria:
Exclusion
 -
criteria:
Age -
= 18
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Chef de Projet 4 Rue Larr justine.go 2.41E+08 CHU Anger Inclusion criteria:
Exclusion
 -
criteria:
Age = -
70 ansD
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain ComisiÃ³n de Investig Calle Cami fernando.b 3.49E+10 Hospital UnInclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Felipe GarcÃa Villarroel fgarcia@cli 3.49E+14 Hospital ClÃ
Inclusion
nic c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Salvador Augustin Passeig Vall d'Hebron, 3.49E+10 FundaciÃ³ HInclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Alberto Borobia Paseo de laalberto.bo 3.49E+10 FundaciÃ³nInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Clara MenÃ©ndez RossellÃ³ clara.menendez@isgloBarcelona IInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Inclusion criteria: 1. Age> 18 yea
tic use 2. COVID-19
Exclusion
positive
criteria:
documente
 1.
(Phase 3. Documented
 2. AST interstitial
/ ALT values
pneug
IV): no a. Fever 3.
= 37.8ÂºC
Neutrophil
in ear values
Spain Rosario GarcÃa de VicuÃ±a
Diego de L mariadelro 3.49E+10 Rosario GarcÃ
 b.
a deIL-6
VicuÃ±a
 4.
in serumPlatelet
= 25 ng values
/ mL of l
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Alberto Borobia Paseo de laalberto.bo 3.49E+10 FundaciÃ³nInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Margarita GarcÃa MartÃ
AvnGran Viamgarciamar3.49E+10 Institut CatalÃ
Inclusion
dâ€™Oncologia
c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Kingdom Cambridge ccturegula 1.22E+09 Carrie Bayl Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Greece President of the Boar 88 Michalainsepsis@o 3.02E+11 Hellenic In Inclusion Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Subdirectora CientÃfica
Avd. MenÃ©
gestioncien 3.5E+10 Instituto d Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain CRO Paseo de l enrique.co 3.49E+10 Effice spi S Inclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain SPONSOR LUIS FONT Lola.serna 3.5E+10 FFIS Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Unidad de InvestigaciÃ³n
Avenida
ClÃnica
Remireia.arc 0034915 5 FundaciÃ³nInclusion
Instituto cdeExclusion
InvestigaciÃ³n
c Sanitaria
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Ghana;NigeDonna Smith Public Heald.smith.6@bham.ac.uUniversity Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase Inclusion criteria: 
IV): yes - RecentExclusion
(=2weekscriteria:
prior to
 -
randP
Belgium HIRUZ CTU C. Heymanshiruz.ctu@ 3.29E+09 University - In some
 -
patients,
mec it may be
2-Mar Iran (Islam Mandana Puladzadeh Ahvaz Jundiparastoom +98 61 337Ahvaz UnivInclusion c Exclusion
4 Iran (Islam Maryam Bahreini Sina Hospi bahreinim +98 21 631Tehran UniInclusion c Exclusion c
2-Mar Iran (Islam Hossein Khalili Departmentkhalilih@tu+98 21 669Tehran UniInclusion c Exclusion c
2-Mar Iran (Islam Hossein Khalili Departmentkhalilih@tu 9.82E+10 Tehran UniInclusion c Exclusion c
2-Mar Iran (Islam Amir Hossein JamshidiNo 847, Behjamshidi.a +98 21 556Iran UniverInclusion Exclusion c
3 Iran (Islam Farzaneh Dastan Dr. Masih f_dastan@s+98 21 261Shahid Behe Inclusion Exclusion
N/A Iran (Islam Zeinab Nikniaz Liver and g znikniaz@ +98 41 333Tabriz UnivInclusion c Exclusion c
3 Iran (Islam Dr Khalil Ansarin Imam Reza dr.ansarin +98 41 333Tabriz UnivInclusion Exclusion c
2 Iran (Islam Dr Ehsan Aali Bahonar en.aali@gm+98 28 333Qazvin UnivInclusion c Exclusion c
N/A Iran (Islam Reihaneh Pirjani MD. Arash Hospipirjani@raz+98 21 778Tehran UniInclusion c Exclusion c
N/A Iran (Islam Narjes Heshmatifar School of nheshmati +98 51 440Sabzevar Un Inclusion c Exclusion c
3 Iran (Islam Nader Tavakoli Rasoul Akratavakoli.n +98 21 665Iran UniverInclusion Exclusion c
1-Feb Iran (Islam Dr Mahdi Khozaei Bozorgmehmahdi_kho+98 31 326Islamic AzaInclusion c Exclusion c
3 Iran (Islam Lotfollah Davoodi Amirmazanlotfdavoo +98 11 333Mazandaran Inclusion c Exclusion c
3 Iran (Islam Hojjat Pourfathi Nem Faculty of hojjatpou +98 41 333Tabriz UnivInclusion c Exclusion
3 Iran (Islam Pooya Payandemehr Imam Khome p-payandem+98 21 631Tehran UniInclusion Exclusion c
2 Iran (Islam Alireza Farsinejad Paramedicalafarsineja +98 34 313Kerman UniInclusion Exclusion c
3 Iran (Islam Dr. Saeed Soleiman MNo 29, 1th dr.saeed. +98 21 441Artesh UnivInclusion c Exclusion
2 Iran (Islam Farzaneh Dastan Valieasr St f_dastan@s+98 21 882Shahid BeheInclusion Exclusion
3 Iran (Islam Saba Ghaffary Shahid Ghazghaffarys@+41 33365 Tabriz UnivInclusion Exclusion
3 Iran (Islam Saba Ghaffary Departmentghaffarys@+98 33266 Tabriz UnivInclusion Exclusion
3 Iran (Islam Seied Amirhosein LatifArak Universeiedalati +98 86 341Arak UniverInclusion c Exclusion c
2-Mar Iran (Islam Dr. Siamack Afazeli Unit704, Nodr.afazeli +98 21 664Fasa UniverInclusion c Exclusion c
2 Iran (Islam Hamidreza Khorram K Kodakyar Av hrkk1@uswr+98 21 221University Inclusion Exclusion
3 Iran (Islam Farbod Rahnama Chit No. 119 Sh farbod.chi +98 21 841Medical CouInclusion c Exclusion c
2 Iran (Islam Sara Mobarak - S.mobarak +98 61 532Abadan UniInclusion c Exclusion c
N/A Iran (Islam Hassan Abolghasemi Baqiyatallah.abolgha +98 21 812Bagheiat-alInclusion Exclusion
3 Iran (Islam Haleh Tajadini No. 9, Jah drhalehtaj +98 34 324Kerman UniInclusion c Exclusion
3 Iran (Islam Dr Khalil Ansarin Immamrezadr.ansarin +98 41 333Tabriz UnivInclusion Exclusion c
1 Iran (Islam Hasan Abolghasemi Hemmat HW h.abolgha +98 21 812Bagheiat-alInclusion c Exclusion c
N/A Iran (Islam Atefeh Ahmadi Pardis of K a.ahmadi@+98 34 313Kerman UniInclusion c Exclusion cr
2-Mar Iran (Islam Kourosh Sadeghi No. 226, Qokourosh.s +98 21 888Tehran UniInclusion c Exclusion c
2-Mar Iran (Islam Dr Nafiseh Abdolahi Sayyad Shirn_abdolah +98 17 322Gorgan UniInclusion c Exclusion c
3 Iran (Islam Armin Sadeghi Golgasht A arm.sad@g+98 41 333Tabriz UnivInclusion Exclusion c
2 Iran (Islam Masoumeh AsgharpouGanjafroozmasi99320+98 11 321Babol UniveInclusion c Exclusion c
3 Iran (Islam Sama Bitarafan Floor 4, Ir Bitarafans +98 21 669Tehran UniInclusion c Exclusion c
3 Japan FUJIFILM Toyama Chemical Co., https://www.fujifilm.co.jp/form/ Inclusion c Exclusion c
2 Japan Tetsuya Nakamura 3-39-15 Sh nakamurt@ -8906 Gunma Univ Inclusion c Exclusion c
Not select Japan Nobuyuki Horita 3-9, Fukuu horitano@ 4.58E+08 Yokohama C Inclusion crExclusion c
Not applic Japan Nobuhito Taniki 35 Shinanonobuhitota -4486 Keio Unive Inclusion crExclusion c
Not select Japan,Nort Nobuyuki Horita 3-9 Fukuu horitano@ 4.58E+08 Yokohama C Inclusion crExclusion c

 
 1. ARDS as defined by the
 
 1. Onset within 1 week
 
Phase 1/PhUnited Ki ;; Danny F McAuley, Pro ;d.f.mcaul ;02890976 Belfast Hea 2. Within the same 24-h
 Inclusion Criteria: Group A -

 
 - Ability to provide written
 
 - Males and nonpregnant,
 
Phase 1 Brazil ;; Esper Kallas, MD, PhD ;clinicaltr ;919-859-1University - Subject weight

 
 - Patients over the age of
 
 - Undergo elective surgery
 
 
 - Patients with vertebral a
 
onal [Patient Registry] Turkey Yasin Tire, MD Konya Trai - Patient with

 
 1. Male or female, aged at
 
 2. Confirmed COVID-19 by
Phase 1 China ; Lei Shi, MD,PhD;Lei S shilei302 86-10-66933333;86-1 any diagnostic sam

 
 1. Age =18 years at time of
 
 
 3. Lung involvement confir
 
Phase 3 China 
 
 
 
 3. Lung involvement confir
 
Phase 3 China 

 
 
 2. 2019-ncov infection (po
 
N/A China Yang Jin, MD whuhjy@si 8.61E+12 3. In compliance with the 2

 
 1. Recruited subjects inclu
 confirmed 2019-n-CoV in
 
 2. NEWS of =1 upon recrui
 
Phase 2 Hong Kong Ivan FN Hung, MD FRCP The Univer 

 
 - 1. Male or female, aged
 
 - 2. Pneumonia that is jud
 
Phase 1 China ; ZHU, Professor;GUO, wulingzhu 00863733029089;008 - 3. Laboratory confirmati

 
 1. Adult patients (18 years
 
 2. Must have a clinical diag
Phase 2 ; Heng Li, MD,PhD;Johnn;info@Tian;63084966 Tianhe Stem
 (e.g., fever =38Â°C, fatigu

 
 - Any permanent medical
 written consent to partic
 
 - Having a social security i
 
N/A France Pierre HAUSFATER, M pierre.hau 3.31E+10 
 
 
 2. negative pregnancy test
 
 3. COVID-19 confirmed by
 
Phase 3 Mexico ; ; ; ; ; ; ; ; Carmen Hernandez-CÃ¡
;;;;;;;cmh ;;;;;;;548 National In 4. Severe COVID-19 diseas

 
 - 18 years old upon study
 
 - Healthcare personnel ex
Phase 3 Mexico ; ; ; ; ; ; ; ; ; Jorge Rojas-Serrano, MD,
;;;;;;;;lf
PhD.;Rogelio
;;;;;;;;+5
Perez-Padilla,
National MD;Felipe
In Jurado-Camacho,
physicians, nurses,
MD. chem
MSc;I

 
 - All consecutive patients
 
 - Age >18 years,
 
 - Clinical diagnosis of COV
 
Phase 2/PhItaly ;; Fabrizio Cantini, MD;F ;fbrzcanti ;+3934080 Hospital of - Patients shou

 
 - Signed the informed con
 
 
 - Dysphagia or symptoms
N/A China Zhuan Liao, MD Changhai H 
 1. High risk close contact w
 period, including one day
Phase 3 Canada ; Darrell Tan, MD FRCP ;Attia.Qam ;416-864-6St. Michael cl

 
 1. Adult patients, 18 years
 
 2. Confirmed SARS-2-CoV-
 
 3. Admitted to the hospita
 
Phase 2/PhNorway ; ; ; ; ; ; ; ; Paul Aukrust, MD, Pro ;;;;;;;pau ;;;;;;;004 Oslo Univer 4. Subjects (or legal
 
 - suspected COVID-19 pati
 
 - known COVID-19 patient
 
 
 - confirmed disease differ
Italy ;;;; Riccardo Inchingolo, ;;;;liberta ;;;;003904 Fondazione 

 
 - Meeting the criteria for d
 positive swap.
 
 
Phase 3 Egypt ; Mahmoud Tantawy, ;drmtanta ;+2012218 Misr Unive - Children below 5 years o

 
 - COVID-19 PCR positive (w
 
 - COVID-19 PCR pending
 
 - COVID-19 high clinical su
 
 
United Sta Rahul Kashya, MBBS Mayo Clini - Patie

 
 1. Patients included in the
 
 2. Patients belonging to on
 
Phase 2/PhFrance - Group 1: patients not
 Inclusion criteria, general:

 
 - Sufficient German langua
 
 - Providing informed cons
 
N/A Germany ; Gunther Meinlschmidt,gunther.me+49 30 300117;+49 (0) Inclusion criteria for the arm

 
 - Patients admitted in a ho
 
 - Patients with COVID19 w
France ; Bertrand Cariou, Pr;B bertrand.c 02 53 48 27 06;02534 radiological diagnosi
 
 1. 18+ years old
 
 2. Diagnosed with COVID-1
onal [Patient Registry] ; Zaher Azzam, Prof;Mir;miri@cor ;97235467 Rambam He symptoms of cough and

 
 - age 18 years or older;
 
 - positive reverse-transcri
 in a respiratory tract sam
 
Phase 4 Spain ; JesÃºs Villar, MD;JesÃ ;jesus.vil ;+3460686 Hospital Un -

 
 - COVID-19 infected patie
 
 - Age 18 years or older
 
 - Presence of pneumonia
 
Phase 3 ; FrÃ©dÃ©ric ADNET, ;frederic. ;+33 1-48- Assistance - PaO2/FiO2 < 300 mm Hg

 
 - Adults aged 18-90
 
 - Confirmed laboratory CO
 
 - Meeting severe or critica
Phase 3 United States 

 
 - Existing patient of the Ev
 
 - Tested positive for SARS
 
United Sta ; ; ; Ethan Berke;Yuan Tu; ;;ethan.b ;;603/286- UnitedHeal 

 
 1. Age = 18 years old.
 
 2. Hospitalized patient (or
Phase 2 Spain ; Felipe GarcÃa, MD;Felipe
;fgarcia@cl;+3493227
GarcÃa, MD Hospital ClÃ
 
nic de Barcelona;
an emergency departme
 Inclusion criera :

 
 - Patient = 18 years old an
 
 - Laboratory proved infecti
 days
 
Phase 3 France ;; Camille TAILLE, MD, P ;camille.ta ;+33 1 40 Assistance - Hospita
 
 - All users of the https://w
 
 
 - not applicable
onal [Patient Registry] France ;; Fabrice DENIS, MD;Fa ;f.denis@c ;24168294 Jean Berna 

 
 - At least 18 years of age o
 
 - Clinically evident or othe
 
Phase 2/PhNetherland ; A Vlaar, MD;Korinna P;korinna.pi ;+49 89 41 University - SARS-CoV2 infection con

 
 - Age over 18
 
 - A person diagnosed with
 
 - Asymptomatic
 
 
Phase 2/Phase 3 ; Lee Goldstein, MD;Le ;goldstein_;972-4-64 HaEmek Med
 - chronic lung disea

 
 - Patients with diagnosed
 
 - Increase in work of brea
 
Phase 1/PhMexico Roberto Ovilla-Marti ovillarob@(55)5246-5000 - Presence of lung change

 
 - Being 65 years old and o
 
 - Being in social isolation d
 
 - Spending at least 1 week
 
N/A Turkey ; Ayse zengin alpozgen; azengin@is+902128663700;+902 
 Suspected covid-19 infectio
 
 
 Age >18 years
onal [Patient Registry] Norway ; Christopher Inchley, P chris.inch 90069276; 
 
 - 20 years and older
 
 - Hospital and RBHS health
United Sta ; ; Jeffrey L Carson, MD; ;;jeffrey. ;;732-235- Rutgers Bio patients/shift) in emerge

 
 - Patient with CHD as defi
 
 - Covid-19 infection over t
 
 Exclusion criteria:
 
France ;; Pascal AMEDRO, MD- ;p-amedro@
;04 67 33 UH MONTPE
 - Patient w

 
 1. high probability CT thor
 day of inclusion
 
N/A Belgium ;; Michiel Thomeer, MD,;michiel.t ;+3289327 Ziekenhuis 2. positive COVID-19 nasop

 
 - All patients visiting the E
 the following years: 2017
 
 
Israel ; Roi Anteby, MD;Roi A roi.anteby 19293011120;+97254 

 
 - Patient enrolled in a PAC
 
 - PACE organization contra
 
United Sta Veronique Michaud, PhD Tabula Ras Exclusion

 
 - Patients admitted to ICU
 positive SARS-Cov-2 PCR
 
 - Patient > or= 18 years
 
onal [Patient Registry] France ;; CLAIRE ROGER;CLAIRE ;claire.ro ;00334666 Nimes Unive
 

 
 - patients with COVID-19:
 or sputum, no age limit
 
Germany ;;; Robert W KÃ¶rner, Dr.;;robert.k ;;+49 221 Children's - control group: any respir
 
 
 2. Patients with C-reactive
 infusion)
 
Phase 2 ; Xavier Mariette, MD, ;xavier.ma ;14521375 HÃ´pital Bi 3

 
 1. Aged 18 to 80 years.
 
 2. History of close contact
 
Phase 3 ; Rupesh Agrawal, MD; ;rupesh_ag;6357100 Tan Tock S 3. Absence of symptoms re

 
 - Patient age =18 years, co
 
 - Within 48 hours of positi
 
 
Phase 2 United Sta ; ; Adam Spivak, MD;Chris;christina ;80121387 University - Patien

 
 - Age 18 to 65 (inclusive)
 
United Sta ; ; David Ho, M.D,;Yang L;yl4459@c ;21230462 Columbia Un
 under emergency use au

 
 1. Suspected cases of COV
 epidemic;
 
 2. Adult aged 18 or over, a
 
Phase 2 Brazil ; Marcus Lacerda, MD; marcuslace+55 92 99114 7633;+ 3. No

 
 - Adults age 40 years and
 
 - with suspected or confir
Phase 3 Nigeria;Pak ; ; Haleema Shakur-Still; ;;haleema. ;;+44 207 London Sch suspected in the presenc

 
 - Adults (men and women
 
 - At least one nasal swab p
 treatment
 
Phase 2 France ; Jacques Cadranel, MDjacques.ca 1 56 01 66 73;01 56 0 
 
 - Adult inpatients >18 yea
 
 - Positive PCR COVID-19 te
 
 - CT evidence of interstitia
 
N/A United Sta ; Jeffery S Kuo, MD;Joh ;englemd9 ;985-768-8Ochsner He
 - >18 years
 
 - Accept study
 
 - live with an addiction
 
 
 - not being able to answer t
France ;; HÃ©lÃ¨ne Donnadieu-;h-donnadi;04673370 University 

 
 - Willing to participate on
 
 
 - No
onal [Patient Registry] Indonesia ; ; Tjhin Wiguna, PhD;Tj ;;twiga00 ;;+628129 Dr Cipto M 

 
 - Any faculty, staff, or train
 being in the study
 
 
 -
N/A United Sta ; ; ; Patty Lee, MD;Sangeeta
;;erika.rat ;;919-681- Duke Unive 
 Donor Eligibility Criteria:

 
 - Age 18-60
 
 - A history of a positive na
 
 - At least 14 days from res
 
Phase 2 United Sta ; ; Michele L Donato, MD;;Mariefel. ;551-996-5Hackensack 
 
 - Adult subjects =18 years
 
 - Quarantined as suspecte
 
 - Asymptomatic upon enro
 
N/A Hong Kong ; ; David Siu, MD FRCP;D ;cwdsiu@h;22554694 HKU; - All subjects give written

 
 1. Adult patients (=18 year
 
 
Phase 2/PhMexico ;; Sergio I ValdÃ©s-Ferr ;sergio.va ;+5255548 Instituto N 3. Confirmatory laboratory

 
 - Patient aged at least 18 y
 
 - Hospitalized in a COVID u
 
N/A France ; ; ; ; ; ; ; ; ; Xavier ELHARRAR, MD;;;;;;;;;rec ;;;;;;;;04 Centre Hos - Spontaneously breathing

 
 - Covid-19 inpatients
 
 
 - assumed Covid-19 patien
Germany;R ; ; Julia Ferencz, MD;Han;;j.ferenc ;;+491768 ClarData;Un 

 
 - Type 1 diabetes mellitus
 
 - Age greater than or equa
 
 - HbA1c assessed in Janua
 
N/A Brazil 

 
 1. Positive test for COVID-1
 
 2. Age 18-79 years
 
 3. Willing and able to perfo
 
 Exclusion Criteria
Phase 2 United Sta ; ; Scott Rickert, MD;Scot;scott.ric ;646-501-7NYU Langon
 - Age greater than 18 year
 
 - Positive SARS-CoV-2 testi
Phase 3 United Sta ; ; Meredith Clement, MD;jeannine. ;50470231 LSUHSC/U e.g. characteristic infiltra
 There are 2 groups of resea

 
 Volunteer plasma donors ca
 
 - have adequate antibody
Phase 1/PhUnited Sta Elliott Bennett-Guerrero, MD Stony Broo 

 
 - Age = 18 years at the tim
 
 - Able and willing to unde
 written informed consen
 
Phase 1/PhColombia ; David A Bernal E., M dbernal.in 3105638254;3105638 
 1. Age = 18 years
 
 2. Admitted to ICU within 4
 
 3. Confirmed or highly susp
 
N/A France ;; Jean FranÃ§ois TIMSIT;jean-fran ;1 40 25 77Assistance 4. Acute hypoxemic respira

 
 1. group 1 : patients not re
 pneumopathy according
Phase 2 France Tristan Mirault tristan.mi 1 56 09 50 41 sym

 
 - Patients Requiring more
 
 - WHO progression scale =
 
 
 - Patients in 9 WHO progr
 
Phase 2 Jacques Cadranel, MDjacques.ca 1 56 01 66 73 <
 
 - Egyptian population
 
 
 - Patients not accepting to
 

 
 - adult aged 18 years to 60
 
 - medical personel gradua
 
 - non medical personel liv
 
 Exclusion

 
 - Patients booked for an o
 Advanced Endoscopy clin
 
; Sujievvan Chandran ;leo.zorro ;03 9496 3 Consultant - Consultation determined
 For epidemiologic analysis:

 
 
 - Age > 18 years
 
 - asymptomatic
 
Italy ;; Giovanni Martinelli, Pr;giovanni.m;+39 0543 IRST IRCCS - One of the following thre

 
 - Patients infected with co
 
 
 - allergy or contraindicatio
Phase 3 Egypt ; Sherief Abd-Elsalam, a;sheriefa ;+2011477 Tanta Unive 

 
 1) Hospitalised symptomati
 signs of progressive disease
Phase 3 Malaysia ; Adeeba Kamarulzamanadeeba@u +603-79492050; co
 
 DKFZ employee
 
 
 Non DKFZ employee
 

 
 1. Written informed conse
 will be accepted in order
Phase 2 Spain ;;;;; Cristina AvendaÃ±o S ;;;;;caven ;;;;;+34 91 Hospital Universitario
 Puerta de Hierro Majadah

 
 - Confirmed covid-19
 
 - hospitalized
 
 
 - None
onal [Patient Registry] Norway ;; Kristian Tonby, MD;A ;aleksande ;+4799275 Oslo Univer 

 
 - Flu like symptoms presen
 obstruction, sore throat)
N/A United Ki ; Neha Sharma;Jaydeep; ; Aarogyam (e.g.

 
 1. All patients of COVID-19
 
 
 
 1. No Valid consent
India ;; Dr Shiv Kumar Sarin, ;doctor.a ;01146300 Institute of 

 
 - Hemodynamically stable
 
 - Hypoxemia, i.e. p/f <150
 
 - Admitted to ICU within 4
 
Phase 4 Turkey ;; Yalim Dikmen;Olcay Di;olcaydilk ;+9055473 Prof; - Not moribund has a life e
 
 - End of the initial phase o
 and / or at least 7 days a
 
N/A Belgium ; Francis Corazza, MD;F francis.co 024772506;32 2 477 2 - Worsening of respirato

 
 Patients With confirmed CO
 
 
 inadequate sample of the p
Egypt ; Fatma Soliman E Ebei dr.fatma_ 01095569596;010955 

 
 - 500 case presented from
 from Ain shams universit
 
 
Egypt ; Sara Hassan;Sara Has ;sarakari ;01223431 Ain Shams - In
 Inclusion Criteria (Group 1):

 
 - A confirmed diagnosis of
 
 - Age = of 18 years.
 
 - absence of conjuntivitis
 
Italy ; Leonardo Mastropasqu;m.lanzini@;+3937030 Ophtalmolog
 Inclusion Cr

 
 - >18 years old
 
 - Consent to participation
 
 - Employed at a Hospital i
 
 
Denmark ; ; ; ; ; ; ; ; ; Kasper Iversen, Prof. ;;;;;;;;;;r ;;;;;;;;;;+ Herlev-Gen - N
 Inclusion Criteria: all partici

 (www.leadstudy.at) -
 
 Exclusion Criteria: pregnanc
 
 -
Austria Otto C Burghuber, Prof.MD Ludwig Bol 
 
 - Be part of the health per
 physical therapists and s
Phase 3 Colombia the

 
 - COVID-19, confirmed wit
 computer tomography (C
 
Netherland ; ; ; ; ; ; ; Marcus Schultz, MD, ;;;;;;m.b ;;;;;;+31-2 Department - Suspected COVID-19 infe

 
 1. Willing and able to prov
 procedures
 
 2. Age =18 years, and =75
 
Phase 1/PhChina ; Shiyue Li, MD;Shiyue lishiyue@ 86-20-83062885;86-2 A confirmed case of

 
 intensive care unit
 
 
Hakim Harkouk, M.D. hakim.har 3.31E+10 - refusal of participa

 
 - Having been diagnosed w
 
 - Having been diagnosed i
 
 
N/A - Patients who continue

 
 - Being between 40-60 ye
 
 - Being in social isolation d
 
N/A - Not having any physical
 
 
 - Patient admitted in ICU
 
 - Patient with COVID-19 d
 
 
France ;; Roberto Martinez-Alej;r-martine ;67795255 University - Explicite denie to participa

 
 - Patients of COVID-19 dis
 
 
 - unconfirmed suspected c
 
China ; Jianguo Sun;Sun JG sunjg09@a023-68774490; - Patients during

 
 - Age > 17a
 
 - diagnosis of SARS CoV 2
 
 - Hospitalized due to clinic
 
Germany ;; Christoph Schmaderer;christoph ;0049-89-4Department - written and informed co

 
 - Patients care at the Montp
 
 
France ;; Edouard TUAILLON, M;e-tuaillo ;467 338 4 UH MONTPE
 - Patient opposed to the u

 
 - COVID-19 positive cases
 
 
 - None
Egypt Aliae AR Mohamed-Hualiaehusse 2.01E+11 

 
 - Healthcare worker at risk
 
 
 - Known hypersensitivity o
Phase 2 ingr
 
 - Suspected or confirmed
 
 - Bilateral Infiltrates on CX
 
 - SpO2 <94% on FiO2 40%
 
N/A Ireland Bairbre A McNicholas bairbre.ni 3.54E+11 

 
 1. Patient over 18 years ol
 
 2. Patient affiliated to a he
 
Phase 3 France ;; Francois STEPHAN, MD;f.stephan ;33140948 Centre Chi 3. Patient who has given th

 
 - Patients requiring mecha
 
 
 -
onal [Patient Registry] Tunisia Malek Khemili, Resident Department 

 
 1. Acceptance of participa
 
 2. Patients of any gender,
 
Phase 2 Spain JosÃ© M. Moraleda, jmoraled@+34 968369532 3. Confirmed diagnosis by

 
 - diagnosis of COVID-19
 
 
 - no informed consent
Italy ; Silvia Bustacchini, M s.bustacchi00390718004613;003 

 
 - Positive COVID-19 RT-PC
 
 - Over 18 years old
 
 - Ability to sign an informe
 
; Shai Efrati, MD;Shai E ;efratisha ;97254921 Head of Re 
 - patients with COVID 19 w
 canakinumab subcutane
 
 - Age> 18 years
 
 - Pneumonia dia

 
 - Patients of both sexes.
 
 - Over 18 years.
 
 - Confirmation of SARS-CO
 
Phase 2 Barbara Juan, MD barbara.so 0034 915 50 48 00 - Respiratory failure requi

 
 - Patients who have given
 obtaining written consen
Phase 2 Spain ; JesÃºs GarcÃa Donas, MD;JesÃºs
jgarciadon GarcÃ
+34 666383649;+34
a Donas, MD 6 disea

 
 - Individuals who have exp
 approved or FDA register
N/A United Sta ; ; Donald Cooper, Ph.D.;;COVID19s ;72043134 Neuroganic 

 
 1. Adult 18 -80 years old
 
 2. Must have laboratory co
 
 3. Must have severe or imm
N/A Egypt 

 
 Patients aged between 18 a
 
 Patients with confirmed CO
 nasopharyngeal swab) at th
 
Phase 3 Egypt ;; Hany Dabbous;Hany D;drhdabbo ;01001798 Ain Shams 

 
 1. Age =18 years,
 
 2. Employment by New Yo
 
 3. Clear assignment to are
Phase 2 United Sta ; ; Anca Askanase, MD, ;ada20@cu;212-305-0Columbia U 
 Inclusion Criteria: CoVid-19
 
 Exclusion Criteria: Decision
 
 -
Phase 2/PhUnited Sta Richard M Fleming, PhD, MD, JD FHHI-OI-C 

 
 - Adults aged 18 years or o
 
 - ARDS according to the B
 
 - COVID-19 pneumonia co
 
N/A France Jean-Christophe RICH j-christop 04 26 10 92 72 - Acute respiratory failure

 
 - Admission on an isolatio
 
 - Detection of a SARS - Co
onal [Patient Registry] Austria ; Martin Rief, Dr.;Martinmartin.rie (+43)0316-385; 

 
 1. Major patient
 
 2. Relating to palliative car
 
 3. With sars-cov-2 infectio
 
Phase 4 France ; Paul-Antoine QUESNE Paul-Antoi +33 (0) 555 056 613;+ 4. Requiring light to moder

 
 - Health professional work
 
 - For the qualitative study
 
 
France Anne-Laure FAUCHAISalfauchais 5.55E+08 

 
 1. Recruited subjects inclu
 confirmed SARS-CoV-2 in
 
Phase 2 Hong Kong ; ; Ivan FN Hung, MD FRC;ivanhung ;22554049 The Univer 2. All subjects give written
 
 - Age = 50
 
 - COVID-19 Confirmed Cas
 
 - Tympanic Temperature o
Phase 4 Iran, Islam ; ; ; ; Ilad Alavi Darazam, ;;;; ;;;; Shahid Behe
 

 
 - Age = 18
 
 
Phase 4 Iran, Islam ; ; ; ; ; ; ; Shervin Shokouhi, MD;;;;;;; ;;;;;;; Shahid Behe
 

 
 - Healthy healthcare work
 rooms, ICUs, and wards o
 
 
Phase 3 Egypt ; Iman Hassan, MD;Fatmdr.imanga 01001502179;010955 

 
 - Patients with covid 19
 
 
 - Allergy or contraindicatio
Phase 2/PhEgypt ; sherief Abd-Elsalam, A;sheriefa ;00201147 Tanta Unive 

 
 - Institutionalized
 
 
 - Life expectancy < 1 mon
 
 - Known hypercalcemia
N/A ; David SEGUY, MD,PhD;david.segu;03204448 University H

 
 - Age >=18 years
 
 - Positive test for SARS-Co
 
 
onal [Patient Registry] Austria ;; Richard Greil, MD;Dan;d.wolkers ;+43 662 6 IIIrd Medic - Due to the non-interven
 
 - Patients with fu like sym
 
 - Mild to moderate sympt
 
N/A United Ki ; Neha Sharma, PhD;Jay; ; Aarogyam - Fl

 
 - Being tested positive for
 ambulatory clinics at the
 
Phase 1 United Sta ; ; Reem Jan;Reem Jan, ;rjan@medi;734-972-7University - A
 ==INCLUSION CRITERIA ===

 
 Negative SARS-CoV-2:
 
 - Aged 18 years of age or o
 
 - Negative SARS-CoV-2 res
 
United Ki ; Timothy D Planche, Drtim.planch 02087252683;020872 Posit

 
 - Age 21 to 65
 
 - Had a history of COVID-1
 
Singapore ; Wing Hang Leung;Mic ;childhood ;82487085 KK Hospita - Has recovered from COV

 
 - The patient must be a m
 
 - Patient hospitalized in re
France ;; Pierre Corbeau;Pierre ;pierre.co ;06.07.23. CHU Nimes Trop

 
 Hospitalized patients with c
 index defined as quotient o
Phase 2/PhPoland ; Prof. Eliano P Navare elianonav +48 885 101 728; a

 
 - Adults =18 years of age
 
 - In-hospitalized with confi
 
 - HADS-A score =8
 
 - Able to read and underst
 
N/A ; Nina Weis, MD, PhD;N;nina.weis ;+45 3862 Copenhagen

 
 
 
; John P Corcoran, BM ;plh-tr.RD ;+44 (0)17 University 

 
 - Hospitalized, COVID-19 p
 
 - Signed Inform Consent F
 
 - Body temperature > 37.3
 
Phase 2/Phase 3 ; Gian Paolo Rossi, Prof ;gianpaolo ;00390498 University - Oxygenation

 
 - Subjects since 18 years o
 
 - Subjects from spanish sp
 COVID19
 
Brazil;Chil ; Alba Dr Camacho-Card;albacc@un;+34 927 2 University 
 - All volunteers who partic
 contacted.
 
 
United Ki ;; Geraldine Blanchard- ;geraldine ;00417955 University - People who have not pa

 
 1. Male or female patients
 
 2. COVID 19 diagnosis confi
 
 3. Ability to give informed
 
 4. Hospitalized
Phase 1 Ryan Welter, MD PhD r.welter@r(508) 576-8325 

 
 - Clinical diagnosis of Covi
 hospital doctor
 
 - Clinical signs started less
 
N/A 
 
 - Patients = 18 yo referred
 RACE teams who have te
 
 
Dr. Derek So dso@ottaw613-696-7000 

 
 - Covid 19 patients
 
 
Phase 2/PhEgypt ; sherief Abd-Elsalam, A;sheriefa ;00201147 Tanta Unive 

 
 1. Birth to <18 years of age
 
 2. Positive nucleic acid tes
 
 3. Hospitalized, <72 hours
 
Phase 2 United Sta ; Frances L Hamblin, M Frances.H 7277672460; 

 
 
 - Patient reachable by tele
 
Yves Boucher, MD, Ph yves.bouc 01 42 16 14 51 - Collection of the consen

 
 - Women with a self-repo
 
 - Presently in the outpatie
 
Phase 2 Haim Abenhaim andrea.spe514-340-8222 - Tested positive for COVID

 
 - 18 years old
 
 - patient with positive rRT
 
 - admission in intensive ca
 
France ; Osama Abou Arab, M ;abouarab ;(33)3 22 0 CHU Amien Exclusion Crite
 
 - Age > 18y
 
 - Mechanical ventilation
 
 - Verified COVID-19 (throa
 
Denmark ;; Ronni R Plovsing, MD, ;ronni.the ;+45 38 62 Dept. of In - ARDS according to the B

 
 - Participants 18 and abov
 
 - living in UK
 
 - reported with or withou
 groups
 
United Ki Vishwesh Kulkarni University 
 - Patients presenting with
 fatigue, shortness of bre
France ;; Benjamin Lallemant;B ;benjamin. ;04.66.68. CHU Nimes 

 
 - age > 18 years,
 
 - confirmed infection (pos
 
 - fullfilled hospital admissi
 
Phase 4 Slovenia ; Miha MeÅ¾nar;Miha meznar.mi +386 3 4233419;+386 
 - All patients diagnosed w
 their severity, but only th
Phase 2 Puerto Ric ; Fernando Cabanillas, ;cabanill ;787-758-2Hospital E ste

 
 1. Males or females = 18 y
 consent.
 
France Alexion Pharmaceuticaclinicaltri 1-855-752-2356 2. Confirmed diagnosis of S

 
 - Confirmed laboratory dia
 polymerase chain reactio
Phase 2 ; Dayana Michel;Jatin S ;jshah@ka ;(617) 658 Karyopharm 
 
 
 - COVID-19 patients.
 
 - Available to comply with
 
Portugal ;;;;; ConceiÃ§Ã£o Calhau, ;;;;;ccalh ;;;;;00351 NOVA Medic
 
 All adults (18 years of age a
 database (SNDS) receiving b
 
France ;; Emilie SBIDIAN, Pr;Emi;emilie.sb ;+33 6 83 Assistance 1. Synthetic an

 
 - Admitted to the hospital
 
 - = 18 years of age
 
 - Clinically suspected or co
 
 - Spontaneously breathing
 
United Sta ; Omar Hyder, MD, MS;ohyder@par
617-724-0151;617-72 

 
 - Diagnosis of COVID-19 b
 
 - Clinically stable with dise
Phase 2 ; Gerry Gin Wai Kwok, ;gggjerry@;+852-225 Queen Mary
 defined as symptoms wit

 
 - Admission to an intensiv
 
 
 - Missing ethical approval
onal [Patient Registry] Switzerlan ; ; ; ; ; ; ; Matthias P Hilty, MD ;;;;;;matth ;;;;;;+41 4 RISC-19-IC 

 
 - DSM-5 Diagnosis of Schiz
 Major Depressive Disord
 
Italy Felice Iasevoli, M.D., felice.iase 3.91E+11 - Linguistic and cognitive a
 
 - all adult patients admitte
 
 
 - bactrial co-infection at a
 
France ; emmanuel besnier, M emmanuel.+33 2 32 88 82 83;+33 - expec
Inclusion criteria:
Exclusion
Participants
criteria: Particip
eligible
 1. Completion
 1. History
of the
ofwritten
allergy io
Phase 4 Australia 2. Male 2.
or female
Contraindication t
Exclusion criteria: Age < 1

 
 Suspected acute SAR
 
 Transferred from ano
 
 Presented to the em
 
Not Applic Australia Inclusion c Presented to an o
Exclusion criteria: â€¢ Kn
Inclusion criteria:
 â€¢ â€¢Currently
Aged 18breastf
to 75
 â€¢ Laboratory
 â€¢ Known
confirmed
maculop
SARS
 â€¢ Advised
 â€¢ to self-manage
Known cardiacCOV
d
Phase 2 New Zealand â€¢ In â€¢
the Investigatorâ€™s
Know renal dis
opi
Inclusion criteria: 1) Adults aged 60 y

 2) Living alone
 3) Cleared to participant in an e
Not Applic Australia 4) Currently
Exclusion
engaging
c in <150 m
Exclusion criteria: a) Parti
 b) Have the COVID-1
 c) Have a musculoske
 d) Be under anxiety,
Not Applic Spain Inclusion c c) Have any health di
Exclusion criteria: Pre ope

Not Applic France Inclusion c 
Inclusion criteria:
Exclusion
â€¢criteria:
Participants
â€¢ Me ag
Not Applic Australia â€¢ Participants
 â€¢ Research
who are study
front-lp
Inclusion criteria:
Exclusion
1. Laboratory
criteria: Subject
exam
N/A China Hongzhou Lu 2901 Caolanluhongzho +86 21-37 Shanghai Pu 2. T 1. Suffering from dise
Exclusion criteria: 1. age<
 2. In the processing o
 3. in the period of pr
 4. known kidney ston
 5. known allergy to v
 6. involved in other c
New Treatm
China Enqiang Mao 197 Secondmaoeq@ye+86 13501 EmergencyInclusion 7.refuse to sign
Inclusion criteria: 1. COVID-19 conva
 2. Cured and discharged
Exclusion patient
criteria: 1. Patie
 3. Aged 
from 18 to 70 years;
N/A China Yang Guiping 249 Huaiyi 13654315 +86 15335 Xiaogan Tr 4. Patients
 2.
with
Accompanied
sleep moodby diso
s
Inclusion criteria:
Exclusion
1. Have
criteria:
informed
1. Poorc
0 China Yin Lin 2 Yinghua Sjade_yl@1 +86 010 8 China-Japa 2. Has 2.
been engaged
previousinormedical
curren
 (2)(1)
There isand lact
no rest
N/A China Min Fang (3)
110 Ganhe fangmin19 +86 18930 Yueyang Int (2) Patients respiratory
diagnosed withfreque
mild
Inclusion criteria: 1. in line with epid
 2. in line
Exclusion
with inclusion
criteria:criteria
1. Peopa
 3. Aged 2.
18 to Pregnant
65 years old;
women;
0 China Guohua Lin 16 Jichang tcmlin-80 +86 13609 The First A 4. Quality
 3. Those
of life who cannot
score<=37
 2. Pregnant or breastf
 3. History of Aliskiren
Inclusion criteria:
 4. 1.
Severe
COVID-19
kidney confir
dise
 2. Hypertension
 5. Cardiogenic
diagnosis;shock
0 China Fengming Luo 37 Guoxue luofengmi +86 18980 West China 3. Aged< >=18 years.
Inclusion criteria:
Exclusion
(1) criteria:
Convalescent
(1) Patip
 (2) The (2)
TCM syndrome
Patients with
type pre-
con
0 China Hongsheng Cui 51 Anwai Xihshcui@si +86 13901 Beijing Uni (3) Voluntary
 (3)test,
Patients
or the
whoim are
 2. 1.
Inclusion criteria: Patients who recei
The subject or le
0 China Kaijiang Yu 23 Youzhengdrkaijian +86 13303 The First A 2. Aged 3.
18 to Patients
75 who have
N/A China Gu Xue 9 Dongfang35307133 +86 15952 Yangzhou JInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Accorded
criteria: 1.with
PatieC
N/A Shao Xianzhi 12 Binhu Ro37286109 +86 18071 Ezhou Hospi 2. The 2.
main clinical
accompanied
manifestatio
by se
Inclusion criteria:
 (2)(1)Severe
The agemental
is great
illn
 (2) COVID-19
 (3)severe
The existence
/ critically
of ie
RetrospectChina Jiang Lai 1665 Kongjjianglaimz +86 13651 Xinhua Hosp (3) Non-COVID-19
 (4) Maternity.
severe / critic
 2. Cured and discharged patient
from 18 criteria:
to 70 years;
1. Patie
N/A China Ba Yuanming 4 Garden H17234261 +86 13871 Hubei Prov 4. Those with Accompanied
 2. insomnia, anxiety,by s
Exclusion criteria: 1. emer
 2. duration of surger
 3. thoracic surgical p
RetrospectChina Su Min 1 Youyi Roams890110 +86 13508 the First A Inclusion c 4. preoperative hypo
Exclusion criteria: 1. Beca
Inclusion criteria:
 2. 1.
Patients
Meet the withconval
diffic
N/A China Xia Ping 215 Zhongsxiapingfm +86 027-8 Wuhan Hosp 2. Short 3.
breath,
There
hyperhidrosis,
are seriousdb
Exclusion criteria: 1. Histo
Inclusion criteria:
 2. 1.
Relying
Patientson who
mechanme
 2. The 3.
pulmonary
Complications
imaging inof thec
N/A China Xiao Mingzhong 856 Luoyu 30945251 +86 18908 Hubei Prov 3. Aged 4.18 to Complications
70 y affe
Inclusion criteria:
Exclusion
1. confirmed
criteria: 1.SARS-
mech
 2. Meet 2.
one of
recent
the following
central nerv
crit
N/A China Feng Zhichun 5 Nan-Men-zhichunfe +86 17710 Seventh Me 1) reversible
 3.respiratory
existence offailure
non-rw
Exclusion criteria: 1. Decla
Inclusion criteria:
 2. 1.
Convalescent
Patients older patie
th
 3.
 2. Patients Second
with readmissio
a definite clinica
RetrospectChina Gao Qinglei 4.
1095 Jiefa qingleiga +86 13871 Tongji Hosp 3. Patients Patients
with clinicalconsidere
or etiolo
Not Applic Spain Inclusion crExclusion cr
Not Applic Liechtenst Lorenz Risch Wuhrstrasslorenz.risc +41 585233000 Inclusion criExclusion cr
MaRS,
Toronto
Medical
Discovery
Tower
101
College
St, Ste 10-
360A
Phase III Canada Julie Wright julie.wrig +1 (0)416 340 4800 Inclusion c Exclusion c
Not Applic Curacao;CyRuth;SandiBenson;Na Vascular a vern.arter +44 (0)121 ; Inclusion c Exclusion c
Clinical
Trials Unit
Warwick
Medical
School
University
of
Warwick
Not Applic United Ki Keith Couper k.couper@ 4.42E+11 Inclusion crExclusion cr
Not Applic Australia;Austria;Belgium;Brazil;Bulgaria;Croatia;Cyprus;Czech Republic;De Inclusion criExclusion c
Not Applic United Kingdom Inclusion crExclusion cr
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Ireland Mandy Jackson RCSI Smurfimandyjack 3.54E+11 Royal ColleInclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
United StatClinical Research Divis55 Fruit Street 1.62E+10 MassachussInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
NetherlandJ.G.J.V. Aerts Dr. Molewaj.aerts@er 3.1E+11 Erasmus MInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Germany Clinical Trial Informat Brunnenstrmarketing 4.96E+11 Fachingen Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Poland Clinical Trial Informat Wybrzeze Lewa.janko 4.86E+10 Wroclaw Me
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain;Thai UOC MALATTIE INFETTPIAZZALE evelina.tac 4.58E+08 AZIENDA OInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain UCEC Avda. PÃo XII,
ucicec@un34948255
36 ClÃnica Universidad
Inclusion de
c Exclusion
Navarra c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Antonio Luque Edificio I uicec@imib 3.47E+10 FundaciÃ³nInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Antonio Luque Edificio I uicec@imib 3.47E+10 FundaciÃ³nInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain MarÃa JesÃºs Coma Avda Islas mjcoma@h 3.46E+10 Research UInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Clinical trial informati Avda Manue
claram.ros 3.47E+10 CTU-HUVR Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Austria Matthias Preusser Spitalgassemattias.pr 4.31E+12 Med. Univ.Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Denmark Hans Hasselbalch Sygehusvejhans.hasse 4.53E+09 Zealand UniInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Belgium Yven Van Herrewege Nationales yvanherrewege@itg.bITM ClinicalInclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
Exclusion
 -Recent
criteria: -Pa
(=6 da
IV): no randomization)
 -mechanical
infectionventilati
with CO
Belgium HIRUZ CTU C. Heymanshiruz.ctu@ 3.29E+09 University test and/or
 -clinical
PCR and/ofrailty scale a
 
 - people who lived in or ou
 spread of COVID-19
 
 - without gender and a
 
China ;; Jiahong Dong, M.D;Xi ;fengxiaob ;+86 1322 Beijing Ts 

 
 - flu-like symptoms: myalg
 
 - Chest X-Rays
 
 - COVID-19 biological test
 
 
Italy;Roma ; ; Alexandru Burlacu, Le ;;alexandr ;;0040744 University - patient r

 
 - Household contact of ind
 individual evaluated at N
Phase 2/PhUnited Sta ; ; Jon T. Giles, MD;Jon T ;jtg2122@ ;212-305-2Columbia Un
 se

 
 - pregnant women with la
onal [Patient Registry] Italy Gabriele Saccone gabriele.s 3.39E+09 

 
 - Any person interested in
 complete the pre/post su
 
N/A United Sta ; ; Rebecca E Wells, MD, ;WFBH_Min;336-716-2Wake Fores Exclus

 
 - COVID-19 positive patient
 samples
 
 
France ; Joe-Elie Salem, MD-P joe-elie.s 01 42 17 85 31;01 42 - Patients who refused the u

 
 - Age> 18 years old
 
 - patients with acute resp
N/A Canada ;; Francois Lellouche;Fr ;francois. ;418-656-8IUCPQ-UL; pneumonia (viral and no
 
 - flu-like symptoms
 
 - a viral test order for COV
 
 - confirmed COVID-19
 
 - concern for exposure to
 
United Sta ; Becky Smith, MD;Mar ;mark.sen ;919-684-3Duke Unive Exclusion Crite

 
 1. Pregnant women or wom
 
 2. Able to give informed co
 
onal [Patient Registry] United Sta ; ; Vanessa Jacoby, MD, ;PRIORITY ;(415) 754 University 3. Diagnosed with COVID-1

 
 - Recent (=2weeks prior to
 antigen detection and/or
Phase 4 Belgium;Ita ; Bart Lambrecht;Anja ;anja.delp ;+32-9-33 University 

 
 - Patients with suspected
 
 
 - Unwillingness to particip
onal [Patient Registry] Germany ;; Tienush Rassaf, MD;M;matthias. ;+4920172 University 

 
 1. Informed consent from
 
 2. Male or female, aged =
 
Early PhaseBrazil Luciana Ferrara Azidus Bras 3. Laboratory confirmation

 
 - UK resident
 
 - Age =16 years
 
 Exclusion Criteria: none
Adrian Martineau, Ph a.martine 4.42E+11 

 
 - Recent ( = 6 days of flu-li
 malaise prior to randomi
 
Phase 3 Belgium ; Bart Lambrecht, MD, ;anja.delp ;+32-9-33 University - Confident COVID-1
 
 
 
 - Group 1: Cases meetin
Phase 2 France <
 Inclusion Criteria:Fulfilling a

 
 
 2. Hospitalized participant
Phase 2 Colombia ; ; Juan M Anaya Cabrera;anayajm@g
;+57 321 2 Universidad 
 Inclusion Criteria:Fulfilling a

 
 
 2. Hospitalized participant
Phase 2/PhColombia ; ; Juan M Anaya Cabrera;anayajm@g
;+57 321 2 Universidad 

 
 1. COVID-19 has been diag
 as sputum or nasopharyn
N/A China ; Guiqiang Wang;Guiqi ;john1312 ;13911405 Peking Univ 

 
 1. Confirmed COVID-19, an
 or nasopharyngeal swab
N/A China ; Guiqiang Wang;Guiqi ;john1312 ;13911405 Peking Univ 

 
 - Patients discharged (dec
 diagnosis or a COVID-19
 
 
onal [Patient Registry] Spain ; IVAN J NUNEZ GIL, MDibnsky@ya 0034 913303002;913 - Th

 
 1. Age 19-45 years inclusiv
 
 2. Capable to and does pro
 
Phase 1 Canada ;;; Eric L Sievers, MD;M ;;;bd@sym ;;;(604) 42 Chief Medic 3. Able to understand and
 
 The subject must satisfy the
 
 1. Male or female, aged 18
 
Phase 3 Justin Slagel jslagel@sl 1.92E+09 2. Provided informed cons

 
 - Age >18 years admitted
 
 - Confirmation of infection
 
Phase 1 United Sta ; ; Matthias Salathe;Matt;msalathe ;91358860 University - Hypoxic respiratory failu

 
 - Positive COVID 19 patien
 
 - Patients hospitalized in i
N/A France ;; Emilie Garrido-Pradali ;francois.s ;; ASSISTANC m

 
 1. Age 18 years or older
 
 2. Hospitalization with a su
N/A United States clinical presentation with

 
 - Age equal to or above 18
 
 - Male or female gender
 
 - In case of women, unwil
 
Phase 2 Greece ; Apostolos Armaganidi ;egiamare ;+3021074 National Ka - Writt

 
 - COVID-19 positive patien
 
 - Treated at the Health Ins
 
Phase 4 Mexico ;; JosÃ© Meneses Calde;;drmendi ;;+52-722- Hospital Ma - With risk factors to get c

 
 - Patients hospitalized wit
 oropharyngeal, or BAL sp
Phase 2 United Sta ; ; ; Markos G Kashiouris, ;;mkashiou;;804-305- Virginia C 
 
 - Patients hospitalized in ca
 of COVID-19 (positive PCR (
France ; Guillaume BONNET, ; ; Hopital E 

 
 - Male or female, Age = 18
 
 - Patient with oxygen dep
Phase 2/PhFrance ;; Jean-Eric BLATTEAU, ;jean-eric. ;48316218 Sainte-Anne than or equal to 6 liters /

 
 1. 18 years or older
 
 2. Confirmed SARS-CoV2 in
 reaction (RT-PCR) assay
 
Early PhaseUnited Sta ; ; LaQuisa Hill, MD;LaQui;LaQuisa.H ;(713) 441 Baylor Coll 3. Respiratory distre
 Inclusion criteria for blood d

 
 - age : >18 and <60 years
 
 - body weight : >50 kg
 
 - confirmed previous SARS
 
Early Phase 1 ; Veronika MÃ¼ller, MD,;eszter.fo ;+3630664 Semmelweis
 - 2 negative SARS CoV-2 te

 
 - Infected patients (COVID
 
 - Patients able to be explo
Spain ;; Pere ClavÃ©, MD, Ph ;pere.clav ;+3493741 Hospital d ph

 
 1. Patients between 18 an
 
 
Phase 2 France RÃ©gis Peffault de L regis.peff 1 42 49 96 39 - Group 1: 60 patients n

 
 - Health Care Personnel an
 Medical
 
 
Austria ;; Thomas J Reiter, MD; ;thomas.re ;+4314040 Medical Uni - Not matching the inclusi
 
 - Confirmed or suspected
 
 - Data available via the EP
 
 - NO age restriction
 
 - NO pregnancy restriction
 
onal [Patient Registry] United Sta ; ; Andrew Ip, MD;Brittany
;Brittany. ;551-996-8Hackensack Exclu

 
 
 2. Male or female, and:
 
 1. aged = 70 years; or
 
Early PhaseBrazil 2. aged < 70 with associ

 
 - Woman who is >= 18 yea
 
 - Woman having just given
 
 - Woman affiliated to a so
 
N/A France ;; Charline BERTHOLDT; ;c.berthol ;+3383344 Centre Hos 

 
 
 - Beaumont Health emplo
 providers
 
 
United Sta ; ; Matthew Sims, MD, P ;Maureen. ;248-551-0William Be 

 
 - Any patient in intensive
 
 1. Receiving invasive me
 
 2. ARDS meeting the Be
 
Phase 3 France ;;; Tarek Sharshar, MD, ;;a.mazera ;;01456589Centre Hosp
 
 
 - Laboratory confirmed in
 
 - Hospitalisation due to SA
 
Phase 2/PhAustria ; Bernd Jilma, MD;Bern ;klin-phar ;+4314040 Medical Uni - Fo

 
 - Clinical suspicion or evid
 
 
 - None
Germany ; Volker Burst, MD;Volkvolker.bur +4922147897222;+49( 

 
 - Healthy adults aged 18-5
 
 - Proven legal identity;
 
 - Participants should be ca
Phase 1/PhChina ;; Fengcai Zhu, Doctor;F ;jszfc@vi ;86-18118 Jiangsu Pro 

 
 - Patient is Under the care
 OR Presenting to a clinic
 
onal [Patient Registry] United Sta ; Andrea Natale, MD;Andr.natale@512-544-8186; - An

 
 1. Health care worker (HCW
 study period. For the pur
Phase 3 United Sta ; ; Bradley A Connor, MD;bconnor1 ;91721389 Dr. Bradley 

 
 - Able to give informed co
 
 - Subjects meeting the fol
 
Phase 2 United Sta ; ; ;phs@prohe;516-656-6UnitedHeal 
Deneen Vojta, MD;Dani Sub-Study 1: 50-75 years of

 
 - Healthy subjects of eithe
 contact with COVID-19 p
 
Phase 3 Anil Avhad, MBBS anil.avhad 9.2E+11 - Subjects with SARS Cov 2
 
 - All patients, children and
 
 - Patients with known chr
France ;; Eric Hachulla, MD,PhD;covid19.fa;32044596 University H rare and non-rare diseas
 Inclusion Criteria for Group

 
 - Men or women ages =18
 criteria
 
Phase 2 United Sta ; ; Michael Belmont, MD;;emily.bea ;+1 212 26 NYU Langon 1. Involved in an aeroso

 
 - 18 years and above
 
 - COVID-19 confirmed by a
 enrollment
 
Phase 3 Israel - Mild disease (no pneumo

 
 - Any pregnant woman giv
 
 - Major patient
 
 
N/A ; Christelle Vauloup Fel ;christelle ;01 45 59 Assistance - Patients not speaking Fre

 
 - Any sex or age
 
 - Providing informed cons
 
 - Agreement with all study
 
 
; Ricardo Palacios, MD, ;ricardo.p ;+55(11)2 Butantan In -

 
 1. Hospitalization for acute
 
 2. Age > 18 years or older
 
 3. Presence of pneumonia
 
Phase 2 France ; Yacine TANDJAOUI-L ;mohammed
;+33 1 48 Assistance 4. PCR
 
 - Patient over 18 years old
 
 - Patient admitted to inten
France ; Yacine TANDJAOUI-LA;yacine.ta ;06 64 17 Assistance the SARS-Cov-2 virus is d

 
 - Age>18 years
 
 - CT examination perform
 
 - Non opposition for use o
 
 
France ;; Marie-Pierre REVEL, ;marie-pie ;+33 1 42 Assistance 

 
 - Scheduled or unschedule
 in hospital
 
 - Chest CT-scan within the
 
France Philippe Gaudard, MD University - N

 
 - ICU patients who require
 
 
 - Patients who require com
 
N/A Poland ;; Radoslaw Owczuk, pro;r.owczuk ;+4858349 Medical Un The

 
 - Male or female, 12 years
 
 - Clinical diagnosis of COV
Incyte Corporation Calmedinfo@i1.855.463.3463 swab should be taken an

 
 - Survivors of PCR-confirm
 
 - 2-6 weeks after hospital
Hong Kong Chung Wah SIU, MD cwdsiu@hk852-2255-4694 reaction (PCR) for severe
 
 - SARS-CoV-2 infection (po
 COVID-19 ARDS
 
 - Male and female patient
 
Phase 3 Switzerlan ; ; Beatrice Beck Schimme;martin.sc ;+4144255 University 

 
 - Eligible participants are a
 
 - Who are currently living
 
Norway ;; Omid V. E Ebrahimi, D ;; ;; University - Who

 
 1. Healthcare workers of a
 Otorhinolaryngology Hea
Denmark ;; Inge J Knudsen, MD;N ;; ;; Rigshospit Hospit

 
 - HCW previous tested for
 
 
 -
onal [Patient Registry] Belgium Maria Goossens, MD, PhD Sciensano 

 
 
 
Phase 1 ; Anya Loncaric;Alexand;Alexandre ;1 514-904 Bausch Hea 3. Currently hospitalized w

 
 - Patients with SARS-CoV2
 
 - With or without ventilato
 
Phase 2 Mexico ; Juan Carlos Olivares jolivares@ 2222438100;2222438 - Treated or not with hydr

 
 People who undergo nasop
 
 
 none
N/A Italy ;; Lorenzo Azzi;Lorenzo ;l.azzi@uni ;+3934767 UniversitÃ 
degli Studi dell'Insubria;
 
 - Age equal to or above 18
 
 - Male or female gender
 
 - In case of women, unwil
 
Phase 2 Greece ; Simeon Metallidis, M ;egiamare ;+3021074 Aristotle U - Writt

 
 - For hospital staff: Adult m
 employees) willing to pa
 
France ; Clemence ISAAC, PhD;; ; CH Ville Ev 

 
 - Informed consent is obta
 
 - Participant has been iden
 
; Arndt Rolfs, Prof.;Vol ;Volha.Sk ;+49 (0)38 Centogene - The participant is 60 yea

 
 â€¢ started outpatient radia
 Cancer Center during the CO
 
 
United Sta Manisha Palta, MD Duke Unive -
 Inclusion Criteria:. Patient a

 SARS-CoV-2 RT-PCR (if no te
 
Phase 2 France ; Philippe Rousselot;La ;lmorisset@;+3313923 CH Versaill 3. Initial phase (= 7 days) of

 
 - Hospitalized with diagno
Phase 1/PhUnited Sta ; ; Brian C Davis, MD;Bri ;Brian.Dav ;804-675-5Staff Physic bronchoalveo

 
 - Age> 18 years
 
 commercial or public hea
 
Phase 2 Spain ;; Rosario Garcia de Vic ;mariadelr ;+34 91 5 FundaciÃ³n - Documente
 
 - Informed consent as doc
 
 - Age >= 18 years
 
 - Suspicion of COVID-19 o
 
Switzerlan ; ; Aristomenis Extradakt;davidshiva;+41 31 63 University - Hospitalis

 
 - Age = 18 years and <75 y
 
 - Admission for confirmed
Phase 2 Spain ;; JuliÃ¡n de la Torre C ;uicec@imi;00346715 Hospital Universitario
 Reina
sample
SofÃ
of athe
; respiratory

 
 - Having at least primary e
 
 - Being literate in Turkish
 
 - There is a level of coope
 
Turkey ;; Ipek Yeldan, PhD;Salih;salihagur ;+9055559 Istanbul Un - Agree to par

 
 - All patients hospitalized
 University Hospital may b
 
onal [Patient Registry] France Marie GRALL-BRONNEmarie.bron02.40.84.76.20 Minors, pregnant or nurs

 
 Population 1: Associated Se
 
 - 18 years or older.
 
 - Hospitalized and intubat
United Sta ; Nakhle Saba, MD;Nak nsaba@tul 504-988-5263;504-98 

 
 1. Weight =100 kg
 
 2. Within 24 hours of reach
 
 1. At admission
 
 2. While already hospita
 
Phase 2 Mark J DiNubile, MD mdinubile 609-706-5866
 
 - Patients aged 18 years o
 
 - Record of ICU stay
 
 
 - Patients aged less than 1
 
United States - Patients for

 
 - Single PCX images collec
 
 
 - CT scans composed of m
 
United States - Single PC

 
 - SARS-Co-V2 positivitity t
 reaction (RT-PCR) assay t
 
Phase 2/PhItaly - Age >18 an

 
 - Patients with respiratory
 ventilation techniques (h
 
Pedro L Gambus, PhD plgambus@c3.47E+10 -

 
 - Employees of CHU NÃ®m
 
 - Approved to participate
 
 
 â€¢ Participation refusal
France ; Jean-Yves LEFRANT;Je jean.yves. +33466683331;+3346 

 
 
 - Patients of either gender
 
Phase 3 Anil Avhad, MBBS anil.avhad 9.2E+11 - Female patients who are
 
 Eligibility criteria for instituti
 
 - Centralized pharmacy de
 
Phase 2/PhColombia ; Hernando GaitÃ¡n, M ;hggaitand ;(+57)-1-3 Universida - Centralized pharmacy de

 
 - COVID-19 patients with m
 
 - PO2/FIO2<300mmHg
 
 - ages>18 years
 
 
 - pneumothorax
 
N/A China Chun C Pan Zhongda hos

 
 2. laboratory-confirmed SA
Phase 2 ; Andreas Neubauer, Pro;neubauer@
;+49 6421 UniversitÃ p

 
 - Age = 18
 
 
Phase 4 Iran, Islam ; ; ; ; ; ; ; Mohammad Fathi, MD;S
;;;;;;;sina ;;;;;;;0914 Shahid Behe
 

 
 - Male = 18 years of age o
 
 - Documentation of COVID
Phase 2 United Sta ; ; Sharon Nachman, MD;C
;PatchStu ;631-371-3Stony Brook new onset (<7 days) clini

 
 1. Patients have to be test
 
 2. Provided written inform
 
 
;; Dirk-Jan Slebos, MD ;;m.van.d ;;+315036 UMCG, Depa
 1. No comprehension of
 
 - Age = 18
 
 Confirmed).
 
Phase 4 Iran, Islam ; ; ; ; ; ; ; ; Mohammad Fathi, MD;S
;;;;;;;sina ;;;;;;;+989 Shahid Behe

 
 required for the study an
 
United Sta ; ; Sabine Hazan, MD;Sab;drsabine ;805-339-0ProgenaBi 2. Male or female of 18 ye

 
 - Have undergone success
 
 - Have sufficient viral RNA
 Covid-19
 
United Ki ; Samuel Robson;Alice samuel.rob+44 (0) 23 9284 2144; Exclusio
 Inclusion criteria (patient w

 
 - Male or female
 
 - >= 70 years of age
 
 - Participants covered by o
 
N/A France ; CLARISSE DIBAO-DINAclarisse.di 2 47 57 74 22;(0)2 47 - With

 
 - adult patients of every a
 
 - admission to hospital wi
 
 - confirmed SARS-CoV-2 in
 
Germany ;; Johannes Ehler, MD;J ;johannes. ;+4938149 University 

 
 - Subject Male or female a
 
 - Subject infected with CO
Phase 3 France ;; FrÃ©dÃ©ric BLANC;F ;frederic. ;03 88 11 University days old and clinical
 
 - Adult patient (<18y)
 
 - With a SARS-CoV-2 infec
 
 - Hospitalized in intensive
 
 
Charles TACQUARD charlesamb 3.7E+08 

 
 1. COVID-19 with evidence
 oximetry.
 
 2. Physician determination
Phase 2/Phase 3 ; Jonathan C Javitt, MD ;rbesthof ;+4842546 NeuroRx; <

 
 - Adult symptomatic patie
 nasopharyngeal sample a
 
 
Phase 2/Phase 3 ; Kamal Okasha, Md, P ;vp_resear ;+2010047 Tanta Unive - Abnormal l

 
 A patient must meet the fol
 
 - DoD personnel covered b
Andrew P Cap, MS, MDandrew.p.c210-539-4858 Department of

 
 - adult patients admitted t
 
 
 - none
United Sta ; Bhakti Patel, MD;Bhakbpatel@med
773-702-6800;773-70 

 
 - Able to provide written i
 
 - Understands and agrees
Phase 2 United Sta ; Cecilia M Shikuma, M ;shikuma@;808 692-1 University 
 
 - SARS-Cov2 positive PCR
 
 
 - pregnancy
Germany ; Christian Bode, MD;Chchristian. +49228287;+4922828 

 
 - Tested for Covid-19 at a
 
 - Age 18 years or older;
 
 - Not requiring immediate
 
Phase 3 South Afric ; ; Sean Wasserman, MBC;;mpumi.m;;+277276 CIDRI-Afric - Mild

 
 - Women over 18 years ol
 
 - Pregnant women coming
N/A France ;; Charlotte Dubucs, MD;dubucs.c@;05 31 15 University University Hospital betw

 
 â€¢ Must be 18 years old, a
 patients within the past yea
 
 
United Sta ; ; Hunter Hoffman, Ph.D;hunthoff ;206-601-5University â€¢ Less than

 
 - Hong Kong resident aged
 
 - Able to communicate in
 
 - Smoked in the past 30 da
 
 
Hong Kong ; Ho Cheung William Li, william3@ +85239176634;39176 

 
 1. Male or Female Adult =
 
 2. Laboratory confirmed SA
Phase 2 randomization an
 
 - Sera/plasma from patien
 SARS-CoV-2
 
 - Sera/plasma from peopl
 
United Sta ; Gary Weil, MD;Gary Wgary.j.wei 314-747-5198;314-27 

 
 - Patients >18 years old w
 compatible with COVID,
 
Phase 2 Iran, Islam ; SBMU;CKDRC,SBMU, ;nooshinda;00989122 CKDRC,SB Exclusion Criteria:

 
 - University students of an
 degree or any other Univ
 
 
 -
Spain ;; Jon Irazusta, PhD;Jon ;jon.irazu ;34-94601 Basque Coun
 

 
 - Confirmed cases of COVI
 
 - Newly diagnosed sympto
 
 - Adults (18-65 Years old)
 
 - Both sexes
 
Phase 2/Phase 3 ; Kamal Okasha, MD, P ;vp_resear ;+2010047 Tanta Unive 

 
 - Clinical and laboratory d
 
 - Age range 18-40
 
 
 1. Hypercholesterolemia
 
Phase 3 2. Hypertriglyce
 All the patients admitted to

 set any restrictions regardin
N/A ; Philippe Jouvet, MD P ;salysalti ;+1-514-34St. Justine' stay before screening) for th
 
 - health care workers with
 
 
 - none
N/A Belgium ; Reinoud Cartuyvels;Re;reinoud.c ;+3211338 Jessa Hospi 

 
 - Males and females aged
 
 - Patients with flu syndrom
Phase 3 Brazil Fernanda Martinez, B.fernanda. + 55 11 5644-8200 the patient associated w

 
 - COVID-19 infection
 
 - Treatment with the Sera
 
 - Voluntary consent to par
 
onal [Patient Registry] Germany Julius J Schmidt, Dr schmidt.ju 4.95E+11 Exclusion

 
 1. Age 18 or older
 
 2. Positive revere transcrip
 respiratory track sample
 
N/A Spain ;; Manuel CastellÃ , MD PhD;Manuel
;mcaste@cl;+3493227
CastellÃ , Hospital
MD PhD;Manuel
ClÃ
 
nic deCastellÃ ,
Barcelona;
3. AcuteMD(less
PhDtha

 
 - Liver Transplant recipien
 
 - Confirmed (PCR positive
 
 - Informed Consent
onal [Patient Registry] Spain ; Jordi Colmenero;Jord ;jcolme@cli;+9322757 Sociedad E 

 
 Inclusion criteria for the 250
 
 - Patient living with HIV (P
 
France Antoine ChÃ©ret, Dr antoine.ch 1.45E+08 - Patient with confirmed in

 
 - Chilblains or vascular abn
 acrocyanosis) of the acra
France ;; Didier BESSIS, PhD;Di ;d-bessis@ ;46733690 University 
 
 - positive analysis for RT P
 respiratory tract sample;
 
 - Imaging (CT / ECO / RX) p
; Enrico Dr Capochiani, ;enrico.ca ;00393473 Azienda US<

 
 adult patients with suspecte
 appropriate.
 
N/A Italy ;; Guido Bertolini, MD;C ;chiara.ger ;+39 03901Mario Negri Exclusion criteria: physical,

 
 - Adults (age 18 years) con
 lower and/or upper limb
onal [Patient Registry] Spain ;; Joaquin De Haro, MD; ;deharojo ;+34 6260 Hospital Un 

 
 1. 18 years old or older
 
 2. Molecular (pcRNA) diag
 
 3. Hyperferritinemia (>700
 
 4. Fever >38 degrees C
 
Phase 3 ; Walter W Chatham, ;wchatha ;800-822-6University 

 
 - Men and women
 
 - Between =18 and = 65 ye
 
 - Healthcare workers (doc
Phase 3 Colombia ; Juan C cataÃ±o, MD.M;kataju@h ;314-617-5infectious in Medel

 
 - Health worker
 
 - Male or Female
 
 - Aged 18-70
 
 - Able to understand the F
 
 
N/A Luisa Weiner, MD luisa.wein 03 88 11 65 11 
 
 - Adults older than 70 yea
 20/04/2020, in the "Perp
 
Spain ;; Pedro Abizanda Soler ;pabizand ;+3463655 Head Geria Exclusion Crit

 
 - Pregnant women hospita
 
 1. Fever with one or mo
 difficulty)
 
Gaston Ofman, MD gofman@inf
01154911-4078-1550 

 
 - patients with covid 19 sy
 
 - patients who had a cont
 
 
 - none
France ; Svetlane DIMI, M.D;Svsvetlane.di +33650002085; 

 
 1. Aged 18 years or older
 
 2. Able to provide electron
 
 3. US Resident
 
 4. Read and comprehend E
 
United Sta ; ; Ingrid Oakley-Girvan, ;reem.yun ;1-877-820Medable In Exclusion

 
 - Willing and able to sign t
 
 
 1. Positive RNA test for
 
Phase 2 ; Dinesh Saralaya, MBBS;clinicalt ;+4411389 Bradford Ro 2.

 
 - Patients aged from 18 to
 
 - With COVID-19 documen
 
 - Undergoing oxygen ther
N/A France ; Mai-Anh NAY, Dr;Aur ;aurelie.de ;+3323874 CHR OrlÃ© 
 
 - No long-term health con
 
 - Doctors
 
 
 - Do not work in high-risk
 
;;; Dina Radenkovic;Anne;;;dina.ra ;;;020 718 King's Coll 

 
 - Patient > or =18 years
 
 - Hospitalization in intensi
 
 - PCR COVID 19+ or compa
N/A France Aurelien Maurizot amaurizot@01.39.63.87.93 

 
 - Confirmed COVID-19 pati
 
 
 - Critical ill patients with a
 
N/A Norma del Carmen Galingalindose 5.26E+11 - Patient

 
 - adolescents aged betwe
 (at least two face-to-face
France ; Emilie Carretier, MD;E;emilie.car ;+33 (0)15 Assistance 

 
 - - adult (= 18 years old, un
 
 - for COVID-19 + patients:
N/A Thomas Similowski, Mthomas.sim01 42 16 77 52 anomalies in taste and sm

 
 - Give voluntary consent t
 
 - Medical profession (para
 Service
 
Poland Excl
 
 - Patients > 18 years
 
 
 - New (within 24 hours) CO
 
 
Phase 2 ; Frank H Lau, MD;Fran ;flau@lsuh ;504 412 1 LSUHSC-NO - Pregnant pa

 
 1. Ability to understand an
 
 2. Individuals aged = 18 ye
 
Phase 4 United Sta ; ; Marcel Curlin, MD;Bre;rodgerbr ;503-494-0Oregon Hea 3. Must have

 
 1. Documented close cont
 the last 48 hours;
 
 2. = 18 years of age;
 
Phase 3 Switzerlan ; ; ; Alexandra Calmy, Prof;;alexandr ;;22372981HÃ´pitaux U 3. Informed consent

 
 1. Clinical suspicion of a ne
 
 2. Patient is admitted to ho
 
 3. Primary reason for hosp

 
 - Hypertensive person, sta
 
 
 - Hypertensive subjects, st
onal [Patient Registry] Ukraine Dmytro Ivanov, MD, P ivanovdd@i5.04E+08 

 
 1. Laboratory-confirmed C
 
 2. Respiratory symptoms o
Phase 1 United Sta ; ; Sara Ghandehari, MD;;Vanessa.V ;31096774 Cedars-Sin saturation
 
 - Hospitalized adult patien
 nasopharyngeal swab;
 
 - radiologically confirmed
 
N/A ; Stefano Fontana, M.D.;enos.bern ;+41 91 81 Servizio Tr - SpO2

 
 Patients admitted from Feb
 according to interim guidan
China Meifang Han, Professor Tongji Hosp China
 Inclusion Criteria

 
 Registry Study: In order to b
 must meet all of the followi
 
 1. Age =18 years of age
 
Phase 2 United Sta ; ; Stuart Katz, MD;Stuar ;Stuart.ka ;212-263-3NYU Langon 

 
 - Between the ages of 28-
 having symptoms of mild
N/A Turkey Tomri?s Duymaz Istanbul Bi pati

 
 - all adults residing in Nor
 
 
 - none
Norway ;; Omid V. E. Ebrahimi, ;; ;; University 

 
 - Age> = 18 years old or <=
 
 - Diagnosis of COVID relat
 
 
Italy Giuseppe Foti, Prof. ASST Monza - pregnant p

 
 
 procedures
 
Phase 2 Len Lazaro llazaro@he858-822-2661 - Severe Acute Respiratory
 
 1. 18 years or older
 
 2. Participant has coronavi
United Sta Mahboob Rahman, MD Mesoblast, transcription polymerase

 
 WP1: Patients of any age w
 whom the LAS were subseq
 
United Ki Rachael Fothergill, PhD London Amb
 WP2: Staff fro
Inclusion criteria: On the pre-defined
 â€¢ Is between the ages of 0 an
Not Applic Australia â€¢ Is Exclusion
admitted to
c the Gold Coa
Exclusion criteria: Unable
 Living
Inclusion criteria: Agedoutside of New
16-30 years
Not Applic New Zealand Living in
 Currently
New Zealandreceiving m
Inclusion criteria: Confirmed or suspe
 Age 18 years or older
 Endotracheal
Exclusion
tube
criteria:
in place
Enrolle
 Heparin
 Intubated yesterdayallergy or he
or today
 PaO2 to APTT > 120
FIO2 ratio less seconds
than or ea
Phase 3 Australia Acute opacities
 Platelet
on chest
countimagin
< 20 x
Not Applic Australia Inclusion Exclusion
Phase II India Inclusion c Exclusion cr
Not Applic Serbia Inclusion crExclusion cr
Phase III Indonesia;Iran;Ireland;Israel;Italy;Kenya;Lebanon;Malaysia;Norway;Peru;Phil Inclusion crExclusion cr

N/A China Zhen-Yan Fu 137 Liyush fuzhenyan +86 13639 The First A Inclusion c Exclusion
RetrospectChina Zhang Weiwei 16 Meiguanzhangweiw+86 15970 Ganzhou PeInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Aged
criteria:
>=18 1. years
Know
 2. according
 2.to Acute
the new
infection
diagnosof
0 China Nanshan Zhong, Jian 151 Yanjia jiw037@uc+86 020 3 The First A 3. after 3.
treatment,
Abnormal
the disease
liver and r
Exclusion criteria: 1) aged
 2) pregnant;
 3) length of hospital
 4) insufficient clinical
RetrospectChina Shusheng Li 1095 Jiefa shushengl +86 13971 Eergency / Inclusion c 5) serious complicati
RetrospectChina Jiang congqing 169 Donghuwb002554 +86 18971 DepartmentInclusion Exclusion c
 2. 1.
Healthywomen;
subjects
 2. Aged 3.
18-70Patients
years old; with seve
4 China Shuihua Lu 2901 Caolan 4.
lushuihua@+86 18930 Shanghai Pu 3. Signed Patients
informed with rand
consent
Inclusion criteria: 1. COVID-19 patien
 2. Isolation
Exclusion
removedcriteria:
and1.homeMee
N/A China Liu Baoyan 16 Nan-Xiaoliuby5505 +86 010-6 TCM Data C 3. Have 2.
signedRefusing to joincon
the informed th
Inclusion criteria: 1. Meeting the diag
N/A China Tong Xiaolin 5 Bei-Xian- xiaolinton +86 010-8 Guang'anme 2. HaveExclusion
signed the c informed con
RetrospectChina Pinhua Pan 87 Xiangya pinhuapan +86 13574 Xiangya HosInclusion c (2) Light: no pneumo
Inclusion criteria:
 2. 1.Patients
Male orwho female
are ao
 2. Patients
 3.diagnosed
Patients withwith mild,
diab
RetrospectChina Chunguang Xie 37 Shi-Er-Qxcg718@al+86 18980 Chengdu Un 3. patients 4.canPatients
generally have
toleany
0 China Wenting Li 1 Swan Lakwtl991100 +86 13866 The First A Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Healthy
criteria:subjects
1. Confi
 2. By asking
 2.forPositive
a medicalin serum
histora
1-Feb China Yanxia Wang 105 Agricu wangyanxi +86 13613 He'nan Prov 3. From 3.
December
Has a 2019
historto now
N/A China Wei Zhang 149 Dalian 35021048 +86 18982 Affiliated Inclusion c Exclusion c
Exclusion criteria: (1) preg
 (2) resting heart rate
 (3) unstable angina o
Inclusion criteria:
 (4)1.mean
Patientarterial
diagnose
pre
 2. The (5)
patientspeak
meetbody the definiti
tempe
RetrospectChina Zhang Jianchu 1277 Jiefa zsn0928@1+86 13971 West Campu 3. The (6)
p resting blood ox
Inclusion criteria:
Exclusion
1. Meet
criteria:
the1.diagno
Patie
 Suspected
 1)
cases:
Shortness of breat
 Epidemiological
 2) In thehistory:
resting state
N/A Shuihua Lu 2901 Caolan tubercle@s+86 021-3 Shanghai Pu Travel 3)
historyArterial
or residence
bloodhisto
oxyg
 2. First-line medical staff;
 3. Isolate residents;
0 China Jiang Hong 236 Jinbo Snxwsyzc@1+86 13309 Ningxia Nin 4. Hospital
Exclusion
staff. c
 2) Female subjects h
Inclusion criteria:
 3) 1)Patients
Aged 18 who
to 75
areyeu
4 China Hongzhou Lu 2901 Caolan luhongzho +86 21 37 Shanghai Pu 2) The 4)
confirmedFactors
participants
th w
RetrospectChina MiaoXing 134 East Stmiaoxing1 +86 13763 Fujian ProvInclusion c Exclusion c
Inclusion criteria: 1. Diagnosed as CO
 2. Aged >=18 years;
 3. Diagnosed
Exclusionas critical
criteria:ill1.patien
Susp
RetrospectChina Hong Qiu 1095 Jiefa tjqiuhong +86 13986 Tongji Hosp 4. 2. Pregnancy and lac
Inclusion criteria:
 (2)(1)
Women
Healthyduring
subject
pr
 (2) Aged (3)
18-70Patients
years; with hea
N/A China Lu Shuihua 2901 Caolan
tuberculos +86 18930 Shanghai Pu (3) Sign (4)
the informed consent an
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Clinical Research Pha 185 Rue Ranbennasr@h3.31E+10 Groupe Hosp
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Denmark www.coptrin.dk KildegÃ¥rdjens.ulrik 4.53E+09 COP:TRIN Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
France Direction de la Rech 80 rue Bro promotion.04 91 38 2 aphm Inclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
France project manager URCIP - Ba carine.lab 33(0)4771 URCIP- CHUInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use Exclusion criteria: -H
 -History
 -Individual
of tuberculo
(M
IV): no -Healthcare
 -People
Workerwith
(medical
acquire
or
France moufida.dabbech@aph
1 avenue Clmoufida.d 3301 44 84Assistance -Participants
 -People
must give
havetheir
already
wri
Human
pharmaco
logy
(Phase I):
yes
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Clinical Trial Unit Avda. AmÃ©rico
fabiola.lo
Vespucio
+34671
15, 53
Edificio
Red AndaluInclusion
S-2; Parque cientÃ
c Exclusion
fico y TecnolÃ³gico
c Cartu
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain CTU Mallorca 1 acruceta@c3.49E+14 Clinical Tri Inclusion Exclusion c
Human
pharmaco
logy
(Phase I):
yes
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Banc de Sang i Teixits Passeig Taurucoll@bst 3.49E+14 Banc de SanInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Antonio Luque Edificio I uicec@imib 3.47E+10 FundaciÃ³nInclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Antonio Luque Edificio I uicec@imib 3.47E+10 FundaciÃ³nInclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Sonia GutiÃ©rrez Sant Ferra sgutierrez +34 647 79Oryzon GenInclusion Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use Inclusion criteria: 1. Hospitalized
(Phase 2. Diagnosed to be COVID-19 PO
IV): no 3. Oxygenation
Exclusioncriterion:
criteria: 1.
Austria;De Sponsor Campus-Viesonja.hoeller@apeironAPEIRON Bi Oxygen 2.
saturation
Known positive
=93% (eith
He
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Germany Coordinating InvestigaBreisacher tobias.wen 4.98E+12 UniversitÃ Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Exclusion criteria: â€
tic use â€¢ Denial of written
 â€¢ â€¢
Any patient
Age 18
case
or
IV): no â€¢ Both â€¢
gendersSerum AST value
Greece Regulatory Affairs de 14th Km Nasoumelas@ 3.02E+15 Uni-Pharma â€¢ For â€¢
womenQTc of childbearing
interval in re
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use Inclusion criteria: 1. Adult pati
(Phase 2. Confirmed
ExclusionSARS-2-CoV-2
criteria: 1.in
IV): no 3. Admitted
 2. toASAT/ALAT
the hospital> 5wa
ti
Norway Sect. Clin. Imm. & InfeSognsvannsandreas.b 4.72E+09 Oslo univer 4. Subjects
 3. (orAcute
legallyco-morbid
authoriz
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Denmark Charlotte Kastberg Le Kettegaardcharlotte. 4.54E+09 DepartmentInclusion c Exclusion c

 
 
 - One of them:
 
N/A China XIAN SHEN, phd The 2nd Af 1. Laboratory (RT-PCR) a

 
 - Provision of informed co
 
 - Exposure to a COVID19 c
 exposure, OR
 
Phase 3 United Sta ; David Boulware, MD, ;covid19@ ;61262499 University - Symptomat
 
 - COVID-19 pneumonia pa
 
 
 - Patients who were youn
 
China - Patients whose entire st
 Cohort 1)
 
 - Documented COVID-19 i
 assay) for SARS-CoV-2
 
Phase 1/PhDenmark ; Lars Ã˜stergaard, Pro ;olesoega ;+45 2499 Head of De - Less than 48 hours since

 
 - Adult (=18 years)
 
 
 - Hospital personnel (expe
 
Phase 3 Netherland Thijs ten Doesschate, t.tendoess 3.16E+10 Inclusion Criteria (case defin

 
 - Consented adults (age =1
 
 - COVID-19 suspicious and
 
 - Admitted to hospital or a
 
Phase 3 Argentina ; ; Rafael Diaz, MD;Andre;aorlandin ;+ 54 341 ECLA- ICR; - Fever (with

 
 - Age = 18 years old (Sub-s
 
 - Competent and capable
 
Phase 2 United Sta ; ; Ravi Amaravadi, MD;A;amelia.a ;215-509-5University - Have access to a smart d

 
 - Participants that, after re
 objectives, possible risks
Phase 3 Spain ;; Rosa Polo, MD,PhD;Mi;;jamo@msc
;;+34 690 Plan Nacion 
 
 I (first step):
 
 - Admission to hospital
 
 - Male or non-pregnant fe
Phase 2 Switzerlan ; Peter M. Villiger, Pro ;stephan.r ;+41 31 63 University known risk factors (art

 
 - 1. Patient or guardian m
 applicable) before any st
 
Phase 2 Germany ; Andreas Hochhaus, Pro;ruxcoflam ;+49 3641 University - 2. Male and female patie

 
 - adult patients (>18 years
 infliximab or vedolizuma
 
 
onal [Patient Registry] France ; Arnaud Bourreille, P arnaud.bou0240083152; - not affiliated

 
 1. > 18 years of age
 
 procedures
 
Phase 1/PhUnited Sta ; ; Teresa Gaither, NP;N ;;nhank@p;;4804716 Athena Med
 3. Confirmed Sars-CoV2 in
 Inclusion Criteria: adult pati

 
 - an acute non-critical me
 
Phase 3 Switzerlan Marc Blondon marc.blon +41.22.372.92.92 - an acute critical ward (IC

 
 - Male or female adult = 1
 
 - Confirmed diagnosis of S
 
Phase 2 United Sta ; ; Matthew Dallos, MD;L;cancercli ;212.342.5 Columbia Un
 - Inpatient hospital

 
 - Men, and women 18 yea
 
 - Participant works in a ca
 
Phase 2 United Sta Thanh Cheng, MD Hope Biosc - High-Risk Exposure jobs
 
 Subjects must meet the crit
 
 1. Men, and women over 6
 
Phase 2 United Sta Thanh Cheng, MD Hope Biosc 2. Participa

 
 1. Symptomatic patients: d
 or shortness of breath (r
 
Phase 4 Pakistan ; Ammar Sarwar, MD;A ;asarwar@ ;0423-530 Beth Israe 2. Nasopharyngeal R

 
 
 
Phase 1/PhBrazil ; Rodrido Esper, MD, P dr.rodrigo +55 11 98179-7949; 3. Acute respiratory distre

 
 - Symptoms occurring wit
 nasopharyngeal swab
 
Phase 2/PhUnited Sta William O Richards, MD University - Nasopharyngeal swab po

 
 - Patient with MS or NMO
 
 - at least one of the follow
 
 - COVID + biologically c
 
France ; CÃ©line LOUAPRE, M celine.lou 1 42 16 57 66; - Typical ground glass o

 
 1. Patients with COVID-19
 
 2. =16 years and < 70 yrs
 
Phase 2 United Ki ; Mark Phillips;Mark Phimark.phill 0208 016 8111; 

 
 - Patient with SARS-CoV-2
 hospitalization with or w
 
France ; Jean-Christophe Gris; ;jean.chri ;04 66 68 CHU Nimes - The patient (or their care
 
 - Adult patient
 
 - with COVID-19 pneumon
 inclusion or very highly s
 
N/A France ; Yonatan PEREZ, MD;Y ;y.perez@c;(0)2.47.47 University - Pat

 
 - Breast reconstruction pa
 
 - Sarcoma patients pre an
 
 - Burns patients pre and p
 
N/A United Ki ;; Steven Lo, FRCS Plast; ;steven.lo ;01412114 NHS Greate - Cleft lip patients pre

 
 1. Male and female partici
 
 2. Participants who are ho
Phase 2 United Ki ;; Joanna Porter, MD Ph ;misha.lad ;0044 20 3 University confirmed by polymerase

 
 For the Covid-19 Group: wit
 to the ICU.
 
 For the Control Group:
 
; Saad Nseir, MD,PhD;S ;saadalla.n ;03204459 University H - Historic cohort of non SA

 
 - This study will enroll all p
 and require supplementa
 
N/A United Sta Todd W Rice, MD, MSc Vanderbilt Exclusio

 
 procedures or have a leg
 
Phase 2 United Sta ; ; Max O'Donnell, MD;M;mo2130@c;212-305-5Columbia U - Age =18

 
 - All clients and health car
 
 
 - None
United Sta Michael Runyon, MD, MPH Atrium Hea 
 
 - Subjects > 60 years of ag
 
 - Diagnosed case (PCR tes
Phase 4 Spain ;; Joaquin De Haro, MD; ;deharojo ;+34 62602Hospital Un (defined as fever, dry cou

 
 healthy adults over 18 year
 
 
 any condition that does not
Germany ; Stefan Brunner, MD;S Stefan.Br +49 89 44000;+49 89 

 
 1. Women or men of = 18
 
 2. SARS-CoV-2 infection co
 
Phase 2 Spain ;;;; Julia Barbado, MD, Ph ;;;jbarbad ;;;+34 616 University Hospital
 RÃ 3.o Admitted
Hortega, Valladolid,
to the Intensiv
Spa

 
 
 - Currently hospitalized or
 
Phase 3 United Sta ; Todd Rice, MD;Amanda
;amanda.j. ;(615) 875 Vanderbilt - Symptoms of acute resp

 
 - Health Care workers with
 
 
; Annie SOBASZEK, MD;;annie.soba;03.20.44. University H - Heath Care Worker with

 
 - Major patient (=18 years
 
 - Admitted in March 2020
 sputum with SARS-CoV-2
 
France ; Yves HANSMANN, MD,Yves.hansm33 3 69 55 09 78;33 3 <

 
 - Male or Female
 
 
 - Laboratory confirmed CO
 
Danielle Evans DEvans@u (501) 526-7906 - Patients currently hospit
 
 - Has previously taken par
 Volunteer Study
 
 - Has agreed to be contac
 
United Ki Lynne Macrae lynne.macrae@manchester.ac.uk 

 
 - Adult = 18 ans,
 
 - Patient with positive SAR
 within the previous 48 ho
 
Phase 3 France Emmanuel MONTASSIEmmanuel.+33 (0)2 53 48 20 38 - Patient

 
 
 2. Healthcare or Hospital W
 
 3. Willing to participate in
 
Phase 3 United Sta Ann D. Chauffe, DO, achauf@ls 337-261-6161 4. Able to understand

 
 - COVID-19 infection confi
 
 - COVID-19 disease manife
 
 
 
N/A ; Olaf RieÃŸ, Prof. Dr.;O;olaf.ries ;+49 (0)70 University - Missing informed conse

 
 - pregnant
 
 - 18 and over
 
 - monofetal pregnancy be
 
Phase 3 France ; Xavier-CÃ´me xcd Donxdonato@hop
33491806642;334918 - presenting a positive CO

 
 1. The patient volunteered
 and was willing to rando
Phase 2/PhChina Cai Yue the first af 
 
 - Patient (of all ages) with sy
 GHPSJ or in one of the estab
 
France ; Benoit PILMIS, MD;Be ;bpilmis@h;14412782 Groupe Hosp
 Exclusion

 
 - All adult patients requiri
 
 
 - Patient under 18 years o
 
N/A Poland Lukasz Szarpak, PhD lukasz.sza 5E+08 - Patients with criteria pre

 
 - 30 days or more after dis
 
 - Patient received informa
 
; Marie-France VAILLAN;mfvaillan ;04 76 76 Centre Hosp
 - Patient capable of answe

 
 - COVID-19 disease patien
 
 
 - unconfirmed suspected c
 
China ; Jianguo Sun;Sun Jiang sunjg09@al023-68774490; - Patients during pre

 
 - Confirmation of 2019-nC
 
 - Diagnosis of ARDS accord
 
 - Requiring supplemental
 
Phase 2/PhIran, Islam ; ; ; Abdol Hossein Shahve;;masoume;;0098212 Royan Insti 

 
 
 - Nasopharyngeal swab po
 
 - COVID-19 stages I - II - III
 
Phase 2 Italy ;; Francesco Pugliese, M;f.puglies ;00390649 University - Hospitalization in the De
 
 For Patients:
 
 - Adult patient, treated fo
 
 - will be treated ou actual
France ; Audrey FAVEYRIAL, M a.faveyrial 0231455050;0231455 

 
 - Undergoing cardiac surg
 inferred when elective su
 
United Ki ;; Julie Sanders, PhD;Jul ;j.sanders ;07960311 St. Bartho - Discharge from hospital

 
 1. Persons over 20 years o
 
 2. Active healthcare perso
N/A Spain ; Raquel Rodriguez Bla raquel.rod +34 958 023 000;+34 professional categories, m

 
 - hospitalized for Covid-19
 
 - severe pneumonia defin
 
 
 - lack of consent
 
onal [Patient Registry] France ; HÃ©lÃ¨ne Gros, MD; ;helene.gr ;01 49 36 Robert Bal 

 
 - paramedic
 
 - consent voluntary partic
 
 - none experience in resus
 
N/A Poland Jacek Smereka, PhD Wroclaw Me
 Exclusion Criter

 
 - Biological and/or radiolo
 
 - WHO-OSCI at 3, 4 or 5 at
 
 - Benefiting from a social s
 
Phase 3 France ;; Marion Plaze, MD, PH ;m.plaze@g;01456586 Service Hos
 
 - patients hospitalized in m
 
 
 - patients< 18 years
France Michel Slama, Pr slama.mich(33)3 22 08 78 41 

 
 -- Single pregnancy
 
 - Birth of a child living with
N/A France ;; Jean Marie JOUANNIC,;jean-mari ;01 44 73 Assistance the accommodation of th

 
 
N/A France ;; Anatole HARROIS;Ana ;anatole.h ;+33(0)1-4 Assistance typical radiological findin

 
 - All patients with COVID-1
 is defined as either a pos
N/A Belgium ;; Janneke Cox, MD, PhD;janneke.c ;+3211337 Jessa Hospi 

 
 - Age = 18 and < 90 years
 
 - PCR confirmed diagnosis
 
 - Radiological image comp
 
Phase 2 ; JosÃ© LÃ³pez Mirand ;md1qugoj ;00346715 Hospital Universitario
 - Reina
Si SofÃa;

 
 - Laboratory-confirmed CO
 
 - ECMO for treatment sev
 
Austria;Be ; Lorusso, Prof. Dr.;Loru;roberto.l ;+ 31(0) 4 Maastricht
 
 - Out-of-hospital cardiac a
 
 - Adult = 18 years old
 
 - Non-traumatic cause of c
 
 
N/A Poland Lukasz Szarpak, PhD Lazarski Un -

 
 - Pregnant women or wom
 
 - Able to give electronic in
 
onal [Patient Registry] United Sta ; ; Diego Wyszynski, MD, ;IRCEP@pre;(747) 200 CEO Pregist - Tested for SARS-CoV-2 (r

 
 1. Patients of either sex ag
 
 2. Patients who are Covid-
 
 3. All patients with positive
India ;; Sandeep Budhiraja, M;sbudhira ;98102629 Max Health

 
 - age >18 years old
 
 - confirmed SARS-CoV-2 in
Italy ;; Matteo Bertini, MD, P ;doc.matb ;+3934740 s.anna univ diagnosis of COVID-19 ba

 
 - Male or female or child w
 
 - Admitted to a Reference
; Enagnon Kazali ALIDJ ;EnagnonK ;(0)3.20.44 University H intensive care unit for su

 
 
 - Proven severe acute resp
 
 
onal [Patient Registry] Germany ; Alexander Grimm, MDalexander +49 (0) 7071-29;+49 ( - active or known history o
 
 
 - Has stayed in Singapore
 
 - Has a WhatsApp accoun
 
Singapore ; ; Jean Liu, PhD;Jean Liu ;jeanliu@y ;66013694;Yale-NUS C Exclusion Cri

 
 - adult patients (> 18 year
 
 
 - inability to understand a
 
 - mentally incapacitated.
Italy ; Stefano Centanni, Full stefano.ce 0281843025;0281843 

 
 - Android smartphone
 
 
 - severe depressive compl
N/A Belgium ;;; Rudi De Raedt, PhD;Er;;kim.rens ;;+32 494 University 

 
 - Dialysis
 
 
 - Not willing to give conse
onal [Patient Registry] Denmark ; Frank Mose, MD;Fran frchri@rm.+4528531257;285312 

 
 - Hospitalized patients at P
 COVIT-19 pandemic in Ita
 
Italy ;; CTC CLINICAL TRIAL CE;abellasi@ ;0039 035 Clinical Tr - COVID-19 positive patien

 
 - Patients with CHC and in
 
 - Hospital and ambulatory
 
France ; Eric NGUYEN KHAC, Prnguyen-kha(33)3 22 08 88 51;(33 - Infection confirmed by C
 
 
 - NewYork-Presbyterian (N
 
 - Understands and reads E
 
onal [Patient Registry] United Sta ; ; Magdalena Sobieszczy;bg2168@c;212-305-1Columbia Un
 Exclusion Crit

 
 - transplant surgeons, refe
 coordinators, transplant
Italy Pulmonologis

 
 - Patients between 15-100
 
 - Patients admitted for CO
N/A Sweden ; Alicia Edin, M.D.;Alici alicia.edi +46907850000;+4690 Infectious Diseases or ICU

 
 - Adult (18 years or older)
 
 - Potential exposure to CO
 
 - Have regular access to a
onal [Patient Registry] United Sta ; ; Nancy Dreyer, PhD, M;barbara.a ;61762164 Iqvia Pty Lt 

 
 - laboratory confirmed CO
 
 - be older than 18 years o
 
 - be hospitalized at the UZ
 
onal [Patient Registry] Belgium ; Koen Vercauteren;Koekvercauter +32 3 247 63 32;+32 2 - willing and able to provid

 
 1. Has been tested positive
 
 2. Patients with cough, sho
N/A Spain ; Carlos Tornero, PhD;C carlostorn 610408381; increased wor

 
 - women older than 18 ye
 
 - women who deliver of a
 
 
bertarnd GACHON, MDbertrand.gachon@chu-poitiers.fr - women younger than 18
 Subjects will be included in
 any linked/participating IRB
onal [Patient Registry] United Sta ; ; Chris Woods, MD;Lynn;lynn.sutt ;919-668-8Duke Unive COVID-related study but me

 
 - Individuals presenting to
 screening for Covid-19 te
 
N/A United Sta ; ; Amy Mathers, MD;Limo
;LIS5AY@vi;434-243-9University - Indivi

 
 1. Fulfilling the 2019 Europ
 Rheumatology classificati
 
 2. Over 18 years of age
 
N/A 3. able t

 
 Hospital staff (doctors and n
 
 
 None
Johannes Siebermair, johannes.s 0049 201 723 84345 

 
 - patients admitted to Em
 SARS-CoV-2 RT-PCR test
France ;; StÃ©phane Bar, MD;S;bar.steph ;03220879 CHU Amien u

 
 - COVID-19 diagnosis
 
 - symptomatic COVID-19
 
 - hospitalization in infectio
 
 
 - Pregnant
Italy Gabriella d'Ettorre, MD, PhD University 
 SARS-CoV-2 infection or
Phase 2 Italy 
 
 - Adults
 
 - COVID-19 +
 
 - Abnormal neurological e
 
 - who underwent a brain M
 
 
France ; Stephane Kremer, MDstephane.k33 3 88 12 78 89;33 3 

 
 1. Participants will be fron
 management of COVID-1
 
Early PhaseCanada ; Akshya Vasudev, MBBakshya.vas 519-667-6693;519-68 2. Participants will be willin

 
 - Healthcare workers of M
 
 
India ;; Sujeet Jha, MRCP (U.K;sujeet.j ;09910609 Max Healthc
 - Out-patients getting test

 
 - aged 18 years or older
 
 - intubated and mechanic
 
 - confirmed COVID-19 infe
 
onal [Patient Registry] Spain ;; Carlos Ferrando;Carlo ;cmferrand;60989273 Medical Res - acute onset of

 
 - Patient may be diagnose
 laboratory studies includ
 
N/A ; Keith A Marill, MD;Kei;kmarill@m;617-643-8Massachuse - Patient with imminent

 
 - Participants of the age o
 
 - Participants residing in In
 
onal [Patient Registry] - Participants with minimu
 
 - Histologically confirmed
 
 - Ongoing systemic antine
 
 
Phase 2 Austria ; Matthias Preusser, M matthias.p +43140400;+4314040 - L

 
 - Participants must be 18
 ability to download the m
N/A ; Diana Speelman, PhD;;dspeelma ;814-868-1Lake Erie C co

 
 1. Males or females = 18 y
 consent
 
Phase 3 Alexion Pharmaceuticalclinicaltri +1 855-752-2356 2. Confirmed diagnosis of S

 
 - All individuals who are a
 
 
 - None
Canada ; RÃ©becca Robillard, ;rebecca.r ;613-722-6University 

 
 - > 18 years of age;
 
 - laboratory or clinical-epi
Phase 4 Brazil ; Leonardo O Reis, MD, ;bethania ;+5519 334UroScience home contact with a labo

 
 - Male or female 18 years
 participate in the study
 
United Ki ; Rajarshi Banerjee, MSc;mary.xu@;01865655 Honorary C - Recent confirmed diagno

 
 - test positive for COVID-1
 
 - be inpatient
 
 - Have signs of respiratory
United States or a respirat
 
 - Adult patient
 
 - Stroke Patients
 
 - Patient who agreed to pa
 
 
France ; RÃ©my BEAUJEUX, MD
remy.beauj33 3 88 12 78 71;33 3 - Refusal to participate

 
 - Patients admitted and m
 who received a pleuro-p
 
 
France ; Philippe LE CONTE, M philippe.l 02 40 08 39 34;

 
 - Fever and/or
 
 - Cough and/or
 
 - Dyspnoea
 
 
 - No one
Italy ;; Roberto Copetti, MD, ;crisdigio ;+39 349 3 Ospedale di 

 
 - All UPMC healthcare pro
 therapists, physical thera
N/A United Sta ; ; Sara P Myers, MD, Ph ;myerssp@;412-647-0University provider

 
 - Positivity to the test for C
 interstitial pneumonia co
Italy ; Gianfranco Parati, MD;gianfranc ;+3902619 Istituto Au severit
 Patient Participant Inclusion

 
 - Less than 24 years old at
 
 - St. Jude patients with lab
 
 
United Sta ; ; Diego Hijano, MD;Die ;referrain ;866-278-5St. Jude Ch 
 
 - Healthcare workers with
 medicine,
 
Phase 3 Canada Kimberley Lewis kimberley. 289-775-7334 - COVID-

 
 - Health Care workers with
 
 
 - HCW working off-site at
 
; Annie SOBASZEK, MD;;annie.soba;03.20.44. University H - H

 
 - Lebanese living in Leban
 
 
 - Not having the inclusion
Lebanon ;; Jeanine El Helou, MD, ;jeanine.h ;96132625 USJ; 
 Inclusion Criteria: Patients w

 Covid-19 test positive
 
 Exclusion Criteria: Age lowe
onal [Patient Registry] Italy ; Massimo Montalto, Prmassimo.mo
+39 06 30155948; 

 
 
 - Age at least 18 years
 
 
United Sta ; John D Beckham, MD; ;David.be ;303-724-4University 
Exclusion criteria: â€¢ Par
 â€¢
Inclusion criteria: Unwilling
â€¢ to beagc
Participants
 â€¢ Medical
 â€¢ Participants who have or psych
atten
Not Applic Australia â€¢
 .â€¢ Both Research
participants st have
that
Inclusion criteria:
 2. 1.
Inability
Age greater
to useorthee
 2. Able o
to provideCognitive
informed impair
con
 3. Proven
 o
diagnosis
Impaired
of COVID-19
dexter
Not Applic Australia 4. Patients
 owho Visual
are being
im mana
0 China Wei Zhang 149 Dalian zhangwei_ +86 18982 Affiliated Inclusion c Exclusion c
Inclusion criteria: (1) age =18 years o
 (2) Laboratory (RT-PCR) confirm
 (3) theExclusion
time fromcriteria:
the first(1)
positi
kno
N/A China Zhang Fujie 8 Jingshun treatment@+86 13001953958 (4) informed
 (2)consent
according hastobeen
the l
N/A China Ling Wang 138 Tongzi wanglingc +86 15274 DepartmentInclusion c Exclusion c
RetrospectChina Wang Yanping 16 Nanxiaowangyanpi +86 010-6 Institute o Inclusion c 2. Patients with seve
Inclusion criteria: (1) nurses who wer
 (2) nurses participated
Exclusion criteria:in(1)
epidem
nurs
N/A China Shi Tieying 222 Zhongsh sty11177@+86 18098 The First A (3) nurses
 (2)
had nurses
read/understood
who hadpr
Exclusion criteria: (1) Criti
 (2) Gastrointestinal p
Inclusion criteria:
 (3)1.Gastrointestinal
COVID-19 patien o
0 China Li-Hao Wu 19 Nonglin wulihao88 +86 13660 The First A 2. COVID-19
 (4)patients
Recentaccompan
history of
 (2) Patients with mild
 (3) Pregnant or lacta
N/A China Xijing He 777 Xitai R czj0606@1+86 17729 Xi'an Inter Inclusion c (4) Upon the investig
Exclusion criteria: 1. Durin
RetrospectChina Enqiang Mao 197 Secondmaoeq@ye+86 13501 Ruijin HospInclusion c 2. During pregnancy
Inclusion criteria: 1. The patient volu
 2. 18-65 years old;
 3. Patients
Exclusion
diagnosed
criteria:
with 1. COVI
Intes
N/A China Xiaohua Hou 1277 Jiefa houxh@hus+86 027 8 Huazhong U At present, 2.hePrevious history of
N/A China Zhao Yin 1277 Jiefa zhaoyin@h+86 13628 Union HospInclusion c Exclusion c
Inclusion criteria: (1) Patients who m
 (2) Aged 18 to 70 years old;
0 China He Shaobin 856 Luoyu heshaobin +86 18986 Hubei Prov (3) SignedExclusion
informedc consent.
Principal
Investigat
or
Queen
Charlotte'
s&
Chelsea
Hospital
Du Cane
Road
London
Not Applic Argentina; Edward Mullins edward.mul+44 (0)20 3313 1111 Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
France DRCI HÃ´pital St Louis 1 av. Claudfrance.guyot@aphp.frASSISTANCInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
France Alain Moussy 3 avenue GDL_MEDICA3.31E+10 AB Science Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Netherlan Clinical Research an Winzerlaer korinna.pil +4989414 InflaRX G Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
France clinical project manag DRS, 80 Ru promotion. 4.91E+08 ASSISTANCInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu Inclusion criteria: 1. Male or fem
tic use 2. Adults (= 18 years old)
(Phase 3. BodyExclusion
weight =40
criteria:
kg 1.
IV): no 4. Informed
 2.consent
Intubated
mustand
beonobm
United Sta Medizinischer Infoser RoonstraÃ infoservic 4.99E+12 Novartis 5. Clinically
 3.diagnosed
Treatment with
with
SARS
bi
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu Inclusion criteria: 1. Male or f
tic use 2. Adults (= 18 years old)
(Phase 3. Body Exclusion
weightcriteria:
=40 kg 1.
IV): no 4. Informed
 2. consent
Intubated
must
andbeo
United States;France;Spain;Germany;Italy;United Kingdom 5. Clinically
 3. diagnosed
Treatment with
with
SA
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
France Direction de la RecherBÃ¢timent dripromote33383 155 CHRU de NInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
France MÃ©lody FORT 177 rue de mfort@ch-ve3.3E+11 CH de VersaInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
France Sandrine ROUX 177 rue de sroux@ch-ve3.31E+10 Centre Hosp
Inclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use Exclusion criteria: -
 - -
Pregnancy
Adults
or bre
pa
IV): no - COVID-19
 - diagnosis
Known Hepatic
in the pf
France Sophie COURTIAL-DE DRCI HÃ´pitsophie.cou 3.31E+10 ASSISTANC - Known Plasma t
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Ki Research and DevelopUnit G2 Haresearch. 2.03E+09 Chelsea an Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Sta Michel Morre 15 rue Tait mmorre@r 3.36E+10 RevImmuneInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Germany Prof. Dr. Carsten MÃ¼Im NeuenheCarsten.Mu+49622156University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki OCTRU Botnar Res octrutrial 1.87E+09 University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Chief Investigator Aldermast afroze.kha 7.89E+09 Hampshire Inclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Hungary Directorate KorÃ¡nyi Frigazgatosa 3.61E+09 National KoInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
United Ki Donal McLornan HaematologDonal.mclo004402071Guyâ€™s anInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Greece President of the Boar 88 Michalainsepsis@o 3.02E+11 Hellenic In Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Austria Univ.-Prof. Dr. Axel B AnichstraÃ kks-regula 4.35E+12 MedizinischInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain DAVID BERLANA VALL HEBR dberlana@ 3.47E+10 VALL HEBR Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Austria Sponsor WÃ¤hringerklin-pharmakologie@ Medical UnInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Alejandro Calle Edit secretaria 3.46E+10 Delos Clini Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Denmark Sponsor/Investigator Nordre Fasalars.erik. 4.54E+09 The Parker Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu Inclusion criteria: ? Age 18-80 ye
tic use ? SevereExclusion
pneumonia
criteria:
COVID-19
 ? Nd
(Phase o Nasopharyngeal
 ? AST/ALT smear
withwith
value
R
IV): no o X-Rays ?
(or other
Neutrophils
technique)
< 1500
pu
Spain RUTH GARCIA EDIFICIO ruth.garci 3.48E+10 CLINICAL T o 1 or more
 ?ofPlatelets
the fo < 50.000 c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Departamento de Ensayos
c/ Azcona,
ClÃnicos
ensayoscli 3.49E+10 Dynamic ScInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
Exclusion
 â€¢
criteria:
Age â€
=18 y
IV): no â€¢ Diagnosis
 â€¢ofRespiratory
SARS-CoV-2 failu
pn
Spain CLINICAL TRIAL UNIT EDIFICIO ruth.garci 3.48E+10 NAVARRABI â€¢ Duratio
 â€¢ Need for glucoco
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Denmark Clinical Trials Informa Blegdamsveanders.per 4.54E+09 DepartmentInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain RUTH GARCÃA EDIFICIO ruth.garci 3.48E+10 CLINICAL T Inclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain MarÃa del Mar GarcÃaAvda. Valdemmar.garci 3.49E+10 IDIVAL Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase Inclusion criteria: ? Patients 1
IV): no ? Patients with a diagnosis of
NetherlandPrincipal Investigator Hanzepleina.rutgers@umcg.nl UMCG ? Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Clinical trial Passeig Olatomas.per 3.46E+10 FundaciÃ³ Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Mar GarcÃa SÃ¡iz Avenida demmar.garci 3.49E+10 IDIVAL Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Tatiana Cobo IbaÃ±ez Paseo de E mtatiana.c 3.49E+10 Hospital Universitario
Inclusion c Infanta
Exclusion
SofÃ
c a
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain UCEC Avda. PÃo XII,
ucicec@un
36 9.48E+12 Clinica Uni Inclusion criteria:
Exclusion
 -Patients diagn
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase Exclusion criteria: 1.P
IV): no Inclusion criteria:
 2.Clinical
 1.Hospitalized
evidence of
Spain Department of ClinicalAv. GeneralIGregulator 3.49E+10 Instituto Gr 2.Has laboratory-confirmed
 3.Th nov
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
Exclusion
 1.
criteria:
Hospitalized
 1.
Spain Department of ClinicalAv. GeneralIGregulator 3.49E+10 Instituto Gr 2. Has 2.
laboratory-confirmed
Clinical evidencnov

 
 1. Positive for RNA of SARS
 
 2. Hypoxemic
 
 3. Severe COVID-19
 
N/A China;Chin ; Zuojiong Gong, MD;Zu; ; Renmin Hos 4. If female, subject must n

 
 Clinical diagnosis of COVID-
 
 
 Previous history of allergy t
 ;
Phase 1/PhIran, Islam ; ; ; ; ; ; ; Yadollah Shakiba, MD,;;alirezag ;;+1-608-6 Regenerati Inclusion Cr
 
 
 - Collection of the subje
 
 - Patient registration on
 
France;France 
 Patients eligible for inclusio
 criteria:
 
;;; Novartis Pharmaceutic;novartis. ;41613241 Novartis P Written patient informed co

 
 - All patients with laborato
 
 
 - Suspected cases of COVI
 ;
 
China;China 

 
 - Age = 18
 
 
 - Oxygen saturation (SPO2
 
Phase 2 Iran, Islam ; ; ; ; ; ; ; ; ; Ilad Alavi Darazam, ;;;;;;;;; ;;;;;;;;; Shahid Behe
 - At least one of the follo

 
 1. The diagnosis of COVID-
 reaction (RT-PCR) assay;
 
Phase 2 United Sta ; ; ; Sudarshan Hebbar, M ;sudarsha ;816-838-7CalciMedica 2. At least 1 of the followin

 
 1. Nasopharyngeal RT-PCR
 
 
 3. BMI 18-28 kg/m2
 
 4. Informed consent
 
Phase 4 Pakistan;P ; Ammar Sarwar, MD;A asarwar@b+92-42-35 ; Exclusion Criteria
 
 
 2. Admitted in the hospita
 WHO classification.
 
Phase 3 Spain;Spai ; ; ; Domingo A Pascual Fig;dpascual ;96836950 HCUVA;;HC 

 
 - Medical doctors, Nurses
 and ICU and dedicated C
 
 - Age between 18 and 70
 
N/A Jordan;Jor ; ; ; Iyad Sultan, MD;Iyad isultan@kh+96265300;

 
 â€¢ Healthcare providers or
 following criteria:
 
onal [Patient Registry] United Sta ; ; ; ; ; Jeremy Warner, MD;Van
;cip@vumc.;800-811-8Vanderbilt - Suspected (presumptive

 
 
 - Patient who signed the s
France;Fra ; ; ; ; ; FrÃ©dÃ©ric COUTANT;frederic.c ;04-78-86- Hospices Ci after the onset of sympto

 
 - Within 7 days of patient'
 
 - Positive SARS-CoV-2 RT-P
 
 - At least one risk factor fo
N/A Israel;Israe ; ; ; ; ; Amir Hadanny, MD;Am;amir.had@;97254470 Shamir Med

 
 - aged >= 18 years
 
 - needing admission to a m
 
 - with a confirmed infectio
 
;;; Paolo Simioni, MD;Gi ;giuseppe. ;+39-0498 Department
 
 - All patients seen the in e
 clinics that are:
 
 - Tested Positive for CO
 
onal [Patient Registry] United Sta ; ; ; Arash Naeim, MD, PhD;ClinicalR ;;; University 

 
 - Adult > 18 years old
 
 - Both Gender (male and f
 
 - Healthy health care work
 
Phase 3 Egypt;Egyp ; ; ; Mariam Amin, MD;Fatmariamage012245327; -

 
 - Patient confirmed COVID
 
 - Patient with acute respir
 
 - Patient hospitalized in th
 
Phase 3 Tunisia;Tun ; ; ; Eshmoun Clinical Reseaeshmounc 002162787; - Age >18 y

 
 - any medical or non-med
 Manila National Institute
Phase 3 ;;; Belen L Dofitas, MD;B ;bldofitas ;+6328554 Philippine fellows-in

 
 - Clinically suspected or co
 
 - SARS-CoV-2 swab test pe
 
Switzerlan ; ; ; ; ; ; ; Raphael Twerenbold, ;;raphael. ;;0041 61 Department - A

 
 - Kidney or kidney-pancre
 
 - SARS-CoV-2 positive (RT-
 
N/A France;Fra ; Antoine SICARD;Antoi sicard.a@c33 4 92 03 ; - COVID-19 symptoms at l
 
 For patients in resuscitation
 
 - Patient under invasive m
 
 - PaO2 / FiO2 <300
 
N/A France;Fra ; ; ; ; ; Emilie EGP GARRIDO-P;Julien.CA ;04 13 42 9Assistance - PCR SARS-Co

 
 - Pregnant women
 
 
 - Diagnosed with COVID-1
 
 
France;Fra ; ; ; ; ; Jean-Olivier ARNAUD, ;florence. ;49138379 Assistance - Patients Refusing to Parti

 
 - Adult diabetic patient (ty
 diabetology consultation
 
; Eric DEMONSANT;Eri eric.demon+33 3 88 1 ; - Subje

 
 1. Confirmed case of Covid
 
 2. Admission to Intensive C
 
 3. Need for intubation and
 
Phase 1 Iran, Islam ; ; ; ; ; Daryoush Hamidi Alam;hamidiad ;+98 51 38 Mashhad Un
 

 
 1. All nurses currently servin
 
 Exclusion criteria
 
 1. Subjects who refuse to p
 
; Samuel EH Tsan, MD, samuel.ts 603794920; 2. Subjects working in ICU,

 
 - COVID-19 hypoxemic pn
 maintain SpO2 > 93%
 
Phase 2 France;Fra ; ; ; ; ; Emilie Garrido-Pradal ;nicolas.sc ;04-91-38- Assistance - For patients included in i
 
 - Inclusion criteria :
 
 - Adult aged 18 to 75 year
 
 - Taken into primary healt
Phase 3 ;;; Julie CHASTANG, Dr; ;sarra.poc ;+331 42 1 Department (maximum

 
 - Patient with clinical signs
 
 - Complete blood count te
 diagnosis
 
France;Fra ; ; ; ; ; ; ; David Chalvet, MD;K ;;;;;;; ;;;;;;; Numa Healt -

 
 - Patients with end-stage
 
 - SARS-CoV-2 positive (RT-
 
N/A France;Fra ; ; ; ; ; sicard antoine, ph;SI ;sicard.a@c;+3349203 NÃ©phrolog
 - COVID-19 symptoms at l

 
 - COVID 19 confirmed pati
 
 
 - <18 years
 
 - Pregnant women
 
Italy;Italy ; Francesco Franceschi ; ; Fondazione - Asymptomatic and norm

 
 - patients with severe COV
 
 - willing to give informed c
 
 
 - patients with mild COVID
 
Early PhaseChina;Chin ; Jianming Tan Tan, M. ; ; Fuzhou Gen 
 - Patient admitted to ICU
 
 - Ventilated or not ventila
 
 - No restrictions on age
 
Belgium;Be ; ; ; ; ; Lieven Herbots, MD, ;Lieven.He ;+3211309 Hartcentru - No restrictions

 
 - = 18 years old.
 
 - Either: i) Meet local testi
; ; ; ; ; ; ; ; Alexandra Calmy, MD,;;;;;;;cohi ;;;;;;;+61 University the opinion of the investi

 
 - Adults aged 18 and over
 
 - Be able to read and unde
 
Canada;Ca ; BenoÃ®t Lamarche;Be; ; University - Have access to Internet (

 
 - Adults (age over 18 yrs) o
 
 - With positive SARS-CoV-
 
 - Having given their writte
 
Phase 2 France;Fra ; ; ; Olivier MIMOZ, Profesolivier.mim054944460; 

 
 1. Age = 18 years.
 
 2. History of or type 2 diab
 hospitalization.
 
Phase 3 Israel;Israe ; ; ; Ran Abuhasira, MD;Raranabu@pos
+972-3-937; 3. Confirmation of infectio

 
 - living in Belgium
 
 - more than 18
 
 
 - living outside Belgium
 
 - less than 18
 ;
N/A ; Sandy Tubeuf, PhD;Sa sandy.tube0032 276 4; Inclus
 
 - Positive SARS-CoV-2 test
 
 - Onset of symptoms <8 d
 
 - NEWS score<4 AND no it
 
Phase 3 ;;; Karine Faure, MD,PhD;karine.fau ;03204459 University H - At least

 
 Subjects meeting the follow
 
 1. = 18 years old or older
 
United Sta ; Hollis R O'Neal, Jr., ; ; Pulmonary 2. The first vital sign (any o

 
 - Critically ill individuals di
 
 - Started mechanical venti
 
Hungary;H ; Bence MogyorÃ³di, M mogyorodi +36208250801;+3620 - Informed consent signed

 
 - A diagnosis of advanced
 
 - as a positive test for S
Phase 2 United Sta ; ; ; ; ; John DiPersio, M.D., P ;jdipersi@ ;314-454-8Washington re

 
 - ICU admission for severe
 defined5 by a ratio of the
N/A France;Fra ; ; ; BÃ©atrice RIU-POUL ;belloc.a@ ;05 61 77 7University in

 
 All students should have co
 
 - Willing to participate in t
 
N/A Egypt;Egypt - None of the participants

 
 - Patients with active mali
 therapy, radiation or a co
 
 - Asymptomatic from infe
 
N/A Canada;Ca ; ; ; ; ; Stephanie Lheureux, M;stephanie ;416-946-2Princess M 
 - Ischemic or haemorrhag
 
 - Participating in a stroke r
Switzerlan ; ; ; ; ; Andreas R Luft, Prof; ;jeremia.h ;+41 (0)44 University 2018-02021/ RE

 
 - Adults (18 years and olde
 
 - Adults (18 years and olde
United Sta ; ; ; ; ; Kari Nadeau, MD, PhD;henadin@;(650) 521 Stanford Un COVID-19

 
 - Patients hospitalized in C
 
 
 
Turkey;Tur ; ; ; ILKE KUPELI;ILKE KUPE;ilkeser20 ;05555485 Dr.;;Dr.; - Patients under the age o

 
 In order to be eligible to pa
 criteria:
 
 - Adult (=18 years);
 
Phase 3 ;;;;;;; Frederik Schaltz-Buch ;;;cbenn@h;;;2588396 Bandim Hea - Hospital personnel carin

 
 - An employee, physician,
 learning, or volunteer of
N/A Canada;Ca ; ; ; Robert G Maunder;Ro;Robert.ma;416-586-4Sinai Healt an

 
 - Positive SARS-Cov-2 RT-P
 
 - Chest CT angiography av
 
 - Patient is aged 18yo or a
 
 
France;Fra ; ; ; MickaÃ«l OHANA, MD,mickael.oh 33 3 69 55 ; - Expressed
 
 1. Adult participants: Signe
 
 2. New admission to hospi
 
 3. Suspected or confirmed
 
Phase 3 United Ki ;;; Pallav Shah;Research ;research. ;020 3315 Chelsea an <

 
 1. Subjects within age grou
 
 2. With either sex, male or
 
 3. Confirmed case of COVI
 
N/A India;India ; ; ; ; ; Sandeep Budhiraja, M;sbudhira ;98102629 Max Health Exclusion Cri

 
 - More than 30 days of Ch
 
 
 - More than three session
 
 - amputated lower limbs
Argentina; ; Esteban L Siga, MD;Es ; ; Dialisis Ma 
 
 
 - Radiographic evidence o
 
United Sta ; Mayur Ramesh;Mayur; ; Henry Ford - Oxygen requirement by

 
 - Patients willing to partici
 
 - Available serum samples
 
 - Ability to complete the s
 
Ecuador;Ec ; Carlos A Robles-Medr carlosoak +593989158865;+593 
 1. Patients positive for COV
 
 2. PENN class 2,3,4 CRS10
 
Phase 2 ;;; W. Larry Gluck, MD;Ju;julie.mar ;86445536 Prisma Hea 3. Respiratory insufficiency
 
 - married
 
 - above 18 yo
 
 - premenopausal status
 
 
 - urinary incontinence
 
Turkey;Turkey - history of gy

 
 - Adults 18 years of age or
 
 - Hyposmia/anosmia of on
 confirmed on Snap n' Sni
Phase 4 Canada;Ca ; ; ; ; ; Leigh Sowerby, MD, FR;Sherry.Pa ;+1519685 Western Un 

 
 - 1. Patients admitted with
 Written informed consen
 
 1. PaO2/ FiO2 <300
 
Phase 2 India;India ; ; ; ; ; Sangeeta Pathak, MBB;sangeeta ;98730816 Max Super 
S

 
 1. Male or female subject
 
 2. Subjects with diagnosis
Phase 2 Spain;Spai ; ; ; Anna Cruceta, MD;Annacruceta@cl
932275400; bronchial aspirate

 
 1. Documented SARS-CoV-
 COVID-19 within 1 week
 
 2. Age =20
 
Phase 2 United Sta ; ; ; Jeffrey L Carson, MD;J ;jeffrey.c ;732-235-7Rutgers, Th

 
 - Age equal or more than
 
 - Symptoms suggestive of
; Jean-Louis GEORGES, jgeorges@ch
33+139638; illness (asthenia, myalgia
 
 - Male and non-pregnant
 
 - Positive RT-PCR for SARS
 
N/A Jordan;Jor ; ; ; Iyad Sultan, MD;Iyad isultan@kh+96265300; - Fever (oral T=39 C within

 
 - Age: = 18
 
 - SARS-CoV-2 documented
 
 
 - Refusal to the sign the ag
 
Italy;Italy ; ; ; ; ; ; ; ; ; Giulio Carcano, Profe ;;;giusepp ;;;+39339 UniversitÃ 
degli Studi- dell'Insubria;UniversitÃ
I d

 
 - Informed consent for pa
 
 - Virological diagnosis of S
 
Phase 2 Italy;Italy - Hospitalized due to clinic

 
 
 - 80 years = age = 14years
 
N/A China ;; Xiao-he Xiao, PD.;Rui- ;wrl7905@;+86 10 6 302 Militar - Within 72 hours after the

 
 1. Admitted to a hospital w
 
 2. Subject (or legally autho
Phase 3 United Sta 20-0006 Central ContaDMIDClinic 1.3E+10 initiati

 
 ability to understand and
Italy ; LUCA GALLELLI;LUCA Ggallelli@uni3339245656;3339245 

 
 Patients >18 years old with
 temperature >37.5 degrees
Phase 2 Gibraltar Spyridon Deftereos spdeftere 3.07E+11 sustaine
 
 1. Adult male and female h
 
 2. Healthcare workers with
 
Phase 2 United Sta Peter A McCullough, MD, MPH Baylor Hea â€¢ One day or more of e

 
 1. Patients 18 years and ol
 
 2. Confirmed SARS-CoV-2 I
 
 3. Serious or life-threateni
 
 Serious:
 
Phase 1 Mexico ;; JosÃ© Fe Castilleja-L ;servando ;+5218112 Hospital S <

 
 1. Volunteers without clini
 
 2. Healthcare workers base
Phase 3 United Sta ; ; ; Michael S. Avidan, M ;;;lindayu ;;;314-273 Washington 

 
 - Patients with proven SAR
 consistent with COVID-1
 
Phase 2 United Sta ; ; Sabiha Hussain, MD;St;;hussaisa ;;732-235- Rutgers, Th - Ability to measure and q

 
 - Duke patients within the
 
 - transthoracic echocardio
 
 - suspected or positive for
 
N/A United Sta ; Sreekanth Vemulapalll;kristine. ;919-668-0Duke Unive 

 
 - Male or female aged 18
 
 - Hospitalized (or docume
Phase 2/PhUnited Sta ; Joaquin Espinosa, PhD;bari-covi ;(720) 507 University department) with sympt

 
 1. Participant is willing and
 
 2. Participant is 18-75 year
 
Phase 3 United Sta ; ; ; William W O'Neill, ;;whipcovi ;;313-574- Henry Ford 3. Participant does not hav
 
 - The inclusion criteria are
 subjects in the age range
N/A ; Syed MR Kazmi, FCPS; ;farhan.ra ;03052225 Aga Khan U 

 
 - Patients included in the C
 
 - COVID-19 cases not requ
Phase 2/PhFrance according to the WHO

 
 - Individual currently work
 ("healthcare worker") in
 
onal [Patient Registry] United Sta ; ; Emily O'Brien, PhD;L ;HERO-reg ;+1 919 66 Duke Unive - Ag
 Inclusion Criteria (each of th

 
 1. Adults (aged =18 years)
 
 2. Confirmed diagnosis of C
 
 3. Hospitalized in the ICU f
 
United Sta ; ; David E Leaf, MD, MM;;deleaf@b;;617-525- Brigham an 4

 
 
 1. At least 18 years of age
 
Phase 2 United Sta ; ; Bonnie Lonze, MD;Bon;bonnie.lo ;212-263-8NYU Langon 2. Confirmed COVID-

 
 - Age = 70 years old
 
 - Infection with COVID-19
Phase 3 France CÃ©dric ANNWEILER cedric.ann 2.41E+08 suggesting viral pneumo

 
 - at least 18 years of old,
 
 - able to speak and comm
 
 - can read Chinese or Engl
N/A Hong Kong ; Kam Pui Lee, MSc;kamlkp032@cu85260996560;852609 
 
 
 - Hospitalized (or docume
Phase 2/Phase 3 ; Joaquin Espinosa, PhD;rux-covid ;?(720) 51 University department) with sympt

 
 transcription polymerase
Phase 2 United Sta ; Dayana Michel;Jatin Sh;jshah@ka ;(617) 658 Karyopharm testing

 
 - mild-to-moderate ARDS
 
 - lung-protective ventilatio
N/A Germany ; Werner Seeger, MD;F ;faeq.husa ;+4964198 University water on mechanical v

 
 Participants eligible for inclu
 
 Voluntary written informed
Belgium;It ; ; ; ; ; ; ; Dirk Timmerman, PhD;;;;;;;;Han ;;;;;;;+32 KU Leuven, rep

 
 - Patients with COVID-19 d
 
 
 
onal [Patient Registry] Germany ; Werner Seeger, MD;F ;faeq.husa ;+49 641 9 University - Patients

 
 
 - Admission for less than 3
N/A France Patrick ROSSIGNOL, Mp.rossigno 3.34E+10 proven serious form of C

 
 - COVID19 positive
 
 - hospitalized because of p
 scale)
 
Phase 4 Spain Alvar Agusti aagusti@cli 3.49E+10 - without contraindication
 
 - Individuals from the gen
 
 - French native speaker
 
 - Majority 18 years and m
 
France ;; StÃ©phane Raffard, ;s-raffard ;46733970 University Exclusion criter

 
 Patients admitted on coron
 elevation defined by the fol
 
;; Guillaume CAYLA, MD ;;guillaum ;;+33 6 22 HÃ´pital U - Symptoms suggestive of

 
 - =18 years of age
 
 - Positive for SARS-CoV-2
 
 - Has symptoms of upper
 
N/A Iceland ; Ragnar Freyr Ingvars ragnari@lan+354 824 6017;+354 - Willing to participate in t

 
 - Person gives written con
 
 - Persons between 18-90
 
 - No positive COVID infecti
 
Austria ;; Andreas Baranyi, Prof ;an.barany ;0043-316 Medical Uni 

 
 - = 18 years
 
 
 - None
onal [Patient Registry] Spain ;;;; Luis Ortega Paz, MD, ;;;LGORTEG;;;+34 932 Hospital ClÃ
 
nic of Barcelona;Hospital ClÃnic of B

 
 - Patients 18 years or olde
 
 - Confirmed diagnosis of C
 
Ecuador ;; JORGE CARRIEL;JORGE;jorge.car ;00346576 Hospital ClÃ
 
nico San Carlos,
- Probable
Madrid;
diagnos
 
 - Patients admitted to VGH
 
 - Admitted to the High Acu
 
Canada ;; Mypinder Sekhon, MD;mypinder ;60487541 University - An arterial line is in place

 
 
 2. ConfirmedSARS-CoV-2 in
 
 3. Disease severity necessi
 
Phase 2 ;; Dagan Coppock, M.D.;;;mxf314@j;;6107160 Thomas Jef 
 - Males and females >=18 y

 
 procedures
 
Phase 2 United Sta ; ; Felix Yang, MD;Felix ;fyang@ma;718-283-6Maimonides
 - Currently hospitalized an

 
 - major
 
 - having given his or her w
 
 - For the prospective COV
N/A France ; Marie-Sarah FANGOUSms.fangous2 90 26 44 05;2 90 26 
 - 3 or more symptoms (ou
 of 4 or 5.
 
 - Fluent Hebrew
 
N/A Israel Yair Bar-Haim, PhD Tel Aviv Un - Having a PC computer at

 
 COVID-19 patients
 
 
 - Subject consulting in the
 SARS-CoV-2 infection
 
France ; FranÃ§oise LAZARINI, ;francoise. ;+33 (0) 1 Institut Pa 
 
 - All consecutive patients
 intensive care unit admis
 
onal [Patient Registry] ; Bruce Biccard;Bruce M;bruce.bic ;+2721404 University Exclusion Criteria

 
 - Age >18 years.
 
 - Acute MI (STEMI and NS
 
 - Sudden cardiac death
 
 - Ventricular tachycardia
 
 - ICD shocks.
 
Jordan ; Ayman J Hammoudeh,;hammoud;00962650 JCC Group; 

 
 - Adult healthcare worker
 
 - Healthcare workers (doc
N/A ; Saira Burney, FRCP (Ed;dr_syra@ ;92301422 SIMS; 

 
 - Patients planned for arth
 
 - Patients seen by an orth
 
Denmark Jesper S Nielsen, MD Zealand Uni Exclusion Crite

 
 - French-speaking or Italia
 
 - Subjects who accepted t
 
Belgium - Inhabitants of a Europea

 
 - Male or non-pregnant fe
 
 - Laboratory confirmed SA
 
Phase 1 United Sta ; ; Walter K Kraft, MD;Ed ;edwin.lam;(215) 955 Thomas Jef - Investigator-estimated h

 
 - â€¢ Male or female over
 
 - Current symptoms of
N/A MITRA Mohanty, MD mitra1989 5.13E+09 following
 
 
 - Age > 18
 
 
 - Pregnancy
 
N/A United Sta Sonia Shah, DO Swedish Ho - P

 
 - Any permanent medical
 signed informed consent
 
Belgium ; Els Duysburgh, MD, Melza.duysb +32 (0)2/642 57 44;+3 - Participants must have a

 
 
Phase 2 United Sta ; Susanne Arnold, MD;S;susanne. ;859-323-8University symptoms or physical ex

 
 - Patients with laboratory
 
 - Patients with moderate t
 
Phase 2/PhBosnia and ; Jasna Dzananovic, MP Jasna.Dzan+38733560603; - Hospitalized patients on

 
 - major
 
 - tested positive for SARS-
 
 - understanding and speak
onal [Patient Registry] France ; David CHARIER, MD;D ;david.cha ;(0)4.77.82 CHU SAINT participate in the study

 
 - All health-care or public se
 study. Vulnerable health-ca
Norway ;; Sverre Urnes Johnson,;; ;; University doct

 
 - Hospitalized patients wit
 
 
 - None
onal [Patient Registry] Poland ;;;; Andrzej Januszewicz, ;;;aprejbi ;;;+482234 National In 
 
 - at least 18 years of age
 
 - COVID-19 infection, confi
 enrollment
 
Phase 2 United Sta ; ; Catherine H Marshal ;chm@jhmi;410-955-0Johns Hopk - Require inpatient h

 
 - Ages 6 and up
 
United Sta ; Eduardo Oliveira, MD;;Chris.Ens ;413.519.7 AdventHeal who can provide informe

 
 - Patients with severe COV
 
 
 - Treatment with Extracor
 
Spain Sergi Bellmunt, MD,PhD Hospital Va
 - Pediatric oncologists wo
 COVID 19 pandemic
 
 
 - Pediatric oncologists n

 
 - Health care worker (HCW
 least 10 shifts over the d
Phase 3 Canada ; Megan Landes, MD;Ke; ; University 

 
 - more than 18 years old
 
 - positive RT-PCR COVID-1
 
 - compatible lung CT with
 
 
Iran, Islam ; ; Dalili;Nooshin Dalili;N ;nooshinda;00989122 SBMU; - not signing info
 
 - person over 18
 
 - person exercising a profe
 
 - person having expressed
 
 
France ; Gautier CHENE, Pr;Gaugautier.ch 04 72 35 69 14;04 72 

 
 - Patients treated in ICCU
 participating hospitals, fo
France ;; ClÃ©ment Delmas;Au;tomasik.a ;5 61 77 85CHU Toulou 

 
 - adult volunteers working
 donning PPE including re
 
 - 5 females and 5 males
 
N/A Belgium ;; Guillaume Lemaire, M;guillaume ;+3227641 Cliniques u Excl

 
 - All patients (pediatric/ad
 who are suspected to be
 
 Exclusion Criteria: No oral c
 
onal [Patient Registry] Belgium ; Mona Momeni, MD, Pmona.mome
003227647029; 

 
 - Uses social media at leas
 
 
 -

 
 - Men and women age = 1
 
 - Diagnosed with SARS Co
 
 - Must have 2 sequential C
 
Early PhaseUnited States - Must have no previo
 
 1. Surgical faculty at partic
 telemedicine early in the
United States same g

 
 1. Adult patients are 18 ye
 
 2. Inpatients diagnosed as
 
Phase 2 Egypt ;; Mohamed M Moussa;;drmohame;+2010015 Ain Shams 3. CT chest with extensive

 
 - Diagnosis of COVID-19 (d
 
 - Age = 18
 
 - The patient has understo
Germany ;; Benjamin Meder, Prof.;benjamin ;0049 (0)6 University signed

 
 - COVID-19 critically ill pati
 
 - Invasive mechanical ven
 
 
 - Age under 18
 
 - Pregnancy
 
France ;; Kada KLOUCHE, MD P ;k-klouche ;+3346733 UH Montpel 

 
 - exposed group: exposed
 resuscitation, screening)
France ;; Marie Bistoquet, MD; ;a-makinso;06630752 University caregi

 
 Signed informed consent on
 
 
 Declined participation, no r
Slovenia Mario Poljak, MD, Ph mario.polja 3.86E+10 

 
 laboratory confirmed dia
 
Denmark ;; Tor Biering-SÃ¸rense ;Tor.Bieri ;+4528933 Research D Exclusion Criteria:
 
 - Eligible participants are all
 18 years, and/or a child ove
Norway ;;;; Miriam Sinkerud Johns;;;; ;;;; Oslo Metro par

 
 - Patients aged 18 and abo
 representative
 
Phase 4 United Sta ; Cheryl McCullumsmit cheryl.mcc 419.383.5651;419-38 - COVID-19 test positive o

 
 - declaration of being preg
 
 - being able to complete t
 
 - answer the screening qu
 
United Sta ; ; ; ; ; ; ; ; Anna Kajdy, MD, PhD; ;;;;;;;;;;;;; ;;;;;;;;;;;;; Centre of - provide info
 Eligibility criteria for the ext

 
 
 - Adult patients
 
 - New onset of neurologic
 
Denmark ; Grethe Andersen, MD ;greander ;78454235 Aarhus Univ - Independent in daily acti

 
 - All adult patients aged =
 clinic at PWH will be scre
; Joseph Walline, MD;J ;jwalline@ ;+852 3505Chinese Un 

 
 
 - Patients with confirmed
 swab and / or bronchoal
 
N/A Italy ;; Stefano M Magrini, Pr ;stefano.m ;++393492 Brescia Uni 

 
 Men and non-pregnant wom
 polymerase chain reaction (
Phase 2 ; PEDRO B FROTA, MD;J;jrazeved ;+5598321 Hospital S prote
 
 1. Age 0 to <19 years old
 
 2. Hospitalized with sympt
 
Phase 2 Canada ;; Julia Upton, MD, MPH;;julia.upt ;;416 813 The Hospita 3. Laboratory-confirmed S

 
 - 18 years of age
 
 
 - Below 18 years of age
United Sta ; ; Robert P Lennon, MD, ;myCOVIDs;717-531-0Penn State 

 
 - No self-medication with
 
 - COVID-19 negative diagn
Phase 3 Tunisia ;;; Faida Ajili, MD;Nejla ;;faida197 ;;+216986 Military Ho Reac

 
 1. Any gender
 
 2. Age 18 and older
 
 3. Informed consent for pa
 
 4. Virological diagnosis of S
 
Phase 4 Israel ; Juli Benbenisty, MPH; ;pizovr@ha;972-50-6 Hadassah M
 - Patient = 18 years;
 
 - Have molecular diagnosi
 Laboratory of Microbiolo
 
France ; Marie-Anne RAMEIX-W;marie-ann;+33 (0)6 6 Laboratoir

 
 - all Health care provider a
 
 
 - NA
N/A Saudi Arab Hani Al Hashmi, MD hashmih@ 9.67E+11 
 General public FORECAST co
 form by confirming they me
 
 
United Ki Alisia Carnemolla, Ph a.carnemol 2.08E+09 - Age
 Inclusion:
 
 - COVID-19 positive on ad
 the past 5 days) with sym
Phase 2 ; Mazen Albaghdadi, M ;MALBAGHD
;617-726-7Massachuse 100.4F), pn

 
 Individuals must meet all of
 in the study, as follows:
 
 - Male or female = 18 yea
 
Phase 1/Phase 2 ; Sant P Chawla, MD;Er ;egordon@a
;818-726-3Mission Co -

 
 - All Omanis and Non-Oma
 or GAD -7 total scores = 1
 
Phase 3 Mohammed Al Alawi, alalawim@ 1.44E+10 - Has access to the interne

 
 - age = or >16 years old
 
 - accepting to participate
 
 
onal [Patient Registry] Spain ; Cris Vilaplana, MD, Ph ;cvilaplan ;+3493033 FundaciÃ³ I - age <16 years ol

 
 - Any parent/caregiver of
 Care centers
 
 
United Sta Keli Hawthorne keli.hawth 7.13E+09 - Not at 2 specified Comm

 
 control hemogram and C
 
 Exclusion
 
 - Patients enrolled with Ca
 Insurance Plan
 
; Veronique Michaud;V ;vmichaud ;40745499 Tabula Ras - Patients with drug claim

 
 1. Patients requiring hospi
 to severe pneumonia and
 
N/A Patrick M Nemechek, research@ 623-208-4226 2. Patients showing fever a

 
 - Infants, children, and yo
 
United Sta ; ; Ericka L Fink, MD;Eric ;FinkEL@c ;412-692-5University admissions to emergency

 
 - Patients infected by SAR
 of intensive care) for oxy
 
N/A France ;; HÃ©lÃ¨ne Salvator;El ;e.hulier- ;+3314625 Pneumology
 - Patients mus

 
 - surgical management
 
 - > 18 years old
 
 
 - < 18 years old
France 

 
 - HIV patients in Hospices
 
 - on-PrEP patients in Hosp
 
 
 -
France 

 
 - Subjects aged 18 and old
 
 - SARS-CoV-2-positive indi
Luxembour Rejko KrÃ¼ger, Dr Luxembourg
 (
 
 - Men and women aged =
 
 - HCW or other frontline s
 contact with, patients wi
Phase 3 South Afric ; Caryn M Upton, MBChdr.caryn@t+27 21 510 2209;021 
 1. Applying only to the " A
 
 1. Hospitalised patients
 
 2. Suspected or known
 
onal [Patient Registry] Italy ; Raffaele Antonelli Inc ;susanna. ;+3367628 Policlinic 2. Applying

 
 - Age=18 and =75 years
 
 - Presenting a confirmed d
 criteria;
 
; David KLATZMANN, M;david.kla ;+33 1 42 Assistance - Good venous capital

 
 1. Adults who agree to par
 
 2. Suspected case, accordi
 
Phase 2 Mexico ;;;; Sonia Mayra PÃ©rez-Tapia,
;;;melissa
PhD;Maria
;;;+52555
C Jimenez-MartÃ
Instituto 
nez, MD PhD;Toni
3. In the case
A Homberg
of confirmed
von T

 
 - Patients with cancer on a
 or surgery) within 6 mon
Phase 1/PhUnited Sta ; Brahm H Segal;Brahm ;brahm.seg;716-845-5Roswell Par 

 
 - MS Diagnosis
 
 
 
 - None
N/A United Sta ; ; Victoria Leavitt, PhD; ;vl2337@c ;212-342-1Columbia U 

 
 - 1. Signed and dated pati
 record of a medical boar
Phase 2/PhRussian Fe Mikhail Samsonov Chief Medi pa
 
 - Eighteen year of age.
 
 - Experienced one or more
United Sta ; ; ; Lisa Taylor-Swanson, ;;lisacon ;;617-718- University shortness of breath, diar

 
 - Tested PCR positive for S
 saliva..
 
Phase 1 United Sta ; ; Jian Campian, M.D., P ;campian.j ;314-362-5Washington - Absolute lymphocyte cou
Not Applic Italy Inclusion crExclusion cr
Centre
for
Workforc
e
Wellbeing
Academic
Centre
College
Keep
4-12
Terminus
Terrace
Not Applic United Ki Gemma Simons g.simons@s+44 (0)2382310764 Inclusion c Exclusion c
Research
Departme
nt of
Behaviour
al Science
and
Health
Institute
of
Epidemiol
ogy &
Health
Care
University
College
London
1-19
Torringto
n Place
Not Applic United Ki Vas James v.james@uc+ 44 (0) 20 3108 3407 Inclusion c Exclusion c
Not Applic Ireland;Un Tom Roberts 7-9 Bream tern@rcem+44 (0)7894234121 Inclusion c Exclusion c
Inclusion criteria: 1. volunteers betw
 2. be able to understand and sig
 3. agree to collect
Exclusion blood 1.
criteria: sample
allerg
0 China Xiaoyu Xiang Room 107, xBiangxiao +86 13521 Beijing TIL 4. blood test results:
 2. perso Hemoglobi
Inclusion criteria:
 2. 1.
Patients
Meet thewithdiagno
diffic
4 China Peng Bo 241 Peng- 15304242 +86 17762 Wuhan Thir 2. Patients 3with fatigue, anorexi
 2. Patients with liver
 3. 1.
Inclusion criteria: Patients
Aged 2with
to 65bloo
yea
4 China Fengjie Xie 5 Tongxiangmdjxfj197 +86 13514 Hongqi Hosp 4.to
 2. According Electrocardio
the diagnostic cr
N/A China Jing Liu 52 Meihua liujing25@ +86 13844 Fifth Affil Inclusion c Exclusion c
Inclusion criteria: (1) Medical staff w
 (2) Can independently complete
N/A China Shi Tieying 222 Zhongshsty11177@+86 18098 The First A (3) Voluntary
Exclusionparticipation
c in thi
0 Yewei Zhang 87 Dingjiaqzhangyewe+86 13813 Southeast Inclusion c Exclusion c
Exclusion criteria: 1. Pneu
Inclusion criteria:
 2. 1.
Clear
Aged bacterial
from 18infe
to
 2. According
 3.with
Subjects
the clinical
who have dia
0 China Jianqing Xu 2901 Caolanxujianqing +86 18964 Shanghai Pu 3. Positive
 4.
result
Thereforare
nucleic
serious
acid
n
Inclusion criteria:
 2. 1.
Patients
Age overwho18cann
yea
 2. Real-time
 3.fluorescent
Patients who RT-PCR
are in
0 China Lunxu Liu 37 Guoxue lunxu_liu@+86 18980 West China 3. The 4.
sequenceOther
of virus
patients
geneswei
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Seve
co
 2. Above 2.
18 years
Estimated
old (inclusive)
Time of
4 China Wang Daowen, Zhao J1095 Jiefa dwwang@tj+86 13971 Department 3. Voluntarily
 3. There
sign written
is clearinform
evid
Inclusion criteria:
Exclusion
To be
criteria:
included
- Noinsmt
 - Be over
 -
18 Under
years of18age
years of a
 - Be recently
 - Inability
unemployed
to understa
as a r
 - Have -
satisfactory
Currently
English
employed
comp
Not Applic Australia - Be a current
 - NotAustralian
experiencing
residensy
Inclusion criteria:
Exclusion
1. criteria: 1.
 2. Confirmed
 2. SARS-CoV-2
Death is deemedby n
 3. Able 3.
to provide
Pregnancy
informed(Coho
co
Inclusion criteria: Diagnosis of active
 Provision of informed
Exclusion consent
criteria: 1) Kno in
Not Applic Australia;United States of America;Germany 2) Contra-indication
Exclusion criteria: 1) Hy
Inclusion criteria:
 2) Adults
Resting
withHRPCR-co
> 110
 In one 3)
of two age
Systolic
strata:BP < 90
 a) Participants
 4) Pregnancy
aged 50-64 oryea
lac
Phase 3 Australia â 5) Presence of any
3 Iran (Islam Bahareh Baghchi Baghabrishbahareh.ba+98 83 342Kermanshah Inclusion Exclusion c
3 Iran (Islam Nassim Anjidani No 42, Attaanjidani. 9.84E+09 OrchidPha Inclusion c Exclusion c
2-Mar Iran (Islam Vahid Ziaee Markaz Tebiziaee@tums +98 21 669Tehran UniInclusion c Exclusion c
2-Mar Iran (Islam Lotfollah Davoodi Razi hospit Lotfdavoo +98 11 422Mazandaran Inclusion Exclusion c
2-Mar Iran (Islam Hamed Hosseini 23rd Unit, ctc@tums.a+98 21 889Tehran UniInclusion c Exclusion c
2 Iran (Islam Sara Mobark Deputy of Es.mobarak +98 61 532Abadan UniInclusion c Exclusion
2-Mar Iran (Islam Mahdi Yousefi School of yousefim@0091 51 3 Mashhad Un Inclusion c Exclusion
3 Iran (Islam Bita Shahrami Sina hospitbita.shah +98 21 224Tehran UniInclusion c Exclusion c
2-Mar Iran (Islam Ahmad Reza Sharifi O Vice-Chancea-sharifi@s+98 21 875Bagheiat-alInclusion c Exclusion c
2-Mar Iran (Islam Monireh Ghazaeian Ibn Sina hoghazaeian +98 11 333Mazandaran Inclusion c Exclusion c
N/A Iran (Islam Alireza Zahedi Neyest Crossroad ali.zahedi +98 34 313Kerman UniInclusion c Exclusion c
2-Mar Iran (Islam Dr. Mohsen Moghada Zand stree moghadami+98 71 323Shiraz UnivInclusion Exclusion
3 Iran (Islam Mehrdad Karimi No. 27, Sarmehrdadka+98 21 889Tehran UniInclusion c Exclusion c
3 Iran (Islam Dr. Reza Khodarahmi School of rkhodarah +98 83 342Kermanshah Inclusion Exclusion c
2 Iran (Islam Rozita Khodashahi Imam Reza khodashah+98 51 38 Mashhad Un Inclusion c Exclusion c
3 Iran (Islam Azadeh Eshraghi Hazrate Ra aepharm@g+98 21 643Iran UniverInclusion Exclusion
N/A Iran (Islam Rahimeh Eskandarian Street Ami are20935@+98 23 334Semnan UniInclusion c Exclusion c
3 Iran (Islam Omidvar Rezaiemirgh Loghman Ha alisaffaei +98 21 554Shahid Behe
3 Iran (Islam Reza Shirvani Shahid Lav bahramiaz +98 25 377Ghoum Univ Inclusion c Exclusion c
3 Iran (Islam Dr. Babak Sayad Emam Rezababaksaya +98 83 342Kermanshah
Inclusion Exclusion c
2 Iran (Islam Hossein HosseinzadehBlv. Vakil hosseinza +98 51 318Mashhad UnInclusion Exclusion c
3 Iran (Islam Roja Rahimi Corner of Trojarahim +98 21 889Tehran UniInclusion c Exclusion
3 Iran (Islam Hamideh Abbaspour KFaculty of dr.abbasp +98 11 420Mazandaran Inclusion Exclusion
4 Iran (Islam Dr Payam Peymani zand streetpeymani.p +98 71 323Shiraz UnivInclusion Exclusion
2 Iran (Islam Gholamreza Karimi Vakil abad karimig@m+98 51 318Mashhad Un
3 Iran (Islam Mehran Varnaseri GhaRazi hospit Dr.varnase +98 61 333Ahvaz UnivInclusion c Exclusion c
1-Feb Iran (Islam Fallah Huseini Hasan Kavosh Blvdh.fallah@ac+98 26 347Institute o Inclusion c Exclusion c
3 Iran (Islam Razieh Borujerdi Shahid Lavaborujerdi. +98 25 361Ghoum Univ Inclusion Exclusion
3 Iran (Islam Fatemeh Roozbeh Miandrood,roozbeh@m +98 11 338Mazandaran Inclusion Exclusion
3 Iran (Islam Hossein Poustchi Karegare Shh.poustch +98 21 824Tehran UniInclusion c Exclusion c
3 Iran (Islam Parviz Kokhaei Semnan Unip_kokha@ +98 23 334Semnan UniInclusion c Exclusion criteria: (As a pl
3 Iran (Islam Sakineh Hajebrahimi Azadi streeHajebrahi +98 41 333Tabriz UnivInclusion c Exclusion
N/A Iran (Islam mohammad namazi niTorbat Heymnamazi99+98 51 522Torbate-HeiInclusion c Exclusion c
3 Iran (Islam Farhang BabamahmooYousefrezafarhang.b +98 11 422Mazandaran Inclusion Exclusion c
3 Iran (Islam Hossein Vahidi Valieasr St h.vahidi@s+98 21 882Shahid Behe
Inclusion Exclusion
2-Mar Iran (Islam Mohammad Moeini NInternal m moeininm@+98 51 380Mashhad Un Inclusion Exclusion c
2 Iran (Islam Seyed Ahmad Emami School of emamia@mu +98 51 318Mashhad Un Inclusion c Exclusion
1-Feb Iran (Islam Ramin Nasimi Doost Ardabil Unimodir706 +98 45 314Ardabil UniInclusion c Exclusion
3 Iran (Islam Seyed Hassan Saadat Tehran, Vansaadat350 +98 21 886Bagheiat-alInclusion Exclusion c
3 Iran (Islam Dr Khalil Ansarin Daneshgahdr.ansarin
S +98 41 333Tabriz UnivInclusion Exclusion c
3 Iran (Islam Ramin Hamidi FarahanEtemadzade Amir.salar +98 21 860Artesh UnivInclusion c Exclusion c
3 Iran (Islam Mohammadreza RouhNo.4, Shahimohamadre+98 86 336Saveh UnivInclusion Exclusion
2 Iran (Islam Hossein HosseinzadehBlv. Vakil hosseinza +98 51 318Mashhad Un
2 Iran (Islam Hossein HosseinzadehBlv. Vakil hosseinza +98 51 318Mashhad Un Inclusion Exclusion c
3 Iran (Islam Masood Ziaee Ghafari Str dr.m.ziae +98 56 323Birjand UniInclusion c Exclusion c
3 Iran (Islam Nematollah Gheibi Shaid Bahongheibi@qu+98 28 333Qazvin UnivInclusion c Exclusion cr
N/A Iran (Islam Shahriar Najafizadeh No. 5, Molldr.najafi7 +98 21 821Bagheiat-alInclusion c Exclusion cr
3 Iran (Islam Mohammadreza ArdalTabriz Univardalan34 +98 41 333Tabriz UnivInclusion Exclusion c
2 Iran (Islam Ali Taghizadieh Gholgasht Salitaghiza +98 41 133Tabriz UnivInclusion Exclusion c
3 Iran (Islam Mehran Varnaseri GhaRazi hospit Dr.varnase +98 61 333Ahvaz UnivInclusion Exclusion c
3 Iran (Islam Roshanak MokaberineFaculty of mokaberi@+98 21 887Shahid Behe Inclusion c Exclusion
2-Mar Iran (Islam Ahmad Reza Sharifi O Vice-Chancea-sharifi@s+98 21 875Bagheiat-alInclusion Exclusion c
2-Mar Iran (Islam Mikaili, haleh Valiasr St. halehmikae+98 41 332Tabriz UnivInclusion Exclusion c
1-Feb Iran (Islam Somaieh Matin Imam Khomei s.matin@ar+98 45 332Ardabil UniInclusion Exclusion c
N/A Iran (Islam Maryam Shaygan Nursing an shayganm@+98 71 364Shiraz UnivInclusion Exclusion
4 Iran (Islam Maryam Esghaei Iran Unive esghaei.m@ +98 21 867Iran UniverInclusion Exclusion c
N/A Iran (Islam Dr Mohsen Seddigh S Departmentseddighsh +98 51 385Mashhad Un Inclusion c Exclusion
3 Iran (Islam Sepideh Elyasi Vakilabad elyasis@mu+98 51 318Mashhad Un Inclusion c Exclusion
2-Mar Iran (Islam Morteza Zarrabi No. 2, Hafem.zarrabi@+98 21 223Royan InstiInclusion crExclusion c
2-Mar Iran (Islam Fereshteh Ghiasvand Keshavarz ghiasvand 9.86E+09 Tehran UniInclusion c Exclusion c
3 Iran (Islam Parisa Kianpour Pharmacy fa parisa_ki +98 21 669Tehran UniInclusion c Exclusion c
3 Iran (Islam Ebrahim Hazrati Etemadzade dr.hazrart +98 21 860Artesh UnivInclusion c Exclusion c
3 Iran (Islam Mohammad Ebrahim Firoozeh Alkhamseh.m+98 21 889The Instit Inclusion Exclusion
3 Iran (Islam Seyed Abbas Mousavi Imam Khome mmm89099+98 11 333Mazandaran Inclusion Exclusion c
2-Mar Iran (Islam Haleh Mikaeili 3rd Floor, halehmikae+98 41 332Tabriz UnivInclusion Exclusion c
2 Iran (Islam Mehrdad Iranshahi Blvd vakil iranshahi +98 51 318Mashhad Un Inclusion Exclusion c
2 Iran (Islam Hossein HosseinzadehBlv. Vakil hosseinza +98 51 318Mashhad Un Inclusion Exclusion c
2-Mar Iran (Islam Najmeh Davoodian Deputy of Enajmeh.da +98 51 572Gonabad Un Inclusion c Exclusion c
3 Iran (Islam Hamidreza Moezi Islamic AzaHmoezi@ia+98 21 220Islamic AzaInclusion c Exclusion c
2-Mar Iran (Islam Ali Sarrafzadeh Sarrafzade ali_sarra +98 13 332Bagheiat-alInclusion Exclusion c
2 Iran (Islam Mikaeili Haleh 3rd Floor, halehmikae+98 41 332Tabriz UnivInclusion c Exclusion c
1-Feb Iran (Islam Masoud Soleimani Jalal - al soleim_m@+98 21 828Tarbiat MoInclusion Exclusion c
N/A Iran (Islam Amrullah Ebrahimi Associate Pa_ebrahim +98 31 366Esfahan UniInclusion Exclusion c
N/A Pakistan Dr. Arshi Naz ST 2/A,Blo labarshi@ +92 21 34 National I Inclusion c Exclusion c
3 Iran (Islam Abdolah Azizi Jomhore hadiazizi +98 71 533Fasa UniverInclusion c Exclusion c
3 Iran (Islam Fariba Ghorbani No. 1,Dara dr.f.ghorb +98 21 271National ReInclusion c Exclusion
2-Mar Iran (Islam Alireza hashemi shiri Shahid Mota Entezar14 +98 902 00Jahrom UniInclusion c Exclusion
3 Iran (Islam Malihe Zangoue Birjand uni mzangoue +98 56 323Birjand UniInclusion c Exclusion cr
2 Iran (Islam Negar Shafaei Bajesta Allameh BoShafaei.n@+98 51 572Gonabad Un Inclusion Exclusion c
3 Iran (Islam mehdi mesri Saveh, at t mesrimd@g+98 86 422Saveh UnivInclusion c Exclusion c
3 Iran (Islam Ehsan Sekhavati Mog Zeiaeian hoDr.esekha +98 21 551Tehran UniInclusion c Exclusion c
N/A Iran (Islam Dr. Zahra Lorigooini Medical Pl zahralorig +98 38 333Shahre-korInclusion Exclusion c
1-Feb Iran (Islam Sahar Shojaei Middle EasS.shojaei +98 21 447Middle EasInclusion c Exclusion c
N/A Iran (Islam Abbas hajifathali Taleghani a.hajifatha +98 21 230Shahid Behe Inclusion c Exclusion c
2-Mar Iran (Islam Dr Hossein Khanahma Hezar Jaribhossein_k +98 31 379Esfahan UniInclusion Exclusion c
1-Feb Iran (Islam Kamran Mansouri Medical Bi kamranman+98 83 342Kermanshah Inclusion Exclusion c
0 (exploratoIran (Islam Hossein Mohammadz Asian Roadhomm1349+98 51 572Gonabad Un Inclusion c Exclusion c
2-Mar Iran (Islam Nematollah Ahangar School of n.ahangar@+98 13 336Rasht UniveInclusion c Exclusion c
3 Iran (Islam Ali Ghazvini Baqiyatallaqazvinia@ +98 21 824Bagheiat-alInclusion c Exclusion c
3 Iran (Islam Dr.Ramin Parvizrad Khorram Ave r.parvizra +98 86 322Arak UniverInclusion c Exclusion c
2-Mar Iran (Islam Farzaneh Dastan Masih Danefzh.dasta +98 21 261Shahid Behe Inclusion Exclusion c
3 Iran (Islam Shahram Habibzadeh Ardabil shahramha+98 45 332Ardabil UniInclusion Exclusion
N/A Iran (Islam Hossein Biganeh Baqiyatallabiganeh75 +98 21 824Bagheiat-alInclusion c Exclusion c
2-Mar Iran (Islam Zahra Shokati Alimentaryzahrashok +98 61 333Ahvaz UnivInclusion c Exclusion c
3 Iran (Islam Sepideh Elyasi Vakilabad elyasis@mu+98 51 318Mashhad Un Inclusion c Exclusion c
3 Iran (Islam Khaled Rahmani Kurdistan Ukhaledrah +98 87 336Sanandaj UInclusion c Exclusion c
3 Iran (Islam Farid Azizi Jalilian Fahmideh Sazizifarid +98 81 383Hamedan UnInclusion c Exclusion c
2 Iran (Islam Samereh GhelichkhaniSchool of sa.ghelich +98 81 383Hamedan Un Inclusion c Exclusion c
2-Mar Iran (Islam Ebrahim Shirzade School of dreshirza +98 51 440Sabzevar UnInclusion Exclusion c
2-Mar Iran (Islam Atousa Hakamifard Alzahra hosa.hakamifa+98 31 366Esfahan UniInclusion Exclusion
2-Mar Iran (Islam Ali Darakhshandeh No 566A,13alidarakh 9.83E+10 Esfahan UniInclusion c Exclusion c
N/A Iran (Islam Gholamreza Askari Hezarjarib askari@mui+98 31 366Esfahan UniInclusion c Exclusion c
2-Mar Iran (Islam Ali Hatami Shahid Rajahatami_a@+98 61 362Shooshtar Inclusion Exclusion c
3 Iran (Islam Parisa Kianpour Pharmacy fa
parisa_ki +98 21 669Tehran UniInclusion c Exclusion c
3 Iran (Islam Parisa Kianpour Pharmacy faparisa_ki +98 21 669Tehran UniInclusion c Exclusion c
3 Iran (Islam Dr. Kamran Mansouri Medical Bi kamranman+98 83 342Kermanshah Inclusion c Exclusion
1-Feb Iran (Islam Effat Irani Jam Iran, Ardabdr.jam733 +98 45 332Ardabil UniInclusion c Exclusion c
2-Mar Iran (Islam Rahim Asghari Resalat st rahimasgh +98 44 322Oroumia UnInclusion c Exclusion
3 Iran (Islam Assie Jokar Khazar Blvda-jokar@raz+98 11 332MazandaranInclusion c Exclusion
3 Iran (Islam Ahmad Zarei Baqiyatallaahmadzare+98 21 824Bagheiat-alInclusion c Exclusion c
2 Iran (Islam Afsaneh Kaffash Tohid ShahDrKaffash +98 51 440Sabzevar UnInclusion Exclusion c
3 Iran (Islam ???? ????? Semnan - Sedr.nbehno +98 23 333Semnan UniInclusion c Exclusion c
3 Iran (Islam Reza Malihi Abadan Schor.malihi@a+98 61 355Abadan UniInclusion c Exclusion c
3 Iran (Islam Sirous Zeinali No. 41, Koszeinali@gm+98 21 889Kowsar Bi Inclusion c Exclusion c
1-Feb Iran (Islam Nazanin Rahnama No 48, Gol Nazanin.r +98 21 227Shahid BeheInclusion c Exclusion c
2 Iran (Islam Dr Abbas Taher School of t_anesthe +98 81 383Hamedan Un Inclusion c Exclusion
NA Korea, RepuGeun Hui Won Daegu CathInclusion c Exclusion c
Phase2 Korea, RepuIN-GYU BAE GyeongsangInclusion c Exclusion c
3 USA;KOREAAyako Mikami 1-21-1 Toy amikami@h -10305 National C Inclusion c Exclusion c
Not applic Japan mari Terada 1-21-1, To registry.c 3.32E+08 National C Inclusion crExclusion c
Not applic Japan,Asia Ryota Niikura 7-3-1 Hongrniikura@tr 3.38E+08 Tokyo UnivInclusion crExclusion c
Not applic Japan Yoshiyama Kenji D3, 2-2, Y yosiyama@p6.69E+08 Osaka UnivInclusion crExclusion c
Not applic Japan Satoshi Ikeda 6-16-1 Tomisatoshi0 4.57E+08 Kanagawa CInclusion crExclusion
Not select Japan Toshiki Horii 38 Kawaguchoriitoshi 0184-27-1 JA Akita KoInclusion crExclusion c
Not select Japan Akira Sezai 30-1 Oyaguasezai.me 3.4E+08 Nihon UnivInclusion crExclusion c
Not select Japan Norihito Kaku Sakamoto 1kaku-ngs@u095-819-7 Nagasaki UInclusion crExclusion c
Not select Japan Tsuyoshi Okuhara 7-3-1 Hongokuhara-ct 03-5800-6 The UniverInclusion crExclusion c
Not select Japan Masafumi Idei 8-1Kawada-masafumi2 3.34E+08 Tokyo Wome Inclusion crExclusion c
Not select Japan Takehiro Izumo 4-1-22, Hir izumo_take03-3400-1 Japanese RInclusion crExclusion c
Not select Japan Tomoyuki Shinohara 501, Naka shinohara- 2.74E+08 Takasaki UnInclusion crExclusion c
Not select Japan Tomoyuki Umemoto 1-5-45, Yu umemoto.c03-5803-5 Tokyo MediInclusion crExclusion c
Aster
Malabar
Institute
of
Medical
Sciences
(MIMS)
PO
Govindap
uram
Kozhikod
e
Kerala
India
Phase 3 India Dr Remesh Bhasi 673016 remesh.bha9.45E+09 Aster MalabInclusion c Exclusion
N/A India DrSujeet Jha Institute o sujeet.jh 9.91E+09 Max HealthInclusion c Exclusion cr
N/A Banglades Md. Shahoriar Ahmed Bangladeshphysiozah 8.8E+12 BangladeshInclusion c Exclusion c
125 BL
Taneja
Block
Departme
nt of
Medicine
Maulana
Azad
Medical
College
New
N/A United Kin Dr Naresh Kumar Delhi drnareshm 9.95E+09 Maulana AzInclusion c Exclusion c
MEDICAL
DIVISION
COMMAN
D
HOSPITAL
AIRFORCE
AGRAM
N/A India SALIL GUPTA POST chickusali 8.2E+09 COMMANDInclusion c Exclusion c
Dr. Atuls
Child
Hospital
Shastri
Nagar
Road
Jaipur
N/A India Varnit Shanker 302016 varnitshanker@gmail 1. DACH JaiInclusion c Exclusion c
Departme
nt of
Medicine,
Niphad
Sub
district
Hospital,
Niphad,
Maharash
Phase 3 India Dr Samadhan Patil tra, India yogesh_do 91-976905 Shreepad SInclusion c Exclusion c
N/A India VIdur Mahajan Defence covidur@mahajanimagi CARING, MInclusion c Exclusion c

Parul
Institute
of
Ayurved,
Parul
University
,
AP Limda,
Tal
Waghodia
Phase 3 India Dr Harish Daga , dr.shailes 9.76E+09 Parul Insti Inclusion c Exclusion c
Departme
nt of
Otolaryng
ology and
Head and
Neck
Surgery,
Teaching
Block 4th
Floor,
AIIMS,
Ansari
Nagar
East,
New
Phase 2 India Alok Thakar Delhi drathakar@gmail.comAIIMS, NewInclusion c Exclusion
N/A India Samreen Siddiqui Max Super sSujeet.jh 9.91E+09 Max Healthc
DEPT OF
ANAESTH
ESIOLOGY
GSL
MEDICAL
COLLEGE
RAJAHMU
N/A India TATIKONDA CHANDRANDRY chandrada 9.59E+09 GSL MEDICInclusion Exclusion
Phase 2 India Dr Anup Agarwal Ansari Nag mailanupa 8.58E+09 Indian Cou Inclusion c Exclusion c
ICMR-
National
AIDS
Research
Institute,
Pune
G 73
BLOCK
MIDC
BHOSARI
PUNE
Phase 3 Argentina; DrSheela Virendra Go sgodbole@n9.42E+09 ICMR-NatioInclusion c Exclusion c
Serum
Institute
Of India
Pvt. Ltd.
212/2,
Hadapsar,
Pune
India
Phase 3 India Dr Umesh Shaligram Pune drhjs@seru 2.03E+09 Serum InstiInclusion c Exclusion c
Departme
nt of
Medical
Oncology,
2nd Floor,
BRAIRCH,
All India
Institute
Of
Medical
Sciences,
Ansari
Nagar,
New
Phase 2 India Akash Kumar Delhi akashjha08@yahoo.c All India I Inclusion c Exclusion c
Phase 1/ P India Meena Dalal 681, 17th jyotrao@g 9.62E+09 InternationInclusion c Exclusion c
N/A India Dr Mahesh Mahich Room no. 11
dr.mahich 9.83E+09 Rabindra NInclusion c Exclusion c
N/A India Shreya Singhal 1, 2, Press singhal.sh 9.81E+09 Max Super ISnclusion c Exclusion criteria: Particip
N/A India Sanjoy Kumar Sureka Departmentdrsksurek 9.79E+09 SGPGIMS Inclusion c Exclusion c
Departme
nt of
Paediatric
s, Women
and
Children
Hospital,J
IPMER,
Dhanvant
ari Nagar
P.O.
Dhanvant
ari Nagar,
Puducher
N/A India Narayanan Paramesw ry narayanan. 9.44E+09 JIPMER, PuInclusion c Exclusion c
1389,
Trasad
Road
Dholka,
Ahmedab
ad 1389,
Trasad
Road
Dholka,
Ahmedab
N/A India Dr Anil Avhad ad anil.avhad@cadilaphaCadila Pha Inclusion c Exclusion c
Phase 1/ P India DrSourabh R Welling Welling Cl drwelling@ 9.77E+09 Welling HoInclusion c Exclusion c
N/A India Rajesh Saxena Max Super dSocmishra@yahoo.co.Internal MeInclusion c Exclusion cr

N/A India Rajesh Saxena Max Super dSocmishra 9.81E+09 Internal MeInclusion c Exclusion cr
Phase 3 India Mr.Kuldeep K Chauha 10th Floor drsushilakataria@gmail.com Inclusion Exclusion c

Phase 3 India Col Anurag Khera Field Hospivksashind 9.2E+11 Armed ForcInclusion c Exclusion c
Phase 4 India DrJHareendran Nair Pankajakasdrshan@pk 9.19E+09 PankajakasInclusion c Exclusion c
N/A India Dr Sulagna Bhattachar96, Gautambhattachar 9.82E+09 AIIMS, NewInclusion c Exclusion c

Phase 2 India Rajesh Saxena Max Super sSangeeta. 9.87E+09 Blood Bank,Inclusion c Exclusion c
Departme
nt of
Medicine
Lady
Hardinge
Medical
College
Shahid
Bhagat
Singh
Marg
New
Delhi
110001
Phase 2 India Anupam Prakash INDIA prakashan 8.59E+09 LADY HARDInclusion c Exclusion
DEPARTM
ENT OF
MEDICINE
,
SHAHEED
BHAGAT
SINGH
MARG,
NEW
DELHI-
Phase 2 India Anupam Prakash 110001 prakashan 8.59E+09 LADY HARDInclusion c Exclusion
dr katre
house
homoeo
clinic civil
line
homoeo
clinic civil
Phase 3 India Prashant katre line priti.katr 9.33E+09 Homoeo cliInclusion c Exclusion c
Mi Lab
LifeScienc
es(P)
Limited
81 & 82,
Shree Om
Ramaswa
my
Reddy
Layout,
Horamav
u,
Bengaluru
,
Karnataka
Bangalore
KARNATA
Post MarkeIndia MrLAKSHMANA PERUM
KA lakshman@m
8.02E+09 Mi Lab Life Inclusion c Exclusion c
Biocon
Biologic
India
Limited
Biocon
House
Semicon
Park
Electronic
s City
Phase 2
Bangalore
560100
Karnataka
India
Phase 2 India Sivakumar Vaidyanat subramani 8.03E+09 Biocon BiolInclusion c Exclusion c
Phase 2/ P India Dr Anil Khurana 61-65, Sewadrdnayak@ 9.87E+09 CCRH Inclusion c Exclusion c
Departme
nt of
Plastic
Surgery
Pithampu
ram,
Road,
Kakinada,
Andhra
N/A India Dr Sumita Shankar Pradesh sum713@y 9.85E+09 Rangaraya Inclusion c Exclusion c
A wing,
402-
A/B/C,
Jaswanti
Allied
business
center,
Ramchan
dra lane
extension
,
Kachpada
, Malad
west,
Mumbai
N/A India Dr Sanjay Tamoli arun.gupt 9.91E+09 Dabur Indi Inclusion c Exclusion c
N/A India Dr PUGAZHENTHAN T No 2220, drpugal23 9.49E+09 ALL INDIA Inclusion c Exclusion c
N/A India Alok Thakar Room no 40drathakar 9.87E+09 All India I Inclusion c Exclusion c
Departme
nt of
Anaesthe
siology,
First
Floor, A
Block,Sanj
ay Gandhi
Post
Graduate
Institute
of
Medical
Sciences,
Lucknow
Rae Bareli
Road,
N/A India Dr Rudrashish Haldar Lucknow rudrashis 9.26E+09 Sanjay GanInclusion c Exclusion c
Indian
Council of
Medical
Research,
HQ office
V
Ramaling
aswami
Bhavan,
New
N/A India Dr Pranab Chatterjee Delhi dr.madhav 9.94E+09 Indian cou Inclusion c Exclusion c
N/A India Dr M Sasikala SurveyNo 1research@a4.04E+09 AIG Hospit Inclusion c Exclusion c

N/A India Dr Raj K Manchanda Ayurvedic anil23101 9.91E+09 CCRH Inclusion c Exclusion c
9th floor,
Mantrala
y,
GT
Hospital
Campus,
Fort,
Mumbai
9th floor,
Mantrala
y,
GT
Hospital
Campus,
Fort,
Phase 2 India Dr Sanjay Mukherjee Mumbai u.padmanab2.22E+09 Haffkine In Inclusion c Exclusion c
Departme
nt of
Medicine
3rd floor,
Teaching
Block
AIIMS
Ansari
Nagar
Phase 2 India Dr Manish Soneja ND manishson 9.01E+09 AIIMS Inclusion c Exclusion c
The
George
Institute
for Global
Health,
India
311-312,
Third
Floor,
Elegance
Tower
Plot No.
8, Jasola
District
N/A India Professor Vivekanand Centre vjha@georg9.11E+11 The GeorgeInclusion c Exclusion c
N/A India Rajesh Saxena Max Super saroj.kum 1E+10 Max Super ISnclusion c Exclusion c
SAI
NIDAN
HOMOEO
PATHY
CLINIC
NEAR SAI
MANDIR ,
BANARAS
ROAD,
AMBIKAP
UR,CHHA
TTISGARH
,
Phase 2/ P India DR DHIRENDRA TIWAR drdhiren1 8.77E+09 SAI NIDAN Inclusion Exclusion c
Central
Council
for
Research
in
Ayurvedic
Sciences
61-65
Institutio
nal Area
Oppo. D
Block
Janakpuri
New
Phase 3/ P India Dr Babita Yadav Delhi drbabitayadav@gmail Central CouInclusion c Exclusion c
108 A, IP
EXTENSIO
N,
PATPARG
ANJ, NEW
N/A India RAJESH SAXENA DELHI Geeta.Kad 9.81E+09 Max Super Inclusion c Exclusion cr
Departme
nt of
Haematol
ogy,
First
Floor,
Room no-
3,
Christian
Medical
College
Departme
nt of
Haematol
ogy,
First
Floor,
Room no-
3,
Christian
Medical
Phase 3 India Biju George College biju@cmcve4.16E+09 Christian MInclusion c Exclusion c
Dept of
Anaesthe
siology,
Pain
Medicine
and
Critical
care
4th Floor
Porta
Cabin
Academic
Block
Phase 3 India Dr Ajisha Aravindan AIIMS ajishaa@g 9.81E+09 All India I Inclusion c Exclusion
Regional
Ayurveda
Research
Institute
for Skin
disorders,
New
Rajeev
nagar,
Payakapu
ram
Vjayawad
a.
Phase 1/ P India Dr B vankatshwarlu drcvenkat@ 6.3E+09 Regional a Inclusion c Exclusion c
Departme
nt of
Critical
Care
Medicine,
SGPGIMS,
Lucknow
(UP).
226014
N/A India Dr Mohan Gurjar India m.gurjar@rediffmail. Sanjay GanInclusion Exclusion c
Phase 2/ P India Dr Sujata pundlikrao Regional A narivbd.v 8.1E+09 Regional AyInclusion c Exclusion c
Room no-
3,
Departme
nt of
Haematol
ogy,
Christian
Medical
College,
N/A India Biju George Vellore biju@cmcve4.16E+09 Christian MInclusion c Exclusion c
Siddha
Central
Research
Institute,
Central
Council
for
Research
in Siddha,
Anna
Hospital
Campus,A
rumbakka
m,
N/A India Dr C Anbarasi Chennai meenaprakashphd@gm
Siddha CentInclusion c Exclusion c
Glenmark
Research
Centre,
Plot No.
A-607,
T.T.C.
Industrial
Area,
MIDC,
Mahape,
Navi
Mumbai
Phase 3 India Amol Pendse Pawan.Sin 9.12E+11 Glenmark PInclusion c Exclusion c
Regional
Ayurveda
Research
Institute
for
Mother
and Child
Health
(RARIMC
H)
Near
Gharkul
Parisar
Nandanva
n Nagpur
Maharash
tra
Phase 3/ P India Dr R Govind Reddy 440009 drrgreddy 9.82E+09 Regional A Inclusion Exclusion c
Room
1081,
Ground
Floor,
Hospital
Block,
JIPMER
Hospital,
Dhanvant
ri Nagar,
N/A India Balaji Bharadwaj bharadwaj. 9.49E+09 Jawaharlal Inclusion c Exclusion c
Opp.
Pharmez,
Changoda
r - Bavla
Highway,
Near
Matoda
Patia,
Post:
Matoda,
Ahmedab
ad,
Gujarat,
Phase 2 India Dr Manish Rachchh India vd.ganatr 9.83E+09 Ganatra AyInclusion c Exclusion c
Phase 2/ P India Dr C Muralikrishna Regional A mkchagamr 9.49E+09 Regional A Inclusion c Exclusion c
Phase 2 India Dr VG Huddar 6th floor, dr.vghudda 9.99E+09 All India I Inclusion c Exclusion c
Phase 2 India Mr Prashant Modi Lambda Hou

namanshah 7.94E+09 Lambda TheInclusion c Exclusion c
Phase 2 India Dr VG Huddar 6th floor,r dr.vghudda 9.99E+09 All India I Inclusion c Exclusion c

 
 - age more than 18 years
 
 - accord with the clinical d
 of Novel coronavirus pne
 
N/A China <

 
 
 
Phase 2/PhChina ;; Wei Zhang;Jiang-Rong ;; ;; Jingzhou Ho 3. Hospitalised with Fever(

 
 
 2. Those who meet the dia
Phase 2/PhChina ;;; Dong Shang, M.D.;Jia ;;; ;;; Wuhan Leis confirmed infection with
 
 - Patient admitted to a Da
 department
 
 - Age >18 years
 
 - Hospitalized <48 hours
 
Phase 2 Denmark Jens-Ulrik StÃ¦hr Jen jens.ulrik 4.53E+09
 1. Informed consent provid

 understands the procedu
 
Phase 2 United Sta ; ; Sabine Hazan, MD;Sab;drsabine ;805-339-0ProgenaBi 2. Male or female subjects

 
 1. Informed consent, provi
 
Phase 2 United Sta ; ; Sabine Hazan, MD;Sab;drsabine ;805-339-0ProgenaBi 2. M

 
 
 - Histologically confirmed
 
 - Receive systemic therap
Belgium Hannelore Denys, MD, PhD Medical On antica

 
 - Must be =18 years at the
 
 - Understand and volunta
Phase 3 Germany ; Diane Egger-Adam, Drdiane.egge+4970712982191;+49 related assessments

 
 - Age 18 years and older
 
 - Prior diagnosis of COVID
 
N/A United Sta ; Julie Karp, MD;Julie K CovidPlasm215-503-4838;215-50 - Either: Complete resoluti

 
 - Signed informed consen
 
 - =18 years
 
 - Confirmed diagnosis Pne
 
 - ECOG functional state 0
 
Phase 2 Spain ;; David Bernal, Ph MD; ;david.ber ;+3491600 Hospital Un 
 
 1. Ability to understand th
 informed consent or hav
Phase 2 France;Ital AstraZeneca Clinical informatio 1-877-240-9479 

 
 1. Over 19 years of age
 
 2. COVID-19 confirmed by
 enrollment
 
Phase 2 Korea, Repu; Woo-Joo Kim, M.D.,P ;bk.E106@ ;+82-2-828Korea Unive 3. Patients with peripheral

 
 - caregivers staff assigned
 
 - or caregivers staff assign
 
France ; Laurent FOURCADE, Mlaurent.fo 0555058070;0555058 - or caregivers staff assign

 
 1. Be =18 years of age
 
 2. Provide adequate medic
 
Phase 2/PhItaly ; Jennifer Ho, MD, PhD;;slu-hinh ;858-452-2Ansun Biop 3. Prior to SARS CoV 2 infe

 
 (RT-PCR) assay
 
 - Hospital admission
 
 
Spain ;;;;; Jose RamÃ³n Arribas, ;;;;; ;;;;; H. Univ. La 

 
 
 - Evidence of cytokine sto
 
 - Peak ferritin > 10,000
 
Phase 2 United Sta ; ; John Mark Sloan, MD; ;mark.sloa ;617-638-7Boston Med - Peak ferritin > 500 ng

 
 - Positive for COVID -19
 
 - Stage 1 or stage 2A COVI
Phase 2 United Sta ; ; Matthew Sims, MD Ph;Maureen. ;248 551-0 Beaumont Stage 2B or stage 3 COVI
 
 1. Patients aged between 4
 
 2. Body weight between 5
 
 3. PCR diagnosis of SARS-C
 
Phase 2 Spain ; Luis Madero, MD;Lui ;luis.made ;+34 9150 Hospital I 4. Clinical diagno

 
 
 - Working in a facility that
 community as a first resp
 
onal [Patient Registry] United Sta ; ; ; ; Peter G. Kaufmann, P ;;;sandra. ;;;610-519 Villanova U -

 
 All health care professional
 in Norway will be invited to
 
 
Norway ;; Irene Lie, PhD;Irene L ;irene.lie ;0047-9902Oslo Univer
 - Participants shall be adu
 
 - Willingness and ability to
 
 
N/A United Sta ; ; ; Russell G Buhr, MD, P ;;rbuhr@m;;310-267- Division of -

 
 1. Laboratory diagnosis:
 
 Respiratory specimen is p
Phase 1 ; M.Sc. Mahmoud Elkazz;mahmoud;00201090 General Or gene sequencing of the r

 
 - Hospitalized at the Kanto
 (laboratory-confirmed),
 
 - with or without mech
 
Switzerlan ; ; ; ; ; ; ; ; David Gisi;Martina Be ;;;;;;;;;; ;;;;;;;;;;+ Kantonsspi
 
 Group A1:
 
 - Age = 18 years and = 70
 
 - Infection with the SARS-
N/A France Florent VALOUR, PhD florent.va 0472 071 107 chain reaction (RT-PC

 
 - all patients hospitalized
 
 
 - patients< 18 years
France ;; Michel Slama, Pr;Mich;slama.mic ;(33)3 22 0 CHU Amien 

 
 - All patients with COVID-1
 
 
Turkey Yasin Tire makifyaza 9.03E+08 - Those receiving blood pr

 
 - Patients with end-stage
 
 
Belgium ; Bjorn Meijers, MD, Ph ;bjorn.mei ;+3216344 UZ Leuven; - Treated at University Ho

 
 children 12 years or olde
 
Phase 2/Phase 3 Andreas Muehler, Dr. andreas.m +49 89 2500 794 64 2. Admitted to the hospita

 
 - Age> = 18 years;
 
 - Cardiovascular disease c
 
 - Symptomatic ischemic h
N/A Brazil ;; Pedro Lemos, MD;Ped;pedro.lem;+55 (11)9 Hospital Is 

 
 
 - Subjects must have a do
 days of randomization
 
Phase 2 United Sta ; ; Genovefa Papanicola ;papanicg@;212-639-8Memorial S - Subject mu
 
 - COVID-19 positive or sus
 
 - Received a cardiopulmon
 
 
 - Did not receive a scan
 
onal [Patient Registry] United Sta ; ; Felipe Teran, MD;Feli ;Felipe.T ;21566230 University 

 
 
 2. A patient must have con
Phase 2 Russian Fe ; Kirill A Zykov, Prof;Kir ;kirillaz@i ;+7925772 Federal Sta ( viral or viral-bacterial w

 
 1. Ability to understand th
 informed consent or hav
Phase 2 United Sta AstraZeneca Clinical informatio 1-877-240-9479 

 
 - Men incarcerated at Ville
 
 - On a given date (May 12
 
 - Major
 
 - French speaking
 
France ;; AurÃ©lie Mieuset, Ph ;a-mieuset ;46733306 University - non illiterat
 Inclusion Criteria :

 
 - a positive RT- PCR,
 
 - a highly suggestive thora
 
 - a severe hypoxemia lead
 
onal [Patient Registry] France Marie Reine LOSSER, MD, PhD Central Hos - mechanical

 
 all patients with a diagnosis
 in the study during the two
 
 
onal [Patient Registry] Italy ; Sergio Alfieri, MD;Serggiuseppe.q+39 3386792010;+39 - p
 
 - Patients infected with CO
 thromboprophylaxis dos
 
 - Admission to hospital.
 
 
Spain ;; Manuel Monreal;Mayr;riete@shm;00349153 Germans Tri<

 
 - Patients infected with CO
 
 - Admission to hospital.
 
 
Spain ;; Manuel Monreal;Mayr;riete@shm;00349153 Germans Tri - Patients treated with EC

 
 - Be at least 18 years old
 
 - Give a declaration of con
 
 - Have access to the intern
 
N/A Switzerlan ; ; ; HansjÃ¶rg Znoj, Prof. ;;julia.heg ;;+41 31 63University - Understand and master

 
 - Patients aged more than
 
 - COVID-19 confirmed by r
 
 - Having severe pneumon
 
Phase 2/PhIndonesia ; Andri MT Lubis, MD, ;rsinto@y ;+6281588 Faculty of 

 
 - SARS-CoV-2 infection as
 laboratories in Luxembou
 
 
Luxembour ; Aurelie Fischer, MS;Auaurelie.fis 00352621328591;003 - Age =1

 
 - Patient with chronic mus
 lasting for 3 or more mon
N/A Greece ;;; Eleni V Kapreli, MSc,P ;;ekapreli ;;0030223 Clinical Ex numeri
 
 
 1. At least 18 years of age
 
Phase 2 United Sta ; ; David J. Cohen, MD;D ;djc5@cum;212-305-3Columbia U 2. Confirmed COVID-

 
 - =18 years old
 
 - Residence in Germany
 
 - Understanding of study p
 
 
Germany ;; Antonio Ciardo, Dr.;An;antonio.c ;0049 622 University - <18 years old

 
 - Major patients (18-90 ye
 
 - Hospitalized following SA
 
 - Mechanical ventilatory s
 
 
France ;; Ramin SÃ©verin, MD; ;s-ramin@c;46733825 University -

 
 - + positive PCR confirmed
 (probable case)
 
 
France ; Gaetan GAVAZZI, Pr;G;ggavazzi@;04 76 76 University - Direct admission in Inten

 
 - Confirmed COVID-19 dia
 
 
N/A Italy ; Alessandra Del Felice ;alessandra;+39-0498 University - Neuromuscular disease,

 
 - Patients 18 to 85 years o
 
 - Lab-confirmed (PCR-posi
Phase 2 Sweden ;; Daniel P Andersson, ;;daniel.b ;;+467363 Karolinska 
 
 1. Male and female patien
 
 2. The patient (or his/her l
Phase 2/PhRussian Fe ; Jean-Francois Rossi, ;dodonovn ;+7 (495) University form) signed an Informe

 
 - Confirmed COVID-19 by
 
 
 - Refusal of consent by pa
Norway ;;; Fredrik G MÃ¼ller, Pr ;;;jacaho@ ;;;+479119 University 

 
 - Patients who are admitte
 or a CT scan compatible
Phase 3 Mexico ; Jose Manuel Arreola, dr.jmag@g4494632049;4494632 

 
 - COVID 19 infected as pro
 diagnosed)
 
 
Phase 2/PhSudan ;; Mustafa KM Nimeiri, ;;rashat3 ;;+249912 Al Neelain - Intubated patients on pa

 
 - Adult patients remaining
 COVID-19 infection
 
 
N/A Belgium Alexia VERROKEN, MD, PhD Cliniques u - Patients from whom

 
 - Adults (=18 years)
 
 - Those living within Scotla
 
 - Those self-isolating at ho
 
N/A United Ki ;; Aziz Sheikh;Aziz Sheik ;aziz.shei ;01316514 University 1. Cl

 
 - health care worker
 
 - employed at inclusion at
Belgium Gilbert Lemmens University intensive care unit or 6 s
 
 - Age> = 18 years
 
 - Diagnosis of COVID-relat
Italy (high-flow nasal cannula,

 
 - Positive COVID-19
 
 
 - Incomplete medical reco
Egypt Ahmed Samir, MD Department artifacts, also unr

 
 - patients with definite dia
 
 - patients who entered th
 
 - 18-80 years old
 
China Yuanmingfei Zhang, Drzymf@pku.+86 15201469083 

 
 - Being healthy
 
 - Previous participation (m
N/A Italy Cristina Ottaviani cristina.ot 3.91E+11 same research group and

 
 1. Age > 18 years of age
 
 2. SARS-CoV-2 positive per
 reaction)
 
Phase 4 United Sta ; ; ; ; ; Sean Cook, D.O.;Jeane;;;;salbrit ;;;;208-62 Kootenai H 3. Acute hypoxia (O2 sat <

 
 - age above 18 years
 
 - respiratory (PaO2/FiO2 r
N/A Italy ;; Marco Alessandro Min;marco.min;+39 011 University o days after withdrawal of

 
 - Recent (=6 days and =16
 infection with COVID-19.
 
Phase 2 Belgium Anja Delporte anja.delpo 3.29E+09 - COVID-19 diagnosis confi
 
 - Adult patients (=18 years
 nasopharyngeal swab or
Spain SÃ¡nchez-Barriga maria.sanc +34 600162652 date (d

 
 - Patients with COVID-19 i
 
 
Phase 3 ; sherief Abd-Elsalam, A;sheriefa ;00201147 ass. Prof. 

 
 1. Male and female subjec
 
 2. Confirmed coronavirus i
 
Phase 2/Phase 3 Nancy Stewart, Ph.D. nstewart@204-928-7905 1. Positive real-time fluo

 
 
 - Use of mechanical ventil
 
 
Phase 1 Jennifer Lister Jennifer.L 416-340-4857 

 
 - Healthy adults aged =60
 
 - Proven legal identity;
 
 - Participants should be ca
Phase 1/PhChina ;; Yuliang Zhao, Master; ;yuliang_ ;86-13315 Hubei Provi f

 
 - Age = 18 years old.
 
 - Mayo Clinic employee in
 
 - Suspected COVID-19 exp
 
N/A United Sta Mark Parkulo, MD Mayo Clini - Completed PCR test twic
 
 - Dentist having bachelor
 
 
 - paramedical staff and de
Egypt 

 
 - Main cohort
 
 1. Diagnosed with CoV-
 
 2. 16 years of age or old
 
Australia ;; Marianne Martinello; ;;r.bull@u ;;0293850 Kirby Inst 3. Have provided inform

 
 - Adults
 
 - medical and paramedica
 specifically during the CO
 
France Marion DOUPLAT, MDmarion.dou 4.79E+08 - not opposed to

 
 - Subject is =18 years of ag
 
 - Patient diagnosed SARS-
 
Switzerland - In case of the subject acc

 
 - severe COVID-19 infectio
 
 
 - Comorbidity ((DM, hyper
Egypt ; Ali Sobh, MD;Ali Sobh ali.sobh@m+201000911288; Malignancy,

 
 1. Patients who had fever
 and laboratory confirmati
Phase 4 Taiwan ;; Shu-Hsing Cheng, Dr. ;shcheng@m
;+886-3-3 Taoyuan Ge 
 
 - Individuals from the gen
 
 - French native speacker
 
 - Majority 18 years and m
 
 
France ;; StÃ©phane Raffard, ;s-raffard ;46733970 University - Patient

 
 - Having type 1 diabetes
 
 - Living in Quebec
 
 - Having took part in the B
 
 
Canada Anne-Sophie Brazeau, PhD McGill Univ 

 
 - Individual (Male and fem
 
 - Healthcare Worker (med
 COVID-19 patients.
 
Phase 3 France ;;; Odile LAUNAY, Profess;;odile.la ;;01 58 41 Assitance P 

 
 For all patients:
 
 A. Patient must sign an info
 
Phase 2/PhChile ;; Raimundo Gazitua, MD;
;christian. ;56981369 Fundacion B. Signed consent to partici

 
 - Diagnosis of COVID-19, d
 SARS-CoV-2 detection, o
 
Switzerland - O

 
 - anaesthetists with more
 successful intubations us
 
 
N/A Malaysia ;; INA I SHARIFFUDDIN, ;shairil@ ;+6012329 University -
 
 1. Participant is < 21 years
 (DOIs) per standard of ca
 
United Sta ; Chi Hornik;Chi Hornik ;chi.horni ;(919) 260 Duke Clinic 2. Paren

 
 - Patients that can give wr
 
 - patients with microbiolo
 infection
 
Italy ; Pierachille Santus, M pierachille +390239042801;0239 

 
 - Patients went to the feve
 
 
 - none
China ; Wenhong Zhang, Doctzhangwenh13801844344;+86 21 

 
 - Patients undergoing ANY
 obstetrics
 
 AND
 
Spain ; Aneel Bhangu;Ana Mi A.A.Bhang +44 1216272949; - The patient had COVID-19

 
 diagnosis of pneumonia; Co
 given informed consent.
 
 
Italy Geltrude Mingrone, MD PhD Fondazione age lower than 18 years; pr

 
 - Men or women 18 to 80
 consent
 
 
Phase 2/PhUnited Sta ; Ruanne V. Barnabas, ;meigs@uw;206-520-3University - Had

 
 - Adults (age =18 years) w
 Acute Respiratory Syndro
 
United Sta Chuck Moser cmoser@ta984-234-0268 - SARS-CoV-2 conf
 Inclusion:
 
 - Completed Informed Con
 
 
 - Individual is currently wo
Phase 3 United Sta ; Adrian Hernandez, MD;rachel.e. ;919-668-5Duke Unive receive healthcare (

 
 - Valid informed consent.
 
 - All Covid 19 positive pati
 infection.
 
N/A Norway ;; Lars Wik, MD;Lars Wi ;lars.wik@ ;91728966;Oslo Univer - Patients with typic

 
 - All consecutive patients w
 because of severe form (eg
France ; Denis DOYEN;Denis D ;doyen.d@c;00334920 CHU de NIC inc

 
 - patients under investigati
 
 - patients that are positive
 
 
United Sta ; Matthew Yocum, MD; ;yocum00 ;612-626-8University - ultrasound contrain
 Donor Inclusion Criteria:

 
 - Age greater or equal to 1
 
 - Able to donate blood pe
 
Early PhaseUnited Sta Maria Lucia Madariaga, MD University - Prior diagnosis of COVID

 
 â€¢ Health Care workers wi
 
 
 - Allergy to hydroxychloro
 
Early PhaseMexico - History of bone

 
 - COVID-19 positive inpati
 
 - Inpatient showing at leas
N/A France ;; Claire-Marie RANGON;ayavchitz ;(0)1 48 03 Fondation auscultation
 
 - Outpatients = 18 years p
 and Florida who test pos
 
N/A United Sta ; Milind Desai, M. D.; ; ; The Clevela - Women of child bearing

 
 
 - Patients who have contr
 
 
onal [Patient Registry] Spain ;;; Mariano MD Provencio,
;;;epereir
MD;Cristina
;;;+349343
MD AvendaÃ±o
Hospital SolÃ¡,
P MD;MarÃ
- Patients
a MD GonzÃ¡lez-Cao,
diagnosed withM

 
 - All patients with proven
 presenting at least one c
France ; Cynthia CAILLON;Thie caillon.c@c+33492034011; 

 
 - History of Systemic Lupu
 Psoriatic Arthritis.
 
 
France Guillaume DEBELLEMANIERE, MD Fondation - beginning, or end,

 
 - Patients testing positive
 VUMC-associated testing
 
 - Age of 18 years or greate
 
N/A United Sta ; ; Kyle Kimura, MD;Just ;;kate.vo ;;615-322- Vanderbilt -

 
 and self-care, and either
 
N/A United Sta ; ; ; Vivek Y Reddy, MD;Ma;;sam.camm;;212-824- Icahn Scho 1. Not admitted to the h

 
 - Age = 18
 
 - Patient admitted in an em
 suspected of being
 
N/A France ;; Pierre HAUSFATER, MD;pierre.ha ;+331 42 1 GH PitiÃ© S - Written informed consen
 
 FOR DONORS:
 
 1. Volunteer enrolment (In
 
N/A Pakistan ;; Dr. Tahir Shamsi, FRC ;labarshi ;00923232 National I 2. All the regulations relate

 
 To be included in the trial th
 
 1. Have given written infor
 
 2. Be aged 18 years to 70 y
 
Phase 3 United Ki ; Joseph Cheriyan, MBC;ella.jame ;01223 34 Cambridge 3. Not previ

 
 
 - Respiratory failure requi
 with confirmation via SA
Early PhaseUnited Sta ; ; Noah Merin, MD PhD;;;Noah.Mer;;310-423- Cedars-Sin <
 Cohort A - Ambulatory

 
 
 1. Adult patients between
 
Phase 2 Canada ;; Jordan Feld, MD;Josh ;joshua.b ;(416) 340 University <

 
 1. Age = 18 years or older
 
 2. Hospitalized as an in-pa
 
Phase 2 United Sta ; ; Mary Beth Graham;Ma;mbgraha ;414-955-0Medical Co 3. Presence of respiratory

 
 - Confirmed COVID-19 dis
 
 - Age > 18 years-old
 
 
 - Age < 18 years-old
 
 - Pregnancy
 
France Sonia Boyer-Suavet boyer-suav+ 33 92 03 55 10 -
 
 - Health care providers inc
 nursing subjects.
 
 
 - Medical students
Egypt ahmed abbas, MD bmr90@hot2.01E+11 
 - Adults patients aged 75 y
 
 - COVID-19 diagnosis in th
Phase 3 France ;; Yonathan FREUND, PU;yonathma ;00 33 663 Assistance SARS-CoV-2 or COVID-19

 
 -Patients who have been di
 
 
 -N/A
United Sta ; ; ; Vivek Reddy, MD;Mart;;betsy.el ;;212-824- Icahn Scho 

 
 - COVID-19 diagnosed
France 
 The inclusion criteria are:

 
 1. Laboratory confirmed d
 chain reaction as per the
Phase 3 Canada ;;;; Michelle Sholzberg, ;;;Michell ;;;416-864 St. Michael 

 
 - Age of 18 years or over
 
 - Patient followed for a ne
France ; CECILE DELORME, MD;cecile.del 142161802;1 42 16 18 presenting a neurologica

 
 - Adult patients with Covid
 
 - Ability to read and speak
 
 
 
Turkey ; Yuksel Peker, MD, Ph ;yupeker@k;+9054434 Koc Univers - Subject
 
 - Male or female= 18 year
 
 
 - Ability for participant to
Phase 3 France ;; Alexandra AUDEMARD;a.audemar;+ 33 2474 University 

 
 - Patient = 18 years old
 
 radio-clinical grounds du
 
France ;; Simon Bessis, MD;Aur ;;Aurelien ;;+33 1 47 Infectious 

 
 - healthcare worker OR
 
 - patient with expected ho
 
 - patient admitted for maj
 
Phase 2 United Sta ; ; Alexandra E Kejner, M;alexandra ;859-323-6Univesity o - COVID19 negative by nas

 
 
 - Patient older than 18 yea
 
 
France Nicolas LIBERT, MD, P nicolas.lib 1.41E+08 - Patient comi

 
 - Subjects must be 45 yea
 
 
 - Subjects who tested pos
Phase 2 United Sta ; ; Chetan Bettegowda, ;cbetteg1 ;410-955-8Johns Hopk

 
 - Volunteer staff member
 mobile de rÃ©animation
 
France ; Damien CLAVERIE, MDdamien.cla178651257;17865125 Exclusion Criteria
 
 - Diagnosis of type 2 diabe
 
 - HbA1c levels at the entra
 
Phase 3 Italy ;; Paolo Fiorina, MD, PhD;
;letizia.te ;02 39042 University - Diagnosis of Covid-19 (sw

 
 - Adult = 18 years old.
 
 
 - Hospitalized patients wh
France ;; JÃ©rÃ©mie ZERBIT, P;jeremie.z ;+3315841 Assistance 

 
 Diagnosis of new acute-ons
 Clinical diagnosis of COVID-
 
 
Phase 2/PhUnited Sta ; Anthony Ting, PhD;Athe
;macovia@;21642635 Athersys, I Moribund subjec

 
 - ICU patients COVID-19 d
 
 - Intubated and mechanic
 
 
France Jean-Pierre GANGNEUjean-pierr (0)2-99-28-42-68 - Patients (or family or leg

 
 - Patients with lab-confirm
 
 - Had dyspnea both on ho
 
N/A China Wei-jie Guan, PhD Guangzhou - The patients volunteered

 
 Individuals who meet all of
 participants:
 
United Sta Nadine Rouphael, M.D. Emory Univ - Participant and/or surrog

 
 obtained prior to any pro
Phase 1/PhFrance Valerie SARTORI v.sartori@ 3.69E+08 
 
 - A written, signed inform
 patient's legally authoriz
Phase 2 United Ki ;; Manu Shankar-Hari, ;mmorre@r;+3360335 Guy's and part

 
 - patients over 18 years of
 of COVID-19.
 
 
 - none
onal [Patient Registry] ; Oscar PeÃ±uelas, P.h. ;openuela ;+3491683 FundaciÃ³n 
 Inclusion Criteria for ARM 1

 
 - Healthcare worker at GO
 
 - >18 years of age
 
United Ki ;; Louis Grandjean, Dr;L ;Louis.Gra ;07712336 Great Ormo - ALL have confirmed dete

 
 - Age = 18
 
 - ECOG 0-3
 
 - For patients who have n
Phase 2 United Sta ; Nancy Lee, MD;Nancy ;leen2@ms;212-639-3Memorial S required to have a plan i

 
 1. Patients (age 18 years a
 positive for CoViD-19 usi
 
N/A United Sta ; ; ; ;;clinicalt ;;412-330- Allegheny 
Tariq Cheema, MD;Boyl 2. Patients with cough, sho

 
 - General population
 
 - Consenting to the study
 
 - Guardians consenting to
 
Greece ;;;;; Christoph U. Correll ;;;;marco.s ;;;;+39049 Northwell H Exclusion Crite

 
 1. Age at least 18 years old
 
 2. For Cases: Laboratory co
 Chain Reaction (RT-PCR)]
 
Malaysia ; Siti Sabzah Mohd Has ;dr_ctsab ;+604 740 Hospital S 3. Pat
 
 - Any adult (18 or more ye
 symptoms suspicious for
 
United Sta Andre D Kumar, MD, MEd Stanford Un - This individual underwen

 
 - COVID-19 (+), inpatient o
 
 - COVID-19 (-) confirmed b
 
onal [Patient Registry] Tunisia ;; AgnÃ¨s Hamzaoui, Pr;E;eshmoun ;00216278 Hopital A 

 
 
 - Intensive care unit admis
 
 - Intubation and mechanic
 
Phase 2 ; Christophe LENCLUD, ;sroux@ch-v
;+3313923 Hospital of - Positive end-expiratory p

 
 - covid -19 pcr positive pre
 
 - no psychiatric diagnosis
 
 
Turkey Non-pregnant patients, A p

 
 - Age = 18 years of age.
 
 - Admitted to an intensive
 
 - Indication for intubation
 
N/A Denmark ;; Morten H Bestle, MD, ;morten.be;48 29 48 NordsjÃ¦ll - No suspicion of signif
 Centre Inclusion Criteria:

 
 - Any centre performing ele
 
 Inclusion Criteria (patient):
 
 - Adults (age =18 years) w
Spain ;; Aneel Bhangu;Aneel ;A.A.Bhan ;+44 12162University 
 
 - Age above 18 years old.
 Hospitalised patients wit
N/A France ; COURJON Johan;COUR;courjon.j@;+3349203 CHU de Nice
 sympt

 
 - inclusion criteria for don
 blood components; poss
 
Phase 2/PhItaly Gabriella Talarico, MDtrasfusion 9.62E+08 - inclusion criter

 
 - Adults (18 years and over)
 on a swab, through routine
 
 
United Ki ; Jessica Manson, Dr;Je ;jessica.m ;02034479 University 

 
 1. Positive virus test for SA
 infection test in the pres
 
Phase 2 United Ki ; Tom Wilkinson;Jody B ;jody.broo ;02380512 Study Princ 

 
 For COVID-19 hospitalized p
 
 - Polymerase chain reactio
 
 - Participation to Toulouse
 
N/A France ;; Guillaume MARTIN-B ;martin-bl ;56177969 University - Ha

 
 - Family member of a Cov
 gave his oral agreement
 
France ;; Julie HELMS;Julie HEL ;Julie.hel ;+33 3.69. CHU de Str 

 
 - age > 18 with one or mo
 Oxygen saturation <=93%
Phase 2 United Sta ; ; Geneva Tatem, MD;G ;gtatem1@h
;313-587-6Henry Ford ra
 INCLUSION CRITERIA (index
 
 - Age >=18 years old AND
 
 - SARS-CoV-2 positive AND
 
 - Well enough to self-isola
 
Phase 2/PhSwitzerlan ; ; ; Blaise Genton, MD-Ph ;;blaise.g ;;+41 21 3 UnisantÃ© - At

 
 - SARS-CoV-2-infection wi
 
 - vv-ECMO therapy
 
 
N/A Germany ;; Alexander Supady, Dr ;alexander ;+4976127 University - known patient will again

 
 - Having participated in th
onal [Patient Registry] Spain ;; FermÃn Mayoral-Cleries;FermÃ
;fermin.ma;+3468795
n Mayoral-Cleries,
Instituto
MD, PhD;MarÃ
 a Quintana, PhD

 
 - Covid-19 pneumonia
 
 - acute hypoxemic respira
 
 - need for nasal high flow
 
France Jean-Damien Ricard, MD, PhD Assistance - admission to intensive c

 
 - Currently pregnant, cons
 and documentation of CO
 
 
Samantha Collazo, M samantha.c856-397-7788 
 ARM 1 - hospital in-patients

 
 
 - In-patient admitted to Ta
 
United Ki ; Margaret Cooper;Edw;edward.ju ;+4416192 Tameside a - Clinical diagnosis of COV

 
 - Patients aged 16 years a
 country-specific)
 
Phase 3 ; Aneel Bhangu;Rachel L;PROTECT-S;+44 (0)12 University - Planned to undergo any
 
 - Cases confirmed by testi
 bronchoalveolar lavage fl
; Adrian I Espiritu, MD; ;aiespirit ;+6392585 University 

 
 - Any baby:
 
 1. That has a diagnosis o
United Ki ;;; Professor J Kurinczu ;;jenny.ku ;;int+ 44 ( University receives inpatient care

 
 - Age = 18 years and < 85
 
 - Documented (chest X-Ra
Early Phase 1 ; Massimo Galli, Profes ;agostino.r ;02-39042 University with respiratory failure (r
 Inclusion Criteria: confirmed

 
 - a positive RT- PCR,
 
 - a highly suggestive thora
 
 - severe hypoxemia
 
 
France MARIE REINE LOSSER, MD, PhD Central Hos - none

 
 - All subjects answering "y
 and/or 2) "Have you lost
 
 
 -
France ; Isabelle precheur, PU precheur.i 33492035547;334920 

 
 - Patients at least 18 years
 hospitalization.
 
Caroline Besson cbesson@ch3.37E+10 - In order not to bias the d

 
 - patient hospitalized at th
 
 - patient seen as outpatie
 infection
 
France ; Sandrine Castelain, Pr castelain. (33)3 22 08 70 61;(33) 
 
 - Pneumonia confirmed by
 
 
 - a history of chronic rena
 
 - a history of kidney transp
 
Russian Fe ; ; Dmitry Enikeev, M.D., ;dvenikee ;+79670897Sechenov U 

 
 - Hospital staff working in
 
 - Of legal age,
 
 - With or without a previo
 
France ;; Sylvie BASTUJI-GARIN ;sylvie.bas ;+33 6 74 Assistance

 
 
 - Diagnosis of osteoarthriti
 
Phase 3 Monica Luchi, MD Sorrento Th - Combined WOMAC A (pa

 
 - Patients with inflammato
 study
 
 
Korea, Repu; ; Yoojin Lee, M.D.;Yooji ;doctorlyj ;82-53-258Keimyung U - Those who are unable to

 
 - Patients having been hos
 PCR- Polymerase chain re
 
 
N/A France ;; Martine MAUGET FAY ;ayavchitz ;(0)148036 Fondation A - Pregnant

 
 - Health care workers pos
 
 - Health workers who had
 
 
India ;;; Neha Sharma;Jaydeep;;;
J ;;; British Ay
 
 - mechanically ventilated
 
 
 - healthy, non-ventilated
United Sta Betsy J Barnes Feinstein I 

 
 - Age> 18 years old
 
 - work for the Humanitas
 Mater Domini, Humanita
onal [Patient Registry] Italy ; Patrizia Meroni, MD;P patrizia.m 02 82241;0282241 <

 
 - Patient over the age of m
 his/her legal representati
 
 - Benefiting from a Social
 
N/A Damien BOUTIN damien.bou3.37E+10 

 
 - All the agents of the 3 lo
 being voluntary to be tes
France Pr RaphaÃ«l O SERRE raphael.se 3.32E+10 

 
 1. Adults 18 years of age a
 
 
 3. Hospitalized for COVID 1
 
 4. Severe disease or risk fo
Phase 2/Phase 3 
 - Patients with acute resp
 
 - Patients with chronic res
 
 - Patients attending a hosp
 
Portugal ; Catarina D Santos, MS; ; University
 
 - Over age 18
 
 - Participant is 4-10 weeks
 
 
 - Male (biologically unable t
onal [Patient Registry] United Sta ; ; Heather Huddleston, ;heather.h ;415-353-3University 

 
 - The person first-line med
 
 - the inspection personne
 
 - self-quarantine at home
 
Taiwan ; Chung-HUa Hsu, PhD; ;dap63@tp;886-2-23 Taipei City - self-quarantine at office

 
 - Patient, male or female,
 
France JEAN F OUDET jf.oudet@e 3.37E+10 (di

 
 - Adulthood
 
 - Informed consent obtain
 
 
 - No informed consent ob
Italy ;; Giacomo Grasselli, MD;giacomo.g;+3902550 Fondazione 

 
 - Accredited to practice at
 
 - All anesthesiology and su
 
 - All anesthesia and ortho
 
N/A United Sta ; Ellen M Soffin, MD, P SoffinE@H 212-606-1036;212-60 - All orthopedic surg

 
 - rheumatoid arthritis reci
 
 
 - patients not used hydrox
Egypt 
 
 - Have no previous confirm
 
 - Fall into one of the high
 
 
Phase 2/Phase 3 ; Thomas Hiemstra, PhD;kerrie.br ;01223 25 Cambridge - Inability to provide inf

 
 - Signed and dated ICF;
 
 - Age 18-75 (inclusive);
 
 - Real time polymerase ch
 
Phase 1/Phase 2 ;; Steven Keller, MD, P ;;psimmon ;;215-488- Brigham & - Endotrac

 
 1. Positive PCR fpr SARS-Co
 
 2. Intensive Care Unit adm
 
Phase 1/PhSpain ; Antoni Torres, MD, Ph;rucoll@bst;34935570 Hospital ClÃ
 
nic de Barcelona;
3. Moderate acute respira

 
 1. Age at least 18 years old
 
 2. Laboratory confirmed C
 Reaction (RT-PCR)]
 
Malaysia ; Siti Sabzah Mohd Has ;dr_ctsab ;+604 740 Hospital S 3. Patients clini

 
 - Age 18 and <81 years
 
 - Active COVID-19 defined
 samples
 
Phase 1/PhSweden Johan Ursing, MD, PhD Danderyd H - Fever =38.5C, admitted

 
 1. Adults > 18 years old
 
 2. Patients living alone or w
 
 3. COVID confirmed or sus
 
N/A United Sta ; ; Neomi Shah, MD, MPH;neomi.sh ;212-241-6Icahn Scho 4. To be discharged home
 
 - Age of 21 to 75
 
 - Right-handed only
 
 
 - left-handed
 
 - serious visual or auditory
 
N/A Singapore Agnieszka Olszewska, aga@nus.e91408707 
Inclusion criteria: 1. Age 18 years and

 2. Confirmed
Exclusion
SARS-CoV-2
criteria: 1.byCurre
nuc
 3. Able 2.
to be randomised
Currently receiving
within
Phase 3 Australia;New Zealand 4. Expected
 3.toCurrently
be remain taking
an inpLP
Inclusion criteria:
Exclusion
1. criteria: 1.
 2. Confirmed
 2. SARS-CoV-2
Previous TNFbyalp P
Phase 1 / Australia 3. Requirement
 3. Confirmed
for invasive
bacteor
Exclusion criteria: 1. Subje
Inclusion criteria:
 2. Subjects
Subjects entering
who requt
 1. Aged 3.
18 to Subjects
80 years who
(inclusive
requ
Phase 2 Australia 2. Subjects
 anticoagulants,
are diagnosed with or rem
Exclusion criteria: Candid
 - The
Inclusion criteria: Doinclusion
not provide
criterc
 - - to provide
Willing Are notconsent
currentlt
Phase 1 Australia - - employed
Currently Do not own as aanJun
in
Exclusion criteria: (a) Pati
Inclusion criteria:
 (b)Cases:
Patients
patients
who hav wit
 (a) Aged (c)
18 yrsPatients
and over on intra-n
 (b) in self-isolation
 (d) Patients
and with
beingimpmo
Not Applic Australia (c) (e) Patients with neu
Cancer
Research
UK
Clinical
Trials
Unit,
University
of
Birmingha
m
Phase II United Ki Anna Rowe catalyst@t - Inclusion c Exclusion cr
Phase II/III Ecuador Inclusion crExclusion cr
Not Applic Norway Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Diagnosed
criteria: 1. as The
invp
RetrospectChina Ze-Fei Jiang Southern Cjiangzefei +86 010 6 The Fifth M 2. Those 2.
who Thehavedate
received
of diagno
at le
RetrospectChina Zhongtao Zhang 95 Yong'an zhangzht@+86 13801 Beijing Fri Inclusion c Exclusion c
Exclusion criteria: (1) Com
 (2) Severe cognitive i
Inclusion criteria:
 (3)(1) EatingWritten
disorders;
signe
 (2) Age=18
 (4) years
Compulsive
old. ment
 (3) Histologically
 (5) Psychotic proven prim
sympto
N/A China Lili Tang 52 Fuchengtanglili_c +86 010-8 Key Laborat (4) Admitted
1. Subjects
Exclusion
are Older
criteria:
thanThe 18CO
ye
 2. No history
 1. ofIn special
additionmedicati
to covi
N/A China Xu Aiguo 1 Jianshe Raiguoxu@h+86 13523 The First A 3. Subjects can
 2. expresspsychotro
Recently themsel
Inclusion criteria:
Exclusion
1. Patients
criteria: with
1. Seveco
 2. Aged 2.
>=18 Estimated
years old; Time of
N/A China Chen Yongping 2 Fuxue Ro13505777 +86 13505 The First A 3. Voluntarily
 3. There
sign written
is clearinform
evid
Inclusion criteria:
Exclusion
1. Incriteria:
accordance
1. Subjew
 2. Gender
 2.
unlimited,
Volunteers age whom
unlimit
RetrospectChina Zhao Xiaoshan 1023 Shatazhaoxs060 +86 18620 Southern M 3. The 3.
subjects Hereditary
were informeddisease a
 2. Pregnant women o
 3. Long - term treatm
RetrospectChina Chen Dongfeng, Wen L10 Changji Chendf19 +86 13883 DepartmentInclusion 4. Patients with seve
Inclusion criteria:
Exclusion
1. The
criteria:
time 1.fromHisto
th
 2. Corresponding
 2. Pregnant
to theand release
lacta
N/A China Jin Yang 1277 Jiefa whuhjy@1 +86 13554 Union Hosp 3. Aged 3. 18~70Patients
years old with incom
Inclusion criteria:
Exclusion
In reference
criteria: Sample
to the
N/A China Daming Wang 88 Keling Rwangdm@si +86 13806010202 (1) suspected
 Statistics
covid-19 found
cases,thatca
Exclusion criteria: 1. Past
 2. Past personality di
N/A China Gang Hou 155 North Nhougangc +86 13840 First Hospi Inclusion c 3. With severe cardio
Inclusion criteria: 1. Recurrent COVID
0 China Zhang Wei 149 Dalian zhangwei_ +86 18982 Affiliated 2. The Exclusion
COVID-19cpatients with L
Exclusion criteria: 1) Asym
 2) The diagnosis of V
RetrospectChina Yu Hu 1277 Jiefa dr_huyu@ +86 13986 Union HospInclusion c 3) Three kinds of imp
N/A Yichen Li 89 Gongnon47232098 +86 13986 Wuhan Ment Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. The
criteria:
COVID-19
1. condpa
0 China Zang Xuefeng 10 Tieyi Rozangxuefe +86 15201 Beijing Shi 2. The 2.
COVID-19Spinal
patient
cord with
injuryseo
RetrospectSpain Oscar Cano-Valderra Hospital ClÃ
oscarcano
nico San Carlos,
+34 9 133
C/Profesor
Hospital
Martin
ClÃ
Inclusion
nico
Lagos
SanSN,
cCarlos
Exclusion
Madrid, cSpain
Exclusion criteria: 1. Durin
 2. 1.
Inclusion criteria: During pregnancy
Patients who wa
RetrospectChina Enqiang Mao 197 Secondmaoeq@ye+86 13501 Ruijin Hosp 2. Aged 3. Underold.
> 18 years the treatme
 2. Identify patients w
Inclusion criteria:
 3. 1.
Patients
Aged 18 with
to 65
disea
ye
4 China Fengjie Xie 5 Tongxiangmdjxfj197 +86 13514 Hongqi Hosp 2. According
 4.toPatients
the diagnostic
with liver cr
Inclusion criteria: (1) Comply with th
 (2) TheExclusion
classification
criteria:
was(1)
judged
Pati
 (3) Body (2)
temperature
Tracheal>intubatio
37.3 deg
0 China Liu Qingquan 23 Art Gall Liuqingqu +86 010-5 Beijing hos (3) Other problems t
 The NetherM. Beckers mil.becker 088-4599717 Inclusion Exclusion c
 The NetherDiederik van Wijk DF.van.Wi 088-085-7589 Inclusion c Exclusion c

 The NetherSofia Ramiro sofiarami 3.16E+10 Inclusion Exclusion c
 The NetherThomas Timmers thomas@int3.17E+10 Inclusion c Exclusion c
 The NetherBart Candel bart.cand 6.45E+08 Inclusion c Exclusion
 The NetherJan Dieleman j.m.dielem 6.14E+10 Inclusion c Exclusion c
 The NetherRianne Slingerland bootr@zgv. 3.18E+08 Inclusion c Exclusion c
 The NetherHanna van der Valk h.kuiperva 6.42E+08 Inclusion c Exclusion c
 The NetherHans Koeleman h.koeleman 3.11E+10 Inclusion c Exclusion c
 The NetherLuc Gidding info@gmda 6.45E+08 Inclusion c Exclusion c
 The NetherHilde Kooistra h.a.m.kooi 3.16E+10 Inclusion c Exclusion c
 The NetherGeertje de Boer G.Boer3@Fr3.16E+10 Inclusion Exclusion c
 The NetherJoost van den Aardweg j.g.vande 020-5669111 Inclusion c Exclusion c
 The NetherCathelijne van Zelst c.zelst@fra06-18975719 Inclusion c Exclusion c
 The Netherstephan papendorp spapendor 0251-265976 Inclusion c Exclusion c
 The NetherPeyman Sardari Nia peyman.sa 0031-(0)-43-3875070 Inclusion c Exclusion c
 The NetherMartijn Spruit martijnspr +31 (0)475 587 600 Inclusion c Exclusion c
 The NetherAnna Roukens a.h.e.rouk 3.17E+10 Inclusion c Exclusion c
 The NetherMarjolein Kluytmans marjolein 06-51215336 Inclusion c Exclusion c
 The NetherAnouk Vaes anoukvaes@ +31 (0)475-587602 Inclusion c Exclusion cr
 The NetherVivan Baggen v.baggen@ 6.52E+08 Inclusion c Exclusion c
 The NetherFemke Hooijberg f.hooijber 2.02E+08 Inclusion c Exclusion c
 The NetherPriya Debisarun priya.deb 2.44E+08 Inclusion c Exclusion c
 The NetherBas van Bussel bas.van.b +31 (0)43 3876387 Inclusion c Exclusion c
 The NetherSvenja Haak s.l.haak@is 3.84E+08 Inclusion c Exclusion c
 The NetherDirk Tjwa dtjwa@umc06-27744381 Inclusion c Exclusion c
 The NetherSimone Moorlag Simone.Mo -3667211 Inclusion crExclusion c
 The NetherRutger Middelburg r.a.middel 3.17E+10 Inclusion c Exclusion c
 The NetherFloris Smeets fl.smeets@088 â€“ 459 9717 Inclusion c Exclusion c
 The NetherJAH VAN Oers jah.vanoer 1.32E+08 Inclusion c Exclusion
 The NetherAlienke Wijmenga-Monsuur alienke.wi NA Inclusion c Exclusion c
 The NetherHamza Yousuf hamza@ham 00 31 20 444 22 44 Inclusion c Exclusion c
 The NetherMarion Frenken marion.fr 040-8888380 Inclusion Exclusion
 The NetherJesper Weehuizen j.m.weehu 8.88E+08 Inclusion c Exclusion c

 The NetherHarm Jan Bogaard hj.bogaar +31020 444 1896 Inclusion c Exclusion
 The NetherFrank Bosch frank.bos 3.12E+10 Inclusion c Exclusion c
 The NetherFrank Bosch frank.bos 3.12E+10 Inclusion c Exclusion c
 The NetherMargriet Dijkstra m.j.dijkstr +31 50 3610468 Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Ki James Chalmers Division o j.chalmers 01382 383 University Inclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Kavi Sharma Clifford Br kavi.shar 2.48E+09 University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Mike Grocott Southampto
mike.groco 2.38E+09 University Inclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use Exclusion criteria: 1.
(Phase 2. Pregnancy or brea
IV): no 3. Allergy to any stud
Belgium clinical trial center U Herestraat ctc@uzleuven.be UZ Leuven Inclusion c 4. Any medical condi
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Portugal;FrChief Investigator HRB Clinicaj.eustace@ucc.ie University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no Exclusion criteria: - Im
Therapeu - End stage renal failu
 - Life
 -
expectancy
Positive COV
<1
(Phase PCR documented
 - ActiveSARS-CoV-2
neoplasia (tr
ca
IV): no images -
of COVID-19
Breastfeeding
associated
and p
Belgium dr Camelia Rossi Boulevard camelia.ro 3.27E+09 CHU AMBRO
 - Hospitalized
 - Known
patients
severe
aged
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Denmark Clinical Institute, OPE J. B. Winsl open.adm@rsyd.dk University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain RaÃºl MontalbÃ¡n Ca C/Azcona, raul.m@dy003491 456Dynamic ScInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Andrew Pollard CCVTM, Chu
andrew.pol 1.87E+09 University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Managing director Avenida Hos
enrique.c 3498510 9 FundaciÃ³nInclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain Mar GarcÃa SÃ¡iz Avenida demmar.garci 3.49E+10 IDIVAL Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Rajeev Saggar 901 Gatew rsaggar@t 1.95E+10 TheravanceInclusion c Exclusion c

 
 1. Laboratory examination
 diagnostic criteria for pn
Hongzhou Lu, Master lunliweiy 021-37990333 Pne

 
 
 - Able to understand the c
 consent
 
Phase 1 China ;; Zhu Fengcai;Guan Xu ;; ;; Jiangsu Pro - Able and willing
 
 
 - Moderate to severe COV
 
 - Hospitalized patient
 
Phase 2 Canada ; Barbara Goodall;Lisa barbara.go(902) 292-0132; - Willing and able to provi

 
 - Positive nasopharyngeal
 years and/or with clinica
Phase 2 Italy ;; Umberto Maggiore, M;umberto.m;00390521 Azienda Os 

 
 
 - Symptomatic infection w
Phase 3 France;Mo Vincent DUBEE vincent.du 2.41E+08 failing that, by thorax CT

 
 - 16 years or above
 
 - Patient requiring hospita
 
 - Clinical or Radiological e
 
United Ki ;; Ravindra Prof. Gupta, ;richard.s ;01223 34 University - Acute respir

 
 - Primary case: laboratory
 chain reaction (PCR), or F
N/A French Gui ; ; Claude Flamand, PhD; ;cflamand@;+33 5 94 Institut Pa 

 
 - All adult patients > 18 ye
 oncological treatment or
 
Belgium ; Bjorn Stessel, Dr;bjor bjorn.stes 003211222107; 

 
 - 12 intubated and mecha
 single time point (29/03/
 
 
 - None
Belgium Group 1: COVID-19 positive
 criteria: All adult (age=18 bu
United Ki ;;; Sam (Saidi) Mohiddin, ;;d.hardin ;;020 7377 Barts & Th infection. Exclusion criteria:

 
 
 - Able to understand the c
 consent
 
Phase 2 China Fengcai Zhu, MD Jiangsu Pr - Able and willing

 
 - Type 2 Diabetes Mellitus
 
 - Age = 18
 
 - Confirmed COVID-19
 
Phase 4 United Sta ; Gianluca Iacobellis, ;giacobell ;30524336 University - Mild COVID-19 define

 
 - Patients with PCR confirm
 
 
 - The most recent PCR pos
 
Phase 2/PhNetherland ; Bart Rijnders, MD, Ph ;b.rijnder ;+3110703 Erasmus Me - Written informed

 
 - naive patient for elective
 
 
 - minor less than 18 year o
France 

 
 Patients had been diagnose
 interim guidance and admitt
 
China Jun Pu, M.D Renji Hospi Exclusion

 
 1. Men or women =18 yea
 practice abstinence or to
Phase 2 Mexico ;; Adrian Camacho-Orti ;md.eduar ;+52 81179Hospital Un 
 Inclusion Criteria after takin
 
 - A healthcare worker at h
 
Phase 2 Pakistan ;;;; Fibhaa Syed, FRCP;Moh
;;;drfibha ;;;+92333 Shaheed Zyl - Persons primarily wor

 
 1. Age >1 year.
 
 2. Active COVID-19 infectio
 
 3. Meets institutional crite
 
Phase 3 United Sta ; ; Richard Kaufman, MD ;rmkaufma;617-732-5Brigham an 

 
 - Has laboratory-confirme
 
Phase 1 United Sta ; Dr.Joshua Rhein, MD; ;rhei0005 ;612-624-3Department - R

 
 - 1. At least 18 years of ag
 
 - 2. Confirmed COVID-19 d
Phase 2 United Sta ; ; Nada Alachkar, MD;Na;nalachk1@;410-614-9Johns Hopk real time RT-PCR using n

 
 - All-comers patients aged
 
 
Phase 3 Italy ; Nuccia Morici, MD;Nu nuccia.mor+396444;+026444 - Patients admitte

 
 (RT-PCR)
 
 - New admission to eligibl
 
Phase 4 United Sta ; ; Ajay Kirtane, MD;Sahi ;sap2196@;212-305-7Columbia U 

 
 
 - High initial clinical suspic
Phase 4 United Sta ; ; Avni Thakore, MD;Avn;avni.thak ;516-563-7Saint Franc cough, myalgias, fatigue,
 
 
 - COVID-19 patients admitt
 or critical patients (admis
 
Portugal ;;;; Fausto J Pinto, PhD;C ;;;;fausto ;;;;003512 Faculty of

 
 - Man or woman > 45 yea
 
 - Patient with a positive SA
 
 - Patient with ENT and / o
Phase 3 France Brigitte DRENO brigitte.d 2 40 08 31 18 
 1. Age 18-80 years ;
 
 2. COVID-19 confirmed cas
 
 3. Cases showing respirato
 
Phase 3 France ;;;; HervÃ© FOEHRENBACH;
;;;;christ ;;;;+33 14 Direction 1.

 
 - Post graduated pharmac
 
 
 - under graduated studen
Egypt ; Asser Ghoneim, phD;N;dr_nosa0 ;04531761 Professor 

 
 - accepted to participate w
 
 - proven positive COVID-1
 
 
 - declined to participate
 
N/A Turkey ; Hasan Onal;Hasan Onahasanonal +905325092988;+905 -
 
 - age = 18 years
 
 - clinical suspicion of COV
 
 - CT scan at ER admission
 
 - RT-PCR sampling
 
France ;; Pierre CROISILLE, PhD ;pierre.cro ;04771275 CHU SAINT Exclusion C

 
 - ETH employee or ETH stu
 the start of the study
 
Switzerlan JÃ¶rg Goldhahn, MD ETH Zurich - Between 18 and 64 year

 
 - moderate-high risk for C
 
 - obtained informed conse
 
 
 - declined to participate
 
N/A Turkey ; Hasan Onal;Hasan Onahasanonal +905325092988;+905 - genetic/chromos

 
 - pcr positive for covid -19
 
 
 - dead patient uncooperati
onal [Patient Registry] Egypt Tamer A Elhadidy, MD assistant p 

 
 1. Age= 18, = 60 years old;
 
 2. Have a fixed sex partner
 
 3. No previous infectious d
onal [Patient Registry] China ;; Jihong Liu, M.D;Tao ;tjhwt@12 ;027-83663Department
 1. Age 18-85 years.
 
 2. Admitted to the hospita
 
 3. Diagnosis of COVID-19 b
 
Phase 2 United Sta ; ; Marvin Konstam, MD; ;mkonstam@
;617-636-6Tufts Medi 1. positive
 
 Signed the informed consen
 
 
 (1) dysphagia or symptoms
N/A China ;; Zhuan Liao, MD;Zhuan;liaozhua ;+86-21-3 Department 
 Inclusion Criteria:+

 
 1. Years age >18 yrs
 
 2. clinical diagnosis of Chro
 
 3. withdrawal treatment a
 
N/A Italy ; Licia Grazzi, MD;Licia licia.grazzi 022394;022394 4. written

 
 1. Willingness of study par
 consent;
 
 
Phase 1 Turkey Mustafa Cetin, Prof TC Erciyes 
 - Adults (age =18 years) un
 
 - With positive PCR in the
 
 
France ; Mickael VOURC'H, MDvourchm@g0253482835;0253482

 
 - PCR- positive for COVID-
 
 
 - <18 years of age
Israel Shaul Lev, MD Rabin Medi 

 
 - Mainly asymptomatic ind
 Barcelona, Madrid and V
Spain ;;; Xavier Santamaria, M ;;carlos. ;;+34 96 3 Igenomix;I i
 
 - Histologically proven dig
 
 - Ongoing treatment from
 
 
Violaine RANDRIAN, violaine.ra 05.49.44.44.44 - Patient refusal for enroll

 
 
 
 - Admitted to an acute car
 
Phase 2 United Sta ; Michael Baram, MD;MMichael.Ba215-955-5161; 

 
 - Patients positive for Cov
 
 
 - Pregnancy
 
 - Breastfeeding
 
Phase 4 -
 Inclusion Criteria for donors

 
 - male patients who have
 Basel, Switzerland or in t
 
N/A Switzerlan ; ; Andreas Buser, Prof. ;nina.khan ;+41 61 32 Blutspendez 

 
 - SARS-CoV2 Infection diag
 
 - CT-scan confirmed inters
 
 - Hospital admission from
 
Phase 2 Armando Gabrielli, M a.gabrielli 7.12E+08 - P/F ratio >150

 
 - SARS-CoV-2 positive Rea
 
 - Moderate to severe Acu
 classification.
 
Phase 1/PhColombia ; ; Alfredo Hernandez-Ru;ahernande;+5745699 Clinica Som 
 
 1. Adult patients (18 years
 respiratory syndrome co
Phase 2 ; Michael J Dawson, MD;inge.bear ;858-775-8Leading Bio established s

 
 - Adult subjects (> 18 year
 classified on the basis of
 
 
Egypt ;; Mahmoud El-Bendary,;mmelbend;00201002 Mansoura U 

 
 - Confirmed COVID-19 dia
 
 - Presence of pulmonary i
 
Phase 1/PhIran, Islam ; ; ; Ahmad Ameri, Prof.;N ;;nazanin. ;;0098912 Shahid Behe
 - Less than 3 days since th

 
 To be included in the trial th
 
 1. Be aged 18 and over
 
 2. Have clinical picture stro
Phase 4 United Ki ;; Frances Hall Hall, FR ;elena.he ;01223 34 Cambridge 

 
 - Patients with a confirme
 require admission to the
 
 
N/A Spain ; Vicente Navarro;Laur ;laura.nav ;00346230 Hospital un 

 
 Group B: SARS-CoV-2 PCR p
 
 
Phase 2 United Sta ; ; Jessica Justman, MD;J ;jj2158@c ;212-342-0Columbia U - Close contact* of a perso
 
 - Adult inpatients (=18 yea
 
 
 - Age <18 years old.
 
 - Outpatients.
onal [Patient Registry] Switzerlan ; ; ; Frank Ruschitzka, Pro ;;;mateusz ;;;+487173 University 

 
 - From patients suspected
 
 - From patients who have
 
; Jordon Thornes;Ellen F;eharris@i ;612.867.1 Laboratory - From patients w

 
 - For the Ambulatory Obe
 
 - Age = 18 years;
 
 - Patient followed in the n
 
onal [Patient Registry] France Kathleen Jacquez, MS kathleen.j 03.21.21.13.19 / Post - Patient

 
 - COVID-19 positive
 
 - Pulmonary compromise
 
 - Able to self prone, or sup
 
Phase 2 United Sta ; Scott Sigman, MD;Mic;Michael.M;978-788-7Lowell Gen 
 - Male
 
 - PCR on nasopharyngeal s
 
 - Age: = 18y - = 50y
 
 
N/A ; Michael De Brucker, ;michaeld ;+3249445 UZ Brussels - When undergoi
 
 - Tested COVID positive
 
 - No other chronic disease
 
 - Above 18
 
 
 - Children
; Dina Mounir Elkady;Di;Dina.elka ;01004297 Lecturer at 

 
 1. Confirmed COVID-19
 
 2. ICU admission
 
 3. Confirmed or imminent
 
onal [Patient Registry] ; Peter Nelson, MD;Ola ;oogunsak ;(504) 715 CytoSorben 4. CytoSorb hemoadsorpti

 
 - Diagnosis of chronic lym
 disease according to the
onal [Patient Registry] ; Luc-Matthieu FORNECK;r.herbrec ;3 88 68 76French Inn 

 
 
 - Verified COVID-19 infecti
 
 - Severe ARDS according t
 
Denmark ; Ana-Marija Hristovskaana-marija +4538625532; 

 
 - Defined cases of COVID-
 manifestation
 
 
Phase 1/PhIran, Islam ; ; Ali Mostafaie, PhD;Ali ;ali_most ;+98 83 34 Medical Bi - Age <10, Pregnancy, Sev

 
 Members of renowned scie
Italy 
 
 1. Patients of any ethnic ba
 minimum of 24-hour hos
 
 2. Age =18.
 
N/A United Sta ; ; Ernesto Molmenti, M ;;anizam1@;;9179570 Northwell 3. Written

 
 - non applicable, already e
 
 
 - non applicable
France ;; Fabrice Carrat, MD;Fab;fabrice.ca ;+33 (0)1 4 Inserm - S 

 
 1. Man or woman aged 18
 
 2. Hospitalization in intens
 
 3. First hospitalization in in
 
France ; Fabienne VENET;Fabi ;fabienne. ;4 72 11 97Hospices Ci 

 
 - any subject with COVID-
 above-mentioned quaran
Phase 3 Egypt ;;; HATEM ELALFY, MD;H;;ELALFY2 ;;+201224 PROFESSOR contraindication

 
 - first ischemic or hemorrh
 
 - time latency within 6 mo
 
 - age between 35-85 year
 
N/A ; Irene Aprile, MD, PhD ;iaprile@d ;+3906330 IRCCS Fond
 - Provision of signed and d
 
 - Stated willingness to com
 duration of the study
 
N/A Pakistan ;; Karamat Hu Bukhari, ;Asghar.a ;00923225 Combined M

 - 40-60 years old male or f
 
 - Confirmed 2019-nCoV in
 
 - Confirmed Pneumonia w
Phase 1/PhTurkey ;; Gokhan T Adas, Prof.Dr;;gokhant ;;0532615 SBÃœ Dr. Sa

 
 
 - Signs and symptoms sug
 
Phase 1/PhUnited Sta Kevin V Grimes, MD Stanford Un - Laboratory-confirmed se

 
 - Reside and Currently in N
 
 - Does not have a blood cl
 
 - Is not abnormally queasy
 
N/A United Sta ; Viral Patel, MD;Matt crew@proo(833)-4-RADISH; - Not

 
 - All adult COVID19+ patien
 2020.
 
 
 - Patients younger than 18 y
onal [Patient Registry] Belgium 

 
 - CoViD-19 positive patien
 
 - Suspicion of SARS-CoV2
 
Italy ;; Carlo Martinenghi, MD;martinengh;+3902264 IRCCS Ospe - Patients of all ages

 
 - Admitted to the ICU due
 
 - APACHE II score> 14 or IC
N/A ; Antonio JosÃ© Ojeda ;ojeda@clin;93 227 54 Pain unit p or Acquired weakness in
 
 1. Age > 18 years-old.
 
 2. Diagnosis of pneumonia
 reaction (PCR) or highly s
 
N/A Spain ; Escarlata LÃ³pez RamÃ;elena.mor
rez, MD, PhD;Elena
;+34 9144Moreno
Fundacion
Olmedo, MD

 
 - Patient with documente
 
 - Hospitalized in Universit
 
 - Patient or family who ha
 
France Damien JOLLY djolly@chu 3.27E+08 

 
 - COVID-19 patients with C
 
 
 - Patients < 18 years of ag
 
Phase 3 Egypt ; Khaled Salem, MSc;Khkhaledsale +201113451163;+201 - Patient

 
 -children (age 0-18 years) w
 impairement), living in Fran
 
 
 -
France 

 
 1. High/moderate risk con
 
 2. Within the 14 days follo
France;Fre ; Xavier Duval, MD;Xavi ;xavier.du ;01 40 25 Institut N case
 Inclusion criteria: (1) Adult p

 (3) Patients who are intuba
 SARS-CoV2 by positive rt-PC
 
Phase 2 United Sta ; ; Lorenzo Berra, MD;Lo ;lberra@mg;+1617643 Massachuse 
 
 - healthy asymptomatic he
 
 
 - SARS-CoV-2 positive or s
onal [Patient Registry] United Ki ;;;; James C Moon;Charlo ;;;bartshe ;;;0757091 BHC & UCL; 

 
 - 1st Line Consultation in P
 
 - All reasons for consultati
 
France ;; FranÃ§ois Dubos, MD ;francois.d ;02044598 University H - Informed and written co

 
 - endometriosis patients
 
 - no psychiatric illness
 
 - no antidepressant use
 
 
onal [Patient Registry] Turkey - women who had not end

 
 
 - Presentation to the ED w
 
 - Patient displays at least o
 
Phase 2 United Sta ; N. Stuart Harris, MD, nsharris@m617-724-3290;617-72 

 
 - Residents in the following
 rectal surgery, general surg
Italy neurological

 
 Subjects enrolled in the tria
 
 - Confirmed COVID-19 pne
 
Phase 2 United Sta ; ; Nishant Gupta, MD;Ni ;guptans@u;51355848 University - Hypoxia as defined by ro
 
 - physicians working in en
 
 
 - physicians not working in
United States;Egypt;Iran, Islamic Republic of;Egypt;Iran, Islamic Republic of;U 

 
 1. men and woman age 18
 
 2. Not hospitalized;
 
 3. Has recently tested SAR
 
Phase 2 United Sta ; Eric J Lenze, MD;Ange ;stevens.a ;(314)362- Washington 4. Currently symptomatic w

 
 - Patients included in the C
 
 - Onset of COVID19 functi
 of onset)
 
Phase 2 France ;; Karine LACOMBE, PU- ;karine.la ;+33 1492 Assistance -

 
 1. Subjects must provide in
 center's institutional revi
Phase 2/PhUnited Sta Elyse Stock, MD clinicaltr 203-404-0410 
 Inclusion Criteria:s

 
 1. Recipients:
 
 We will use the confirme
Phase 2 Saudi Arab ; Hani Al-Hashmi, MD;H;hanih.has ;00966564 King Fahad POSITIVE rRT PCR test fo

 
 - hospitalized in intensive
 
 - requiring invasive ventila
 
 - intubated for less than 7
France ;; Thibault Duburcq, MD;thibault.d ;3 20 44 4 University H - INCLUSION CRITERIA:

 
 
United Sta ; ; Blake M Warner, D.D.S;eileen.pe ;(301) 594 National In 1. Willing and able to sign
 
 - Body mass index (BMI) =
 
 - Medically healthy with n
Phase 1 United Ki ;; Medical Monitor;Ther ;medinfo@;1-855-633Theravance 

 
 - Rheumatoid arthritis Qu
 
 
 - Non adult patient RA pati
France RenÃ©-Marc FLIPO, MD,PhD University H 

 
 - Patient with osteoporosi
 
 - Patient in confinement
 
 - Patient with sufficient un
 
 
France Bernard Cortet, MD,PhD University H 

 
 - Patient with chronic pain
 
 - Patient in confinement
 
 - Patient with sufficient un
 
 
France Anne BERA, MD University H 

 
 - A diagnosis of advanced
 
 - A positive test for SAR
Phase 2 United Sta John DiPersio, M.D., Ph.D. Washington re

 
 
 - Cardiac injury, including
 
 - Elevated troponin lev
 
Phase 2 United Sta ; Reza Ardehali, MD, P ;arabbani ;310-517-8University 
 
 - any child over 7 days old
 
 - parent of the enrolled ch
 
 
N/A France ;; Isabelle SERMET-GAU ;isabelle. ;+ 33 1 44 Assistance - child young

 
 - Age 18-80 years
 
 - Symptomatic CoVID-19 d
 
 - SARS-CoV-19 PCR positiv
 
 - Elevated hsTPN
 
Early PhaseUnited Sta ; Dean J Kereiakes, MD;;lindnermd;513-585-1The Christ Exclus

 
 1. Informed consent must
 
 2. Adult patient = 18 years
 
Phase 3 United Sta Novartis Pharmaceuticnovartis.e 1-888-669-6682 3. Severe Acute Respirator

 
 - SARS-CoV-2 positivity co
 
 - orotracheally intubated
 
 - pressure control ventilati
 
N/A Hungary ;; AndrÃ¡s Lovas, MD Ph;lovas.and ;00366254 SZTE AITI; - sedati

 
 - Being tested positive for
 ambulatory clinics at the
 
Phase 1 United Sta ; ; Michael Millis, MD;Mic;mmillis@s;773 702 6 University - A

 
 - Infection with Covid-19 (
 
 - possible encephalitis (at
 
 - clinical severity requiring
N/A France MickaÃ«l BONNAN mickael.bo 05 59 92 49 66 <
 
 - Men, and women, over 1
 
 - Patient is hospitalized du
 
Phase 2 United Sta ; ; Rajiv Thakur, MD;Kat ;katie@ho ;83297588 Advanced D - Agrees to the collection
 Inclusion Criteria: Subjects e

 
 
Phase 2 United Sta ; ; Paul C Cremer, M. D.; ;cremerp@c;216-445-6The Clevela 2. Ho

 
 - COVID-19 survivors (i.e.,
 and/or a family member
 
 - Aged 18 years or above;
 
Hong Kong ; ; Agnes YK Lai, PhD;Agn;agneslai@;39176328;The Univer <

 
 â€¢ Higher education stude
 
 
 â€¢ Subjects refuse to answ
Hong Kong ; ; Agnes YK Lai, PhD;LAI ;agneslai@;+8523917 School of N 

 
 - admitted for severe Covi
 with SpO2<96%)
 
 
France Joe-Elie Salem, MD, P joe-elie.s 01 42 16 00 00 - patients who were previ

 
 - Adult (age = 18 years)
 
 - Suspected or Confirmed
N/A United Sta ; ; Stacy A Johnson, MD; ;Stacy.A.J ;801-581-7University COVID-19 assay; Confirm

 
 - Male and female adults w
 infection. Able to give co
 
 
N/A Greece ;;; ELENI KORTIANOU, PhD
;;ekortian ;;0030694 Clinical Ex - the presence o
 
 
 2. Laboratory-confirmed se
Phase 2 United Sta ; Todd Rice, MD;Margar;margaret ;615-322-3Vanderbilt infection by Reverse tran

 
 1. Healthy, ASA 1-2 memb
 anesthesia assistants, nu
N/A ; Anahi Perlas, MD,FRC ;rongyu.ji ;41660358 Toronto We Netwo

 
 - Age 18 years old or older
 
 - Willingness to participat
 
 - Presents with red eye co
 
 
United Sta ; ; Sezen Karakus, MD;Se;skarakus@;410-955-5Wilmer Eye - Adults lacki

 
 - Fractured neck of femur
 
 - Received operative inter
 
 
 - open fracture
 
United Ki Babar Kayani, MBBS Barts & Th -

 
 - only for physicians
 
 
 - not physicians
Argentina 

 
 - Patient aged 18-85 years
 criteria (typical upper res
Phase 2 ; Lin H Chen, MD;Lin H ;lchen@ma;617-499-5Mount Aubu
 
 
 - PCR-confirmed or suspec
 
 
 - None
Finland;Fr Fausto Biancari, Profe faustobian 3.58E+11 

 
 - All outpatients whose med
 11th 2020 were contacted b
 
France Isabelle LAFFONT, Professor University Exclusion criter

 
 1. Provide written informe
 
 2. Subjects age > 18 years
 
 3. Male or Female
 
Phase 1/PhUnited Sta ; ; ; George C Shapiro, MD;;;clinical ;;;1-888-9 Chief Medic 4. Must have a

 
 - Patients referred for ERC
 
 
 - Patients refusing to parti
United States;Egypt;Germany;Peru;Singapore;Egypt;Germany;Peru;Singapore; 

 
 - Adult patients with COVI
 
 - The clinical decision to u
 registry.
 
onal [Patient Registry] United Sta Thomas E Serena, MD SerenaGrou - A signed and dat

 
 
 - Diagnosis of pneumonia
 
 - Respiratory and/or syste
Phase 2 France;Ital ; Tiziana Meschi, MD,P ;tiziana.me;05217020 Azienda Os 
 
 - Adult patient age more t
 
 - Symptomatic , positive s
 
 - Patients who have mild t
 
Phase 2 Saudi Arab ; Osama Kentab, MD;Os;oykentab ;+9665042 Princess N 

 
 1- Suspected cases of COVID
 patients
 
 -
 
 
Saudi Arab ; ; ; ; OSAMA KENTAB, M.D;;;;OYKENT ;;;009665 Princess N 1. The cases of children

 
 Navarra with a positive S
 
Phase 2 Spain ;; Carlos J Chaccour, MD;icanales@ ;+3494825 Clinica Uni 2. Residents of the Pamplo

 
 -Included in the SIR with CO
 
 
 -Age below 18 years.
; Miklos Lipcsey, PhD; ;bjorn.ahl ;+4670834 Uppsala Uni 

 
 For plasma donors:
 
 - Over 18 years of age
 
 - Men or nulliparous wom
Phase 3 Colombia ; ; Oliver Perilla Suarez, ;gerardope;+5731363 Hospital S SARS-CoV-2 infection by

 
 - Participant is aged 18 ye
 
 - Has been admitted to ICU
 
 - COVID-19 disease has be
 
France Francois Pattou, MD Centre Hosp
 
 
 - 18 years or older patient
 
 - Patient with hematologic
 transplantation
 
Phase 2 France ; ValÃ©rie SARTORI;Va v.sartori@ 0368767223;3687672 - Non severe Covid

 
 - Male or female between
 
 - Female subjects must be
 
Phase 1 United Sta Laura J. Szewczyk laura@rid 786-687-2495 - Male participants must a
 â€¢ Eligibility Criteria

 
 - Participants will be 16 ye
 
 - COVID-19 infection dem
 
Phase 2 United Sta ; Thomas E. Coyle, MD; ;William_J ;513 865 5 TriHealth I - Admitted to the hospital

 
 1. Women and men over 1
 
 2. Clinical diagnosis of COV
Phase 4 Spain ; Olga Sanchez Pernaut ;osanchez@;00349155 FUNDACION
 specific IgM isotype Ac a

 
 1. Adult (= 18 years old) m
 SARS-CoV-2 infection by
Phase 2/PhFrance ;; Eric CUA, MD;Paul GI ;paul.gine ;+33 62583Centre Hosp
 

 
 - Any gender
 
 - Age > 18 years on day of
 
 - Informed written consen
 
Phase 2 Italy ;; Francesco Menichetti ;marco.fal ;05099673 Azienda Osp
 - Virological diagn

 
 1. Adult (=18 years old) at
 
 2. Positive COVID-19 test r
 test pending
 
United States 
 
 - Diagnosed Sars-Cov2 pati
 
 - Intensive or critical care
 
France ; Jean DELLAMONICA, dellamonic+334 92 03 55 10;+334 - ARDS with PaO2/FiO2 <3

 
 
 - COVID-19 confirmed by p
 
 - at least one urine sample
 
 
France ;; Romaric Larcher, MD, ;r-larcher ;4.67.33.7 UH Montpel - Persons un

 
 - Ages between 18-95 yea
 
 - Currently experiencing a
United Sta ; ; Arun Jayaraman, PhD;;Lmcgee@s;312-238-2Shirley Rya shortness of breath, trou

 
 - Any gender
 
 - Age > 18 years on day of
 
 - Informed written consen
 
Phase 2 Italy ;; Francesco Menichetti ;marco.fal ;05099673 Azienda Osp
 - Virological diagn

 
 - Healthcare worker OR pa
 a person who is co-residi
Phase 1 United Ki ;; Afroze Khan, MBBS M ;Afroze.Kh ;+4478859 Hampshire 

 
 - proved SARS-COVID-2 in
 
 
 - none
; Paolo Simioni, Prof.;Pa;paolo.sim ;+39 0498 Department 

 
 Healthcare workers having
 centre (any setting) during t
 
Phase 3 We will include professiona
 
 The investigators will evalua
 outpatients and inpatients f
 
United Ki ;; David J Pinato, MD;Da;david.pin ;+44 (0) 2 Clinical Se 1

 
 - Adult participants
 
 
 - None
N/A Malaysia Siew Li Teoh, MPharmteoh.siew (+603) 5515-9646 
 To find out vitamin D levels

 25-hydroxy-vitamin D levels
 
 Intensive care unit patients
onal [Patient Registry] Turkey <

 
 - Read/Write English,
 
 - feels stress due to Coron
 
 
 - current psychological or
 
N/A Israel ; Jonathan Huppert, Ph jonathan.hu+97225883376;+9722 

 
 - Major Subject (=18 years
 
 - Subject with COVID 19 (r
 
France ; Bob HEGER, MD;Bob Bob.Heger@
33 3.69.55.04.43;33 3 - Subject hospitalised in th

 
 Confirmed cases of SARS-Co
 
 
 less than 18 years old know
Phase 2 Saudi Arab ; Samah M Lutfy, MD;S omar1star +966581244415;+966 

 
 - COVID-19, either confirm
 of the assay pending;
 
N/A Canada ; Ivan Pavlov, MD;Ivan ivan.pavl 15143621000;514362 - Lung infiltrates documen
 
 - Diagnosed with Acute Re
 Covid-19), according to t
 
Phase 2 1. Demonstration of SA

 
 laboratory confirmed dia
 
Denmark ; Morten KjÃ¸bek Lambemorten.kjo+4522434186; Exclusion Criteria:

 
 - Age > 18,
 
 - No Trimethylxanthine co
 secondary effects),
 
Alexandre BLEIBTREU alexandre. 1.42E+08 - Infectious Disease Unit a

 
 - patients with IVF treatm
 
 - patients with signed info
 
 - patients with more than
 
Italy 

 
 
 2. Provision of informed co
 
 3. Diagnosis of active COVI
 
 
Phase 2 ; Karin Ried, PhD;Karin ;karinried ;00613991 National In 

 
 - Asymptomatic medical e
 Ministry of Health of the
 
onal [Patient Registry] Russian Fe ; Alexander B Romanovabromanov+79137172652;+7913 - Filled questionnaire befo
 
 - health care staff
 
 - working during the outb
 
 
 - refuse to participate
Egypt 

 
 
 - Positive COVID-19 test
 
 - Must be receiving medic
 
N/A Eric Schlorff Eric@seas 844-427-8100 - Non-pregnant fe

 
 - Person who has come in
 
 - Willing to take study dru
 
 
N/A United Ki ;;;; Vishwes Kulkarni;Am ;;;dr.mat ;;;+44 748 University - Confirmed current COVI

 
 - Hospitalized or in a hosp
 
 - SARS-CoV-2 positive
 
 - Initial COVID-19 symptom
 
Phase 2 United Sta Clinical Trials Adminis AteaClinic 888-481-1607 <

 
 - having a confirmed diagn
 
 - being mechanically venti
 
 - surviving to critical care
 
United Kingdom Exclusio

 
 - patients that did not star
 
 - patients for which a trea
Belgium ;; Frauke Vanden Meersc;rebecca.d ;09/332 37University tre
 
 - a) survivors of COVID-19
 disorder scale (DSM-V) m
 
 - b) age >18 years,
 
N/A ; Cristina Bravo Navarr ;david.bar ;+34 6493 Department -

 
 - Healthcare workers (HCW
 departments
 
 
 - None
United Sta ; ; Cristina S Albott, MD; ;leex6682 ;612-367-6University 

 
 - Informed consent as doc
 
 - Adult ICU Patients with A
 
Switzerlan ; ; Werner Z`Graggen, M ;werner.zg ;+41316327UniversitÃ¤ 

 
 - Age > 18 years;
 
 - Patients fitting classificati
; David Saadoun, MD, ;david.saa ;+33 1 42 PitiÃ©-Salp systemic lupus erythema

 
 1. Age over 40 with two or
 higher risk of mortality in
 
Phase 3 ; Michael J Borrie, MB ;memory@s;519-685-4Lawson Hea chronic lung diseas

 
 - Patients = 16 years old
 
 - Patients able to read and
 
 - Patients able to give info
 
United Ki ;; David J Lowe, MBChB ;david.low ;01414522 NHS Greate - Patients being triaged th
 
 Blood donors:
 
 1. Age: >18 and <60 years
 
 2. Body weight : >60 kg
 
 3. Confirmed previous SAR
 
N/A North Mac ; ; ; Rada Grubovic Rastvo ;;drgrubov ;;+389232 Institute f 4. Two negative SARS Co

 
 - All COVID-19 patients, ad
 
 - Tested positive by RT-PC
France ;; Nicolas Nesseler, doc ;;cecile.fe ;;0299282 Rennes Univ
 aspiration, bronchoalveo

 
 - Cancer patients at Steph
 
 - Demonstrate > 6th grade
 
 
 - None
United Sta ; ; ; Katherine Moxley, MD;;katherin ;;405-271- The Univer 

 
 - Men and Women positiv
 airway
 
 - Persons over 18 years of
 
N/A France ; Edouard KOCH;Edoua ekoch@ch-v
01 39 63 90 60;01 39 - patients of both sexe

 
 1. Participants are capable
 
 2. Male or female aged 18
 
Phase 1 United Ki ; John Radford;Wes Dal;wes.dale@;01614463 The Univer 3. Diagnosis of any solid tu

 
 - Patients suffering from C
 care unit.
 
 
France ;; Fanny BOUNES;Fanny ;bounes.f@;05 61 32 2University - Patients suffering from m
 
 - All participants of the M
 area).
 
 
France ;; Emilie BÃ©rard;Emili ;emilie.ber ;5 61 14 59Service d' - Opposition to participate

 
 HCW currently working at T
 Sunnybrook Health Science
 
Canada ;; Rima Styra, MD, MEd; ;Rima.styr ;(416) 340 University Exclusion Criteria: Not a hea

 
 - >18 years-old
 
 - Pregnant women admitt
onal [Patient Registry] Luis M Gomez, MD. Mluis.gomez 2.68E+09 Pregnancy, pre-operative
 Inclusion Criteria: Active Me

 COVID-19 Pandemic -
 
 Exclusion Criteria: NONE
 
 -
N/A United Sta ; ; Doug Delahanty, PhD; ;;kcoifma ;;1330672 Kent State 

 
 1. Age 18 or above
 
 2. Proven COVID-19 viral in
 enrolled.
 
Phase 2 United Sta ; Roger A Alvarez, D.O.; ;rogeralv ;305-926-7University 3. Presence of radiographi

 
 
 2. Confirmed positive test
Phase 1/Phase 2 Laura Fairbairn regulatory 403-921-5854 chain reaction (RT-PCR) a
 
 - Confirmed infection of S
 
 - Mild COVID-19
 
 - Symptoms of respiratory
 
 - Cough
 
 - Fever (T >38 Â°C)
N/A Mexico ; Guadalupe Espitia, M lupitaespi 01 5554471424;01 55 
 - Age of 18 years and olde
 
 
 - On invasive mechanical v
 
Phase 1 Canada ;; Duncan J Stewart, MD;djstewart ;+1 613 73 Ottawa Hosp
 - ARDS as per the internati

 
 1. Patients =18 years of ag
 
 2. Hospitalized with COVID
Phase 2 Mahalia Desruisseaux mahalia.de203-737-4057 breath, fever, or oxygen
Exclusion criteria: -
 - Not discharged t
 - For palliative car
 
Not Applic Australia Inclusion c 
Inclusion criteria: Medical practitione
Not Applic Australia Exclusion c
Exclusion criteria: Age <16
Not Applic Australia Inclusion c Miscarriage <20 wee
Inclusion criteria: Age greater than o
Not Applic Australia Exclusion
 Confirmed c
COVID-19 infection b
Exclusion criteria: 1. <18 y
 2. Patient is known to
Inclusion criteria:
 3. 1.
Known
Male active
or female,
mali
 4. WHO
 2. ICU admission dueClass III or IV
to strongly
Phase 1 / Australia 5.
 3. P/F ratio Venous
<300 mmHG thromboe
for less
Inclusion criteria: (1) Pregnant wome
 (2) Women aged >=18 years;
 (3) Pregnant women with an EP
 (4) Women
Exclusion
with criteria:
singleton (1)pregn
Wom
N/A China He-Feng Huang 910 Hengshhuanghefg +86 021 6 Internation (5 (2) Women with inte
0 China Hu Zhao 107 West Wesdhuzhao@+86 18560 Shandong UInclusion c Exclusion c
Inclusion criteria: 1. Subjects aged 20
 2. Those who work night shift at
 3. Subjects
Exclusion
who have
criteria:
worked
1. Patie
on
0 China Chen Jun 2 Xihuamen,chj200281 +86 15991 Shaanxi Tr 4. Those 2.
who Pregnant
voluntarilyandparticip
lacta
N/A China Zhang Wei 149 Dalian zhangwei_ +86 18982 Affiliated Inclusion c Exclusion c
0 China Zhang Wei 149 Dalian zhangwei_ +86 18982 Affiliated Inclusion c Exclusion c
Inclusion criteria:
 2. 1.Those
Agedwho >=18can
years
no
 2. On the
 3.
basisSubject
of routine
withprotec
the m
N/A China Shi Li 1478 Gongn15948000 +86 15948 Affiliated 3. Agreed 4.
to participate
Inability toinwork
this w
c
Inclusion criteria:
Exclusion
(1) criteria:
Pediatric(1)patien
Loss
RetrospectChina Zhiping Li 399 Wanyua zplifudan +86 021-6 Children's (2) Treated
 (2)with
theheat-clearing
time measurin a
N/A Iraq Fahmi Hussein Kakam Doctor cityRawizh.m +96 477 1 University Inclusion Exclusion c
Inclusion criteria:
 2. 1.Women
Conform whotoare
thepd
0 China Zhang Wei 528 Zhanghzhangw119+86 13601 Shuguang Ho 2. Aged 3.
18-65Combining
years old male or
patient
Inclusion criteria:
Exclusion
1. Patients
criteria: were
1. Pneu
di
 2. After 2.
treatment,
Have contraindica
the viral nuc
 3. Adults
 3.
overMental
18 years disorders,
of age m
N/A China Ming Wu 17 Lujiang ahslyywm +86 18655 The First A 4. 4. Patients wit
 (2)(1)
There isand lact
no rest
N/A China Min Fang (3)
110 Ganhe fangmin19 +86 18930 Yueyang Int (2) Patients respiratory
diagnosed freque
with mild
N/A China Allen Ting Chun LEE Prince of Wallenlee@c+852 2607 DepartmentInclusion c Exclusion cr
Inclusion criteria: 1. Adults (defined a
 2. The Exclusion
CT findings criteria:
of patients
1. The
wip
N/A China Xiansheng Zeng 39 Jingzhou31035505 +86 0710- Xiangyang 3. In-patients,
 2. Severe liver diseas
accompanied by f
Inclusion criteria:
 2. 1.Progressive
The novel exacer
coron
0 China Zhang Shunxian 9 Jinsui R zhangshun +86 15221 Guangzhou 2. It conforms
 3. Intothe
theacute
aboveexdiag
 2. 1.
Inclusion criteria: Patients
Patients with
havemenbe
N/A China Wang Lei 300 Guangz12711713 +86 13776 Thoracic su 2. Patients 3.whoPatients
were classified
without ca
Inclusion criteria:
Exclusion
1. Patients
criteria: meet
1. Miss
D
 2. Over 2.
18 years
28 day
old; follow-up is
 3. Patients
 3.with
Co-infection
hypertension,di
with i
RetrospectChina Zhang Hua-nian 100 Hong Kwhet_ctr@+86 027 8 Wuhan Wome 4. Co 4. Discontinuation of
Inclusion criteria: 1. No physical disco
16 yearscriteria:
old and Ifabove;
one o
N/A China Tang Jianyuan 39 Shi-Er-Qtangjiany +86 13910 Hospital of 3. Take (1)
the medicine
Has fever,
recommen
cough,
Not Applic Hungary Inclusion crExclusion c
Not Applic United Kingdom Inclusion c Exclusion cr
Not Applic United Kingdom Inclusion crExclusion c
Taydside
Clinical
Trials Unit
TASC
Level 3
Ninewells
Hospital
and
Medical
School
Phase III United Ki Margaret Band m.band@du
+44 (0)1382 383097 Inclusion c Exclusion c
Compreh
ensive
Clinical
Trials Unit
at UCL
Institute
of Clinical
Trials &
Methodol
ogy
90 High
Holborn
2nd Floor
Not Applic United Ki James Blackstone cctu.hoci@+44 (0)203 108 6584 Inclusion crExclusion c
Not Applic United Kingdom Inclusion c Exclusion c
Cambridg
e Clinical
Trials Unit
Cambridg
e
University
Hospitals
NHS
Foundatio
n Trust,
Addenbro
oke's
Hospital
Phase IV United Ki Elena Hernan Sa cctu@adde+44 (0)1223 349132 Inclusion crExclusion c
Cambridg
e Clinical
Trials Unit
Box 401
Addenbro
okes
Hospital
Hills
Road
Phase II/III United Ki Kerry Brusby add-tr.pro +44 (0)1223 25 4472 Inclusion c Exclusion cr
Not Applic Germany Inclusion crExclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase Exclusion criteria: Fo
 1. For
PregnantPart
or breast
1 (Ran
United StatClinical Trial Call Cent 121 Oysteracertamc@+1888 292 Acerta Pha 1. Ability
 2.
to understand
Are not committed
the purp
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Sta Renaud MARTIN 2 Avenue Mrenaud.mar555056349CHU de Li Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes Exclusion criteria: -Pa
Therapeu -non-eligible for ICU
tic use -Patients without leg
 -No -Patients
personal or olde
fami
IV): no -with proven
 -Ongoing
infection
pregnancy
with COV
France Direction Recherche 80 rue Bro promotion. 3.3E+11 Assistance -COVID19 -Patient
infection being
at s treate
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Asmaa Jobic 54 rue Henrasmaa.jobi 3.3E+11 Centre HosInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain INTERNAL MEDICINE PL DR ROB lboix@mutuaterrassa.HOSPITAL Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France CLINICAL OPERATION 5 rue de l Paul.Gineste@abivax ABIVAX Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Portugal;SpLaimonas Griskevicius Santariskiu laimonas.g 3.71E+10 Vilnius Uni Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Sta European Clinical Tria 103â€“105 clinicaltri +331 47 10Alexion Eu Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase Exclusion criteria: 1.
III): no 
Therapeu 2. Pregnancy or brea
tic use 
(Phase 3. Allergy to any stud
IV): no 
Belgium Caroline Devooght Herestraat caroline.devooght@uzUZ Leuven Inclusion c 4. Any medical condi
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase Inclusion criteria: â€¢ Clinically d
IV): no â€¢ Hospitalized
Exclusion criteria:
with COVID-19
 â€
Hungary;D Medical Information Edvard Thosrkiv.til@novartis.comNovartis H â€¢ Impaired
 â€¢respiratory
In the opinion
functio
of
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Greece Ioulia Tseti 14th km Naunipharma 3.02E+11 Uni-PharmaInclusion Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Serbia;Uni Regulatory Unit 103 Haros regulatory 3.61E+09 Accelsiors Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Greece President of the Boar 88 Michalaheadad@se3.02E+11 Hellenic In Inclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Gloria Luque Estudios ClÃ
gloria.luq
nicos. 7 planta,
3.5E+10
pabellÃ³n
FIMABIS
A. Hospital
Inclusion
Regional
c Exclusion
Universitario.
c Avda Ca
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
France Clinical Research Asso 2, Bd Ton e.mousset@3.36E+10 CHRU de T Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Belen Ruiz AntorÃ¡n c/ Manuel dmariabelen 3.49E+10 Hospital U Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain InÃ©s PÃ©rez Francisc/JosÃ© AtINES.PEREZFRANCISCOInvestigati Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
Exclusion
 1.
criteria:
Patient
 1.
hosp
IV): no 2. Hyperinflammation.
 2. Patient already wi
Spain Alberto Cecconi Calle Diegoalberto.ce 3.49E+10 Sociedad EspaÃ±ola
 3. Verbal
de 3.
CardiologÃ
informed
Pregnant,
aconsent
lactating
(wri
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Kingdom Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Denmark www.Clinicaltrials.govOle Wormsus@biomed4.56E+09 Aarhus UniInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase Inclusion criteria: Patients are el
IV): no 1.Age =18
Exclusion
years criteria: 1.E
United Sta Clinical Trial Informat 85 Wells A clinicaltrials@karyo Karyopharm 2.Confirmed
 a.Respiratory
laboratory diagnos
failure
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Germany KKS Marburg Karl-von-Fryasmin.mo 4.96E+12 Koordinier Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Inclusion criteria: Adult intensiv
tic use Confirmed COVID-19 infection
(Phase Need forExclusion
mechanical
criteria:
ventilation
 Pre
IV): no Endothelial
 Known
biomarker
hypersensitiv
(sTM) = 4
Denmark Kristine Pedersen Blegdamsvekristine.h 4.54E+09 Section fo Are Consent
the trial subjects
cannotunder
be o
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): yes
Spain InÃ©s PÃ©rez FrancisC/JosÃ© AtINES.PEREZFRANCISCOInvestigati Inclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Spain Miguel Cervero Avenida Ormcerveroj 3.49E+14 Miguel Cer Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Spain Lixin Jiang 2600 Hilltolxjiang@st 1.63E+10 Staidson B Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase Inclusion criteria: 1. Age =18 yea
IV): no 2. Participants
Exclusionmust:
criteria: 1.
United Sta GSK Clinical Support 980 Great GSKClinic 4.4E+12 GlaxoSmith a. have 2.
positive
Multiple
SARS-CoV-2
organ resu
fail

 
 1. Adult male or female pa
 
 2. Eastern Cooperative On
 for COVID-19 Expansion)
Phase 1 United Sta ; Medical Director;Take;globalon ;+1-844-66Millennium<

 
 - Parents/legal guardians
 consent for participation
 
United Ki ;; Matthew Snape, Profes;info@ovg.;01865611 University - Male or Female, aged 0 -

 
 specimen and/or detecti
 
Phase 2 United Sta ; Lorenzo Berra;Lorenz lberra@mg+16176437733; 2. Hospital admission wit
 
 1. Adults >18 years of age
 
 
 3. A confirmed diagnosis o
United Sta ; ; Girish B Nair, MD;Joa ;joanne.g ;248-898-0William Be 90% on room

 
 1. Males and females aged
 
 
 Presenting with one of the f
 
Phase 3 Brazil ; OtÃ¡vio Berwanger, P ;aro.clinic ;+55 (11) Hospital Is - Need for oxygen sup
 INCLUSION CRITERIA

 
 1. age >=60 years OR age 1
 
 1. chronic lung disease
 
 2. chronic cardiovascula
 
Phase 4 Poland Marta Duda-Sikula, M marta.dud 48 71 784 00 34 

 
 - Evidence of a positive SA
 three days
 
 - Not currently hospitalize
 
Phase 3 United Sta ; ; ; Catherine Oldenburg, ;;ACTIONTr;;(415) 51 University - Willing and able

 
 - Children < 18 years old
 
 - Admitted in French pedia
 
 - With a confirmed COVID
onal [Patient Registry] France Corinne Levy, MD corinne.lev 1.49E+08 

 
 1. Male or female subjects
 
 2. Diagnosis of SARS-CoV-2
United Sta ; ; Raj Makkar, MD;Siegf ;clinicalr ;310-358-3Cedars-Sin polymerase cha
 
 - Patients admitted to hos
 warranting a chest CT sca
 
 
onal [Patient Registry] France Gilles MANGIAPAN, gilles.mang 3.32E+10 - Patient not a

 
 - to. Covid 19 positives b. So
 odynophagia, respiratory di
 
 c. Age between 18 years an
 
Colombia ; ; yohanny andrade, res ;;eduardoi ;;+573007 Genesis Fo Cri

 
 - Patients from the age of
 
 - Coronavirus infection co
 
Phase 3 Russian Federation - Hospitalization of the pa

 
 
 
 - Hospital personnel takin
Phase 4 United Sta ; ; ; ; Jeffrey D Cirillo, Ph ;;;;jdciril ;;;;979 43 Texas A&M infection and providing, o

 
 - Symptomatic with COVID
 clinical symptoms)
 
 - Call into office within the
 
Phase 2 United Sta Priya Nori, MD Montefiore 

 
 - Legal age
 
 - Currently working on a h
 
 - Give informed consent
 
 
United Sta ; RubÃ©n Alvarado, Ph ;ralvarado ;+56 2 297 University 
 
 1. Adult St. Jude employee
 naive, or have a recent d
 
United Sta ; ; Paul G. Thomas, PhD; ;referralin ;866-278-5St. Jude Ch 2.

 
 1. - Subjects who voluntar
 
 2. - Both genders.
 
 3. - Subjects aged between
 
Phase 3 ;;;;;; MartÃn MartÃn, MD;Nicolas
;;;;;;gang
Batlle,
;;;;;;809
MD;Raymundo
3 ;;;;;; HernÃ¡ndez;Natalia
 4. -Subjects
GarcÃcapable
a;M. Polanco;G
of c

 
 - Patient initially hospitaliz
 
 - Admitted in post-ICU setti
 
 - Age > 18 years old;
 
France ; Aymeric LE NEINDRE, ;nbennasr@;01.44.12. HÃ´pital For - Members

 
 - Age = 18 year
 
 - All patients refused to do
 and preferred private ho
 
Early PhaseEgypt Mohammed K Elbadrawy, PhD Chest depa - Ch

 
 Household members who m
 study participants:
 
United Sta Tina V. Hartert, MD, MPH Vanderbilt - The index participant, de

 
 - Patients aged 18 years a
 
 - Hospitalization due to pr
 
Regis G Rosa, MD regisgoula 5.55E+12 - Meeting eligibility criteri
 
 Age ranging from 3 to 10 ye
 
 - Children attending to sch
 
 - Informed consent
 
 - French insurance subscri
 
N/A France Exclu

 
 
 
 - Willingness to comply w
N/A Nicholas D Young, Ph ndyoung@(414) 214-7140 <

 
 - Confirmed cases of Covid
 
 - Mild to severe clinical pr
Phase 1/PhCanada;Mo Aldar Bourinbayar, MD/PhD Immunitor National Ea

 
 - COVID-19
 
 
 - kidney transplantation
 
 - eGFR < 30 ml/Min
 
 - dialysis within last 90 da
 
Germany Timo Brandenburger, timo.brand -8107220 

 
 1. Patients of both gender
 
 2. Patients infected by SAR
 
Phase 2 Argentina ; Alejandro Krolewieck alekrol@h +54-911 3183 8673;+ 3. Hospitalized patients wi
 
 - Patients with cancer
 
 - Patients who are receivin
 diagnosis
 
 - Age 18+
 
onal [Patient Registry] Denmark ; Stefan S Jeppesen, M ;stefan.je ;30502948 Odense Uni E

 
 - Confirmed cases of SARS
 by the Ministry of Health
 
Phase 3 Senegal ;;; Moussa Seydi, MD;Ama
;;;Fabien. ;;;002217 Fann Hospit - Adults (=18 years if

 
 - Students from 1st year o
 and Tourism of the Unive
 
N/A Spain - Students from 1st year o

 
 - patients with positive co
 
 
 - patients with negative te
N/A Egypt ; Mahmoud Alalfy, PhD ;mahmouda;01002611 Algezeera 

 
 - ARDS according to Berlin
 
 - PCR confirmed COVID-19
 
 - Length of mechanical ve
 
Phase 3 Argentina ; ; ; Pablo O Rodriguez, M ;;prodrigu ;;+541152 Centro de EducaciÃ³n
 Exclusion
Medica Criteria:
e Investigaciones
 Inclusion Criteria (COVID-19

 
 - Patients 18 years old or a
 
 - Positive confirmation wi
Italy;San M Emanuele Rezoagli emanuele.r039/2339323 naso-pharyngeal swab, b

 
 - COVID-19 suspected cas
 
 - COVID-19 confirmed cas
onal [Patient Registry] ; Judith Ju Ming Wong; ;judith.wo ;+6592355 KK Women's
 coronavirus; serum spec
 
 1. Patient admitted to the
 
 2. Patients who were cons
 
; Jonghun Lee, M.D., p ;guenheu@;+82-53-65Daegu Cath Exclusion

 
 - Adults (= 18 years of age
 
Phase 2 Italy ;; Lorenzo Dagna, MD;L ;dagna.lor ;+3902264 Ospedale S is not capable of giving c

 
 
 - Patient undergoing treat
onal [Patient Registry] France ; CÃ©cile GIRAULT;Astr;astrid.lie ;+33 (2) 99 Federation not yet started treatmen

 
 
 - Male of female gender
 
Phase 2 Greece ; Garyfallia Poulakou, ;egiamare ;+3021074 National Ka case of patients una
 Inclusion criteria for the pha

 
 - Healthy adults from 18 t
 
Phase 1/PhCanada ;;; Scott A Halperin, MD ;;helen.ma ;;484-919- Canadian C - Able to provide consent

 
 - All the cases received ga
 
 
 - High-risk personal throu
N/A China ;; Bin Lu;Yue Hu;Yue Hu,;jiuyueqi ;+8615158 First Affil n

 
 1. Age greater or equal to
 
 2. Able to provide informe
 
 3. Proven diagnosis of COV
 
N/A Australia ; Sze-Yuan Ooi;Sze-Yua ;SzeYuan. ;+6129382 Prince of W 4. Pati
 
 - Age >=1 year (as children
 
 - Household contact of so
 
N/A United Sta ; ; Anthony Sung, MD;La ;lauren.b ;919-668-2Duke Unive - Willingness to stop takin

 
 - adult patients with ARDS
 
 - need for mechanical ven
 
 - P/F ratio <200mmHg
 
 - PEEP of at least >5cmH2
 
N/A ; Marcus Lance, MD, Ph;mlance@h;+9743353 Hamad Medi
 

 
 - Positive SARS-CoV-2 (PCR
 
 - No requirement for hosp
 
 
Phase 2 ; Harry P Selker, MD;Do;ddulko@tu;617.636.7 Tufts Medi - Evidence of respiratory f

 
 
 
United Kingdom - Patients who have devel

 
 - All patients with an infor
 
 - Admission to emergency
 
 
N/A Turkey ; Ramazan Guven;Seda drramazan +902124041500;+905 - Absence of i

 
 - Ability to obtain informe
 knowledge regarding Bar
Phase 2 ;; Carlomaurizio Montecu
;;sara.sar ;;0382501 Rheumatolog
 th
 
 - To be completed at least
 autohemotherapy in the
Turkey Kardelen Gencer Marmara Un
 

 
 1. Adult aged =18years old
 
 2. Provide voluntary, fully
 procedures are conducte
 
Phase 3 3. Able

 
 - Potential participants wi
 distancing due to the cur
N/A Canada Sandy L Courtnall scourtna@u250-472-5288 p

 
 - subjects diagnosed with
 mechanical ventilation;
 
 - have received invasive v
 
Spain MarÃa-Natividad Seisdedos-Nunez,
marianativ 3.49E+10
PT, MSc 

 
 1. Patients aged 50 years o
 and eligible for ambulato
 
Phase 3 ; Nils Kucher, Prof.;Nils ;nils.kuch ;+4144255 University 2. Presence of respiratory

 
 - General population with
 Governerate, Egypt and a
 
 
Egypt - be

 
 - Adults aged 18 or older (
 
 - Adults aged 56 or older (
 
 - Children aged 5-12 inclu
 
Phase 2/PhUnited Ki ; Andrew Pollard, Prof; ;vaccinetr ;01865 61 University - Able and willing (in
 
 - Outpatients presenting t
 (ED) or drive-through CO
Phase 2 ; Marvin R McCreary;Ma;suppleme ;(614) 526 Mount Carm
 

 
 - SARS-CoV-2 PCR-confirm
 
 - Presence of acute hypox
 
Phase 2 ; Jenny Low, MBBS;Jen ;jenny.low ;65767757 Singapore - Saturation < 94% on roo

 
 Egyptian population
 
 
 none
Egypt ; Noha el bassiouny, P dr_nosa07 045317617;04531761 

 
 Egyptian population of diffe
 
 
 none
Egypt ; Noha El Bassiouny, P dr_nosa07 045317617; 

 
 All consecutive patients wit
 to the ICU and survived of I
France ; ClÃ©ment SACCHERI; saccheri.c 0033492035510; guardia

 
 - All patients arriving at su
 gastrointestinal surgeries
 
; Zhongtao Zhang, M.D.;pang_kai ;18811792 Beijing Fri Exclusion Criteria

 
 
 - Admitted to hospital (wa
 
 
Phase 3 Canada ;;; FranÃ§ois Lamontagne;;marie-he ;;819-346- UniversitÃ - Receiving or has received
 
 - Patients with COVID19 u
 
 - Adult (18 Years and abov
 
Phase 2 Saudi Arab ; Abdulrahman Koshak, aekoshak@6400000;6400000 - Written informed consen

 
 - RT-PCR + SARS Cov2 pne
 
 
 - < 18 ans -* GOLD 3 or 4 C
Belgium 

 
 - patient suspected of COV
 
 
 - patient unsuspected of C
Monaco 

 
 1. COVID-19 patients who
 
 2. Patients aged over17 ye
 
 
Australia Carol Hodgson, PhD carol.hod 6.14E+10 - Previous enrolment in th

 
 - all 5th year dental stude
 universities was invited t
 
 
Egypt Maha Moussa Fayoum Uni - in

 
 specimen type < 5 days b
 
Phase 1 United Sta ; ; Premal Lulla;Premal L ;lulla@bcm;832-824-4Baylor Coll 2. Currently hospitalized a

 
 - Moderate COVID-19: Ad
 oxygen therapy (any leve
 
Phase 2 Jeanine D'Armiento, jmd12@cum
212-305-3745 - COVID positive by PCR o
 
 1. 18 years of age or older
 
 2. Diagnosed COVID-19 dis
 
Phase 2 ; Hope Pharmaceuticals;question ;480-607-1Hope Pharm
 3. Able to sign the informe

 
 - Infants born to mothers
 
 
 - If PCR values of mother n
onal [Patient Registry] Turkey ;; Mehmet K Kanburoglu;kanburog ;+9053266 Head of Pe 

 
 - clinical suspicion of coro
 
 
 - unable to give written in
N/A United Ki Karen Tanner research@t 1.82E+09 

 
 1. Age: Male or female pati
 
 2. Respiratory samples tes
 
 3. Initial symptoms will wit
 
Phase 2/PhBanglades ; Ahmedul Kabir, MBBS,ahmedul_9+88 01720910541;+8 

 
 - Age>18 years old
 
 
 - Opposition to participate
France ; Gwenaelle Jacq, RN;G gjacq@ch-ve
013963856;CH Versail 

 
 - Received confirmed posi
 
 - Age >18 years old.
 
United Sta ; Fadi Haddad, MD;Kath;kathryn.m;858-939-7Sharp Heal - Access to a phone in the
 
 - Subjects age 18 to 80
 
 - Subjects with PCR docum
 transfer to intensive care
 
N/A United Sta ; ; Ali R Rezai, MD;Padma;ptirumala ;30429349 West Virgin - B

 
 
 - Being diagnosed with CO
 
N/A Turkey ;; Esra Pehlivan, PhD;Esr;fztesrak ;+90 216 4 Saglik Bilim - Having technological fac

 
 - The patients with Corona
 
 - Positive result on real-tim
 
China ; jianheng zhang, MD;j ;58283325 ;13480226 First Afili - Positive result on chest c

 
 - Covid-19 testing has bee
 hospital.
 
 
 - Consent obtained
 
United Sta ; ; Melphine Harriott, Ph ;melphine. ;313-3436 Ascension S 

 
 - Man or woman aged 75
 
 - SARS-coV2 infection con
 
Phase 2 France ; MÃ©lody FORT;Laure mfort@ch-ve
+33139239776; - Hospitalized in the acute

 
 
 - Being diagnosed with FM
 
Turkey nejla uzun, MSc, Pt Istanbul U - A diagnosis of BiH at leas
 
 1. Respiratory rate > 30 br
 
 2. Severe respiratory distre
 PLUS
 
Phase 2 Banglades ; ; Mohammad S Rahman,;srkhasru ;+88 0197 Professor 3. Radiologica

 
 - COVID 19 positive patien
 
 
Phase 2/PhEgypt ; sherief Abd-Elsalam, A;sheriefa ;00201147 ass. Prof. 

 
 - doctors from different sp
 
 
 - doctors who stopped wo
; Riham H Raafat, MD;R;drriham8 ;01000948 Ainshams u 

 
 - Participant has clinical in
 sample from which whol
 
N/A United Ki Justin Pepperell, MD justin.pepperell@tst.nhs.uk Exclusion Cr

 
 1. Male and female adults,
 
 2. Current diagnosis of Adj
Phase 2 United Sta ; Matt Turzilli;Ann Drai mturzilli 212-595-5012;212-59 Diagnostic and Stat

 
 - Adults over 40 years of a
 
 - Tested positive for SARS
 
 - Being treated as an outp
 
Phase 2 ;; Michael Farkouh, MD,;;Michael. ;;416-340- Peter Munk
 - confirmed mild COVID-1
 
 
 - unable to take oral medi
 
 - pregnancy or breast feed
 
Phase 2 Korea, Republic of 

 
 1. Should be at least 18 ye
 
 2. Male or female,
 
 
Phase 3 United Sta ; James Welker, MD;Pa ;pzheng@ ;20275168 Anne Arund 4. Able to sign the

 
 - age >=18 yrs
 
 - positive for reverse trans
 respiratory syndrome (SA
 
N/A Italy Cesare Perotti, MD Foundation - Acute res

 
 
 - In Europe: Healthcare wo
Phase 3 Australia ; Prof Nigel Curtis;Prof ;nigel.curt ;+613 934 Murdoch Ch working onsite in patient

 
 - Patients >/= 18 years old
 
 - Hospitalised with PCR-co
 
 
onal [Patient Registry] Belgium ;; Joost Wauters, MD Ph;joost.wau ;00321634 UZ Leuven; - Age < 18 years old

 
 - A healthcare worker at hig
 
 - Persons primarily workin
Phase 3 United Sta Radha Rajasingham, MD University staff, tri
 1. Laboratory-confirmed SA
 public health assay in an
Phase 2 Vietnam ; Guy Thwaites, PhD. M;jday@oucr;+84 8 392 University hospital admission in the
 
 
 2. Hospitalised;
 
 3. Confirmed or suspected
 
Phase 4 United Ki ;; Richard Beale, MD;Nd ;ndaba.maz;02078485 Guy's and 4. National Early Warning

 
 - Adults (>= 18 years) adm
 
 - Severe confirmed COVID
N/A France ;; Muriel FARTOUKH, P ;muriel.fa ;01 56 01 Assistance parenchymal infiltrate; a

 
 - Patients between 18-80
 
 - Confirmed HCoV-19 infe
 
 - Temperature above 38.0
 
Phase 1/PhDenmark - Pulmonary symptoms an

 
 
 - Telephone consultation
 
 
 - New patient in the depa
France ;; GÃ©rard Amarenco, Ph
;greengrc ;01560175 Sorbonne U 

 
 - =18 years of age
 
 chain reaction (PCR)
 
Phase 3 Denmark ;;;;;;; Sandra Hansen, MD;Si;;;;;;;thom ;;;;;;;+45 Hvidovre Un
 - Evidence of pneumon

 
 
 
 - Mild to moderate sympt
Phase 2/PhGermany Michael Bitzer, MD michael.bi +49 7071 2985629 hospital admissio
 
 - Men or women 18 to 80
 consent
 
 
Phase 2/PhUnited Sta ; Christine Johnston, ;cjohnsto ;206-520-4University - Lab

 
 - trouble "making ends me
 
 
N/A Canada - confirmed positive for CO

 
 For all three groups:
 
 - Major patient
 
 - In patients in ICU
 
 - Patients intubated and m
 
France ;; Saad Nseir, MD,PhD;S ;saadalla.n ;03204459 University H 

 
 - Age =18 years old
 
 - Confirmed COVID-19 pos
 
 - Within 24 hours of mech
 
 - Assent or professional as
N/A ; Michael P Grocott, MD;danny.pra ;02381204 University

 
 
 2. Age >/= 18 years, and
 
 3. A history of SARS-CoV-2
 
United Sta ; ; Steven Deeks, MD;Reb;rebecca.h ;415-476-4University 

 
 - All patients accepted to
 will be enrolled in the stu
N/A Italy 
 
 Patients who meet all of the
 study:
 
 
 2. Must have laboratory co
Phase 1/Phase 2 Madhavi Malladi, PhD M.Malladi 1.513-384-6717
 Patient Participant Inclusion

 
 1. Healthy American Socie
 scheduled for elective su
 
N/A Canada ;; Anton Chau, MD;Tim ;timothy9 ;613 816-2 University 

 
 - adults (from general pop
 
 
 - younger than <18 years
Australia; ; Aleksandra Luszczynsk;aluszczy@;+4860457 SWPS Unive 
 Inclusion Criteria (Phase 1):

 
 - Healthy adult males or fe
 (Phase 1). Healthy status
Phase 1 Australia Biljana Georgievska B.Georgie 61 3 8593 9817 

 
 - Hospitalized
 
 - COVID-19 pneumonia co
 specimen and radiograph
 
Phase 3 United Sta ; Clinical Trials;Refe ;global-ro ;888-662-6Hoffmann-L - SpO2 < 94%

 
 
 - Patients COVID-19 :
 
 - hospitalized for less th
N/A France ; Florian REIZINE, MD;F florian.rei 02 99 28 42 48; (P
 
 - Age = 65
 
 - pneumonia at CT scan
 
 - PaO2/FiO2 =300 mmHg
 
 - Presence of one or more
Phase 2/PhItaly Raffaele Landolfi, Prof raffaele.la 06 30154435 
 - Proven or expected COV
 less than 12 hours,
 
 - Patients requiring oxyge
 
France ;;;; Antoine KIMMOUN, MD
;;;;a.kimm ;;;;+33 3 8 CHRU de NA
 - A

 
 - Patient or designated pr
 enrollment in the study.
 
 - COVID-19 PCR positive o
 
Phase 2 United Sta ; ; Boglarka Gyurkocza, ;gyurkocb ;646-608-3Memorial S 

 
 - Being admitted to one o
 
 
 - Expected ICU stay greate
 
Brazil ;; Juliana C Ferreira, MD ;juliana.fe ;+5511983 University of
 
Sao Paulo - hospital das ClÃnicas d

 
 - Individuals who are betw
 
 - Individuals who are fluen
 
N/A United Sta Ekaterina Ninova, Ph.D. University - Individuals who are able

 
 - Expected ICU stay > 48 h
 
 - Rectal and nasal BMR sc
 
 
France ;; Saad Nseir, MD,PhD;S ;saadalla.n ;3.20.44.4 University H - Patients aged <
 
 - Any physician who is cur
 provisional, or post-grad
 
 
Canada ; Jonathan Bailey, MD jon.bailey 902-473-4326??????? 

 
 SARS-CoV-2.
 
Sweden ;; Erland Ã–stberg, M.D. ;bjorn.sjo ;+46-73-6 Region VÃ¤ - Patients admitted to the

 
 - PCR-confirmed Covid-19
 
 - respiratory failure
 
 
 - diagnosed cancer
Phase 1/PhBelarus ;; Andrei Y Hancharou, Dr;; ;; Director, t 

 
 - Age 18 or older
 
 - Admitted to a study hosp
 
 - Active COVID-19 defined
Phase 1/PhSweden ; Johan Ursing, MD, PhD;joakim.dil ;+46 (0) 72 Danderyd H samples

 
 - Patients over 18 years of
 
 - Diagnosed Covid-19 by R
 
France ; Ferhat MEZIANI, MD, ferhat.mez33 3 69 55 10 24;33 3 

 
 1. Heightened anxiety trigg
 
 2. Anxiety it least mild-mo
 
 3. English speaking and livi
 
N/A United Sta ; Brian A Fallon, MD;El ;eb3048@c;646-774-8Columbia Un
 - Inclusion criteria:
 
 - Patients hospitalized in
 criteria) equipped EIT ov
 
 - Exclusion criteria:
 
France ; Hadrien ROZE, Dr;Hadhadrien.ro 557656866;05 57 65 6 

 
 1. Healthcare staff (Physici
 
 2. Directly involved in care
 
;;; Leticia Peroni, MD;V ;;;maria.st ;;;+54 011 HIBA;HIBA; 3. Working in any of the tw

 
 1. Adult =18 years of age
 
 2. Laboratory-confirmed S
Phase 1 United Sta ; ; Katharine J. Bar, MD;K;BarK@pen;(215) 349 University approved assay in any sp

 
 - Admitted to ICU in Madr
 
 
 - Admitted to ICU without
onal [Patient Registry] Spain ;; Miguel SÃ¡nchez GarcÃ
;miguelsan
a, MD;Miguel
;+3491330
S Sanchez
Hospital
Garcia,
ClÃ
MD;Miguel
 
nico San Carlos;
Sanchez Garcia, MD. PhD

 
 - Diagnosis of SARS-CoV-2
 days before enrollment o
N/A ; David Kozono, MD, P ;tjohnson ;(617) 582 Brigham an sugg

 
 -
 
 
 - Under the age of 18 and
United Sta ; Alexandra M DelCollo delcollo@n856-769-0090;856-76 

 
 - Ability to provide inform
 
 
 - Prior medical or laborato
 
United States - Prior experience with CO
 
 - Enrollment within 24 ho
 
 - Patients with oxygen sat
 
N/A United Sta ; ; Ashik Tal, MD;Vladisl ;vzamfirov ;+1-410-23Beyond Air - Shortness of

 
 - Patients contacted by te
 pandemic in outpatient c
 
onal [Patient Registry] - Follow-up of patients wi

 
 - Man or woman, age>18
 
 - Diagnosis of cancer (solid
 
 - Out patient or patient Un
 
 
N/A ; Gwenaelle GRAVIS, M ;drci.up@ip;+3349122 Institut Pa 
 study procedures. Subjec
Phase 2 United Ki ;; Medical Monitor;Ther ;medinfo@;1-855-633Theravance 

 
 - Patients who have recov
 
 - Adult patient (= 18 years
 
N/A MAHEVAS Matthieu, matthieu. 01 49 81 20 76 - Adult patient (= 18 years

 
 
 - COVID PCR + patient: Pa
 
France ;; Christine Katlama, M ;yasmine.d ;33142164 Pitie-Salpe - or COVID-like patient: Pa
 
 - pregnant woman
 
 - diagnosed with Sars Cov
 
 - singleton or twin pregna
 
 - informed consent
 
N/A France ; Benazet Louis;MOTTETlbenazet@c+33 381 219 147; Exclusion Crit

 
 - Patients with a diagnosis
 
 
 - No informed consent
 
Spain Jose L Casado, Md, Ph jcasado.hr 3.49E+10 - Presence of chronic ther

 
 - Signed inform consent
 
 - COVID 19 with the mild a
Phase 2 Russian Fe ; Julia Begrambekova, julia.beg +79854679273;+7985 polymerase chain reactio

 
 - Over 18 years of age hos
 definition of "Confirmed
N/A Maria M Piskorz, MD neurogast 5.49E+12 (https://www.argentina.

 
 - Samples with positive RT
 IEDCR will be selected as
 
onal [Patient Registry] Banglades ; ; Zahid Hassan, MBBS, ;sultanaro ;+88 0171 Bangladesh - Samples with negative R

 
 - Male and females with 1
 
 
 - More than 3 days of sym
 
Phase 3 Brazil ; Viviane C Veiga, MD;V;veigavivi ;+55-11-99BeneficÃªn -
 
 
 - An understanding, ability
 and restrictions.
 
United Ki Jorg Taubel, MD Richmond P Exc

 
 - All COVID-19 positive priso
 
 
 - Any patient being shifted
Pakistan 

 
 1. Children below 18 years
 
 2. Children below 18 years
 
 
Egypt ;; Fatma Ebeid;Fatma Eb;dr.fatma ;+2010955 Excuitive 
 
 - Patients admitted for les
N/A France Florian Reizine, MD florian.rei 02.99.28.42.48 ventilation according to t

 
 - Confirmed COVID-19 (po
 specimen)
 
 - Patients older than 18 ye
 
Phase 2 ;;; FranÃ§ois Lellouche, ;;;pascale. ;;;418-656 IUCPQ-UL;

 
 1. Healthcare workers volu
 
 2. Understanding the stud
 
 3. Having between 18 and
 
Phase 3 Argentina ; ; ; ; ; ; ; ; Waldo H Belloso, MD; ;;;;;;;;;;; ;;;;;;;;;; Hospital I 4.
 
 - Adults 18 to 70 years of
 
 - Serious or critically ill pa
 
Phase 2 Mexico ; ORLANDO CARILLO-TO;gmemiinv ;+5255423 Hospital G - Meet the criteria for Dise

 
 - Patients already followed
 subscribed to L'EncÃ©ph
 
 
; Arnaud Leroy, MD;Ar ;arnaud.ler;03 20 44 University H - Ref
 Common criteria for the 3 p

 
 - Persons over 18 years of
 
 - Beneficiary or person en
 
 Population 1 (Patients) :
 
N/A Thierry Naas thierry.na 3.31E+10 - Patie

 
 - At least 18 years of age
 
 - Confirmed SARS-CoV-2 b
 
 - Beginning of symptoms i
 
Phase 2/Phase 3 -

 
 - Confirmed infection with
 
 - Hospitalization in Intensi
 
 - Age over 18 years Old
 
France ; Charles TACQUARD, charlesamb33 3 69 55 16 08;33 3 
 1. Age of 18 years or more
 
 2. Negative test (PCR) for S
 
 3. The absence of clinical m
 
Phase 4 Russian Fe ; Evgeny Mikhailov, MDevgenymik +79217553237;+7812 
 
 - Individuals sampled from
 dialling.
 
 - Subjects aged 18 and old
 
Russian Fe ; ; Lubov Barabanova, MD;barchuk.a ;+7812386 Clinic "Sca -

 
 1. Patients who have evide
 
 2. Patients with symptoma
 following
 
Phase 2 United Sta ; ; Adam Nelson, MBBS, F;Jamie.Wi ;513-803-1Children's 

 
 - Patients >18 years infecte
 for mechanical thrombecto
 
France ;; Federico Cagnazzo, M ;f-cagnazz ;06 95 05 UH Montpel
 - 18 Years and older ;
 
 - hospital stay less than 48
 
 - length of hospital stay to
 
Brazil Bruno Gualano, Phd gualano@u 5.51E+11 Ex

 
 
 
 - Patients who have inher
 
Phase 4 Mexico ;; JosÃ© Meneses CalderÃ³n,
;inv.mater
MD.;Hugo
;+52-722-2Research
Mendieta ZerÃ³n,
U 
MD., PhD.;Nancy
- Patients
SantamarÃa Benh

 
 - Male or Female, aged > 1
 
 - With a positive diagnosis
 symptoms
 
France ; Renaud Tamisier, MD,;rtamisier ;+33 476 7 University - Signed informe
 
 - Age >18 years old
 
 - COVID-19 positive on (RT
 with detectable SARS-Co
 
Phase 4 United Sta ; ; Maria T DeSancho, M ;mtd2002@;646-962-2Weill Medic -

 
 - Covid-19 patient admitte
 
 
 - patients who do not agre
N/A Israel Michael Cleiner, M.D. shochat@hy
972-50-6246926 

 
 1. Age 18 and older.
 
 2. Symptoms suggestive of
 smell/taste).
 
N/A ;; Joe Verghese, MBBS; ;;emmeline;;7184303 Albert Eins 3. Covid-19 screening don

 
 1. aged 18 or over,
 
 2. with pancreatic adenoca
France ; Olivier BOUCHE;Olivi obouche@c03 26 78 31 13;03 26 biopsy but with suspicion

 
 1. Moderate or severe ARD
 
 2. SARS-CoV2 positive test
 
 
 
Germany ; Alexander Zarbock, M ;aki@anit. ;+49-251- University Ex

 
 - Registered with the Max
 
 - Were scheduled to recei
India ; Rajesh Saxena;Rajesh rajesh.sa 9818474003;9818474 
 
 - A patient who has under
 Hospital or currently belo
 
Sweden ;;; Mihai Oltean, MD, Ph ;;;john.m. ;;;0046(0) Transplant - Must be able to take par

 
 - Patients = 18 years old w
 infection, admitted in the
 
Spain ;; LluÃs Masana, Dr;LluÃs;luis.masa
Masana, Dr;LluÃ
;+3497775
s Masana,
IISPV; Dr Exclusion Cr
 Inclusion Criteria for Part 1

 
 1. Adult age 18 or older
 
 2. Previous positive test re
 
Phase 1 United Sta ; ; ; James B Adams, PhD;Sa
;;jkkirby1 ;;480 234 Arizona St 3. Able to communicate cl

 
 - adult patient with diagno
 
 
 -
Egypt Mervat Eissa Cairo Unive 
 Cohort A:
 
 
 - Physicians
 
 - Nursing staff
 
 - Midwives
 
Austria ;; Christian Hengstenberg;christian ;+43 1 404 Medical Uni - Medical-technical assista

 
 - Patient records with the
 
 - Patients over 18 years of
 
 - Patients of both genders
 
Mexico ; Orlando R Perez Niet ;Orlando_ ;55 1015 4 Hospital Ge - Patients diagnosed with
 
 - Diagnosis of acute sever
 infection defined by RT-P
 
Phase 2 ; Alma M Perez, MD;Car;carmen.de;+52 (33) Centro de - Asymptomatic, or with m

 
 
 - Owning a smartphone an
 
 
Canada ; StÃ©phanie Chevalierstephanie. 514-934-1934;

 
 1. Confirmed clinical diagn
 
 2. Ability to provide inform
 
 3. Adults aged over 40 yea
 
United Ki ;; Neil J Greening, PhD ;hjcm1@lei;+44 (0)11 University <

 
 - All potential volunteers i
 
 
; Alexander R Precioso, ;alexander ;+55 11 37 Instituto b - All potential eligible parti

 
 - Ages 12 to 17 years old
 
 - Meet criteria for anxiety
 
 - Parent(s)/primary caregi
 
N/A Canada ; Suneeta Monga, MD, ;suneeta.m;416-813-8The Hospita

 
 
 - COVID-19 disease falling
 
Phase 2 United Sta ; Kent Holland, MD;Sta ;stacey.b ;404-780-7Northside H - Critical disease: respirato
 
 - Consecutive patients adm
 2020.
 
United Sta Sanja Jelic, MD Columbia U - Laboratory confirmed CO
 Inclusion Criteria (all require

 
 - Positive SARS-CoV-2 diag
 
 - Severe pneumonia defin
Phase 3 Italy ;; Marco Marietta, MD;M;marco.mar;05942246 Azienda Os
 1. Adult patients (= 18 yea
 
; Nuttha Lumlertgul, M ;Marlies.O ;0044 207 Guy's & St infection res

 
 - Consecutive adult patien
 hospital due to COVID-19
France ;; Benjamin Lallemant;B ;benjamin. ;04.66.68. CHU Nimes 
Exclusion criteria: 1.
Not Applic Australia Inclusion c 2. Patients with ex
Inclusion criteria: Aged 18 years or a
 COVID-19Exclusion
positivecriteria:
and undergoi
High ris
 Able to No
follow and
consent
complete
signedins
 Able to 
provide own informed c
Not Applic Australia;United States of America Inclusion c Exclusion cr
Exclusion criteria: Staff in
 - Junior Medical Offi
Inclusion criteria:
 - ToGeneral
be eligible
practitio
for in
 -
 - Doctors must be Doctors not emp
Staff Specialis
Not Applic Australia - Doctors employe
Inclusion criteria:
Exclusion1. criteria: 1.
 2. At 2.
least 18 Currently
years of agereceiv
 3. Living
 3.in NewCurrently
Zealanddoing
 4. Ability
 4. to provide
Diagnosed
informed
with
Not Applic New Zealand 5. Ability
 to u
Inclusion criteria: Adult patients who
Not Applic Australia;Italy;United Kingdom;Germany;Canada;Belgium A Exclusion c
 2. 1.
Inclusion criteria: Recent
Adultscardiac inte
with posi
 2. Body 3.
weight Pulmonary
more thanfibrosis
45kg;
0 Iraq Dr. Houssam RaaD Bordeaux2 raadhouss +96 1 710 Beirut Arab 3. Consent
 4. forEnd
voluntary
stage kidney
participo
RetrospectChina Ze-Lin Zhang 183 Yiling 42131734 +86 18671 Yichang CeInclusion c Exclusion c
Exclusion criteria: Non rec
RetrospectChina SHUI TIEJUN 158 Dongsi67637539 +86 13987 Yunnan CenInclusion c Refused to attend in
Inclusion criteria: People with demen
N/A China Prof. Timothy Kwok 9/F., Lui C tkwok@cuh+852 3505 Chinese Un FamilyExclusion
caregivers: c Family caregi
0 China Suixin Liu 87 Xiangya liusuixin@ +86 13618 DepartmentInclusion Exclusion c
Inclusion criteria:
Exclusion
1. Male
criteria:
or non-pre
1. Seve
 2. With 2.
sustained
Pregnancy
positiveordetec
brea
4 China Jiqiu Wen 305 Zhongswjqkidney +86 13851 Jinling Hos 3. The 3.
last time
Known
detection
allergy
of or
vira
h
Not Applic Bangladesh;India;Pakistan Inclusion c Exclusion c
MRC
Epidemiol
ogy Unit
University
of
Cambridg
e School
of Clinical
Medicine
Box 285
Institute
of
Metabolic
Science
Cambridg
e
Biomedic
al
Campus
Not Applic United Ki Jenny Woolston jenny.wool+44 (0)1223 769204 Inclusion crExclusion cr
Not Applic Italy Inclusion c Exclusion cr
Not Applic Spain Inclusion c Exclusion c
Northum
bria Sleep
Research
Laborator
y
Northum
bria
University
Not Applic United Ki Greg Elder g.elder@no+44 (0)191 227 3241 Inclusion crExclusion cr
Epidemiol
ogy,
Biostatisti
cs and
Preventio
n
Institute
(EBPI)
University
of Zurich
Hirscheng
raben 84
Not Applic Switzerlan Jan Fehr jan.fehr@u+41 44 634 46 79 Inclusion c Exclusion cr
CTSU,
Nuffield
Departme
nt of
Populatio
n Health
University
of Oxford
Richard
Doll
Building
Old Road
Campus
Phase II/III United Ki Michelle Nunn recoverytr - Inclusion crExclusion cr
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Sta Clinical Trials Depart 9 Bond Couclinicaltr 4401138954D pharmaInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
yes
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Belgium Regulatory Industriep regulator 00329310 argenx BV Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Poland National Study Coordi al. Kopist hanna.czaj 4.86E+10 University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use Inclusion criteria: 1. Male or f
(Phase 2. Signed
Exclusion
informed
criteria:
consent
 1.
IV): no 3. Admitted
 2. toPresence
hospital of
forresp
tre
Bulgaria Spas Petkov 3A Nikolay Spas.Petk 3.6E+11 HUVEPHAR 4. Patient
 3.within
Participation
7 day in t
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Germany Diane Egger-Adam Wilhelmstrdiane.egg 4.97E+12 UniveristÃ Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Germany Clinical Trial Informat Mellendorfe
info@vakz 4.95E+11 Vakzine P Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Sweden Adam Linder SkÃ¥nes unadam.lind 4.65E+09 Region Sk Inclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Sta Regulatory Unit 103 Haros regulatory 3.61E+09 Accelsiors Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Canada;SpaSzpital nr 1, Klinika Ka ul. Curie-S jkubica@c 4.89E+10 UniwersyteInclusion Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use Exclusion criteria: Ge
 1. General
Healthcare-associa
REMA
IV): yes 1. Adult a.
patient
Prior
admitted
to this illness
to an I
Portugal;G W.W. van Bentum-PuiUniversite w.w.puijk- +31(0)887 University a. symptoms
 b. or
Resident
signs orofboth
a nurs
th
Human
pharmaco
logy
(Phase I):
yes
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no Inclusion criteria: 1. Have give
Germany Clinical Study Manag An der Gol David.Lan 4.96E+13 BioNTech 2. They Exclusion
must bec willing and ab
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no Inclusion criteria: -Recent (=6 da
Belgium HIRUZ CTU C. Heymanshiruz.ctu@ 3.29E+09 University -COVID-19
Exclusion
diagnosis
c confirmed
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Inclusion criteria: Patients with S
tic use 1. age Exclusion
= 18 years
criteria:
and = 1.
75 yea
(Phase 2. SARS-CoV-2
 infection
less confir
than
IV): no 2.
swap)In the opinion of
Germany Sixten KÃ¶rper Helmholtzss.koerper@ 4.97E+10 IKT Ulm 3. severe
 disease defined
i by a

 
 A subject must meet all of t
 study:
 
Phase 1 United Sta 20-0003 Central ContaKPWA.vacc 1.21E+10 1. Provides written inform

 
 procedures (participants
Phase 3 United Sta Gilead Study Director Gilead Sci y

 
 who can provide informe
Phase 3 United Sta Gilead Study Director Gilead Sci 
 
 PCR of any specimen; e.g
Phase 3 United Sta Clinical Trials Hoffmann- 

 
 intensive care units
 
 
Phase 3 Brazil ; Alexandre Biasi, PhD; ; ; Hospital do - Need for oxygen supplem

 
 1. Clinical and radiological
 
 2. Positive microbiological
 
Italy Giuseppe GRITTI, MD ASST PAPA 3. Diagnosis of acute respi

 
 - Confirmed SARS-CoV-2 in
 
 - COVID-19 patient in stab
 
 
Phase 4 Mahmoud M.A. Abulme
mabulmeat 9.67E+11 - Tube feeding o

 
 
 - Confirmed OR suspected
 
 - Confirmed: Positive as
 
Phase 2 United Sta ; Samuel M Brown, MD ;Valerie.A ;80150746 Intermounta
 - Suspe

 
 - Must have positive naso
 within the previous 48 ho
 
 
Phase 4 United Sta ; Brian Kendal, MD;Tri ; ; Providence - Not hosp
 
 Group 1:
 
 - Diagnosed with RA, PsA,
 conventional synthetic d
Denmark ;; Salome Kristensen, M ;l.uhrenho ;+45 2170 Department

 
 - Confirmed case: Criticall
 suspected case and who
onal [Patient Registry] Mexico ;; Silvio A. Ã‘amendys-S ;; ;; Instituto N He

 
 - Nursing home resident w
 
 - Nursing home resident w
 
 - fever
 
N/A Achille TCHALLA, MD achille.tch +33 5 55 05 86 26 -

 
 - All patients with microbi
 from March 15 to April 1
 
 
Christophe BURUCOA christophe 5.49E+08 - All

 
 
 - Peripheral capillary oxyg
 
 
Phase 2 United Sta ; ; Mark Sulkowski, MD;S;ssneddo2 ;410-955-7Johns Hopk 

 
 
 - Both genders
 
 - For women of childbeari
Phase 2 Greece ;;;;;;; Helen Sambatakou, MD
;;;;;;; ;;;;;;; Athens Gene
 contraceptive method du

 
 - Patients of any age and g
 
 - Hospital admission with
onal [Patient Registry] Spain ; MARIA DEL MAR GARCmmar.garci942203333; microbiological crit
 
 - All staff in the governme
 care and in the provision
Egypt ;; Aya Mostafa;Aya Most;aya.kama ;01005217 Ain Shams 

 
 require mechanical venti
 
 - Male and female with Ag
Phase 2 Greece ; Georgia Kostopanagio ;gkostopa ;+30 210 5 ATTIKON Un
 
 
Phase 2 United Sta Arnaud Bastien, MD arnaud.bas(609)-410-2691 informed consent, whic

 
 - Adult patient (age = 18 y
 
 
Phase 3 France ;; Charles GrÃ©goire;Je ;jpdesilles ;01480370 HÃ´pital Fo - With severe COVID-19 p

 
 - Maxillo-facial fracture
 
 - Requiring
 
 - Trauma that occured bet
 
 - All ages
 
France Marie de BOUTRAY, PH UH MONTP Ex

 
 1. Patients with COVID-19
 
 2. Non-intubated patients
 
 3. Patients with full consci
 
N/A Iran, Islam Mohammad Javaherian, Ph.D. cand. Tehran Uni 

 
 Patients fulfilling all the foll
 
 - Mechanically ventilated
 
Switzerlan ; ; Walid Habre, MD, PhD;walid.hab ;+41223468University - Fit the Berlin Definition f
 
 - Hospitalization with COV
 reaction (PCR) of any spe
Phase 2 United Sta ; Clinical Trials;Refe ;global-ro ;888-662-6Hoffmann-L bodi

 
 1. Male or Female, aged >=
 
 2. SARS-CoV-2-exposed su
Phase 2 Italy ;;; Giovanni Martinelli, Pr;;oriana.na ;;+390543 Istituto Sc (Group 1). In this group a

 
 - COVID-19 PCR positive,
 
 
onal [Patient Registry] France ; Marie KROEMER, Pha mkroemer@
0370632281; - Cohorte C : patients with

 
 - Child aged 7 to 11 years
 France on 17 March 2020
 
France ;; Erwan VION;Maryline ;maryline. ;00331307 Centre Hos - Child receiving care at th

 
 1. Have one or more of the
 
 1. Age = 65 years;
 
 2. Obesity (BMI = 30);
 
Phase 2/Phase 3 Christopher Barnum, trials@in +1 (858) 964-3720 3. Hypertension (on one

 
 - blood donors whose last
 
 
N/A China - Blood donors who were

 
 - Positive polymerase chai
 coronavirus 2 (SARS-CoV
Phase 2 United Sta ; Heinz-Josef Lenz, MD; ;Tali.Hom ;(323) 273 University 
 
 
 - Age = 18
 
 Arm A:
 
Phase 2 United Sta ; ; Santosha Vardhana, M;vardhans ;646-888-3Memorial S - Admission to an intensiv

 
 - Between 1 month and 18
 
 - Determined to be at high
Phase 1 United Sta ; ; Sanjay K Jain, MD;Ore ;ogordon3 ;41061412 Johns Hopk Academy of Pediatri

 
 - Have unipolar depressive
 
 - Have previous response
N/A Canada ;; Daniel Blumberger, MD;nicole.sc ;416-535-8CAMH; 

 
 
 
Phase 2 Colombia ; AndrÃ©s F Zuluaga, ;andres.zu ;30140202 Universida - Meet any of the followin

 
 
 2. Able to understand and
Phase 1 Jeff Safrit Jeffrey.Sa 310-404-6534 Institutional Review Boar

 
 - Pregnant women with CO
 
 
 - Having a chronic disease t
onal [Patient Registry] Turkey 

 
 unless they have a legally
 
Phase 2 United Sta ; ; Yogendra Kanthi, MD ;neshah@u;734-232-4University - Confirmed coronaviru
 
 - Rheumatoid arthritis sati
 
 - Ongoing DMARD therapy
 
 
 - Inhability to consent
France ; Dewi GUELLEC;Dewi Gdewi.guell +33298347264; 

 
 Adult SARI patients with 20
 lymphocytes < 0. 6x 109/L;
Phase 2 ; M.Sc. Mahmoud Elkazz;mahmoud;00201090 Damitta Uni admission to ICU.

 
 1. Adult =18 years of age
 
Phase 1 United Sta ; ; Katharine J. Bar;Katha ;BarK@pen;(215) 349 University approved assay in any sp

 
 
 2. Able to understand and
Phase 1 Lennie Sender, MD lennie.se 714-615-2350 Institutional Review Boar

 
 - signed Informed Consen
 
 - residing in The Czech Re
 
 - demographic criteria: (i)
Czechia ; ; ; ; ; ; ; ; Roman ChlÃbek, Prof.;Rastislav
;;;;;;;;;;;;; Madar,
;;;;;;;;;;;;;
Assoc.
University
Prof.;MariÃ¡n
 HajdÃºch, Assoc. Prof.;Ladislav

 
 - Men and women betwee
 
 - Laboratory-confirmed di
 
Phase 2/Phase 3 Blair Gordon, PhD info@edes 289-800-9600 - Hospitalized for COVID-1

 
 - HCW older than 18 years
 
 - Highly exposed to COVID
 
 - Negative (cases) or positi
Spain ;; Jose L Casado, MD, Ph;jcasado.h ;34913368 Ramon y Ca
 
 illness (ILI) symptoms OR
N/A Canada ;; Ken Parhar, MD, MSc; ;;ken.parh ;;403-944- University 

 
 - >18 years old
 
 - symptoms suggestive of
 
 
Spain Francisco J MartÃn, MD
fjjms@hot
PhD 6.19E+08 Exclusi

 
 
 - Out-of-hospital pneumo
N/A Russian Fe ; ; Oleg I Vinogradov, MD;olvinog@m;+7916270 N.I. Pirogo with changes correspond

 
 - patient admitted to ICU
 
 - initiation of vv-ECMO
 
 - definite SARS-CoV-2-infe
 
 
 - none
Germany ;; Alexander Supady, MD;alexander ;+4976127 University 
 Inclusion Criteria :

 
 - Age = 18 years.
 
 - Hospitalized patient suff
N/A France ;; Bertrand Glize;Bertra ;bertrand. ;05567955 bertrand.g transcription polymerase

 
 All adult patients whose op
 
 All patients who did not hav
 
N/A Belgium ;;;; Jan Nijs, MD;Mark La ;;;veerle. ;;;+32247 Universitai A
 - Age> 18 years admitted to

 
 - SARS-CoV-2 positive real
 
 
Brazil ; Eduardo Tibirica, MD, etibi@uol. +55-21-99914-6075;2 - Presence of non-COVID i
 
 
 2. Age = 18
 
 3. Patients who have signe
 
Spain ; Mariano Provencio, M;epereira@;+3493430 Hospital P Exclu

 
 
 - Diagnosis of CoVid-2 SAR
simon valentin, MD S.VALENTI 3.34E+10 and CoVid-19 positive m

 
 - Population over 18 years
 
 - Subjects with mild to mo
Phase 2 Ecuador ; Martha Heras Veloz;Ma
martha.her0999970284; coronavirus infection as

 
 - Healthcare providers (ph
 suspected COVID-19.
 
 
Kara Pavone, PhD nursing.re (617) 373-2774 - Nurses and physicians

 
 - Confirmed COVID-19 cas
 
 - Stage IIb of COVID-19 or
 
 - Consent was given by th
 
Phase 1 Indonesia ; ; Nana Sarnadi, Sp.OG;Ma
;marlianas ;+6281323 director o

 
 - Hospital census is review
 -19 diagnosis with hypox
United Sta ; David Dayya, DO, PhD ; ; Phelps Hosp m

 
 
 2. Age 70 or older, inclusiv
 
Phase 2 Denmark ; Morten Scheibye-Knu mscheibye +4542507060; 3. Body mass index betwe
 
 - Symptoms compatible w
 
 - Close exposure to a confi
 
France FrÃ©deric VENAIL, PU-PH UH Montpel - Ambulatory (asymptoma

 
 - Samples from a pre-July 20
 (patients over 18 years old)
 
 
France Rosanna FERREIRA, MD UH Montpel - Patients who have t

 
 - obese adults (> 18 years
 years
 
 - patients undergoing bari
 
Italy 

 
 - Juvenile Idiopathic Arthr
 
 - Ongoing DMARD therapy
 
 
France Valerie DEVAUCHELLE valerie.de 02 98 34 72 64 - Inhability to con

 
 - Living in the city of Mars
 
 - Being homeless
 
 - Be over 18 years of age
 
 
N/A France ;; Jean-Olivier ARNAUD, ;Aurelie.t ;49132452 Assistance - Persons under guardians

 
 - Aged 18 and over who li
 current serious mental h
N/A ; Federica Picariello, P ;federica.p ;+4420718 King's Coll 
 
 - Patients presenting/refe
 infection
 
; Richard Body;EloÃ¯se ;emerging ;0161 276 Manchester - Patients will require testi

 
 - patients admitted to the
 study and their caregiver
 
 
; Irene APRILE, MD,PH ;iaprile@d ;+3906330 IRCCS Fond 

 
 1. Age >18 years
 
 
N/A Greece ; Meletios Athanasios D;aniarcho ;+30 6949 National an 3. Onset of the disease sym

 
 - Adult 18 years or older; l
 Ontario; access to a com
 
 
N/A Canada ;;; Swati Mehta, PhD;Eld ;;swati.me ;;5196466 Lawson Heal
 

 
 - Patients over 18 years ol
 between march and may
 
 
Turkey aygen tÃ¼rkmen, MD.aygenturk 9.02E+11 - Under 18 years o
 Inclusion:
 
 1. Asymptomatic individua
 
 2. Asymptomatic individua
 
 Exclusion:
Phase 3 India ; Deba P Dhibar, MD;De;drdeba_p ;+9172275 PGIMER, Ch<

 
 Patients who have previous
 and a matched number of h
 
 1. Consent: Subject able to
 
 - BMI > 25 kg/mÂ² and/or
 
 - Persons registered in the
 
France ;; Jean-Louis PEPIN;Jean;jpepin@ch;04767687 University - Be legally able to give co

 
 - Informed consent must b
 assessment is performed
 
 - Adults (male and female
Phase 3 United Sta ; Medical Director;Medi;clinicaltr ;857-315-5Restorbio I 

 
 - Suspect, probable or con
 
 - Men and women aged =
 
 - SpO2 =93% on room air
 
Phase 3 ;; Rebecca F Grais;Eric ;;rebecca. ;;+331402 Epicentre 

 
 
 - Positive for SARS CoV 2 i
 
 - Chest CT scan or X ray re
Phase 2 ; Study Director;Trial R ;clinicaltr ;610-878-4CSL Behrin

 
 positive RT-PCR test for C
 
 - Oxygen saturation drop
 
N/A Iran, Islam ; Mohammad Sadegh Basadegh.ba 0098 9356318204; 

 
 - Urban and rural living re
 ethnic origin, any health
United Sta Carla Wilhite, DOT University 18-

 
 
 - Access to the internet
 
 - Lifetime history and/or c
N/A United Sta ; Andrea Goldstein-Piek;agoldpie@;650-497-9Stanford Un Neuropsychiat
 
 - close relatives or friends
 intermediary care wards
 
 - capable of completing on
N/A ; Annika von Heymann, ;annika.v ;0045 35 4 Department
 - Admission between 01/0
 COVID-19 Age 30-60 yea
United Ki Katriona Brooksbank katriona.b 1.41E+09 hy

 
 - Ability to gargle
 
 - Not having any condition
 
 - Not having an allergy to
 
Phase 2 United Sta ; ; Stuart A Gansky, DrPH;stuart.ga ;415-502-8Professor 

 
 - Patients selected for uro
 
 
 - Patients admitted in the
Spain ;; Francesco Sanguedolc;fsanguedo;+3493416 Fundacio P 

 
 - pharmacy students
 
 
 - non pharmacy students
Egypt Noha El Bassiouny, P dr_nosa07 45317617 

 
 - Previous laboratory confi
 of reverse polymerase-tr
Brazil ; Danilo C Berton, Dr;Da;dberton@;+5551335 Universidade
 
Federal do Rio Grande do Sul/Hos

 
 - Age =18 years on day of
 
 
 - Hospitalization in intensi
 
Switzerlan ; ; ; Silvio Brugger, SB;Phi ;;philipp. ;;+41 43 2 USZ;USZ; 
 1. Age =18 years.
 
 2. Hospitalization.
 
 3. SARS-CoV-2 viral nucleic
 
Phase 3 ; Amit Singla, MD;Amit ;as3321@nj;31951235 Rutgers Uni 4. Lab test result pending p

 
 
 

 
 Patients recovered of covid
 
 
 Chemotherapy on going Co
onal [Patient Registry] Spain ; Magdalena Salcedo, ;magdalena;+3460975 Liver Trans 

 
 - Adults over 18 years old.
 
 - Diagnosis (suspected or
Phase 2/Phase 3 Margarita Manrrique, mmmanriqu5946161 indication according to th

 
 age >18 yrs diagnosis of MO
 
 
 co-existent severe medical
N/A Italy Licia Grazzi, MD licia.grazzi 39022394 <

 
 (part A)
 
 - Severe pulmonary coron
N/A Italy ; MATTEO MONTORFANO,
montorfano0226437331;0226437 (microvascular COVID-19

 
 - Presenting with fever (=3
 (cough, dyspnoea, chills,
Phase 3 Spain Clara MenÃ©ndez, M clara.mene+34 932275400 
 
 - National University of Sin
 
 
 - N/A
N/A Singapore Teck Ho, PhD National Un 
 The ICU cohort - Inclusion c

 
 - Informed and written co
 
 
 - Verified COVID-19
 
 - Admission to the ICU wit
 
Denmark Andreas Andersen, M andreas.an+45 31717755 

 
 - Asymptomatic pregnant
 curettage due to missed
Turkey evacu

 
 - Subjects aged between 1
 
 - Patients with symptoms
 observed within the last
Phase 3 Turkey ; Prof. Ates KARA, MD;Pateskara@h+90 532 4135130;+90 

 
 - Children between 4 - 18
 
 - Living in The Netherland
 
 
Netherland ; ; Anita CE Vreugdenhil;A;a.vreugd ;00314338 Maastricht - No signed informed cons

 
 - All patients between the
 specific treatment should
 
onal [Patient Registry] Turkey ; ; ; ; ; ; ; ; Gokhan T. Adas, Prof;A;;;;;;;asu ;;;;;;;009 Bakirkoy Dr - COVID 19 diagnosis of pa
 
 
 - Severe or Immediately li
 
 - Dyspnea
 
 - Respiratory frequency >
 
Phase 1 United Sta ; ; Shukri David, MD;Debr;;yulia.ab ;;248-849- Ascension 

 
 - Patients aged = 18 years
 
 - Test positive for SARS-Co
 
 - Admitted to hospital
 
Phase 2 Fiona Garner, PhD ileukpulm (781)819-4949 - Presence of acute hypox

 
 - Participants who want to
 
 
 - Participants who do not
ASIM E OZBEK, MD drenesozb -4169 

 
 New, smear-positive drug-s
 Access to a mobile phone (s
 
 
N/A Pakistan Farman Ul Khan, Mastfarmankha 3.32E+09 Patient

 
 - 65+ years old
 
 - be able to speak and rea
 
 - one participant in the stu
N/A Canada ;; Mark R Beauchamp, P ;ryan.hult ;604 822 University members

 
 - Patients >18 years old
 
 
 - Troponin I elevation >99
 
United Ki ; Jason M Tarkin, MBBS ;jt545@cam;+44(0)12 University - Able to give writte
 - Covid-19 patients aged =
 University Hospital.
 
 - Control group: medical d
onal [Patient Registry] ; DOMENICO GIRELLI, ;chiara.moz;+39 0458 Universita Ver

 
 - Patients tested positive (
 
 - Adult patients with age >
 
Phase 2 Egypt ; Rehab Hegazy, PhD;R ;rehab_he ;+2010015 National R - Patients willing and able

 
 - Age above 18 years
 
 - Covid-19 disease
 
 - invasive Ventilation
 
 
 - none
Germany ; Harry Magunia, MD;H harry.mag +4970712986564;+49 

 
 - Major Subject (=18 years
 
 - Subject hospitalised in H
 
France ; Vincent CASTELAIN, MVincent.CA33 3 88 12 82 69;33 3 - The diagnosis COVID-19

 
 1. Age = 18
 
 2. Clinician judged serious
 develop serious COVID) m
Early PhaseUnited Sta ; ; Gailen D Marshall, Jr. ;gmarshal ;601-815-5University 
 - Working at Covid 19 Pan
 
 - Being at between 18 and
 
 - Having menstruation
 
 
Turkey ; Sevcan Arzu Arinkan, pataraa96@
+905056837557;+905 - Or
 - Inclusion criteria Commun
 
 - Exclusion criteria Inabilit
onal [Patient Registry] ; Dolores Sanchez-Rodr ;dolores.s ;00324934 Division of telephone/video-call for

 
 - It conforms to the diagno
 the common type;
 
China - The age ranges from 18

 
 - Critical COVID-19 with re
 
 - Physician determination
 
 
Phase 2 United Stat ; Jonathan C Javitt, MD ;rbesthof ;+1484254 NeuroRx, In 

 
 - Adult =18 years of age at
 
Phase 3 France;Lu ; Florence Ader, MD;Fl ;florence. ;+33 (0)4 7 Hospices Ci commercial or public hea

 
 - Healthy subjects
 
 
 - Drugs
 
 - Surgery
 
 - Neurology diseases
 
 - Rheumatic diseases
 
N/A CÃ©sar Calvo Lobo, P cescalvo@ 91 394 1544 <

 
 - Probable or confirmed in
 
 - Intubated and mechanic
 
Phase 3 Brazil ; Luciano Cesar Pontes ;luciano.a ;+5511992 Teaching Director
 of Teaching
- Moderate/severe
& ResearchARDS
Institd
 
 1. Aged 18-90 years
 
 2. PaO2/FiO2 (PFI) below 2
 
 3. Suspected or verified SA
 
Phase 2/PhGermany;S ; ; ; Anders Kjellberg, MD ;;;anders.k ;;;+468123 Karolinska 4. At least two risk factors

 
 - turkish physicians
 
 - work active in pandemic
 
 
 - work in another country
 
 - retired physicians
Turkey 
 
 1. Male or female, age > 1
 
N/A United States 2. Positive

 
 - Participants with diagno
 
 - Presence of symptoms c
 
Phase 1 United Sta Clinical Sciences & Operations Sanofi -

 
 - Judged to be healthy by
 examination and vital sig
 
Phase 1 United Sta ; ShuPing Yang, MD, PhD;clinical.t ;(267) 440 Inovio Pha - Able and willing to comp

 
 - Adult (>18 years) within
 suspected COVID-19 infe
Phase 3 Czechia ; FrantiÅ¡ek DuÅ¡ka;Frafrantisek. +420608405541;6084 
 Inclusions:
 
 1. Trauma patients presen
 
 2. Trauma patients presen
 
 Exclusions:
 
onal [Patient Registry] United Sta ; ; Jose L Diaz-Miron, MD;jose.diaz ;720-777-6University 1. Patie

 
 - Symptomatic caregivers
 consultation with the occ
 
 - Age: = 18 years old
 
N/A France Jean-Baptiste Mr FASSjean-baptis04 78 86 12 05 

 
 -1. Patients with age above
 pneumonia in the ward acc
 
Phase 1 Iraq ; Faiq I Gorial, Profess ; ; University 2. Unders

 
 - Male and female residen
 
Phase 3 United Sta Matthew Bardin, Pha matthew.b813-282-8544 of the protoco

 
 1. Aged 18-75 years old;
 
 2. Pneumonia patients wit
Phase 4 China Yahong Chen, MD Ascletis Ph and clinical manifestation

 
 i. Subject (or legally authori
 to initiation of any study pro
 
Phase 3 United Sta ; ; Todd Seto, MD;Todd ;tseto@que;808 354-3 Queen's Me ii. Understands and agrees

 
 
 - Positive Sars-CoV-2 RT-P
 
 - CT scan suggestive of Sar
 
 
Phase 3 
 - Current active and conse
 Program of Northern Alb
 
onal [Patient Registry] Canada ; Stephanie O Keeling ; ; University <

 
 1. approved Covid-19 diag
 
 2. urine status during hosp
 
Germany Oliver Gross, MD gross.oliv -541 3. Patient expressed willin

 
 - Age >18 at the time of sc
 
 - Subject must be able to
 
Phase 2 United Sta ; Noriko Ammerman, P noriko.am 310-248-8186;310-24 - Hospitalized with COVID

 
 1. Age = 18 years of age
 
 2. Hypotension requiring v
United Sta Debra Foster dfoster@sp647-205-5314 vasopressors listed below

 
 - Aged 18 years or older
 
 
 
 - Hospitalization in the pre
 
Phase 2 Argentina ; ; ; Francisco Azzato, MD;;;safc@ama;;+54-911 Department 
of Internal Medicine, Hospital de C

 
 All patients with COVID-19 t
 
 1. Respiratory difficulty
 
Phase 1/PhMexico ; Luis M Villela, MD;Lui ;luisville ;+5266247 ISSSTESON 2. Sat O2 <93% without O2
 
 
 - Admitted to ICU
 
 
N/A United Sta Eeke Romo, MD eua@marke1-877-339-4228 1. Early acute lung injur

 
 - Adult patients = 18 years
 
 - Hospitalized with a prove
 medicine or in intensive
 
Phase 3 ; ; ; ; ; ; ; ; LOUIS BERNARD, MD, ;;;;;;;;;;;; ;;;;;;;;;;;; CHRU DE T 

 
 - Males and females at lea
 
 - Healthcare workers at in
Phase 3 United Sta Matthew Bardin, Pha matthew.b813-282-8544 (Subject meets the defin
 Study subjects will be inpati

 at the discretion of the trea
 
 
Phase 2 United Sta ; ; Westyn Branch-Ellima ;Sara.Schi ;857-364-2VA Boston 1. Posi

 
 - Male or female greater t
 
 - Confirmed positive for C
 
 - Patient admitted to Inten
 
N/A United Sta ; ; Dhanunjaya Lakkiredd;dhanunjay;913-449-1Kansas City 
 1. Patients =18 years old
 
 2. Patient diagnosed with i
 
France ; FranÃ§ois-ClÃ©ment ;a-jacquet ;33771508 Institut Cur 3. Patient in active phase o
 
 - Male or female over 18 y
 
 - COVID-19 test positive p
 
N/A Andrea Natale, MD St. David`s - Consecuti

 
 1. Patients =18 years of age
 informed consent who requ
Phase 2/PhUnited Sta ; ; ; Patrick R. Lawler, M ;;;rzarych ;;;204-787 Peter Munk microbiologica

 
 1. Clinical diagnosis of the
 for COVID-19 in 2020 Tri
 
 2. 18-70 years old;
 
N/A China ;;; Xiaopin Wang;Zhongyu;;handsom ;;+86 134 Guang'anme
 

 
 - All resident and fellow p
 E. McDowell Rd, Phoenix
 
 
N/A United Sta Mike Foley, MD Chair - BU - Non-

 
 1. Confirmed SARS-CoV-2 i
 
 2. Hospitalized COVID-19 p
 admission).
 
Phase 2 Israel ; 
Rubi Zomer;Nadia Lis ;nadyal@ga;+9725295 MGC Pharma 3. Subjects mu

 
 1. Patient who agrees to p
 
 2. Men and women (non-p
 
Phase 1 Spain ;;; Vicente Estrada, MD; ;;;mjpont ;;;+ 34 91 Hospital ClÃ
 
nico San Carlos;Hospital
3. COVID-19 infection
Universitar
confi

 
 1.Laboratory diagnosis:
 
Phase 1 ; M.Sc. Mahmoud Elkazz;mahmoud;00201090 General Or lymphocytes < 0. 6x 109/L;
 
 - Aged 18 - 70 years;
 
 - Healthcare workers in a
 either proven or suspect
 
N/A Brazil ; Elisabete A Moraes, P betemora@+5585991219290;+55 -

 
 - Not currently hospitalized
 
 
 - Persons with a known pos
United Sta ; James Neaton, PhD;Ei ;edenning ;612-626-8University 

 
 - >Age of 18
 
 - Positive COVID-19 diagn
 
 
 - Age of <18
N/A United Sta Chelsea Harrison, DPT harrisonch 573-884-0655 

 
 Patients with COVID-19:
 
 - = 17 years old
 
 - Both sexes
 
 
Phase 3 - Patients with dementia,

 
 Age >18 years; Ability to giv
 Famotidine use during COV
 
 
 none
United Sta David A Tuveson, MD PhD Cold Sprin 

 
Phase 2 M.Sc.Mahmoud Elkazza
mahmoudr 2.01E+11 admission to ICU.
 
 1. Men or women aged 18
 
 2. The presence of COVID-
 
Phase 2 Russian Fe ; ; ; Alexander V Averyano;;mkonopl@;;+791540 Federal Pul 3. The presence of the COV
 General Inclusion Criteria:

 
 - Be aged 18 and over
 
 - Have clinical picture stro
 positive COVID-19 test) A
 
Phase 2/PhUnited Ki ;; Joseph Cheriyan, MBC;sonakshi. ;01223 34 Cambridge 

 
 Patients may be included in
 
 1. Ability to understand an
Phase 3 United Sta ; Ashkan Emadi, MD, P aemadi@u410-328-2596; 

 
 - Female or male patients
 receptor 2-positive (HER
United Sta ; Clinical Trials;Refe ;global-ro ;888-662-67Genentech, combi

 
 - All pregnant women SAR
 
 
 - 18 years to 48 years
 
 
France ;; Souhail ALOUINI, M.D.;aurelie.de ;+3323874 CHR ORLEA 

 
 - Between 18-64
 
 - Still working or pre-retire
 
 - Currently completing les
N/A Eli Puterman, PhD eli.puter 604 822 2854 minutes i
 
 - History of hospitalisation
 PCR and/or a radiologica
 
 - Age 18 years or more
 
United Ki ; Colin Berry, MBChB/P ;colin.ber ;01413303 University 

 
 1. Patient is at least 18 yea
 
 2. Patient meets either of
 
N/A United Ki ; Samer Elkhodair;Jayne;capture@ ;01786 43 University 1. Patient is presenting

 
 
 
 - Able and willing to comp
 
 - Adult healthcare profess
 
Phase 2 United Sta ; Medical Monitor;Rup jmaslow@g484-965-9147;215-57 <

 
 1. Adult patients (= 18 yea
 care consultants
 
 
United Ki ;; Marlies Ostermann;Ma;Marlies.O ;0044 207 Department 3. ARDS de

 
 - Hong Kong residents age
 
 - Enrolled in a smoking ce
 Centre on Smoking Cessa
N/A Hong Kong ; ; Tzu Tsun Luk, PhD, R ;luktt@con;+852-391 The Univer 
 - Covid 19 infected health
 
 
 - Risky healthcare workers
Mariam elkhayat, lect mariam.el 2.01E+11 
 
 1. Age =18 years (male or f
 
 2. Acute infection with sev
 
Phase 4 ;; Marc S Sabatine, MD, ;;vbaird-z ;;800-385- TIMI Study 3. Currently admitted to an

 
 - Patients with IBD +/- flar
 
 
 - Patients below 16
 
 - Patient with inactive IBD
United Ki Shaji Sebastian Hull and Ea 

 
 - SARS-CoV-2 confirmed in
 
 - Admission to a hospital i
 
 - Expected hospitalization
 
Phase 4 Argentina ; ; ; ; ; ; ; Walter Manucha, PhD;C
;;;;;;ja_m ;;;;;;+541 IMBECU, Un 

 
 
 - ICU admission because o
 related pneumonia (swa
 
Italy Lorenzo Gamberini, l.gamberin 3.93E+11 Exclusion
 Inclusion Criteria (all three c

 
 - Healthcare personnel or
 
 - Age 18-99
 
Sweden ; Joakim Dillner, MD, P joakim.dill +46 (0) 72-468 24 60; - Provided consent to parti

 
 - Confirmed COVID-19 pos
 
 - Hospitalization
 
Phase 4 United Sta ; George Sakoulas, MD;K;kathryn.m;828-939-7Sharp Heal - Requiring =4 liters/min O
 
 - Patients aged 16 -100 inc
 
 - Acute Severe Ulcerative
 managed during the stud
 
United Ki Shaji Sebastian Hull Univer 

 
 1. Positive local SARS-CoV-
 
 2. At least one of the follow
 
 1. Fever
 
 2. Cough
 
Phase 2 Canada ;; Subodh Verma, MD, P ;subodh.ve;1-416-864Canadian M

 
 - Participant must be 18 y
 
 - Volunteer patients, care
France 

 
 (PCR) or other commerci
 
Phase 2 Sweden Jonas SundÃ©n-Cullb Jonas.sund-58579962 2. SARS-CoV-2 infection wi

 
 - Phase Ia:
 
 1. Healthy adults aged 1
 women.
 
 2. Proven legal identity.
 
Phase 1/PhChina ;;; Qin Yu;Xiaoqiang Liu; ;;liqihan ;;86-0871 West China
 - Covid-19 confirmed by p
 
 - oxygen by mask or nasal
onal [Patient Registry] Sweden ; Maria HÃ¥rdstedt, MDmaria.hard+46-738089464; fraction of inspir
 
 - Patients admitted in a ho
 
 - Patients with COVID19 w
Algeria ALI LOUNICI, Professo ali.lounic 2.14E+11 radiological diagnosi

 
 - ii. Hospitalized with COV
 Evidence of hyperinflamm
Phase 3 United Sta ; ; Todd Seto, MD;Todd ;tseto@que;808 354-3 The Queen' 

 
 1. Provision of signed and
 
 2. Stated willingness to com
 
Phase 1 United Sta ; ; Emily Blumberg, MD;J ;jgilmore ;215-746-8University Inclusion Criteria: Seeking s

 multi-disciplinary clinic, or h
N/A Canada ;; Brigitte C Sabourin, P ;bsabourin ;204-787-1University participate in the video con

 
 - Any Age
 
 - Any Sex
 
 - non pregnant women
 
 - RT-PCR positive for SARS
 
 
Egypt ;; Mohamed F. Mostafa,;mo7_fath ;01001123 membershi - Patient R

 
 - Patients between 18 and
 
 - COVID-19+ patients diag
 
 - Hospitalized patients
 
Phase 2 France ; Emmanuel DISSE, Pr;Pemmanuel.d
+33 4 78 86 14 84; 

 
 - Patient = 18 years at tim
 
 
N/A France ;; Vincent DEGOS, Pr;Vi ;vincent.d ;142163761Assistance - Intubated/ventilated pati
 
 
 - Confirmed or imminent r
 
 - At least one of the follow
 
onal [Patient Registry] Erdie De Peralta erdie@ext 925-839-2079 1. Early acute lung

 
 Population 1 :
 
 - Children of priority staff
N/A ; Eric LACHASSINNE, ;mohammed
;01 48 95 Assistance i.e. from 15 March to 9 M

 
 - Male of female aged 18
 
 - Patients with at least on
 an infection by the virus
 
France ; Shahnaz KLOUCHE;St klouche@e(0)1 58 56 41 71;(0)1

 
 1. Patients = 18 years.
 
 2. SARS-Cov2 infection con
 
 3. Presence of COVID-19 se
 
Phase 2 Marcelo Iastrebner, miastrebn 5.49E+12 

 
 - Be male or female, =18 y
 
 - Be willing and able to giv
 
N/A United Sta ; Mark Wingertzahn, P ;clinicals ;(617) 674 Kaleido Bio - Screening/Randomizatio

 
 - 18 or older
 
 - Enrolled in 4-year univer
 
 - Not graduate in May 202
 
 
N/A United Sta ; ; Tracy F Chang, Ph.D.;T;tracy.cha ;20526664 Rutgers Uni - Younger tha
 Inclusion Criteria: patients a
 had at least 1 critical care e
 
 -
 
France Antoine Vieillard-Baron, MD, PhD Hospital A Exclusion Criteria: Patients w

 
 - Informed Consent as doc
 
 - admitted to the hospital
 COVID-19 infection
 
Phase 2 Switzerlan ; ; Michael Osthoff, PD D ;michael.o ;+41 61 32 University 

 
 - Men 18-50 years of age
 
 - Already attending hospit
 
 - Low risk of prior COVID-1
United Ki Channa Jayasena c.jayasena@imperial.ac.uk

 
 Type of Subject and Disease
 
 1. Documented or confirm
Phase 2 United Sta ; Michael S. Gordon, M.;sfischer@ ;781-795-9HonorHealt nasopharyngeal swab or

 
 1. Participants who are wil
 plan, laboratory tests, lif
 
Phase 2 ; Hyung Chun, MD;Hyu ;hyung.ch ;(203) 785 Yale School 2

 
 Covid 19 pneumonia, hospi
 
 
 younger than 18 years old,
onal [Patient Registry] Turkey zuhal Ã§avus, MD zuhalcavu 9.02E+11 

 
 - Subject must be willing,
 
 - Subject must be a man o
 
Phase 3 Germany ;;;; Ulf Landmesser, Prof. ;;;;ulf.la ;;;;+49 30 Charite Un - Subjec
 
 - Subjects who underwent
 
 
 -
Hong Kong Jonpaul Sze Tsing Zee, MBChB Hong Kong 

 
 - Female and male patient
 
Austria ;; Ivan Tancevski, Doz. Dr;judith.loe ;+43-512-5Medical Uni Federal Ministry of Socia

 
 shortness of breath, chill
N/A d

 
 - Bilateral pneumonia due
 
 - With SARS-Cov2 PCR RN
 
 - Severe ARDS
 
 - PaO2/FiO2 <150
 
Phase 2 Mexico ; Martin Iglesias, MD;Maiglesias@d +1 52 55 5580097509 - L

 
 - All organs procured for t
 period. These include kid
 
France ;; Alexandre Loupy;Alex ;alexandre ;+33 1 53 Paris Trans Exclu

 
 - Employees of voluntary e
 
 - Employees over the age
 
 - Having signed a free, info
 
N/A France ;; Christophe PARIS, ;ronan.gar ;+33 (0)2 9 CHU RENNE 
 1. Inclusion Criteria:
 
 Children / adolescents:
 
 - autism spectrum diso
 hyperactivity disorder
 
N/A France ; Malika DELOBEL-AYO ;delobel.m ;05 67 77 University 
 Inclusion Criteria: Pregnant

 maternities.
 
 Exclusion Criteria: RT PCR S
 
 -
Portugal ; Nadia Charepe, MD,Mnadia.char 00351213184000;003 

 
 - Patient with PV, ET, PMF
 pandemic
 
;; Jean-Jacques KILADJIA;;jean-jacq ;;1 42 49 9 FIM;FIM; - Seen in consultation or t

 
 1. All individuals older than
 
 
N/A United Sta ; ; Houssein Youness, MD;Houssein ;405-271-6University 1. Individuals with known

 
 - Participants acquired fro
 Diabetes Mellitus. Becau
N/A ; Renee Murray-Bachma;rmurrayb ;212-434-2Northwell 

 
 - Adult (= 60 years)
 
 
 - Fever (>38 ÂºC) within th
 
 - Suspicion of current acti
Phase 4 Netherlands 
 1. Male or female, aged >
 
 2. Provide a valid electroni
 
United Sta ; ; Lauren Vitalie, BA;La ;lvitalie@ ;70778714 Soniphi LLC 3. Eligible patients are tho
 
 - Patients with a cancellati
 2020 through June 7, 202
N/A United Sta Anne Cappola, MD, S acappola@215-573-5359 

 
 - known or suspect COVID
 
 - Oxygen saturation as
Phase 4 Melisa Lai-Becker, MDmelaibeck 617-394-7424 (
Institute
of Health
Informati
cs
University
College
London
222
Euston Rd
Not Applic United Ki Maria Krutikov m.krutikov - Inclusion crExclusion c
Not Applic Mexico Inclusion crExclusion cr
Strangew
ays
Research
Lab
Worts
Causeway
University
of
Cambridg
e
Not Applic United Ki Amy McMahon helpdesk@t+44 (0)1223747228 Inclusion crExclusion c
Not Applic Singapore Inclusion c Exclusion c
0 China Pu Liao 104 Pipash liaopu@si +86 023-6 Chongqing Inclusion c Exclusion c
Inclusion criteria:
Exclusion
1. Heart
criteria:
failure:
1. Patie
NY
N/A China Chuan Yang 36 Sanhao Syangc@sj-h+86 18940 Shengjing H 2. All kinds
 2.
of Patients
mechanical
withheart
brea
Exclusion criteria: 1. age <
 2. pregnant;
 3. length of hospital
 4. insufficient clinical
RetrospectChina Minghao Fang 1095 Jiefa fangmhtj@+86 15071 EmergencyInclusion c 5. serious complicati
RetrospectChina Jirong Yue 37 Guoxuexyuejirong +86 18980 West ChinaInclusion c Exclusion c
Inclusion criteria: 1.??=60?;
 2.???????;
 3.?????????;
RetrospectChina Jirong Yue 37 Guoxuexyuejirong +86 18980 West China 4.?????????
Exclusion c
Exclusion criteria: 1) Cann
RetrospectChina Junhua Zhang 10 Poyanghuzjhtcm@fo+86 13902 Evidence-BaInclusion c 2) Subjects who have
Inclusion criteria: 1. Aged between 2
4 China Zhimin Chen 3333 Binshechenzhimi +86 13958 Children's 2. Laboratory
Exclusion c
(RT-PCR) and clinic
Inclusion criteria:
Exclusion
1. At
criteria:
the time1. The
of sii
4 China Yaocai Li 101 Weimi 12651142 +86 18666 Maoming Pe 2. Patients
 2.with
People
respiratory
who are symkn
N/A China Zhang DY, Huang CL, 1 Yintan R 18138863 +86 13507 Wuhan JinyInclusion c Exclusion c
Inclusion criteria:
Exclusion
1. At
criteria:
the time1. The
of sii
4 China Guan Ling; Chen Yiyun3 South Wa81300850 +86 13922 Dongguan P 2. Patients 2.with
People
respiratory
who are symkn
N/A Spain Amaia Martinez Mendcalle Viria amaia.mar +34 6 990 Hospital R Inclusion c Exclusion c
Inclusion criteria:
Exclusion
(1) criteria:
Diagnosed (1) as
Preg
CO
 (2) aged (2)
> 18 years
Alanine
old;transamin
4 China Xijing Zhang 15 Changlezhangxj91 +86 13384 Department (3) IL-6 (3)
level > Diagnosis
7 pg/mL. of rheu
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
(Phase 2. Hypersensitivity
 3. 1.
Electrocardiogra
Patients =
Denmark Department of Nephr Blegdamsbej 9 4.54E+09 Rigshospita 2. Competence
 4. P to understand
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
France DRCI 1 Avenue Ceunice.nub 1.4E+08 Assistance Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Denmark Clinical Trial Informat KlÃ¸vervÃ¦nget 10 4.57E+09 Odense UniInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use Exclusion criteria: Un
 Participants
 Participants
with criti
m
IV): no Laboratory-confirmed
 Any contraindication
SARS-CoV
France;HunMedical Information 410 Thamesuk-medical 4.48E+11 sanofi-ave Onset of Any
COVID-19
medical conditio
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Sta Medizinischer Infoser Roonstr. 2 infoservic +49 911 2 Novartis Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Germany Clinical Trial Informat Mellendorfinfo@vakz 4.95E+11 Vakzine P Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
Exclusion
 Patients
criteria: Pa
are el
IV): no 1. Age 1.
=18 years
Evidence of critica
United Sta Clinical Trial Informat 85 Wells A clinicaltrials@karyo Karyopharm 2. Confirmed
 a. Respiratory
laboratory diagnos
failure
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase Inclusion criteria: 1. Age: 18 and
IV): no and including
Exclusion60criteria:
years old 1.
and a
United Sta Mounia Chabane De Sa14 Avenue mounia.ch +33(0)144 Biophytis S 2. A confirmed
 2. Moribund
diagnosisconditio
of COV
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Sta Regulatory Unit 103 Haros regulatory 3.61E+09 Accelsiors Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Sta Medical Monitor 3030 Calla DAS181@an
858452 26 Ansun BiopInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Austria Markus Zeitlinger Waehringermarkus.zeitlinger@meDepartmentInclusion c Exclusion c
N/A Germany Jonas Hosp Breisachersjonas.hosp 0761-270- Klinik fÃ¼r Inclusion c Exclusion c
N/A Germany Rebecca Diekmann AmmerlÃ¤nd rebecca.d 4.42E+09 UniversitÃ Inclusion c Exclusion c
IIb Germany Torsten Slowinski Augustenbutorsten.sl 3.05E+10 CharitÃ© CInclusion Exclusion c
N/A Germany Kristin HÃ¶sel Hegewischskristin.ho 0431/5002Klinik fÃ¼ Inclusion c Exclusion c
I Germany Dirk Wilhelm Ismaningerdirk.wilh 4.99E+11 Klinikum reInclusion c Exclusion
N/A Germany Christoph Stein-Thoe Im Neuenhec.stein-th 4.96E+11 German Can Inclusion c Exclusion c
N/A Germany Jessica Koschate AmmerlÃ¤nd jessica.ko 4.94E+11 Carl von O Inclusion c Exclusion c
N/A Germany Henning GrÃ¼ll FÃ¼rst-PÃ¼henning.gr (0221) 478 Institut fÃ Inclusion c Exclusion c
N/A Germany Oliver MÃ¼ller MÃ¼nsterstoliver.mue 0231 9531 Klinik fÃ¼ Inclusion c Exclusion c
N/A Germany Prisca Bauer HauptstraÃprisca.bau 0761 270- UniversitÃ Inclusion Exclusion c
N/A Switzerlan Thirza Singer-CornTellstrasse thirza.sin 4.16E+10 KantonsspiInclusion c Exclusion c
0 Germany Georg Frie Hoffmann Im NeuenheGeorg.Hof 6221 56-4 Zentrum fÃInclusion c Exclusion c
N/A Germany Dominik Bettinger Hugstetter dominik.be0761/270- UniversitÃ¤Inclusion c Exclusion c
N/A Germany Nils Schallner Hugstetter nils.schall -24042 UniversitÃ¤Inclusion c Exclusion c
N/A Germany Christine Rummel-KlSemmelweispia_chat@m3.42E+09 UniversitÃ¤Inclusion c Exclusion c
N/A Germany Jakob Armann Fetscherst Covid19-s 3514580 UniversitÃ Inclusion c Exclusion c
N/A Germany Sarah Schwarz Ostmerheim sarah.sch 2.22E+11 Kliniken d Inclusion Exclusion c
N/A Germany Wolfgang Miesbach Theodor-Stwolfgang. 6.96E+09 HÃ¤mophilie Inclusion c Exclusion c
I Germany Antje Blank Im Neuenheantje.blan 06221 56 MedizinsichInclusion c Exclusion c
N/A Germany Daniel Sedding Ernst-Grubedaniel.sed 0049-345- UniversitÃ¤Inclusion Exclusion c
I Germany Marcus Schuchma Mainaustr marcus.sc +49 7531 8MedizinischInclusion c Exclusion c
N/A Germany GÃ¶tz MartRichter Kriegsbergsg.richter@k0711/278- Klinikum StInclusion c Exclusion c

N/A Germany Andreas Umgelter Am Nordgrandreas.um3.01E+10 Vivantes H Inclusion c Exclusion c
N/A Germany Mathias Harrer NÃ¤gelsbacmathias.ha09131 85 Lehrstuhl Inclusion c Exclusion c
N/A Germany Tobias Nitschke Marchionintobias.ni 8.94E+10 Klinikum d Inclusion c Exclusion c
N/A United Sta Alain Vandormae130.3 Im Nalain.vand 6221560 Heidelberg Inclusion c Exclusion c
N/A Germany Christian Zobel ScharnhorsChristian 4.93E+11 Bundeswehr Inclusion c Exclusion c
N/A Germany Achim Lother Hugstetter achim.loth 0761-2707 UniversitÃ Inclusion c Exclusion c
N/A Germany Ulrich Pecks Carl-Pulvri gs@dgpm-o3.64E+10 Deutsche GInclusion c Exclusion c
N/A Germany Stefan Schreiber Arnold-Hells.schreib 0431 500- Klinik fÃ¼r Inclusion c Exclusion cr
N/A Germany Ulrich Limper Ostmerheim limperu@kl 2.22E+10 Klinik fÃ¼ Inclusion c Exclusion c
N/A Germany Dilara KersebaumArnold-Hel dilara.ke 4.32E+10 UniversitÃ Inclusion c Exclusion c
N/A Germany AndrÃ© Mihaljevic Im Neuenheandre.miha06221-563 Klinik fÃ¼r Inclusion c Exclusion c

N/A Germany Johannes Hellmuth Marchioninijohannes. +49 89 440MedizinischInclusion Exclusion c
Allocation: Other;. MaGermany Claudia Denkinger Im Neuenheclaudia.de +49 6221 UniversitÃ Inclusion c Exclusion c
N/A Germany;Au
Dagmar Schaffler Strubergas dagmar.sch -3039 Paracelsus Inclusion c Exclusion c
Allocation: Other;. M Germany Christian Jassoy Johannisal christian.j 0341 9714 Institut fÃ Inclusion c Exclusion c
N/A Germany Michael Hauptman Fehrbellin michael.h +493391 3 Institut f Inclusion c Exclusion c
N/A Germany Venja Musche Virchowstr venja.mus 0201 4387 Klinik fÃ¼ Inclusion c Exclusion c
N/A Belgium;GeJÃ¶rg Jann Vehreschil Herderstra janne.vehr +49 221 4 University Inclusion c Exclusion c
N/A Germany Georg Behrens Carl-Neuberbehrens.g 0511 532 Medizinisc Inclusion c Exclusion c
N/A Germany Hanna HeckendorUniversitÃ¤getcalm.m +49 4131. Leuphana UInclusion c Exclusion c
N/A Germany Armin Kalenka Viernheimer armin.kale 6.25E+09 KKH BergstInclusion c Exclusion c
N/A Germany Alexander BÃ¤uerle Virchowstr alexander. 0201 7227 Klinik fÃ¼ Inclusion c Exclusion
II-III Germany Alexander Supady Hugstetter alexander. 0761/270- UniversitÃ Inclusion c Exclusion c
N/A Germany Hendrik Streeck Venusberg Hendrik.S 2.28E+10 Institut fÃ Inclusion c Exclusion c
N/A Germany Jan Neumann Schillerstr jan.neuma 0421-361- Performa NInclusion c Exclusion c
N/A Germany Claudia Sommerer Im Neuenheinfo@niere06221 911 Sektion Ne Inclusion c Exclusion c
N/A Germany Claudia Sommerer Im Neuenheinfo@niere06221 911 Sektion Ne Inclusion c Exclusion c
N/A Germany Andrea Borho Schwabachandrea.bo 09131-854 Psychosoma Inclusion c Exclusion c
IV Germany Sven Pulletz Schillingal sven.pulle +49 (0)381 Klinik fÃ¼ Inclusion c Exclusion c
N/A Germany Jonas Herzberg Hamburgerjonas.herz 4.94E+11 Krankenhaus Inclusion c Exclusion c
N/A Germany;Arg
Jan Wilke Ginnheimerwilke@spor0049 69 7 Goethe-UniInclusion c Exclusion c
N/A Germany Sven Laudi Liebigstras anaesthesi +49 341 97Klinik fÃ¼r Inclusion c Exclusion c
N/A Germany Markus KÃ¼per Schnarrenbmkueper@b-6070942 BG Unfallk Inclusion Exclusion c
N/A Germany Markus Qreini Im Neuenhecarecockpi 06221 56- UniversitÃ Inclusion c Exclusion c
N/A Germany Antonia Domke Habelschweantonia.do +49 30 838Freie UniveInclusion c Exclusion c
N/A Germany Christine Rummel-KlSemmelweis Christine. +49 341-9 UniversitÃ¤Inclusion c Exclusion c
N/A Austria Klaus Hackner Mitterweg klaus.hack 4.33E+13 Universits Inclusion c Exclusion c
Allocation: Single arm Germany Alexander Hein UniversitÃ¤alexander. 09131-85- UniversitÃ¤Inclusion Exclusion c
IV Germany Anke MÃ¶ckel Zum Hospitcoronatest 4.94E+11 KassenÃ¤rzInclusion c Exclusion c
N/A Germany Sascha Kreuer GebÃ¤ude sascha.kre 06841-16- Klinik fÃ¼ Inclusion c Exclusion c
N/A Germany Uta Merle Im Neuenheuta.merle@4.96E+12 UniversitÃ Inclusion c Exclusion c
N/A Germany Stephan WalterspacMainaustr. stephan.wa 7.53E+10 Klinikum KoInclusion c Exclusion c
N/A Germany Milena Zimmer Klostenstr. milena.zi 7.82E+09 OrtenauklinInclusion c Exclusion c
N/A Germany Sebastian Rasch Ismaningersebastian. 0049 89 41Klinikum r Inclusion c Exclusion c
Allocation: Single arm Germany Maria CristPolidori NeKerpener Smaria.poli 0221-4783 SchwerpunkInclusion c Exclusion c
N/A Germany Niels Teich NordstraÃŸteich@igvs -6003942 GesellschafInclusion c Exclusion c
N/A Germany Christoph Ehlken Arnold-Hellchristoph. 4.32E+10 Klinik fÃ¼ Inclusion c Exclusion c
N/A Germany Florian Kurth Augustenbuflorian.ku 4.93E+12 CharitÃ© - Inclusion c Exclusion c
N/A Germany Antje AschendorfKillianstr.. antje.asch 7.61E+10 UniversitÃ¤Inclusion c Exclusion c
N/A Germany Sarah Riemann Killianstra sarah.riem 4.98E+12 Klinik fÃ¼r Inclusion c Exclusion c
N/A Germany Michael Pritsch Leopoldstr koco19@me 0049 152 5Abteilung Inclusion c Exclusion c
N/A Germany Johanna Schneider Hugstetter johanna.sc 0761-270 Uniklinik F Inclusion c Exclusion
0 Germany Kathrin Potkowski Kilianstrasskathrin.po 0761-270- HNO- Univer Inclusion c Exclusion c
N/A Germany Joachim Risse Hufelandstjoachim.ri 4.92E+11 UniversitÃ Inclusion c Exclusion c
Allocation: Non-randoGermany BÃ¼rkle-destudien-an 0234-3020 BG-UniversInclusion c Exclusion c
N/A Germany Christian JunghanÃŸErnst-Heydklinisches 0381 494 Klinik III Inclusion c Exclusion c
Allocation: Single arm Germany Ekaterina Schneider Bergheimersodi.studi 6.22E+09 Institut fÃ Inclusion c Exclusion c
N/A Germany Nikolaus LÃ¶ffelhar SÃ¼dring 1nikolaus.l 07633 402 UniversitÃ Inclusion c Exclusion c
N/A Germany Felix Giebel Heusnerstrfelix.gieb 0202-896- Helios Uni Inclusion c Exclusion c
N/A Germany Joachim Beige Delitzschercovidval@s 3.42E+09 Klinikum S Inclusion c Exclusion c
N/A Germany Christine Rummel-KlSemmelweis pia_ocd@me 3.42E+09 UniversitÃ¤Inclusion c Exclusion c
N/A Germany Claudia MaDenkinger Im NeuenheClaudia.De 6.22E+10 UniversitÃ Inclusion c Exclusion c
N/A Germany Benedikt Reuter Rudower Creuterbe@h0049 30 2 Lehrstuhl f Inclusion c Exclusion c
IV Germany Philipp Maier Hugstetter philipp.ma +49 761 27Institut f Inclusion c Exclusion cr
N/A Germany MagdalenaSitter Josef-Schnesitter_m@ 0931/201- UniversitÃ Inclusion c Exclusion c
N/A Germany Siegbert Rieg Hugstetter siegbert.ri 7.61E+10 Abteilung I Inclusion c Exclusion cr
Allocation: Other;. M Germany Christiane Kuhl Pauwelsstrckuhl@uka+49 241 80Klinik fÃ¼r Inclusion Exclusion c
N/A Germany Sebastian Noe Karlsplatz Sebastian. +49(0)558 MVZ KarlspInclusion c Exclusion c
N/A Germany Sebastian Wolf Schleichstr sebastian. +49 (0)707 UniversitÃ Inclusion c Exclusion c
Departme
nt of
Medicine,
Faculty of
Medicine,
University
of
Kelaniya Inclusion criteria: 1. All consenting m
P.O.Box 6 
Sri Thalagolla 2. Exposure
Exclusion
to a criteria:
patient with
1. Preg
co
Lanka Road 
Phase 4 Niriella MA Ragama maduniln@+94 11 29 Professor 3. The 2.exposureSuspected
should beor for
confi
>3
3 Iran (Islam Dr Hossein Poustchi Shariati Hoh.poustch +98 21 824Tehran UniInclusion c Exclusion cr
3 Iran (Islam Majid Farhadifard No 10, All majidfarh +98 25 366Ghoum UnivInclusion c Exclusion c
3 Iran (Islam Sara Mobarak Abadan Schos.mobarak +98 61 533Abadan UniInclusion c Exclusion cr
3 Iran (Islam Maryam Azimi Crossroad dr.azimm@+98 34 321Kerman UniInclusion c Exclusion cri
N/A Iran (Islam Maryam Azimi Crossroad dr.azimm@+98 34 321Kerman UniInclusion crExclusion cri
3 Iran (Islam Sara Mobarak Abadan Schos.mobarak +98 61 533Abadan UniInclusion c Exclusion cr
3 Iran (Islam Hossein Biganeh Vanak, MullBiganeh75 +98 31 547Bagheiat-alInclusion c Exclusion cr
3 Iran (Islam Nadia Soltani Gerdefa Unit 701,F nadia.slt7 +98 35 352Yazd UniverInclusion crExclusion cr
3 Iran (Islam Zhila Maghbooli Emamkhomei
zhilayas@g+98 21 667Tehran UniInclusion crExclusion c
3 Iran (Islam ?Dr. Mitra Ranjbar Firoozgar hmitrearan +98 21 821Iran UniverInclusion crExclusion cr
2 Iran (Islam Abdorahman Rostami Shariati Hoarostamian+98 21 611Tehran UniInclusion c Exclusion c
2 Iran (Islam Mahboubeh Darban Semnan Uniare20935@+98 23 334Semnan UniInclusion crExclusion cri
2 Iran (Islam Ahmadreza Jamshidi Shariati Hojamshida@s+98 21 882Tehran UniInclusion c Exclusion c
3 Iran (Islam Ali Dabbagh Sa'adat Ab alidabbag +98 21 238Shahid Behe
Inclusion c Exclusion cr
3 Iran (Islam Zhila Maghbooli Emamkhomei zhilayas@g+98 21 667Tehran UniInclusion c Exclusion c
1-Feb Iran (Islam Morteza Zarrabi No. 2, Hafem.zarrabi@+98 21 223Royan InstiInclusion crExclusion cr
3 Iran (Islam Seyedeh Sedigheh YouTouba Clin s.yousefi@+98 11 332Mazandaran Inclusion crExclusion c
2-Mar Iran (Islam Lotfollah Davoodi Ghaemshahr lotfdavoo +98 11 422Mazandaran Inclusion crExclusion cr
3 Iran (Islam Esmail Shariati No 63. Alleshariati.e +98 23 323Shahroud UInclusion c Exclusion c
2 Iran (Islam Amirhoushang Moha School of Mohamadp+98 51 318Mashhad Un Inclusion crExclusion cr
2 Iran (Islam Leila Roshangar Faculty of lroshanga +98 41 333Tabriz UnivInclusion c Exclusion cri
2-Mar Iran (Islam Rozita Khodashahi Imam Reza khodashah+98 51 38 Mashhad Un Inclusion crExclusion c
3 Iran (Islam Ali Nazari Modares Anazari-a@m+98 84 322Ilam UniverInclusion crExclusion cr
3 Iran (Islam Bahman Pourabbas Prof. Albor pourabbas +98 71 364Shiraz UnivInclusion crExclusion c
2 Iran (Islam Nasim Anjidani No. 42, Ataanjidani. +98 21 434Orchid Phr Inclusion crExclusion cr
3 Iran (Islam Mohammad RezapourBaqiyatalladrrezapou +98 21 824Bagheiat-alInclusion crExclusion cr
N/A Iran (Islam Shadi Shafaghi Masih Daneshafaghish +98 21 271Shahid BeheInclusion crExclusion cri
3 Iran (Islam Dr. Mohammad Fathi Shahid Modm.fathi@sb+98 21 235Shahid Behe Inclusion crExclusion cr
3 Iran (Islam Naser Gharebaghi Kashani strhajizadh.r +98 44 334Oroumia UnInclusion crExclusion cr
3 Iran (Islam Bahareh Ahadi Basij Blvd drahadi89 +98 23 334Semnan UniInclusion crExclusion cri
N/A Iran (Islam Assie Jokar Khazar Blvda.jokar@ma+98 11 332Mazandaran Inclusion c Exclusion cri
3 Iran (Islam Seyed Mohammad RezMasih Danes smrhashem+98 912 11Shahid Behe Inclusion crExclusion cr
1-Feb Iran (Islam Amir Sarabi Basij Blvd drsam_ami+98 23 334Semnan UniInclusion crExclusion
3 Iran (Islam Seyyed mohammad bag Faculty of dr.fazljo +98 41 333Tabriz UnivInclusion crExclusion cr
3 Iran (Islam Farhad Pourfarzi Ardabil Unifarhad.pou+98 45 335Ardabil UniInclusion c Exclusion cri
3 Iran (Islam Azadeh Mottaghi Hemmat himottaghi. +98 21 860Iran UniverInclusion crExclusion cr
2 Iran (Islam Nima Mousavi DarzikoImam Khome mousavi-n@+98 21 669Tehran UniInclusion c Exclusion cr
2-Mar Iran (Islam Sadrollah Mehrabi Shahid Mofasadrollah +98 74 332Yasouj UnivInclusion c Exclusion cr
2-Mar Iran (Islam Mohamad Fathi Shahid Modfathi_man +98 21 235Shahid Behe Inclusion c Exclusion c
3 Iran (Islam Roshanak MokaberineFaculty of mokaberi@+98 21 887Shahid Behe Inclusion crExclusion cr
N/A Iran (Islam Seyyed Salman Alavi Roozbeh hossasi1979 +98 21 554Tehran UniInclusion crExclusion c
3 Iran (Islam Farrokh Habibzadeh R&D Headqu Farrokh.H +98 71 322Petroleum Inclusion c Exclusion c
3 Iran (Islam Mohammad FathalipoEmam Hossm.fathalip +98 76 337Bandare-abInclusion crExclusion cr
2-Mar Iran (Islam Ahmad Hosseinpour No. 256, Alahosseinp +98 71 373Health MedInclusion c Exclusion cr
3 Iran (Islam Payam Tabarsi Dr. Masih tabarsi@nri+98 21 271Shahid BeheInclusion crExclusion cr
2-Mar Iran (Islam Farahzad Jabbari-Aza Allergy Re jabbarif@m+98 51 380Mashhad Un Inclusion c Exclusion cr
3 Iran (Islam Dr. Mohammadreza B Vali-e-Asr mhmmdrz_+98 86 322Arak UniverInclusion crExclusion cr
2 Iran (Islam Dr Abbas Taher School of t_anesthe +98 81 383Hamedan Un Inclusion crExclusion cr
3 Iran (Islam Ashraf Karbasi Bagiyatollaashraf.ka +98 21 812Bagheiat-alInclusion crExclusion cr
3 Iran (Islam Maryam Hafizi No.1, Afshimhafizi@na+98 21 889Sodour Ah Inclusion crExclusion cri
2 Iran (Islam Alireza Ostadrahimi Nutrition Rostadrahim+98 41 133Tabriz UnivInclusion c Exclusion cr
3 Iran (Islam Parisa Kianpour Pharmacy fa
parisa_ki +98 21 669Tehran UniInclusion crExclusion cr
3 Iran (Islam Seyed Hasan Saadat Baqiyatallasaadat350 +98 21 824Bagheiat-alInclusion crExclusion cr
3 Iran (Islam Dr. Mohammad Fathi Shahid Modm.fathi@sb+98 21 235Shahid Behe
Inclusion c Exclusion cr
3 Iran (Islam Seyed Hasan Saadat Baqiyatallasaadat350 +98 21 824Bagheiat-alInclusion crExclusion cr
3 Iran (Islam Mohammad FathalipoEmam Hossm.fathalip +98 76 337Bandare-abInclusion crExclusion cr
3 Iran (Islam Rouhollah Ahmadiyan Pharmacy faRoohollah +98 21 669Bagheiat-alInclusion crExclusion cr
2-Mar Iran (Islam Ramin Nasimi Doost Ardabil Unimodir706 +98 45 314Ardabil UniInclusion c Exclusion cr
N/A Iran (Islam Morteza Kosari No. 16, Hakkosarimor +98 31 543Kashan UniInclusion c Exclusion
2-Mar Iran (Islam Seyed MohammadrezaDr. Masih iran.criti +98 21 271Shahid Behe Inclusion crExclusion c
2-Mar Iran (Islam Hamideh Moradi ShahUnit 3, No. hamidehmo+98 34 341Shahid Behe Inclusion crExclusion cr
2 Iran (Islam Seyed Mohammad RezMasih Danes iran.criti +98 21 261Shahid Behe
2-Mar Iran (Islam Seyad Jalil Tavakol AfsBu-Ali squaTavakolaj@+98 51 371Mashhad Un Inclusion crExclusion cr
N/A Iran (Islam Dr. Alireza Moslem Khorasan Ra alirezamo +98 51 440Sabzevar UnInclusion crExclusion cr
N/A Iran (Islam Maryam Mohammadi Ibn Sina Boba_zendeg +98 35 382Yazd UniverInclusion crExclusion cr
3 Iran (Islam Hossein Mazaherpour Valiasr Hosh.mazaher 086-32222 Arak UniverInclusion c Exclusion cr
3 Iran (Islam Seyed Mohammad RezMasih Danes iran.criti +98 912 11Shahid Behe
Inclusion crExclusion cri
N/A Iran (Islam Javad Ahmadian heris Sheshgelan,Jahmadian +98 41 352Tabriz UnivInclusion crExclusion cr
3 Iran (Islam Ali Asadirad No. 8, Sha ali.asadir +98 61 333Ahvaz UnivInclusion crExclusion cr
2-Mar Iran (Islam Payam Tabarsi Shahid Bahpayamtaba+98 21 261Shahid Behe Inclusion crExclusion cr
2-Mar Iran (Islam maryam Khoshkhui Ghaem hosp b.ghaem@m +98 51 384Mashhad UnInclusion crExclusion c
N/A Iran (Islam Mohammad RezapourBaqiyatalladrrezapou +98 21 824Bagheiat-alInclusion c Exclusion cri
N/A Iran (Islam Sajad Yarahmadi Lorestan uns.yarahma +98 66 332Khoram-Aba Inclusion c Exclusion cr
2-Mar Iran (Islam Ahvaz University of M Alimentaryzahrashok +98 61 333Ahvaz UnivInclusion c Exclusion cr
3 Iran (Islam Saeed Mohammadi Iran Blood smohammad +98 21 886Iran Blood Inclusion c Exclusion cr
3 Iran (Islam Sara Ghaderkhani Keshavarz sghaderkha+98 21 669Tehran UniInclusion c Exclusion cr
3 Iran (Islam Seyed Mohammad RezMasih Danes smrhashem+98 912 11Shahid Behe Inclusion crExclusion c
3 Iran (Islam Javad Ahmadian HerisSheshgelan.ahmadianj +98 41 352Tabriz UnivInclusion crExclusion cr
3 Iran (Islam Mohammad Sistaniza Madani Avesistanizad +98 21 775Shahid Behe Inclusion crExclusion cr
3 Iran (Islam Dr Rahim Raoufi Shahid Motsarahim15 +98 71 544Jahrom UniInclusion c Exclusion c
Phase2 Korea, RepuJoon Youn Song Koera UnivInclusion Exclusion c
Inclusion criteria: Age > 18 years
 Living in Lebanon
1 Lebanon Rami Bou Khalil rami.boukhrami.boukh 1615300 Saint Josep Speaking Exclusion
EnglishcArabic or Frenc
3 Lebanon Rasha Hamra Beirut rashahamr 01-830300 MOPH Inclusion c Exclusion c
3 Japan Chugai Pharmaceutical Co., Ltd. Clclinical-trials@chugai-pharm.co.j Inclusion c Exclusion c
N/A Japan Yoshiyuki Watanabe 3-13-1 Nakponponta@ -9532 Kawasaki RInclusion c Exclusion c
3 USA;EUROPAyako Mikami 1-21-1 Toy amikami@h -10305 National C Inclusion c Exclusion c
2 Japan Tetsuya Nakamura 3-39-15 Sh nakamurt@ -8906 Gunma Univ Inclusion c Exclusion c
2 Japan Terada Junko 1-21-1, To jterada@ho -10305 Center Hosp Inclusion c Exclusion c
3 Japan Ikeda Mahoko 7-3-1, Hon mhk-ikeda -9148 The UniversInclusion c Exclusion c
1-Feb Japan Kenji Wakabayas1-5-45,Yus waka-tmd@ -11684 Tokyo MediInclusion c Exclusion c
2 Japan Masashi Kondo 1-98 Dengamkond@fuji -9981 Fujita Heal Inclusion c Exclusion c
2 Japan Eiki ICHIHARA 2-5-1, Shi ichiha-e@m -7467 Okayama Un Inclusion c Exclusion c
Not select Japan Hironori Yamamoto3311-1, Yakireef@jichi 0285-58-7 Jichi MedicInclusion crExclusion c
Not select Japan Takuma HIGURASHI3-9 Fukuur takuma_h@045-787-2 Yokohama C Inclusion crExclusion c
Not select Japan Ikuro Matsuba 1-3 Fujimi ikuro@mat045-241-7 Kanagawa PInclusion crExclusion c
Not select Japan Tomoka Ebisui 1-22-17, K jimukyoku 03-6433-3 Takanawa CInclusion crExclusion c
Not select Japan Ryota Sagami Oaza Ichi 1 sagami198 -1868 Oita San-a Inclusion crExclusion
Not applic Japan,Asia Tomoko Nakayasu Tokyo Buil nakayasu@03-3815-0 The JapanesInclusion crExclusion c
Not select Japan,Nort Tomohiro Katsuta 2-16-1 Sug katsuta-7- +81-(0)44- St. Marian Inclusion crExclusion cr
Not select Japan Atsushi Ogata 2-6-40, Kara24ogata@06-6773-7 Daini Osak Inclusion crExclusion c
Not select Japan Yuki Ohta 1-8-1, Ino ohta.yuki@ -2271 Graduate SInclusion crExclusion c
Not select Japan Ryota Sagami Oaza Ichi 1 sagami198 -1868 Oita San-a Inclusion crExclusion
Not select Japan Junichiro Nakata 3-1-3 Hongjnakata@ju03-3813-3 Juntendo UInclusion crExclusion c
Not select Japan Takuma HIGURASHI3-9 Fukuur takuma_h@045-787-2 Yokohama C Inclusion crExclusion
Not select Japan Shingo Matsumot 6-11-1 Omoshingomat 8.13E+10 Toho UniverInclusion crExclusion c
Phase II South AmerUbiratan Adler Rodovia Was ubiratanad 5.52E+11 Sao Carlos Inclusion crExclusion c
Not select Japan Kazuhiro Araki 617-1, Tak kaz-araki@ 2.76E+08 Gunma prefInclusion crExclusion c
Not applic Japan Satoko Fujihara 5322 Endo,sfujihara@ 0466-48-3 Keio Unive Inclusion crExclusion c
Not select Japan Masakatsu Nishikawa 4-1-3 Anot nishikawa 5.93E+08 Kinki Healt Inclusion crExclusion c
Inclusion criteria:
Exclusion criteria: 1. ALT/
 1. Subject
 2.
(or Stage
legally4authorized
severe chr
 2. Understands
 3. Pregnant
and agrees
or breast
to co
Phase-3 Nigeria Hussein AbdurRazz 2, Jinadu Ohaderazz0 2.35E+12 Head of He 3. Agrees
 4.
to the
Anticipated
collecti transfe
Exclusion criteria: acute s
 â€¢ recent receipt of
 â€¢ history of throm
 â€¢ Pregnant female
 â€¢ any chronic med
Inclusion criteria:
 â€¢ Health
Any participant
care workerr
Not Applic Egypt Mahmoud Nassar Al-Motamay
dr.nassar 2.01E+11 investigato â
Exclusion criteria: Pregna
 Patients with diabete
Inclusion criteria:
 Chronic
Adult patients
medical diso
with
Not Applic Nigeria;NigJude Duru Ishaga Rd, jduruonwe 2.35E+12 Consultant Patients Subjects
with normalwho liverhave
and anre
Inclusion criteria: 1. Health care w
 2. Asymptomatic carriers wi
 3. Non-critical symptomatic
Phase-2 Egypt Hala Salah Manial str hala.salah 2.01E+11 Dean of the Exclusion c
Exclusion criteria:
 â€¢ Procedures unde
Inclusion criteria:
 â€¢ â€¢Symptomatic
Patients aged CO
Phase-3 Ghana Sohini Chakrabor Edgbaston s.chakrab 4.41E+11 NIHR Globa â€¢ Planned
 â€¢ to Existing
undergoregular
any typp
Inclusion criteria:
 â€¢ â€¢Planned
Healthy receipt
adult
Phase-1 Kenya Marianne Munene KEMRI-WelMMunene@k
2.55E+11 Research â€¢ Able â€¢
and willing
Prior (in
receipt
the Inve
Exclusion criteria: (i) Know
 (ii) pregnancy or brea
 (iii) ECG abnormality
 (iii)(i)Patients
Inclusion criteria: patientswith ALAt
above
Phase-3 Senegal Cheikh T. NDOUR Avenue Checheikh.nd 2.21E+11 Fann Teachi (ii) absence
 (iv)
dangerPatiesigns such as
Exclusion criteria: ?
Inclusion criteria:
 ? ? Those Individuals
with cardab
 ? Individuals
 ? Those with bronchial
with othea
 ? Individuals
 ? Those exposed onto SARS
supple
 ? Individuals
 ? Those that has been
with psycis
Not Applic Nigeria Sonill Maharaj varsity drivmaharajss@2.78E+10 Supervisor ? Those with stat
Inclusion criteria: Adults aged betwe
 â€¢ COVID-19
Exclusion confirmed by a RT
criteria: Contra
 â€¢ Patients
 â€¢ with moderate
Patients whosign
req
Phase-2 MadagascaMIORAMALSedera Itaosy sedera.mi 2.61E+11 MD â€¢ Patients
 â€¢ consenting
Patients whovolunta
par
Inclusion criteria: Patients between 1
N/A Spain Carlos Utrera Cefiro 14 cbernal49 3.46E+10 Universidad Exclusion c
N/A Brazil;Can Janari Pedroso Rua Augustpedrosouf 5.59E+12 Universida Inclusion c Exclusion c
N/A Brazil Julio Alencar Av. Dr. Enejulio.alen -9.44E+08 Universida Inclusion c Exclusion c
Exclusion criteria: Do not
N/A Brazil Michelle Chechter Av. Mazzei mchechter 5.51E+12 Centro MedInclusion c Present previous hea
N/A Brazil Cleandro de Albuqu Rua das Paicleandro. +55(61)99 Hospital UniversitÃ¡rio
Inclusion c Exclusion
de BrasÃclia
2 Brazil Marcos AurBarboza deAv. dos Fl mabolivei -35171811 Hospital S Inclusion c Exclusion c
N/A Brazil Welder Zamoner Rua DamiÃ£welderzam55-11-997 Departamento
Inclusion
de ClÃ
cnExclusion
ica MÃ©dica
c da Faculdad
N/A Brazil Pedro Kurtz Rua do Reskurtzpedr 5.5E+12 Instituto Inclusion c Exclusion c
N/A Brazil Welder Zamoner Rua DamiÃ£welderzam55-11-997 Departamento
Inclusion
de ClÃ
cnExclusion
ica MÃ©dica
c da Faculdad
N/A Brazil AlessandroHeubel Rodovia Waadheubel@+55(14)99 Universida Inclusion c Exclusion c
Exclusion criteria: Presenc
3 Brazil Alexandre Cavalcanti Rua AbÃlio abiasi@hco11-3053-66Hospital
Soares, 250, 11Âº andar. d Inclusion c azithromycin or othe
N/A Brazil DiamantinoSalgado;Vi PROFESSORd.salgado +55213938Hospital U Inclusion c Exclusion c
N/A Brazil Luis Nakano 754, Rua B luiscnakan 5.51E+11 Disciplina Inclusion c Exclusion c
2 Brazil Carlos Miranda Rua Bernarchmiranda-32371431 Faculdade Inclusion c Exclusion c
Inclusion criteria: COVID-19 diagnosi
 
1-Feb Brazil Bruno Pires Avenida Babrunogarci +55(16)36 Hospital das 
ClÃnicas da
Exclusion
Faculdadec de Medicina
N/A Brazil Luis Nakano 754, Rua B luiscnakan 5.51E+11 Disciplina Inclusion c Exclusion c
1-Feb Cuba Zurina Cinza Este Ave. 31 en zurina.cin +53-72085 Center for Inclusion c Exclusion c
2 Cuba Iraldo Bello River Ave. 31 en iraldo.bel +53-72085 Center for Inclusion c Exclusion c
1 Cuba Hugo Nodarse CuAve. 31 en hugo.noda +53-72085 Center for Inclusion c Exclusion c
1-Feb Mexico Juan Paz Garcia Avenue Lic dr_juanpa -3.12E+09 CancerologyInclusion c Exclusion c
4 Cuba Lilliams Rodriguez Corner G a liliamrodr 5.38E+09 Research CInclusion c Exclusion c
N/A Cuba Mayra Ramos-Suz216 and 15mayra@cim-2141609 Center of Inclusion c Exclusion c
N/A Cuba Johann Perdomo D201, 23rd tradiciona -78396251 DepartmentInclusion c Exclusion c
N/A Cuba Maria DominguezAve. 31 en mcarmen.d -2715485 Center for Inclusion c Exclusion c
N/A Cuba Maria Toledo Ro Novia del mariaeugen+53772020""Pedro KouInclusion c Exclusion c
N/A Cuba Rinaldo Puga GomeCalle 20 Nopuga@info-72042758 Clinica CenInclusion c Exclusion c
N/A Cuba Jorge Perez- Oliv Avenue 26 scnefro@in-78816389 National I Inclusion c Exclusion c
1-Feb Cuba Idania Baladron CaAve. 31 en idania.bal +53-72085 Center for Inclusion c Exclusion c
4 Cuba Ricardo Pereda GonStreet 23 2pereda.gon+53-78383 Medical Sc Inclusion c Exclusion c
N/A Cuba Luis Heredia GuCorner G a viceamcite-78382109 Research CInclusion c Exclusion c
N/A Cuba Zullyt Zamora Ro Ave 25 y 19zullyt.zam -53056476 National CeInclusion c Exclusion c
Inclusion criteria: The inclusion criter
 i) Malaysian citizen
Exclusion criteria: The exc
 ii) HCWs working
 i) HCWs in on
Klinik Kesiha
medical/m
 iii) on-duty since
 ii) HCWs 3 February 202
with underl
Phase 0 MALAYSIA DR MUNAZAB AZIZ KLINIK KE pdl_moon 6.01E+10 MINISTRY 
Inclusion criteria: (1) age >18 years
 (2) confirmed
ExclusionCOVID-19
criteria: pneumo
(1) Preg
N/A Thailand Nattachai Srisawat 1873 Ramadrnattach 8.18E+08 Excellence (3) had (2)leftoverImmunocomprom
blood samples in
Inclusion criteria: (1)
 (2) Gender:
Exclusion
Malecriteria:
or female
(1) Fe
 (3) Patients
 (2)who meet all
Patients of Sp
with the
Phase 2/PhThailand Rujipas Sirijatupha 2 Wanglangrujipas.si 8.41E+08 Faculty of 1) Patients
 (3)with SARS-CoV-2-p
Patients who sho
Inclusion criteria: 1) Person who are

 2) Healthcare personnels in hosp
N/A Thailand Krit Pongpirul 1873 Ramadoctorkrit 662-252-78Chulalongk 3) Patients
Exclusion
who will
c be performe
Inclusion criteria: (i) Thai citizens, pe
 (ii) can read and communicate w
N/A Thailand Surapon NochaiwonFaculty of surapon.n 6.65E+09 Pharmacoep
 (iii) aged
Exclusion
18 yearsc or above
Exclusion criteria: 1. Expe

 2. Pregnancy
 3. Platelet count <30
Inclusion criteria:
 4. 1.
Terminally
Age Ã¢?Â¥18
ill with
ye
 2. Diagnosed
 5. with
History
COVID-19
of allergybyt
 3. Admitted
 6.toCoagulopathy
intensive careunc un
N/A Thailand Nattachai Srisawat 1873 Ramadrnattach 8.18E+08 Excellence 4. serum 7.
IL-6 Ã¢?Â¥400
white bloodpg/mL
cell c
Inclusion criteria: Health care person
N/A Thailand Tongluk Teerasarnt 1873 Ramakulgnotb@ 8.46E+08 Chulalongk Patients Exclusion
who willc be performed
Inclusion criteria:
Exclusion
1. criteria: 1.
 2. Male 2.
or female
Abnormal labora
 3. At 3.
least onePregnant
household or plan
mem
Phase 4 Thailand Suvimol Niyomnait His Majest suvimol.n 6.68E+10 Faculty of 4. Has 4.
a negative
HIV pregnancy
patients te
Inclusion criteria: Ã¢?Â Adults (aged

 Ã¢?Â Residing in Thailand, Italy
 Ã¢?ÂExclusion
Provided criteria:
consent Ã¢?Â
to parti
 Ã¢?Â Ã¢?Â
Able to useIndividuals
a computerwho
N/A Thailand;Ma
Phaik Cheah Mahidol-Oxphaikyeon 66 2 203 6 Mahidol-Ox 
N/A France Enrique Casalino 46 rue Henenrique.ca 3.31E+10 Assistance Inclusion Exclusion c
Inclusion criteria: Patients suspected
N/A France;Fra Enrique Casalino 46 rue Henenrique.ca 3.31E+10 APHP qSOFAExclusion
>=1 (respiratory
c rate Ã¢?
0 India;Iran Patricia Garcia Av. de la C patricia.g 9.92E+08 MINISTERIOInclusion c Exclusion c

 
 (PCR), result from any sp
Phase 2/PhUnited Sta ; Clinical Trial Managem;clinicalt ;844-734-6Regeneron 

 
 - Hospitalised
 
 - Adults 18 year or older
 
 - Moderately severe disea
 
 - SARS-CoV-2 positive nas
 
Phase 4 Norway Olav Dalgard, MD PhD Akerhus Un 
 The inclusion criteria are:

 
 1. age over 60 years;
 
 2. informed consent to par
 
 The exclusion criteria are:
 
N/A Hungary ;; PÃ©ter Hegyi, MD, Ph;hegyi200 ;+3670375 Insitute fo 1. confirmed COVID-19 inf

 
 - Classified as having SSc b
 
 - PROMIS Anxiety 4a v1.0
 
 - Have regular, reliable int
 
N/A Canada ;; Brett D Thombs, PhD; ;carrier.m ;514-340-8Lady Davis 

 
 1. Informed consent form
 
 Note: If no written ICF ca
Phase 2 Spain ; Javier CortÃ©s;Alicia GarcÃ
;alicia.gar
a ;+34 611 2 IOB Institu 

 
 - who haven't been exerci
 isolation period
 
 - Who are willing to exerc
 
N/A Turkey ; Ayse Zengin AlpÃ¶zgen; ; Istanbul Un 
 
 - Male and Female patien
 
 - COVID-19 confirmed pos
 
Phase 2 United Sta ; ; Michael Gordon, MD; ;klewando ;480-583-0HonorHealt - High risk for complicatio

 
 - Volunteers ages 18 to 99
 
 - able to sign own informe
 
 - considered high-risk hea
Phase 2 United Sta Jawad Kirmani, MD Hackensack 
 - COVID-19
 
 - SpO2 between 92 and 96
 
 
N/A Belgium - Chronic obstructive pulm

 
 Plasma Ig Donors
 
 - Adult (>18 and <65-yr-ol
 
 - Convalescent donor who
N/A Italy Piero Luigi Ruggenent pruggenent0039 035 267 

 
 - Confirmed SARS-CoV-2 (
 5
 
 - Patients admitted in Cor
 
Phase 3 Pakistan ;;;;; Shoaib Ashraf, PhD; ;;;;;sohai ;;;;;+9233 Massachuse

 
 - =16 years old (>18 years
 
 - Admitted to hospital wit
 
 - Receiving supplemental
 
Phase 3 United Sta ; Donald M Arnold, MD ;arnold@m;90552591 McMaster U

 - Open to any adult individ
 United States
 
onal [Patient Registry] United Sta ; Parth Shah, MD;Parth COVID19St(888) 928-1423;888-9 - Have regular access to sm

 
 - Critically ill COVID-19 pati
 requiring mechanical ven
United Sta ; ; Paul E Wischmeyer, M;paul.wis ;919-681-6Duke Unive Surgical/Trauma

 
 - women over 18
 
 - gynecological cancer (br
 
 - therapeutic managemen
 
France ; GÃ©ry LAMBLIN;GÃ©r;gery.lamb ;472 35 58 Gynaecolog 

 
 1. Verified COVID-19
 
 2. Hospital admitted
 
 3. Daily administration of R
 
 4. Age 18 years and above
 
N/A Denmark ; Filip K Knop, MD, PhD ;filip.kra ;38674266 Center for 5. Inform

 
 - adult patient with systemi
 departments of rheumatolo
 
 
France ;; Christian JORGENSEN ;j-holubar ;4 67 33 72University - patient not

 
 
 - Able to comply and perfo
 
 
 - N/A
United Sta Britt Burton-Freeman, Ph.D Illinois Ins 
 
 - Male or female, age = 18
 
 
 - Patient is intubated and
 
Phase 2 France ;; Jean-Michel CONSTAN;Jean-mich ;+33(0) 1 4 Assistance -

 
 - Signed Informed Consen
 patient is not capable of
Croatia ;; Rok Civljak, MD, PhD; ;rcivljak@ ;++385914 University represent

 
 1. Age = 18
 
 2. Clinical diagnosis of Pne
 
 3. Life expectancy > 48 hou
 
Phase 1/PhSpain Ana Cardesa Gil ana.cardes 697 95 69 41 4. Commitment to u

 
 - Person aged over 18 yea
 University Hospital for sc
 
 - Person affiliated to a soc
N/A France ;; 
 - Any adult patient admitt
 infection (PCR Test or CT
 
N/A France ; Paul BILLOIR, pharma ; ; Rouen Univ - Patient who accept to pa

 
 - Male or female participa
 years, inclusive, or 18 an
Phase 1 United Sta ; Pfizer CT.gov Call Cent;ClinicalTr ;1-800-718Pfizer; 

 
 - Diagnosis of COVID-19 co
 Acute Respiratory Syndro
Phase 3 Spain Alberto HernÃ¡ndez, albimar23 +34 637930993 
 
 - All patients over the age
 
 
onal [Patient Registry] France FrÃ©dÃ©ric Balen, MD University - Patient admitted to shoc

 
 
 - SARS-COV-2 confirmed in
 
onal [Patient Registry] France - Prescription of associatio

 
 Inclusion Criteria Cohort A:
 
 - = 18 years old
 
 - Employee of healthcare
Phase 3 United Sta Susan Hoover, MD Sanford He location and w

 
 - Patients must be 18 year
 
Phase 2 United Sta Kristen M Petros De KMP6F@hscm
434) 924-5059 to a"floor" bed (non-ICU

 
 - Covid-19 pneumonia at l
 
 
 - no typical infiltration and
 
Turkey Hasan Haciosman academic s 

 
 - Adult patients with confi
 a Penn Medicine advanc
N/A Tim Gaulton, MD, MS timothy.g (484) 243-0682? 

 
 - Male or Female, aged at
 
 - Assessed by the attendin
 (outpatient) managemen
 
Phase 3 United Ki ; Paul Little, MD PhD;L ;atomic2@;01865 227University -
 
 - cancer patients or surviv
 
 
 - No exclusion criteria
Egypt ; Aalaa Abdou, MSc;Ah aalaamahm01222926457; 

 
 - Army Training Hospital s
 
 
 - Individuals who have alr
 
France Elodie VALERO, Phar elodie.val 4.83E+08 - Individuals taking preven

 
 1. Hospitalized for laborato
 via nasopharyngeal swab
 
Phase 2/PhUnited Sta Marion Morrison, MD mmorrison919-313-2977 

 
 - Patients who are on the
 than 18 years old (adult c
 
N/A Netherland ; Peyman Sardari Nia, peyman.sa 0031-433875070; 
 Inclusion Criteria (all of the

 
 
 2. Sars-Cov-2 found in the
 disease episode
 
N/A Sweden ;; Jonas Tverring, MD;Jo ;jonas.tve ;+4642406 Lund Univer 3. Pe

 
 
 - Admitted to the intensiv
 
 - Positive COVID-19 PCR
 
 - Mechanical Ventilation f
 
Phase 4 United States - Pa
 
 to initiation of any study
 
Phase 3 United Sta ; Alex C Spyropoulos, M;dinlall@n ;(516) 600 Northwell 2. Understands and agrees

 
 1. Aged >=18 years.
 
 2. Diagnosis of COVID-1
 assay.
 
United Sta ; Irini Sereti, M.D.;Irini ;isereti@ni ;(301) 496 National In 3. Meets one of

 
 - Be at least 18 years of ag
 
 
Phase 1/PhUnited Sta Apellis Clinical Trial clinicaltri 1-833-284-6361 - Have respiratory failure

 
 Patients with RT-PCR diagno
 and respiratory symptoms,
 
Phase 3 Brazil ; Gilmar Reis, MD, PhD; ;greisbh@u;+5531332 Cardresearc A. Persistent dry cough asso

 
 All dentist actively working
 
 
 - non dentist
 
 - resident outside egypt
Egypt 

 
 - Active military or civilian
 (BA110) during the perio
 
France ; Sandrine DURON, MD,sandrine.d 179865745;36536695 
 Inclusion criterion:

 
 1. Bangladeshi aged 40-65
 (hospitals)
 
 2. Either sex
 
Phase 2 ; Wasif Ali Khan, MBBS ;wakhan@i;9827001- Internation 3. At the enrollment havin
 
 - 18 years of age or older;
 
 - Military or civilian or con
 COVID-19 pandemic.
 
France ; Jean-Nicolas TOURNI jean-nicol 178651065;14146687 Exclusion Criteri

 
 - Diagnosis of COVID relat
 
 - Informed consent freely
 
 Exclusion criteria
 
 - Age less than 18 years
Italy ; Giuseppe Bellelli;Giusegiuseppe.be+39 039 233 9638; 

 
 - Verified Covid-19 infectio
 
 - Intubated due to respira
 
 - Informed consent from p
 
N/A Sweden ;; Henrik Bergquist, Asso;henrik.be ;+46 31 34 Sahlgrensk 
 - Age = 18 < 75 yr;
 
 - Gender: both;
 
 - COVID-19 positive: disea
 
 
N/A Italy ; ; ; ; ; ; ; ; Nagarathna Raghuram,;;;;;;;pres ;;;;;;;+39 Vivekanand 

 
 - Age = or > than 18 years
 
 - Laboratory-proven COVI
Phase 2 Brazil ;; Esper G KallÃ¡s, PhD ;zelinda.b ;55-11-26 University symptom onset less than
 
 
 - Cleveland Clinic Employe
 
 - Must not be pregnant
 
 
N/A United Sta ; Matthew Kampert;Makamperm@c
2162195751;216-219- - Medical condition that w

 
 - Participant is willing and
 trial
 
 - Male or Female, aged 18
 
Phase 2 ; Mona Bafadhel, MBBS;mona.baf ;(+44) (0) University - New onset of

 
 - Unvonluntary commitmen
 march 12th to april 19th (20
 
 
France Emilie Olie, MD PhD University - refusal
 - Inclusion Criteria:

 
 1. 18 years old or older
 
 2. Patients who have be
 pneumonia
 
Phase 2/Phase 3 ; IN-GYU BAE, MD;IN-G ;ttezebae ;+82-55-75Gyeongsang - Con

 
 - Adult patients (18+)
 
 - Infection with COVID-19
Monaco ; Atul PATHAK, MD Ph atul.patha +377 97 98 97 74;+377 by thorax CT-scan sugges

 
 - age = 18 years,
 
 - patients with confirmed
 
 - or patients suspected (ev
 
N/A France ; LEROY Sylvie;Leroy Syl;ARCSpneu;+3349203 CHU de Nic - OR patie
 
 - Patients positive for SAR
 May 2020
 
France;Mar Julien Frandon CHU Nimes - Patients undergoing low

 
 - Hospital staff (medical an
 
 
;;;;; Nathalie Dr DEMORY, ;;;;;marie ;;;;;+33 1 AP-HP, HÃ´p
 - Benefiting from or havin

 
 - Confirmation of COVID-1
 
 - Experiencing moderate t
 
 - Between 18-65 years of
 
N/A Canada ; Andrea Berk;Andrea Binfo@covidl1-800-517-8010; 

 
 - =18 years old
 
 - Admitted to hospital wit
 
 - Receiving supplemental
 
Phase 3 United Sta ; ; Marshall Glesby, MD;C;cea4002@;212-746-4Weill Corne - 500 mL of ABO compatib

 
 Plasma Ig Donors
 
 - Adult (>18 and <65-yr-ol
 
 - Convalescent donor who
N/A Italy Piero Luigi Ruggenent pruggenent39035267 

 
 - COVID-19 infection at an
 direct contact with a pos
 
 - Pregnancy documented
 
onal [Patient Registry] United Sta ; Rachel Pope, MD, MP rachel.pop 4129792939; 
 - Adults (age > 18 years ol
 
 - Admitted with confirmed
 
 - Patient exhibiting acute
 
Switzerlan ; ; Emanuela Keller, Prof.;emanuela.;0041 44 2 University 

 
 - Patients undergoing eme
 
 
 - None
United Kingdom 

 
 - Known diagnosis of activ
 
Phase 1/Phase 2 John Mei jmei@teli 650-542-0136 

 
 - All COVID-19 positive pa
 
 - Participant must commu
 
 - An email address and ac
 
N/A Canada ; Anthony Tang, MD;Maanthonysl 519-663-3764;519-68 E

 
 1. Age between 18 and 60
 
 2. Health care worker in th
 COVID-19.
 
N/A ; Beatriz H Aristizabal, ;beatriz.a ;31044987 Unidad de 3. Negative IgM antibod

 
 - Adult women (aged 18 a
 from January 1, 2019 to
 
 - Able to read English
 
N/A United Sta ; June K Robinson, MD; ;june-robi ;312-503-5Northweste 
 
 - Hospital having ICU durin
 
 
 - Hospital refuse to partici
France ; Jean-Yves LEFRANT, Mjean.yves. +33466683050;33466 

 
 - patients >18 years,
 
 - admitted for acute COVI
 hospitalization,
 
France - COVID-19 diagnosis conf

 
 - Adults =18 years
 
 - COVID positive by RT-PC
 
 - = 6 months post-transpla
 
Phase 2/Phase 3 ; Jamil Azzi, MD, PhD; ;fmccausl ;61773264 Birgham an - use of anti-metabolite (m

 
 1. Age = 60 years.
 
 2. COVID19 + confirmed by
 
 3. Thoracic imaging study (
 involvement.
N/A Spain ; Manuel Gonzalo Vazq manuelgonz913003000;91300300 
 - > 18 years
 
 - Students of any undergr
 online
 
 
Mexico Alejandro Gonzalez O avygail5@ 5.23E+10 - St

 
 - Age < 18 years
 
 - Admitted to PICU from A
 
 - Presented with an acute
 infection
France ;; Marion Grimaud;Sylva;;marion.g ;;1 87 89 2 Assistance Covid-19 infection treated w
 public hospitals)
Austria Vanessa Stadlbauer, vanessa.st 43316385 

 
 
 - Covid-19 infection diagn
 result from a nasopharyn
 
N/A Austria - Su

 
 - (early)postmenopausal w
 
 - Osteopenia and osteopo
 
 
N/A Germany Michael Hettchen, MSc Institute o 
 
 2. Severe or life-threatenin
United Sta ; Marc Klapholz, MD, ;klapholz@;973-972-4Rutgers New
 the following: i) dyspnea

 
 - Informed consent, provid
N/A United Sta ; ; James Veltmeyer, MD;;thomas.i ;18583534 Therapeutic 

 
 
 - At least 18 years old
 
 - Symptoms of shortness o
 
Phase 3 United Sta ; ; Hunter Gilles, MD;Vale;valerie.p ;908-574-4Belleropho - Subjects must

 
 - Positive reverse-transcri
 CoV-2 in a respiratory tra
 
 
Phase 2/Phase 3 - Know
 
 - Age >= 18 years
 
 - Population in Cancer cen
N/A France ; Magali Briere;Magali magali.bri 0240679900;0240679 a treatment in process, p

 
 Age 18 years of age or olde
 
 WITH
 
 Symptomatic COVID-19 dise
Phase 3 United Sta ; Todd C Lee, MD MPH ;quebec@id;51493419 Research In 
 Inclusion Criteria:All patient

 ward/ICU of Max Hospital S
India ;; Kaushal Madan, DM;K;K_madan_;99587877 Max health or MAX Smart Super Specia

 
 - all residents, staff physic
 both inpatient and outpa
United Ara ; Wael Almahmeed, MD;;ovidiu.ba ;?+971 2 8 Cleveland C 

 
 - Patients admitted to inte
 
 
Spain ;; Javier Hortal, MD PhD ;mati@plag;00346578 Hospital U - Patients in critical care u

 
 - All emergency departmen
 
 
 - Negative screening for C
 
Norway ; Lars Petter BjÃ¸rnsen ;lars.p.b. ;+4793212 NTNU/St. Ol - recent negative CO

 
 - diagnosis of an SCI; are 1
 Louis area, and have the
 
 
United Sta ; ; Kerri A Morgan, PhD; ;walker.k@;314-273-7Washington
 
 
 2. All genders
 
 3. Hospitalization for suspe
Phase 3 ; Susanne Benseler, MD;jacinda.l ;40395555 University defined as positive on re

 
 - patients diagnosed with
 25th, 2020 in the emerge
 
Turkey Murat Civan, M.D. civanciva 9.05E+11 

 
 - pregnant women
 
 
 - non pregnant women
Egypt ; Mahmoud Alalfy;Mahm
mahmoudal01002611058;+20100 

 
 signed inform consent COV
 with positive polymerase ch
Phase 3 Russian Fe ; Julia Begrambekova;J julia.beg +79854679273;+7985 (

 
 
 - Suspicion or confirmed d
 confirmation)
 
N/A United Ki ; Sandy Jack, pHD;Sandys.jack@sot 02381205308;023812 Excl
 Inclusion Criteria for Enrollm

 
 1. COVID-19 diagnosed by
 
 2. men and women
 
 3. any race/ethnicity
 
 4. 18-65 years of age
 
Phase 2 United Sta ; ; Jeffrey D Hasday, MD; ;jhasday@ ;410-328-8University 5. endot

 
 - Severe Pneumonia defin
 (cough, sputum producti
Phase 3 United Sta ; Joe Levitt, MD;Joe Lev;jlevitt@st ;650-723-6Stanford Un 
 Study Participants The stud
 delivering direct care to pati
 
 
N/A Thailand;U William Schilling, MD Mahidol Ox 1. Participant

 
 1. Male or female, aged = 1
 but with tomographic and c
Phase 2 Brazil Florentino de Araujo florentino +55 19 991232882 (COVI

 
 1. Males and females, at le
 consent;
 
Phase 3 United Sta ; ; Jean-Claude Tardif, M ;;jean-cla ;;514-376- Montreal H 2. Patient must have recei

 
 - COVID-19 induced adult
 
 - PaO2/FiO2 is less than 2
N/A United Sta ; ; Jie Li, PhD;Jie Li, PhD; ;Jie_Li@ru ;312-947-0Rush Unive HFNC trea

 
 - Adults = 18 years of age
 
 - Approval from the patien
 
 - Admitted as an inpatient
 
Phase 2 United Sta Pankti Reid, MD, MPH University - Fever,

 
 At least 18 years of age at t
 
 Hospitalized for COVID-19.
 
Phase 2 United Sta ; Maria Walters, M.P.H.;mwalters@(650) 443-7366; Diagnosed with COVID-19 a

 
 
 
Phase 4 Netherland ; 
Niels van Royen, MD ;Roland.v ;+3124361 Radboud Un - Confirmed SARS-CoV-2 in
 
 - from covid 19 positive m
 
 - newborn mothers had n
 
 
 - from covid 19 negative m
 
Turkey <
 Prevention Study Inclusion

 
 1. Capable of understandin
 to the requirements and
 
Phase 2 Canada Jeremy Road, MD Private Pra 2. Men

 
 - Symptomatic patient wit
 
 - Presenting at least one c
 
N/A ;; Pierre PATOZ, Pharm ;;ppatoz@c;;0320694 CH Tourcoi - Respiratory fai

 
 - Positive COVID-19 test
 
 - Outpatient
 
 - Age >/= 19 y.o.
 
 
 - Allergic reaction to trane
 
Phase 2 United Sta ; ; Timothy J Ness, MD P ;tness@ua ;20590797 University 

 
 - Age: 18 years or older (in
 
Phase 1/PhUnited Sta ; Claire Xu, MD, PhD;US;US.Info@ ;240-767-6I-Mab Biop chain reaction (PCR

 
 - The following 2 criteria m
 
 - Worrying about Covid
N/A Sweden ;; Erik M Andersson, Ph ;erik.m.an ;+4673671 Karolinska fear of death, econom
 
 - All clients and health car
 
 
United Sta ; John W Sanders, MD, ;jwsander ;336-70-C Wake Fores - Health care workers who

 
 1. Male or female adult = 1
 
 2. Subjects with mild-to-m
Phase 2 United Sta Kush Dhody, MBBS, Mkushd@ama
301-956-2536 2019 infection

 
 - Ability to read, speak and
 
 - Being professionally acti
 unit;
 
Belgium Julien Tiete, PhD UniversitÃ Exclusion

 
 - Age = 18 years old,
 
 - Hospitalization for COVID
 method,
 
Phase 2 France ; Jean-FranÃ§ois MORNE
;vincent.co;4 27 85 77Hospices Ci - Peripheral saturation by

 
 - Patient with respiratory
 
 - Patient who is selected f
 
Canada ; Tarek Loubani, MD;Ta tlouban@u5194886475;(519)488 INCLUSION CRITERIA:

 
 1. Provide written informe
 
 2. Age greater than or equ
 
United Stat Sharon Segal Raim sharon.seg 240-669-5219 3

 
 - 18-75 years old SARS Co
 the 96 h before randomi
 
Phase 2/PhFrance Jacques REYNES, MD,PhD Montpellier - Beginning of COVID-19 s
 
 - General practitioners pra
 consent to receive e-mai
France ; Jean-Pascal FOURNIERjean-pasca 2.40.41.28.28;2.40.41 

 
 - If symptomatic, presence
 distress, with positive for
Phase 2 United Sta ; Yvonne (Bonnie) A M ;altamira@;650-721-5Stanford Un to.in

 
 - Critically ill patients infec
 
 - Patient aged 18 years or
 
N/A India ;; Anil Avhad, MBBS;Nom;;sanjay.p ;;+912714 Cadila Pha - Illness of any duration w

 
 1. Male or female adult = 1
 
 2. Subjects hospitalized wi
Phase 2 United Sta Kush Dhody, MBBS, Mkushd@ama
301-956-2536 infection as define

 
 
 
N/A Brazil Florentino de Araujo florentino +55 19 991232882 3. Laboratory confirmation

 
 - Primary care professiona
 
 - Any patient undergoing
 
 
 - None
France ; Jean-Pascal FOURNIERjean-pasca 2.40.41.28.28;2.40.41 

 
 - Adults > 18 years of age
 capable of giving consen
 
Phase 3 United Sta ; Cameron Durrant, M ;oahmed@;201-509-0Humanigen, - Virologic confirmation of

 
 - Study A: All patients bein
 (USB) and with residency
Switzerlan ; Adrian Egli, Prof. Dr. ;adrian.eg ;+41 61 55 Division of incl
 
 - Female and male patient
 
 - Proven and symptomatic
 
 - Patient age = 18 years
 
Phase 4 Austria;Ge Axel Bauer, MD axel.bauer 4.35E+12 - Provi
 1/ Medical personnel expos

 
 
 - Every willing member of
N/A France Barbara SEITZ-POLSK seitz-polsk 33 4 92 03 55 02 transfer of patients with

 
 - Patients requiring clinica
 require hospital admissio
 
Phase 2 United Sta ; Kevin Schulman, MD; ;jcunning@;650-724-7Stanford Un - Patients who are within

 
 - Positive SARS-CoV-2 infe
 
 - Onset of symptoms < 72
 
 
Phase 3 France ;;;; Denis MALVY, Pr;Xavi ;;;denis.m ;;;0557822 University 
 1. Signed Informed Consen
 any study mandated pro
 
 2. At least 18 years old
 
Hunter Gilles, MD Acting Chie 

 
 - Ability of subject to unde
 
 
United Sta ; ; Kamille A West, M.D.;K;kamille.w ;(301) 594 National In - Abilit

 
 - Patient over 18 years of
 
 - Patient with a suspected
Phase 3 France ;; Mary DAVAL;Mary Dav;mdaval@fo;01480368 Hopital Fon confirmed by PCR, or con
 Key inclusion Criteria:
 
 - Adults = 18 years old (fo
 
 - Body weight =40 kg
 
Phase 3 United Sta Novartis Pharmaceuticnovartis.e 1-888-669-6682 - Informed consent must b

 
 - Diagnosed with Covid-19
 
 - Ventilated in ICU for at le
 
 - ICU discharge between 4
 
N/A France ; JÃ©rome MOREL, MD;jerome.mo;04778285 CHU de Sai - Approval received from a

 
 - hospitalization at Univer
 
 - hospital discharge max. 4
 
 - requiring supplemental o
 
Switzerlan ; ; Christian F Clarenbac ;christian ;+41 44 25 University E

 
 - Confirmed respiratory tr
 sample or a bronchoalve
 
Phase 2 France ; David DELARBRE, MD;J;jean-phili ;04 94 14 French Arm - Patient hospitalized with

 
 1. Informed consent prior
 testified to prevent pape
 
 2. Patient of both sexes, an
 
Phase 1/PhSpain Ana Cardesa Gil ana.cardes 697 95 69 41 
 1.Patients confirmed positiv
 
 
 1.Patients with flu like symp
India ; Bharat Aggarwal;Raje Bharat.Ag 9810077484;9818474 
 
 - Presentation with severe
 COVID-19, currently intu
 
 
N/A United Sta Maxwell Weinmann, MD Emory Univ 
 1. A test for COVID-19 take
 
 2. Signed, informed consen
 
 
Denmark ;; Henning Bliddal, DMS ;henning.b ;+4538164 The Parker 1. Former

 
 
 - CALL score = 9 (progress
 
 - PCR-confirmed COVID-19
Phase 2 Chile ;; Maria Elvira Balcells, ;ebalcells@;+562 235 ebalcells@u 

 
 1. age over 18 years
 
 2. definitive proof of COVID
 
 3. acute respiratory failure
Phase 1/Phase 2 ; Jim Lewis, MD;Gordon;gordon.ba;519-685-8Lawson Hea<

 
 Patients eligible for enrollm
 
 1. Male and female adults
 
Phase 3 United Sta Dr Clemency, MD bc34@buff716-604-7554 2. Positive S

 
 - A referral from the atten
 
 - Suspected pneumonia
 
 
 
N/A Russian Federation 
 
 - Hospitalized
 
Phase 2 United Sta ; Janssen Pharmaceutica;JNJ.CT@sy;844-434-4Janssen Ph infection as determined

 
 - Phase I
 
 - Undergoing routine th
 endotracheal tube at
 
 - Phase II
N/A United Sta Joseph Woo, MD Stanford Un
 1. Provision of written info
 Representative.
 
 
N/A Argentina ; ; Dante M Beltramo, P ;dantemig ;54 9 351 Centro de 3.

 
 - All patients tested for COV
 
 No exclusion Criteria.
France Nicholas MOORE, Pr nicholas.m 5 57 57 15 60 

 
 
 - Confirmed diagnosed of
 
United Sta ; Tiziano Barbui, Prof;A ;amasciull ;03526789 Fondazione
 
 - Need for orotracheal int
 
N/A Brazil ; Ernesto Cesar Leal Ju ernesto.le +55 11 33859134;+55 - Invasive mechanical ven

 
 1. Older than 18 years old
 
 2. Meet the diagnostic crit
Phase 2/PhIran, Islam ; ; ; ; ; Mohamadali Sahraian,;;;;zhilay ;;;;+98 21 Tehran Univ 
 
 - Participant or legally aut
 consent
 
 - Receiving care at a partic
 
United Sta ; ; Charlie Kim, PhD;Will ;;leerac@v ;;650-880- Verily Life - Ag

 
 
Phase 2 United States;Israel - Male or non-pregnant fe

 
 - Pregnant Patient with CO
 
 
 - Those with known sexua
Turkey ; Merve Aldikactioglu T drmrve@ho+905325602366;+905 

 
 - Pregnant patients with C
 
 
 - Patient giving Preterm La
Turkey Merve Aldikactioglu T drmrve@ho9.05E+11 

 
 - Patients aged 18 years o
 
 
 

 
 - RT-qPCR SARS-CoV-2 pos
 pneumonia
 
 - Hospitalization by medic
 
Phase 3 Mexico ; Jose Manuel Arreola dr.jmag@g4494632049;4494632 
 
 - The study population wil
 subspecialties (Glaucoma
United Sta ; Megan C Barrett, CPO M.barrett 615-875-4216;615-87 

 
 1. Persons over 1 years of
 
 2. .Meet COVID-19 confirm
 
onal [Patient Registry] Mexico ;; Adrian Camacho-Ortiz;md.eduar ;+52 81179Hospital Un 1. Living in the same ho

 
 - being Turkish
 
 - understanding Turkish
 
 - currently living in Turkey
 
 - being between the age o
 
 - being literate
Turkey <

 
 - Patients with confirmed
 
 - Onset of symptoms lead
 
 - Patients = 18 year old;
 
Phase 4 Brazil ;; Renato D. Lopes, MD, ;renato.lo ;55 11 590 BCRI; 

 
 1. Obtaining the informed
 the patients.
 
Phase 2/PhColombia ; Santiago Jaramillo;Sansjaramillo@+573128092776;+57 2. Adult patients =18 years
 Inclusion Criteria (must mee

 
 
 2. Documented COVID19 p
Phase 2 United Sta ; ; Paul C Cremer, M. D.; ;cremerp@c;216-444-6The Clevela
 - Any patient that has don
 of March and 31:st of Ma
 
Sweden ;;;; Jens Wretborn, MD;Pa;;;daniel.w ;;;+46103 Emergency - Any patient that has
 
 - Age 18 or older.
 
 - Reports having had a po
 
 - Reports resolution of CO
United Sta ; ; Larry Corey;Shelly Kar ;;ckarg@fr ;;(206) 66 HIV Vaccine 

 
 - Healthy workers asympt
 
 - Ability to consent with th
 
 - Age above 18 years old
 
Germany ;; Barbara von Ingerslebe;Sandra.Ka ;02204 830Miltenyi Bi - Full time empl

 
 - Immunocompromised pa
 
 - Immunocompromised pa
 
United Sta ; ; Grace Aldrovandi, M.D;AshleyGr ;310 825-6 University - Patient with a diagnosis

 
 - Being pregnant with a di
 
 
 - Suspected COVID-19 dia
Turkey 

 
 - Within 7 days of patient'
 
 - Positive SARS-CoV-2 RT-P
 
 - At least one risk factor fo
N/A ; Ory Wiesel, MD;Ory W;owiesel@ ;718-283-7Maimonides
<

 
 - National Health Service s
 students, as well as bank
 
N/A United Ki ; Dr Holly Blake, PhD;S holly.blak +44(0)115 8231049; -
 
 1. adult aged 18 years and
 
 2. able to understand instr
 
 3. Stage 1 COVID-19
 
 4. < 5 days of illness or dia
 
Phase 2 Malaysia ;; NURUL A MOHAMED;N;drnurul@u;+6012964 Universiti Exclu

 
 - Minimum age 18 years
 
 - voluntary participation
 
 
 - Subject refuses to partic
Austria ;; Eva Reininghaus, Prof.;eva.reini ;00433163 Medical Uni 

 
 - Male or female between
 breastfeeding. WOCBP m
 
Phase 2 United Sta ; Pfizer CT.gov Call Cent;ClinicalTr ;1-800-718Pfizer; - P

 
 - being Turkish
 
 - understanding Turkish
 
 - being between the age o
 
 - being literate
 
 - have internet access
 
Turkey Inclusion Criteria: STEMI Pa

 
 -
Italy 

 
 
N/A Spain ; Carlos Ferrer Albiach ;francisco. ;96435445 Hospital Pr by the presence of ALL th
 
 1. Adult male or female =1
 
 2. Proven COVID-19 infecti
Phase 2 United Sta ; ; Mark L Levitt, MD, P ;mark@red;+972-3-54RedHill Bi oropharyngeal) AND pne

 
 1. Adults =18 years of age
 
 2. Mechanically ventilated
 
 3. Positive or possible COV
 
 
Phase 3 Canada Angela Jerath, MD angela.jer 416.480.6100 1.

 
 - Patient included in a Me
 and 43 years of age
 
 - Patient who has already
France ; Catherine RONGIERES catherine. 33 3 69 55 34 56;33 3 
 - Males and females, at le
 
 - Patient must have receiv
 confirmed by PCR test.
 
Phase 3 Spain Carlos Richard carlos.ric 9.42E+08 
 1. Informed consent.
 
 2. Age of 18 years or more
 
 3. Patient with suspected C
 
Phase 2 Spain ; Antonio Cubillo, MD;A;secretar ;+34 9175 Director; 4. D-dimer> 500 ng / m

 
 - Volunteers
 
 - aged over 50 years
 
 - both sexes
 
 - clinical diagnosis of idiop
 
N/A Brazil ;; Leonardo A. PeyrÃ©-T;leonardo. ;+5551330 Federal Uni - PD staging between 1 an
 
 - Patient is SARS-COV2 po
 
 - Without oxygen a satura
 
 - At least 3L/min oxygen d
 
Phase 1/PhNetherland Roger Bruggemann roger.bru 3.12E+10 - Patient is 16 years and o

 
 - Patients aged > 18 year
 
 - Diagnosis of primary fibr
 
 - Newly diagnosed and fol
 
Egypt Ahmed Abogamal Al-Azhar Fa - Patients who have physi

 
 - Pulmonologists of Langu
 
 - Actively working
 
 - Registered
 
 
 - refusal to participate
France Arnaud Bourdin, MD PhD University 

 
 - All patients over 15 year
 
 
onal [Patient Registry] France Paul-Henri Auboiroux, MD University - Patient admitted to shoc

 
 - Patient with COVID-19 p
 
 - Positive PCR for COVID-1
 tracheal aspiration or LB
 
N/A France ;; Elise NoÃ«l-Savina, M ;noel-savi ;05 67 771 University 
 
 
 
 - ICU admission
 
 - Mechanical ventilation d
 
; PÃ©ter Hegyi, MD, Ph;hegyi200 ;+3670375 Insitute fo 

 
 - Patients with PCR positiv
 
 - Hospitalized with moder
Phase 3 ; Hany ASSAAD, MD, Ph;samir.ass ;00201223 University Ministry of Health Nation

 
 - Aged 18 years or older
 
 - Willing and able to unde
 
 
 
United Kingdom 

 
 - patients with proven or s
 endoscopic interventions
 
 
onal [Patient Registry] Germany - all other pati

 
 - an age of 18 years or old
 
 - availability of a mobile d
 internet, and
 
N/A Spain Oscar Len, MD, PhD Vall d'Hebr - discharged fro

 
 Laboratory of IMSS
 
 
Mexico ;; Constantino LÃ³pez MacÃ
;constanti
as, PhD;Constantino
;52 55 562 UIMIQ
LÃ³pez
Hosp
MacÃ
 as, PhD;Suria
- Patients
Loza
with
Jalil,immunosu
MD
 
 - Primary dental practice i
 
 
 - Dentist
 
 
United Sta ; ; Cameron G Estrich, M ;estrichc@ ;312.440.2 American D - Primary dental pract

 
 
 
Phase 2 Florentino de Araujo florentino +55 19 991232882 3. Laboratory confirmation

 
 - Patient admitted to cove
 
 - Patient had COViage app
N/A United States COVID-19 test

 
 - MURDOCK Study particip
 have a valid email addres
 
 
; Kristin Newby, MD;Ab ;abha.sin ;91055493 Duke Unive - MURDO

 
 - Not previously diagnosed
 
 - Not currently symptoma
 
Egypt Khaled Eissa Amer, MD Exclusion Criteria:

 
 Covid-19 positive patients o
 
 -
 
 
 - Exclusion criteria is ongo
N/A Sweden ;; BjÃ¶rn Persson, MD P ;jacob.karl ;+4685177 Karolinska 
 
 - workers in health service
 biologists
Italy Eleonora Giuntoli, MDeleonoragu0039 0831 537323 

 
 pneumonia and respirato
N/A United Sta ; Lucie Uncapher;Sara ;sara.twom;970-297-6University 

 
 
 - COVID-19 confirmed by p
 
 - CT scan at intensive care
 
Turkey ; Isil K GÃ¼ldogan;Isil isilkose66 02324330810;+90232 <

 
 1. Adults =18 years of age.
 
 2. COVID-19 positive by PC
 respiratory severity as fo
 
Phase 2 United Sta ; ; Bruce Liang, MD;Patti ;keltonic@ ;860-679-4UConn Heal 

 
 1. Clinical and / or radiolog
 
 2. Positive test for SARS-Co
 
 
Italy 1. Age les

 
 - Men and women submitt
 
 - Not engaged in regular e
 
 
N/A Brazil ;; Bruno Gualano;Bruno ;gualano@ ;+5511 30 HC FMUSP; -
 
 - Participants resident in I
 
 - Voluntary completion of
 
 
 - People can not use mobi
India Vishwes Kulkarni University 

 
 - Female
 
 - Undergoing IVF/ICSI trea
 
 - Planned for an oocyte re
 
N/A Liese Boudry, MD liese.boud 3.25E+08 - PCR positive of SARS-CoV

 
 - Adult patients =18 years
 
 - Laboratory confirmed 20
 nasopharyngeal/orophar
 
Qatar ;; Dr. Eman Elmekaty, P ;Eelmekat ;40254259;Hamad Medi
 -

 
 1. Voluntarily participating
 informed of the study an
Phase 3 China;Ger Dionisio Barattini, M barattini@ 4.08E+10 

 
 - Students must be enrolle
 MontrÃ©al.
 
 
N/A - Students who have retur

 
 
 
 3. Hospitalized adult patie
 
Phase 2 United Sta ; ; Paul Mathew, MD;Chri;clawlor3@;617-636-5Tufts Medi 4.
 
 randomization
 
Phase 1/Phase 2 ; Clinical Trial Managem;clinicalt ;844-734-6Regeneron - Is experiencing =1 of the

 
 - Asymptomatic mild case
 RNA swap
 
 
N/A Egypt ;; houssam ho masoud, ;ehabkama;01006162 COVID scein - Contraindications for the

 
 - Has virologically confirm
 
 - Has respiratory symptom
 
Phase 1 Medical Director Merck Sha - Requires supplemental o

 
 1. age =18 years old, gend
 
 
N/A 3. the time from the first p

 
 All patients
 
 
 - Patients = 18 years of ag
 
Phase 2/PhColombia ; Guillermo E Quintero, quiquequin5716030303;5716030 - Patients in standard care

 
 - All healthcare workers w
 days or more had passed
 
Mexico Exclusion Criteria
 Recipient Inclusion Criteria:

 
 - Patients with severe COVI
 convalescent plasma within
Phase 3 India Dr Meenu Bajpai, MD meenubajp 1.15E+09 
 
 1. Adult 18 years-old and o
 
 2. Person in employment (
N/A France ; Brice RICHEZ, MD;Bri b.richez@b+33.5.56.33.32.17;+33 17th, 2020, the date of n

 
 - stroke, spinal cord injury
 all severities, including co
 
 - live in the community
 
Canada ; Eldon Loh, MD;Eldon ;Eldon.Loh ;51968542 St. Joseph' 

 
 - Cases: Admitted to inten
 Swedish intensive care re
onal [Patient Registry] Sweden 

 
 1. A written, signed inform
Phase 2 ;; Steve Pastores, MD;M;;mmorre@;;+336033 Memorial S part

 
 - confirmed covid 19 infec
 
 
 - informed refusal
Hungary MÃ¡rta SzÃ©ll, MD, Ph.D. University 

 
 - Patients with rheumatoi
 biological DMARD (bDMA
; Jean-Guillaume Letaro;jeanguilla ;03204469 University H 

 
 - Any adult employee of th
 participate in the study.
 
 
N/A Belgium ; Sabine Allard, MD;Lausabine.all 1923369;1929849 - UZ Brussel employee
 
 - patients recruited by fam
 physical distancing meas
 
 
N/A Belgium - Patients

 
 - Ages 18 years old and up
 
 - School district employee
 
 - Smartphone or device th
 
N/A Simon B Goldberg, Ph sbgoldber (608)265-8986 Excl

 
 1. Patients above the age o
 
 2. Patients with a diagnosi
 
N/A United Sta ; Anne Drewry, MD;Kati;cmdalton ;314-747-6Washington 3. Patient maximum baseli

 
 
 - COVID-19 symptom onse
 
Phase 1/Phase 2 ; Clinical Trial Managem;clinicalt ;844-734-6Regeneron - Hospitalized for COVID-1

 
 - Nursing staff working 8 o
 the hospital of Saint Etie
 
France ; Jean-Luc PERROT, MD ;j.luc.perr ;(0)4 77 82 CHU SAINT - Subjects affiliated to or e

 
 - Suspected COVID-19 infe
 
 - Metastatic or advanced
United Ki ;; Sheela Rao, MD FRCP;;Sue.Crom ;+44 (0) 2 Royal Mars 

 
 1. The study should includ
 San Gerardo Hospital of
 
Italy ; Dante Jean Garavello werner.gar0392333626; - discharged from the C
 
 - Patients 18 years old or a
 
 
 
 - Explicit refusal to particip
Italy ; Paolo Bonfanti;Paolo paolo.bonf +39 039 233 9310; 

 
 - Age> 70years
 
 - Patient hospitalized on t
 a diagnosis of COVID-19
 
France ; Maxence MEYER, MD;maxence.me
33 3 88 11 56 16;33 3 

 
 - Age 3-11y
 
 - English used as a main la
 
N/A United Ki ; Tamsin M Holland B drtamsinh 07977160976;079771 - Glue ear with a hearing l

 
 - Continuous inclusion of p
 myocardial infarction and
 
 
China ;; Hongwei Li;Hongwei Li;lhw19656 ;0086 10 6 Beijing Fri

 
 - Confirmed SARS-Cov-2 d
 lavage
 
 - Respiratory failure onset
 
Phase 2 

 
 1. Documentation of Covid
 PCR.
 
 2. Patients who have no cl
Phase 1 Frank Tung, Ph.D info@gene 1.77E+10 
 - Individuals aged 18 or ol
 
 - Diagnosis of Major Depre
 
N/A Spain ; Mauro GarcÃa-Toro, PhD;Mauro
mauro.garc+34
GarcÃ
971
a-Toro,
259966;971
PhD - Two previous treatment

 
 - Age above 18 years.
 
 
 - Subjects should have ban
Phase 2 ; Derek W Guillory, MD.;celler@ce ;713-590-1Root Cause screen tests for HIV,

 
 - patients with SARS for CO
 
 
onal [Patient Registry] Brazil ; Sergio Brasil, PhD;Ser sbrasil@al +5511981210990;551 - the absence of legally au

 
 1. Healthy adult volunteer
 
 2. Subjects negative for hu
Phase 1 Singapore ; ; Jenny Low, MBBS;Justi;justin@ty ;+65 9002 SingHealth virus surfa

 
 - Severe COVID-19.
 
 - Infection confirmed by P
 
 - Hospitalized in general r
 
 
Phase 2 ;; Guillermo SÃ¡nchez-Vanegas,
;;jjsprock
MD,;;+573538
PhD;CarlosFundaciÃ³n
Escobar-Soto,
 MD, PhD;Jhon Jaime Sprockel D

 
 1. Subject (=18 years old) o
 prior to initiation of any s
 
Phase 2 Belgium ; Geert Meyfroidt, MD, ;geert.mey ;00321633 UZ Leuven; 2. Subject (or legally autho
Inclusion criteria: 1. Study participan
 2. Be aged
Exclusion
18-70criteria:
years at1.the Pri
tim
 3. High 2.
risk exposure
Presence
health
of any
care
Phase 2 / Australia 3. Any cardiac arrh
 â€¢ Less than 18 yea
 â€¢ Pregnancy
 â€¢ Displaying active
 â€¢ History of deme
Not Applic Australia Inclusion c â
Phase 1 Australia Inclusion c Exclusion c
Exclusion criteria: Current

 or
Not Applic Australia Inclusion c Have facial beard
 â€¢ Less than 18 yea
 â€¢ Have been intub
Inclusion criteria:
 â€¢ Patients
Documented
includedsigi
Phase 1 / Australia â€¢ Proven or highly
 â€¢ Deathsuspected
is immin
Not Applic United States of America Inclusion c Exclusion c
PediatrÃ
a ClÃnica
InfectolÃ³
gica y
Traslacion
al
Hospital
ClÃnico
Universita
rio de
Santiago
de
Composte
la
A
Choupana
Not Applic Austria;Fr Federico MartinÃ³n- Federico.M+34 (0)981 955373 Inclusion crExclusion cr
Primary
Care Unit
Departme
nt of
Public
Health &
Primary
Care
Not Applic United Ki Faye Forsyth fc349@cam+44 (0)7921072847 Inclusion c Exclusion c
Not Applic Sweden Inclusion crExclusion cr
Phase III Brazil Inclusion c Exclusion c
Centre
for
Women's
Health
Research,
Institute
of
Populatio
n Health
Sciences,
Barts and
The
London
School of
Medicine
and
Dentistry,
Queen
Mary
University
of
London,
Yvonne
Carter
Building,
58 Turner
Street
Not Applic United Ki Julie Dodds Inclusion c Exclusion cr
Not Applic Saudi Arabia Inclusion crExclusion cri
Mental
Health
and
Addiction
Research
Group
Departme
nt of
Health
Sciences
University
of York
Heslingto
n
Not Applic United Ki Liz Littlewood liz.littlew +44 (0)1904 321828 Inclusion crExclusion cr
MRC CTU
at UCL
90 High
Holborn
Phase I United Ki Denise Ward mrcctu.cov- Inclusion crExclusion c
Phase II Germany Inclusion crExclusion cr
Phase III Nigeria Inclusion crExclusion cr
Compreh
ensive
Clinical
Trial Unit
at UCL
90 High
Holborn
Phase III Cameroon;C Gemma Jones cctu.ccoro + 44 (0)20 3108 6833 Inclusion c Exclusion c
Not Applic Oman;Saudi Arabia;United Arab Emirates Inclusion c Exclusion cr
Nuffield
Departme
nt of
Primary
Care
Health
Sciences,
University
of Oxford
Radcliffe
Observat
ory
Quarter,
Woodstoc
k Road
;
Nuffield
Departme
nt of
Primary
Care
Health
Sciences,
Phase III United Ki Emma;Juli Ogburn;All Uni principle@ +44 (0)800 ; Inclusion crExclusion c
Not Applic Norway Inclusion crExclusion c
Inclusion criteria: 1. History of epidem
 (1) Travel history or residence h
N/A China Depeng Jiang 74 Linjiang depengjia +86 15922 The Second (2) History
Exclusion c
of contact with new c
Exclusion criteria: 1. Infor
 2. The pregnant wom
0 China Shiwen Xia 745 Wuluo shiwenxia +86 18971 Maternal aInclusion c 3. The patients disap
N/A China Linda Chiu Wa LAM Lui Che Woo cwlam@cuh+852 2607 DepartmentInclusion c Exclusion c
Inclusion criteria: 1. Patients with ach
18â€“65criteria:
years; 1. refus
 3. education
 2.above primary
abnormal scho
vision;
N/A China Wei Zhao 154 Anshanzhaoweiho +86 15022 Tianjin Med 4. no history
 3.of digestive
Nervous system
system di
N/A Pakistan Sibtain Ahmed Aga Khan Usibtain.a +92 21 34 Clinical Ch Inclusion c Exclusion c
Inclusion criteria: All medical team m
N/A China Chen Li 149 Jimo R leetangba +86 13585 Shanghai O The subject whocsigned an infor
Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Exclusion criteria: 1.
tic use 2. Stage 4 severe chr
(Phase 3. Pregnancy or brea
IV): no 4. Allergy to any stud
Belgium Laurens Liesenborghs Herestraat laurens.liesenborghs UZ Leuven Inclusion c 5. Any medical c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu Exclusion criteria: Pa
tic use 1. Evidence of critica
 a. Patients
Mechanical ventila
are el
IV): no 1. Age b.
=18 years
Shock
United Sta Clinical Trial Informat 85 Wells A clinicaltrials@karyo Karyopharm 2. Clinically
<b suspected and subse
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Germany Project management, Wilhelmstrdiane.egg 4.97E+12 UniversitÃ Inclusion c Exclusion
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Tim Felton Academic Htim.felton +44 (0) 16 ManchesterInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use Inclusion criteria: 1. Patient or g
(Phase 2. MaleExclusion
and female
criteria:
patients
 1.
age
IV): no 3. Patients
 2.
with
Uncontrolled
temperature activ
>3
Germany Study Department Am Kliniku ruxcoflam 4.94E+11 Study Dep 4. P 3. Active Tuberculosi
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use Inclusion criteria: 1. Provision of
(Phase 2. Female and male patients =18
IV): no 3.COVID-19
Exclusion
positive
criteria:
or typical
 1.C
Sweden Co-ordinating investig Theme Hearmagnus.ba 4.67E+10 Karolinska 4. Clinical
 2.
status
Known
requirin
hypersensi
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Norway;SwMedical unit for infect deseases soo.aleman 4.67E+10 Karolinska Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Magda Laskawiec-Szk Churchill H magda.las 1.87E+09 Oxford RespInclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
Exclusion
 1.
criteria:
Participant
 1.
United Sta Clinical department 1 Red Plac contact@3+44 (0)123 Thirty Resp 2. Participant
 2. Unable
has laboratory-con
to safely re
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
 2. 1.
KnownAbility
medicalto res
un
IV): no 2. Men 3.
and women
Pregnant
=18oryears
breast
of
Spain;Turk Clinical Trial Call Cent 121 Oysteracertamc@+1888 292 Acerta Pha 3. Confirmed
 4. infection
Suspectedwith
uncontr
SAR
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
Germany Kristin Herzog CharitÃ©plkristin.he 4.93E+12 CharitÃ© RInclusion Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
Exclusion
 1.
criteria:
Patients
 1.
18
IV): no 2. Hospitalized
 2. Known
patients
intolerance
who hav
Sweden Gunilla WahlstrÃ¶m Sankt GÃ¶rgunilla.wahlstrom@caCapio S:t 3. Verified
 3.
Covid-19:
Concomitant
Positive
treat
tes
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
Finland Dept. of Public Health Haartmaninkari.tikkinen@gmail. University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): no
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Sta European Clinical Tria 103â€“105 clinicaltri +331 47 10Alexion Eu Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): yes
Therapeu
tic use
(Phase
IV): no
United Ki Andrew Pollard CCVTM, Chu
Andrew.pol 4.42E+12 University Inclusion c Exclusion c
Human
pharmaco
logy
(Phase I):
no
Therapeu
tic
explorato
ry (Phase
II): yes
Therapeu
tic
confirmat
ory -
(Phase
III): no
Therapeu
tic use
(Phase
IV): no
United Ki Emma Perry Southampto
sponsor@uhs.nhs.uk University Inclusion c Exclusion c

 
 - Patients with clinical diag
 intensive care.
 
 - Manifest Acute kidney in
 
N/A Sweden ;; Robert Frithiof, Asso ;tomas.lut ;+46 6110 Uppsala Uni 

 
 1. Age = 18 y
 
 2. Moderate or severe ARD
 criteria
 
N/A Laurent Brochard, MDBrochardL 416-864-6060 3. Clinical suspicion or con
 
 - Adult
 
 - PCR confirmed COVID-19
 
 - Symptoms developed m
 
 - PaO2/FiO2 < 200 mmHg
 
Phase 2/PhChina - Positive pressur

 
 1. Adult male or female pa
 
 2. The newly diagnosed CO
N/A Shuiping Zhou, PhD Tasly Phar the "Guidance of Diagno

 
 
 2. Hospitalized
 
Phase 2 China Fu-Sheng Wang, MD, PhD The fifth m

 
 - The subject has to grant
 informed consent form b
Phase 3 Thailand Subsai Kongsaengdao,skhongsa@ 6.68E+10 
 Inclusion Criteria for a case:

 
 1. Patients who meet the r
 <5 days respiratory infec
Phase 3 Spain 

 
 - Positive laboratory test f
 
 
Phase 2 United Sta ; ; Christopher Tignanell ;;Covid19t ;;612-624- University - One of the following: Up

 
 - Presumptive positive lab
 
 
Phase 2 United Sta ; ; Christopher Tignanell ;;Covid19t ;;612-624- University - Admission to the hospita
 
 
 2. Scheduled to work with
 
 
Phase 2 United Sta ; Lorenzo Berra, MD;Lo lberra@mg+16176437733; 1. Previous documented S

 
 1. Subjects must have a po
 
 2. COVID-19 signs and sym
Phase 2 United Sta ; Colin Broom, MD;Col ;clinicalt ;713-579-9Pulmotect, with onset within the 7 d

 
 1. Subjects must have docu
 exposure to an infected i
Phase 2 United Sta ; Colin Broom, MD;Col ;clinicalt ;713-579-9Pulmotect, i

 
 
Italy Giovanni Landoni, Pro landoni.gi 3.9E+11 char

 
 - Critical/Intensive care or
 
 - Admission for/with acute
onal [Patient Registry] United Sta ; Stephane LEGRIEL, MD;neurocovi ;33139638 Ictal Group than 4 weeks, but usua

 
 1. SARS-CoV-2 positive
 
 2. Age >17 years and < 80
 
 3. P/F < 250 mmHg
 
 4. Bilateral pneumonia (infi
 
onal [Patient Registry] Italy Marco Confalonieri, MD University 5. C

 
United Sta ; Gilead Study Director; ;GileadClin ;1-833-445Gilead Scie H
 
 1. Subjects must be 18 yea
 
 2. Close contact* exposure
Phase 2 United Sta ; Shmuel Shoham, MD; ;TOID_CRC ;410-614-6Johns Hopk hours of receipt of plasm
 Outpatient trial:

 
 
 1. Symptomatic and labora
 
 2. Age =18 years.
 
Phase 3 Canada ;;;; Richard Whitlock, MD ;;;ACT.Pr ;;;905-297 Population 3. High risk: either age =70

 
 - Affiliated with or benefiti
 
 - State of health compatib
 
 
France ; Bruno HOEN, Pr;Sandri;sandrine. ;+3314568 Institut Pa 
 Participants must be =18 ye
 equal to 7 days with eviden
Phase 3 Argentina;B; Clinical Sciences & O ;Contact- ;800-633-1Sanofi; categories

 
 - Adult healthcare worker
 dentists, physiotherapist
 
Phase 3 France ; Elisabeth Botelho-Ne ; ; CHU de Sain - HCW involved at the tim

 
 - Female sex
 
 - Greater than or equal to
 
 - English-speaking
 
N/A United Sta ; ; Mike Foley;Rachael Sm;rachael.s ;1-541-601Director D - Established obstetrics/gy

 
 
 2. Self-reported symptoms
Phase 3 Canada ; Luanne Metz, MD;Mich; ; University 
 
 1. = 18 years of age
 
 2. Has laboratory-confirme
Phase 2 Canada ; Vaseeharan Sathiyamo;srinivas. ;(604) 875 World Heal commercial or public hea

 
 
 
 
 - Receiving oxygen by non
 
N/A United Sta ; Jeffrey Miller, MD;Jef ;jeffrey.m ;404-778-7Emory Univ -

 
 1. Age = 18 years and = 75
 
 2. Able and willing to unde
Phase 2 United Sta ; ; Upinder Singh;Upinder;usingh@st;65072340 Professor ( written informe

 
 
 2. Currently hospitalized o
 
Phase 3 United Sta Boyd Taylor Thompson, MD Massachuse 3. Symptoms of acute resp

 
 I1. Age 18 or older at the tim
 diagnosis of advanced or m
Phase 2 France Philippe CASSIER Centre Leo 

 
 1. Hospitalized male or fem
 
 2. Diagnosed to be COVID-
 
 3. Signed Inform Consent F
 
 
Phase 2 Austria;D ; Henning Bundgaard, Pr;sonja.hoe ;43 1 865 The Capital 1. Any patie
 
 
 - 18 years of age and olde
 
United Sta ; Joyce Y Chung, M.D.;J ;chungj@ma
;(301) 443 National In - Able to re

 
 - 1. NCP with severe acute
 of arterial oxygen over fr
 
N/A China ;; Yun Long;Yun Long, M;ly_icu@al ;+8610169 Peking Uni 

 
 - COVID-19positive(+) ARD
 
 - ratio of partial pressure a
N/A Germany ; Peter Rosenberger, Pr ;peter.ros ;+4970712 +49707129 =10

 
 - greater than 18 years of
 
 - COVID-positive status
 
 - Being monitored in an ou
 
Phase 3 United Sta ; Sherry Mansour, MD, ;sherry.ma ;203-737-2Yale Univer - Yale New Haven

 
 - Are hospitalized for less
 COVID-19
 
Phase 2 United Sta ; Call 1-877-CTLILLY (1- ;Clinicaltr ;1-317-615Eli Lilly a - Are able and willing to gi

 
 - All genders
 
 - Age > 18 yrs and < 90 yrs
 
 - Must have laboratory co
 
 - Must provide informed c
 
Phase 2 United Sta Latha Dulipsingh, MD Saint Fran - Must

 
 1. Suspected cases of COV
 
 2. Adult aged 18 years or o
Phase 2 Brazil 
 
 - confirmed COVID-19 defi
 
 
 - none
France CÃ©dric Annweiler, M.D., Ph.D. University 

 
 
 
Phase 2 United Sta Raymond Chung, MD Massachuse - Confirmed COVID-19 dia

 
 
 - Pneumonia defined as h
 sputum production, or d
 
N/A United Sta ; Luu Pham, MD;Luu P ;luu.pham ;410-550-2Johns Hopk - Hypox

 
 - Assigned to or admitted
 only admit patients who
N/A United Sta Allan J Walkey, MD Boston Uni 

 
 - COVID 19 patients
 
 
 - allergy or contraindicatio
Phase 2/PhEgypt ;;;; Sherief Abd-Elsalam, a;;;sherief ;;;+20114 Tanta Unive 

 
 
 
Italy Lorenzo Dagna, MD dagna.lore-26434646 3. Presence of a SARS-CoV

 
 - age > 18 years
 
 - Informed consent for pa
 
 - Real time polymerase ch
 
Phase 2 Italy ; Carlo Salvarani, M.D.; ; ; Azienda UnitÃ
 Sanitaria Locale-IRCCS di Reggio
 
 -
 
 Recipient:
 
 Severe COVID -19 infections
Phase 2 India and Treatment of COVID-19
 Healthy children of healthca

 
 
 Not currently receiving anti
United Ki ; Thomas Waterfield, ;t.waterfi ;07872990 Queen's Uni not receiving immunosuppr

 
 
 
 - Allergy to "iodine," shellfi
 
Phase 1/PhUnited Sta ; ; Jayakar V. Nayak, MD ;;covid19s ;;650-725- Stanford Un - Rece

 
 All the following criteria mu
 
 - Aged 18 years or above A
 
 - Confirmed SARS-CoV-2 (
 
Phase 3 Denmark Anders Perner, MD, PhD Rigshospit - Use

 
 1. Provision of informed co
 
 
 3. Currently hospitalized
 
Phase 3 United Sta ; Mikhail Kosiborod, M ;swindsor@;816-932-9Saint Luke' 4. Hospital admission no m

 
 - Patients with covid 19
 
 
 - Allergy or side effects to
Phase 2/PhEgypt ;; sherief Abd-Elsalam, A;sheriefab ;00201147 Tanta Unive 
 
 - Patients who have shown
 January 2018 and 31st Mar
India Dr Shiv Kumar Sarin, DM Institute o tre

 
 - Healthcare workers from
 SARS-CoV 2 infection
 
 - Not having a previous CO
 
Phase 2/PhSpain ; ; ; ; ; ; ; ; Pedro de la Oliva, MD,;;;;;;;;;;a
PhD;Antonio;;;;;;;;;;+
J Carcas;Irene
Hospital
GarcÃ
Un 
a GarcÃa;Amelia RodrÃguez Maribla

 
Phase 3 Egypt ;;; M.Sc. Mahmoud Elkazza
;;mahmoud;;0020109 Faculty of admission to ICU.

 
 - Present for enrollment w
 result.
 
 
Phase 2 United Sta ; ; Joseph Vinetz, M.D.;J ;joseph.vi ;(203) 737 Professor, - Stated willin

 
 
 - High clinical suspicion of
 specialist (s) and the ICU
 
Phase 1 Canada ; Christopher W McInty;Christoph ;519-685-8Western Un 

 
 - >18 and confirmed diagn
 
 
 - None of the above
onal [Patient Registry] United Ki ;; Richard S Nicholas;N ;;r.m.midd ;;01792 60 Clinical Le 

 
 - Age: From 25 to 60 years
 
 - Department: physicians
 emergency department,
Egypt Ahmed M Mukhtar, M.D Cairo Unive<
 
 1. Adult conscious male an
 consciousness is assesse
 
Phase 2/PhEgypt ;; Ahmed Rezk;Ahmed Na
;ahmed.na ;11180809 Cairo Unive 2. Diagnosed initially with

 
 1. Presenting (in person or
 
 - Have clinical symptom
 
onal [Patient Registry] Australia ;; Mark Polizzotto, MD; ;coria@kir ;+61 2 938 Kirby Inst - Fever (= 37.8 Â°C) on

 
 Patients >/= 18 years old di
 infection with SARS-CoV-2)
Phase 1/PhUnited Sta ; ; Camillo Ricordi, MD;C ;cricordi ;305-243-6University criter

 
 - COVID-19 diagnosis
 
 - Hypoxia, (Oxygen satura
 blood gas analysis) and p
N/A Bahrain ;; Manaf Al Qahtani, Dr. ;mqahtani ;+9733976 Royal Colle 
 Subjects who meet all of th
 study:
 
Phase 3 United Sta ; John H Stone, MD;Jo ;JHSTONE@;61772679 Massachuse 1. Must have provided info

 
 - Age 18-50 years old
 
 - Subjects who are willing
Phase 3 Egypt Ahmed M Mukhtar, MAhmed.Muk1.11E+09 scheduled visits (for exam

 
 Criteria Include patients inf
 one of the following:
 
 - Hypertension
 
Saudi Arab ; ; Hakeam A Hakeam, M;hakeam@k;+9665054 King Faisal - Coronary artery diseas
 
 - HIV patients over 18 yea
 
 - Follow-up for an HIV infe
 
 - Treated with antiretrovir
 
onal [Patient Registry] France Alice RAFFETIN, MD alice.raffe 01 43 86 20 68 - Resident in France durin
 Inclusion Criteria: We will in

 suspected COVID-19 infecti
Phase 2 United Sta ; ; Ernest E Moore, MD;E;ernest.m ;(303) 602 Denver Hea SpO2 if ABG is unavailable (

 
 - Documentation of confir
 (SARS-CoV-2) infection.
 
Phase 2 United Sta Davey Smith, MD University - Experiencing at least one

 
 
 - Patients with diagnosis o
 
 - Hospitalized patients
 
 
 -
Argentina Marcelo O Silva, MD Austral Uni<

 
 1. Adults (18-80 years old)
 
 1. within 48 hours of th
 
Phase 2 United Sta FPHU Study Coordinatfavipiravircontact.fphu@fujifilm 2. PCR positive for SARS

 
 - Patients age 18 and olde
 
 - COVID-19 positive and re
 
 - Legally authorized repre
 
N/A ; Mackenzie Cervenka, ;mcerven1 ;443-287-0Johns Hopk Exclusion Crite
 
 1. >18 years of age
 
 2. Hospitalized patient wit
 
 3. Elevated D-dimer within
Phase 3 United Sta ; ; Jeffrey Berger, MD;Jef;PROTECT. ;212-263-4NYU Langon 

 
 
 
 - Requires hospital admiss
 
Phase 4 United Sta Usha Perepu, MBBS usha-pere 319-356-2195 - Modified ISTH Over

 
 
 - Patient COVID-19 diagno
N/A France ; Nelson Trelles;Marylin;maryline. ;00331307 Centre Hos thorax CT-scan suggestin

 
 - Diagnosis with SARS-CoV
 Administration [FDA] app
 
Phase 3 United Sta Ajay K Nooka Emory Univ - Should be hospitalized a

 
 Patient or guardian/health
 before any study assessmen
 
Phase 3 United Sta ; Novartis Pharmaceutic;novartis. ;1-888-669Novartis P Male and female patients a

 
 1. All anaesthesiologists and
 Department of Anaesthesio
 
Malaysia Exclusion criteri

 
 - - Patients (=18 years of a
 needing admission to MC
 
Phase 4 Netherlands - Patient has moderate to
 
 - Individuals who meet on
 
 - Patients with a confirm
 or resolved; or,
United Sta ; ; Robert J Kreitman, M.D;monica.le ;(301) 435 National Ca<

 
 - willingness to take the st
 
 - able to be contacted by
 
Phase 3 United Sta Salomeh Keyhani, MD MPH San Francis - willing and able to give in

 
 - Diagnosis of COVID-19 co
 
 - Any age
 
 - Membership in the gene
 
N/A France ; Bernard Maitre, Ph D bernard.mai01 57 02 20 82; - Inform consen

 
 - Patients 18 years or olde
 
 
Phase 2 Mexico Oscar G Arrieta, MD Mogar@una 56 28 04 00 - Diagnosis of serious or cr

 
 
 2. Hospitalized with labora
 
 3. One or more of the follo
Phase 2 United Sta ; Mila B Ortigoza, MD, ;Mila.Orti ;803-240-8NYU Langon 

 
 1. Male or female, =18 yea
 
 2. Confirmed infection wit
 
 3. High risk of COVID-19 di
 
Phase 2 Austin Keyser, Pharm covid19tri 682-285-1733 
 
 angiotensin receptor;
 
 - Patients = 18 years old;
 
N/A Brazil ;; Renato D. Lopes, MD, ;renato.lo ;55 11 590 D'Or Instit - Maximum us
 Patient Inclusion Criteria:

 
 1. Patient has confirmed p
 
 2. Patient is experiencing a
 
Phase 1/PhUnited Sta ; Corey Casper, MD MP ;CYNK-001-;(206)858- IDRI; 1.

 
 1. Either patients over 50 y
 diabetes, obesity, cancer
Phase 3 France ; Jean-Marc Naccache, ;hbeaussie ;1.44.12.7 Groupe Hosp
 

 
 - Patients with Covid-19
 
 - non-opposition of the pa
 
 
 - Non-Covid-19 acute resp
France ; Yesim DARGAUD, Pr;Y ydargaud@u
472118810;47211881 
 - Have had a positive test
 
 - Have had clinical signs of
Phase 1/PhUnited Sta ; ; ; 
Clayton B Hess, MD, ;;cbhess@ ;;404-686- Emory Unive cough, with nee

 
 - Individuals aged 18-99 w
 and who have a medical
 
United Sta David B Peden, MD University - Patients may be included
 
 - Male over the age of 18
 
 - First time present at the
 
 
 
Spain ;;; Sabina Herrera, MD;C ;;sabinapi ;;94938745Hospital Un
 - Patients with Covid-19
 
 - American Society of Ane
 
 - >= 21 years old
 
 - <= 40 years old
 
N/A Egypt Exclusion

 
 - Person, adult volunteer o
 paragraph indication), w
N/A France ;; Pierre Fumoleau, PhD;O
;olivier.la ;+33 1 56 2Institut Cur 

 
 
Phase 2 United Sta Mark Mulligan, MD, FIDSA NYU Lango 1. Hospitalized adult (=18 y

 
 to initiation of any study
 
Phase 3 United Sta ; Joseph Conigliaro, MD;jdigregor ;(516) 493 Northwell 2. Understands and agrees

 
 - Subjects must have an a
 months of initiation of pr
 
Phase 2 United Sta Richard F Little National Ca - Subject

 
 - Patient above 18 year-ol
 
 - COVID-19 assessed by PC
 
N/A France ; Renaud PREVEL, Dr;Rerenaud.pre5 56 79 55 17;5 56 79 - Oro-tracheal intubation
 
 - patients undergoing an e
 
 - Staff allocated in the end
 
 
Spain ;; Juan J Vila, PhD;Juan J ;juanjvila ;00348484 Tertiary re -

 
 
 - Patient has coronavirus d
Phase 3 United Sta ; ; ; Annetine C Gelijns, ;;;mary.ma ;;;(212) 65 Icahn Schoo polymerase chain reactio
 Inclusion Criteria: Hispanic a

 oversample of those with le
 do not identify as above
 - INCLUSION CRITERIA

 
 - FOR Cohort 1 (Existing N
 by their NIH study team)
United Sta ; Leslie G Biesecker, M. ;covidcode ;Not Listed National H 

 
Phase 1 Egypt ; M.Sc. Mahmoud Elkazz;mahmoud;00201090 Damitta Uni admission to ICU.

 
 
 - Competent and capable
 
 - Positive RNA test for pre
Phase 2 United Sta ; David J Sullivan, MD;D;dsulliv7@ ;410-502-2The Johns 

 
 - Adult patient hospitalize
 serology/polymerase cha
Phase 4 France ;; El Mehdi Siaghy;StÃ© ;;y.bernar ;;+33.3.83. Research a 

 
 - Patients admitted in inte
 
 - For an out-of-hospital or
 
onal [Patient Registry] France;Mar ; Jonathan Chelly, MD;J ;jean-phili ;04 94 14 Centre Hos - Or an in-hospital card
 
 - age> 18
 
 - having been admitted to
France ;; Emilie Olie, MD PhD;E ;e-olie@ch ;+33 4 67 University Lapeyronie, CHU Montpe

 
 - Requires hospitalization
 
 - Has Severe Acute Respir
Phase 2 United Sta ; AbbVie Inc.;ABBVIE C ;abbviecli ;847.283.8 AbbVie; polymerase chain reactio

 
 - Participants aged >=18 y
 
 - Participants must:
 
Phase 2 United Sta ; GSK Clinical Trials;US ;GSKClini ;877-379-3GlaxoSmith 1. have positive severe

 
 
 - Patients currently (at the
 
 - Patients transplanted wi
 
France 
 positive RT-PCR test for C
 
 - Requiring hospitalization
 
N/A Iran, Islamic Republic of 

 
 
 1. 18 years of age and olde
 
N/A United Sta ; ; Monique Ernst, M.D.; ;deborah.r ;(301) 594 National In 2. Able to re
 
 - COVID-19-positive subje
 
 - Horowitz index = 200
 
 - Bilateral opacities on fro
 
Phase 2 Germany ;; Valbona Mirakaj, Prof ;peter.ros ;+4970712 University - requirement for positive

 
 - Participant or guardian h
 assessment is performed
 
 
Phase 3 United Sta Incyte Corporation Calmedinfo@i1.855.463.3463 
 Transplanted Kidney or Kidn
 Transplant Medicine Unit -
Italy Antonio Secchi IRCCS San 

 
 - Age >=18 years old
 
 - Moderate to severe COV
N/A Spain ;;; Angel Montero, MD, ;;;angel.m ;;;+346677 Hospital Un currently receiving stand

 
 
 - Clinically diagnosed with
Phase 2 Denmark;G ; Novartis pharmaceutic;novartis. ;+4161324 Novartis P by other ap

 
 1. Hospitalization for COVI
 
 2. Severe Acute Respirator
Phase 2 United Sta ; Todd Zimmerman, MD;clinicaltr ;+1-877-82BeiGene; 

 
 
 1. Male and female patien
 
Phase 2 United Sta ; Novartis Pharmaceutic;novartis. ;1-888-669Novartis P 2. Signe
 
 - Diagnosis of type 2 diabe
 
 - Diagnosis of COVID-19 (p
Italy Paolo Fiorina, MD, PhD ASST FBF S an increase in

 
 To be eligible to participate
 criteria:
 
United Sta ; ; Steven M Holland, M.D.
;lbarnhart ;(301) 496 National In 1. Works at an NIH facility

 
 1. The patient is attending
 
 2. Subject has provided inf
 
 
onal [Patient Registry] Sweden ; Ronny K Gunnarsson, ;ronny.gun ;+4631786 Primary He 4. Flue

 
 (qRT-PCR -GeneDX Co, Lt
 
N/A Argentina ; ; ; ; ; ; ; ; Nora A Fuentes, MD;F ;;;;;;;wal ;;;;;;;+54 Hospital Pr - Imagining-diagnosed pne

 
 1. Patients = 18 years of ag
 
 
 3. Able to lie on their stom
N/A Canada ;;; Michael Fralick, MD, ;;;fahad.r ;;;416-864 Sinai Healt 
 - Adult patients (18 years
 
 - Admitted to a participati
France;Ger ; Matthieu Jabaudon;Lis;promo_int;+33 4 73 University a result of the COVID-19

 
 - Pregnant women or wom
 
 - Able to give electronic in
 
 
United Sta ; ; Karestan Koenen, PhD;; ;; Department - <18 ye
 
 - 18 years or older, ECOG
 
 
 - Active COVID-19 infectio
Phase 1/PhUnited Sta ; ; Robert O Dillman, MD;;candace@a;949-872-2AIVITA Bio antibodies, Preg

 
 - Patients treated in Nanc
 COVID-19 ARDS, requirin
 
France Matthieu Koszutski, MD CHRU de NA
 - Trial of airway pressure r

 
 PCR of any specimen; e.g
Phase 2 United Sta ; Clinical Trials;Refe ;global-ro ;888-662-67Genentech, 

 
 - Veterinary students and
 
 
 -
Egypt 

 
 
 
 - Hospital personnel with
 
Phase 3 Germany ; Leander Grode, Dr rer ;grode@va;+4951116 Vakzine P - Subject is contractually c

 
 - STEP 0 ELIGIBILITY CRITE
 
 - Patient must have a prio
United Sta Larissa A Korde National Ca hematologic malignancy

 
 - COVID-19 diagnosis in th
 
 - Symptomatic with at lea
Phase 2/PhBahrain ;; Manaf Al Qahtani, Dr. ;mqahtani ;+9733976 Royal Colle cough
 
 - diagnosis of pneumonia;
 given informed consent
 
 
Italy Geltrude Mingrone, MD Fondazione - age lower than 18

 
 
 - Hospitalization due to di
 
Phase 2 United Sta ; ; Thomas Marron, MD;Ly
;lynn.bui ;212-824-7Icahn Scho - Sp02 < 93% on ambient

 
 1. Provide informed conse
 
 2. Be able to communicate
 
 3. Aged =18 years
 
Phase 2 United Sta ; Gary Barnette;Gary Ba;gbarnett ;(919) 426 Veru Inc.; 4. Severe Acute Respirator

 
 
 2. Time from a positive tes
 
Phase 3 ;;; Machelle Wilchesky, ;;;machell ;;;(514) 22 Lady Davis 3. Time f

 
 - 1.>20 years old. 2. Medic
 Taiwan. 3.Community re
 
 
 - 1.<

 
 - patients with one of the
 failure, multiple sclerosis
France 

 
 - COVID-19 pneumonia ac
 inclusion or very strongly
 
 - Patient treated by nasal
 
N/A Spain Oriol Roca, MD PhD oroca@vhe+34 93 274 62 09 <
 
 
 
Phase 2 United Sta ; ; Mark Wurfel, MD, PhD;mwurfel@;206 897-5 University 3. Presence of SARS-CoV-2

 
 1. Participants who hav
 completed screening a
 
United Sta ; ; Vijay A Ramchandani, ;vijayr@ma;(301) 402 National I 2. Willing and ab

 
 1. Should be at least 18 ye
 
 2. Male or nonpregnant fe
 
 
N/A Saudi Arab ; ; Ahmad Alaskar;Moha ;dr.bosaee ;+966(11)8 KAIMRC; 4. Ab

 
 Potential participants must
 
 1. Laboratory-confirmed d
 
 
Phase 4 Australia ; Meg Jardine;Meg Jard;mjardine@;+61 2 805 The George 3. a) Systolic

 
 - Medical doctors and me
 Hospital de Occidente.
 
N/A Honduras ; ; ; JosÃ© R Galindo-Donai;;tesisdei ;;+504972 Universida - Medical doctors and me

 
 1. Confirmed cases of Covi
 
 2. Age >18 years.
 
 3. Patients with National E
 
 4. Consent
 
N/A India ;; Daya Nand Sharma, M;sharmadn ;+91-9868 AIIMS, New 
 
 
 1. Ability to provide inform
 
United Sta ; Michail S Lionakis, M. ;lionakism ;(301) 443 National In 

 
 - All healthcare personnel
 
 
 - non healthcare workers
Egypt 

 
 1. Critically ill patients with
 
 2. Patients with SARS from
 
Phase 1 United Sta ; Sabine Hazan, MD;Sa ;drsabine ;805-339-0ProgenaBi 

 
 - Ocular pathology requiri
 AMD, diabetic macular e
 
France ; Martine MAUGET FAY ;ayavchitz ;(0)1 48 03 Fondation - B

 
 - Men and women recove
 
 - With or without symptom
 
Brazil ;; Marcelo R Santos, PhD;marcelo.r ;55112661 University - Patients with disease con

 
 conclusion of panel of in
 
Phase 3 Russian Federation 2. Males and non-pregnan

 
 - Male Veterans admitted
 
 - Age 18 and 85; patients
Phase 2 United Sta ; Matthew B. Rettig, M ;matthew.r;(310) 478 VA Greater obstructive pulmonary d
 
 - Laboratory-confirmed di
 Control and Prevention (
United Sta Kenneth J Olivier, PhDkolivier@t 617-949-1575 molec

 
 
 
 - None
United Sta ; ; Annapoorna Kini, MD;;yuliya.ve ;212-241-0Icahn Scho 

 
 1. All competent adult and
 
 2. Subjects agree to:
 
 1. Gift saliva (spit) samp
 
United Ki ; Dr Mohammed Kamra;director@ ;00441216 Future Gen 2. Provide Consent for

 
 1. The patient or legally au
 understand and the willin
 
Phase 1/PhUnited Sta ; ; ; Joanne Kurtzberg, MD;;;cordbloo ;;91966811Duke Healt 

 
 - Hong Kong residents age
 
 - Smoke at least 1 tobacco
 
N/A China ;; ;+852 3917The Univer 
Man Ping Kelvin Wang;mpwang@h - Able to communicate in

 
 
United Sta Anthony F Suffredini, M.D. National In Subjects within 1-28 days o

 
 
Phase 3 United Sta 20-0006 Central ContaDMIDClinic 1.3E+10 initiation of any
 
 - ICU admission for pneum
 
 - RT-PCR (or equivalent) c
 
Phase 2 Robert Fowler robert.fow 6.17E+09 - Intubated and on mecha

 
 1. Male and female hospit
 consent.
 
Phase 2 Daniel A Muruve, MD info@archb403-220-2418 2. Clinical and laboratory d

 
 
United Sta ; Stavros Garantziotis, ;nicole.ed ;(984) 287 National In 1. Stated willingness to com

 
 - Hospitalized or will be ho
 severe COVID-19 with SA
Phase 3 United States re

 
 Each participant must meet
 Day 1, unless noted otherw
 
Phase 2 United Sta Moderna Clinical Trial clinicaltr 855-663-6762 1. Male or female, 18

 
 
 2. =18 years of age.
 
 3. =120 hours from first sy
 
Phase 2 United Sta ; Laura Szewczyk;Susan EIDD2801@786-687-2495;919-96 4. A

 
 1. Has COVID-19 disease, d
 signs (within 7 days):
 
 - Fevers OR
 
Phase 2 United Sta Laura Szewczyk EIDD2801@786-687-2495 - At least o
 
 1. Healthy adult male or fe
 
 1. For the adult group: 1
 
Phase 1 Australia ; Min Dong;Lara Hatchumin.dong@c
86 010 82022300;130 2. For the elderly group

 
 - PositiveSARS-COV-2 RT-P
 Hached in Sousse Tunisia
 
Phase 3 Tunisia ; Amel Letaief, Professoameletaie 21673102501; - Had either not received

 
 - Participants must have c
 
 1. be a potential hospita
 
N/A ; Judith Breuer, MD;Le ;l.hockey@;0203 108 University 2. potential workplace i

 
 Registered in the Danish Na
 
 
 None
Denmark Claus A Bertelsen, PhD Nordsjaell 

 
 - covid-19 positive pregna
 
 - under 18 or more than 4
 
 
 - vitamin D , Vitamin B12 o
Turkey 
 Study Inclusion Criteria - ap

 
 - Are based in the UK (are
 have listed a UK postcod
 
United Ki ; Inbar Linenberg, MSc; inbar.line +447791871699;+447 

 
 - A written, signed inform
Phase 2 France ; Bruno FranÃ§ois, MD ;mmorre@;+3360335 University part
 
 1. Moderate or severe resp
 
 2. COVID-19 positive
 
 
 
; Marlies Ostermann, M;Marlies.O ;0044 207 Guy's and 
 Key inclusion criteria:

 
 - Known diagnosis of canc
 
 - Known diagnosis of CoVI
 
 
 
onal [Patient Registry] Germany ;; Katja Weisel, MD;Kat ;k.weisel@ ;+4940741 University Key exclus

 
 reaction (PCR) of any spe
Phase 3 United Stat ; Clinical Trials;Refe ;global-ro ;888-662-6Hoffmann-L flu

 
 1. Verbal informed consen
 an impartial witness. The
Phase 1 ; Jonathan Spicer, MD, ;aya.sibli ;514-934-1McGill Univ 

 
 - At least 18 years old
 
 - Confirmed SARS-CoV-2 v
 
 - Advanced COVID-19 with
 
Phase 2 United Sta ; Andrew Badley, MD;A ;badley.a ;507-266-1Mayo Clinic - Has at least one of t

 
 
United Sta ; ; Michael C Sneller, M.D;bryan.hig ;(301) 402 National In 1. Stated willingness to com

 
 - Are hospitalized or in the
 laboratory determination
Phase 1 United Sta ; Call 1-877-CTLILLY (1- ;ClinicalTr ;1-317-615Eli Lilly a 
 
 1. Subject/legally authorize
 
Phase 2 United Sta ; H. Jeffrey Wilkins;H. J ;jwilkins@ ;610-457-5Aevi Genom 

 
 - laboratory confirmed po
 
 - admitted to ICU because
 
 
Sweden Maria Cronhjort, PhD Karolinska - patients

 
 - Children under 15 years
 
 - Prescription of a PCR-Sar
 
 - VIGIL information note g
 
 
onal [Patient Registry] France Corinne Levy, MD corinne.lev 1.49E+08 

 
 - Adult patients (>18 years
 Covid-19.
 
 
N/A United Sta ; ; Kirby P Mayer, PhD;Ki ;kpmaye2@;859-323-1University - pre-existing neurological

 
 - Confirmation of SARS-Co
 
 - Severe pneumonia relate
Phase 2 United Sta ; Gennyne Walker;aTyr ;clinicalt ;877-215-5aTyr Pharma
 respiratory infection with

 
 - Have overcome the SARS
 positive result on a rever
Spain 
 
 - All patients with confirm
 
 
 - All patients <18 years old
Turkey ; Yasin Tire, Dr;Yasin Ti dryasintir 090 5055665758;090 

 
 
 2. Male or female
 
 3. Age more than or equal
Phase 4 Greece ; Antonios Papadopoulo;egiamare ;+3021074 National Ka participants are allo
 Workstream 1
 
 
 - Adults (aged =18 years).
 
 - Patients attending SGHF
 
 
United Ki ; Timothy D Planche, Drtim.planch 02087252683;020872 - Children and adolescent

 
 
 - Admission to the intensi
 
 - Pneumonia due to prove
 
Portugal ; LuÃs Filipe Azevedo, Prof.;Cristina
;cristinag ;35191220
Granja, Prof.
Universida 

 
 1. Subjects must exhibit sy
 
 2. Subjects must be 45 yea
 
Phase 2 Canada ; Ramy Saleh, MD;Jean-;jmhoule@;514-941-2McGill Univ 3. Subjects must have at le

 
 
United Sta ; ; ;(301) 594 National H 
Vence L Bonham, J.D. ;bonhamv@n 1. Stated willingness to com
 
 - veterinary students who
 
 
 -
Egypt 

 
 A subject will be eligible for
 criteria apply at the time of
 
Early Phase 1 ;; DAVID OWEN;Katrina ;;d.owen@i;;0757508 National H 1. Hospitalised due to confi

 
 - Adult Males and non-pre
 
 
Phase 3 Brazil ALVARO REA-NETO, reaneto@g 5.54E+12 

 
 - Subject of 18 years of ag
 
 - Chronic hemodialysis pa
 
 - signed consent
 
N/A France ;; Jean-Olivier ARBAUD, ;philippe ;49138304 Assistance - Social

 
 - Adult intensive care pati
 
 
 - Need for mechanical ven
 
Phase 2 Denmark ;; Anders Perner, MD, P ;;Per.joha ;;+ 45 354 Copenhagen
<

 
 - Hospitalized with corona
 reaction (PCR) test or oth
Phase 3 United Sta ; Call 1-877-CTLILLY (1- ;ClinicalTr ;1-317-615Eli Lilly a 
 Inclusion Criteria for Enrollm

 
 
 
 3. Enrolled within 72 hours
Phase 2 United Sta ; ; Priscilla Hsue, MD;An ;;kelvin.m ;;628-206- University 
 
 - Patient over 60
 
 - sent to the intensive car
 
 - whose COVID diagnosis h
 
France ; Claire Falandry, MD;C ;claire.fal ;33 4 78 86Hospices Ci Exclusion Criter

 
 
 - Any previously or curren
 
 - Laboratory confirmed or
onal [Patient Registry] Russian Federation <

 
 family contact of confirmed
 
 
 - refuse to participate and
Phase 2/PhEgypt Waheed Shouman, M shouman6 2.01E+11 hypersensitivit

 
 - adult individuals living in
 
 
 -
Italy ;; Elisa Mazzini, MD;Elis ;elisa.mazz ;+39 0522 Azienda USL 

 
 - A referral from the atten
 
 - Suspected pneumonia
 
 
 
Russian Fe ; Olga Panina;Olga Pani olgayurpa +79266210179;+7926 

 
 To be eligible to participate
 criteria:
 
 1. NIH staff member partic
United Sta ; ; Karen M Frank, M.D.;R;rebecca.n ;(914) 462 National In 
 - We include the patient w
 (diagnosed with polymer
Turkey ;; ayse su cinar;mustafa ;m_altina ;+9053339 ; 

 
 - Fulfill Inclusion criteria a
 
 - COVID-19 patients confir
 
 - be regular on appointme
 
 
onal [Patient Registry] Congo, The ; ; GUYGUY KABUNDI TSH;guyguyts ;15143819 University - COVI

 
 - Acutely admitted to the
 
 - Aged = 18 years AND
 
 - Receives supplemental o
Phase 4 Denmark ;;; Bodil Steen Rasmussen;;bodil.st ;;+4597661Aalborg Un system

 
 - Adult patients with COVI
 April 18th 2020.
 
France Olivier Ziegler, PU-PH CHRU of N - Infection confirmed by re

 
 verbal or other method d
 
Phase 1/PhUnited Sta Barbara L Powers, Ph. clinical@c (617) 765-2252 2. 18 years of

 
 - Covid-19 positive patien
 
 - Does not require in-patie
 
 
 - Allergic to sensor patch
 
N/A United Sta ; Jonathan Leff, MD;Jon;jleff@mon;71892043 Montefiore - Has impl
 
 - All the professionals wor
 subjects).
 
 
 - None.
onal [Patient Registry] Spain ;; Pere ClavÃ©, MD, Ph ;pere.clav ;+3493741 Hospital d 

 
 Negative oral/nasal swabs
 
 
 Ages 4 or under Pregnant w
Argentina 

 
 patients with positive oral/n
 
 
 Children under 5 years old P
Argentina Alfredo Secchi, M.D. President used in t

 
 The participant must have a
 
 
 none
Hungary Lajos KemÃ©ny, Prof. Dr. University 

 
 - For both interventional s
 eligible to be included if
 
 
Phase 2 Italy ; Pierluigi Viale, MD;A ;aromagno ;0039 050 Infectious 
 - Currently are experiencin
 based on the MINI with o
 
N/A Canada ;; Daniel Blumberger, ;Hannah.T ;416-535-8CAMH; - Have previous respons
 
 - healthy individuals (base
 
 
 - endocrinological disease
 
Russian Federation - health deviations at the

 
 - Are currently not hospita
 
 - Have one or more mild o
Phase 2 United Sta ; Call 1-877-CTLILLY (1- ;ClinicalTr ;1-317-615Eli Lilly a malaise, headache, musc

 
 (RT-PCR) within 14 days o
 
Phase 2 United Sta ; ; Arnab Chakravarti;Arn;Arnab.Ch ;614-293-0James Canc - CT findings typical of CO

 
 - health care workers at ri
 
Phase 2/Phase 3 - No symptoms compatibl

 
 - Male or female = 18 yea
 
 - Patients testing positive
 
 - Patients affiliated to soci
 
N/A France ; Vanina OLIVERI, PM;V oliveri.v@c0033 4 92 03 42 54; - Signing of free and inform

 
 - Age 60 or greater
 
 
 - End-stage renal disease (
Phase 2 William B Ershler, MD william.er 571-472-1069 are expecte
 
 
 2. Oral tolerance or access
 
 3. PCR or IgM for SARS-CoV
 
Phase 2 Mexico ;; Adrian Camacho Ortiz ;md.eduar ;+52 81179Hospital Un 4. Negativ

 
 1. Provided informed cons
 approved)
 
 2. Age 18 to 75 years (inclu
 
Phase 2 France ;; Jean-Jacques Garaud, ;covtrem@;+33 (0)9 6 INOTREM S 3. Invasive mechani

 
 specimen, e.g., blood, re
 
Phase 2 ; Kazuko Matsuda, MD ;dojillo@m;858-246-8Medicinova - Ches

 
 molecular confirmation of C
N/A Israel ; Eli Schwartz, Prof.;El Eli.schwar 972 3 5308456;+972- 

 
 - Staff on duty in the healt
 
 - Eligible to be drawn
 
 - Beneficiary subject affilia
 
N/A ;;; Pierre PATOZ, Pharm ;;;ppatoz@;;;+33 (0)3 CH Tourcoi Exclusion

 
 
 - Subject who will require
 care.
 
; Christian Rabaud;Chri ;c.rabaud@;00333831 Nancy Unive
 - Group 1: Active smoker s

 
 - Healthcare students (e.g
 
 - Ability to give informed c
 
N/A Holly Blake, PhD holly.blak +44(0)115 8231049 - Ability to attend an indiv
 
 - Admitted to Wellstar Ken
 
 
 
 - At least 1 of the followin
 
Phase 4 United States 

 
 - Relative of patient who w
 non-invasive ventilation
France ; Lise Laclautre;Lise Lac promo_inte+33473754963;03737 

 
 - preoperative or post-ope
 for SARS-CoV-2
 
Italy - surgical procedure in ele

 
 - Patient hospitalized in CO
 during the COVID 19 pan
 
France ; Vincent DINOT;Nadi vincent.di 387553323;38755775 - PCR positive or COVID co

 
 1. Patients who admitted t
 cardiovascular condition
 
onal [Patient Registry] Qatar ;; Dr.Jassim Alsuwaidi S ;MRC@hama
;44396168 HMC; 2. Patient with confirming

 
 1. Hospitalized with confir
 method OR hospitalized
N/A Denmark ;; Peter L. Kristensen, M ;carina.ki ;00454829 NordsjÃ¦lla 

 
 
 
 
 - severely obese patients
 
 
 - patients do not experime
France ;;; Emmanuel DISSE, MD;;;emmanuel;;; Centre Int 

 
 - Mount Sinai Hospital em
 
 
 - None
N/A United Sta ; Jeffrey Zahn, MD;Jeff ;jeffrey.z ;212-241-6Icahn Scho 
 Inclusion Criteria: hospital e

 
 -
 
 Exclusion Criteria: none
Denmark ; Thea K Fischer, profes ;thea.koel ;+45 2440 NordsjÃ¦lla 

 
 - Age 18 years or older.
 
 - Test result indicating pre
United Sta ; Will Hahn;Clinical Tri ;shelly@fr ;206-667-6Fred Hutch assays that are approved

 
 - Aged < 18 years of age w
 according to local law an
Phase 2/Phase 3 ; Gilead Study Director; ;GileadClin ;1-833-445Gilead Scie 

 
 - Diagnosis of infection by
 
 1. symptoms of acute re
Phase 2 Brazil ; Henrique Pott Junior, henriquepo+55 16 3351-8340; the following: cough,

 
 - consent to participate vi
 
 - indicate a mild or greate
 and/or traumatic stress
 
N/A United Sta ; ; Jill Ehrenreich-May, P ;j.ehrenre ;30528427 University -
 
 - Pregnant females, 18 yea
 PRC, or antibodies in a bi
onal [Patient Registry] United Sta Jose L Diaz-Miron, MDjose.diaz- 7.21E+09 

 
 
 - Stated willingness to com
 
; R Peter Manes, MD, F ;rpeter.ma ;(203) 785 Associate P
 - Patients have been diagn
 
 - Patients in the intensive
 
 
N/A Turkey SIBEL BEKTAS sibel_bek 090 212 945 30 00 - Patients not diagnose

 
 Donors:
 
 1. Age: >18 and <60 years
 
 2. Body weight : >60 kg
 
 3. Confirmed previous SAR
 
Phase 3 ;;; Francisco Moreno, MD;Irma
;;;ptrapag
Hoyo,;;;+52551
MD PHD;BenjamÃ
ABC Medica
n Valente,
 MD
4. MSc
negative
DTMH;Paulina
SARS CoV-2TrÃ¡
tes

 
 
 - Hospitalized with confirm
 
Phase 2 United Sta ; ; Matthew Sims, MD Ph;Maureen. ;248 551-0 Beaumont - Symptoms consistent wi

 
 
 
 3. Respiratory compromise
Phase 2 United Sta Gustavo Lorente glorente@ 650-273-2264 at lea
 
 1. Hospitalized male or fem
 being treated for COVID-
 
Phase 2 Spain Navarro Puerto Jordi jordi.nava 3.49E+10 2. Has laboratory-confirme

 
 laboratory-confirmed SA
Phase 1 (PCR)

 
 - For pregnant women, all
 
 - For children follow up: c
Belgium ;; Tessa Goetghebuer, ;tessa_goe ;+3225354 Centre Hosp
 

 
 
 - Gestational age greater t
 
 - Pregnant women suspec
 
N/A France ;; Jean-Olivier ARNAUD, ;julie.bla ;49196467 Assistance 

 
 - Adults, age 45-75
 
 - Had screening or surveill
 
United Sta Karen Sepucha, PhD Massachuse - Either first screening colo

 
 - Major patients
 
 - Living in metropolitan Fr
 
France Alice RAFFETIN, MD alice.raffe 01 43 86 20 68 - Being or having been ho

 
 - All pregnant women ove
 caesarean section)
 
 
 - psychiatric disorders
Greece ;; Georgia Micha, Dr;Geo;mgeo3@ya;+3069748 Elena Veni <
 
 - Male and female
 
 - Age range: 18 to 100 yea
 
 - Patients admitted to Cam
 testing
 

 
 - Being 18 or older
 
 - Approving the Informed
 
 - Being diagnosed with CO
 
Phase 2 Turkey ;; Ercument Ovali, MD;Er;ercument.;+9053257 Acibadem L - H

 
 - Admitted to hospital war
 positive rtPCR swab and
 
 
Italy ;; David Bennett, MD;Pie;piersante. ;+3933562 Azienda Os - Unable/

 
 
 2. Positive laboratory test
 
 3. Presenting with at least
Phase 3 ; Yan Zhao;Hui Zi Chua ;hzchua_t ;+65 9229 Nanyang Te

 
 - patients with COVID-19 (
 
 
Areej Saleh areej.201 2.01E+11 - Patients who had stroke

 
 - Patients with COVID-19 o
 
 
 (1) Degraded quality of CT s
Egypt Ahmed Samir, MD Department motion artifacts
 
 - Confirmed or highly susp
 coronavirus 2 (SARS-CoV
Phase 2 United Sta ; ; Arthur M Feldman, M ;Arthur.F ;215-707-4Temple Uni hos

 
 1. Aged >=18
 
 2. Electronic consent
 
 3. Either:
 
 a - healthcare workers in co
; Ajay Gupta, MD, PhD; ;ajay.gupt ;020 7882 Queen Mary
 H

 
 - The Survey is targeting s
 Neurosurgery, Oral and M
Egypt ;;; Mostafa Shalaby, MD ;;;mostafa ;;;002010 Mansoura F Or

 
 - Both sex
 
 - Patients their elective su
 
 
onal [Patient Registry] Egypt ;;;; Mostafa Shalaby, MD ;;;mostaf ;;;002010 Mansoura U - Patients underwent surg

 
 
 15/04/2020
 
France ; BenoÃ®t Painvin;Nico ;dri@chu-r ;02992825 CHU Renne - Patients (or legal represe
 Inclusion Criteria: 18 years o

 participating hospital during
 with Covid-19 during pregn
 
onal [Patient Registry] Sweden ; Verena Sengpiel, MD, ;verena.se ;+4670422 Sahlgrensk 

 
 1. Written or witnessed ve
 representative (LAR) or r
Phase 2 Clinical Trials Clinicaltr 888-521-2805 c
 
 - Patients with amylase an
 without pneumonia
 
 
 - Patients with pregnancy
Turkey <

 
 - Children and parents or
 
 - Patient followed-up in a
 
onal [Patient Registry] France ;; JÃ©rÃ©mie Rouger-G;rouger-j@ ;+3323106 University - Patient followed-up

 
 Patients with SARS-CoV-2 in
 
 1. age = 18 years and = 75
 
 
Phase 2 Germany ;; Hubert Schrezenmeier,;;s.koerpe ;;7311505 IKT Ulm;Ge 

 
 - Have had a positive test
 
 - Have had clinical signs of
Phase 3 United Sta ; ; Mohammad K Khan, M;drkhurra ;404-778-3Emory Unive
 cough, fever) t

 
 - Data of all definite cases o
 records of patients by a tea
Egypt collecti

 
 1. Patients must be 18 yea
 
Phase 2 United Sta Michelle Harkins, MD MHarkins@505-272-4751 SARS-CoV-2 RT-PCR testi

 
 1. Adult patients (aged =18
 
 2. Clinical (Positive RT-PCR
 infection by COVID-19
 
Mexico 3
 
 1. Signed Patient Informati
 study.
 
 2. Men and women aged 1
 
Phase 2/PhRussian Fe ; Elena Pavlikova, MD, ; ; Moscow Stat
 3. Patients hos

 
 - Patients with elective su
 any type of cancer;
 
Brazil ;; Andre Lopes, MD;And ;andrelope ;+5511347 Instituto B - Patients who will underg

 
 1. Suspected cases who m
 
 1. Epidemiological histo
Italy ;; Giuseppe Curigliano, ;;atanasio. ;;+390257 European I before

 
 1. . Positive COVID-19 test
 
 2. Diagnosis of COVID-19 a
Phase 1/Phase 2 ; Arya Mani, MD;Arya ;arya.mani ;203-785-4Yale Univer D-Dimer, fibrinogen, TnT

 
 - cancer patients receiving
 any cardioprotective age
 
 - aged 30-60, and
 
Egypt - female s

 
 -
 
 
 -
onal [Patient Registry] United Kingdom 

 
 - Diagnosis of acute respir
 
 - Hospitalised in intensive
 
 - Age older than 18 years
 
Turkey Ozden Ozyemisci Taskiran, Prof Koc Univer Exclusio
 
 - hospitalized patients wit
 reverse-transcriptase-po
 
Israel - patients with severe dise

 
 - Living in the nursing-hom
 epidemic (March-April 20
 
France CÃ©dric ANNWEILER, MD, PhD University - Being suspected or diagn

 
 1. Willing to provide writte
 
 2. Willing to comply with a
 study
 
Phase 2 United Sta ; ; Charles J Lowenstein, ;clowens1 ;(410) 955 Johns Hopk 3. Male

 
 - 2 of the following criteria
 (>=38 Â°C) Hypothermia
 
France - At ad

 
 - Only anesthesia attendin
 
 - Any working anesthesia
N/A Rongyu ( Cindy) Jin rongyu.jin 416-603-5800 and operat

 
 
 - Subject of both genders
 years or over;
 
Phase 2 ; Reginaldo Raimundo F;mcmf1964;+55 11 98 Federal Uni<

 
 - Age = 18 and = 80 years
 
 - Able to sign informed co
 
 - Real time PCR diagnosis
 
Italy ; Paola Faverio, MD;Paopaola.fave +390392339040; - Hosp
 
 1. adults
 
 2. P/F less 300 torr
 
 3. ARDS by Berlin conventi
 
 4. COVID 19 bilateral pneu
 
 
N/A Kazakhstan Irina Mukatova, PhD mukatovai 8701 535 96 79 

 
 1. Male or female adult (=
 
 2. Subject is contractually
 signed informed consent
 
Phase 3 Germany ; Leander Grode, Dr. rer;grode@va;+49 (0)51 Vakzine P 

 
 - Men and non-pregnant w
 confirmed COVID-19
 
onal [Patient Registry] ; Justin L Grodin, MD, ;Carolyn.K ;214-645-8UT Southwe - Were alive at the time o

 
 - SAR-CoV2 detected by P
 
 - Asymptomatic or upper
 
 - No history of fever or ora
Phase 4 Thailand ; Yupin Suputtamongko;ysuputta ;+6681754 Department<

 
 1. Patients over 18 years o
 collected verbally and wi
Phase 2 Spain ; Jose A Perez-Molina, jperezm@sa
+34913368108;+3491 d

 
 Symptomatic adult patients
 Provision of Informed Cons
 
 At Day 0, patients should be
 
Phase 2/Phase 3 Nicole Ezer nicole.eze (514)-934-1934 Exclusi
 
 asymptomatic for known
 
Phase 1/PhUnited Sta ; Walter Dehority, MD; WDehority 505-272-5551;505-27 2. UNMHS HCWs include:

 
 - Participant must sign an
 understands the purpose
Phase 1/PhUnited Sta ; Janssen Vaccines & Pre;JNJ.CT@sy;844-434-4Janssen Va and

 
 - Patients hospitalized for
 expected to remain in ho
Phase 2 Tony Opipari, M.D. tony@firs 734-546-0228 

 
 1. males and females with
 
 2. written informed consen
 
 3. subject body mass index
 
Phase 1/PhRussian Fe ; Inna Dolzhikova, PhD; info@gama1933001;193 30 01 4.

 
 - Patients attending UHP w
 
 - Participants capable of g
 personal or nominated c
United Ki ;; Ashwin D Dhanda, MRC
;plh-tr.RD ;+4417524 University

 
 1. Parents of children and
 
 2. During the lockdown pe
 
Greece Odysseas Androutsos, M.Med.Sci., Ph.D. University 3. Parents signed an inform

 
 - All pregnant women ove
 caesarean section)
 
 
Greece ; Georgia Micha, PhD;G ;mgeo3@ya;+3069748 Elena Veni - Not eligible in writin
 
 - 18 years or older, all hea
 (ex: physicians, nurses, p
Phase 3 ; Nasser Al Ansari, FRC ;nalansar ;33554409 Hamad Medi
 

 
 - Positive COVID-19 test re
 participant
 
 - Resident of Durham Cou
 
United Sta ; ; Erich Huang, MD, PhD ;margaret ;919-613-6Duke Unive 

 
 - Patient over 18 years of
 
 - Patient followed in the m
 Paris in France
 
N/A France ;; Eric Raymond, MD;Er ;eraymond ;01441234 Groupe Hosp
 - Patient Hav

 
 - Provide written informed
 
 - Male or female subjects
 
Phase 2 Pakistan ;; Moazzam N Tarar, MBB
;;riazuddi ;;+924293 Jinnah Burn - Must have a clinical diag

 
 1. males and females with
 
 2. written informed consen
 
 3. subject body mass index
 
Phase 1/PhRussian Fe ; ; Lola Morozova, Md;In ;info@gama;1933001; I.M. Seche 4.

 
 - Patients admitted with h
 
 
 - Formal opposition by the
onal [Patient Registry] Belgium;It ; ; ; ; ; Elena Arbelo, MD, PhD;;;;;EARBEL ;;;;;+34 93 Hospital Cl 
 
 - Women who are positive
 
 - Women who are 18 year
 
 - Women who had sexual
 
Turkey ; Ozguc Takmaz, MD,Assi
ozguctakm +905554006591;0555 Exclu

 
 
 - Symptoms of COVID -19
 
Phase 2 United Sta Nicholas Van Hise, P nvanhise@630-655-6952 - Symptoms less

 
 
 - Able to provide oral cons
 
 - Able to perform a self-co
 
N/A Canada ; Timothy O'Shea, MD; osheat@mc905-521-2100;905-52 Excl

 
 - age>18,
 
 - positive at COVID-19
 
 - manifesting symptoms th
; Stefania Fugazzaro, M;stefania.f ;+39 0522 Azienda USL pneumonia or other sym

 
 - Hospitalized adults affec
 other clinical studies suc
 
Italy ;; VINCENZO BRONTE, M;stefano.ug;04581264 University Exclusion Cr

 
 - Must have laboratory co
 hospital.
 
 - Admitted to acute care f
 
Phase 1/PhEgypt ; Nermeen ElDesouky, nermeen.el01006029006; - Must have sev
 
 - Adult participant (>18 ye
 
 - HCW who had a contact
 confirmed COVID-19 pati
 
N/A Israel ;; Mical Paul, MD;Nesri ;n_ghanem;97247772 Rambam; -

 
 
 - Positivity at RT-PCR per S
 
 
Phase 2 Italy;Spain ; Zeno Bisoffi;Zeno Biso;zeno.bisof;+3904560 IRCCS Sacr <

 
 1. without dyspnea and wi
 admission to ICU.
 
 2. All patients =55 years ag
 Criteria for inclusion :

 
 - Major patient (=18 years
 
 - Patient hospitalized in in
France ; Bob HEGER, MD;Bob Bob.Heger@
33 3.69.55.04.43;33 3 VD session of which at le

 
 - patients with a confirme
 Expanded Disability Statu
 
Turkey 

 
 - You must be 18 years of
 
 - You must have access to
 
 - You must have access to
 
United Sta ; ; Natasha Belfor, PhD;N;natasha@ ;415-655-3Miro Healt - You

 
 - Age =18 years old.
 
Phase 3 Spain ; IÃ±igo Les Bujanda, P ;ilesbujan ;00346363 Complejo H reaction (RT-PCR) on nas
 
 
 2. In-patient in UHH within
 
 3. COVID-19 disease confir
United Ki ;; Robin A Weir, MD;Rob;robin.wei ;00441355 NHS Lanark 

 
 - History or active diagnos
 (monoclonal gammopath
Phase 2 United Sta ; ; Jennifer A Woyach, M ;OSUCCCCli;1-800-293Ohio State lymphocy

 
 - Eighteen years of age or
 
 - Front-line employee of p
 
 - Adequate organ and bon
 
Phase 3 ; Alexandre R Zlotta, M ;cynthia.k ;416-586-4University Exclusio

 
 - Signed and dated inform
 
 - Agrees to the collection
 protocol-specified proce
Phase 2/PhUnited Sta ; Quintus Ngumah, OD, ;medinfo@;1-866-562PTC Therap 
 
 - Personal history of eithe
 
 - Chronic hepatitis C
 
 - Chronic hepatitis B
 
United Sta Renumathy Dhanasekaran, MD Stanford Un -

 
 (including positive RT-PC
Phase 2 ; Ying Yan, MD MS;Ying ;yyan@sorr;(858) 203 Sorrento Th 
 
 - 18-35 years old
 
 - Currently living in the Un
 
 Exclusion Criteria
 
 - Those under 18 years, or
 
United Sta Viviana E Horigian, MD University -

 
 - 1. Male or female adult =
 
 - 2. Subject is hospitalized
 
Phase 2 Spain ; VÃctor DomÃnguez, MD;Rosa
;rmmunoz@c
MarÃ
;+34
a MuÃ±oz
93 22 Hospital Un - 3. SARS-CoV-2 infection

 
 
 - Subject of both genders
 49;
 
Phase 2/Phase 3 ; Edimilson Migowski, ;thiagowe ;+55 21 99 NEPS SEMU 

 
 - 49 critically-ill COVID-19
 
 - All of the patients were w
 
 - Age = 18 y
 
N/A Iraq Ahmed S Abdulamir, PhD Alkarkh hea - With dyspnea

 
 - Patients were included if
 a positive result of RT-PC
Monaco h

 
 
 2. Positivity to the test for
 
 3. Informed consent to en
 
Italy ;; Marco Ranucci, MD;Ek;ekaterina ;+3902527 IRCCS Polic 4. For Intensive Care patie
 
 - Front-line healthcare pro
 respiratory therapists, re
N/A United Sta ; ; Jack Green, MD;Jack ;jack.gree ;31042380 Cedars-Sin physi

 
 - Any person, male or fem
 
 - Any person affiliated to a
 
N/A France ; Samira FAFI-KREMER, samira.faf +33 3 69 55 14 38; - Any person abl

 
 - Elegibility to annual LDCT
 
 - Absence of tumors for at
 
Italy Ugo Pastorino, MD Fondazione

 
 1. Male and female subjec
 
 2. The body weight no less
Phase 1 China ; Jing Zhang;Jing Zhang 13816357 021-52888189;02152 subjects. Body ma

 
 
 Midtown, or Emory Saint
 
Phase 4 United Sta ; Cheryl Maier, MD, Ph ;cheryl.m ;(203) 980 Emory Univ 

 
 - Patient must be undergo
 solid malignancy, lympho
Phase 3 ; Rebecca A Auer;Chris ;cocallagh ;613-533-6Ottawa Hosp
 
 Original inclusion criteria in

 ages of 21-35, expecting a c
N/A Rwanda ;;;; Kate E Doyle, MA;Ruti ;;;; ;;;; 
Promundo-U living in a stable partnership

 
 - Any individual enrolled in
 household for at least 3 m
; Marc-Alain Widdowson;nherssens ;+32 2470 Institute o ag
 
 1. A written, signed inform
Phase 2 ; Richard Hotchkiss, M ;mmorre@;+3360335 Washington part

 
 - Patients 40 years-old and
 (UIC) due to COVID-19
 
Phase 2 United Sta Jesica A Herrick, MD, Christe5@u312-996-1834 - Positive oropharyngeal a

 
 
;;; Omid Ebrahimi, Doubl;;;omideb@;;;+47-228 University p

 
 
 
;;; Omid V. Ebrahimi, Dou;;;omideb@;;;+47-228 University - Who

 
 1. Able and willing to prov
 informed consent before
Phase 2 Christine Orlando corlando@(240) 654-1450 

 
 - Health care or public ser
 
 
 - None
;; Omid Ebrahimi, Mr;Asl;;sverreuj ;;+47 4163 University 

 
 
 
;;;; Ole AndrÃ¨ Solbakken;;;;s.u.joh ;;;;416333 University - Who

 
 years and above
 
;;;; Miriam S Johnson, PhD;;;;s.u.joh ;;;;+47-22 Oslo Metro - Who are currently living
 
 
 
;;;; Omid V. Ebrahimi, Ph ;;;;omideb ;;;;+47-22 University - Who

 
 
 - Currently living in Norwa
 
;;;;; Nora Paulsen Skjerdin ;;;;;omide ;;;;;+47-2 University - That provide digital cons

 
 Clinical diagnosis of Acute R
 
 
N/A Turkey Salih SS Sevdi, Md Istanbul Ba Patients whose age lower th

 
 - taking part in the medica
 
 - of 18 to 50 years old
 
 - did not take antibiotics w
 
China ;; Xiancang Ma, M.D.;Fe ;gaofengj ;0086-132 First Affil 

 
 - First consecutive 100 pre
 between March 15, 2020
 
 
onal [Patient Registry] Turkey ;; Resul Karakus, MD;Re ;dr.rsl.ci ;+9050591 Zeynep Kam -

 
 - Pregnant mothers with a
 
 - Infants with and without
 neurodevelopmental con
United Ki GrÃ¡inne McAlonan, grainne.mc 2.08E+09 
 - Health Care Workers as fi
 
 - Initial polymerase chain
Phase 1 Mexico ; ; ; ; ; ; ; ; Sandra MuÃ±oz-LÃ³pez;;;;;;;;;; ;;;;;;;;;;; CMN "20 d 
 
 
 
;;; Asle Hoffart, PhD;Omi ;;;s.u.joh ;;;4163331 University - Who

 
 - Any age.
 
 - Any sex.
 
 - With COVID-19 confirme
 
N/A Mexico ;; Mario H Vargas, MSc; ;mhvargas ;52+ 55 56 Instituto - With a clinical decision o

 
 
 
;;;; Omid Ebrahimi, Double;;;;omideb ;;;;+47-22 University - Who

 
 CoV-2 in a respiratory tra
 
 
Phase 2/Phase 3 - ? Kno

 
 migrants.
 
 - Adults including those of
 
;;;; Sverre Urnes Johnson,;;;;s.u.joh ;;;;416333 University - Who

 
 - Adult (at least 18 years o
 anesthesia and placemen
 
Randy W Loftus, MD randy-loft 6.03E+09 Exc

 
 - Capable of understandin
 to the requirements and
 
Phase 2 ; Jeremy Road, MD;Chris;chris@san;778-899-0SaNOtize M - Men and Women = 18ye
 - Inclusion Criteria:
 
 - Age 18-80 years.
 
 - Severe pneumonia CO
 
 - Nasopharyngeal smea
 
Phase 2/PhSpain ; Patricia Fanlo Mateo, ;patricia. ;84842216 Complejo H - X-

 
 
 
 - none
;;; Omid Ebrahimi, Cand P;;;asle.ho ;;;+479059 University 

 
 
Phase 2 Pakistan ;; Qamar un nisa Chaudh;drraheel ;00923335 AFBMTC/N reaction (RT-PCR) from a

 
 - close contacts of confirm
 
 
onal [Patient Registry] Egypt - symptomatic close conta

 
 
 
;;; Omid Ebrahimi, Doubl;;;omideb@;;;+47-228 University - Who

 
 - Patients > 18 y.o.
 
 - Patients with a NEN of a
 
Italy ;; Nicola Fazio, M.D., P ;darina.ta ;+39(0)29 European In - Patients with SARS-CoV-

 
 
 - severe pneumonia with
 
Spain - PaO2/FiO2 r
 
 
 - Hemodialysis history of m
 
 
Turkey Mustafa Sevinc, MD Sisli Hamid - Patients who can not spe

 
 
 - A confirmed COVID-19 d
 
 - Signed and dated declara
 
 - The patient fell ill in Tyro
 
N/A Austria Teresa Rauchegger, Drteresa.rau 0043 504 24184 Exc

 
 1. All patients =16 years ol
 
 2. All patients = 16 years o
; Peter Kelleher, MD Ph;p.kellehe ;00 44 (0) Imperial C asthma, COPD or Idiopa

 
 - participants of the FrOST
 
 
 - medication and diseases
Germany wolfgang Kemmler, PhD Institute o 

 
 - Healthy adults aged 18-6
 
 - Documented result of no
Phase 1/PhSouth Afric ; Shabir A Madhi, MD, ;cutlandc@;+27-11-98University antibody test) within two

 
 
 - Proven or suspected (no
 
; Marco von Strauss un ;marco.von;+41 61 77 Clarunis Un - Undergoing urgent or em
 
 protocols;
 
 - Admitted to hospital;
 
 - =18 years of age;
 
Phase 3 Brazil ;;;;; Peter Juni, MD, FESC ;;;;hassan. ;;;;+55112 St Michael's< Hospital, Li Ka Shing Knowledge Ins

 
 COVID-19 pandemia
 
 
 - none
;;; Asle Hoffart, PhD;Omi ;;;asle.ho ;;;+479059 University 

 
 - Comply with the observa
 included) adults.
 
Phase 1 ; Hong Ren, master;Hon;22168398 ;023-6369 The Second - The subjects themselves

 
 - At least 12 years of age
 
 - Covid-19 Convalescent P
 goals of care (i.e. recipien
United Sta ; ; Jonathan Gerber, MD;J;cancerre ;508-856-3UMASS MED
<

 
 
 - AKI as determined by the
 
 - Receiving or planned to
 
Phase 1/Phase 2 Brian Miller brian.mill 781-361-9031 
 COVID-positive index cases
 
 - Any patient greater than
United Sta ; ; Jessica Lin, MD, MSCR ;christop ;919-280-7UNC-Chapel nasopharyngeal or nasal
 
 
 2. O2 saturation =<92% on
 
 3. On CPAP, HFNC or Invas
 
Phase 2 Qatar ;; Nadir Kharma, MD;Na ;nkharma ;+9744439 Hamad Medi

 1. Adults (aged =18 years)
 
 
 3. Hospitalized in the ICU f
 
 4. Any of the following:
United Ki ;; Nuttha Lumlertgul, M ;Marlies.O ;0044 207 Guy's & St

 
 - Provide oral informed co
 
 - At least 18 years of age.
 
 
Phase 2 Spain ; Jose Antonio PÃ©rez ;raul.m@dy;+34 6390 Hospital Un - Hav

 
 1. Male or Female age 18 o
 
 2. On high flow oxygen =/>
 
 3. On mechanical ventilatio
 
Phase 2 United Sta ; Jon D Simmons, M.D.; jdsimmons 12514459834;251-471 4. Clinical diagnosis of COV

 
 COVID-19 patients during p
 
 
Phase 2/PhEgypt ; Waheed Shouman, M shouman66+201114812048;+201 refuse to participate pregna

 
 
 
N/A Canada ; Jean-Francois Pelletie ;jean-franc ;51457458 Research Ce Exclusion
 
 - Any patient between the
 (via rRT-PCR) requiring cr
 
N/A - Signs or sy

 
 - Recovered from COVID 1
 
 
 - Do not have any Respira
 
 
N/A ishtiaq ahmed ixhtiaq8@ 9.06E+11 -

 
 Each participant must meet
 
 1. Able and willing to comp
Phase 1/PhKorea, Repu; Yoon-Jeong Choi, M.S.yoonjeong 82-31-628-3233;82-3 

 
 - Hematologic, Oncologic
 
 - Tested for COVID-19
 
 - Age up to 21 years of age
 
 
onal [Patient Registry] United Sta ; Prakash Satwani, MD; ;ps2087@c;212-305-0Columbia Un
 

 
 - â€¢ Covid 19 infected he
 
 
 - â€¢Risky healthcare wor
Samar Salah Eldin samarsala 2.01E+11 

 
 - Living in a household wh
 Age above 50.
 
 
Phase 4 Guinea-Bis ; Ane Fisker, MD, PhD;A;a.fisker@ ;+245 9666Bandim Hea - Previous adverse events
 
 - Any patient over 18 year
 
 
 
Burkina Fa ; Halidou Tinto, PhD;Ha;halidouti ;00226703 IRSS - URC COVID-19 patients Inclusion

 
 - Male or female patients
 
 - Diagnosed with microbio
Phase 1/PhBelgium ;; Yves Beguin, MD,PhD;;yves.begu ;(0032)43 CHU de LiÃ 

 
 
 
Phase 2 James McMahon james.mc 6.14E+10 - Confirmed SARS-CoV-2 b

 
 - suspected stroke in the p
 
 - patient at risk for COVID
 
 
 - scalp laceration
 
Lisa Distenfield lisa.diste 954-552-4206 - Patient

 
 1. Moderate disease with a
 with increasing oxygen re
 
United Sta Kwame Dapaah-Afriyie, MD The Miriam 2. All patients with severe

 
 
 - < 70 years old
 
 - Tested positive or negati
 
N/A Belgium ; Laura Van Gerven;Lau laura.vang +3216336390;+32163 Exclusion Cri
 
 - All patients with confirm
 
 - Any age or gender
 
 
 - - Any patient refusing to
Egypt ; Amira Al Balakosy, M. ;drbalako ;01221977 Ain Shams 

 
 - Covid-19 pneumonia
 
 - Age over 18 years
 
 - Willingness to express co
 
 
Phase 3 Italy Pietro Minuz, Profess pietro.min 045-8124414 - Active neoplasia or in ma

 
 - Every adult patient enter
 31/12/2020
 
 
 - <18 yo
France ; Mathias BRUGEL;Damimbrugel@ch
326832763;32678847 

 
 - Adult patient (= 18 years
 
 - Positive COVID-test
 
 - Under mechanical ventil
 
 - D-Dimers>1.2 mg/L
 
Phase 4 Qatar ;; Marcus Lance, MD, P ;mlance@h;00974;00 HMC; Exclusion Criter

 
 - all patients with COVID-1
 ventilation
 
 
Russian Fe ; Andrey I Yaroshetskiy ;dr.intens ;+7985990 Sechenov U - Patients who reached th
 
 - Volunteer healthcare wo
 
 - 25 years old and over
 
 - Not having been diagnos
 
Phase 2/Phase 3 ; Elard S Koch, PhD;Cri ;cvargas@m;+5641246 MELISA Ins - A he

 
 Subjects must meet all the o
 
 - Men residing in dormito
 
Phase 3 Singapore ; Raymond Chee Seong mdcrscs@n67722597; - Willing and able to give i

 
 - Male Sex
 
 - Age>18 years
 
 - Will to participate to the
 
Italy ;;; Mauro Gacci, MD;Sergi;;simone.mo
;;+39 347 Careggi Uni - Documented past infecti

 
 - Patient over the age of 1
 
 - Diagnostic COVID-19 by
 
 - Hospitalisation in resusc
France ; Pierre-Emmanuel FAL pierre-emm33 3 69 55 11 34;33 3 

 
 - Employees of the health
 
 - voluntary request for tes
 
 
 - None
Germany ; Focke Ziemssen, MD;Ffocke.ziem +49 7071 29 88088;+4 

 
 1. Presence of SARS-CoV-2
 
 2. Presence of great than o
Phase 2 United Sta Peter Young, PhD pyoung@ai415 860-8370 
 
 1. Male
 
 2. Age =50 years old
 
 3. Presenting "Gabrin sign"
 
N/A Brazil ;;; Flavio A Cadegiani, M ;;f.cadegi ;;+556199 Corpometria
 4. Positive SARS-CoV-2 rtP
Condition Interventi Primary o results dat results da results url RetrospectiBridging fl Bridged ty results yes no
2019 NovelDrug: Convmortality Yes 0
CoronavirusDrug: LopinThe rate of virus inhibition Yes 0
Cardiovascular Death; Cardiovascular Death Yes 0
Virus; Pneumonia GHQ-12(general health questionnaire-12) Yes 0
2019-nCoVDrug: Arbi Virus negative conversion rate in the first w Yes 0
2019-nCoVDrug: Intr Clinical improvement based on the 7-point s Yes 0

2019-nCoVDrug: ASC09The incidence of composite adverse outcom Yes 0
2019-nCoVsurvival g duration of in hospital;in hospital mortality; No 0
Novel CoroCase serie inhospital length;inhospital mortality;ECMO Yes 0
Novel CoroexperimentLung function; Yes 0
Novel Coroexperiment Number of worsening events; Yes 0
Novel CoroConventionLength of hospital stay; No 0
Novel CoroCase serie Length of hospital stay; No 0

COVID-19 Case seriesclinical features and risk factors;validity and Yes 0
Novel CoroCase seriesIncidence of co-infection; No 0
novel coro Case serie Conversion rate of mild and common type pat
No 0
Novel CoroGold Standadetection of SARS-CoV-2 nucleic acid;SEN; Yes 0

Novel CoroGold StandPositive/Negtive;SEN, SPE, ACC, AUC of ROC Yes 0
Novel Coroexperiment14 day outcome of the subjects, including: r No 0
Novel CoroExperimentBody temperature returns to normal time;P Yes 0
Novel CoroChinese tr TCM symptom score;Antifebrile time;The time

Yes 0
Novel CoroExperimenttime and rate of temperature return to normYes 0
Novel CoroexperimentFatality rate; Yes 0

Novel CoroExperimentLength of admission;mortality rate; No 0
Novel CoroCase seriesTime to clinical recovery; No 0
Novel CoroExperimentrate of cure; No 0
Novel CoroObservatioCD4+;CD3+;HAMA;HAMD;STAI; Yes 0
Novel CoroExperimentClinical and laboratory indicators;Viral load; No 0
Emotional Case seriesSelf-rating depression scale, SDS;Self-Rating No 0

Novel Corocontrol gr Time fo fever reduction;Time of nucleic aci Yes 0
Novel CoroExperimentTime of viral nucleic acid turns negative;AntiYes 0
novel coro ExperimentTime to disease recovery; Yes 0
Novel CoroGold StandSEN, SPE, ACC, AUC of ROC; Yes 0
Novel CoroThymosin tProportion of patients with a lung injury sc No 0
Novel Corocase series 28-day mortality and 90-day mortality.; No 0
Novel CoroCase serie Inpatient mortality; No 0
Novel CoroControl gr TCM symptoms efficacy; Yes 0
Novel CoroExperimentSt. George's Respiratory Questionnaire; Yes 0
Novel CoroControl gr Antipyretic time;Pharyngeal swab nucleic ac Yes 0
novel coro Case seriesPSQI; No 0

Novel CoroGold StandChest CT findings;Epidemiological history;L Yes 0
Novel CoroTCM Group:Length of hospital stay;fever clearance time;Yes 0
severe nov experiment14 day outcome of the subjects, including: r No 0
Novel CoroexperimentaTime to Clinical recovery; No 0

novel coro Experiment28-day survival;Inflammatory factor levels; Yes 0
Novel Coroexperimenta
Time to Clinical recovery; No 0
new coron control gr cure rate; No 0
Novel Corocase series imaging feature; Yes 0
novel coro experimentRate of conversion to severe or critical illnes Yes 0

novel coro Case serieslength of stay;length of stay in ICU;Antibio No 0
novel coro experimenta

vital signs (Body temperature, blood pressu Yes 0
Epilepsy, Epilepsy g Physical and mental health; No 0
novel coro Suspected blood routine examination;CRP;PCT;Chest CT;No 0

Novel CoroExperimentChest CT;Routine blood test;liver and renal Yes 0
Novel CoroGeneral paChest imaging (CT); No 0
2019 NovelexperimentLength of stay;Length of severe;oxygenation Yes

i 0
Novel CoroExperimentthe condition worsens and develops into seveYes 0
Novel Coronon-severeincidence;mortality; No 0
Novel CoroCase seriesEpidemiological history;haematological;Firs No 0
novel coro Vitamin D ROX index; Yes 0
novel coro Gold StandSensitivity of detection of NCP;Specificity of Yes 0
novel coro control gr ECG;Chest imaging;Complications;vital sign Yes 0
novel coro doctors groPhysical examination;Nucleic acid;Oxygena Yes 0
novel coro ExperimentCompletely antipyretic time: completely an No 0
novel coro Case serie 2019-nCoV nucleic acid turning negative timeYes 0
novel coro ExperimentTime to completely antipyretic time:completYes 0
novel coro Normal groTCR sequencing;BCR sequencing;HLA sequenYes 0
novel coro Gold StandLymphocyte subpopulation analysis;CytokineYes

d 0
novel coro Case seriesTime for body temperature recovery;Chest CT

Yes 0
novel coro ExperimentVirus negative conversion rate in the first w Yes 0
novel coro mild-modervirus nucleic acid negative-transforming tim Yes 0
Novel CoroexperimentMortality in patients; No 0
novel coro ExperimentThe incidence of composite adverse outcom Yes 0
Novel CoroExperimentIncidence of onset at home / designated iso No 0
novel coro Control gr the negative conversion ratio;the proportio No 0
novel coro Group A:alpDeclining speed of Novel Coronavirus by PCRNo 0

novel coro Treatment Cure rate;The cure time;The rate and time a Yes 0
novel coro control gr PSI; Yes 0

novel coro control gr PSI; Yes 0
novel coro experimentaThe time when the nucleic acid of the novel No 0
novel coro single arm blood routine;urine routines;CRP;PCT;ESR;cr No 0
novel coro A:Baloxavi Time to viral negativityby RT-PCR;Time to cl Yes 0
novel coro Experimenta

Time to viral negativity by RT-PCR;Time to c Yes 0
novel coro Experimentviral negative-transforming time;30-day causYes 0
novel coro DRV/c grouTime to conversion of 2019-nCoV RNA resultYes 0
novel coro experimentThe incidence of adverse outcome within 14 Yes

d 0
novel coro (ordinary) Recovery time;Ratio and time for the generalYes 0
novel coro treament gRelief of clinical symptoms and duration; Yes 0

Self-rating depression scale, SDS;Self-Rating Yes 0
novel coro experimentpulmonary function;St Georges respiratory Yes 0
novel coro Experimenta

body temperature;Whole blood count and five
Yes 0

Patient survival rate; No 0
novel coro Case serie Clinical characteristics;TCM syndrome; No 0
Novel Coroexperimentpulmonary function;Antipyretic time;Time ofYes 0
novel coro experimentpulmonary function;St Georges respiratory qYes 0

new coronaexperimentpulmonary function;St Georges respiratory Yes 0
novel coro control gr Antipyretic time;Time of virus turning negatiYes 0
novel coro control gr CURB-65;PSI score;Mechanical ventilation tim

Yes 0
novel coro Case seriesall available outcome; Yes 0
novel coro Group 1:TCDuration of PCR normalization;Clinical symp Yes 0
novel coro CommunityViral nucleic acid detection;CT Scan of the Yes 0
novel coro Case seriesTime for body temperature recovery;Chest XYes 0
novel coro A:Critical CT of lung;CT and MRI of hip; No 0

novel coro Case seriesTCM syndroms; Yes 0
novel coro ExperimentCritically ill patients (%); Yes 0
novel coro Group A:trathe rate of remission; Yes 0
Novel CoroGroup 1:Xupneumonia severity index (PSI); No 0
2019 nCoV,Drug: PD-1 lung injury score Yes 0
Pneumonia,Biological Oxygenation index Yes 0
Novel CoroExperimentTCM symptom score;Becomes negative timeNo

o 0
novel coro Gold Stand28day mortality; Yes 0
Novel CoroExperimentCure rate;Mortality; Yes 0
Novel CoroExperimentpulmonary function;Novel coronavirus pneum

No 0
Novel Corosevere NCPSevere NCP group: Time to clinical improvemNo 0
Novel CoroExperimentCD8+ T cells numbers;CD4+ T cell numbers;NK

Yes
c 0
Novel CoroControl gr CT scan of the lungs;Nucleic acid detection oYes 0
Novel Corocontrol gr Chest CT;Whole blood cell analysis;Recover Yes 0

Novel CoroCase seriesthe daily treatment intensity; Yes 0
Novel CoroExperimentClinical index; Yes 0

Novel CoroCase seriesSelf-rating depression scale; Yes 0
CoronaviruHumanisticrecovery time; Yes 0
Novel CoroExperimentChest CT scan;Nucleic acid of novel coronavirYes 0
Novel CoroCombinatioClinical recovery time; No 0
Novel CoroTwo groups:Time to leave ventilator on day 28 after rec No 0
Novel CoroCase serie Cortisol;ACTH;Form of Adrenal tissue; Yes 0
novel coro Control groBlood routine tests, Liver function examinat No 0
Novel Corocontrol gr Chest imaging;RNA test of COVID-19;Time toYes 0
Novel CoroCase seriesSARS-CoV2 Nucleic Acid Quantification; No 0

Novel CoroAdolescentmenstruation changes;TCM body constitutioYes 0
Mental hea1:Simplify State anxiety; Yes 0
Novel CoroSevere gro M mode echocardiography;two-dimensionalNo
e 0
Novel CoroExercise pr Mood index; Yes 0
Novel CoroExperimentTTCI (Time to Clinical Improvement); Yes 0

Novel CoroExperimentThe nucleic acid of the novel coronavirus is Yes 0
Novel CoroLight grou Three-dimensional ultrasound;Two-dimension No 0

Novel Corogeneral an CT image of lung of close contact medical st Yes 0
novel coro Psychologi the score of Hamilton depression scale;the s Yes 0
Novel CoroExperimentThe days from positive to negative for viral nYes 0
Novel Corocase series ICU hospitalization days;Death rate; Yes 0
Novel CoroHydroxychlClinical recovery time; Yes 0
Novel CoroCase seriesThe changes of clinical symptom, laboratory No 0
Novel CoroExperimentpneumonia severity index (PSI);Incidence of Yes 0
Novel CoroCase serie The novel coronavirus nucleic acid negative Yes 0
Novel CoroExperimentSARS-CoV-2 DNA;SARS-CoV-2 antibody levels;

Yes 0
Novel CoroExperimentBody temperature;TCM syndrome integral;Mur

No 0
Novel CoroInterventi Proportion of COVID-19 close contacts who Yes 0
Novel CoroCase seriesDistribution of 'B' line around lungs of bot No 0

Novel CoroCase seriesAcute kidney injury; Yes 0
Novel CoroCase seriesclinical cure rate;Incidence of mechanical v No 0

Novel coro Case serie Release rate of discharge standards for isola Yes 0
Novel CoroCase seriesClinical characteristics; Yes 0
Novel CoroCase serie Coronavirus nucleic acid markers negative r No 0
Novel CoroTraining:N Accuracy; Yes 0

Novel CoroSevere gro Death;Recovered;Discharged; No 0
Novel Coro1:inhalate viral negative-transforming time;30-day causNo 0
Novel CoroCase seriesmenstruation changes; No 0
Novel CoroCase serie NA; Yes 0
Novel CoroExperimentImprovement of clinical symptoms (Clinical i Yes 0
anxiety an Case seriespsychological scale;Intestinal flora abundan No 0
Novel CoroExperimentClinical symptoms;Blood routine;the viral l No 0
Novel CoroExperimentRecovery rate; Yes 0

Novel Corocollege st Mental health status; Yes 0
Novel CoroGroup 1:Tr hospital stay;Discharge rate;Site-specific h Yes 0
Novel Corocontrol gr cure rate; No 0
Novel CoroExperimentTime to Clinical recovery; No 0
PneumoniaGanovo / r Rate of composite advers outcomes:SpO2,PaO

No 0
novel coro Mild Groupgut microbiome;Fecal metabolomics;Blood roYes 0
Novel CoroLow-dose grTime to Clinical Recovery; Yes 0
Anxiety; N pneumoniaSelf-Rating Anxiety Scale;Self-Rating Depres Yes 0
Novel CoroControl gr lung function;ADL;6min walk; Yes 0
Novel CoroChloroquinClinical recovery time;Clinical recovery tim No 0
pneumonitiexperimentImproved respiratory system function (bloodNo 0
Novel CoroexperimentArterial Blood Oxygen Saturation;TTCR,Time Yes 0
Novel CoroExperimentTime to Clinical Recovery; No 0
NO Case seriesHSCS;SCSQ;GHQ-12; No 0
Novel CoroGold StandaSARS-COV-2 nucleic acid;SEN, SPE, ACC, AUCYes 0
Novel CoroControl gr Length of hospital stay; Yes 0
Novel CoroExperimentTime to Clinical recovery;Butyrate in feces; No 0
Novel CoroExperimentthe rate of Coronary virus nucleic acid nega Yes 0

Novel CoroControl gr TCM syndrome; Yes 0
Novel CoroCOVID-19 pCoVID-19 Perinatal Outcomes; No 0

Novel CoroExperimentQuality of life;Anxiety assessment;Depres Yes 0
Novel CoroControl gr Recovery time;Pneumonia psi score; Yes 0
novel coro Gold StandCytokine detection;Lymphocyte subpopulatioYes 0

Novel Corocommon gro
blood cell count;C-reactive protein (CRP);art Yes 0
Novel Corocontrol gr SOFA; Yes 0
Novel CoroA1:HydroxyNumber of patients who have progressed to Yes 0
Novel CoroexperimentDisappearance rate of fever symptoms; Yes 0
Novel CoroexperimentRecovery time; Yes 0
Novel Corohydroxychloxygen index;max respiratory rate;lung radi Yes 0
2019-nCoV The cure rate of 2019-nCoV.;The improvemen

Yes 0
COVID-19 Drug: thal Time to Clinical recoveryTime to Clinical Re Yes 0
COVID-19 Drug: plac Time to Clinical Improvement (TTCI) Yes 0
2019-nCoVsDrug: Mepl2019 nCoV nucleic acid detection Yes 0

COVID-19 Other: nCa Accuracy of nCapp COVID-19 risk diagnostic Yes 0
Pulmonary Drug: N-ac High-resolution computed tomography (HRCT)

Yes 0
CoronaviruOther: ComSurvival rate Yes 0
Coronavirus Positive rate of 2019 Novel Coronavirus RNAYes 0
Neonatal Infection;Pe The death of newborns with COVID-19;The SYes 0
CoronaviruDrug: Fing The change of pneumonia severity on X-ray Yes 0
CoronaviruCase serie Inhospital time; Yes 0
2019-nCov one group:RPCL;HRQL;IPAQ;PASE; Yes 0
Novel CoroCase seriesPCL;PSQI;FSI; Yes 0

Novel CoroCase serie Sputum/nasal swab/pharyngeal swab/lower Yes
resp 0
Novel CoroControl gr Psychological status;Treatment compliance;To

Yes 0
Novel CoroGroup 1:EigPost-traumatic stress disorder checklist;Clini Yes 0
Novel CoroExperimenta
Pharynx swabs, lower respiratory tract samplNo 0
Novel CoroCase serie cure rate;virus negative rate;time of virus neYes 0
Novel coro Gold StandCT;SEN, SPE, ACC, AUC of ROC; No 0
Novel CoroExposure gLung CT;TCM symptoms; No 0
Novel CoroMild groupEpidemiological and clinical characteristics; Yes 0
Novel CoroCase serie mood assessment; Yes 0

Novel coro Case serie pulmonary iconography; Yes 0
Novel CoroMonitor caEpidemiological characteristics;clinical fea No 0
Novel CoroGold StandSEN, SPE, ACC, AUC of ROC; No 0
Novel CoroPirfenidon K-bld questionnaire survey;Refers to the pul Yes 0

Novel CoroCase seriesBlood Routine;Liver function;Blood electroly No 0
psychologi InterventioPsychological questionnaire; Yes 0
Novel CoroTwo groupsTemperature;Respiratory symptoms; Yes 0
Novel CoroLight and Epidemiological and clinical characteristics; No 0
Digestive The experi During the operation, the patient's volume oYes 0
novel coro Case serie Critically ill patients (%);Mortality Rate; No 0
pediatric Case serie temperature;respiratory symptoms; Yes 0

Novel CoroCase seriesblood RNA; Yes 0
Novel CoroCase seriesClinical indicators; Yes 0

Novel CoroCase seriesQuality of Life;Epidemic Prevention Medica No 0
Novel coro case series imaging feature; Yes 0
Novel CoroHigh infla Inflammation factor; No 0

job burnouBurnout pono; Yes 0
psychologicCase seriesGHQ-20; No 0
Novel CoroExocrine g Lung CT; Yes 0
NRS 2002 score;BMI;triceps skinfold thickne Yes 0
Novel CoroExperimentRate of composite advers outcomes: SpO2, PNo 0
Novel CoroExperimenttemperature;respiratory rate;Blood oxygen No 0

Novel CoroCase seriesINR;PT;TT;APTT;FIB;DD; Yes 0
Novel CoroRoutine treClearance rate and time of main symptoms (fYes 0

Novel CoroCase seriesClinical characteristics; No 0
Novel CoroExperimentLength of hospital stay;Discharge time of ge No 0

BiopsychosGeneral poQuality of life;Socio-demographcis and otherNo 0
Geriatrics the elderly health status;Mental health status; No 0
Novel CoroCase seriesClinical symptoms;TCM syndrome;Lung imagin

No 0
Clinical recovery time;Pneumonia Severity InNo 0
Novel CoroExperimentRoutine physical examination;Vital signs: b Yes 0

cytokine r Case serie the relive of CRS; No 0
Cancelled Cancelled; Yes 0
Novel CoroExperimentMood index; No 0
Novel CoroCase seriesROC;calibration curve; Yes 0
Novel coro ExperimentCOVID-19 nucleic acid detection time from po

Yes 0
Novel CoroExperimentBlood routine examination;Chest CT;Arterial Yes 0
novel coro Kesuting sycough; Yes 0
Novel CoroExperimentviral negative-transforming time;30-day causYes 0

COVID-19 Case seriesClinical symptoms;Test result;Examination reYes 0
Novel CoroCase seriesexposed factors;latent period;preventive meYes 0
Novel CorohydroxychloTime to Clinical Recovery, TTCR; Yes 0
Novel CorohydroxychloTTCI (Time to Clinical Improvement); Yes 0

Novel CoroCase seriesWorsening condition;Death;Heart fatty acid Yes 0
Novel CoroExperimentNegative conversion rate of COVID-19 nucleiYes 0
Novel CoroLow-dose gNegative conversion rate of 2019-nCoV nucleYes 0
novel coro ExperimentTime to clinical recovery; Yes 0
Novel Corocontrol grotime to recovery.; Yes 0

Validity observation index; Yes 0
novel coro Case seriesThe proportion of patients diagnosed with Yes 0
Novel Coroarm A:RibavThe time to 2019-nCoV RNA negativity in patNo 0

Novel CoroExperimentSOFA score; Yes 0
CoronaviruBiological Adverse reaction (AE) and severe adverse re Yes 0
Novel CoroDiagnostic Screening accuracy Yes 0
Novel CoroDrug: pirf chest CT;Finger pulse oxygen;blood gas;K-BI Yes 0
CT Scores Other: CT 7-day mortality Yes 0
Novel CoroDrug: Carri Fever to normal time (day);Pulmonary inflamYes 0

Novel CoroExperimentTempreture;Virus nucleic acid detection; No 0
Novel CoroCase serie ALT; Yes 0

Novel CoroCase seriesintrusion;avoidance; No 0
Novel CoroCase seriesclinic outcome; No 0
Novel CoroExperimentPulmonary function;6 minutes walking dista No 0
Novel Corocase series Immunity function;cytokines;viral load; Yes 0
Novel Coromonitor casChild Stress Disorders Checklist evaluation; Yes 0

Novel CoroCase serie Unplanned shutdowns; Yes 0
Novel CoroCase seriesviral load;virus genotyping;Classification of Yes 0
Novel CoroGold StandVolatile organic compounds, VOCs;SEN, SPE, Yes 0
2019 novelCase seriesLung ultrasound index;Right ventricular funcYes 0
2019 novelCase seriesin-ICU mortality;mortality of 28 days; No 0

Novel CoroCase seriesA cycle threshold value (Ct-value); No 0
Novel CoroPatients w Pulmonary image findings;Relevant clinical Yes 0

Novel CoroMedical st PSS-14; Yes 0
Novel CoroCRRT groupChest imaging;Oxygenation index;ExtravasculYes 0
Clinical therapeutic course;Pathogenic dete No 0
Novel CoroexperimentTime to Clinical Recovery (TTCR); Yes 0
Real-time fluorescent RT-PCR detection of p No 0
Novel CoroExperimentMortality; No 0
sleep disor cross-secti Pittsburgh sleep quality index; Yes 0

Novel CoroControl gr TCM syndrome; Yes 0
Novel CoroPatients i length of stay;length of stay in ICU;Hospital No 0
Novel CoroCase serie Cure rate; No 0

Novel CoroCOVID-2019Nuclei acid test of SARS-CoV-2 of conjuncti No 0
Novel CoroAzvudine PSputum/nasal swab/pharyngeal swab/lower Yes

resp 0
Novel CoroGroup 2:co28-day mortality;ICU 14-day mortality; Yes 0

Lung injurytreatment gPaO2 / FiO2 or respiratory rate (without ox No 0
Novel CoroCase serie Cardiac injury;Death in hospital and/or EndoYes 0
Novel CoroEarly corti The time of duration of COVID-19 nucleic aciNo 0
Novel CoroInterferon Incidence of side effects; Yes 0
Novel CoroControl grolasting time of fever;lasting time of novel No 0
Novel CoroCase serie 28 day mortality; Yes 0
Novel CoroCase serie 28 day mortality; Yes 0
Novel CoroExperimentRate of composite advers outcomes: SPO2, PNo 0
Novel CoroLipoic acid Progression rate from mild to critical/severe Yes 0
Novel CoroControl gr fever clearance time;Effective rate of TCM No 0
Novel CoroPRE-GROUP1
disease incidence;Duration of PCR normalizaNo 0
Novel CoroControl gr Psychological status; No 0
Novel CoroGroup 2:SMOSpO2 during intubation;the total time of in Yes 0

Novel CoroCase seriesClinical characteristics; Yes 0
Novel CoroACEIs/ARBsratio of severe cases; Yes 0
Novel CoroCase seriestime in range; Yes 0
Novel CoroCase seriesClinical symptom improvement rate: improveYes 0
Novel CoroCase seriesMental status;Social support; Yes 0

Novel CoroCase serie cure rate;duration of hospitalization;days of Yes 0
Novel CoroExperimentMRC breathlessness scale;6MWD; No 0
Novel Corogroup A:Ar Main symptom relief time; Yes 0
Novel Coropatient groCT image of lung; Yes 0
novel coro Experimentthe number of days between randomised groYes 0
novel coro ExperimentSafety; No 0
novel coro Case seriesCytokines; No 0
influenza ExperimentCRP;ESR;PCT;Tn;Mb;D-Dimer;blood routine eNo 0

novel coro ExperimentSevere conversion rate;Oxygenation index;20No 0
Novel CorointerventioClinical improvement time of 28 days after r No 0
Pneumonia Caused byMortality;The time interval of Nucleic acid Yes 0
Coronavirus The virological clearance rate of throat swabYes 0

COVID-19; Drug: RecoThe incidence of side effects;The incidence oYes 0
COVID-19 Drug: LopinClinical recovery time Yes 0
CoronaviruDevice: MeRT-PCR confirmed COVID-19 infection Yes 0
COVID-19;EOther: sev Success rate of intubation;Infection rate of Yes 0
Mental Dis Other: Exp The prevalence and incidence changes of c Yes 0
Novel CoroCase serie mental health status and influence factors; No 0

Novel CoroCase seriesTransmission dynamics of COVID-19 in Hong NoK 0
Novel CoroPopulation Confirmed 2019-ncov pneumonia; No 0
Novel CoroControl gr serum albumin;siderophilin;prealbumin;lungNo 0

Novel CoroCase serie Improvement of symptoms; No 0
Novel CoroCase seriesnosocomial infection ratio of SARS-Cov-2; No 0
Novel CoroGroup 1:FaClinical cure rate; No 0

psychologi ObservatioSymptom Checklist 90; Yes 0
Fibrosis a ExperimentHRCT pulmonary fibrosis score; No 0
Novel CoroCase seriestemperature;Systemic symptom;Respiratory No

s 0
Novel CoroMSC group:Oxygenation index (arterial oxygen partial prNo 0
COVID-19 Case seriesMaternal and neonatal morbidity; No 0
Novel CoroCase serie 2019-ncov-RNA;Chest CT;Routine blood tes No 0
Novel CoroCase serie chest CT images; No 0
Novel CoroOrdinary C Laboratory inspection index;Oxygen therapyNo 0
Novel CoroCase seriesCT; No 0

Novel CoroCase seriesRT-PCR test for SARS-CoV-2; Yes 0
Novel CoroGroup 1:Tr Mortality rate; No 0
Novel CoroCase serie Discharge rate; No 0
Novel CoroCase seriescytology;proteomics;chest X-ray;Oxygenatio No 0
Novel CoroGold Standasensitivity;SPE; No 0

Novel CoroCase seriesLength of stay in ICU;Diaphragm movement;No 0
COVID-19 The triple white blood cell;lymphocyte;creatinine;CRP; No 0
Novel CoroCase serie CK-MB;CTnI;neuron-specific enolase,NSE;BUN;

No 0
Novel CoroCase seriesDeath; No 0
SomatopsycObservatioChinese health status scale;Self-rating Anxie Yes 0
Novel CoroCase seriesSCL-90 scale; Yes 0
Novel CoroExperimentTime to Clinical Improvement (TTCI); No 0

Novel CoroCase serie SAA;Detection of respiratory pathogen ser No 0
Novel CoroGold StandPrecision;SEN, SPE, ACC, AUC of ROC; No 0
Novel CoroGroup 2:Tr 14 day outcome of the subjects, including: r No 0
Novel CoroHigh dose group:routine treatment + MSc (2 x10^6 / kg No 0
Novel CoroCase seriesEpidemiological characteristics;SARS-CoV-2 IgYes 0

Novel CoroGold StandRNA of 2019-nCov;SPE, SEN, ACC, AUC of ROYes 0
Novel CoroGroup 1:miPHQ-9;GAD-7;PHQ-15;PSS-14;ISI;SHARPS;ACTYes 0
Novel CoroCase seriesLaboratory inspection index;Imaging examinaNo 0

Novel CoroCase seriesAbnormalities on chest CT;Exposure to sourcNo 0
Novel CoroCase seriesLiver function; No 0
Novel Coro Case seri ymphocyte subsets; No 0
Novel CoroCase serie Mortality of ICU 28-day; No 0
Novel CoroCase seriesOcular Symptoms; No 0

Novel CoroCase serie Single cell sequencing; No 0
COVID-19 Experimenta
Average discharge time;WBC;ALT, AST, gama-G
No 0
Novel CoroCase seriesClinical outcomes after discharge; No 0
Novel Coronon-cancerlynphocyte;cytokine;cancer history;order of No 0
Novel Coroexperimentablood RT;ABG;blood clotting function;liver a No 0

Novel CoroCase seriesQuantitative CT characteristic; No 0
Novel CoroExocarpiumCough Score;Expectoration score; No 0

Novel Corosevere pat age;sex;comorbidities;chest-CT examination;No 0
Novel CoroCase seriestime and rate of cure; proportion and time No 0
Novel Corodischarge discharg time; No 0

Novel CoroGold Standard:Epidemiological history + CT + clinical No 0
Novel CoroGold Standcure rate;propotion of progression;SEN, SPE No 0
Novel CoroCase seriesblood biochemistry; No 0
Corona Vir Case serie all-cause death;fatal arrhythmias; No 0

Novel CoroCase seriesmortality;effective rate; No 0
Rheumatic Case seriesClinical features; Yes 0
Novel CoroCase seriesEpidemiological characteristics;clinical fea No 0

Novel CoroCase serie 28-day prognosis; No 0
Novel CoroExperimentblood gas;SOFA score; Yes 0

COVID-19 Case seriesEpidemiological features; No 0
Novel CoroCase seriesdeath;Number of failure organs;Length of hos

No 0
Anxiety; N Case seriesanxiety; No 0
Novel Coro4 groups:NPSQI;PPHQ-9;GAD-7;PTSDChecklist-Civilian VNo 0
Novel Corocase series Pulmonary function;Cardiac function;neural No 0

Novel CoroCase seriesClinical characteristics according to TCM; No 0
Novel CoroCase serie CRP;IL-6;TNF-alpha;IL-8; Yes 0
Novel Corotwo groupsthe clinical, laboratory and the radiologic chaYes 0
Novel Corocontrol gr The time for the positive nucleic acid of th No 0
Novel coro NIV group: Dose of analgesic and sedative drugs;28-day No 0
novel coro Case seriesPsychological assessment; Yes 0

Novel CoroCase seriesSARS-CoV-2; No 0
Novel coro Case seriesCritical illness ratio; Yes 0

Novel CoroGold Standfalse positive rate of SARS-CoV-2 IgM antib No 0
Novel Corocase series ICU hospitalization days;The recurrence rate No 0

Novel Corocase series:Outcome; No 0
Novel CoroCase serie nucleic acids probing;blood routine;blood b No 0
Novel coro Control gr CT Scan-Chest; No 0
Novel CoroECMO group

Inpatient mortality;ICU hospital stay; No 0
Novel coro Case seriesin-ICU mortality; Yes 0
Novel Corotransnasal PaO2;PaCO2; No 0
Novel Corocase series mortality;ICU hospital stay;mechanical ventilNo 0

Novel Corocase series Tempreture;cough;dyspnea;Blood Routine;AtNo 0
Novel CoroCase seriesascultation; No 0
Novel CoroGold Standdetection of SARS-CoV-2 RNA;SEN, SPE, ACC Yes 0
Novel CoroGroup 2:WeMedical imaging improvement rate in patientNo 0
Novel CoroIntegrated Mortality rate;Common-severe conversion rat

No 0
Novel CoroExperimentTime to Clinical Recovery; No 0
Novel CoroExposed gr14-days mortality;28-days mortality; Yes 0

Novel Coroin hospita SARS-CoV-2 virus;sex hormones;sperm quali No 0
End-stage Case series:Levels of anxiety, stress and depression; No 0

Novel CoroCase seriesBlood oxygen saturation; Yes 0
Novel CoroGold StandSensitivity, specificity and accuracy; No 0
Lung CT; Yes 0
Novel CoroeperimentaTime to clinical recovery after randomizationNo 0
Novel CoroexperimentTime to Virus Eradication; Yes 0
Novel CoroexperimentTime to Virus Eradication; No 0
Novel CoroCase serie SDS;SAS;PSQI; Yes 0
Novel CoroTwo groupsLymphocyte grouping; No 0
Novel CoroInfection wtemperature;heart rate;respiratory rate;blo No 0
malignant tumor pati impact on the treatment of tumor patients; No 0
Novel CoroGold StandIn-hospital mortality;ACC, SEN, SPE, ROC; Yes 0

Novel CoroGroup A:Secough;agitation; Yes 0
Novel Corocase series Clinical characteristics;Clinical outcomes; No 0
Novel CoroCase seriestreatment effect; No 0
novel coro Chinese meImaging; Yes 0
Novel CoroCase seriesDisease Severity;Imaging;Syndrome Feature Yes 0

Novel Coroexperimentchest computerized tomography;Nucleic acidNo 0
Novel Coro1:Throat swCT image features;Fever;Throat swab virus nYes 0
Novel CoroControl groRecovery time;Pneumonia psi score; No 0

Novel CoroGroup 1:BaGAD-7; Yes 0
Novel CoroexperimentTime and rate of novel coronavirus become Yes 0
novel commtreatment group :Ba duanjin; No 0
Novel CoroPositive dr lasting time of fever;lasting time of novel No 0
Novel Coro1:meditati Self-rating depression scale;self-rating anxi Yes 0

Mental heaCase seriesComprehensive psychological assessment;MeNo 0
Novel CoroExperimentTemperature returns to normal for more than

Yes 0
Novel coro Experimenta

The percentage of patients who convert to mo
No 0
Novel CoroExperimentClinical symptom improvement rate: improveYes 0

Novel CoroControl gr Status of immune function;The time of nucleiYes 0
Novel CoroCase seriesTime to disease recovery;Time and rate of Yes 0

Sleep; Nov Case seriessleep status and related factors of insomnia;No 0
Novel coro ExperimentEndotracheal intubation rate;mortality;RatioYes 0
Novel CoroExperimentVentilation-free days;mortality; Yes 0

novel coro Gold StandLung ultrasound;Chest computed tomography
Yes
( 0
Novel CoroGold StandPositive/Negtive;False positive of rate ; Yes 0
The time when the nucleic acid of the novel Yes 0
2019-nCoVRoutine tr Complete Blood Count;CRP;blood coagulatioNo 0
Novel CoroPhosphoricTime of conversion to be negative of novel c No 0
Novel CoroGold Standadetection of SARS-Cov-2 nucleic acid;SEN, A Yes 0
novel coro ExperimentIFN-gama;TNF-alpha;Blood routine index;TimYes 0
novel coro Case serie Ventilation-free days;mortality; Yes 0
Novel CoroCase seriesThe negative conversion rate and negative coYes 0
Novel CoroPhosphoricTime of conversion to be negative of novel c Yes 0
Novel CoroPhosphoricMortality rate; Yes 0

Novel CoroCase seriesDEATH; No 0
novel coro ExperimentTime to disease recovery; Yes 0
novel coro High dose Time to disease recovery; Yes 0
Novel CoroExperimentTime to disease recovery; Yes 0
Novel CoroExperimentTime to disease recovery; Yes 0

novel coro Case serie Patientsâ€™ general information: epidemiolog
Yes 0
novel coro Two cohort2019-nCoV RNA;2019-nCoV antibody;Chest Yes 0

Vitamin C; Drug: VC;DrVentilation-free days Yes 0
COVID-19 28 day mortality Yes 0
Treat and Biological: Frequency of vaccine events;Frequency of serYes 0
COVID-19 Biological Disppear time of ground-glass shadow in theYes 0
Pneumonitis survival status No 0
Stress, Psychological Stress Yes 0

Novel CoroCase series25(OH)D; No 0
Novel CoroCase seriesAbnormalities on chest CT; Yes 0
Novel CoroCase serie Neonatal outcome; No 0
Novel CoroCase seriesPulmonary function evaluation;Changes in blNo 0

Severe CO Pirfenidon HRCT score; No 0
Novel CoroCase seriesT lymphocyte subsets; Yes 0
Novel CoroDiagnosed Metagenomics Sequencing; No 0
Novel CoroGroup 1:psPittsburgh sleep quality index;Self-rating anxYes 0
COVID-19 experimentsyndrome;nucleic acid of nCoV-19; No 0

Novel coro COVID-19 demographic information;exposure history;clNo 0
cancer Group 2:th postoperative complication;occupancy rate of

No 0
2019-nCOVSARS-COV-2Serum SARS-COV-2 RNA;Swallow swab SARSNo 0
novel coro Experimentinsomnia;anxiety;depression;comfort; No 0
Novel CoroGold StandPT-PCR test;SEN, SPE, ACC, AUC of ROC; No 0
Novel CoroGold StandSEN, SPE, ACC, AUC of ROC; No 0
Novel CoroSFBT groupGAD-7;STAI-Y (C); Yes 0
improvement or recovery of respiratory sympNo 0
Novel CoroCritical gr T lymphocyte count; Yes 0
sleep disor cross-secti Pittsburgh sleep quality index;hospital anxie No 0
Novel CoroCase seriesClinical Characteristics, Treatments and ProgNo 0
Novel CoroCase seriesClinical characteristics and risk factors; No 0

Novel CoroGold StandCT image;sensitivity;Specificity;Time efficien Yes 0
Novel Corothe patien Nucleic acid; No 0
Novel CoroCase serieshospital mortality; No 0
Novel Coro1:7/5000 The biochemical indicators; No 0
Changes of serum inflammatory factors;PatieYes 0
Novel CoroCase seriesVenous Thrombosis; Yes 0

Novel CoroCase seriesBlood routine test; No 0
novel coro Case seriesclincical characteristics; No 0
Novel CoroCase serie nuclear acid test of faeces;nuclear acid tes No 0
Novel coro Case seriesImmune response multiomics; No 0

Novel CoroGroup 1:LiuMaximal inspiratory pressure;Respiratory muYes 0
Novel CoroCOVID-19 pa Length of hospital stay; No 0
Novel CoroCOVID-19 pTime to negative conversion of severe acute Yes 0
Novel CoroExperimentImprovement of clinical symptoms (Clinical i Yes 0
Novel CoroA:Long-actiCOVID-19 nucleic acid negative conversion raNo 0
Novel CoroTricholomaAlbumin;Cellular immune indicators (total l No 0
Novel Coroobservationauto B line method;Semi-automatic manual me

Yes 0
Novel Coro1:Low doseadverse reactions 7 days post injection; No 0
Novel CoroGold Stan RNA;DNA; No 0

Novel Coronavirus Pn prognosis; No 0
Novel Corocontrol gr novel coronavirus nucleic acid; Yes 0
Novel CoroCase seriesRNA of Coronavirus; Yes 0

Clinical recovery rate of day 7; No 0
Novel Coro1 the criti SP02;lesions of lung CT;temperature;Blood Yes 0
Novel CoroExperimentCompared with the control group, the positi Yes 0

2019 - nC Case seriesdetection of virus nucleic acid; Yes 0
Novel CoroGold StandFirst pass perfusion i;Delayed enhancement Yes 0
Novel CoroExperimentViral nucleic acid test; No 0
malignant tumor pati psychological states; No 0
novel coro experimentthe lowest SpO2 during intubation; Yes 0
novel coro Mild Type The time required for RNA Yin conversion o Yes 0
Novel CoroInterventionovel coronavirus nucleic acid clearance rateNo 0

Patients wi Trade Main Objective: To shorten the period of viruNo 0
COVID-19 1.Date of ECMO discon ### No 0
COVID-19 COther: wasNumber of participants with improvement f Yes 0
2019-nCoVDrug: Abid Rate of disease remission;Time for lung rec Yes 0

2019-nCoVDrug: AbidoRate of disease remission;Time for lung rec Yes 0
2019-nCoVDrug: ASC0Rate of comprehensive adverse outcome Yes 0
2019-nCoVDrug: MethRate of disease remission;Rate and time of enYes 0
2019-nCoV;Drug: ImmuTime to Clinical Improvement (TTCI) Yes 0
2019-nCoV Occupancy rate in the intensive care unit (I Yes 0
Pathogen I Biological: Clinical improvement based on the 7-point s Yes 0
Novel CoroCombinatiorecovery Yes 0

COVID-19 Drug: RecoTime course of body temperature (fever);VirYes 0
COVID-19 Drug: Huai Mortality rate Yes 0
SARS-CoV-2;Outcome,all-cause mortality Yes 0
COVID-19 Biological Size of lesion area by chest imaging;Blood o Yes 0
COVID-19 Drug: SildenRate of disease remission;Rate of entering the

Yes 0
CoronaviruBehavioral Assessment of COVID-19 situation;Depression

Yes 0
Covid-19;S Drug: Toci Proportion of Participants With Normalizat Yes 0

Corona Vir Drug: Tetr Survival rate Yes 0
CoronaviruOther: oxy Incidence of respiratory failure Yes 0
COVID-19;COther: nonThe myocardial injury incidence;The risk factYes 0
Use of Ste Biological Clinical outcome;CT Scan;RT-PCR results Yes 0
Coronavirus;SARS Change in viral expression in association to Yes 0
Novel Coronavirus Pn characteristics of cardiopulmonary ultrasou Yes 0

CoronaviruDrug: Any Renal failure Yes 0
Infection V Other: pre Maternal and perinatal outcomes Yes 0
CoronavirusDevice: Vi Number of patients with constant negative rYes 0
COVID-19;Organ Dysfun
Acute Kidney Injury Yes 0
COVID-19 Severe COVID-19 Yes 0
fever; Nov Case seriestemperature;novel coronavirus;Influenza vir Yes 0

Novel CoroGold Standproteomics;metabonomics;SEN, SPE, ACC, A No 0
Cesarean dCesarean sefever;Chest CT;cough;;Anesthesia during cesYes 0
Novel Coromild recov brain volume;white matter;brain function; Yes 0

Myopia; NoCase serieseye axial length;corneal diopter;Tear film r No 0
Novel CoroGold Standsensitivity;accuracy;specificity; Yes 0
Myopia Case seriesAxle length;Visual acuity;corneal diopter;Te No 0

Rheumatic Case seriesmedication possession ratio;selfrating anxietNo 0
Novel CoroGroup M:PlaSelf-assessment of sleep quality;Efficient o No 0

Novel CoroCase serie Incidence of medical adhensive-related injurYes 0
Novel CorohDPSCs groTTCI; Yes 0

Novel CoroCase seriesECG; No 0
Novel CoroSurvival a clinical features of COVID-19 patients and risNo 0
Novel CoroCase seriesEpidemiological characteristics;clinical fea No 0

Sleep, stre mindfulnesAnxiety level;Sleep; No 0
Novel CoroControl gr Hospital stay or death ratio of experimental Yes 0
Novel CoroCase seriesDemographic data;Epidemiological characteris

No 0
Novel CoroCase seriesmental state; No 0
Novel CoroCase serie IgG antibody;IgM antibody;Throat swab virusNo 0

Novel CoroCase seriesRate of COVID-19, distribution, time of ons No 0
Novel CoroCase seriesRT-PCR test for Covid-19;CT image;Covid-19 Yes 0
Novel CoroCase seriesClinical features and prognosis; Yes 0
Novel CoroCase seriesModified dyspnea index scale;St.George's ReYes 0
Novel CoroExperiment Clearance time of virus RNA; No 0
Novel Coro1:Blank;2: TCM Syndrome Scale; No 0

Novel CoroCase serie mortality; Yes 0
Novel Corotreatment gtime till the SARS-CoV-2 clearance; No 0

Novel CoroCase seriesPT-PCR test; Yes 0
Chronic di HomeopathiPatient satisfaction; No 0
Novel CoroExperimentInflammation absorption on Chest CT; Yes 0
Novel CoroCase serie fatality rate;the ratio of patients transform No 0
Novel CoroExperimentQuantitative table of main symptom grading;Q

No 0
Novel Coroconfirmed traditional Chinese medicine symptom; No 0
Novel CoroExperimentThe change of TCM syndrome integral of defiYes 0
Novel CoroCM group:XBody temperature returns to normal time;AfNo 0
Novel CoroSuspected Incidence of COVID-19 pneumonia;COVID-19No 0

Novel CoroLight grou Two-dimensional ultrasound;M mode echocar
No 0
Novel CoroExperimentPO2/FiO2;ROX INDEX; No 0
Novel CoroCase serieswalking distance;oxygen saturation;heart ratYes 0
Novel CoroexperimentThe time to 2019-nCoV RNA negativity in patYes 0

Novel CoroCase seriesEpidemiological and clinical characteristics; No 0
Novel Coroexperimentpulmonary function; No 0
novel coro ExperimentNeutrophil count;Lymphocyte count;Monocyt

Yes 0
novel coro COVID-19 gPatients' general information: epidemiologi Yes 0

Corona
virus
infection
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Phase 2: To evaluate the clinYes True parent
SARS-
CoV-2
infection
 Med
DRA
version:
20.0
Level: HLT
Classifica
tion code
10047490
Term:
Virus
identifica
tion and
serology
System
Organ
Class:
10000000
4848
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Timepoint(s) of evaluation of this end poin Yes 0
COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: To assess whether SNG001 isYes 0
CoronaviruDrug: Eculizumab Yes 0
CoronaviruDrug: Nitri SARS-free patients at 14 days Yes 0

COVID-19 Drug: Beva The time from randomization to clinical im Yes 0
COVID-19;Acute Kidney
Rate of Acute Kidney Injury Yes 0
Healthy Pe Other: DeteBeck Depression Scale;Health-Related QualityYes 0
Novel CoroDrug: favipTime of Improvement or recovery of respira Yes 0
CoronavirusDrug: Esci Mortality rate;Clinical status evaluated in Yes 0
Covid-19, Drug: ACE iIncidence of influenza No 0

COVID-19 Drug: TradiLength of hospital stay (days) Yes 0
Hospitaliz Dietary Su In-hospital mortality Yes 0
COVID-19 Drug: Hydr Number patients developing severe infectio Yes 0
CoronaviruDiagnostic Point prevalence of COVID-19 infection Yes 0
COVID-19 Biological Clinical response;Side effects in the treatm Yes 0
COVID-19; CardiovascuThe incidence of cardiovascular complicatio Yes 0

CoronavirusOther: No Clinical;Virological;Microbiological Yes 0
COVID-19;CoronavirusDataset size Yes 0
COVID-19 Other: No CT or Xray images from COVID-19 patients Yes 0

COVID-19 (SPatients wiTime from COVID-19 tes4/1/2021 Yes 0
Acute Inso Group 1:si Sleep diary;The insomnia severity index;SleeNo 0
Novel CoroExperimentProstaglandin E2; No 0
Novel CoroControl gr CRP;SAA;IL-6;PCT;tRNA; Yes 0
sleep disor cross-secti PSQI; No 0

Novel Coroordinary grChest computed tomography (CT); No 0
Novel CoroExperiment6minu tewalkingtest,6MWT;mMRC;Rating ofNo

P 0
Novel CoroMedical peASDS;PSS;PHQ;GAD; Yes 0
depressionCase seriesThe score of PHQ-9; Yes 0
rheumatic Rheumatic Infection; No 0

Novel CoroControl:NAExposure time in the medical cabin;HospitaliNo 0
COVID-19 Group 1:Rohospital mortality; No 0
Novel Coroexperimentbody surface temperature; No 0

Novel Coroeye patch aQuality of sleep; No 0
Corona Vir ExperimentChest Imaging;lung function;ADL; No 0
Novel CoroGold Stand2019-nCov IgG; No 0
Novel Coroexperiment 2019-ncov nucleic acid yin rate;Blood 2019- No 0
Novel CoroNintedanibFVC; Yes 0
Novel Coronavirus Pn Success rate of intubation;Exposure classificaNo 0
Cervical sp Case seriesPhone time before and during the outbreak;PYes 0
Novel CoroDifferent d Safety and tolerance; Yes 0
Novel CoroExperimentElectrocardiogram;St George's Respiratory QNo 0
Novel CoroCOVID-19 wBlood cell number;Biochemical markers;MetYes 0
Novel CoroGold StandaSARS-CoV-2 antibody;SEN, SPE, ACC, AUC of No 0
Novel CoroGold StandSPE, SEN, ACC, AUC of ROC; No 0
Novel CoroMild:No;se Safety;Effectiveness; No 0

Novel CoroCase seriesCure rate;improvement rate; No 0
Patient att Trade Main Objective: Lâ€™objectif principal est dâ€™Ã©valuer
Yes lâ€™efficacitÃ©
0 de lâ€™hydroxychloroquine
covid-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10070267
Term:
SARS
virus test
positive
System
Organ
Class:
10000000
4848
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10022519
Term:
Intensive
care
System
Organ
Class:
10042613
- Trade Main Objective: to describe the pharmacokinYes 0
COVID-19
- Has
laborator
y-
confirme
d SARS-
CoV-2
infection
as
determin
ed by
PCR, or
other
commerci
al or
public
health
assay in
any
specimen
< 72
hours
prior to
randomiz
ation.
- Illness of
any
duration,
and at
least one
of the
following:
â€
¢Clinical
assess Trade Main Objective: The overall objective of the Yes 0
Covid19 is Trade Main Objective: To test whether treatment wYes 0

SARS-
COV-2
infection
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10037373
Term:
Pulmonar
y disorder
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To assess whether early treaYes 0
COVID-19 in Trade Main Objective: ;Secondary Objective: ;PrimaNo 0
2019 SARS-C
In patients Mortality [At hospital discharge or 28 daNo 0
RespiratoryDrug: Nitri Measure the safety of 160ppm inhaled nitricYes 0
CoronavirusDrug: Beva Partial arterial oxygen pressure (PaO2) to fraYes 0
Influenza Drug: DAS1Percent of subjects who have returned to ro Yes 0
2019 NovelDrug: reco new-onset COVID-19 Yes 0
CoronaviruBehavioral Rate of COVID-19 infection Yes 0
CoronaviruOther: ObseDefine Natural Symptom Course Yes 0

Early CPAP Ventilatio Death or need of intubation Yes 0
Corona Virus InfectionSurvival;WHO progression scale COVID 19 Yes True parent
CoronaviruDevice: vv interleukin-6 (IL-6) level after 72 hours Yes 0
Angina PecOther: Tel Providing a special electronic platform (e-h Yes 0
Pulmonary Procedure:
A Incidence of Treatment-Emergent Adverse EYes 0
CPAP VentiDevice: CP Death or need of intubation Yes 0

CoronaviruDevice: bi Pulse oximetry level Yes 0
Infection Viral;Coron Correlation between nasal and deep PCR posiYes 0
CoronavirusBiological Mortality changes in day 10;Mortality changeYes 0
COVID-19 FLUS findings and respiratory failure Yes 0
COVID19 Drug: Hydr National Early Warning Score equal to zero Yes 0
CoronaviruOther: retr Time to negative conversion of severe acute Yes 0

COVID-19;RDiagnostic To perform a study in patients with clinica Yes 0
COVID-19;Liver CirrhosAll-cause mortality of COVID-19 patients withYes 0
Contact Pe Drug: Hydr The rate of COVID-19 Yes 0
COVID-19;SOther: ExpoClinical characteristics of children with S Yes 0
Cancer;COVID-19 Number of participants who fill out the surv Yes 0
COVID-19 Drug: Cicl Rate of SARS-CoV-2 eradication at day 14 f Yes 0

COVID-19;HypertensioNumbers of COVID-19 patients enrolled thatYes 0
COVID-19;ABiological Adverse reaction (AE) and severe adverse re Yes 0
Infection V Other: biol COVID-19 desease description;COVID-19 desYes 0
CoronaviruDrug: Angi ventilator free days Yes 0
Pneumonia,Biological: reduction in oxygen and ventilation support Yes 0
COVID-19;CDrug: Picl Duration of viral shedding in days;Time to c Yes 0

Vascular S Procedure:30-days mortality Yes 0
SARS-CoV-2 Fraction of healthcare workers infected wit Yes 0
2019-nCoVOther: Pul Association of pulmonary lesions on ultrasouYes 0
Patients WDrug: Defibto able to reduce the progression of acute reYes 0

COVID-19;Re
The primaryIntegration to community as measured on the Yes 0
COVID-19 (kExposure toDescribe the clinical features of COVID-19.< Yes 0
inflammatorExpressive/Distress measured on Kessler Psychological DYes 0

COVID-19; <Based on pDose adjustment required to attain a steady No 0
COVID-19;APatients w Mortality[During Intensive care unit stay < Yes 0

Pregnancy;All women Maternal mortality from COVID-19[During pre Yes 0
COVID-19 inCOVID-19 syIn non-ventilated patients- Mean change in th

Yes 0
Novel Corointerventiocardiopulmonary function;motor function; Yes 0
Novel Coromild, modepartial pressure of arterial oxygen; No 0

Novel CoroExperimentTotal distances of 6 minutes walk test; Yes 0
Novel CoroCase seriesclinical characteristics and risk factors of d No 0
Novel CoroCase serie attitudes toward COVID-19;Consciousness No 0
Novel CoroPatients w Incidence of SARS-CoV-2 infection (includi Yes 0
Novel Coro1:Middle d Adverse reactions 0-14 days post vaccinationNo 0

COVID-19 1:none; semen;feces;blood;urine; No 0
Autism SpeExperimentPsycho Educational Profile,PEP;Self-Rated A No 0
Novel CoroCase seriesFever; No 0
Novel Corosurvival g survival; No 0
Novel CoroCase groupColour Sonography;electrocardiogram;PulmoNo 0
Novel CoroNK cell gro Monitoring of adverse events within 24 hoursNo 0
Novel CoroCase seriesRate of composite advers outcomes: SpO2, PNo 0
renal injuri Case seriesNGAL;MAU;cystatin C;Beta 2-MG; No 0
Novel CoroGold Standanew coronavirus nucleocapsid (N) antigen;S Yes 0

Novel CoroGold Standproteomics;metabonomics;S antibody IgG;S No 0
Cesarean Case seriesPerioperative fever;Perioperative cough;Ou Yes 0
Novel CoroExperimentLung CT Score; No 0
Novel Corocommon typ

Shorten the duration of the disease;AntipyreNo 0
Novel CoroNovel coro mortality; No 0
COVID-19 Case series:NA; No 0

Lung CT after 3 days;Lung CT after 7 days;O Yes 0
COVID-19 In PharmaMain Objective: To demonstrate the superiorYes 0

Severe
pneumon
ia in
context of
COVID-19
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10035737
Term:
Pneumoni
a viral
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: The primary objective of PhaYes 0
Healthcar
e workers
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10008434
Term:
Chemopr
ophylaxis
NOS
System
Organ
Class:
10000000
4865
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10061986
Term:
SARS
System
Organ
Class:
10000000
4862
; Trade Secondary Objective: 1. To evaluate the occuYes True parent
Patients wi ProducMain Objective: The main objective is to comYes True parent
Adult patie PharmaMain Objective: To compare the effect of disYes 0

Patients el Trade Main Objective: To determine the prevalenceYes True parent
severe acut Trade Main Objective: The main objective of this t Yes 0

COVID-19;Th
 ProducMain Objective: The aim of this core protocolYes 0
acute hypox Trade Main Objective: The main objective is to ass Yes 0

Hospitaliz
ed
patients
with
severe
pneumon
ia
secondar
y to
COVID-
19.
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10070 ProducMain Objective: Main objective: - To stuNo True parent
COVID19;The
 Trade Main Objective: To evaluate in-hospital mortNo 0
COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To assess the efficacy of a No 0
COVID-19;T Trade Main Objective: To determine the efficacy ofNo 0

Acute Respi Trade Main Objective: Assess, in patients with A Yes 0
Patients on Trade Main Objective: To evaluate the efficacy of Yes 0

COVID-19 in Trade Main Objective: To determine the protectiveNo 0
COVID-19;Th
 Trade Main Objective: To compare the efficacy of tNo 0
SARS-
CoV-2
infection
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10049924
Term:
Infection
prophylax
is
System
Organ
Class:
10042613
- Surgical
and
medical
procedur
es
;
Therapeu
tic area:
Health
Care [N] -
Environm
ent and
Public
Health
[N06] Trade Main Objective: To assess the efficacy of h No 0
COVID-19
infection
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10070255
Term:
Coronavir
us test
positive
System
Organ
Class:
10022891
-
Investiga
tions
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Demonstrate the therapeuticYes 0
Adult respi Trade Name:

Main Objective:
Solu-ModerÃ
To evaluate
n 1 g polvo
theyefficacy
disolvente
of para
No soluciÃ³n inyectable Pharmaceutical
0 Form: Powde
Organ
dysfuncti
on by the
novel
SARS-
Cov-2
virus
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10035738
Term:
Pneumoni
a viral
NOS
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Our aim is to conduct one t Yes True parent
Sepsis;Vit Drug: Vita Number of deceased participants or with perYes True parent
New CoronDiagnostic Detection sensitivity is greater than 95%;DetYes 0
Pneumonia,Drug: DarunThe virological clearance rate of throat swabYes 0

Pneumonia,Drug: Hydr The virological clearance rate of throat swabYes 0
Critically I Other: Nutr28-day all cause mortality Yes 0
Infection V Other: nosonosocomial infection Yes 0
COVID-19 Drug: GanoRate of composite adverse outcomes Yes 0
CoronaviruDrug: Remdesivir Yes 0
Blood DonaOther: QueDifferences of attitude about blood donatio Yes 0
COVID-19 Drug: Favi Clinical cure rate Yes 0

SARS Pneu Drug: Toci arrest in deterioration of pulmonary functi Yes 0
COVID-19 Drug: Tocil One-month mortality rate Yes 0
COVID-19 Other: sur Number of physicians affected by social medYes 0
COVID-19;Elderly Patien
Survival Yes 0
Infections, Diagnostic Accuracy of patient administered tests Yes 0
Corona Vir Drug: RoAcTime to independence from supplementary Yes 0

SARS-CoV- Biological Treatment success Yes 0
CoronaviruBiological RNA in SARS-CoV-2;ICU Admissions;Hospital YMes 0
PneumonitiDrug: Plaq Protection against COVID-19 Yes 0
SARS-CoV-2Drug: lopinNational Institute of Allergy and Infectious Yes 0
SARS-CoV-2Other: NA (Immunogenicity primary outcome: Geometric

Yesm 0
Hypertens Drug: ThiazNumber of Covid-19 positive participants who

Yes 0
COVID 19;I Drug: Hidr Incidence rate of new COVID-19 cases in botYes 0
Anxiety Re Diagnostic Characteristics of COVID-19-related anxiet Yes 0
COVID-19 Drug: Leva Clear chest CT-scan;PCR test Yes 0
COVID-19 Other: No Physical health symptoms;Lack of physical Yes 0
COVID-19; Drug: RuxolProportion of patients with COVID-19 pneumo

Yes 0
COVID-19 Drug: Hydr Confirmed cases of a COVID-19 Yes 0
COVID-19 Drug: Toci In-hospital mortality;Need for mechanical ven

Yes 0
COVID-19 Pneumonia Percentage of patients with complete recoveYes 0
COVID-19 Drug: Aspi All-cause mortality at 30 days after admissio Yes 0
Coronavirus Preferred means of communication for elderly

Yes 0
HIV/AIDS; Other: No Mortality Yes 0
Patients I Dietary Su Composite of cumulative death (i.e. mortalityYes 0
COVID-19 Drug: Hydr Hospitalization within 14 days of enrollment Yes 0
COVID Other: ProsChest x-ray;Chest CT;Supportive care - ICU;S Yes 0

Cardiovasc Diagnostic Prevalence of cardiomyopathy, myocardial infa
Yes 0
COVID-19 Biological: TTCI Yes 0
COVID-19 Device: ox Recovery time Yes 0
COVID-19 Other: QuesMeasure frequency of people suffered from Yes 0
Covid-19;C Other: Sur International Physical Activity Questionnair Yes 0
COVID-19 Drug: FavipTime from randomization to clinical recover Yes 0
MAGEC Ro Device: MATitanium level Yes 0

COVID;AcutBiological: ACE2 level change over time Yes 0
COVID-19 Drug: Mav Time to resolution of fever Yes 0
CoronaviruDevice: Se Deterioration resulting in healthcare review Yes 0
CoronaviruDiagnostic Predictive performance No 0
COVID-19 Other: SurgReduction in COVID-19 infection frequency Yes 0
COVID-19 Health Outcomes Yes 0
CoronaviruDevice: Tr Body temperature;Blood pressure;Pulse (heaYes 0

COVID;CoroProcedure:Risk of unfavourable outcome at D14 Yes 0
COVID19 Biological: COVID-19 convalescent plasma No 0
COVID 19 Drug: Hydr Laboratory Result;Clinical Outcome Yes 0
COVID-19;NDrug: Nint Changes in forced vital capacity (FVC) Yes 0
COVID Drug: CamoNot hospitalized Yes 0
CharacterisOther: Fol Demographics of Coronavirus Disease 2019 (C

Yes 0
Coronavirus;CoronavirSuitable for discharge Yes 0
COVID-19 COVID-19 positive case Yes 0
COVID-19 Biological The immune function (TNF-a ?IL-1ÃŸ?IL-6?T Yes 0
Liver Dise Diagnostic Breath volatile organic compound profiles;UtiNo 0
COVID-19;LDrug: Tacr Time to reach clinical stability Yes 0
Solid Organ Transplan Assessing the utility of AlloSure dd-cfDNA t Yes 0

Cancer & CDrug: Hydr Prevalence and the 3-months incidence of SAYes 0
GynecologiDrug: Che SARS-CoV-2 infection Yes 0
COVID-19 Device: No ECG changes associated with COVID-19 Yes 0
Corona ViruBehavioral PTSD Family members sup 22 Yes 0
Infection Viral;Coron Rate of secondary aggravation Yes 0
RespiratoryOther: MoniHACOR score efficacy;HACOR score addapta Yes 0

Musculoskeletal Pain The Rapid Office Strain Assessment (ROSA) Yes 0
COVID-19, Drug: Hydr Effect of HCQ on in vivo viral clearance Yes 0
Respiratory Distress Retrospective description of COVID-19 pati Yes 0
COVID-19 Drug: Hydr Incidence Yes 0
COVID-19 Device: Cy Percentage of patients with a significant sta Yes 0
Surgery;COOther: globoverview of surgical management on preventi

Yes 0
Anxiety;DeThere are tAnxiety and depression represent a compositYes 0
Ventilatio This study Recorded tidal volumes whilst continuously uYes 0
COVID-19;ReWe are testPatient comfort and tolerability as assessed Yes 0
Mental healThis is des the prevalence of depression which will be aYes 0
COVID-19 PoInterventioImpact of Nasodine on the reduction in virusYes 0

Severe loweStudy desigProportion of health care workers (HCW) contYes 0
COVID-19 (SAirway presVentilation free survival days as assessed b Yes 0
COVID-19;PCord bloodSafety and tolerability of UCB cell administr Yes 0
PsychologicParticipant Scores on the Perceived Stress Scale. The PSYes 0
Novel CoroCase serie Blood routine;Blood biochemistry;C-reacti No 0

Mental illn Group 1:phChanges in anxiety and depression scale sco No 0
Novel CoroCase serie 28-day mortality; No 0
Novel CoroTwo groups:temperature;area of facial indents;gray levelNo 0
Novel Coro1.5ATA:1.5Oxygenation index; Yes 0
Novel CoroGold Standsensitivity;specificity;accuracy; Yes 0
Novel CoroCase seriesCritical event rate;Critical event rate; No 0
Novel CoroCase seriesRelief time and rate of symptoms of larynge No 0
Novel Corocontrol gr SARS-CoV-2;IgM;IgG; No 0

COVID-19 Case seriespregnancy maternal complications;labor comNo 0
Novel Coroexperimentthe rate of 2019-nCoV RNA positive; Yes 0
Novel CoroCase seriesBlood routine tests;Liver function;Renal fun No 0

Novel CoroCase seriesDelineate the true prevalence of SARS-CoV-2Yes 0
Novel Coroexperimentsyndrome;nucleic acid of nCoV-19;blood coun

No 0
Novel CoroPatient:Su Environment viral load; No 0
Novel CoroCase serie Time to disease recovery;Exacerbation (transNo 0

Novel CoroIn-hospital cough;Degree of expiratory dyspnoea; Yes 0
Novel CoroRoutine treClinical symptoms (fever, weakness, cough) Yes 0
suspected Routine treClinical symptoms (fever, weakness, cough) Yes 0
Severe
confirme
d COVID-
19
pneumon
ia
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] Trade Main Objective: To assess the efficacy of a Yes True parent
SARS-CoV-2 ProducMain Objective: To investigate the effect of Yes True parent
COVID-19 in Trade Main Objective: The main objective of this s Yes 0
Patients in Trade Primary end point(s): Discharge from the patiNo 0
acute respi ProducMain Objective: To assess the feasibility, s Yes True parent
Coronavir
us
Disease
2019
(COVID-
19)-
Pneumoni
a
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To assess the efficacy â€“ No 0
COVID-19 in PharmaMain Objective: To assess the efficacy of th No 0
Patients
with
confirme
d COVID-
19
infection
and
criteria
for mild-
moderate
pneumon
ia (CURB-
65 =1 i
SatO2
=90%,
MEWS
score less
than 3)
and IL6
values of
20 pg /
ml, will be
randomly
assigned
to a
sarilumab
treatmen
t group or
another
group
receiving
treatme Trade Main Objective: To assess the efficacy and s No 0
infection C Trade Main Objective: Evaluation of efficacy of a Yes 0
viral
pneumon
ia
 Med
DRA
version:
20.1
Level: LLT
Classifica
tion code
10047474
Term:
Viral
pneumon
ia
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] Trade Main Objective: RÃ©duire le nombre de pat Yes True parent
Patient att Trade Main Objective: Evaluer lâ€™efficacitÃ© dâ€™une
Yes forteTrue
dose de cholecalciferol
parent 400 000 UI per os en un
Pneumonia Trade Main Objective: To compare and evaluate theNo 0
COVID19;The
 Trade Main Objective: To assess the efficacy of si No 0
Severe
COVID-19
pneumon
ia
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10035737
Term:
Pneumoni
a viral
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To assess the mortality imp No 0
SARS-CoV-2 Trade Main Objective: The main objective is to eva No 0
SARS-
SoV-2
infection
and
CoVid-19
disease
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: 1.To assess the effect of H No 0
COVID-19 in Trade Main Objective: -To evaluate the efficacy of No 0
Men and wom
 Trade Main Objective: The main objective of this s No 0
SAR COV2
virus
infection,
without
radiologic
al
affectatio
n.
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10070255
Term ProducMain Objective: To determine the efficacy o No 0
Coronavir
us
disease
2019
(COVID-
19)
caused by
the
infection,
SARS-
CoV-2
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: The principle research obje Yes 0
Lower
respirator
y tract
infection
by Covid-
19 at high
risk for
developm
ent of
severe
respirator
y failure
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10035738
Term:
Pneumoni
a viral
NOS
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Disease Trade Main Objective: Recent data coming from theYes 0
Acute
Respirato
ry
Distress
Syndrome
caused by
COVID19
infection
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10001052
Term:
Acute
respirator
y distress
syndrome
System
Organ
Class:
10038738
-
Respirato
ry,
thoracic
and
mediastin
al
disorders
 M ProducMain Objective: To evaluate the effect of 4 Yes 0
COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: Assessing the safety and eff No 0
COVID19;Th Trade Main Objective: To study whether the adminis
No 0
Respiratory ProducMain Objective: The main objective of this p Yes 0
Preventin
g
Pulmonar
y
Complica
tions in
Surgical
Patients
at Risk of
COVID-19
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10035664
Term:
Pneumoni
a
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
21.1
Level: LLT
Cla Trade Main Objective: Primary Objective To
No 0
Acute
hypoxic
respirator
y failure
of COVID-
19
patients
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10074615
Term:
Hypoxic
respirator
y failure
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: The primary objective is to Yes 0
COVIDE-19.InterventioPrimary outcome: complete remission of clinYes 0
COVID-19. InterventioDeath. Timepoint: 3 months. Method of meaYes 0
COVID-19 InterventioClinical response. Timepoint: Every other d No 0
COVID-19 Interventi Response to the treatment. Timepoint: DailyNo 0
COVID-19 Interventi Response to the treatment. Timepoint: DailyNo 0
COVID-19. InterventioResponse to the treatment (Significant clinic No 0
COVID-19 pInterventioClinical response to therapy. Timepoint: Da No 0
U07.1. <br Interventi Hospitalization duration. Timepoint: until Yes 0
COVID-19 InterventioResponse to the treatment (improvement ofNo pa 0
Condition InterventioLung symptoms. Timepoint: At baseline (befoYes 0
Novel CronInterventioCough. Timepoint: Daily. Method of measureNo 0
Covid-19 p InterventioCovid-19 infection. Timepoint: One, two andNo 0
Job Stress. InterventioJob stress. Timepoint: Before the intervent No 0
COVID-19. InterventioDeath. Timepoint: Up to 28 days after starti No 0
Infectious InterventioThe treatment of patients with corona infectNo 0
COVID-19. Interventi CT-scan findings. Timepoint: Before the int No 0
Covid-19. InterventioOxygen saturation. Timepoint: Clinical exam Yes 0
Covid 19. <InterventioHospital stay. Timepoint: discharge date. M No 0
Corona viruInterventioPulmonary Condition. Timepoint: Before inteYes 0
Condition InterventioPatient discharge. Timepoint: Daily. Method No 0
COVID-19 pInterventioFever. Timepoint: Daily. Method of measur No 0
corona vir InterventioDecreased hospitalization period. Timepoint No 0
corona viruInterventioDecreased need to hospitalization. Timepoi No 0
Patients wiInterventi Level of CRP in serum. Timepoint: One day bYes 0
Corona vir Interventi Response to treatment in Lymphocytes countNo 0
Infection c Interventi Number of admission days. Timepoint: everyNo 0
covid-19. Interventi Fever. Timepoint: The first day, the second Yes 0
Covid-19. InterventioNumber of hospital days. Timepoint: Daily si Yes 0
COVID-19 DInterventioImproving Respiratory function of patients. No 0
COVID-19. InterventioResponse to the treatment (Significant clini No 0
Condition InterventioImprovement of the symptoms of lung, pulmon Yes 0
COVID-19 DTreatment R g espiratory function of patients. Timepoint: No 0
Condition 1InterventioAnxiety,. Timepoint: Before the interventio No 0
COVID-19. InterventioTime to clinical improvement (TTIC). TimepoiYes 0
COVID-19. Interventi Improvement in SpO2 (increasing in level of Yes 0
Corona vir InterventioMortality. Timepoint: 28 days. Method of m No 0
Condition Interventi Improving the general condition of the pati No 0
COVID-19. InterventioWBC, CRP, IL6,TNF-a, IFN-G ? ESR. TimepointNo 0
Patients w Interventioefficacy Time to alleviation of body tem Yes 0
patients i oral adminiexpected value and 95% CI of ratio of C-reac Yes 0
COVID-19 Odds ratio for death ### No 0
COVID-19
Hepatobil
iary-
pancreati
c disease mortality rate ### Yes 0
COVID-19 All cause death (odds r ### Yes 0
Acute RespBiological Oxygenation index (OI);Incidence of Serious Yes True parent
COVID-19;YDrug: Galidnumber of subjects with treatment emergentYes 0
Anesthesia,Other: SpinInter spinal distance Yes 0
COVID-19 Biological: Size of lesion area by chest radiograph or C Yes 0
COVID-19; Drug: RemdTime to Clinical recoveryTime to Clinical Re Yes 0

COVID-19;RDrug: RemdTime to Clinical Improvement (TTCI) [Censor Yes 0
2019 NovelBiological Pneumonia severity index;Oxygenation inde Yes 0
Novel CoroDrug: LopinTime to negative NPS Yes 0
Novel CoroBiological: Improvement of clinical symptoms including Yes 0
Severe AcuCombinatioDetermine the number of Covid-19 patients Yes 0
Sars-CoV2 Other: blo Quantify the proportion of patients with d Yes 0

COVID-19;SDrug: Hydr All-cause hospital mortality Yes 0
COVID-19;SDrug: Hydr Symptomatic COVID-19 infection rate Yes 0
PharmacoloDrug: BaricThe percentage of patients requiring transfe Yes 0
GastrointesDevice: No Technical success Yes 0
CoronaviruDrug: LopinMicrobiologic evidence of infection Yes 0
SARS-CoV IDrug: Hydr In-hospital mortality Yes 0

CoronaviruDiagnostic Lung ultrasound grading system for COVID- Yes 0
COVID-19 Dietary Su Rate of recovery from positive to negative Yes 0
CoronaviruOther: obs ICU and hospital mortality of COVID-19 pati Yes 0
Corona ViruDrug: Sari Survival without needs of ventilator utiliza Yes 0
COVID-19;PBehavioral Change in Short-Form-36 (SF-36) Health Su Yes 0
CoronaviruOther: no i Assess the prevalence of severe forms amonYes 0

CoronaviruDevice: Co Voice anaysis Yes 0
Acute RespDrug: Dex 60-day mortality Yes 0
COVID-19 Drug: 1: N Mortality all causes at day30 Yes 0
CoronaviruDrug: TradiTime to improvement on a 7-point ordinal s Yes 0
SARS-CoV IDiagnostic Detection of SARS-CoV-2 virus Yes 0
COVID-19 Drug: Silt Proportion of patients requiring ICU admissi Yes 0
Covid-19 InDrug: 2: U Time (in days) to clinical improvement withi Yes 0

COVID-19 Device: WeTo assess of the evolution of the number of Yes 0
COVID-19 Drug: Best Change in PaO2/FiO2 Yes 0
COVID-19 Drug: chlo change in virus duration (viral shedding);c Yes 0
COVID-19;SDrug: RuxolRecovery of Pneumonia Yes 0
TelerehabilOther: TelePhysical Activity Scale for the Elderly;Nottin Yes 0
Pediatric Respiratory Risk Factors for severe infection;Immunulo Yes 0

CoronaviruOther: NonPrevalence;Incidence Yes 0
Congenital Heart Dise Prevalence of Covid-19 infection in the over Yes 0
COVID-19 Diagnostic Accuracy of the diagnosis of interstitial syn Yes 0
EmergencyOther: COVRates of emergency visits needing surgical c Yes 0
COVID;DrugOther: Sim To determine the Medication Risk Score of deYes 0
Pneumonia,Other: No Mortality at day 28 Yes 0
COVID-19; Other: this Clinical course of COVID-19;Analysis of deve Yes 0

Corona ViruDrug: AnakSurvival without needs of ventilator utiliza Yes 0
CoronaviruDrug: Hydr positive serology or reverse transcriptase ( Yes 0
CoronavirusDrug: Hydr Duration of viral shedding Yes 0
COVID-19;CProcedure:Number of antibodies against coronaviruses Yes 0
COVID-19;SDrug: Chlo Proportion of patients with onset of severe Yes 0
Covid-19 Drug: AspirDeath Yes 0
COVID19- IDrug: Nivo Time to clinical improvement Yes 0

COVID-19 Device: Hy Decrease incidence of intubation by 30% or Yes 0
Addiction, Substance Evolution of consumption;Evolution of con Yes 0
Mental Stress;Mental Depression;Anxiety symptoms;Stress relate Yes 0
COVID-19 Behavioral Change in stress level as measured by surve Yes 0
COVID-19 Biological For patients hospitalized for COVID-19 but Yes 0

COVID19 Device: BI Time to diagnosis of COVID-19 by RT-PCR in Yes 0
COVID-19; Drug: Pyri Critical condition or death;IL-6 Yes 0
CoronaviruProcedure:Proportion of "responder" patients to prone Yes 0
COVID-19 Outcome comparison between different antivir

Yes 0
COVID;DiabBehavioral Variation in HbA1c levels Yes 0
COVID-19 Drug: Salin Viral load (and/or cycle time to PCR as a pro Yes 0
COVID-19 Drug: Hydr Most severe outcome Yes 0
COVID Biological 28 day ventilator free days Yes 0
COVID Biological: Adverse effects and Safety Yes 0
Acute HypoDrug: DexaThe time-to-death from all causes;The time Yes 0
COVID19 P Drug: TinzaSurvival without ventilation (VNI or mechanica

Yes 0
COVID19 P Drug: Beva Proportion of surviving patients without neeYes 0

Mental HeaDiagnostic Depression;Anxiety;Obsessive compulsive di Yes 0
Covid 19 P Other: quesEvaluate the ethical requirement of controll Yes 0
Colon Poly Other: NonFailed to attend patients Yes 0
COVID-19; Other: seroepidemiology Yes 0
COVID Drug: ACEI number of patients with virological cure Yes 0
COVID-19 Drug: Toci The proportion of patients requiring mechaniYes 0

COVID-19 Infection COVID-19 infection Yes 0
COVID-19 Other: BlooCategory Changes in Ordinal Scale Yes 0
COVID-19 Mortality;Severe disease Yes 0
Flu Like Sy Other: Ind Time to achieve afebrile Yes 0
Liver Cirrh Other: no Spontaneous recovery or death in both grouYes 0
Respirator Drug: Spir p/f ratio Yes 0

COVID-19 Diagnostic IL6 concentration;IL6 concentration change Yes 0
Coronavirus Disease ( Dominant viral genome strain Yes 0
Coronavirus Disease Exploring the presence of COVID-19 Yes 0
COVID;ConjDiagnostic virus molecular analysis;host molecular anal Yes 0
COVID Diagnostic Positive IgM/IgG tests;Positive IgM/IgG testsYes 0
Virus Dise Diagnostic Prevalence of SARS-CoV-2 antibody titres Yes 0

COVID Drug: Hydr Adverse effects Yes 0
COVID;Mechanical Vent
Ventilation Mode;Tidal volume set;ExpiratorYes 0
CoronaviruBiological: Changes of oxygenation index (PaO2/FiO2);SYes 0
COVID-19;Bu
Other: Pat Stress in a recovery room transformed into aYes 0
TelerehabilOther: TeleVisual Analogue Scale;Modified Borg Scale; Yes 0
Healthy Lif Behavioral International Physical Activity Questionnai Yes 0

Sars-CoV2 Other: Phs Time of physiotherapy;Time of physiotherapNo 0
COVID-19 DOther: oth discrimination;Calibration;Net benefit Yes 0
COVID Presence of sHLH as determined by expert cha

Yes 0
SARS-CoV- Other: blo Number of confirmed COVID-19 Yes 0
COVID-19;BDiagnostic Pneumonia severity index;Need for ICU admYes 0
Covid-19 Drug: Hydr COVID-19 Seroconversion rate Yes 0

ARDS, Huma
Procedure:The effect of prone positioning on requiremeYes 0
Respirator Drug: DexaDay-28 mortality Yes 0
Ventilator Behavioral MDR pathogens in endotracheal aspirates No 0
COVID19 Drug: Defib1. Mortality rate Yes 0
COVID-19 Descriptive-epidemiological analysis of heal Yes 0
COVID-19 Diagnostic Proportion of symptomatic patients with i Yes 0

COVID-19 Drug: Canaintensive care treatment Yes 0
COVID;RespDrug: Allo Efficacy of the administration of allogeneic Yes 0
CoronaviruDrug: RuxolPercentage of patients who develop severe re

Yes 0
Communicab
Diagnostic Clinical accuracy of the antibody-based rapidYes 0
CoronaviruOther: Ant viral COVID-19 clearance Yes 0
CoronaviruDrug: favipViral clearance;Clinical improvement Yes 0
COVID Drug: ChlorNumber of symptomatic illness in at risk he Yes 0

CoVid 19 PoDrug: Hydr Improvement in FMTVDM Measurement with
Yes 0
Acute RespOther: PR A composite score based on all-cause mortalYes 0
Risk FactorDiagnostic ICU CV risk and Biomarker (e.g. Troponin) Yes 0
COVID-19 InDrug: Trea Efficacy of mild to moderate palliative sed Yes 0
EmotionnalOther: que anxiety;anxiety;anxiety;anxiety Yes 0
COVID Drug: Inte Time to negative NPS viral load Yes 0

COVID-19 Drug: Inter Time to clinical improvement Yes 0
COVID-19 Drug: UmifeTime to clinical improvement Yes 0
CoronaviruBiological: incidence of confirmed COVID-19;Effectiven Yes 0
COVID Drug: FavipNumber of patients with viral cure Yes 0
SARS-CoV Dietary Su Survival rate in asymptomatic subjects at incYes 0
Infectious Disease;CO Documentation of natural course and the th Yes 0

Flu Like Ill Dietary Su Time to achieve afebrile;Severity of sympto Yes 0
COVID-19 Drug: Hydr Tolerability of high dose HCQ as measured b Yes 0
COVID-19 Antibody titres to SARS-CoV-2;Antibody titr Yes 0
COVID-19 Other: Blo Success rate in production of SARS-CoV-2 speYes 0
SARS-CoV-2Other: ImmMembrane expression of Human Leukocyte Ant

Yes 0
COVID-19 Drug: AmioClinical improvement Yes 0
COVID-19;M
Other: Psy Anxiety 1 month Yes 0
COVID-19 Diagnostic Diagnosis of COVID-19 on lung ultrasound;DifYes 0
COVID19 Drug: Nafa Time-to-clinical improvement Yes 0
Sedentary Other: Onl Impact of International Physical Activity Qu Yes 0
COVID-19 Other: Sur How vaccination and other attitudes are aff Yes 0
Covid-19 P Biological Safety - Incidence of unexpected adverse even

Yes 0
COVID19;MDevice: moChange from Baseline amount of SARS-CoV-2Yes 0

COVID Diagnostic Sensitivity Yes 0
COVID-19;CDrug: Chlo Number of patients with virological cure Yes 0
Infection Drug: EnoxaSafety of in-hospital thromboprophylaxis Yes 0
Orofacial Other: QuePain score evolution measured by a 0-10 numYes 0
COVID-19; Drug: hydr COVID-19-related hospital admissions Yes 0
Epidemiology;Sars-CoVVariation of age between critically ill patie Yes 0

COVID-19;Respiratory White blood cell counts;White blood cell c Yes 0
COVID 19 Other: No Physical symptoms;Contact History;Travel HiYes 0
COVID-19 Other: olfa SARS-CoV-2 infection status;Olfactory and guYes 0
Covid-19 Drug: BromDuration of hospitalization;Duration of dise Yes 0
Covid-19 Drug: MethClinical complete response criteria;Clinical P Yes 0
COVID-19;PBiological: eculizumab Yes 0
CoronaviruDrug: Selin Percentage of Participants with at Least a 2 Yes 0

COVID-19 Other: Exp Differences in gut microbiota composition b Yes 0
AMD, ACEi'Other: - Sy Identification of serious COVID-19 infections Yes 0
Respirator Device: Ai Endotracheal intubation during present hospYes 0
COVID-19;SDrug: Nivo Viral clearance kinetics Yes 0
Critical I Other: ICU ICU mortality Yes 0
Psychologi Other: PSS Perceived Stress Scale (PSS) outcome Yes 0

Covid-19;Endothelial DAssociation of InterCellular Adhesion MolecuYes 0
COVID-19 InOral 500mgNumber of sick days (SDS) during the study pYes 0
COVID-19;SA
Patients whIncidence of in-hospital cardiac complicationYes 0
COVID-19; <Oral adminEfficacy of Hydroxychloroquine in the comm Yes 0
mental
health
;Physical
inactivity;
 ment
al
health 
 Physi
cal
inactivity;
Physical
Medicine
/
Rehabilita
tion -
Other
physical
medicine
/
rehabilita
tion;Ment
al Health
-
Depressio
n;Public
Health -
Health
promotio
n/educati
on This study Feasibility. Measured by: 1. Participant Yes 0
Stress;Anx A home-base
Anxiety ass ### No 0
SARS-CoV-2incidence oIncidence of Sars-COV-2 infection during hosp

Yes 0
CoronavirusFront-line To determine the rate of front-line health No 0
Novel CoroControl gr Clinical recovery time ; Yes 0
Novel CoroHDIVC grouC-reactive protein;ESR;existence of SIRS; No 0
novel coro Control g N/A; No 0
Novel Coron
ExperimentAcute stress disorder;Anxiety;Depression;PerNo 0
Novel CoroGroup 2:CoHospital stay;Modify Borg Dyspnea Score; No 0
novel coronInterventi Quality of life score; No 0
Novel CoroGroup 2:Al Improvement rate and time required for imprNo 0
TCM syndrome curative effect; Yes 0
CoVID-19 ExperimentVirus negative time;Medication 3, 5, 7, 9, Yes 0

New coronaGroup A:noHospital stay; No 0
Clinical symptoms include fatigue, poor appeNo 0
COVID-19 COVID-19 crserum thyroid levels;cortisol levels;ACE2; Yes 0
Novel CoroExperimentVisual analog score of symptoms; Yes 0
Novel CoroCase serie oxygen saturation; Yes 0
Novel CoroExperimentVAS; No 0
Novel coro Control Gr Six-minute Walk Test; Yes 0
Novel CoroECMO group

in-hospital mortality; Yes 0
Novel CoroCase seriesClinical outcomes; No 0

Complicatio 1. ### Yes 0
COVID-19 ( Occurrence of COVID-19 ### Yes 0
COVID-19 ( Microbiologically conf ### No 0

Any vascula 1. 4/1/2022 No 0
Respirator Composite outcome comp5/5/2021 Yes 0
Individual COVID-19 Anxiety (ada 1/1/2021 Yes 0
Aspergillos 1. I 8/5/2021 Yes 0
acute
respirator
y distress
sydnrome
(ARDS)
secondar
y to
Covid-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] -
Immune
System
Diseases
[C20] Trade Main Objective: The aim of the study is to c Yes 0
ARDS caused
 ProducMain Objective: To assess the rate of chang Yes 0
COVID-19;Th
 ProducMain Objective: Does addition of azithromyciYes 0
Efficacy
and
tolerabilit
y
investiga
tions of a
healing
water in
symptom
atic
treatmen
t of
heartburn
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10019326
Term:
Heartbur
n
System
Organ
Class:
10000000
4856
;
Therapeu
tic area:
Diseases
[C] -
Digestive Trade Main Objective: The primary objective is:Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: The study that chlorchine p Yes 0
COVID-19;Th
 ProducMain Objective: The aim of this core protocolNo 0
Severe
pneumon
ia caused
by
infection
with SARS
CoV 2.
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Evaluate the impact of saril No 0
Confirme
d SARS-
CoV-2
respirator
y
infection
with poor
prognosti
c factors
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
20.1
Level Trade Main Objective: Decrease the risk of develo No 0
SARS-
CoV-2
infection
causing
respirator
y disease
and
cytokine
release
syndrome
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
 Med
DRA
version:
21.1
Level: PT
Classifica
tion Trade Main Objective: Decrease cases of ARDS in aNo 0
COVID-19;Th
 Trade Main Objective: The aim of this study is to No 0
Prevention Trade Main Objective: To assess the efficacy of hy No 0
Cancer;Ther Trade Main Objective: Cumulative number of SARS-C

Yes 0
COVID-19
Pneumoni
a
Severly
afflicted
COVID-19
infected
patients
in
respirator
or in the
time
window
with
urgent
need of
respirator
before
intubatio
n
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ Trade Main Objective: Efficacy of therapy with ruxoYes 0
COVID-19
 Med
DRA
version:
20.0
Level:
HLGT
Classifica
tion code
10047438
Term:
Viral
infectious
disorders
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To assess if 10 doses of HC Yes 0
COVID-19 pa
 Trade Secondary Objective: -to investigate whethe No 0
Susceptibil Other: mobipositive number diagnosed by national guideYes 0
COVID-19;PDiagnostic COVID-19 positive X-Rays;COVID-19 negativeYes 0
COVID-19;CDrug: Hydr Number of participants with symptomatic, Yes 0
Infection V Other: pre Maternal and perinatal outcomes Yes 0
Migraine DBehavioral:Helpfulness of the session;Platform effectiv Yes 0
COVID-19;M
Diagnostic Incidence of acute myocardial events in COVYes 0
CoronaviruOther: Sta The number of interventions;Duration of int Yes 0

COVID-19;SARS-CoV-2;C
Number of participants who experience inpaYes 0
Pregnancy;Other: Pre Clinical presentation;Disease prognosis o Yes 0
COVID-19 Drug: Sarg Improvement in oxygenation at a dose of 250Yes 0
Cardiovasc Diagnostic All-cause mortality Yes 0
COVID-19 Drug: Hydr Evolution of acute respiratory syndrome, ox Yes 0
COVID-19 Incidence of confirmed COVID-19 Yes 0
COVID-19 Other: Usu Time to Clinical Improvement Yes 0

Corona ViruDrug: Toci Survival without needs of ventilator utiliza Yes 0
CoronaviruDrug: Plas Change in Viral Load;Change in ImmunoglobuYes 0
CoronaviruDrug: Plas Change in Viral Load;Change in Immunoglob Yes 0
COVID-19 Drug: FavipViral nucleic acid test negative conversion r Yes 0
COVID-19 Drug: Anlu Changes in high-resolution computer tomogrYes 0
COVID 19 CombinatioDeath Yes 0
COVID-19 Biological: Frequency of Adverse Events Yes 0

SARS-CoV- Drug: EicosEvaluation of EPA-FFA efficacy compared to Yes 0
COVID-19 Drug: Losa Number of participants with treatment-relatYes 0
COVID 19 Other: blo overactivity of the renin / aldosterone syst Yes 0
COVID-19 Other: Dis Hierarchical composite endpoint Yes 0
COVID-19;VDrug: AnakChange of baseline total sequential organ Yes 0
CoronaviruDrug: Nita Mechanical ventilation requirement Yes 0
COVID-19;LDrug: L-ascNumber of ventilator-free days Yes 0

Infection Viral;Infect Death rate;Transfer to intensive care unit;VeYes 0
Covid-19 CombinatioTime to normalize the oxygen requirement Yes 0
Sars-CoV2; Genetic: MIncidence of unexpected adverse events;Im Yes 0
COVID 19 Biological Changing of viral load of SARS-CoV2 Yes 0
OropharyngDiagnostic Prevalence of oropharyngeal dysphagia Yes 0
SARS-CoV- Drug: Ecul Survival without needs of intubation at day Yes 0
SARS-CoV 2;ImmunizatiStatus of Immunization Yes 0

COVID-19 Need for hospitalization;Duration of hospita Yes 0
Covid-19 Drug: Hydr Change in Clinical Condition Yes 0
PostpartumOther: Sel "Labor Agentry Scale questionnaire" score i Yes 0
COVID-19;CDiagnostic Prevalence COVID antibodies in employees Yes 0
Acute RespDrug: HumaVentilator-free days Yes 0

COVID-19 Drug: Chlo sustained improvement (>48h) of one point Yes 0
Corona Vir Other: RetrIdentification of risk factors present at the e Yes 0
COVID-19 Biological Safety indexes of adverse reactions;ImmunogYes 0
Covid19 Diagnostic prevalence of COVID-19 exposure Yes 0
Prophylaxi Drug: Hydr Cumulative Incidence of COVID-19 Infection Yes 0
CoronaviruDrug: GrouSub Study 1: Patients;Sub Study 2: Health C Yes 0
COVID-19 Drug: Susp Number of subject acquiring COVID-19 infec Yes 0

Sars-CoV2;Chronic I Proportion of patients presenting a severe f Yes 0
COVID-19 Drug: Hydr Frequency of seroconversion to SARS-CoV-2 Yes 0
COVID - 19 Drug: hydr clinical state as reflected by NEWS scoring;p Yes 0
Pregnancy Diagnostic Seroprevalence or Number of women who are

Yes 0
COVID-19 Incidence of SARS-CoV-2 infection;Incidenc Yes 0
Pneumonia;Drug: capt Efficacy of captopril nebulization addition t Yes 0

Covid-19;Viral Infecti Estimate the proportion of patients hospital Yes 0
COVID-19 Diagnostic Predictive values of CT criteria Yes 0
COVID 19;SARS-Cov-2 Confirmed diagnosis of COVID-19 infection No 0
RespiratoryDevice: VenNumber of cases in which it was necessary toYes 0
COVID-19 Drug: Ruxolitinib Yes 0
COVID-19 Diagnostic New-onset cardiac arrhythmia;Elevation of NYes 0

ARDS, HumDrug: Sevo Composite outcome of death rate (rate of pati
Yes 0
DepressionOther: CrosPatient Health Questionnaire 9;Generalized Yes 0
COVID-19 Diagnostic Incidence of healthcare workers with SARS Yes 0
COVID-19;Serology Percentage of serological positive healthca Yes 0
COVID19 Drug: 50 mChange in the clinical status severity (CSS) Yes 0
COVID-19 Biological Lung injury;Overall survival Yes 0
COVID-19;SDiagnostic Sensibility;Specificity Yes 0

COVID-19;ViDrug: AnakThe ratio of patients who will not develop seYes 0
Anxiety StaOther: it is State Anxiety assessed by the State-Trait AnxYes 0
Fever;Pneumonia;CouIdentification of prognostic parameters for Yes 0
COVID-19; Other: Tel Radiation Oncology providers perception of oYes 0
SARS Virus Drug: Expe To evaluate the benefit of early imatinib th Yes 0
COVID-19; Drug: L-ascIncidence of adverse events;Incidence of serYes 0
Covid-19 Drug: Sari Mean change in clinical status assessment usYes 0

COVID;COVOther: Equ Diagnostic accuracy of smartwatch data in prYes 0
SARS-CoV Drug: Sari Ventilation requirements Yes 0
Healthy COVID-19 Awareness Survey Yes 0
Psychiatric Other: Brieimpact of the COVID-19 pandemic on psychi Yes 0
COVID-19 Biological: Biological: COVID-19 convalescent plasma Yes 0
Sars-CoV2 Drug: RecoEfficacy: Proportion of subjects alive not on Yes 0

COVID-19;PDevice: CO Mortality outcome in COVID-19 ICU patientsYes 0
COVID-19 Device: Co Identification of COVID-19 Yes 0
COVID;PneDrug: BaricTo assess the safety of baricitinib combined Yes 0
Acute RespDrug: DexmMechanical ventilation Yes 0
Critical Illness;Sars- Anxiety Yes 0
COVID-19 Drug: Susp Number of patients with increased disease s Yes 0

COVID-19 Drug: HydroMortality;Number of Participants with Trea Yes 0
COVID-19;M
Other: Gas Respiratory system compliance improvemenYes 0
ARDS, HumDrug: RuxolOverall survival Yes 0
COVID-19 Drug: Hydr Time to clinical improvement Yes 0
COVID Drug: EstraRate of Hospitalization;Rate of Transfer to I Yes 0
COVID-19 Nasal epithelial transcriptional response to Yes 0

COVID-19 Drug: Favi Time to clinical improvement Yes 0
Gut MicrobOther: TherCorrelation of Microbiome to Disease via R Yes 0
Coronavirus Infection To produce whole genome sequences for theYes 0
Cardiovasc Behavioral Hospitalization(s) at 1 month Yes 0
Critical Illness;COVI Incidence of delirium/neurocognitive impai Yes 0
COVID-19 IDrug: Hydr Two-weeks survival rate Yes 0

COVID-19 IOther: Ext Platelet activation intensity with the occurr Yes 0
SARS-CoV 2Drug: AviptProgression to ARDS Yes 0
COVID-19 CombinatioNumber of Patients with COVID-19-negative Yes 0
Severe AcuOther: Anti-Sars-CoV-2 Convalescent Plasma Yes 0
Critical Il Other: QualQuality of Life score Yes 0
COVID-19 Drug: TelmMaximum clinical severity of disease Yes 0

SARS-CoV Other: Blo Immune response Yes 0
Covid-19;HDrug: Chlo Event-free survival at 28 days post-random Yes 0
Pregnancy Diagnostic number of positive COVID-19 women Yes 0
Online The Behavioral:responses to the survey questions Yes 0
Smoking CeOther: Tel Smoking behaviors;Knowledge;Readiness to Yes 0
COVID-19; Drug: DexaVentilator Free Days (VFD) at Day 28 Yes 0

COVID;CoroDiagnostic Test Sensitivity;Test Specificity Yes 0
COVID-19 Drug: ColchCRPxN/R ratio change;Clinical deterioration Yes 0
Physical AcOther: On- : International Physical Activity Questionnai Yes 0
COVID-19 CombinatioNumber of patients with COVID-19-negative Yes 0
COVID-19 Drug: Isotr Clinical clearance Yes 0
COVID-19;PProcedure: SpO2/FIO2 Ratio Yes 0

Covid-19;S Other: samsensitivity Yes 0
CoronaviruDrug: Hydr Individual response rate Yes 0
COVID-19 Device: Se Survival Yes 0
CoronaviruDevice: Cy Mechanical ventilation-free days Yes 0
Liver Tran Other: ObsIncidence of COVID19 in LT recipients;Clini Yes 0
Adult Pati Biological: Describe the course of COVID-19 disease in pYes 0
COVID 19 Biological acquired thrombophilia Yes 0

Severe AcuDrug: RuxolNumber of patients who avoid mechanical ass
Yes 0
COVID-19 Other: homSpO2 Yes 0
COVID-19 Other: DeeDeep Venous Disease Incidence Yes 0
Cytokine S Drug: AnakNo increase in oxygen requirement and no i Yes 0
COVID-19 Biological: Primary outcome Yes 0
Stress - Pr Behavioral Significant score reduction at the Perceived Yes 0

COVID-19 Drug: BaricMortality Yes 0
Covid19;Pregnancy RelVertical transmission;Neonatal protection d Yes 0
Covid-19 Other: obs clinical description of covid 19 ambulatory c Yes 0
Coronavirus;COVID;COV
Development of population-based models ofYes 0
COVID-19 Drug: MRx-Change in mean clinical status score in eac Yes 0
COVID19;OxOther: pro Percent age of patients who will have endotrYes 0

Covid19 Device: WeCOVID-19 Yes 0
Deep Vein Other: DopIncidence of Deep Vein Thrombosis at DopplYes 0
COVID-19; Device: Ele Hospitalization time;Patients needing intens Yes 0
Remote Consultation; Exploration of themes emerging from analysiYes 0
Covid19;NeOther: hyp Intensity of the emotional response to hypo Yes 0
Cardiac ArrProcedure:Number of visible puncture Yes 0

COVID;VitaDrug: Aspi Hospitalization Yes 0
COVID-19; Drug: Hydr Clinical Status at Day 5 Assessed by a 6-Poin Yes 0
PreventionDrug: Hydr 21-day incidence of COVID-19 in individuals Yes 0
COVID-19;SARS-CoV 2 Pneumonia Severity indexes;Need for supplemen

Yes 0
Hypertens Drug: Angi BP (hypertensive efficacy) Yes 0
COVID-19; Drug: Prog Change in clinical status of subjects at Day Yes 0

Blood Plas Biological: Titers of anti-SARS-CoV-2 antibodies in the Yes 0
COVID-19 Find the prediction factors associated with Yes 0
COVID-19 Drug: AT-0 Proportion of subjects with decreased left v Yes 0
COVID-19 Other: RehaDyspnea Yes 0
Loneliness Other: CrosUCLA Loneliness Scale-8 (ULS-8);Patient Hea Yes 0
Sars-CoV2 Procedure:Number of patients in whom the prone positYes 0
COVID-19 Drug: RamiComposite of mortality or need for ICU admisYes 0

Moderate tDrug: Remestemcel-L Yes 0
COVID-19 Define the characteristics of patients with Yes 0
CoronavirusAll childre The primary outcome of this study is the proYes 0
mental heaThe app incEmotional wellbeing: assessed via the WorldYes 0
COVID-19 ReNebulised (Time to separation from invasive ventilation Yes 0

COVID-19; <This projec Need for resuscitation - collected from hospiYes 0
COVID-19 ( Proportion of patients ### Yes 0
Depression, Severity of psychologic ### No 0
COVID-19 ( All-cause mortality, s ### Yes 0

Cardiovasc Case seriesLDL-C;HDL-C;Exercise; No 0
Novel CoroGold Standchest CT;RT-PCR;SEN, SPE, ACC, AUC of ROC;No 0
Novel CoroControl:co St George's respiratory questionnaire score No 0
Novel Coronon-critic In hospital mortality; Yes 0

Novel CoroCase seriesthe virus particles by electron microscopy;2 Yes 0
COVID-19 ExperimentDetection of nucleic acid and antibody of ne No 0
Novel CoroCase seriessyndrome scale;Record of Disease;Record ofYes 0
Novel CoroCase serie COVID symptom;Intervention record of TCM No

t 0
Novel CoroCase serie Treatment outcome; No 0
Novel CoroCase seriesconversion rate among mild, common, severe Yes 0

Novel CoroGold StandaCRP, Cys, SAA, IL-6, ESR, PCT;myoglobin, tro No 0
Novel CoroPhase I A1 Incidence of adverse reactions/events; Yes 0

Novel CoroConfirmed WBC account;Plt; No 0
ADL score;MMRC score; Yes 0
Novel CoroExperimentImprovement of anxiety, depression;CAP s No 0
novel coro COVID-19 co

Mental health status;sleep;emotion; No 0
Novel CoroExperimentamild cases: the critical illness rate of subj Yes 0

Novel CoroCase seriesMental health index; No 0
Novel CoroCase seriesTime of death;The hospitalization time; Yes 0

Novel CoroExperimentCOVID-19 Nucleic acid; Yes 0
COVID-19 pa
 Trade Main Objective: The primary objective of theYes 0
This trial
will
investigat
e
infection
with
coronavir
us
(COVID-
19) in
patients
who are
admitted
to
hospital
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
 Med
DRA
version: Trade Main Objective: In patients who are admitt Yes 0
Coronavir
us
infection
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: -Early evaluation criteria: Yes 0
covid-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10070267
Term:
SARS
virus test
positive
System
Organ
Class:
10000000
4848
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10022519
Term:
Intensive
care
System
Organ
Class:
10042613
- Trade Main Objective: To describe the pharmacokine
Yes 0
COVID 19
Health
care
workers
(medical
or non-
medical)
in French
hospitals
in direct
contact
with
COVID-19
patients,
including
nurses,
medical
doctors
and other
personnel
working
in wards
in charge
of COVID-
19
patients
(emergen
cy,
intensive
care
units, in Trade Main Objective: To evaluate among health c Yes 0
Severe
COVID-19
pneumon
ia
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10070255
Term:
Coronav Produ Main Objective: To evaluate the safety and No 0
coronavir
us (covid-
19)
infection
with
respirator
y failure
requiring
mechanic
al
ventilatio
n.
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA Trade Main Objective: To assess the impact of plas No 0
Acute
respirator
y distress
syndrome
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10001052
Term:
Acute
respirator
y distress
syndrome
System
Organ
Class:
10038738
-
Respirato
ry,
thoracic
and
mediastin
al
disorders
;
Therapeu
tic area:
Diseases
[C] - Produ Main Objective: All-cause mortality at day No 0
Severe
Acute
Respirato
ry
Syndrome
in
subjects
with
COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10061986
Term:
SARS
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
1005 Trade Main Objective: To demonstrate that in patieNo 0
Acute
respirator
y distress
syndrome
in
patients
with
COVID-19
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10001052
Term:
Acute
respirator
y distress
syndrome
System
Organ
Class:
10038738
-
Respirato
ry,
thoracic
and
mediastin
al
disorders
 Med Trade Main Objective: - To evaluate the crude mortNo 0
Acute
Respirato
ry
Distress
Syndrome
(ARDS)
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10003083
Term:
ARDS
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: To investigate the efficacy oNo 0
Severe COVI ProducMain Objective: To assess clinical efficacy Yes True parent
Severe
COVID-19
pneumon
ia
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10061229
Term:
Lung
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] Trade Main Objective: Evaluation of the efficacy a Yes True parent
Possible
preventio
n of
pneumon
ia from
SARS-
CoV-2 in
patients
staying
home and
improving
symptom
s of SARS-
CoV-2
pneumon
ia in
patients
treated in
hospital
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10035738
Term:
Pneumoni
a viral
NOS
System
Orga Trade Main Objective: Achieving one of two goals oYes 0
SARS-
COV-2
infection
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10037373
Term:
Pulmonar
y disorder
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To investigate the effect o Yes 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: The aim of this study is to Yes True parent
Novel Cor Drug: BromTime to clinical recovery after treatment;Ra Yes 0
Corona Vir Drug: Hydr Incidence of COVID19 Disease among those w

Yes 0
COVID-19;Hypertensi Rate of Death Yes 0
Corona ViruDrug: CamoCohort 1: Days to clinical improvement fro Yes 0
COVID-19 Drug: BCG Health Care Workers absenteeism Yes 0
COVID-19 Drug: ColchAll-cause mortality Yes 0
COVID-19 Drug: Hydr Median release from quarantine time;Rate ofYes 0
CoronaviruDrug: Emtr Number of confirmed symptomatic infectionYes 0

SARS-CoV-2Drug: Toci Number of patients with ICU admission;Numb
Yes 0
Covid-19 Drug: Ruxoloverall response rate in reversal of hyperin Yes 0
IBD;COVID IgG and IgM anti SARS-CoV-2 Yes 0
COVID-19 Drug: Hydr Improvement of clinical status Yes 0
COVID;Sar Drug: Enox Composite outcome of arterial or venous thrYes 0
Solid TumoDrug: BMS Time to Improvement in the 7-point ordinal Yes 0
COVID-19 Drug: HB-a Incidence of hospitalization for COVID-19; Yes 0

COVID-19 Drug: HB- Incidence of hospitalization for COVID-19;I Yes 0
Sars-CoV2; Drug: Hydr RT-PCR result Yes 0
COVID-19 Drug: MethChange in clinical conditions Yes 0
Covid 19;CoDrug: Hydr Percentage of virus free subjects;Disease sevYes 0
Multiple S Other: EvalClinical severity Yes 0
COVID Drug: nebutreatment efficacy - Percentage change in P Yes 0
Sepsis;Blo Other: Thr 28-day survival rate;Absolute thrombin generYes 0

Acute RespOther: Pro Therapeutic failure within 14 days of rando Yes 0
Telehealth Other: 3D University Hospitals of North Northway questYes 0
COVID19;HDrug: DornMeasuring the change in inflammation Yes 0
Sars-CoV2 Composition of the fecal bacterial and fungaYes 0
COVID-19 Other: Pro Modified WHO Ordinal Scale Yes 0
SARS-CoV IBiological Time to Improvement Yes 0
CoronaviruOther: dail Seroprevalence of SARS-CoV-2 infection in t Yes 0

COVID-19 Drug: LenalClinical improvement;Immune-inflammator Yes 0
Cardiovascular PrevenChange of physical activity Yes 0
COVID-19 Biological Proportion of patients who have achieved wiYes 0
COVID-19;CBiological COVID Ordinal Outcomes Scale:Day 15 Yes 0
Sars-CoV2 Other: self the incidence of SARS- Cov2 infection Heath Yes 0
Covid-19 Identification of risk factors for severity (de Yes 0
COVID-19 Biological: Convalescent Plasma Yes 0

SARS Virus Other: 40mPrevalence and abundance of CD4+ T lymph Yes 0
COVID-19 CombinatioRate of positive SARS-CoV-2 RT-PCR Yes 0
COVID-19;CDrug: Hydr Incidence of symptomatic COVID-19 infectio Yes 0
COVID-19 Genetic: WViral evolution Yes 0
COVID19 Drug: Hydr Percentage of patients with a negative RT-P Yes 0
Novel CoroDrug: Aspi clinical recovery time (TTCR);the time of SA Yes 0

COVID Clinical consequences of a Covid-19 infectio Yes 0
Intubation Procedure:Intubation success rate during at the first l Yes 0
COVID-19 Other: Int Evaluation of food intake at 1 month after d Yes 0
COVID-19 Other: oth the consistency of predicted severe rate andYes 0
Covid-19 Biological: Adverse events assessment;Blood oxygen saYes 0
COVID;SARSOther: Oxy Delta in the number of patients requiring or Yes 0

COVID-19; Other: QueTo assess the impact of the COVID-19 pandem
Yes 0
Cardiac Su Other: Car Change in Impact of Events scores Yes 0
Covid-19 Dietary Su Incidence of SARS CoV-2 infection in health Yes 0
COVID;SARS-CoV 2 Composite of death and mechanical ventilat Yes 0
Cardiac Ar Device: In successful rate of first intravascular access Yes 0
COVID-19 Drug: CHLOTime To Response (TTR) Yes 0

COVID-19; Other: ven Variation of thrombin time (in secondes) in Yes 0
Post Partu Behavioral Proportion of patients with postpartum dep Yes 0
COVID;ARDBehavioral:Proportion of patients who meet one or bothYes 0
COVID-19 Procedure:Determination of cause of death and contribu

Yes 0
SARS-CoV 2Drug: BAT +Admission to Intensive Care Unit;Death Yes 0
COVID;SARS-CoV-2;ARD
Age;Gender;Weight;Height;BMI;Pre-existing Ypes 0
EmergencyDevice: NIOSuccess rate of first intravascular access at Yes 0
Covid-19 Other: TestPregnancy outcomes;Birth outcomes;Birth Yes 0
COVID we will compare the clinical outcome of the Yes 0
SARS-CoV IDiagnostic Phase 1: ECG characteristics in patients pr Yes 0
Sars-CoV2 Diagnostic Sensitivity and specificity of the COR-DIAL Yes 0
COVID;SarsDiagnostic Rate of elevated creatine kinase in hyperac Yes 0

CoronaviruBehavioral Change in DASS scores across 9 days;ChangesYes 0
COVID-19 Other: Bio Retrospective study on individuals with or wiYes 0
RuminationBehavioral Changes in depression-, anxiety- and psych Yes 0
COVID;Terminal Renal AAntibody response Yes 0
COVID-19 Cardiac pathological findings from series of Yes 0
Hepatocell Diagnostic Incidence of COVID-19 infection in patients Yes 0

Covid-19;C Other: COVProportion seropositive Yes 0
COVID-19 Other: Sur Management of Solid Organ Transplant durinYes 0
COVID-19 Procedure:Mortality Yes 0
COVID-19 COVID-19 symptom occurrence and severity;Yes 0
COVID;SARS-CoV 2;Coro
provide proof-of-concept that (longitudinal) B
Yes 0
Covid-19 Device: ga Need for mechanical ventilation Yes 0
Postnatal Other: Ass Report postnatal depression between 4 of 6 Yes 0

COVID-19 Development of data repository to provide aYes 0
COVID19 Device: Co Number of subjects for which the prototype Yes 0
SLE Other: Tel The percentage of patients in remission or L Yes 0
PsychologicOther: No PCL5 Questionnaire;BSI - Brief symptom in Yes 0
Covid-19;L Diagnostic Lung ultrasound/biological correlation resea Yes 0
COVID;PneDietary Su delta of time of disappearance of acute diar Yes 0
Pneumonia,Drug: Tirof P/F ratio;PaO2 difference;A-a O2 difference Yes 0

Covid-19 Neuroradiological analysis of patients brain Yes 0
Job Stress Other: Sud Rate of participant recruitment;Rate of ret Yes 0
Covid-19 Development of antibodies Yes 0
Acute Respiratory Fai Discontinuation from mechanical ventilationYes 0
RespiratoryDevice: MeArterial oxygenation;Arterial oxygenation Yes 0
COVID-19 Behavioral:Prevalence (magnitude) of anxiety of generaYes 0

COVID Drug: Azit Cumulative number of severe acute respirat Yes 0
Anxiety;WeBehavioral Anxiety;Well-being Yes 0
COVID-19 SBiological Survival (based on all-cause mortality) at Da Yes 0
COVID-19;Chronic DiseMental health - Stress;Mental health - Anxi Yes 0
COVID-19;TBiological: Clinical evolution of COVID-19;SARS-CoV-2 e Yes 0
COVID-19 Diagnostic Characterise prevalence and severity of org Yes 0
CoronaviruOther: No Mortality during the COVID-19 treatment hoYes 0

Stroke, Acute Study of the effect of pandemic covid-19 on Yes 0
Acute RespOther: pul Construction of a composite clinical-echo s Yes 0
COVID-19;Pneumonia,Negative Predictive Value of Lung Ultrasoun Yes 0
Perceived Behavioral:Feasibility of undertaking task Yes 0
COVID-19;CardiovasculPredictive modeling of in-hospital outcome; Yes 0
Corona Virus InfectionCharacteristics and outcomes of acute respiraYes 0

Corona ViruDrug: Apo- Positive for SARS-CoV-2 Yes 0
Sars-CoV2 Other: self the prevalence of SARS- Cov2 infection Hea Yes 0
Sleep Hygi Other: QueSleep Hygiene Yes 0
COVID;Pneumonia To identify the best predictors of critical Yes 0
COVID-19; Biological: COVID-19 Convalescent Plasma No 0
CoronavirusCoronoviruTo determine proportion of people with nuc No 0
Severe AcuTCC-COVIDRate of avoidable Emergency Department pres

Yes 0
Novel Coroasymptomat
Treatment cycle; No 0
Novel CoroExperimentOn day 7 and 14, Change (reduction) in viralYes 0

Breast can Case seriespain level; No 0
Novel CoroCase seriesrate of survival; Yes 0
CoronaviruCase seriessleep quality; No 0
Novel CoroRoutine tr SARS-Cov-2 nucleic acid test; Yes 0
Novel CoroControl gr Recovery time; No 0
Novel Corosevere grouC-reactive protein;lymphocyte;CD4+ T cell; No 0
Novel CoroSingle pati Changes of microbiota,virology and metabo No 0

Novel CoroCase seriesBirth; No 0
Novel coro Control gr Qualitative RT-PCR results of SARS-CoV-2 nu Yes 0
COVID-19 (The study w 1. ### No 0

Patient
=18 with
SARS Cov
2
pneumon
ia
requiring
oxygen
administr
ation.
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: To demonstrate the efficacyYes 0
Hospitaliz
ed
Moderate
and
Severe
COVID-19
Patients
 Med
DRA
version:
20.0
Level:
SOC
Classifica
tion code
10021881
Term:
Infections
and
infestatio
ns
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseas ProducMain Objective: To compare the Safety and EYes 0
Severe
pneumon
ia in
context of
COVID-19
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10035737
Term:
Pneumoni
a viral
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: The primary objective of PhaYes 0
Patients wi Trade Main Objective: To show the interest of trea Yes 0
COVID-
19-
induced
pneumon
ia (CAN-
COVID)
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Trade Main Objective: To demonstrate the benefit Yes True parent
COVID-
19-
induced
pneumon
ia (CAN-
COVID)
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C0 Trade Main Objective: To demonstrate the benefit Yes True parent
Preventio
n of
thromboe
mbolic
events in
hospitalis
ed
COVID-19
infected
patients
 Med
DRA
version:
20.0
Level:
HLGT
Classifica
tion code
10014523
Term:
Embolism
and
thrombos
is
System
Organ
Class:
10047065
- Vascular
disorders
;
Therapeu
tic area:
Diseases
[C Trade Main Objective: To evaluate the effectivene Yes True parent
Patients
aged 75
years and
older
with
confirme
d
infection
Covid19
and
saturatio
n SaO2=
under
95% O2>
5 L / min
disqualifi
ed from a
care in
the ICU
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ Cl Trade Main Objective: Evaluation of the efficacy o Yes 0
Acute respi Trade Main Objective: To show that the drug as us Yes 0
Patients wi Trade Main Objective: To assess the efficacy of 5- Yes True parent
COVID-19
Infection
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: To determine whether early Yes
i True parent
Lymphopenia
 ProducMain Objective: The primary objective of th Yes 0
Coronavirus ProducMain Objective: To assess the time from randYes 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10070255
Term:
Coronavir
us test
positiv Trade Main Objective: Can a course of antibiotics Yes 0
Covid-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10061986
Term:
SARS
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Does Povidine-Iodine reduceYes 0
healthy vol Trade Main Objective: To reduce absenteeism among
Yes 0
Severe
COVID-19
infection
with risk
of need
for
mechanic
al
ventilatio
n.
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
23.0
Level: Trade Main Objective: Primary objective of this tri Yes 0
Managem
ent of
infection
by SARS-
CoV-2
(COVID-
19)
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10035738
Term:
Pneumoni
a viral
NOS
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Recent information appearing
Yes 0
The study w PharmaMain Objective: Patients with coronary arterYes True parent
Critically Trade Main Objective: In critically adult patients No 0
Infection
with
SARS-
COV-2
(=COVID-
19)
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10035737
Term:
Pneumoni
a viral
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10003083
Term: ProducMain Objective: To investigate the efficacy Yes 0
COVID-19;Th
 PharmaMain Objective: To assess the impact of treaNo 0
SARS-
CoV-2
infection
 Med
DRA
version:
23.0
Level: LLT
Classifica
tion code
10070267
Term:
SARS
virus test
positive
System
Organ
Class:
10000000
4848
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
Hyperinflam Trade Main Objective: To assess the effect of anak No 0
Non-
severe
pneumon
ia caused
by COVID-
19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To assess the impact of admNo 0
CoVid-19 pn Trade Main Objective: To assess the efficacy of No 0
Adult
patients
with
COVID-19
and
severe
hypoxia.
 Med
DRA
version:
23.0
Level: LLT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10000000
4862
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10021143
Term:
Hypoxia
 Trade Main Objective: To assess benefits and harmYes True parent
PRE-EXPOSU
 Trade Main Objective: To assess the efficacy and No 0
Adult
patients
over 70
years of
age
diagnose
d by
COVID-19
with
outpatien
t follow-
up
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10070255
Term:
Coronavir
us test
positive
System
Organ
Class:
10022891
-
Investiga
tions
;
Therapeu
tic area:
Diseases [ Trade Timepoint(s) of evaluation of this end point No 0
Hypoxia;The
 Trade Secondary Objective: To asses in a randomiz Yes 0
SARS COVID-
 Trade Main Objective: Demonstrate the effectivenes
No 0
SARS-
CoV-2
infection
(COVID-
19)
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To evaluate the efficacy of No 0
COVID-19
PNEUMO
NIA
 Med
DRA
version:
23.0
Level: LLT
Classifica
tion code
10084383
Term:
Novel
COVID-
19-
infected
pneumon
ia
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To determine the efficacy o No 0
Patients
with Mild
to
Moderate
Coronavir
us
Disease
(COVID-
19)
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
23.0
Level: LLT
Class Trade Main Objective: To determine if high dose IVYes 0
Patients
with
Coronavir
us
Disease
(COVID-
19)
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
23.0
Level: LLT
Classifica
tion code
10 Trade Main Objective: To determine if Prolastin pl Yes 0
COVID-19; Drug: DAS Improved clinical status;Return to room air; Yes 0
COVID-19; Drug: Defe Mortality rate;Mortality rate Yes 0

Stress, Psy Other: que quantify and qualify distress over a large po Yes 0
Severe/VerDrug: Ruxolitinib;Drug: Ruxolitinib Yes 0
Follow-up;COVID-19;In36-Item Short Form Survey Instrument (SF-36)

Yes 0
COVID-19; Drug: HydroTime to clinical improvement;Time to clinic Yes 0
PneumoniaDrug: CM46Improvement on a 7-point Ordinal Scale;Inci Yes 0
SARS-CoV-2Drug: Hydr RT-PCR negative status;RT-PCR negative statYes 0

COVID19;CDrug: ColchChanges in the patients' clinical status thr Yes 0
COVID-19; Drug: HCQ Effect of HCQ and AZ in preventing infecti Yes 0
COVID-19;IOther: WebWeb-based REDCap survey;Web-based REDCYes 0
COVID;COVOther: Blo Production of several human monoclonal antib

Yes 0
COVID-19;DDevice: Hy PaO2/FiO2;SpO2;NEWS Score;Inflammation level

Yes 0
COVID-19 Drug: thro the cumulative proportion of any distal or Yes 0

Recovered From COVI Serological testing of COVID patients;Immu Yes 0
CoronaviruDrug: Leva Decrease the incidence of COVID-19 infectionYes 0
COVID19;InDrug: Toci the mortality rate;the mortality rate Yes 0
COVID-19; Drug: Hydr Efficacy of HCQ Prophylaxis in Preventing COYes 0
COVID-19;SARS-CoV 2 short-term prognosis;short-term prognosis Yes 0
Kidney Tra Other: blo Predictive value of IL-6 contents of whole bl Yes 0
COVID-19; Other: dra Show an overexpression of C5a receptor in pYes 0
Pregnant Behavioral Compare the complications rates;Compare thYes 0
Diabetes;C Other: careComparison of metabolic control (HbA1C) betYes 0
Covid-19;C Drug: MCN Proportion of patients remaining free of neeYes 0
Burnout, P Diagnostic Prevalence of burnout among ICU nurses durYes 0
COVID;COVBiological: Number of patients alive and no longer hospYes 0

Covid-19;C Drug: Hydr Rate of patients with occurrence of an unfa Yes 0
Sars-CoV2; Diagnostic STC-19 score;STC-19 score Yes 0
COVID-19 bOther: blo Predictive value of IL-6 contents of whole bl Yes 0
COVID;COVID 7-day death;7-day ICU;7-day death;7-day IC Yes 0
COVID-19 Drug: Osel Changes of oxygenation index (PaO2/FiO2) ,bYes 0

Covid-19;C Other: No Death (all-cause mortality) or discharge fromYes 0
HIV-infection/Aids;CorClinical features of symptomatic COVID-19 i Yes 0
Eating Habits;Eating HChange in diet quality;Change in food insecuYes 0
COVID-19; Drug: Povi Change from baseline naso-pharyngeal viral Yes 0
COVID 19;CDrug: LinagTime to clinical change;Time to clinical chan Yes 0
Health CareOther: Onl Health care use;Postponed heath care use;F Yes 0
Sars-CoV2; Other: Sta death;clinical worsening (composite criteria)Yes 0
Sepsis;COVID-19;Seps To demonstrate the performance of the SeptiYes 0
Ventilator Diagnostic 28-day all-cause mortality;28-day all-cause Yes 0
COVID-19; Drug: DuveOverall survival;Overall survival Yes 0
COVID-19;ADiagnostic Delay from the start of Mechanical Ventilat Yes 0
Distance L Other: implStudents' Learning Perception QuestionnaireYes 0
Covid-19;C Diagnostic Rate of asymptomatic COVID-19 infection amYes 0

Stroke;RehBehavioral Rehabilitation data;Motor Activity Log - 14 Yes 0
CoronaviruOther: TherTesting Immunity to SARS-CoV-2 over time;TYes 0
Pleth VariaDiagnostic Pleth variability index;Pleth variability index Yes 0
COVID-19;NBiological: Number of days of unplanned absenteeism fYes 0
Burnout;B Behavioral Change in instances of burnout for hospital Yes 0
Covid-19 With Positiv Rate of positivity for Acute Pulmonary EmboYes 0

CoronavirusDrug: Favi Time to improvement by two points on a sevYes 0
COVID;COVDrug: Iver effect of Ivermectin on eradication of virus.; Yes 0
End Stage Other: les Mortality;Mortality Yes 0
COVID;PneuDrug: MethTransfer to Intensive care unit (ICU);Need f Yes 0
COVID;COVDiagnostic Rate of COVID-19 nosocomial infection among

Yes 0
Cytokine R Procedure:Overall Response Rate;Overall Response Rat Yes 0

Sexual BehBehavioral:FSFI (Female Sexual Function Index)SCORE d Yes 0
Olfactory DOther: OlfaChange from Baseline Snap and Sniff ThreshoYes 0
COVID 19; Drug: ConvThe primary outcome is a composite measureYes

o 0
CoronaviruBiological Impact of plasma exchange;Impact of plasm Yes 0
SARS-CoV-2Drug: Hydr The primary outcome is the rate of decline i Yes 0
COVID-19;COVID-19 Prior treatment by ACEi;Prior treatment by Yes 0

COVID-19 PDrug: HCQ Time to Clinical improvement (TTCI);Time to Yes 0
COVID-19;SDiagnostic Immune cells activity;Immune cells activity Yes 0
COVID-19; Drug: ColchRate of entering the critical stage;Rate of entYes 0
PneumoniaDrug: ConveThe incidents of acute respiratory distres Yes 0
COVID-19 Other: Pla Time to recovery Yes True parent
CoronaviruDiagnostic Biomarkers expression;Liver Biomarkers exp Yes 0
Corona Vir Drug: Colc Clinical deterioration in the semiquantitat Yes True parent
COVID-19 Drug: Hydr Rate of COVID-19 positive conversion Yes 0
COVID-19 Biological Side effects Yes 0
COVID 19 Drug: Low- Symptomatic COVID-19;Peak severity of COVYes 0
SARS-CoV- CombinatioChanges in patients viral load;Second evaluatYes 0
COVID-19 Device: CapPercent of patient echos that are not interp Yes 0
COVID-19 Drug: BaricPhase 2: Cumulative incidence of Grade 3 anYes 0
COVID-19;CDrug: HydroTo determine if the use of hydroxychloroqui Yes 0

Covid-19 Drug: Gar Intraoral viral load Yes 0
COVID19;SADrug: Sari Need for ventilation (including invasive and Yes 0
Health Care Worker Number and percent of participants who enrol

Yes 0
CoronaviruOther: No 28-Day Mortality Yes 0
COVID-19 Drug: Claz Cumulative incidence of serious adverse eveYes 0
CoronaviruDrug: choleNumber of death of any cause, during the 14Yes 0
Stress Behavioral rate of recruitment;rate of attendence Yes 0

COVID-19 Drug: RuxolPhase 2: Cumulative incidence of Grade 3 anYes 0
CoronaviruDrug: Seli Percentage of Participants with at Least a 2 Yes 0
ARDS;HyperDevice: E Delta change in arterial partial pressure of Yes 0
COVID;PregDiagnostic Diagnostic performance of LUS to predict p Yes 0
Acute Kidney Injury;CoIncidence of AKI Yes 0
COVID 19 Procedure: Worsening of renal function by at least KDIGYes 0
CoronaviruDrug: Inha Proportion of patients in both arms fulfilling Yes 0

Mental Disorder Total score of the Cardiff Anomalous Percep Yes 0
Myocardial Infarction Rates of patients presenting with acute myocYes 0
COVID-19 Device: KerNumber of days until complete resolution o Yes 0
COVID19 Other: QuesDevelopment of phobias Yes 0
Sars-CoV2;Covid19;CarCardiovascular mortality Yes 0
COVID Clinical characteristics of patients with COV Yes 0

COVID 19 Diagnostic Inflammation;Oxygenation Yes 0
COVID-19 Drug: AscorClinical Improvement Yes 0
CoronaviruDrug: ColchPercentage of Patients requiring supplemen Yes 0
Corona ViruBiological: Serological test evaluation Yes 0
Anxiety Behavioral Change from baseline of the total score of Yes 0
CoronaviruOther: NasaMolecular and cellular defects in olfactory Yes 0

Severe Acute Respira In-hospital mortality Yes 0
Acute Myocardial Infa Acute cardiovascular event triggered by COVIYes 0
SARS-CoV-2Drug: Hydr Prevention of SARS-CoV-2 as determined by Yes 0
ArthroscopBehavioral Change in preference Yes 0
Resilience Other: Sur Self-rated measure of Resilience;Self-rated Yes 0
SARS-CoV-2Drug: Siro Change in SARS-CoV-2 viral burden from baseYes 0
COVID-19 Diagnostic Compare the efficacy of detection of viral in Yes 0

Sars-CoV2 Device: Ho Hospitalization in COVID-19 patients with Yes 0
SARS-CoV-2;COVID-19Change of prevalence of COVID-19 infection Yes 0
COVID;Sar Drug: Hydr Clinical Deterioration Yes 0
COVID-19 IDrug: meten

Time to onset of change in the patient's clin Yes 0
SARS-CoV Other: ECGPercentage of dysautonomia patients found wi

Yes 0
Post Traumatic Stress PTSD Checklist for DSM-5 (PCL-5) Yes 0
COVID;HypeOther: Clin Adverse events Yes 0

COVID-19; Drug: Bica Number of participants who have clinical i Yes 0
COVID;SARBiological: SARSCoV2 Convalescent Plasma Yes 0
COVID-19;CDiagnostic Venous thromboembolisms Yes 0
Covid19 pediatric cancer care pattern during COVID Yes 0
Pre-ExposuDrug: Hydr Microbiologically confirmed COVID-19 (SARSYes 0
Oxidative SDiagnostic MDA concentration Yes 0

Covid 19;StOther: QuesStress state score, during the confinement p Yes 0
Acute MyocDiagnostic Evolution of the proportion of positive SARS Yes 0
COVID Device: FF Evaluation of airtightness (Fit test) Yes 0
COVID-19 Global evaluation of the implication of the Yes 0
Anxiety Behavioral Anxiety Yes 0
COVID-19;SDrug: 18F- Administration of 18F-avÃŸ6-BP;AdministratYes 0

COVID;Sur Other: ComEvaluate surgeon perceptions to telemedicinYes 0
COVID-19 Biological improvement of condition Yes 0
COVID-19 Device: Ap Biomarker Yes 0
COVID-19;Pneumonia;A
Changes of Extra Vascular Lung Water Yes 0
Caregivers Other: Sur Proportion of caregivers and agents with a pYes 0
COVID-19; Diagnostic Prevalence of SARS-CoV-2 RNA in nasopharynYes 0
COVID-19 In-hospital mortality during hospitalization Yes 0

Parental Stress;Depre Measure of parental stress;Patient Health Q Yes 0
COVID-19;CDrug: Fluo Hospitalizations;Intubation;Death Yes 0
Anxiety;DeOther: Pan Anxiety;Depression Yes 0
NeurologicaDiagnostic Prevalence of COVID-19 infection in consecuYes 0
COVID-19;Qu
Other: SF1 Six-month SF-12v2(HK) Scores Yes 0
COVID-19 Radiation: Lenght of hospital stay (days);Number of In Yes 0
Cytokine R Drug: Toci Patient clinical status 15 days after randomi Yes 0
HospitalizeBiological: Clinical recovery Yes 0
Public Health;Demogr Knowledge and Confidence in Knowledge of C

Yes 0
Sars-CoV2 Drug: Hydr SARS CoV2 infection Yes 0
Covid19 P Drug: Toci Survival Yes 0
COVID-19 Sensibility and specificity Yes 0
COVID 19 Diagnostic Health care provider safe return to work Yes 0

COVID-19; Other: GenPercentage of people reporting changes in sm
Yes 0
Cardiovasc Drug: Enox Number of patients with the composite effi Yes 0
COVID-19;CDrug: Delt Maximum Tolerated Dose Yes 0
DepressiveBehavioral Change in Depressive symptoms measured by

Yes 0
SARS-CoV 2Behavioral Psychological impact of the outbreak, total Yes 0
Food Insec Other: Dur Food Insecurity Score Yes 0
Covid-19;MDiagnostic Change in PDW and MPV parameters Yes 0

COVID;Drug Effect;DruTo determine the Medication Risk Score of dYes 0
Severe AcuDevice: Tr Survival without need of mechanical ventila Yes 0
COVID;NeurOther: ObsFrequency of neurologic manifestations of Yes 0
COVID-19 Device: Vo Profiles of volatile organic compounds (VOCsYes 0
Digestive Biological: Symptoms of Covid after surgery Yes 0
HIV;Pre-ex Other: DataCovid attack rate Yes 0
COVID19 Prevalence and dynamics of the SARS-COV 2 Yes

i 0
COVID-19; Biological Incidence of HCWs hospitalized due to COVI Yes 0
COVID-19 Health status (WHO classification);Incidence Yes 0
COVID-19 A list of COVID-19 specific TCR sequences Yes 0
COVID-19;SDrug: DialyChange in the score of the "Contingency scalYes 0
Malignant Biological Incidence of adverse events (AEs);Reduction Yes 0
MS (MultipBehavioral Rate of completion;Rate of adherence Yes 0
COVID-19 Biological Proportion of patients, responded to the stu Yes 0

CoronaviruDietary Su Patient reported main complaint;Patient re Yes 0
COVID-19; Biological Change in absolute lymphocyte count (ALC) Yes 0

Oral Micro Characterization of th ### Yes 0
Wellbeing A minimum set of meas ### No 0

Mental Hea Meas ### No 0
Psycholog
ical
distress
and
trauma in
doctors
treating
patients
with
COVID-19
(SARS-
CoV-2
infection)
 Ment
al and
Behaviour
al
Disorders
 Psyc
hological
distress
and
trauma in
doctors
treating
patients
with
COVID-19
(SARS-
CoV-2
infecti Participant 1. ### No 0
Novel CoroDC injectio Adverse events; Yes 0
Changes in the degree of clinical symptoms sNo 0
Novel CoroExperimentTolerance;Viral load of nCoV;Blood routine No 0

Novel CoroCase serie chest CT;lung function;blood routine examinat
No 0
Novel CoroCase seriesThe duration of medical staff wearing dispo No 0

Novel CoroGroup 1:StaViral load;Clinical features;Inflammation;Pu No 0

Novel CoroTreatment ?g???;time to clinical improvement;overall ra Yes 0
Novel CoroLow dose gTime to disease recovery; Yes 0

Depressio
n
;
Anxiety;E
motional
wellbeing
;Stress;Su
icidal
ideation;
 Depr
ession 
 Anxie
ty
 Emo
tional
wellbeing
 Stres
s
 Suici
dal
ideation;
Mental
Health -
Anxiety;
Mental
Health -
Depressio
n;Public
Health -
Health
promotio
n/educati
on;Public 'Anchored' Depressive symptom change as measured byYes
t 0
COVID-19; <This is a p Primary outcome is the evolution of an imm Yes 0
COVID-19; <2 trial ar Composite: Change in severity and duration oYes 0

COVID-
19;corona
ry
(ischaemi
c) heart
disease;h
ypertensi
on;asthm
a;chronic
obstructiv
e
pulmonar
y disease
(COPD);di
abetes
;previous
stroke;ac
tive
cancer;
immunos
uppressio
n;
 COVI
D-19
 coro
nary
(ischaemi
c) heart
disease
 hype
rtension
 asth
ma c Initial tre Compostite primary endpoints of rate of hospi Yes 0
Pulmonary InterventioThe scales of pulmonary involvement changes Yes 0
COVID-19. InterventioAll-cause mortality rate during the study (d No 0
COVID-19. InterventioImprovement of pulmonary manifestations an No 0
CoronaviruInterventioCRP level in Blood. Timepoint: At the begin No 0
COVID-19. InterventioTime to Clinical Improvement (TTCI): TTCI is No 0
COVID-19. InterventioTime to clinical improvement defined as starNo 0
COVID-19. InterventioChanging the patient's clinical status in the Yes 0
Covid-19. Interventi Clinical improvement includes fever rupture No 0
COVID-19. Interventi Measurement of cough severity. Timepoint: No 0
COVID-19 pInterventioClinical response to therapeutic regimen by No 0
CoronaviruInterventioTemperature. Timepoint: 0-1-2-3-14 days af No 0
the 2019 n InterventioPAO2/fio2. Timepoint: 5 days after interve Yes 0
COVID-19. InterventioO2 saturation percentage. Timepoint: Clinic No 0
COVID-19. InterventioClinical status. Timepoint: Beginning of the Yes 0
COVID-19 dInterventioFever. Timepoint: before and after treatme Yes 0
COVID-19. InterventioMeasurement of inflammatory markers (CRP). No 0
CoronaviruInterventioClinical symptoms (Coronavirus infection). No 0
Patients wiInterventioLevel of CRP in serum. Timepoint: One day bYes 0
COVID-19. InterventioNot need hospitalization, feels well, and is No 0
Covid-19. InterventioTime interval until clinical symptoms impro Yes 0

COVID-19. InterventioBody temperature. Timepoint: At the beginnNo 0
The effecti InterventioNeed of invasive and non invasive mechanical
No 0
CoronavirusInterventioPrevent the development of pneumonia cause Yes 0
Covid-19. InterventioTime interval until clinical symptoms impr Yes 0
COVID 19. InterventioViral diagnostic test. Timepoint: The first Yes 0
COVID-19 pInterventioBlood oxygen saturation. Timepoint: At beg No 0
CoronavirusInterventioClinical signs Includes oxygen saturation, t No 0
COVID-19. Interventi Symptoms ending. Timepoint: During the stuNo 0
COVID-19. InterventioPrimary Outcome: All-cause mortality. TimepYes 0
COVID-19. InterventionChecking
1: Intervention
the amount
group:
of Administration
ventilation. Timepoin
of 2 units
Yes of CP (Convalescent
0 Plasma obtained from COVID-19
COVID-19. InterventioIncidence of clinical symptoms of COVID-19 Yes 0
Stress. Interventi Stress. Timepoint: Stress will be measured o No 0
COVID-19. InterventioFever. Timepoint: Every day for 7 days. Me No 0
Condition 1InterventioCOVID-19 incidence rate in cancer patients No 0
COVID-19 dInterventioFever. Timepoint: Days 3, 7 and 14 after t Yes 0
Condition In the inte Oxygen saturation. Timepoint: Clinical exam Yes 0
COVID-19. InterventioAdmission to intensive care unit. Timepoint Yes 0
Condition 1InterventioHospitalization days. Timepoint: At baseli Yes 0
Novel CoroInterventioClinical improvement within 14 days of admiNo 0
Corona vir InterventioBody temperature. Timepoint: before the st No 0
COVID-19 dInterventioDetermining the efficacy of trifluoprazine i Yes 0
COVID-19. InterventioChest image(CT scan). Timepoint: at hospita Yes 0
COVID-19. InterventioThe oxygen blood saturation. Timepoint: EveNo 0
Condition InterventioImproving the general condition of the patie Yes 0
Condition InterventioThe general condition of the patient. TimepoYes 0
COVID 19. InterventioViral diagnostic test. Timepoint: The first Yes 0
COVID-19. InterventioTemperature. Timepoint: Daily. Method of Yes 0
COVID-19. InterventioMeasurement of cough severity. Timepoint: Yes 0
COVID-19 dInterventioPercentage of effect of Tocilizumab on COVIDYes 0
COVID-19. InterventioDeath. Timepoint: At the time of discharge Yes 0
CoronaviruInterventioSelf-efficacy. Timepoint: Before, one week Yes 0
covid-19 diInterventioRecovery in COVID-19 patients. Timepoint: ANo 0
COVID-19 DInterventioMortality rate in first month from the time Yes 0
COVID-19 pInterventioFever. Timepoint: daily. Method of measurem Yes 0
Acute RespInterventioAdverse events assesment. Timepoint: At theNo True parent
covid-19. <InterventioImprovement of SPO2 (stands for peripheral Yes 0
COVID-19. InterventioRespiratory symptoms (dry cough). Timepoint: No 0
COVID-19 DInterventioMortality rate. Timepoint: from including No 0
Covid-19. InterventioReduction of incubation time. Timepoint: DaYes 0
COVID-19. InterventioStop the fever. Timepoint: It will be revie No 0
COVID-19 Di
In 30 patie Effect of convalescent plasma. Timepoint: Bl Yes 0
Covid-19. InterventioLymphopenia. Timepoint: 3 days, 1 week andYes 0
covid-19. InterventioTime interval until clinical symptoms impro Yes 0

COVID-19. InterventioConfirmed and possible Coronavirus 2019. TiNo 0
COVID-19 i Interventi Time to clinical improvement (TTIC). TimepoiNo 0
COVID-19. InterventioQuantitative CRP. Timepoint: Before and aft Yes 0
COVID-19 dInterventioOxygenation. Timepoint: daily. Method of mNo 0
Acute RespInterventioAdverse events assesment. Timepoint: At theNo 0
the care t InterventioQuality of work life score in Walton's ques No 0
COVID-19. InterventioFever. Timepoint: registration day and week No 0
Covid 19. <InterventioHaving covid 19. Timepoint: 3-7-14. Method Yes 0
corona vir Interventi Time to Clinical Improvement. Timepoint: 1, No 0
New CoronaInterventi Symptoms of disease. Timepoint: During the Yes ho 0
COVID-19 dInterventioLung involvement in X-ray and CT-scan, SPO2,Yes 0
COVID-19 dInterventioPulmonary manifestations. Timepoint: bef No 0
COVID 19. InterventionImprovement
group: In thisofstudy,
clinical
2 herbal
symptoms.
medicines
Timepoin
(in No
addition to standard0treatment) will be used as follows. 1.
SARS-COV2InterventioPeripheral capillary oxygen saturation. Time Yes 0
COVID-19. InterventioTime to clinical improvement. Timepoint: Ev No 0
Condition InterventioFever. Timepoint: Days 1, 3, 7, 14, and 28. Yes 0
CoronaviruInterventioSize of lesion area in lung. Timepoint: On No 0
COVID-19- InterventioFever. Timepoint: BID. Method of measuremNo 0
COVID-19. InterventioBiomarker expression. Timepoint: two weeksYes a 0
COVID-19. Patients in Fever. Timepoint: At the beginning of the stuYes 0
COVID-19. Interventi Time to clinical improvment: normalization Yes 0
COVID-19. InterventioClinical symptoms (dry cough). Timepoint: DaNo 0
COVID-19. InterventioThe number of confirmed cases. Timepoint: At No 0
PneumoniaInterventioFever. Timepoint: Daily, From admission to Yes 0
COVID-19. Interventi Vital signs. Timepoint: daily. Method of m Yes 0
covid-19. <InterventioReduce the mortality rate of patients with No 0
COVID-19 pInterventioFever. Timepoint: daily. Method of measure Yes 0
Patients w InterventioImprovement in disease symptoms (Fever and Yes 0
COVID-19 InterventioPulmonary symptoms. Timepoint: 4 weeks afYes 0
COVID-19. InterventioDyspnea. Timepoint: Every day for 3 weeks. Yes 0
CoronavirusInterventioComplete recovery of clinical symptoms of 2No 0
SARS-cov2(InterventioClinical response. Timepoint: During hospit No 0
PneumoniaInterventioTime to clinical recovery. Timepoint: Contro Yes 0
coronaviru InterventioCT of the chest. Timepoint: Before interven Yes 0
COVID-19. InterventioPercentage of oxygen saturation. Timepoint:Yes 0
COVID-19. InterventioClinical symptoms (dry cough). Timepoint: DaYes 0
COVID-19. InterventioDisease recovery. Timepoint: The beginning Yes 0
covid 19. InterventioReduction in all causes mortality. Timepoin Yes 0
COVID-19. InterventioHospitalization time. Timepoint: 0, 1, 3, 7, Yes 0
ARDS. InterventioBlood oxygen saturation level. Timepoint: 0 No 0
COVID-19. Interventi Need to receive ICU service (occurrence of s No 0
COVID-19 tInterventioNeed mechanical ventilation. Timepoint: duriYes 0
COVID-19. InterventioClinical symptoms (Coronavirus infection). Yes 0
Covid-19. <InterventioCough. Timepoint: First and 30 days after th Yes 0
Emerging pInterventi Clinical improvement within 14 days after paYes 0
COVID-19 pInterventi Increase in arterial oxygen pressure. Timep Yes True parent
COVID-19. InterventioNeed to mechanical ventilation. Timepoint: Yes 0
;Mental and behavioraPHQ-9 (Pat ### Yes 0
;Certain in Drug : 1. C Proportion ### Yes 0
Novel CoroDosing andThe overall objective of the study is to evalu Yes 0
COVID-19 none ### Yes 0
Covid-19 Endoscopy-related CO ### No 0
People with mild cognReliability and validit ### Yes 0
Novel Coronavirus Inf The odds ratio for imp ### Yes 0
COVID-19 Diagnosis wAccuracy of rapid kit a ### No 0
Chronic heart failure D-dimaer ### Yes 0
COVID-19 Detection rate of SA ### Yes 0
behavioral Reading a behavioral intention ### Yes 0
Patients with infecti Time required to int 5/8/2020 Yes 0
COVID-19 Aggravation rate R ### No 0
frailty Frailty Screening Inde ### Yes 0
COVID-19 Wearable bremote rehabilitation ### Yes 0
COVID- 19 (Interventi Infected Non infectedTimepoint: Time to cl Yes 0
Healthcare Workers ofTo identify suspected cases of COVID-19Tim Yes 0

Not applic InterventioKnowledge, attitude, practice, fear to COVI Yes 0
Other viral pneumoni To create a real time COVID-19 registry of c Yes 0

CoronavirusInterventionumber of days of hospitalizationTimepoint:Yes 0
Other specified viral d 100% sensitivity in ruling out COVID-19 cas Yes 0
CoronavirusInterventioImprovement in ambulatory patients who areYes
a 0
Other specified viral d A single source of patient-level clinical dat Yes 0

Healthy HuInterventioEpisodes and severity of symptoms of respiraYes 0
Other speciInterventi 1)The Ct values on Day 0, 3, 7, 10 shall be Yes 0

Healthcare workers orSeropositivity in the collected samplesTime Yes 0
NO ACTIVEInterventio1.To prepare a modul 5/1/2020 Yes 0

Other speciInterventi The primary outcome is a composite measureYes
o 0
Other speciInterventioAll-cause mortality, subdivided by the seve Yes 0

Encounter Interventio1.Number of subjects with laboratory confi Yes 0
Other speciInterventioProportion of patients with negative viral t Yes 0
RespiratoryInterventi -Safety, efficacy -Side effects Yes 0

Viral pneu InterventioTo asess sensitivity and specificity of scre Yes 0
General Population of To understand the prevalence (magnitude) ofYes 0

Practice pattern of ur Reduction in outpatients after Covid outbre Yes 0
Health careInterventioProportion of HCW with symptomatic COVIDYes

19 0
Factors inf InterventioTo evaluate the efficacy of Mw by measuringYes 0
CoronavirusInterventi Lesser percentage of admissions to critical Yes 0
Other specified viral d To study clinical profile and outcome of hospYes 0

Other speciInterventi This study aims to confirm the antivirus eff Yes 0
RespiratoryInterventioPercentage of patients progressing to seriousYes 0

Other speciInterventi COVID Ordinal Outcomes Scale is defined as:Yes 0
CoronavirusInterventi The Odds of Ratio for Improvement on a 7-poYes 0
Other viral pneumoni To assess ICU mortality in COVID-19 patientsYes 0

CoronavirusInterventioThe primary outcome is a composite measureYes 0
Other speciInterventi Proportion of patients having virologic cure Yes 0
Other speciInterventi Proportion of patients having virologic cure Yes 0
self volunt Interventi with refrance to time scale T1-T4 -- Yes 0
Other speciInterventioi.Improvement in Immunity and anti viral pr Yes 0

RespiratoryInterventioOne-month mortality rate between the two ar
Yes 0
CoronavirusInterventioClinical outcome in terms of recovery of patiYes 0
Other speciInterventiocomparing the reduction in the progression, Yes 0

Immunity inInterventi 1.Comparative assessment of incidence of COYes 0
Other specified viral d virological clearanceTimepoint: day-6 post-i Yes 0

Influenza InterventioThe sensitivity of nasal and throat swabs fo Yes 0
Anaesthesiology Post Analysis of responses obtained from the 20 Yes 0

Health care workers o The proportion of healthcare workers who l Yes 0
Other speciInterventio-Identification of variants in host factors AC Yes 0

CoronavirusInterventioConfirmation of diagnosis for COVID-19 infecYes 0
RespiratoryInterventi Primary Outcome Measures: 1.Tota

Yes 0
Other speciInterventioProgression to moderate- severe diseaseTi Yes 0
Prophylaxi Interventi Proportion of laboratory confirmed symptomYes 0

Coronavirus as the cau1.Determine the radiographic findings in cheYes 0
Other speciIntervent Primary endpoint of this trial will be measu Yes 0

ApparentlyInterventi Incidence of COVID 19 positive cases (as co Yes 0
Neoplasms Our study aims to identify the challenges f Yes 0

Other speciInterventi To study if Ivermectin can reduce the viral Yes 0
CoronavirusInterventi Difference in the area under the curve (adju Yes 0
Participant Interventio1.Comparative assessment of occurrence of Yes 0
Health Care Workers tChange in QTc intervalTimepoint: Before an Yes 0

Preventive Interventi 1.Comparative assessment of occurrence of CYes 0
CoronavirusInterventioTo study the clinical profile and outcomes o Yes 0

Contact with and (sus Estimate awareness regarding COVID-19 preYes 0
CoronavirusInterventi Time until cessation of oral shedding of SA Yes 0

Other speciInterventi 1.Clinical cure rate: Time to negative conve Yes 0
Doctors andInterventioPittsburgh Sleep Quality Index (PSQI) for sl Yes 0
Other infecInterventio1)Rate of Recovery 2)Symptom ReYes 0

Participant Interventi Primary outcome parameter: 1.CoYes 0
healthy InterventioImprovement in Bala of an individual Yes 0
CoronavirusInterventi To characterize virologic and clinical resp Yes 0

Healthy VoInterventioImprovement in Bala of an individual Yes 0
COVID-19;NDrug: Meththe incidence of treatment failure in 14 daysYes 0
CoVID-19;CDrug: YinH Mean clinical recovery time (hours) Yes 0
COVID-19;SDrug: Yinh changes in the ratio of PaO2 to FiO2 from baYes 0

Virus DiseaDrug: Azit Number of days alive and discharged from hoYes 0
COVID-19;CDrug: Hydr The rate of recovery of mild or moderate COYes 0
COVID-19;CDrug: Hydr Prevention of COVID-19 symptoms as recorde

Yes 0
Cancer Other: Sur Distress at baseline measured by the COVID-1

Yes 0
COVID-19 Drug: Hydr Difference in time to resolution of clinical Yes 0
COVID-19 Other: Pla Number of patients who screen eligible for Yes 0
COVID-19 Drug: Hidrotime to clinical improvement Yes 0

COVID-19 Drug: AcalaSubject alive and free of respiratory failure Yes 0
COVID-19 Drug: Clev The rate of subjects tested as negative SAR Yes 0
Infection, Other: Blo Seroconversion;Seroconversion;SeroconversYes 0
COVID-19 Drug: DAS1COVID-19 Clinical Classification (CCC);Retur Yes 0
Covid19 Overall mortality Yes 0
COVID-19 Drug: Etop Change in pulmonary status Yes 0
COVID-19;ADrug: Nalt Progression of oxygenation needs Yes 0

COVID Biological: Mortality due to lung involvement due to SAYes 0
Occupational Exposur Sample Size of enrolled CHAMPS Study particYes 0
COVID-19;Cr
Behavioral:Views and experiences of health care profes Yes 0
Covid-19;CrBehavioral:Improvement in knowledge surrounding SRAYes

p 0
COVID-19 Drug: RecoTime course of body temperature (fever);VirYes 0
Covid-19 ( Other: PhysHealth-related quality of life; EuroQoL (EQ- Yes 0

Infection, Biological: Initial biological profile of children and ad Yes 0
COVID-19;HOther: ven Variation of thrombin time (in secondes) in HYes 0
Corona ViruOther: File Relationship between severity of disease andYes 0
SARS-CoV 2;Other: dial Antibodies against SARS-CoV-2 Yes 0
COVID-19 Drug: IMU-Proportion of patients without any need* forYes 0
Coronary AProcedure:Successful cardiovascular intervention;Perfo Yes 0
COVID-19; Drug: Hydr Clinical improvement on the Ordinal Scale foYes 0

CoronavirusOther: ObsPatient requires invasive mechanical ventilatYes 0
COVID-19;VDrug: MelpThe changes of COVID Ordinal Outcomes Scale

Yes 0
COVID-19 Drug: AcalaOccurrence of Adverse Events and Serious Adv

Yes 0
People Incarcerated; percentage changes in the consumption of pYes 0
COVID-19;Hypoxic Resp
Changes from baseline PaO2 (mmHg);ChangeYes 0
Pancreatic Procedure: Changes in pancreatic cancer management No 0

COVID-19 Bleeding events and complications Yes 0
COVID-19 VTE events and complications Yes 0
PsychologicBehavioral:Patient Health Questionnaire (LÃ¶we et al., Yes 0
COVID;AcutBiological: All-cause mortality Yes 0
Covid19 Biological: Description of clinical manifestations Yes 0
Chronic Pa Other: Exe Anxiety and Depression;Quality of Life and ovYes 0

COVID-19 Drug: Claz Cumulative incidence of serious adverse eveYes 0
Covid-19;P Other: No How do people assess their oral health-relat Yes 0
Mechanical Ventilati Duration of mechanical Ventilation No 0
Risk Factors for COVI mortality;Risk factors for death;mortality;Ri Yes 0
Corona Vir Other: Pul Length of ICU stay Yes 0
Covid-19;P Drug: Cicle Duration of received supplemental oxygen t Yes 0

Infections, Drug: azox Clinical status of the patient (according to 7- Yes 0
SARS Virus Diagnostic Death;Recovery from COVID-19;Progression Yt es 0
COVID-19 Drug: Plas Mean hospitalization time;Mean OxigenationYes 0
COVID 19 Dietary Su Mean change from baseline score of ImmuneYes

R 0
COVID-19 Diagnostic % of COVID-19 co-infections Yes 0
Upper RespiOther: NaCTime to resolution of symptoms as defined byYes 0
Mental HealOther: Onl Depressive symptoms at baseline;Change in dep

Yes 0
Covid-19 Device: NonThe number of patients treated with non-inva
Yes 0
COVID Radiological pattern of initial presentation, Yes 0
Covid19;ResCombinatioSymptoms and signs;Respiratory function;T Yes 0
Behavior, Other: DeeDispositional questionnaire 1;Dispositional Yes 0
SARS-CoV- Drug: Hydr Change from Baseline Oxygenation on Day 1 Yes 0
COVID-19 Other: NeurShort Physical Performance Battery (SPPB) S Yes 0
COVID-19 Drug: Zilu Mean change in oxygenation;Median changeYes 0

COVID-19 IDrug: NO-I Invasive ventilation or death Yes 0
COVID;CoroDrug: Nita Number of patients with virological cure Yes 0
COVID Drug: NP-12Patient clinical status (on the WHO 7-point oYes 0
COVID-19 Drug: Nitri COVID-19 PCR status at completion of treatmYes 0
COVID-19 Biological: Safety index-incidence of adverse reactions Yes 0
SARS-CoV Other: SeroPrevalence of COVID19 Antibody Positivity Yes 0

COVID fear among dentist during COVID 19 epidem Yes 0
COVID Other: Biol Coronavirus sequencing Yes 0
EmergencyOther: stre Change of emergency department staff's leveYes 0
COVID;CVDOther: Covimobidity discharge;mobidity at 30 days;mobidi

Yes 0
Genetic BasDiagnostic Mutations leading to increase susceptibility Yes 0
CoronaviruDrug: Hydr Time to negatively RT-PCR Yes 0

Mental Disorder;Genernumber of perception distortions Yes 0
Type1diabeOther: Onl Self-reported acute diabetes complication Yes 0
Infection;VBiologica Incidence of documented COVID-19 among he

Yes 0
COVID-19 IBiological in-hospital mortality secondary to COVID-1 Yes 0
Coronavirus Infection;To evaluate the relative contributions of comYes 0
COVID-19; Device: Ae Time to successful intubation Yes 0

CoronaviruDrug: The PClearance (CL) or apparent oral clearance (C Yes 0
CoronavirusOther: sta Real life data of the severe acute respirato Yes 0
COVID-19 Diagnostic Sensitivity, spectivity turnaround time of t Yes 0
COVID-19;CProcedure:30-day mortality Yes True parent
Pneumonia, Viral;Hyperate of recovery Yes 0
COVID-19;CDrug: Hydr Polymerase chain reaction (PCR) confirmed Yes 0
COVID-19;CoronavirusNatural history of COVID-19: Characteristics Yes 0

COVID-19 Drug: Hydr Number of participants with clinical infecti Yes 0
COVID 19 Device: Bi Stop home isolation;NEWS score Yes 0
COVID;Acute CoronaryDetermine the incidence of cardiomyopath Yes 0
CoronaviruDiagnostic POCUS Score - Lungs;POCUS Score - Heart Yes 0
CoronaviruBiological Feasibility of performing study pathway con Yes 0
HydroxychlDrug: Hydr Polymerase chain reaction assay (PCR) negatiYes 0
Covid19;SAProcedure:Comparison of the percentage of clinically Yes 0

COVID;CoroDietary Su Symptom Reduction Yes 0
Covid-19;Lung Cancer Clinical data of lung cancer patients with Yes 0
Skin Manifestations;C Clinical skin manifestations Yes 0
SARS-CoV-2Other: QueAdjusted Odds Ratio Yes 0
COVID 19 Other: Sali Change in SARS-CoV-2 mucosal immune respon

Yes 0
COVID-19;CDiagnostic Number of different arrhythmias;TemperatuYes 0
COVID-19 Other: blo Identification of prognostic factors for prog Yes 0

Covid-19 Other: con Change in COVID-19 severity status Yes 0
COVID-19 Drug: Hydr Time to positive COVID-19 disease Yes 0
Covid-19;S Biological Proportion of subjects who consent to the s Yes 0
Sars-CoV2; Drug: Pegi Cohort A (Ambulatory) - Proportion swab nega

Yes 0
COVID-19 Biological Overall Mortality within 60 days Yes 0
COVID;Kidney Injury Kidney involvement in COVID-19 disease Yes 0

COVID Other: sel The percentage of knowledge regarding COVYes 0
Covid 19;H Drug: Almi Rate of endotracheal intubation Yes 0
COVID 19 Cardiac;COVFrequency of cardiac arrhythmias Yes 0
COVID-19 by SARS-CoVAnosmia;Ageusia;Duration of the loss of an Yes 0
COVID-19 Drug: Ther Composite outcome of ICU admission (yes/no),

Yes 0
Neurologic ManifestatCentral or peripheral neurological symptomsYes 0
COVID;ObstDiagnostic The rate of clinical improvement Yes 0

COVID-19 IDrug: AnakTreatment success Yes 0
COVID-19 clinical, biological and radiological characteriYes 0
COVID-19; Drug: Povi Percent of healthcare workers testing positi Yes 0
Respiratory Tract Infe Mortality;Immune response - Plasma cytokine

Yes 0
COVID-19 Drug: PrazoDeath;Hospitalized, requiring mechanical ve Yes 0
OccupationBehavioral:Professional burnout;Mindfulness level Yes 0

Covid19;Di Drug: Sitag Time for clinical improvement;Clinical paramYes 0
COVID-19 Drug: RemdClinical course on Day 15. Yes 0
ARDS Biological: Ventilator-Free Days;Safety and Tolerabilit Yes 0
Covid-19 Opportunistic fungal co-infections. Yes 0
Covid-19; Device: Hy The proportion of patients with improved disYes 0
CoronaviruProcedure: Mortality Rate Among COVID-19 Patients;ProYes 0
COVID19;AcDrug: LEAF proportion of patients showing an increase oYes 0

COVID-19; Drug: Inter Improvement of the absolute lymphocyte cou
Yes 0
COVID-19;Critical Illn ICU mortality Yes 0
SARS-CoV-2Other: Blo Change in serial monthly log-transformed anYes 0
COVID-19; Drug: Hydr cumulative incidence of SARS-CoV-2 infectio Yes 0
COVID;CoroDevice: ga change in initiation of mechanical ventilati Yes 0
Mental Health Wellne Mental health symptoms, well-being change Yes 0
SARS-CoV IOther: Pat Presence or absence of olfactory and taste dYes 0

COVID-19;PDiagnostic Number of Patients Experiencing Death, ICU Yes 0
Covid 19;B Diagnostic Differences related to epidemiological demogYes 0
COVID-19; Drug: poracEvolution of the PaO2 / FiO2 ratio between Yes 0
COVID;AnxiBehavioral Evaluation of depression and anxiety score Yes 0
COVID-19 Procedure: Days alive without respiratory life support ( Yes 0
COVID-19;CProcedure:30-day postoperative COVID-19 infection ra Yes True parent

COVID-19 bOther: COVLevel of activation of inflammasomes in mo Yes 0
COVID-19 Other: pla decrease in mortality Yes 0
COV-HI;COVID-19;COVITo collect retrospective demographic informYes 0
SARS-CoV- Drug: Inte Ordinal Scale for Clinical Improvement Yes 0
COVID-19 Biological: Immune signature;Dosage of cytokines and Yes 0
Covid-19;S Other: QueExistence of a post-intensive care syndrome Yes 0
CoronaviruBiological Improvement in respiratory disease;ImproveYes 0

COVID-19 Drug: Hydr Proportion of poor outcomes (in index casesYes 0
CoronaviruDevice: vv IL-6 reduction by 75% or more after 72 hou Yes 0
Mild Cogni Other: Tel Change on cognitive function in people with Yes 0
Respirator Device: patChanges in ROX index Yes 0
Corona ViruOther: COVIPregnancy Outcome Yes 0
COVID-19;Vitamin D DCOVID-19 infection;Oxygen therapy for COVIYes 0
Pulmonary Drug: Lopi Pneumonia free survival; acute respiratory dYes 0

Coronavirus Disease Mortality (binary outcome);Respiratory fail Yes 0
Neonatal COther: No iIncidence of neonatal COVID-19;Incidence ofYes 0
COVID19 Drug: Saril Proportion of patients who show an improveYes 0
SARS-CoV-2;Immune SChanges in monocytes HLA-DR expression;C Yes 0
Nutrition Poor;Infecti Body Mass Index;Body Mass Index Yes 0
COVID;Lymphoma mortality;transfer to ICU Yes 0
Sars-CoV2;RT-PCR;SaliDetection of SARS-CoV-2 RNA in the saliva Yes 0

COVID-19;KDiagnostic The effect of COVID-19 severity on the severiYes 0
COVID-19 Other: CohSARS-COV-2 infection;SARS-COV-2 infection Yes 0
OsteoarthriDrug: ResinChange in pain and function: WOMAC Yes 0
COVID-19;Pe
Other: Int Patient's perception of COVID-19 and medicaYes 0
COVID19;OProcedure:Description of the ophthalmological proble Yes 0
Covid-19 Dietary Su Physical Health;Psychological Health Yes 0

COVID-19;M
Drug: DornNumber of participants discharged from the Yes 0
COVID-19 Diagnostic SARS-CoV-2 levels of IgG antibodies Yes 0
COVID-19;CDiagnostic Study of the link between SARS-CoV-2 infectYes 0
CoronaviruDiagnostic o study the prevalence of Covid-19 infection Yes 0
COVID-19 Biological: Severity and death;Adverse events that requYes 0
Respirator Other: Pul Patient's self-efficacy Yes 0

Corona Virus Infectio Prevalence of SARS-CoV-2 infection throug Yes 0
Corona Virus Infectionthe number confirmed COVID-19 cases;The Yes 0
COVID;Embo
Diagnostic percentage of patients with one or more DV Yes 0
COVID-19;Critical IllneOverall number and characteristics of patie Yes 0
COVID Diagnostic Correlation between serology testing and cli Yes 0
RheumatoidDrug: Hydr immunoglobulin mesurement Yes 0

COVID-19 Drug: Hydr Time to confirmed diagnosis of COVID-19 Yes 0
COVID-19;ADrug: Luci Oxygenation index (OI) area under the curv Yes 0
COVID-19;SDrug: XCEL All-cause mortality at day 28 Yes 0
SARS-CoV IOther: Pat Presence or absence of olfactory and taste Yes 0
COVID-19 Biological Disease progression Yes 0
COVID-19; Device: Co Efficacy Endpoint composite score Yes 0

Stress;AnxiOther: Pub EEG power in alpha band;EEG power in bet Yes 0
COVID-19 (SInterventi Proportion of participants alive and not hav Yes 0
COVID-19; <Patients wiThe number of days alive and free of ventil Yes 0
COVID-19 inThis is a t Changes in PaO2/FiO2 assessed by arterial blYes 0
DepressionThe aim of Depression symptom change: DepressionYes

wil 0
Olfactory To determinPrevalence of UPSIT score <26 (anosmia or seNo 0

coronavirusInterventi We want to check the amount of time taken Yes
t 0
PsychologicThis study To evaluate the psychological impact of COVYes 0
COVID-19 ( The ratio of the oxyge 5/1/2021 Yes 0

COVID-19 ( Case fatality rate ass ### No 0
COVID-19 (S Positive COVID-19 amo ### Yes 0
breast can Case seriesDTT;NTS;STA; No 0

Malignant Case seriesSurgery-related parameters; Yes 0
Cancer Case seriesEQ5D;Patient Health Questionnaire-9, PHQ-9No 0

Novel CoroA?B?C:Huma Immune intervention effect; No 0
Novel CoroCOVID-19 ppulmonary function test;the antibodies leve No 0
Novel CoroExperimentTime to disease recovery; No 0
Novel CoroHealth:Nonthe score of Sub-Health Measurement Scale No 0
Novel CoroCase serie mortality; No 0
novel coro recovered Patients' general information: epidemiologi No 0
Novel CoroGold StandCOVID-19 nucleic acid;SEN, SPE, ACC, AUC o No 0
Novel CoroGroup A:sel30-second sit-to-stand test score;treadmill No 0
Novel CoroCase serie Duration of negative changes; No 0
Novel CorosymptomatiSymptomatic venous thromboembolism; Yes 0

healthy Case seriesPost traumatic stress disorder self rating sca Yes 0
Novel Coroprone posi pulse oxygen saturation;respiratory rate;RO No 0

Novel CoroControl:NuNumber of acute care surgeries per day; No 0
Novel CoroExperimentC-reactive protein;temperature;Erythrocyte No 0
Novel CoroCase seriesViral load of nCoV;Blood test;Immunologica Yes 0
novel coro control gr Antipyretic time; Yes 0

COVID-19 Incidence of neurological symptoms Yes 0
COVID-19 mortality and end of mechanical respiratory No 0

COVID-19 Methylpred1.Time to clinical improvement: defined as Yes 0
COVID-19 NA Number of people that download the app and No 0
Suspicion f Telemedici Number of PPE used per patient No 0
COVID-19, The adminisChange in PaO2/FiO2 (P/F) ratio, oxygenatio Yes 0
SARS-CoV-2 To measure body composition and specificallyNo 0
COVID-19 QuestionnaRisk perception Yes 0
COVID-19 i not applicaThe primary outcome measure is the numberYes 0
COVID-19 infection COVID-19 infection Yes 0
COVID and None Prevalence of VTE No 0
Asthma Surveys -mental health status before and during a Yes 0
Corona vir Three condiA change in the two-dimensional variable (S Yes 0
Covid-19 inAny patien ?- BMI ?- Hip- waist ratio ?- Covid Yes 0
COVID-19 All COVID-1Duration of mechanical ventilation Yes 0
Cardiovasc All partici -What is the effect of an interactive Digita Yes 0
COVID-19 None Generic quality of life, measured with the 5 Yes 0
coronaviru N/A Biomarker profiles or signature which correlaNo 0
COVID-19 Not applic Seroprevalence of SARS-CoV-2 neutralising aYes 0
COVID-19 Err:508 No 0
COVID-19 Prevent a sHospital length of stay (days). Yes 0
All systemic autoimm Our primary study parameter is the percentag Yes 0
COVID-19, 1.Placebo The main study parameter is the fold-incre Yes 0
Severe acu None. Clinical data, laboratory results, EIT measu No 0
Covid-19 POCUS Admission or discharge No 0
Pulmonary embolism, The percentage of preventable CTPA in the wYes 0
COVID-19 BCG-vaccinâ€¢SARS-CoV-2 related hospital admission No 0
COVID-19 Incidence of COVID-19 (association with BMINo 0
COVID-19 SARS-CoV-2 RT-PCR of cerebrospinal fluid Yes 0
Lower respiDuring rout28-day mortality Yes 0
COVID-19, Not applic To assess achieved immunity against COVID-1Yes 0
SARS-CoV- InfotainmenElevation of proper hygiene behaviour (behaNo 0
COVID-19 dNone -To describe the clinical presentation (sym Yes 0
COVID-19 All treatm -Composite endpoint with disease progressioYes 0

Covid19 poImatinib o time to liberation from ventilation and sup Yes 0
SARS-CoV2Lung Ultra Diagnostic accuracyof LUSand CT in COVID-1No 0
SARS-CoV2Lung Ultra Patients will receive regular care as indica No 0
COVID-19 wPatients in 30-day mortality (from randomization) Yes 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: The overall objective of the Yes True parent
Sars-Cov-2; ProducMain Objective: To evaluate the efficacy of Yes 0

COVID-19
infection
in
patients
requiring
endotrac
hael
intubatio
n
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus Trade Main Objective: To assess whether administra
Yes 0
COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10038700
Term:
Respirato
ry
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: The overall objective of the Yes 0
COVID-19;Th
 ProducMain Objective: The aim of this core protocolYes True parent
viral
pneumon
ia caused
by the
new
coronavir
us (SARS-
CoV-2)
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10035737
Term:
Pneumoni
a viral
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C Trade Main Objective: to evaluate the safety anYes 0
Healthy
volunteer
s, health
care
workers.
Immune
system
activation
after BCG
vaccinatio
n. Work
absenteei
sm and
COVID-19
will be
monitore
d.
 Med
DRA
version:
23.0
Level: LLT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class: 100 Trade Main Objective: To reduce absenteeism amon
Yes True parent
COVID-19
pneumon
ia
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To evaluate the effectivenesNo 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: To assess efficacy of ChAdO Yes True parent
SARS-
COV-2
infection
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10084268
Term:
COVID-19
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: The objective of the study isNo 0
SARS-
CoV-2
infection
(COVID-
19)
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
Acute
lung
injury
associate
d with
COVID-19
 Med
DRA
version:
20.1
Level: HLT
Classifica
tion code
10047468
Term:
Viral
lower
respirator
y tract
infections
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: Part 1 The objectives ar Yes 0
2019 NovelDrug: XiyanClinical recovery time Yes 0
COVID-19 Biological Safety indexes of adverse reactions Yes 0

COVID-19 Drug: LopinClinical status of subject at day 15 (on a 7 poYes 0
CoronaviruDrug: ColchClinical improvement;Hospital discharge Yes 0
CoronaviruDrug: Hydr Number of death from any cause, or the need

Yes 0
Acute DiseaDiagnostic SAMBA COVID-19 POC PCR Test Yes 0
CoronaviruProcedure:Evaluation of the extent of the virus transm Yes 0
COVID 19 Other: QuePrevalence of symptoms;Prevalence of positiv

Yes 0
COVID-19;Deep Vein Tthe prevalence of a DVT in patients at the IC Yes 0

Cardiovasc Biological T-cell immunophenotype Yes 0
COVID-19 Biological Occurrence of adverse reactions;Anti SARS- Yes 0
CoronaviruDrug: LinagChanges in Glucose Llevels Yes 0
COVID-19 Biological Overall mortality until discharge from the h Yes 0
Surgery;Complication Rate of UCI admission for surgery-related c Yes 0
Covid19;EcOther: Ech Death Yes 0
CoronaviruBiological: Early all-cause mortality Yes 0

COVID 19 Drug: Hydr COVID-19-free survival in experimental arm Yes 0
COVID;InfeBiological: Modified WHO Ordinal Scale (MOS) score Yes 0
COVID-19 Drug: FT51 Number of participants with Dose Limiting T Yes 0
COVID Drug: Claz Change in C-reactive protein (CRP) level Yes 0
Covid19 Drug: Enox Incidence of venous thromboembolism deteYes 0
COVID-19;VDrug: Enox Total Number of Patients with Clinically Rel Yes 0
COVID-19 Drug: Hydr Time to Resolution of Symptoms relative to ba

Yes 0
COVID-19 Other: Exp Differences in vitamin D blood levels betweeYes 0
COVID19 Drug: DoxyPercentage of Patients with Clinical Respira Yes 0
COVID-19 Drug: Tran Survival time without needs of a ventilator. Yes 0
Covid19 community pharmacists facing covid-19 Yes 0
COVID-19 Biological: mortality Yes 0

COVID 19 Other: CT- diagnostic of COVID disease composite Yes 0
Covid-19;Virus Diseas seroprevalence as well as the titer of serum Yes 0
COVID-19 Dietary Su Prevalence of COVID-19 calculated using a q Yes 0
COVID measurement of pulmonary function changesYes

ei 0
CoronaviruOther: Cor Sperm density;Sperm activity;Erection hardnYes 0
COVID-19 Drug: Nitri Prevention of progressive systemic de-oxygen

Yes 0
Gastrointe Device: no Maneuverability score Yes 0
Migraine Behavioral Efficacy of Mindfullness by Smartphone Yes 0
Corona Vir Biological: Adverse reaction (AE) and severe AE (SAE);E Yes 0
Patients U Other: No Highest VIS (Vasoactive-Inotropic Score) in t Yes 0
COVID-19 Diagnostic IP-10 levels Yes 0
COVID-19 Prevalence of contagiousness in asymptomatYes 0

Chemeother
Other: Psy Overall survival of patients with metastatic Yes 0
COVID-19 Drug: ConvNumber of patients who receive COVID-19 con

Yes 0
Covid 19 Drug: Desf Mortality rate Yes 0
CoronaviruOther: con Serious adverse events in convalescent plasmYes 0
Pneumonitis
Drug: Tofa Prevention of severe Respiratory Failure req Yes 0
Acute RespDrug: WharIntergroup mortality difference with treatm Yes 0

COVID-19;CDrug: LB11 Effect of LB1148 on disease progression via Yes 0
Genetic Predispositionfor the patients Yes 0
COVID;SARSRadiation: Change from baseline blood oxygenation;Num

Yes 0
COVID19 Drug: RavulTime to incidence of the composite endpointYes True parent
COVID-19;CDietary Su Cases with discharge to ICU. Yes 0
SARS-CoV Biological: Rate of Severe Disease Yes 0

COVID-19;CardiovasculIn-hospital mortality. Yes 0
SARS-CoV- Diagnostic Identification of nucleic acid sequencing, a Yes 0
COVID-19;ODiagnostic The resting energy expenditure (in Kcal / 24hYes 0
COVID-19 Device: MLPatient Disposition Post treatment;oxygenatYes 0
COVID-19;SDiagnostic detection of SARS-CoV-2 in the semen Yes 0

Oral Health and COVI Oral manifestation Yes 0
COVID-19 Device: Cy ICU mortality Yes 0
Chronic Ly Behavioral:Prognostic factors for healing of COVID-19 i Yes 0
COVID-19;RDevice: MaChanges in cerebral oxygenation (ScO2) dur Yes 0
COVID-19 Drug: Stan Mortality rate Yes 0
Proctologic Practice Predictive power of respondents' and hospitaYes 0

Sars-CoV2 Diagnostic COVID-19 Test Conversion Yes 0
SARS-CoV Biological: Cumulative incidence of SARS-Cov2 infectionYes 0
Intensive Biological: Kinetics over time of HLA-DR expression on Yes 0
COVID;DrugDrug: Treatnegative test result for COVID-19 Yes 0
Stroke Device: Ro System Usability Scale (SUS);Technology Ac Yes 0
COVID Drug: IvermNegative PCR Yes 0

Covid19;PnBiological: Clinical improvement Yes 0
COVID-19 Drug: UlinaTime to recovery Yes 0
COVID19;CDevice: Pr Does Participant Accurately Read Result;AcceYes 0
COVID19;T Other: thr 2 week mortality Yes 0
Viral Pneumonia;COV Describe qualitative and quantitative variabl Yes 0
Post ICU S Behavioral Impact of intervention program on health-relYes 0

Pneumonia,Radiation: Oxygen Therapy Status at Day 2;Oxygen SatuYes 0
CORONAVIROther: meaAssociation between concentration of circulaYes 0
COVID-19;VDrug: Sily Time to clinical improvement Yes 0
Identify Emerging HeaExperience during lockdown;Health risk duri Yes 0
CoronaviruBiological Time to SARS-CoV-2 nasopharyngeal excretion

Yes 0
SARS (SeveDrug: Nitri Change of arterial oxygenation at 48 hours Yes True parent
Health Car Diagnostic Seroconversion to SARS-CoV-2 positivity Yes 0
CoronaviruDiagnostic Prevalence of positivity of COVID-19 virus Yes 0
Endometriosis;Covid1 Covid 19 Anxiety levels in Endometriosis Pat Yes 0
COVID19 Drug: Nitr Rates of return visits to the ED Yes 0
COVID Behavioral Measure of the impact of COVID Emergency Yes

on 0
COVID-19 Drug: Siro Proportion of patients who are alive and fr Yes 0
COVID-19 Other: PracEffect of GI societies recommendations on Yes 0
COVID 19;CDrug: Fluv Time to clinical worsening Yes 0
Covid19 Drug: Tran Survival without needs of ventilator utiliz Yes 0
COVID-19 IDrug: Vaze To evaluate efficacy of vazegepant (BHV-350Yes 0
ConvalesceOther: con ICU length of stay;Safety of convalescent pl Yes 0
COVID-19;ARDS;Sars- intrapulmonary shunt ratio Yes 0
COVID-19 To determine SARS-CoV-2 viral load and infecYes 0

Acute LungDrug: TD-0 Safety and Tolerability of SAD of TD-0903: Yes 0
Sars-CoV2; Other: que Frequency of RA patients with emotional impa

Yes 0
Sars-CoV2; Other: que percentage of patient with feeling of disabili Yes 0
Sars-CoV2; Other: que Hospital Anxiety and Depression Scale quest Yes 0
COVID-19 Drug: RuxoOverall survival Yes 0
COVID-19 Drug: ColchComposite of all-cause mortality, need for mYes 0

COVID-19 IBiological: Seroconversion against SARS-CoV2 in childreYes 0
COVID 19 Biological Reduce mortality Yes 0
PneumoniaDrug: HCQ;Percentage of participants who achieve clini Yes 0
COVID-19;VProcedure:Changes in lung compliance;Change in globalYes 0
COVID-19 Drug: Lefl Tolerability of high dose leflunomide as me Yes 0
COVID-19 IBiological: Change of neurodegeneration markers level Yes 0

COVID-19 Drug: HB-a D-dimer;Interleukin-6;C Reactive protein;O Yes 0
COVID-19; Drug: CanaTime to clinical improvement up to day 14, dYes 0
Mental Health Wellne Stress level Yes 0
Mental Health Wellne Stress level Yes 0
Covid-19;ARDS;PneumComposite of death and mechanical ventilat Yes 0
Respirator Behavioral:Change in imputed partial pressure of oxygenYes 0
COVID-19;CDevice: TelPhysical Performance;Cardiorespiratory fitneYes 0

COVID-19 Drug: Hydr Modified COVID Ordinal Outcomes Scale: St Yes 0
Covid19 Device: cu Incidence of contamination of any part of th Yes 0
Conjunctivitis;SARS-C Proportion of conjunctival samples tested p Yes 0
Femoral NeOther: Sur Mortality;Morbidity Yes 0
COVID 19 Number of physician using los flow nasal c Yes 0
COVID-19 Drug: AtorvProportion of patients that progress to seve Yes 0

COVID-19;EDevice: Ex In-hospital mortality Yes 0
Chronic Disabling;COVProportion of patients necessitating the sch Yes 0
Corona Vir Biological: Incidence of any infusion associated advers Yes 0
Cholangiti Other: End Age, gender, nationality;Indication for proc Yes 0
COVID-19 Gather information on patients treated wit Yes 0
Covid-19;C Drug: Oxyt Proportion of cases who during 14 exhibit onYes 0

Covid 19 PoDrug: Arte length of stay in hospital Yes 0
Anosmia;AgOther: NHAcorrelation of anosmia and ageusia to covid1Yes 0
Covid-19;C Drug: Iver Proportion of patients with a positive SARS Yes 0
COVID-19;Cr
Other: COVChronic medications as risk factor of intensi Yes 0
SARS-Cov- Drug: ConvIntrahospital mortality from any cause Yes 0
SARS-CoV Other: Pat Relationship between body mass index (BMIYes 0

COVID19;HDrug: Hydr Evaluation of the efficacy of hydroxychloroq Yes 0
CoronaviruDrug: EIDD Safety and Tolerability of Single Ascending Yes 0
CoronaviruDrug: ConvSurvival Rate Yes 0
COVID19 InDrug: Cycl Severity Category Yes 0
COVID-19 Drug: ABX4Rate of patients with no invasive or non-in Yes 0
Covid-19; Drug: BaricNeed of invasive mechanical ventilation Yes 0
COVID-19;AOther: COVSix minute walk distance (6MWD) Yes 0

COVID Procedure:LUS applicability with COVID 19 Yes 0
COVID-19;ROther: [TI Sensibility and specificity of urinary Yes 0
COVID-19;HDevice: A Body temperature;Cough Frequency;Respirato

Yes 0
COVID;SARBiologica Need of invasive mechanical ventilation Yes 0
CoronaviruDrug: Povi Change in viral load in the oral and nasopha Yes 0
COVID-19;HDrug: Low Bleeding;Thrombosis;Mortality Yes 0
Mental HeaBehavioral Depression, anxiety and stress Yes 0

Cancer;Sars-CoV2 Describe presenting characteristics and seveYes 0
Mental HeaBehavioral Loneliness (UCLA-8 Loneliness Scale);MindfuYes 0
COVID Dietary Su laboratory measured vitamin D levels Yes 0
Stress;Stre Behavioral:The CoRonavIruS Health Impact Survey (CRISYes 0
Sars-CoV2 Analysis of risk factors for intubation tube o Yes 0
COVID-19 Drug: Hydr time to viral clearance;% of mortality Yes 0
CoronaviruProcedure:Rate of Therapeutic failure, defined as a co Yes 0

Acute RespDrug: AMY-The proportion of patients who are alive, wi Yes 0
COVID-19 Device: C3 In-hospital mortality during hospitalization Yes 0
CoronaviruOther: DataComparison of vital status Yes 0
Infertility Behavioral Severity of anxiety;Severity of depression Yes 0
COVID19 Dietary Su Symptoms;Length of hospital stay;invasive mYes 0
Sars-CoV2 Diagnostic SARS-CoV-2 positive test Yes 0

Sexual Dys Other: ElecThe percentage of study participants diagno Yes 0
AKI;ARDS; Device: SC Mortality at Day 60;Dialysis Dependency;VenYes 0
Covid-19 Other: Ayu Clinical confirmation of Covid-19 Yes 0
COVID-19 Drug: AT-5 Proportions (active vs. placebo) of subjects Yes 0
COVID-19;COther: Phy Mobility level;Time taken to first mobilise Yes 0
CoronavirusOther: QuePatients perspectives on the abruptly disconYes 0

PostTraumaBehavioral Change in Davidson Trauma Scale (DTS) Yes 0
Stress ReacBehavioral Change in professional quality of life Yes 0
COVID;CoroProcedure:Short Form (36) Health Survey (SF-36) Yes 0
COVID-19;Systemic LupCOVID-19 seroconversion;COVID-19 infectio Yes 0
COVID-19 Drug: Hydr Incidence of symptomatic fever >37.8, dry coYes 0
Pyrexia;CODevice: Th Temperature Yes 0

ConvalesceBiological Duration of oxygenation and ventilation suppYes 0
ARDS Related to SeverHospital mortality Yes 0
Sars-CoV2; Other: mHePercentage of ecological momentary assessmYes 0
Covid 19 , Diagnostic the SARS-Cov-2 positivity rate in patients wi Yes 0
COVID;Onco
Device: PatDevice Tolerability (Attrition);Correlation of Yes 0
COVID-19 Biological: Activation of platelet NLRP3 inflammasome; Yes 0

COVID-19;Anxiety;Depworsening of cardiovascular risk (treatmentsYes 0
Mental Health Wellne Impact of Event Scale - Revised (IES-R);Gen Yes 0
Corona Vir Other: COVIAsymptomatic COVID-19 positive pregnant Yes 0
PsychologicBehavioral:Patient Health Questionnaire - 4;Patient He Yes 0
COVID-19;HDrug: InhalIncidence of treatment emergent adverse e Yes 0
COVID-19 Biological: Mortality at day 30 Yes 0

COVID Drug: IvermViral clearance Yes 0
Acute RespBiological Number of Participants With Treatment-RelaYes 0
Corona ViruBiological: Clinical Status at 14 days Yes 0
COVID- 19;PAs an obserNutrition service delivery assessed from pat Yes 0
Airway procFollowing Assessment of PPE use - this will be assesNo 0
Influenza v Effect of c Rate of influenza vaccination in women givi Yes 0
COVID-19; <Establish a Create biological bank of clinical samples ( No 0
COVID-19; Treatment:To evaluate the early efficacy of CYP-001 in Yes 0
Perinatal ExperimentPerinatal depression; Yes 0

Novel CoroExperimentSARS-CoV-2 clearance; No 0
Posttraumat
PLC-C =38 The PTSD Checklist Civilian Version, PLC-C;m No 0
COVID-19 Case seriesRT-PCR; No 0
???? faster ver ESR; No 0
Novel CoroCase seriesConfirmed 2019-ncov pneumonia; Yes 0
Novel CoroCase seriesBody temperature;Respiratory syndrome;Pulm

Yes 0
Novel CoroCase serie Rate of cure; No 0
COVID-19 Control:GuThroat Swab Nucleic Acid Test; No 0
Novel CoroCase serie cardiopulmonary function;exercise capacity;qu

Yes 0
Novel CoroExperimentModify Borg Dyspnea Score;Fatigue scale-14;No 0

Novel CoroCase series:psychiatric admissions; No 0
time to recovery; No 0
Novel CoroExperimentVital Capacity;Total Vital Capacity;Forced Yes 0
Novel Corointerventi Appetite score; No 0
Novel CoroARBs GroupIncidence of ARDS;Mortality within 28 days; No 0
common coExperimenta the occurrence of a patient-reported commoNo 0

Parental s In t ### No 0
COVID-19 ( Amounts of cultured SA ### Yes 0
ThrombosisThis observ 1. ### No 0
COVID-19 ( Participant clinical st ### Yes 0

Hospital-o 1. ### Yes 0
COVID-19 ( COVID-19 symptoms me ### No 0
Late stage
1/stage 2
COVID-
19-
related
disease
COVID-19
(SARS-
CoV-2
infection)
 Infec
tions and
Infestatio
ns
 COVI
D-19
(SARS-
CoV-2
infection) Time 5/1/2022 No 0
COVID-19 (S Time 5/3/2025 Yes 0
COVID-19 (According Extravascular lung wa ### No 0
Subjects
with life-
threateni
ng
COVID-19
symptom
s
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducTimepoint(s) of evaluation of this end point: Yes 0
SARSCo-V-2;
 ProducTimepoint(s) of evaluation of this end point: Yes 0
COVID-19-a Trade Timepoint(s) of evaluation of this end point Yes 0

Covid-19 di Trade Main Objective: To compare clinical and biolYes True parent
COVID-19 in Trade Main Objective: 1. Incidence of symptomaticNo 0

COVID-19 in ProducMain Objective: The primary objective of theYes 0
COVID-19;Th
 ProducMain Objective: The aim of this core protocolYes True parent
COVID-19
severe
pneumon
ia, acute
lung
injury, or
acute
respirator
y distress
syndrome
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10061229
Term:
Lung
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Disease Trade Main Objective: To evaluate the effect of r Yes 0
COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10038700
Term:
Respirato
ry
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: The overall objective of the Yes 0
COVID-19
pneumon
ia and
impaired
respirator
y function
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10061986
Term:
SARS
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: Evaluate the effect of DFV8 Yes True parent
ICU
patients
diagnose
d with
pulmonar
y
infection
due to
COVID-19
and
require
mechanic
al
respirator
y support
or ECMO
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and in ProducMain Objective: The primary objective of th Yes 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: To evaluate the efficacy of Yes 0
Preventio
n of
COVID-19
infection
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10036897
Term:
Prophylac
tic
vaccinatio
n
System
Organ
Class:
10000000
4865
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10046859
Term:
Vaccinati
on
System
Or Trade Main Objective: The aim of the study is to d Yes 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10084268
Term:
COVID-19
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To evaluate the effectivenesNo 0
COVID-19 in Trade Main Objective: The main objective of the A Yes True parent
SARS-CoV-2 Trade Main Objective: To evaluate the efficacy of No 0
COVID-19 in Trade Main Objective: Assess whether the group ofNo 0

Hyperinfla PharmaMain Objective: To determine whether the use
No 0
Acute respi Trade Main Objective: 1.Efficacy: Investigate the Yes 0

Infection
with
COVID19
 Med
DRA
version:
21.1
Level: PT
Classifica
tion code
10001052
Term:
Acute
respirator
y distress
syndrome
System
Organ
Class:
10038738
-
Respirato
ry,
thoracic
and
mediastin
al
disorders
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry T ProducMain Objective: To treat respiratory insuff Yes 0
COVID-19
 Med
DRA
version:
20.1
Level: HLT
Classifica
tion code
10047468
Term:
Viral
lower
respirator
y tract
infections
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: The primary objective of th Yes 0
Severe
COVID-19
Infection
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: Day 14 Ordinal Scale Impro Yes True parent
SARS-CoV-2 Trade Main Objective: Overall survival after 28 daysYes 0

COVID-19
induced
respirator
y failure
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10038696
Term:
Respirato
ry failure
(excl
neonatal)
System
Organ
Class:
10000000
4855
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10040050
Term:
Sepsis Trade Main Objective: The primary objective is to Yes 0
Covid-19 in Trade Main Objective: To compare the proportion of

No 0
COVID-19 P Trade Main Objective: The aim of this trial is to No 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: Efficacy and safety assessm No 0
Severe
pulmonar
y COVID-
19
related
disease
 Med
DRA
version:
23.0
Level: LLT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: To compare the efficacy of oYes True parent
NeoplasmsDrug: TAK- Dose Escalation and Cancer Treatment ExpanYes 0
Serogroup Procedure:Feasibility of developing an England based s Yes True parent
CoronaviruDrug: Nitri Reduction in the incidence of patients with Yes 0

SARS-COV2;Device: CT Predictive association between CT-V, PBM s Yes 0
CoronaviruDrug: Hydr Evaluation of the clinical status Yes 0
COVID-19 Drug: Chlo COVID-19-related hospitalization or all-caus Yes 0
COVID-19; Drug: Azit Hospitalization Yes 0
COVID-19 Other: hospPercentage of children with severe or critica Yes 0
COVID-19 Biological: CAP-1002 Allogeneic Cardiosphere-Derived CYes 0

Pneumonia,Other: No sCharacteristics of pulmonary ultrasound for Yes 0
COVID-19 Drug: chlo negative testing of covid19 Yes 0
Acute RespProcedure:The change of viral load in patients with SA Yes 0
CoronavirusBiological: Incidence of COVID 19 Infection Yes 0
COVID;Cor Drug: Hydr Time to resolution of symptoms Yes 0
Covid-19;MOther: Exp Anxiety and depressive symptoms Yes 0

COVID-19;CoronavirusProportion of asymptomatic subjects;Positiv Yes 0
COVID-19 Biological: Clinical recovery;Clinical worsening Yes 0
COVID-19;IDiagnostic Mean in quality of life score at one year on Yes 0
PneumoniaDrug: Sodi Time to clinical recovery Yes 0
CoronaviruProcedure:Cumulative Incidence of SARS-CoV-2 RNA DetYes 0
Quality of Other: COVOne-year utility score of health-related qualitYes 0

Infection; Diagnostic evaluation of the prevalence of positive rea Yes 0
Health BehBehavioral Hand Washing Behavior Yes 0
Covid19 Biological: Effect on CBC as per CTCAE v4.0;Effect on b Yes 0
COVID-19 predicitive value of noncoding RNAs in COVI Yes 0
COVID-19 Drug: IVER Reduction in SARS-CoV-2 viral load Yes 0

Cancer Other: No Overall Quality of Life Yes 0
COVID-19 Drug: Hydr SARS-CoV-2 viral load level Yes 0
PsychologicBehavioral Change on the Five Facets Mindfulness QuestNo 0
Virus Combinatiothe number of patients with positive covid 1 Yes 0
Respirator Drug: Dex Ventilator-free days at 28 days Yes 0
covid19 Other: LungA qualitative analysis of parenchymal lung Yes 0
COVID;Pediatric Disor Overall severity of illness Yes 0

Covid19;PsyBehavioral:Change of PHQ-9 (Patient Health QuestionnaiYes 0
Covid-19;ADrug: MavrReduction in the dependency on oxygen su Yes 0
Cancer;COVID;Solid T Number of cases of SARS-COV-2 infection and

Yes 0
COVID-19;VDrug: Clar Clinical outcome negative for two parameterYes 0
COVID-19 Biological Incidence of the Solicited AE in all groups;I Yes 0
Daily RoomOther: afteQualified rate of room disinfection;The num Yes 0
COVID Device: TC Rate of avoidable Emergency Department pre

Yes 0
MicrobiomDietary Su Change in Shannon Diversity Yes 0
ARDS AssocDevice: Floarterial oxygen partial pressure (PaO2) Yes 0
COVID (SARDrug: Nicl Change in respiratory viral clearance (by PCRYes 0
COVID Other: no Variation in inflammatory mediators in patieYes 0
COVID;PneuDevice: Be Presence of viral pneumonia caused by COV Yes 0
Corona ViruDrug: BaricResponse to treatment: absence of moderateYes 0

Corona Virus InfectionThe survey that was taken by telephone call Yes 0
Covid-19 Biological Stabilization or Improvement in Clinical Stat Yes 0
Physical AcBehavioral:Recruitment rate (monthly);Participant retenYes 0
COVID-19 Other: DataMedical Research Council sum score (MRC- SS

Yes 0
COVID-19;PDrug: Enox hospitalizations;all-cause death Yes 0
COVID-19 Other: que Knowledge about COVID-19 by questionnaireYes 0
CoronaviruBiological Assess the efficacy of the candidate ChAdOx Yes 0

COVID-19 Drug: Resv Hospitalization rates for COVID-19 Yes 0
COVID;Sar Drug: Sarg Measuring oxygenation Yes 0
Covid 19 Attitude of the Egyptian population during Yes 0
COVID 19 awareness of Egyptian population Yes 0
COVID;ARDS;Quality ofEvaluation of recovery of quality of life in Yes 0
Gastric CanOther: no treatment of fevers at arrival;treatment of Yes 0
Vitamin C; Drug: Vita Death or persistent organ dysfunction Yes 0

COVID-19; Dietary SupProportion of patients who are clinically re Yes 0
COVID19;PnOther: predadmission to ICU Yes 0
Covid19 routine biomarkers and blood cell count are Yes 0
COVID-19;Critical IllnePhysiotherapy intervention;Disability-free suYes 0
Distance Education L assessment of distance education learning e Yes 0
SARS-CoV 2Biological: Safety of administering partially HLA-matcheYes 0
COVID-19 Drug: TXA1Incidence of acute kidney injury;Incidence ofYes 0

COVID-19;ADrug: Sodi Survival with Unassisted Breathing Yes 0
COVID-19;Neonatal DiVertical Transmission Yes 0
Diagnoses Diagnostic kappa value Yes 0
COVID-19;Fa
Drug: Favi Number of participants negative by RT-PCR foYes 0
Nurse;Student;Post TrPrevalence of PTSD-related symptoms assessYes 0
SARS-CoV Diagnostic IgG/IgM antibodies Yes 0

Acute RespProcedure: Adverse events related to SGB;All Adverse Yes 0
Covid19;TelOther: Phy Modified Medical Research Council Dyspnea Yes

Sc 0
CoronaviruOther: no Lymphocyte cell;d-dimer;PLT;CRP;LDH;CK;PT;Yes 0
Covid-19 Diagnostic Test characteristics Yes 0
Sars-CoV2 Drug: IgIV Mortality Yes 0
Behcet Di Other: it w IPAQ-SF;Numeric Rating Scale Yes 0

Covid19;CoBiological Proportion of In-hospital mortality;Time to Yes 0
COVID Drug: Iver The number of patients with resolved viral i Yes 0
Covid-19 Other: QueCross-sectional descriptive study: Egyptian Yes 0
COVID;SARDiagnostic To compare the result of SARS-COV2 PCR testYes 0
AdjustmentDrug: PH9 Hamilton Anxiety Scale Yes 0
COVID Dietary Supplement:

7-point ordinal
AÃ§aÃsymptom
palm berry
scale
extract - naturalYes
product;Other: Placebo
0
COVID-19 Drug: LopinViral load Yes 0
Severe Cor Drug: CD24Improvement of COVID-19 disease status Yes 0
COVID-19 Other: hy death Yes 0
CoronaviruDrug: BCG COVID-19 disease incidence;Severe COVID-19Yes 0
CoronavirusOther: Pat Clinical Features;Immune host response at syYes 0
COVID-19;CDrug: Hydr COVID-19-free survival Yes 0
SARS-CoV-2Drug: Chlo Viral clearance time Yes 0

CoronaviruDrug: Ibup Disease progression;Time to mechanical ventYes 0
Covid19;P Procedure:Number of antibiotic free days Yes 0
RespiratoryDrug: StemChanges in clinical critical treatment index Yes 0
Efficacy, S Other: Sati Efficiency of the telephone consultation Yes 0
COVID;CoroBiological: All-cause mortality or need of invasive mechYes 0
SARS-CoV Drug: Hydr ? Rate of hospitalization or death at day 7 af Yes 0

COVID-19; Drug: Asco Lower respiratory tract infection (LRTI) rate Yes 0
COVID-19 Other: CashSymptoms consisent with COVID-19 Yes 0
SARS-CoV 2 Cumulative incidence of ventilator-associatedYes 0
RespiratoryDevice: CO Oxygenation Improvement;Pulmonary venti Yes True parent
COVID Participant age;Participant sex;Participant r Yes 0
COVID 19;PDiagnostic Conjunctival swab results based on RT-PCR Yes 0

COVID-19 Drug: AVM0Dose-Limiting Toxicities;28 day all-cause morYes 0
COVID-19 Device: CO Time to tracheal intubation (TTI) Yes 0
Health BehOther: No Handwashing adherence;Frequency of hand Yes 0
COVID-19 Biological Subjects with solicited AEs - Phase 1;Safety Yes 0
COVID-19 Drug: Plac Cumulative Proportion of Participants Requi Yes 0
SARS-CoV-2Biological: Number of increased immune population;Num

Yes 0
CoronaviruBiological Rate of COVID-19 progression Yes 0
COVID-19 Other: Datathe number of intubations in COVID-19 patient

Yes 0
COVID-19 Drug: Toci Progression of respiratory failure or death Yes 0
SARS-CoV 2;Other: risk ICU survival at 28 days Yes 0
Well Aging Behavioral Change in mindfulness skills as measured by Yes 0
Sars-CoV2;Critical Illn Cumulative incidence of ICU-acquired colonizYes 0

Burnout, PrOther: COVBurnout;Psychological Distress Yes 0
Covid-19;CriOther: ObsDemographic characteristics of patients withYes 0
COVID;CoviBiological: Number of cured patients Yes 0
COVID-19 Biological Number and proportion of patients with pro Yes 0
Acute Respiratory Dis Analysis of Clinical, Biological and Histolo Yes 0
Generalize Behavioral:GAD-7;Whiteley 8 Yes 0

Acute Respiratory Dis Comparison of the PV curves Yes 0
COVID-19;SDiagnostic Prevalence of anti SARS-CoV-2 antibodies (I Yes 0
Covid-19 Biological Participants with serious adverse events.;Ti Yes 0
COVID-19;ARDS, Hum Mortality Yes 0
SARS-CoV Radiation: Phase 1: Feasibility and safety of treating Yes 0
Health BehOther: Sur Health Behavior Change Regression Questio Yes 0
COVID-19 Diagnostic Valid SARS-CoV-2 Test Yes 0

Corona Vir Device: Nit Time to deterioration Yes 0
Covid-19 Acceptance of telemedicine Yes 0
Cancer Other: SurvScore of the Impact of Event Scale Revisited Yes 0
Acute LungDrug: TD-0 Part 2: SaO2/FiO2 ratio;Part 2: Ventilator-fr Yes 0
COVID-19;SOther: 35 Immunological memory: resolution of COVID-Yes 0
Coronavirus Infection COVID-PSL Cohort Yes 0

Sars-CoV2 Diagnostic Vrological profile of newborns.;ImmunologicYes 0
Disease, V Diagnostic Changes in cytokines associated with SARS CYes 0
COVID 19 Drug: Colc change from baseline in clinical assessment Yes 0
COVID-19;SDietary Su Time to hospital discharge Yes 0
High SensitDevice: pe Performance evaluation of RealDetectâ„¢ C Yes 0
COVID;SARDrug: Toci Evaluation of clinical status Yes 0

COVID-19 Diagnostic Identification of asymptomatic carriers of Yes 0
COVID-19 Other: COVRecovery;Mortality;ICU admission Yes 0
Coronavirus COVID-19Incidence of COVID-19 among children with Yes 0
ARDS Seco Dietary SupSOFA Yes 0
COVID-19 Drug: OzanThe mean oxygen flow required to maintain tYes 0
HealthcareDrug: Emtr COVID-19 incident cases Yes 0

COVID-19 Biological Death Yes 0
SARS-CoV 2;TraumaticNumber of patients with post-traumatic stresYes 0
SARS-CoV Device: TakClinical performance of several diagnostic t Yes 0
COVID-19 Drug: Iver Time to event Yes 0
Pulmonary Thromboe Analysis of incidence of thromboembolic eveYes 0
Increased RDrug: BromPolymerase chain reaction (PCR) Yes 0

COVID19 Prevalence of the SARS-COV-2 infection in SaYes True parent
Viral Infec Biological: Successful production of viral specific T-cells Yes 0
Ischemic S Other: Me Intrahospital mortality;short-term morbidityYes 0
SARS-CoV 2 Time to medical discharge Yes 0
CoronaviruDrug: Nita Health workers that require hospitalization Yes 0
COVID-19 Other: No Diffusion Capacity for Carbon Monoxide (CO Yes 0

COVID-19 Drug: Enox 30-day mortality Yes 0
ARDS;COVIDiagnostic Correlation between impudence deterioration

Yes 0
Covid-19 Behavioral:Change in pulmonary function (St George's RYes 0
Pancreatic Other: Dat Pancreatic adenocarcinoma treatment Yes 0
Acute Kidney Injury; Occurence of acute kidney injury (AKI) Yes 0
Oncology Patients Oncology patients Yes 0

Transplant Recipients Seroprevalence of SARS-Cov-2 antibodies (pos
Yes 0
COVID;StatDrug: obse SARS-cov-2 scale of severity (9 steps) in Cov Yes 0
Covid 19;V Dietary Su Vitamin D levels;severity of COVID 19 symp Yes 0
COVID Behavioral:Score of five-item Brief Symptom Rating Sca Yes 0
SARS-CoV- Diagnostic Prevalence of antibody status in healthcare Yes 0
COVID;ARDProcedure:analyze the relationship between the prone Yes 0

COVID-19 Drug: Iver Participants with a disease control status de Yes 0
COVID-19 Other: DietDietary intake Yes 0
COPD Exacerbation;C Change in COPD Exacerbation Rate Yes 0
COVID;SARDiagnostic Prevalence of antibodies against SARS-CoV-2Yes 0
Anxiety Di Behavioral:Participation Barriers;Number of Eligible P Yes 0
COVID Biological Arms 1 & 2: number of critical and severe COYes 0

Oxygen DefOther: AwaChange in SpO2 Yes 0
COVID;PneuDrug: Enox Clinical worsening, defined as the occurrenceYes 0
COVID;Shock Plasma bio-adrenomedullin, proenkephalin, dYes 0
Covid-19; Other: Bra Brain regional homogeneity between COVID-Yes 0
COVID-19;Me
This is a P Efficacy will be determined by an audit conduYes 0
COVID-19 po
Patients re To assess the feasibility of the Everion arm Yes 0
COVID-19;Ve
Our primarPrimary Outcome- the impact of the COVID-1Yes 0
PsychologicCoaching wPsychological distress, as measured by the Yes 0
chronic ill The propose

Depression scores are assessed by the brief Yes 0
COVID-19; <The ACES Pa

Time until being discharged alive from the i Yes 0
Novel Coro1:placebo; Reduction of viral load and treating COVID-1Yes 0

Novel Coro1:Nano shorprealbumin;lymphocyte;Length of stay; No 0
Novel CoroCase serie Viral nucleic acid test; No 0
Dementia Case seriesCognitive functioning; Yes 0

Novel CoroCase seriesWeight;Exercise habits;Anxiety state;DepressNo 0
Novel CoroCase seriesSARS-CoV-2 viral RNA PCR test; No 0

Peer suppoAfter provi 1. ### Yes 0
Severe menWe will co Depression, anxiety a 2/1/2022 No 0
Overweight Self-reported weight ### Yes 0

The severe Mea ### No 0
Out-of-hosp Survival at hospital d ### No 0
Acute inso Insomnia severity mea 4/6/2022 Yes 0

COVID-19 ( Hospital admission for ### Yes 0
Severe Acu Cur ### No True parent

Symptom
s of
Covid-19
infection
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10061986
Term:
SARS
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: To determine the effect of Yes 0
PCR-confirm
 ProducMain Objective: To evaluate the safety and toYes 0
not applic Trade Main Objective: 1) To confirm that, after a Yes 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Assess the efficacy of favipi Yes 0
confirmed S ProducMain Objective: To evaluate the efficacy of Yes 0
Acute
coronavir
us
disease
2019
 Med
DRA
version:
23.0
Level: LLT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Difference in time to resol Yes 0
infectious
respirator
y diseases
(e.g.
COVID-
19)
 Med
DRA
version:
20.0
Level:
HLGT
Classifica
tion code
10024970
Term:
Respirato
ry tract
infections
System
Organ
Class:
10038738
-
Respirato
ry,
thoracic
and
mediastin
al
disorders
;
Therapeu
tic area:
Diseases ProducTimepoint(s) of evaluation of this end point Yes 0
SARS-corona
 Trade Main Objective: To compare the treatment efYes 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: To evaluate the efficacy of Yes True parent
Infection
with
Severe
Acute
Respirato
ry
Syndrome
Coronavir
us 2
(SARS-
CoV-2)
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases PharmaMain Objective: A randomized study assessi Yes 0
Severe
Communi
ty
Acquired
Pneumoni
a
 Med
DRA
version:
20.1
Level: LLT
Classifica
tion code
10010120
Term:
Communi
ty
acquired
pneumon
ia
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] Produ Main Objective: The primary objective of thi Yes True parent
Protectio
n against
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: To describe the safety and t Yes True parent
COVID-19 pa
 ProducMain Objective: The primary objective of th Yes 0
Patients
with
SARS-
CoV-2
infection
and:
1. age =
18 years
and = 75
years
2.
SARS-
CoV-2
infection
confirme
d by PCR
(BAL,
sputum,
nasal
and/or
pharynge
al
swap)
3.
severe
disease
defined
by at
least one
of the
following:
a.
respir Trade Secondary Objective: - Time to clinical impr Yes 0
COVID-19; Biological Frequency of solicited local reactogenicit Yes 0
COVID-19 Drug: RemdThe Odds of Ratio for Improvement on a 7-poYes 0
COVID-19 Drug: RemdThe Odds of Ratio for Improvement on a 7-poYes 0

COVID-19 Drug: Toci Clinical Status Assessed Using a 7-Category Yes True parent
CoronavirusDrug: Hydr Evaluation of the clinical status Yes 0
Severe Acute Respira mortality in siltuximab treated patients Yes 0
COVID-19 Dietary Su Change from baseline score of Nutrition risk Yes 0
COVID-19 Drug: Hydr COVID Ordinal Outcomes Scale at 14 days Yes 0
COVID-19;CDrug: Hydr Total Hospitalization;Total Mechanical Venti Yes 0

RheumatoidOther: COVDisease activity Yes 0
Coronavirus Infectio Hospital mortality Yes 0
CoronaviruOther: tele Impact of Gerontological telemonitoring on Yes 0
Ventilator Other: BactPrevalence of the microorganisms responsibYes 0
Sars-CoV2 Drug: Pegi Proportion of participants with no evidence Yes 0
Pneumonia,Drug: UNIK50% reduction in symptom score for patientsYes 0
SARS-CoV- Drug: Pati Effectiveness of current drug treatments for Yes 0

Coronavirus Disease ( Risk categorization of healthcare workers;COYes 0
Pulmonary Drug: T3 soAssessment of weaning from cardiorespiratoYes 0
Lung Injur Drug: GimsPrimary endpoint Yes 0
COVID-19;ADrug: DornEfficacy of intratracheal administration: oc Yes 0
MaxillofaciProcedure: evolution of number of maxillofacial trauma Yes 0
Covid-19; Other: Pul Mixed venous O2 pressure (PVO2);Mixed venYes 0
Severe AcuOther: Pro Tidal electrical Impedance Yes 0

COVID-19 Drug: Toci Serum Concentration of interleukin-6 (IL-6) Yes 0
COVID19;HyDrug: Hydr the proportion of subjects of Group 1 who Yes 0
SARS-CoV-2Other: AddiSpecific immune responses Yes 0
Sleep Dist Behavioral Comparison of sleep quality during COVID-19Yes 0
COVID-19 Drug: XPro Proportion of participants with disease pro Yes 0
Blood DonaBehavioral Blood donation rate Yes 0
SymptomatiDrug: Bari Proportion of patients requiring invasive mecYes 0

Covid-19 Drug: N-aceArm A: number of patients who are successfuYes 0
Corona ViruBiological Safety of treatment with high-titer anti-SA Yes 0
Major DeprDevice: MaProportion achieving remission on Hamilton Yes 0
Infections, Drug: Inac Mortality reduction in CoViD-19 patients tr Yes 0
COVID-19 Biological: Preliminary safety and efficacy evaluation of Yes 0
COVID-19; Other: Blo Compare D-dimer values of COVID-19 patie Yes 0
COVID;CoroDrug: Dipy Change in D-dimer Yes 0

Rheumatoid Arthritis Reduction or discontinuation of the DMARD th
Yes 0
COVID -19 Drug: Aeroslung injury score Yes 0
COVID-19 Biological Participants with serious adverse events.;Co Yes 0
COVID Biological: Incidence of AEs;Mortality;Death;Number ofYes 0
COVID;SARDiagnostic Estimation of the actual prevalence of SARS-Yes 0
COVID-19; Biological An improvement of two points on the seven-Yes 0
Health Car Diagnostic Susceptibility to SARS CoV-2 infection accor Yes 0

Severe AcuProcedure: Hospital mortality or discharge to hospice Yes 0
Coronavirus Disease severe COVID-19 Yes 0
Encephalo Diagnostic The percentage of patients who have devel Yes 0
COVID-19; Device: v overall survival Yes 0
SARS-CoV Procedure: Latency of electrophysiological response;DelaYes 0
Anxiety an Behavioral Anxiety/depression by means of Hospital AnxYes 0
CoronaviruOther: evalTo evaluate, through laser doppler, the pres Yes 0

Lung CanceDiagnostic Description of the characteristics of patients Yes 0
COVID Other: no Percentage of patients who reached, during tYes 0
Covid-19;S Dietary Su Symptom resolution Yes 0
COVID-19;M
Other: Exp Emotional Impact Yes 0
ConvalesceBiological Plaque reduction neutralization test (PNRT) Yes 0
COVID -19;Device: Ox Oxygen saturation;In-hospital Intubation/Mec

Yes 0
COVID Dietary Su Hypoxic respiratory failure;Hypoxic respiratoYes 0

COVID-19 Biological: Diagnostic values of anosmia and ageusia f Yes 0
COVID-19;ROther: SeroEvaluate the false positive results rate Yes 0
Bariatric S Other: TeleEvaluation of feasibility of telemedicine in ouYes 0
Juvenile Idiopathic Ar Reduction or discontinuation of the DMARD th

Yes 0
Homeless Biological: the covid mortality rate Yes 0
COVID Behavioral Warwick-Edinburgh Mental Wellbeing Scale Yes 0

CoronaviruDiagnostic If the participant has an active SARS-CoV-2 Yes 0
Rehabilitation Short Form-36 Health Survey (SF36);Short FoYes 0
COVID-19 IProcedure:Survival;Survival;Survival Yes 0
Spinal CordOther: WebTreatment Satisfaction Yes 0
CoronaviruOther: obs estimation of inflammatory changes in Covi Yes 0
CoVID-19 Drug: HCQ;Incidence confirmed case of COVID-19;Incid Yes 0
COVID;Sars-CoV2 Characterization of specific T cell response Yes 0

Comorbidities;Confin Analyse the variation in weight loss kinetic Yes 0
COVID19 Drug: RTB1The percentage of subjects who develop laboYes 0
Covid-19 Drug: Lopi Hospitalization or death Yes 0
CoronaviruBiological The incidence of tracheal intubation or deathYes 0
COVID-19 Drug: MelaMelatonin Yes 0
Activities; Other: WH World Health Organization Quality of Life-BriYes 0
Sleep Dist Behavioral Change in Insomnia Clinical Diagnosis;ChangeYes 0

PosttraumaBehavioral:Recruitment rate;Completion rate;Peri-trauma
Yes 0
COVID;HypDiagnostic ABPM systolic blood pressure Yes 0
COVID-19;SDrug: Oral Change in SARS-Cov-2 viral load Yes 0
COVID-19;UDiagnostic Rate of SARS-CoV-2/COVID-19 in a selected cYes 0
Event, Life Change Impact of Covid-19 on pharmacy Education sYes 0
COVID-19;SDiagnostic Short-form 36 questionnaire (SF-36);6-minute

Yes 0
Corona Vir Diagnostic Change of pro-inflammatory response over the

Yes 0
Covid19 Drug: Dipy Covid (Coronavirus Disease-19) Ordinal Scal Yes 0
Liver Tran Diagnostic Incidence of IgG against SARS-CoV-2 Yes 0
COVID;CoroDrug: P2Et Evaluate the efficacy of P2Et in reducing the Yes 0
Migraine, Drug: SympDrop out rates Yes 0
Covid19;P Diagnostic optical coherence tomography pulmonary mYes 0
Pregnancy Drug: Hydr Number of PCR confirmed cases among pr Yes 0

Health Know
Other: Pre Predictions of COVID-19 Cases and Deaths Yes 0
Diabetes Me
Other: GlycPlasma glucose levels and left ventricular ejeYes 0
COVID-19; Diagnostic Rate of positive COVID-19 cases in asympt Yes 0
Sars-CoV2 Drug: Favi Time to recovery (discharge);Decrease in vir Yes 0
Covid-19;Ob
Other: Exp Change in weight child;Change in weight pa Yes 0
Prognosis Other: TakiDetermination of the relationship between thYes 0

Severe AcuDrug: SARSTransfusion of patients in the ICU with conv Yes 0
COVID-19; Drug: Sarg Change in oxygenation parameter of P(A-a)OYes 0
Intubation Device: aerFirst pass success Yes 0
TB - TubercBehavioral:Efficiency of the telephone consultation,;PatYes 0
Well-Being Behavioral:Well-Being (Psychological Flourishing) Yes 0
COVID19;CaDiagnostic Number of participants with a diagnosis of Yes 0

Covid-19 Diagnostic NETOSIS AND MORTALITY;NETOSIS AND DCOYes 0
Corona Vir Dietary SupSurvival rate.;Rate of disease remission.;Th Yes 0
COVID;ARDS, Human ICU Mortality Yes 0
Sars-CoV2 Analysis of Respiratory Distress and Antithr Yes 0
COVID-19 Biological Change in PaO2/FiO2 after CCP transfusion.;CYes 0
Menstrual Irregularity Rate of irregular menstrual cycle;Length of Yes 0

Frailty Syndrome;COVIIncidence of frailty Yes 0
COVID-19 Drug: TCM Chest CT absorption;The relief of main sym Yes 0
Critical CO Drug: AviptMortality;PaO2:FiO2 ratio Yes 0
Corona ViruDrug: RemdPercentage of subjects reporting each severitYes 0
Disease, In Device: Ins COVID-19 disease diagnosis Yes 0
CoronaviruDrug: Dex Ventilator-free days Yes 0

SARS (SeveDrug: HypeICU admission Yes True parent
COVID-19;PBehavioral:Evaluation of covid-19 knowledge level of tu Yes 0
COVID-19 Device: hy Mortality Yes 0
CoronaviruDrug: Hydr Change from baseline to Day 3 in nasopharynge

Yes 0
CoronaviruDrug: INO- Percentage of Participants with Adverse EvenYes 0
COVID-19;RDrug: Azit Proportion of alive patients free off mechaniYes 0

COVID;Tra Diagnostic Correlation of FAST+ pulmonary findings wit Yes 0
Covid19 Diagnostic The positivity (Yes/No) of the serological testYes 0
COVID 19 Drug: Iver Number of cured patients Yes 0
COVID-19;ViDrug: Nita Symptomatic laboratory-confirmed COVID-1Yes 0
COVID-19 Drug: DanoRate of composite adverse outcomes Yes 0
COVID-19 Drug: Hydr i. Clinical status Yes 0
Sars-CoV- Drug: Hydr Rate of patients reaching a significant hypo Yes 0

Covid-19 InOther: HydImpact of anti-malarials on the developmentYes 0
Covid-19 Time to Disease-Aggravation Yes 0
COVID19 Drug: Claz Evaluate the safety of clazakizumab for the Yes 0
Septic Sho Device: Toraymyxin PMX-20R (PMX Cartridge) Yes 0
COVID-19 Drug: TelmiC reactive protein Yes 0
COVID-19;SBiological: Clinical improvement;improvement in tomogra

Yes 0
Respirator Device: MaAll-cause mortality Yes 0
COVID-19 Drug: Pred Clinical improvement defined by the improvem

Yes 0
COVID-19;ViDrug: Nita The proportion of subjects with symptomaticYes 0
COVID Biological Intubation or death Yes 0
CoronaviruBehavioral:Impact of multi-denominational prayer on clin

Yes 0
Oncology To evaluate the ability of SARS-CoV-2 immuno

Yes 0
COVID-19 Drug: Hydr Time to reach normal body temperature;DevYes 0
COVID-19; Drug: HepaIntubation and mortality Yes 0
COVID-19; Other: MoxThe change of the average VAS score from b Yes 0
Perceived Device: Ca Perceived Stress Scale;Perceived Stress Scal Yes 0
COVID-19;CDrug: Arte Time to clinical improvement, defined as a Yes 0
COVID-19 Drug: Pliti Frequency of occurrence of Neutropenia = g Yes 0
COVID CombinatioTime course of body temperature (fever) Yes 0

CoronavirusDrug: Hydr Proportion of participants in whom there waYes 0
COVID;COVOther: DataTime to Hospitalization;Time to Expiration Yes 0
SARS-CoV Behavioral Change in 6 Minute Walk Test;Change in ShoYes 0
COVID-19 Dietary Su Symptoms recovery Yes 0
COVID-19 Drug: FamoSymptomatic improvement Yes 0
COVID-19 Drug: Drug:lung injury score Yes 0

COVID-19 Biological The number and proportion of patients with Yes
t 0
COVID-19 Drug: EDP1Time to incidence of the composite endpointYes True parent
COVID-19 Drug: ImatiThe proportion of patients with a two-point Yes 0
HER2-positDrug: Fixed-Dose Combination of Pertuzumab and Tras Yes 0
Maternal FDiagnostic COVID-19 by positive PCR in cord blood and /Yes 0
DepressiveBehavioral:Changes in depressive symptomology over the

Yes 0
COVID The primary cardiac outcome is the proporti Yes 0
COVID-19 Diagnostic Performance of the LumiraDx Assay versus ref

Yes 0
SARS-CoV 2Drug: GLS- Evaluate the number of GLS-1200 topical nasYes 0
COVID;AcutDrug: AngioProportions of patients with mean arterial Yes 0
Smoking CeBehavioral Biochemically-validated tobacco abstinence Yes 0
Infection, Coronavirusthe time of Covid 19 viral clearance in medi Yes 0

COVID-19;VDrug: Unfr Primary endpoint: Venous or arterial thrombYes 0
Inflammatory Bowel DiFlare of IBD needing change in therapy or su Yes 0
COVID Drug: Vita Respiratory SOFA.;Need of a high dose of ox Yes 0
COVID-19;M
Other: InvaDuration of mechanical ventilation and 28 daYes 0
SARS-CoV Diagnostic SARS-CoV-2 infection Yes 0
Sars-CoV2 Drug: Oct Mechanical Ventilation Yes 0

Inflammatory Bowel DPrimary outcome measure: The need for in-hYes 0
COVID-19; Drug: IcosaChange in hs-CRP levels from the randomizatio

Yes 0
to Predict Other: nonNeed of mechanical ventilation, transfer to No 0
Covid-19 Drug: AnakiTime to recovery Yes 0
COVID-19 Biological Seroconversion rate of IgG antibodies againsYes 0
Corona Virus InfectionIdentification of requirement of mechanical Yes 0

CoronaviruDrug: MANPrevalence of diabetes among all hospitalizeYes 0
COVID-19 Drug: Toci Clinical status (on a 7-point ordinal scale) at Yes 0
COVID-19 Drug: Cycl Safety-oxygen, ICU transfer and ventilation; Yes 0
Chronic Pa Behavioral Change over time in Scores on the Pain DisabYes 0
COVID-19 Other: Pre Patient Prognosis Score Yes 0
Obesity, C Drug: NIVOPatient's clinical state Yes 0
SARS-CoV Other: Inf Change of inflammatory cytokines concentratYes 0

COVID-19; Device: Se Rate of known, expected, or unanticipated aYes 0
CoronaviruDiagnostic Assess the serological status/rate of past inf Yes 0
SARS-CoV 2;Hospitalis Complications onset Yes 0
COVID-19 Drug: INC42Evaluate the efficacy of ruxolitinib in the Yes 0
Mild-to-moOther: KB10Number of patients experiencing study-prodYes 0
Stress;Anx Other: Yog Stress;Stress;Stress;Wellbeing;Wellbeing;W Yes 0

COVID;Sars-CoV2 Incidence of Left ventricular systolic dysfu Yes 0
CoronavirusDrug: ConesDisease severity Yes 0
Infertility Other: ExpoSemen parameters;Sperm Parameters;Spe Yes 0
CoronaviruDrug: SNDXProportion of subjects alive and free of respiYes 0
COVID-19 Drug: Tofa Disease Severity Yes 0
Extracellul Device: NI ECW Yes 0
COVID-19 Drug: Riva Composite endpoint of venous thromboembolis

Yes 0
COVID Diagnostic Proportion of asymptomatic subjects Yes 0
Covid-19;P Diagnostic Pattern of pulmonary abnormalities in SARS-Yes 0
Photodynam
Procedure:Participants Achieving Either a Major Clinic Yes 0
Covid 19 Biological: Functional Respiratory changes: PaO2 / FiO2 Yes 0
COVID-19 Organ transplantation activity during COVI Yes 0
CoronaviruDiagnostic rate of presence of anti-SARS-CoV-2 antibo Yes 0

Autism SpecOther: InteInterview of the parents : contextual data;I Yes 0
CoronavirusDiagnostic SARS-CoV-2 Neonatal Infection Yes 0
Myeloproliferative N Rate of serious coronavirus infection in di Yes 0
CoronaviruOther: Ass Success Percentage Yes 0
Diabetes MDevice: Fr Comparison of values between two devices Yes 0
COVID-19 Biological: SARS-CoV-2 related hospital admission Yes 0
COVID-19 Device: DevSensitivity and Specificity Yes 0

CommunicaOther: ComPercent with visit or procedure with provide Yes 0
COVID;SarsDrug: N-ac Decrease in Respiratory Rate;Hospital lengthYes 0
COVID-19 ( 1. Proportion of care ### No 0

COVID-19 ( The Clinical-Therapeut ### Yes 0
COVID-19 (Participant 1. 6/6/2021 Yes 0

COVID-19 ( The risk of clinical d ### No 0
Diphtheria 1. ### No 0
Novel CoroCase seriesserum proten; No 0
heart failu Heart Fail Heart Sound;Breath Sound; No 0
Novel Coroconvalesceall cause in-hospital mortality; Yes 0

COVID-19 Case seriesMortaility; Yes 0
Novel CoroCase seriesSevere disease; Yes 0
Novel CoroCase serie Tongue image; No 0
Novel CoroExperimentRate of aggravation; No 0
Sore throa Case seriesPharyngeal discomfort symptoms such as sore

No 0
Novel CoroCase seriesFollow-up questionnaire: included improved No 0
Sore throa Case seriesPharyngeal discomfort symptoms such as soreNo 0

Novel CoroCase seriesless complications with ambulatory surgery; No 0
Novel CoroTocilizuma clinical manifestations;laboratory examinati No 0
Severe
acute
respirator
y
syndrome
coronavir
us 2
(SARS-
CoV-2)
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
21.1
Level: PT
Classi Trade Main Objective: The main objective of the folYes 0
COVID-19;Th
 ProducMain Objective: To demonstrate the efficacyYes True parent
Healthy
volunteer
(Prophyla
xis for
COVID-
19)
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10049087
Term:
Antiviral
prophylax
is
System
Organ
Class:
10042613
- Surgical
and
medical
procedur
es
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion cod Trade Main Objective: To investigate whether proph
Yes 0
Coronavir
us
infection
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Evaluate the effect of hydro Yes True parent
COVID-19 as
 Trade Main Objective: To evaluate the efficacy (as Yes True parent
infectious
respirator
y diseases
(e.g.
COVID-
19)
 Med
DRA
version:
20.0
Level:
HLGT
Classifica
tion code
10024970
Term:
Respirato
ry tract
infections
System
Organ
Class:
10038738
-
Respirato
ry,
thoracic
and
mediastin
al
disorders
;
Therapeu
tic area:
Diseases ProducPrimary end point(s): Number of days absentYes 0
Severe
COVID-19
Infection
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: Day 14 Ordinal Scale impro Yes True parent
Confirme
d
infection
with
SARS-
CoV-2
(COVID-
19)
 Med
DRA
version:
20.0
Level: HLT
Classifica
tion code
10047465
Term:
Viral
infections
NEC
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
1 ProducPrimary end point(s): For end-of-part-1 interYes 0
COVID-19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: To evaluate the efficacy of Yes 0
Treatmen
t of Lower
Respirato
ry Tract
Parainflue
nza
Infection
in
Immunoc
ompromis
ed
Subjects
 Med
DRA
version:
20.0
Level: HLT
Classifica
tion code
10033796
Term:
Parainflue
nzae viral
infections
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases ProducMain Objective: To demonstrate the efficacyYes True child
Respiratory Trade Main Objective: to assess the effect of nebulNo 0
Pulmonar
y
permeabil
ity
oedema
in SARS-
Cov-2
positive
patients
with
moderate
-to-
severe
ARDS
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10003083
Term:
ARDS
System
Organ
Class:
10038738
-
Respirato
ry,
thoracic
and
mediastin
al
disorders
 Med
D ProducMain Objective: Assessment of the efficacy Yes 0
COVID-19;UInterventioPredictive value of the clinical symptoms ag Yes 0
older peoplInterventioFeasibility: The feasibility of videotherapy No 0
;U07.1 - E Interventiotime to resolution of vasoplegic shock (defi Yes 0
;U07.1 - EmInterventioSARS-CoV-2 RNA detection in tears No 0
;J12.8 - O Interventi Equivalence of the method measured by corrNo 0
;U07.1 - E InterventioThe main outcome is the association of orophNo 0
deconditio InterventioThe primary outcome of the study is the diff No 0
;U07.1 - E Interventio- Prevalence (ELISA) (Baseline) - Risk fac Yes 0
;U07.1 - E Interventioidentification of a characteristic index of No 0
AdjustmentInterventi The primary goal criterion is the qualitativ Yes 0
;U07.1 - E InterventioThe aim of the study is to include 100 patie Yes 0
COVID-19;UInterventioPart A: What is the rate of SARS-CoV2 R Yes 0
COVID-19;J1 Interventio1. Prevalence of bacterial superinfection i Yes 0
;J80 - Adul InterventioContingency table: mRS categories vs. infla No 0
;F41 - OtheInterventiofeasibility and acceptance of the group chat No 0
;U07.1 - E InterventioGoals: Prospective surveillance of all ho No 0
;U07.1 - E InterventioThe aim of this study is the prospective reg Yes 0
;U07.1 - E InterventioBlood sampling (6 ml Plasma) at day 1 and 7 No 0
healthy vo InterventioEvaluation of the effect of the proton-pump Yes 0
COVID-19;UInterventioPrognosis and epidemiology of COVID-19 in Yes 0
SARS CoV-2Interventi Validation of a new detection method for S No 0
Pneumoni
a in
COVID
infection
# Multi
organ
failure,
sepsis InterventioSeverity levels of COVID pneumonia and mortNo 0
;J12.8 - O InterventioCohen`s kappa regarding the binary outcomeNo 0
;F32.0 - Mi InterventioDepressive Symptoms, Patient Health Questio Yes 0
;U07.1 - E InterventioAssociation between coagulation alterationsYes 0
Behavioral InterventioThe primary outcome Behavioral intent to upYes 0
;U07.1 - E InterventioInvasive or non-invasive ventilation within Yes 0
;J12.8 - Ot InterventioAssociation of biomarkers with incidence an No 0
;U07.1 - E InterventioTrying to identify the risk/risk factors for Yes 0
ICD: U07.1 InterventioFrequency of hospitalization with a continuoYes 0
;U07.1 - EmInterventioCorrelation of the cumulative 7-day amplit Yes 0
painful po InterventioPain development during the corona crisis.< Yes 0
SARS-
CoV-2
infection
COVID-19
disease;U
07.1 -
Emergenc
y use of
U07.1 Interventio1. SARS-CoV-2 infection associated symptomsYes 0
;J12.8 - Ot Interventi The aim of this project is to characterize th Yes 0
COVID-19;UInterventioPoint estimates of sensitivity and specificit Yes 0
Challenges InterventioThe aim of this project is to conduct a regul Yes 0
;U07.1 - E InterventioThe study determines if the test identifies Yes 0
Covid-19 d InterventioThe primary endpoints are composed of admiss No 0
oncologicalInterventi Psychological distress and behavioural chan No 0
;U07.1 - E InterventioTo identify independent predictors of outco No 0
;U07.1 - E InterventioSeroconversion (IgG) with quantitiative ELIS No 0
Worry InterventioWorry: Penn State Worry Questionnaire: Meyer Yes 0
;U04.9 - Se Interventi measurement of transpulmonary pressure, end Yes 0
psychologi InterventioThe primary outcome is psychological distre Yes 0
SARS-CoV-2Interventi IL-6 at 72 hours after initiation of vv-ECMO No True parent
COVID-19;UInterventioThe primary endpoint i4/6/2020 No 0
;U07.1 - E InterventioThe aim of the study i ### No 0
;U07.1 - E InterventioIt is an explorative study to get better unde No 0
;J06.9 - Ac Interventi incidence of a severe COVID-19 infection (hosNo 0
PsychologicInterventioPrimary Outcomes are the working conditions Yes 0
;U07.1 - EmInterventi regional distribution of ventilation Yes 0
;U07.1 - E InterventioHow many employees develop a COVID-19 pos No 0
Fitness tra InterventioPhysical and mental well-being assessed wit Yes 0
;J12.8 - Ot Interventi genetic and epigenetic risk profiles Yes 0
Acute injurInterventioTotal number of emer 6/2/2020 No 0
U07.1 COVIInterventioHospitalization due to COVID-19 No 0
NON CLINI Interventi Increases in automaticity of hand washing in Yes 0
Psychiatric InterventioOpinions and personal situation of patients Yes 0
;U07.1 - E InterventioSensitivity and specificity of 3 commerciall No 0
;U07.1 - E Interventi Rate of seropositive pregnant women in pre No 0
;U99.0 -;U InterventioPeriod prevalence of infection with SARS-CoVYes 0
;U07.1 - EmInterventioMortality from Covid-19 and influenza in hosYes 0
U07.1 COV InterventioAnalysis of immune reactions in combinationNo 0
;U07.1 - E InterventioDescriptive evaluation of the DURO-SIN concNo 0
;E87 - OtheInterventioabsolute numbers and dynamic of sodium leYes 0
COVID-19;UInterventi 1. Support of clinical research (e.g. progno No 0
PNEUMONIE, Interventio Err:508 ### No 0
;U07.1 - E InterventioRetrospective observation of the course of aNo 0
;H33.0 - ReInterventioRate of patients indicating a delay in Trea Yes 0
;U07.1 - E Interventi WHO scale for clinical improvement on day No 0
;H90.5 - Se InterventioComparison of different aspects of rehabili No 0
;D37.0 - NeInterventioAnalysis of ressources in the ENT departemeYes 0
COVID-19 #Interventi sero-prevalence and -incidence of SARS-CoVNo 0
;U07.1 - EmInterventioAcute kidney injury ### No 0
U07.1 COVIInterventioA COVID-19 infection leads to functional chaYes 0
COVID-19 l InterventioAre there parameters to discriminate betw No 0
;U07.1 - EmInterventioPrevalence of neuromuscular symptoms afterYes 0
inpatients InterventioAssessment of the mental stress caused by vis No 0
Persons in InterventioSubjective well-being, psychological and ph No 0
;U07.1 - E InterventioLeft and right ventricular ejection fraction Yes 0
U07.1 COV Interventi Determination of SARS-CoV-2 antibodies in HNo 0
Covid-19 Interventiocombined clinical improvement (7-category ord Yes 0
;F42 - Obs InterventioFeasibility and acceptance of the program, a Yes 0
SARS-CoV-2InterventioAge-group specific prevalence of antibodies Yes 0
;F42 - Obs InterventioExploration of the impact of the COVID-19 Yes 0
physical actInterventioPhysical activity questionnaire in minutes p Yes 0
COVID-19;UInterventioOutcome of mother and child after SARS-CoVNo 0
;U07.1 - E InterventioIn-hospital mortality No 0
COVID-19 InterventioAnalysis of the presentation form of the SARNo 0
PrevalenceInterventioThe primary goal of the ArcHIV substudy is t Yes True parent
Depression,InterventioChange in psychopathology (PHQ-D, PCL-5, PNo 0
Post-exposThis will b Number of participants symptomatic for COVI Yes 0
COVID-19. InterventioClinical recovery (composite) within 14 days Yes 0
covid-19. <InterventioRate of O2 saturation. Timepoint: 1-3-5-7- No 0

corona viruInterventioTime to clinical improvement defined as starYes 0
COVID-19. InterventioTemperature. Timepoint: 0-1-2-3-4-7-14 dayYes 0
COVID-19. InterventioTemperature. Timepoint: 0-1-2-3-4-7-14 dayYes 0
Covid-19. <InterventioTime to clinical improvement defined as sta Yes 0
COVID-19. InterventioAdmission to intensive care unit. Timepoint Yes 0
COVID-19. Interventio-Clinical symptoms including fever, cough, s No 0
COVID-19. InterventioInfection duration. Timepoint: during stud Yes True parent
COVID-19. InterventioMeasurement of patients fever. Timepoint: Yes 0
COVID-19 dInterventioRadiographic features Findings. Timepoint: No 0
Covid-19. InterventioNumber of breaths per minute. Timepoint: Bef
No 0
COVID-19 dInterventioRadiographic features findings. Timepoint: No 0
Mortality InterventioTime for mechanical ventilation. Timepoint: No 0
COVID-19. InterventioAffected by COVID-19. Timepoint: Sign of COV Yes 0
Acute RespInterventioAdverse events assesment. Timepoint: At theNo 0
COVID- 19.InterventioLength of hospitalization. Timepoint: Hospit No 0
COVID-19. InterventioRT-PCR test.IL-6,CRP. Timepoint: at the be No 0
Covid -19. InterventioPerceived Stress. Timepoint: At the beginninNo 0
Covid-19. InterventioPatients' mortality rate. Timepoint: During Yes 0
COVID-19. InterventioOxygenation. Timepoint: During 10 days fromNo 0
COVID-19 diInterventi Fever. Timepoint: Before and after treatme No 0
covid-19. <InterventioFerritin changes. Timepoint: Daily. Method No 0
CoronaviruInterventioCOVID-19 infection. Timepoint: Time Frame: Yes 0
COVID-19. 200 mg int Incidence of death during the study. TimepoYes 0
COVID-19 DInterventioDyspnea grade. Timepoint: Dyspnea grade be No 0
COVID-19. InterventioNo fever for 3 days. Timepoint: Daily. Met Yes 0
COVID19. Immune Glob Increasing of patient's O2 saturation above No 0
COVID-19 DInterventioScore of Fatigue Severity "Visual Analogue F Yes 0
COVID-19. InterventioBlood oxygen saturation level. Timepoint: 0 No 0
covid-19. Patients wiOxygenation. Timepoint: Up to four days af No 0
Covid-19. InterventioBlood lymphocytes. Timepoint: Befor enteri Yes 0
COVID-19. InterventioSymptoms of corona-virus. Timepoint: Day 5No 0
Pulmonary InterventioHospitalization outcome. Timepoint: Last dayNo 0
Covid-19. InterventioWeaning time of ventilator. Timepoint: Bef No 0
COVID-19 pInterventioBlood pressure. Timepoint: Before interven Yes 0
COVID-19. InterventioClinical symptoms ( presence and severity o Yes 0
COVID-19. InterventioDeath. Timepoint: Up to 28 days after starti No 0
COVID-19. InterventioTempreture. Timepoint: Daily. Method of m No 0
COVID19. <b InterventioImproving the psychological states of patie No 0
COVID-19. <InterventioThe age-adjusted incidence of COVID-19 in vYes 0
COVID-19 dInterventioBody temperature. Timepoint: Before interv No 0
PneumoniaInterventioTime to clinical recovery. Timepoint: Contro Yes 0
Severity of InterventioSeverity of disease. Timepoint: before int No 0
covid-19 d InterventioInvestigation of mortality rate of CIVID-19 p Yes 0
COVID-19. InterventioNeed to mechanical ventilation. Timepoint: Yes 0
COVID-19. InterventioThe primary outcome was defined as the Time Yest 0
COVID-19. Interventi Hospitalization period. Timepoint: Hospital No 0
COVID - 19 Interventi Recovery trend. Timepoint: At baseline and Yes 0
COVID-19. InterventioLength of stay in the intensive care unit. No 0
COVID-19 dInterventi Body temperature. Timepoint: Before interv No 0
Condition 1InterventioOxygen saturation. Timepoint: Clinical exam No 0
covid 19. InterventioShortness of breath, medicine, dry cough, c No 0
COVID-19 pInterventi Need for invasive mechanical ventilation. No 0
COVID 19 PInterventioThe amount of lung involvement in a CT scanNo 0
Covid-19. Use plasmap Oxygen percentage. Timepoint: One day befoNo 0
Covid-19 d InterventioRespiratory symptoms and pulmonary function Yes 0
COVID-19. Interventi White blood cells (WBCs). Timepoint: BaselinYes 0
covid19. < InterventioImproving the clinical course. Timepoint: Da No 0
COVID-19. InterventioOxygen saturation following combination theYes 0
covid-19. <InterventioImprove oxygenation. Timepoint: 0,1,2,3,7a No 0
COVID-19. InterventioSerum CRP level. Timepoint: Before-After i Yes 0
COVID-19. Interventi Gene expression of inflammatory cytokines iYes 0
COVID-19 pInterventioNeed for invasive mechanical ventilation. T Yes 0
COVID-19. InterventioBody temperature. Timepoint: Before interveNo 0
COVID-19. InterventioNeed to receive ICU service (occurrence of s No 0
Covid-19. InterventioMean blood pressure. Timepoint: At 0, 30, 6 Yes 0
covid-19. <InterventioReduce the mortality rate of patients with Yes 0
COVID-19 dInterventi Reduce 3 points on clinical signs or score l No 0
covid 19. < InterventioPercentage of people improved with arbidol.No 0
Covid-19. InterventioPain in hospitalized patients based on the p No 0
COVID-19. InterventioRespiratory Rate. Timepoint: Daily. Method Yes 0
COVID-19. InterventioNo need for hospitalization. Timepoint: Duri Yes 0
COVID-19. InterventioIn this study, Sequential Organ Failure Asses Yes 0
;Certain in Drug : inte Rate of SA ### No 0
Mental Dis Online survName: Mental disorders (Depression; anxiet No 0

COVID-19 <Local standName: All-cause mortality, subdivided by se Yes 0
COVID-19 Interventiosafety, efficacy Safety : Incidence and se Yes 0
COVID-19 patients < Evaluate the positive match rate, negative Yes 0
Novel CoroDosing and-The overall objective of the study is to eva Yes 0
patients i oral adminiexpected value and 95% CI of ratio of C-reac Yes 0
COVID-19 CiclesonidePneumonia incidence on day 8 of ciclesonideYes 0
CoronaviruCOVID-19 pTime to alleviation of body temperature, Sp Yes 0
COVID-19 inUsing an u (1) Stable usage rate 24 hours after the sta Yes 0
COVID-19 i Immediate Proportion of subjects with clearance of S Yes 0
COVID-19 Teprenone Intubation rate Yes 0
COVID-19 infection The positive rates of ### Yes 0
medical staff engage The change of COVID-1 ### Yes 0
COVID-19 SARS-CoV-2 positivity ### Yes 0
COVID-19 We reduce Plasma
t cytokine levels ### Yes 0
COVID-19 To assess the change ### Yes 0
novel coronavirus (COThe implementation r 7/3/2020 Yes 0
COVID-19 Duration: Plasma cytokine levels ### Yes 0
COVID-19 to assess parental at ### Yes 0
COVID-19 Total number of COVID ### Yes 0
COVID-19 Using the l Plasma cytokine levels ### Yes 0
COVID-19 The positive rate of P ### Yes 0
COVID-19 To assess ### ### No 0 Yes
Patients diagnosed wi Changes in various blo ### No 0
Participants who rece The positive rate of CO ### Yes 0
COVID-19, CadiovasculIn-hospital death ### Yes 0
Mild cases One drop oftime to recovery, def ### Yes 0
COVID-19 Survival rate ### No 0
COVID-19 Pathological results ( ### No 0
COVID-19 Correlation between b ### No 0
COVID-19/SARS-nCoV evaluation of changes 6/7/2021 No 0
Healthy workers Stress responses, Men ### Yes 0
CoronaviruBoth COVID-
We examine the distrib ### Yes 0
 Covid ;Chloroqui Status on 7-point ordinal scale Yes 0

 COVI ;Placebo;MSerologic evidence of infection Yes 0
 COVI ;IHP Detox The mean time to negative test to COVID-19 Yes 0
 COVI ;Folic acid a.The conversion of health care https://me Yes 0
 COVI ;Hydroxychlâ€¢Pneumonia â€¢Acute respunder consYes 0
 COVID;COVID19 v1. Occurrence of serious adverse https://we Yes 0
 Respi ;HydrochloPercentage of patients with undetectable viraYes 0
 Respi ;IFT WITH PULMONARY FUNCTION TEST Will be av Yes 0
 COVI ;Isotonic S This project will provide a better understa No 0
COVID19 <bGroup 1: RePeak Expiratory Flow (PEF). The evaluator wiNo 0

VolunteersInitially, It is expected that social isolation will hav No 0
Severe acu A total of Reduction in in-hospital mortality in 5%, ver Yes 0
Covid-19; Initial sa Better results with reduced morbidity and mNo 0
CoronavirusSubjects 18We anticipate a reduction in the total durat Yes 0
non specifi 1. Control Negative viral load; RT-PCR was taken from aNo 0
CoronavirusWhen renalControl groups and intervention groups will No 0
CoronavirusHyperimmune Temporal improvement in inflammatory biomar No 0
Acute renalOne group A o ssess the presence of acute kidney injury. TNo 0
CoronavirusAfter PHASECardiovascular health profile: in Phase 1 (H Yes 0
non specifi 1. Control Evaluate patient's health condition after 15 Yes 0

RespirationInterventioAssess need for hospitalization due to a COVYes 0
Severe AcuThe only inIt is expected to find new sites for the pass No 0
covid-19
acute
respirator
y distress
syndrome
 Coro
navirus as
the cause
of
diseases
classified
to other
chapters ;
A00-
B99;Coro
navirus as
the cause
of
diseases
classified
to other
chapters Patients wiEvaluation of gas exchange between D0 / D4Yes 0
CoronavirusThis projec Overall survival of patients who started tre No 0

Severe AcuThere is nothe number (proportion in%) of deaths;the No 0
Contacts a - Control G Activation ### ### No 0
patients i Group A: H1) Virologi ### ### No 0
Pharmacody Group I: ReLevels of l ### 6/9/2020 Yes 0
COVID-19 Patients tr Disease pro ### ### Yes 0
Prevention Group I: Bi Adverse Eve ### ### No 0
severe SA TREATMENT Reduction
S o ### ### No 0
COVID-201The homeopa Safety (Saf ### ### No 0
COVID-19 reGroup CIGB- Mortality o ### ### No 0
COVID 19 Study Group EIndicators ### ### No 0
ImmunosenesInmuno-1: ILymphocyte ### ### No 0
Immune resGroup 1 ExpHemogram ( ### ### Yes 0
Confirmed Group I (exReduction o ### ### Yes 0
Patients w IFN-?2b 3 mProportion ### ### No 0
Prevention BiomodulinRespiratory 8/1/2020 ### No 0
Covid 19 Group 1 (ExReal-time p ### ### Yes 0
DepressionMental HealDepression Score [Time ### Yes 0

COVID-19
pneumon
ia
Endotoxe
mia
 COVI
D-
19 En
dotoxemi
a Circ
ulating
bacterio
me;COVI
D-
19 En
dotoxemi
a Circ
ulating
bacterio
me Patients d Endotoxin level [Timef ### No 0
COVID-19 <Supportive Time to improvement i ### Yes 0
Antibody
for Covid-
19
RT-PCR
for Covid-
19
Ethical
issues in
implemen
tation of
Rapid
antibody
test kit of
Covid-19
 Coro
navirusCOVID-
19
 COVI
D-19
diagnositc
testing EthicsPande
mic S
ARS-CoV-
2
 ;Coro
navirusCOVID-
19
 COVI
D-19 d Person whoAntibody to Covid-19 in ### No 0
Healthcar
e workers
General
public
 Ment
al
health Psychos
ocial
problems
 Healt
hcare
workers Gener
al
public Coronavi
rus C
OVID-
19;Menta
l
health Psychos
ocial
problems
 Healt
hcare
workers Gener
al
public Coronavi
rus C
OVID-19 The survey Mental health problem ### No 0
COVID-19
ARDS
 COVI
D-
19 AR
DS Pn
eumonia Hemo
adsorptio
n IL-
6;COVID-
19 AR
DS Pn
eumonia Hemo
adsorptio
n IL-6 HA330 hemop
28-day mortality [Time5/1/2022 Yes 0
Health
care
personnel
in the
endoscop
y unit
Patients
who will
be
performe
d
endoscop
y
procedur
es
 healt
hy he
alth care
personnel
 endo
scopy Covid-
19 ra
pid
test a
ntibody;h
ealthy health
care
personnel
 endo
scopy Covid-
19 ra
pid tes Health car Antibody to Covid-19 i ### No 0
Household ChloroquinSeroconversion of SAR ### Yes 0

Illiterate
Serious
illness
 Socia
l, Ethical,
Behaviour
al, Novel
coronavir
us,
Pandemic
;Social,
Ethical,
Behaviour
al, Novel
coronavir
us,
Pandemic
About 600 oCorrelation between CO ### Yes 0
Prepared
ness and
responsiv
eness of
french
Hospital
and ED by
electronic
survey.
Head of
Emergenc
y
Departme
nt will be
questionn
ed.
 Covid
-19,
Prepared
ness,
Responsiv
eness,
Emergenc
y, Quality,
Organizati
on,
Formatio
n,
Resources
,
Managem
ent,
Interoper
abi Head of dePrepredness measureme ### Yes 0
Covid-19 c Patients suED time interval [Time ### Yes 0

-B342
Coronavir
us
infection,
unspecifie
d site
 Coro
navirus
infection,
unspecifie
d
site;B342;
Coronavir
us
infection,
unspecifie
d site Group name:
Outcome name:Ratio of the number of deathNo 0
COVID-19 Drug: Sari Percent change in C-reactive protein (CRP) leYes 0
Corona ViruDrug: Hydr Rate of decline in SARS-CoV-2 viral load Yes 0
SARS-CoV- Behavioral Primary composite rate of intensive care uni Yes 0
SclerodermOther: SPI Anxiety: Patient-Reported Outcomes MeasurYes 0
COVID-19;PDrug: Toci Percentage of patients with normalization o Yes 0
Social Isol Other: Vid World Health Organization Quality of Life QuYes 0
Covid19 Drug: Atov Virology Cure Rate Yes 0
COVID19 Drug: Hydr Recruitment Feasibility;Recourse utilization Yes 0
COVID;HypOther: Sta Change in O2 output Yes 0
Pneumonia,Biological Number of mechanical ventilation days. Yes 0
CoronaviruDrug: HoneDays required to get a positive COVID-19 PC Yes 0
COVID-19 Biological Intubation or death in hospital Yes 0

COVID-19 Registry Data Yes 0
COVID-19 Device: Q- Metabolic and Nutritional Needs of COVID-1Yes 0
GynecologiOther: modpercentage of patients with a change in th Yes 0
Covid-19 Other: Dis Days alive and out of hospital within 14 daysYes 0
Systemic Lupus Eryth prevalence and severity of Covid-19 infectionYes 0
ALL, Adult Automated Self-Administered 24-Hour Dietary

Yes 0
COVID 19 Drug: 1: I The PaO2/FiO2 ratio at D11 Yes 0
COVID-19; Drug: Toci serum interleukin-6 and soluble interleukin- Yes 0
Sars-CoV2 Drug: ALL Safety of the administration of allogeneic m Yes 0
COVID;RT-dDiagnostic Number of positive patient using saliva me Yes 0
COVID-19 Procedure:Clinical worsening (yes/no) of the patient Yes 0
SARS-CoV-2Biological Percentage of participants reporting local r Yes 0
COVID-19 Biological Rate of patients achieving improvement in clYes 0

Emergenci Other: REC Describe the characteristics of patients admitted
Yes to reCOP units according
0 to their virological status vis-
COVID-19 Corrected QT (QTc) interval measurement Yes 0
COVID-19; Drug: Hydr Cohort A: Percentage of COVID-19 exposed he

Yes 0
Corona Vir Drug: High Transfer to ICU;28 day mortality Yes 0
Covid-19 Drug: ACE extend of lung involvement;oxygen saturati Yes 0
Severe AcuDevice: He Ventilator-Free Days (VFD) Yes 0
COVID-19 Drug: Azit Proportion progressing to respiratory failure Yes 0

Cancer Other: sur patients' and survivors' perspective of thei Yes 0
Sars-CoV2 Diagnostic Anti-SARS-Cov2 seroconversion between DayYes 0
COVID-19;ADrug: Doci Proportion of participants who are alive and Yes 0
CardiovascuOther: Digi MACEs Yes 0
COVID;AcutDevice: He Ventilator-Free Days (VFD) Yes 0
Covid-19;ADrug: HepaMean daily PaO2 to FiO2 ratio Yes 0

Sars-CoV2 Drug: Enox Composite outcome of arterial thromboembol
Yes 0
Corona Virus Disease Evaluation of lymphocyte subsets in patientsYes 0
COVID;CoviDrug: APL- Cumulative incidence of treatment-emergenYes 0
COVID-19;CDrug: HydroProportion of participants who were hospitaYes 0
COVID 19 Other: Sur Personal protection measures Yes 0
Sars-CoV2 Diagnostic Proportion anti-SARS-CoV2 seropositive Yes 0
COVID-19 PDrug: Iver Remission of cough;Remission of fever;Virol Yes 0

Sars-CoV2 Other: Clin Induced SARS-CoV2 immunity;Long-term prote
Yes 0
Covid19 Other: RelaDevelopment of a tool to measure frailty Yes 0
Covid-19;AProcedure:Mechanical ventilation Yes 0
CoronaviruBehavioral Mortality;Mortality-suicide Yes 0
COVID-19 Biological: Time elapsed until clinical improvement or hYes 0

COVID-19 Device: N-9Exercise Capacity Yes 0
CoronaviruDrug: BudeEmergency department attendance of hospita

Yes 0
COVID 19;DOther: DescNumber of hospitalized patients Yes 0
Corona Vir Drug: Nafa Proportion of patients with clinical improv Yes 0
Coronavirus Number of death from any cause, or the need

Yes 0
Covid 19 Other: pat IgA specific cells of SARS Yes 0

Covid-19 Diagnostic Vital status;Patient requiring more than 3 l Yes 0
COVID-19 Identification of markers associated with as Yes 0
COVID-19 Device: VieTime to recovery Yes 0
COVID-19 Biological Intubation or death in hospital Yes 0
Pneumonia,Biological Time to weaning of oxygen support Yes 0
COVID;PregDiagnostic Presence of COVID-19 virus Yes 0

Neurologic Other: furt Prevalence of neurological complications;PreYes 0
COVID-19;EProcedure:30-day mortality Yes 0
COVID-19;SDrug: Part Part 1 - Recommended dose of TL-895;Part 2Yes

- 0
Covid-19 Other: Vir 28 Day Patient Satisfaction Questionnaire Yes 0
COVID Dietary Su Seroconversion of IgM for COVID-19. Yes 0
Melanoma Behavioral:Change in SSE performance;Identification of Yes 0

Coronavirus Infection origin of the ICU beds created during the C Yes 0
Pulmonary Embolism; Prevalence Yes 0
COVID;KidnOther: Mai Change in IL-6 concentration from baseline tYes 0
Covid19 Radiation: Radiological response;Radiological response Yes 0
DepressionOther: Sur Academic Self-Concept Scale Score;PHQ-9 S Yes 0
COVID-19 Acute myocarditis;Multi-systemic inflamma Yes 0

COVID liver disease Yes 0
COVID Dietary Su Diarrhea Yes 0
Exercise;D Other: HIT Body composition Yes 0
COVID-19;SBiological: COVID-19 Convalescent Plasma Yes 0
Covid19;CoDietary S Prevention of COVID-19 Yes 0
COVID-19;CCombinatioThe proportion of subjects who died or had rYes 0
COVID-19 Drug: LactoTime to clinical improvement Yes 0

COVID-19 Diagnostic Establishment of a clinical basis for to desc Yes 0
Corona Vir Drug: Hydr Ordinal Scale of COVID19 Disease Severity a Yes 0
COVID-19 COVID-19 Positive Case;COVID-19 Positive C Yes 0
Cardiovascular Risk F Change from Baseline Burnout at 2-3 monthsYes 0
Coronavirus Infection;Assessing the QT and QTc interval in patient Yes 0
COVID-19;PDiagnostic Mortality;Level-of-care Yes 0
Spinal Cord Injuries NIH Toolbox Instrumental Support Survey - Yes 0

Covid19;COBiological: All-cause mortality Yes 0
Corona Virus Infecti length of hospital stay Yes 0
Viral Infec Other: QueThe number of pregnant women who have kYes 0
COVID 19 Drug: BromChange from baseline in clinical assessmen Yes 0
Cancer;CO Other: Exe Physical Function Yes 0
Respirator Device: Hy Targeted temperature compliance Yes 0
Pneumonia;Drug: Inha Acute respiratory failure (ARF) Yes 0

COVID19;CoDrug: Chlo Number of symptomatic COVID-19 infection Yes True parent
COVID-19 Biological: Change in Clinical Condition Yes 0
Corona ViruDrug: ColchNumber of participants who die or require h Yes 0
Prone Posi Device: higTreatment failure;Intubation rate Yes 0
COVID-19 Drug: Toci Clinical response;Biochemical response Yes 0
Sars-CoV2 Drug: BLD- Time to recovery;Change in oxygenation Yes 0
Acute RespDrug: Valsafirst occurrence of intensive care unit admis Yes 0

Covid19;MaOther: newEvaluation of apgar status of newborns fromYes 0
Corona ViruDrug: NORSPrevention Study: Measure the effect of NORYes 0
COVID-19 Diagnostic Comparison of the proportion of patients claYes 0
COVID-19 Drug: TraneHospitalization Yes 0
CoronaviruDrug: TJ00 Proportion (%) of subjects experiencing deteYes 0
Dysfunctio Behavioral:â€¢ Covid-19-adapted version of the self-ra Yes 0

Coronavirus;COVID Seroprevalence of SARS-CoV-2 infection in t Yes 0
CoronaviruDrug: Plac Clinical Improvement as assessed by change Yes 0
COVID-19 Burnout;Emotional Distress;Insomnia Yes 0
Viral Pneu Drug: Pred Number of patients with a theoretical respi Yes 0
COVID-19 Device: Ae Total Leak Volume of Non Invasive Ventilat Yes 0
Coronavirus Disease Identification of eligible donors and collec Yes 0
CoronaviruDrug: Hydr Time to clinical improvement of at least 1 le Yes 0

Patient Saf Other: GPs Describe patient safety incidents (types, seveYes 0
COVID Drug: FavipTime until cessation of oral shedding of SAR Yes 0
COVID-19 Drug: Susp Sequential Organ Failure Assessment (SOFA)Yes 0
CoronaviruDrug: Plac All-cause mortality at Day 28 Yes 0
COVID-19 Drug: Nita Viral load Yes 0
Patient Saf Other: PrimDescribe patient safety incidents (types, seveYes 0
CoronaviruBiological: Incidence of invasive mechanical ventilation Yes 0
SARS CoronOther: Stu Identification of factors associated with (i) i Yes 0

SARS-CoV- Drug: ACE iCombination of maximum Sequential Organ Fai
Yes 0
New Corona
Other: blo Level of IFN-gamma after a non-specific sti Yes 0
COVID-19 Biological: Time to disease progression Yes 0
Corona Vir Dietary Su Proportion of participants with an occurrencYes 0
CoronaviruDrug: iNO (inhaled nitric oxide) delivered via the INOpu Yes 0
COVID-19 Collection of convalescent plasma Yes 0
BudesonideDrug: BudePatient with more than 2 points on the OD Yes 0

PneumoniaDrug: CanaNumber of patients with clinical response Yes 0
Chronic Fa Other: Quesvoluntary maximum force reduction Yes 0
SARS-CoV Other: QueHealth-related quality-of-life Yes 0
Covid-19 Drug: AnakiBiological criteria Yes 0
SARS-CoV Biological Safety: Incidence of Adverse Events and Seri Yes 0
COVID Radiographic findings and their temporal ch Yes 0

Acute RespDevice: V/ Change in Arterial Oxygenation Levels Yes 0
CoronaviruDiagnostic Hospitalisation Yes 0
Severe AcuBiological Percentage Mechanical Ventilation, hospitaliYes 0
ARDS, HumDrug: BovinAdverse events (patient) - Decrease in oxyg Yes 0
COVID-19 Drug: Cicl Percentage of patients hospital admission o Yes 0
Pneumonia;Diagnostic Evaluate the correlation between standard Yes 0

Severe or Drug: Siru Time to Improvement of at Least 2 Categories
Yes 0
COVID-19 Device: EmeCompletion of 1-minute test;Completion of Yes 0
CoronavirusDrug: Inha Change in the scale of ordinary COVID result Yes 0
CoronaviruOther: QueDescribe medications used prior to admissionYes 0
Myeloproliferative N pulmonary embolism (PE) Yes 0
COVID-19;RDevice: Ac Time until discharge Yes 0
COVID 19 Drug: Oral COVID-19 (SARA-Cov-2) infection;Severity o Yes 0

Acute Respiratory Di Performance (discrimination / calibration) o Yes 0
COVID;ARDBiological: Number of ventilator free days Yes 0
COVID-19;DyspareuniaEvaluation of pregnant women diagnosed wiYes 0
COVID-19;Prenatal CarEvaluation of pregnant women diagnosed witYes 0
COVID-19;CDevice: CO Mechanically ventilated patient outcome Yes 0
COVID-19 Drug: Hydr Mean days of hospital stay;Rate of Respirat Yes 0

Visual Imp Other: NonBest Corrected Visual Acuity (BCVA) Per Eye Yes 0
Coronavirus Infection Identify antibodies Yes 0
Depression;Other: Onl Sociodemographic information form;Zung Depr

Yes 0
CoronaviruDrug: GrouHierarchical composite endpoint composed of

Yes 0
CoronaviruBiological Admission to ICU and/or mechanical ventilatYes 0
COVID 19; Drug: MavrProportion of subjects alive and off of oxyge Yes 0
COVID-19; Diagnostic Is there an increased prevalence of venous Yes 0

SARS-CoV- Other: SamHumoral responses to peptide antigens derivYes 0
COVID-19 Procedure:Immune responses to components of SARS-CYes 0
Immunosuppression To define the role of household contact wit Yes 0
COVID-19;PDiagnostic the factors affecting prognosis in pregnan Yes 0
COVID, CorDevice: Hy Oxygenation index;SpO2 Yes 0
Mental HeaOther: StafWarwick-Edinburgh Mental Wellbeing Scale Yes 0

COVID-19 Drug: PovidEarly Viral Clearance Yes 0
Corona ViruDiagnostic Global symptom load (Anxiety, SomatisationYes 0
COVID-19 Drug: TofacClinical status using ordinal scale Yes 0
COVID;IsolaOther: Onl Exercise Benefits and Barriers Scale;Sociod Yes 0
ST Elevate Device: Pe Number of patients undergoing primary angiYes 0
COVID;PneuRadiation: blood oxygen saturation level;Torax X-ray Yes 0

CoronavirusDrug: OpagEvaluation of the total oxygen requirement Yes 0
Covid19 Drug: Isofl Hospital Mortality;Ventilator-Free Days;ICU- Yes 0
Covid-19 Study of the evolution of pregnancies in t Yes 0
SARS-CoV-2Drug: Colc Number of participants who die due to COVID

Yes 0
Covid-19 Drug: BemiProportion of patients that worsen Yes 0
Parkinson Other: VideQuality of life (QoL);Depressive symptoms - GYes 0

COVID-19 Biological: oxygen Yes 0
Fibromyalgia, Primary Number of FM patients Yes 0
Covid 19 covid 19 serology;risk factors for positive se Yes 0
Emergenci Other: REC Develop a predictive model of the risk of b Yes 0
Pneumonia,Diagnostic Alteration of the DLCO Yes 0

SARS-CoV-2;COVID-19Change in the partial pressure of oxygen/fra Yes 0
COVID-19 Drug: Imat Primary endpoint: Disease Progression Yes 0
End Stage Renal DiseaQualitative assessment of the effect of COVIDYes 0
Change; EnProcedure:death in time of observation Yes 0
Face-to-fa Other: Far Re-consultation Yes 0
SARS-CoV- Other: Act Serum levels of cytokines and chemokines;S Yes 0

Severe AcuOther: No COVID-19 probable or confirmed case Yes 0
covid19 Drug: Nita Viral load Yes 0
COVID-19;CDevice: CO Mortality outcome Yes 0
COVID 19 Other: COVEstimate the prevalence of COVID-19 infecti Yes 0
COVID;CoroBiological: Describe the serological status of individual Yes 0
Coronavir Other: Remo

change in carbon dioxide elimination (VCO2)Yes 0
COVID;PostBehavioral Number of patients with diagnosis of PTSD. Yes 0
COVID-19 Other: PronIncidence of intubation Yes 0
COVID-19 Diagnostic Invasive respiratory support in patients wit Yes 0
COVID-19 PDrug: Dipy Coagulation system Yes 0
Sars-CoV2 Other: ObseCovid19 infection clinical evolution Yes 0
Bariatric S Other: HomChange from baseline on waist circumferencYes 0

Covid19 Other: Oth Fever Yes 0
Infertility Diagnostic Presence or absence of SARS-CoV-2 in follic Yes 0
Coronavir Drug: DarunTime to Clinical Improvement and/or VirologYes 0
COVID-19 Drug: FavipTime from randomization to clinical recover Yes 0
Advanced Su
Other: Lea Retention of the correct technique for runni Yes 0
COVID-19 Drug: Infli Time to improvement in oxygenation Yes 0

COVID-19 Drug: REG Proportion of patients with treatment-emergYes 0
Covid19 Drug: Iver to evaluate the role of Ivermectin as a line Yes 0
CoronaviruDrug: MK-5Number of Participants Who Experience an AYes 0
COVID-19 Drug: FNC+Change (reduction) in viral load from baseli Yes 0
Sars-CoV2; Biological Mortality;Adverse events;ICU admission;MecYes 0
COVID-19; Diagnostic Presence of antibody Yes 0
COVID Biological Efficacy of convalescent plasma in severe COV

Yes 0
Sars-CoV2; Other: PR Serological immune status to an infection b Yes 0
Brain Injuries;Stroke;SChange in Fear of COVID-19 Yes 0
COVID-19 Other: HypSevere Covid-19;Severe Covid-19 with pulm Yes 0
COVID-19; Drug: CYT1Improvement of the absolute lymphocyte coun

Yes 0
COVID-19;Sars-CoV2 Identification of genetic factors determining Yes 0
Sars-CoV2; Other: que the number of patients with severe Covid-1 Yes 0
Sars-CoV2 Diagnostic Seroprevalence;seroconversions Yes 0

Covid 19;S Other: comChange in patient-reported Emotional SupporYes 0
Anxiety;DepBehavioral Change from baseline on an aggregate measuYes 0
COVID 19 Device: en Viral load measured in tracheal aspirate 72 hYes 0
COVID-19 Drug: REG Proportion of patients with treatment-emergYes 0
Nurse Device: AR Evaluate the feasibility of the use of an ARF Yes 0
Infectious Disease;Ca Proportion of patients, at each sample timepYes 0
covid19 Other: InveIdentification of demographic and clinical fa Yes 0

covid19 Other: PredIdentify risk factors for intra-hospital mortal Yes 0
Covid-19 Analysis of the rate of RT-PCR SARS-CoV-2 p Yes 0
Hearing ImDevice: Bo acceptability of management strategy, ques Yes 0
STEMI MACE (major adverse cardiovascular events)No 0
COVID-19 Drug: Stan 30-days survival Yes 0
COVID Biological: To evaluate the safety of a therapeutic Covi Yes 0

DepressiveBehavioral Depression severity Yes 0
COVID-19 Biological: Tolerability and acute safety of AdMSC infu Yes 0
IntracraniaDevice: Ce Detection of cerebral compliance impairmenYes 0
CoronaviruBiological: Number of participants with treatment-rela Yes 0
COVID-19 Biological: Clinical deterioration or death Yes 0
COVID-19 Biological: Patients requiring mechanical ventilation or Yes 0
COVID-19 ina) Hydroxy Incidence of COVID-19 using standard PCR anYes 0

Infectious Phase 1 med
Clinical safety assessment will be performed Yes 0
COVID-19; Subjects wiTo assess the safety and tolerability of SAR Yes 0
Airborne trWe will perFit test re ### 6/5/2020 No 0
COVID-19 re 8 million a ventilator free days score (VFD, composite o Yes 0

Atrial fibr Our primaryPrimary Outcome- the impact of the COVID-1Yes 0
Patients wiThe researc Gen ### No 0

COVID-19 (All partici Userâ€™s test result 7/3/2020 No 0
Heart failu Interviews Perspectives on care p ### No 0

Respiratory Rate of intubation for ### Yes 0
COVID-19 ( Virologically confirm ### Yes 0
COVID-19 (This study Lung function for moth6/6/2022 No 0

Neurologica 1. ### No 0
Depression Self-reported depress ### Yes 0
COVID-19 ( 1. ### Yes 0

Hypercytok 1. ### No 0
A spectrum 1. ### Yes 0
COVID-19 ( Viral RNA load measure ### Yes 0
COVID-19 ( Clinical diagnosis of ### Yes 0

Serious and 1. ### No 0
COVID-19 ( Patients who die or re ### No 0
COVID-19 ( Incidence of pandemic ### No 0
COVID-19 (S Cu ### Yes True parent
Pediatric 1. ### No 0
Pneumonia 1. ### No 0
Stroke Rates of cognitive im ### No 0
Acute stro 1. 5/1/2021 No 0
Novel CoroCase serie chest CT;pulmonary function;viral nucleic aciNo 0
Novel CoroConfirmed SARS-CoV-2 RNA;SARS-CoV-2 antibodies (Ig No 0

Novel CoroCase series:mood; No 0
Novel CoroHave underEckardt score;Hospital Anxiety and DepressioNo 0

Novel CoroLaboratory Survey responses; No 0
sleep disor For the mi PSQI; No 0

COVID-19
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10038700
Term:
Respirato
ry
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducPrimary end point(s): Clinical status of subje No 0
Severe
COVID-19
Infection
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: Time to Clinical Improvement
Yes True parent
Acute
coronavir
us
disease
2019
 Med
DRA
version:
20.1
Level: PT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Primary objective: Effect of Yes True parent
Suspecte
d or
confirme
d SARS-
CoV-2
infection
(confirme
d by RNA-
PCR)
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Vir Trade Main Objective: Principal question/objectiveYes 0
Covid-19
infection
 Med
DRA
version:
23.0
Level: LLT
Classifica
tion code
10053983
Term:
Corona
virus
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: Reversal of hyperinflammatio
Yes 0
SARS-
COV-2
Infection
 Med
DRA
version:
23.0
Level: LLT
Classifica
tion code
10084272
Term:
SARS-
CoV-2
infection
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To establish the effects of Yes 0
SARS-
COV-2
infection
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10037373
Term:
Pulmonar
y disorder
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
COVID 19;Th
 Trade Primary end point(s): Hospitalisation or em Yes 0
Coronavir
us
disease
2019
(COVID-
19)
 Med
DRA
version:
20.0
Level: LLT
Classifica
tion code
10061986
Term:
SARS
System
Organ
Class:
10000000
4862
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: â€¢ To evaluate efficacy of Yes 0
Subjects
with life-
threateni
ng
COVID-19
symptom
s
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: The overall objective of the Yes True parent
SARS-
Coronavir
us 2
disease
2019
(COVID-
19)
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10084268
Term:
COVID-19
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] Trade Main Objective: To assess the safety and to Yes 0
Covid-19 p Trade Timepoint(s) of evaluation of this end point Yes 0

SARS-
COV-2
infection
 Med
DRA
version:
21.1
Level: LLT
Classifica
tion code
10037373
Term:
Pulmonar
y disorder
System
Organ
Class:
10000000
4855
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: To investigate the effect of Yes 0
COVID-19
severe
pneumon
ia, acute
lung
injury, or
acute
respirator
y distress
syndrome
 Med
DRA
version:
20.0
Level: PT
Classifica
tion code
10061229
Term:
Lung
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Disease Trade Main Objective: To evaluate the effect of r Yes True parent
SARS-
CoV-2
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] - Virus
Diseases
[C02] ProducMain Objective: To assess efficacy of the c Yes True parent
COVID 19
 Med
DRA
version:
23.0
Level: PT
Classifica
tion code
10051905
Term:
Coronavir
us
infection
System
Organ
Class:
10021881
-
Infections
and
infestatio
ns
;
Therapeu
tic area:
Diseases
[C] -
Respirato
ry Tract
Diseases
[C08] ProducMain Objective: â€¢Stage 1: To evaluate the Yes 0
Sepsis, Se Other: Pla Change in renal blood flow and renal oxygenat
Yes 0
ARDS Other: Res All-cause 60-day mortality Yes 0

COVID-19 IDrug: methLower Murray lung injury score;Lower Murray
Yes 0
CoronaviruDrug: T89 The time to oxygen saturation recovery to n Yes 0
Corona Vir Biological Change in lesion proportion (%) of full lung Yes 0
SARS-COV-2Drug: Oral SARS-CoV-2 eradication time Yes 0
COVID-19 Drug: Trea Clinical and virological outcome in exposed Yes 0
Corona Vir Drug: Losa Hospital Admission Yes 0
Corona Vir Drug: Losa Difference in Estimated (PEEP adjusted) P/F Yes 0
CoronavirusDrug: InhalCOVID-19 diagnosis Yes 0
COVID-19 Drug: PUL- Severity of COVID-19 Yes 0
COVID-19 Drug: PUL- Severity of COVID-19 Yes 0
CoronavirusOther: ObsCharacterize Patients With SARS-Cov-2 Infec Yes 0
COVID-19;En
Other: Fol prevalence Yes 0
Severe AcuDrug: MethComposite P6/4/2020 https://cl Yes 0 Yes
SARS-CoV2Drug: Remdesivir Yes 0

CoronaviruBiological Cumulative incidence of composite outcomeYes 0
CoronaviruDrug: CholcOutpatient trial - Colchicine vs. control and AYes 0
SARS (SeveOther: HumPresence of specific anti-SARS-CoV-2 antibodYes 0
Corona ViruDrug: Sari Time to improvement of 2 points in clinical Yes 0
COVID-19 Drug: Hydr Occurrence of an symptomatic or asymptoma

Yes 0
Perceived Other: "Ca Perceived Stress Scale;Perceived Stress Scal Yes 0
COVID-19 Drug: Hydr Composite of hospitalization, invasive mechaYes 0

COVID-19 Drug: Lopi Efficacy of Interventions as assessed by all- Yes 0
COVID-19 Device: G Change in Oxygen Saturation by Pulse OximeYes 0
COVID-19 Drug: Pegi Duration of Viral shedding of SARS-CoV-2 b Yes 0
CoronaviruDrug: Hydr COVID Ordinal Outcomes Scale on Day 15 Yes 0
SARS-CoV-2Drug: Chlo 28-day survival rate Yes 0
COVID-19 Drug: RhACCause of death or invasive mechanical ventilYes 0

Healthy Volunteer;Moo
NIMH COVID Study survey - adult responses Yes 0
COVID-19 Device: Lo PaCO2;Driving Pressure;Tidal volume Yes 0
ARDS, HumProcedure:28 day all cause mortality Yes 0
COVID-19 Drug: Diet Rates of hospitalization for a COVID-19 rela Yes 0
COVID-19; Drug: LY31 Number of Ventilator Free Days Yes 0
SARS-CoV-2Biological Mortality;Viral Load;Serum Antibody Titers Yes 0
SARS-CoV IDrug: MethMortality rate at day 28 Yes 0

SARS-CoV- Other: obs symptoms of COVID-19 in older patients Yes 0
COVID-19; Drug: Pegy Undetectable COVID PCR at day 7 Yes 0
COVID;Hypo
Other: PostIncidence of Mechanical Ventilation Yes 0
COVID-19 Other: Sel Change in respiratory status Yes 0
COVID Drug: Chlo Number of patients with decreased viral loa Yes 0
COVID;ARDBiological: IC14, a monoclonal antibody against CD14 Yes 0
COVID-19 Drug: Toci Entry into Intensive Care with invasive mechaYes 0
COVID Drug: ConvProportion of patients remaining free of mecYes True parent
COVID;CoroDiagnostic Immunoglobulins (G and M) to SARS-Cov2 inYes 0
COVID-19 Drug: Povi Mean change in viral titers of SARS-CoV-2 Yes 0
Covid-19;HDrug: Hydr Days alive without life support at day 28 Yes 0
COVID-19 Drug: DapaTime to first occurrence of either death fro Yes 0
COVID Drug: Iver Number of patients with virological cure Yes 0

COVID 19 Other: No Assessment of the fear levels during the CO Yes 0
Covid19;SADrug: MelaSARS-CoV 2 infection rate Yes 0
COVID19 Drug: Drug lung injury score Yes 0
COVID-19 Drug: CamoChange in SARS-COV-2 viral load Yes 0
COVID-19; Device: Co Efficacy of a L-MOD against controls receivinYes 0
Multiple Sclerosis;CO Incidence of COVID-19 Infections within an Yes 0
Immunologic
Diagnostic Number of IGg seropositive health care wor Yes 0
COVID-19 Drug: Chlo Clinical improvement Yes 0
HIV-1-infection;Canc percentage of patients who required hospitalYes 0
Corona Vir Biological: Incidence of pre-specified infusion associa Yes 0
SARS-CoV Other: pla Requirement for invasive ventilation Yes 0
SARS-CoV Drug: Toci Time to mechanical ventilation or death Yes 0
Covid19 Drug: MeasCOVID-19 disease incidence Yes 0
COVID-19 Drug: AngioAssess the rate of requirement of invasive mYes 0

HIV PatientOther: No Comparison of the incidence of COVID-19 infe
Yes 0
Severe AcuDrug: Alte PaO2/FiO2 improvement from pre-to-post inYes 0
COVID-19; Drug: Hydr Proportion of participants who died from an Yes 0
Liver InjuryOther: LiveLiver injury in patients with COVID-19 Yes 0
COVID-19 Drug: FavipTime to viral clearance Yes 0
COVID-19 Dietary Su Change in the partial pressure of carbon dio Yes 0

COVID-19 Drug: Enox Composite incidence of: all-cause mortality Yes 0
COVID 19 ADrug: Inte Mortality Yes 0
CoronaviruOther: Coll Assessment of the presence of the SARS-COVYes 0
CerebrovasOther: Best7-day length of invasive mechanical ventilat Yes 0
Cytokine S Drug: RuxolProportion of patients who die, develop respiYes 0
Burnout, P Diagnostic Prevalence of burnout among anaesthesiology

Yes 0
COVID-19 Drug: Chlo Composite endpoint with disease progressionYes 0

COVID-19 Characterize immune response Yes 0
SARS-CoV- Drug: Hydr Days to resolution of cough, fever and short Yes 0
Covid-19 Biological: Phenotype/genotype correlation research mo

Yes 0
Sars-CoV2 Drug: Toci Hematic biometry;Blood chemistry;Blood gasYes 0
COVID-19;CBiological: Score on the WHO 11-point ordinal scale for Yes 0
COVID-19 Drug: RBT- Evaluate the effect of RBT-9 versus placebo Yes 0
Corona Vir Other: Sus Median days alive and out of the hospital Yes 0
CoronavirusBiological Phase 1: Frequency and Severity of Adverse Yes 0
COVID Drug: Azit Hospital admission Yes 0
ThrombosisDiagnostic Coagulability;Coagulability;Coagulability;Co Yes 0
Pneumonia;Radiation: Rate of extubation (for intubated patients) Yes 0
Asymptomat
Diagnostic Percentage of Asymptomatic patients with aYes 0
SARS-CoV 2Diagnostic Hospital-free days to Day 28 [ Time Frame: 2Yes 0
Covid 19 Device: Ox Arterial Blood Gases (ABG): Partial Pressure Yes 0
VolunteersDiagnostic Antibodies against the SARS-CoV-2 virus in Yes 0
COVID-19 Drug: Hydr Cumulative incidence of SAEs through day 30Yes 0
COVID-19 Drug: SOC Mortality Yes 0
Hematopoie
Biological: Clinical outcome as evaluated by the 7-catego
Yes 0
ARDS;COVIOther: PSGProportion of patients with altered spleep Yes 0

Covid-19 Disease;End Rate of new Covid infection of patients and Yes 0
Mesenchyma
Biological Number of all-cause mortality Yes 0
CoronaviruBehavioral Knowledge Beliefs and Practices related to Yes 0
COVID-19;CoronavirusMolecular etiology of host susceptibility to Yes 0
COVID-19 Drug: SnPPlung injury score;Serum ferritin Yes 0
SARS-CoV Biological Cumulative incidence of hospitalization or d Yes 0
COVID;Thr Drug: Enox Venous thromboembolism Yes 0
Sars-CoV2; Other: Car Incidence of unexpected cardiac arrest Yes 0

DepressionOther: QueDepressive Symptomatology Yes 0
CoronaViruDrug: IbrutPercentage of Participants Alive and WithoutYes 0
Severe AcuBiological: Proportion of participants alive and free of r Yes 0
Transplant Other: TranCompliance precautions with COVID-19 Yes 0
COVID-19;FDrug: FavipMortality;long of hospitalization;Laborato Yes 0
Anxiety;HeBehavioral Patterns of neural connectivity as predictors Yes 0

ARDS;COVIBiological: lung injury score Yes 0
COVID-19 Drug: PlaceProportion of participants who have died du Yes 0
Kidney TranOther: PracGlobal Prevalence of COVID-19 TX;HospitalizYes 0
Pneumonia,Radiation: Efficacy of low-dose pulmonary irradiation Yes 0
COVID 19 PDrug: DFV8APACHE II severity of disease score on Day 15Yes 0
COVID-19 PDrug: ZanuRespiratory failure-free survival rate at day Yes 0
COVID-19 PDrug: MAS8APACHE II severity of disease score on Day 15Yes 0

Covid19 Drug: RetroClinical parameter of acute lung disease;Clin Yes 0
COVID-19 SARS-CoV-2 RT-PCR test result Yes 0
CoronavirusDevice: RI Agreement between the new camera based m

Yes 0
SARS Virus Other: ConClinical status during follow-up at 30th day Yes 0
Covid-19; Other: Pro Composite outcome of in-hospital all-cause m

Yes 0
Critically Drug: Intr Number of days off the ventilator (VFD28, foYes 0
COVID-19;POther: ThisPost-traumatic Stress Disorder;Anxiety and Yes 0

COVID-19 Biological Confirm safety Yes 0
ARDS;COVIOther: AirwProportion of patients improving PaO2/FiO2 Yes 0
COVID-19 Drug: MST Clinical Status, Assessed Using a 7-Category Yes 0
COVID-19 Other: sur Measure the effect of COVID-19 pandemic onYes 0
Infection, Biological: Number of days absent from work due to resYes 0
Asymptomat
Procedure:Patient variables (factors) associated with Yes 0
SARS-CoV Drug: Hydr Primary outcome measure will be time to virYes 0

Pneumonia,Diagnostic Serology Yes 0
SARS-CoV- Drug: Pegi Number of participants with resolution of h Yes 0
Respirator Drug: Veru Proportion of subjects that are alive without Yes 0
COVID-19 Drug: MontEmergency Room Visits and Hospitalizations Yes 0
The PsychoOther: Sta Psychological impacts by CoronaVirus Disea Yes 0
Chronic Co Other: life % adherence to each pharmacological class; Yes 0
COVID;ARDS
Other: Pro Therapeutic failure death or intubation Yes 0
SARS-CoV2Biological: Acute respiratory failure Yes 0
Alcohol Drinking;Alco AUDIT Score;ADS Score Yes 0
COVID19 CombinatioClinical Improvement Yes 0
SARS-Cov- Drug: Angi 7-Point National Institute of Health Clinical Yes 0
Anxiety;DeBehavioral:Rate reduction in Depressive symptoms;RateYes 0
COVID-19; Radiation: Symptomatic improvement by National EarlyYes 0

COVID-19 To characterize the immunologic mechanisms
Yes 0
COVID-19;SOther: Webmeasure sleep quality in healthcare worker Yes 0
COVID;CoviBiological: The rate of recovery of mild or moderate COYes 0
Age Relate Procedure: Change of visual acuity in patients treated Yes 0
COVID-19;SOther: ElecNumber of hospitalizations Yes 0
COVID-19 Drug: Levi Mortality rate Yes 0
CoVID19 Drug: DegarA composite endpoint of mortality, ongoing Yes 0

Identify the Viral Ep Identify the viral epitopes of memory CD8+ TYes 0
COVID-19;Myocardial RNumber of In-Hospital Death Yes 0
COVID-19, SARS-CoV 2Identify COVID-19 specific host-defence ("proYes 0
COVID;CoroBiological Safety of the Investigational Product;Safety Yes 0
Smoking CeBehavioral Biochemical validated quit rate;Biochemical Yes 0
Acute and Long Term EInflammatory responses of cells in lung and cYes 0
COVID-19 Other: PlacTime to recovery Yes 0

COVID Drug: PulmVentilator-free days at 28 days Yes 0
COVID;SeveDrug: LSAL Development of Acute Respiratory Distress Yes 0
COVID-19 Levels of senescent CD16+CD8+ T cells prior Yes 0
COVID Drug: PacriProportion of patients who progress to IMV Yes 0
SARS-CoV- Biological Solicited local and systemic adverse reacti Yes 0
SARS-CoV Drug: 200 Virologic Efficacy;Number of Participants w Yes 0
SARS-CoV Drug: 200 Number of Participants that achieve Virolog Yes 0

COVID-19 Biological Incidence of solicited adverse events (AEs) Yes 0
SARS-CoV- Drug: Hydr Clinical recovery at day-14, from the start o Yes 0
Covid-19;NOther: Use Incidence rates of IPC-defined hospital-ons Yes 0
Appendicit Behavioral Appendectomy No 0
COVID;ZincOther: SeruSerum zinc, vitamin d vitamin b12 deficiencyYes 0
Covid-19 Diagnostic SARS-CoV-2 infection;SARS-CoV-2 infection Yes 0
COVID-19; Drug: Inter Improvement of the absolute lymphocyte coun

Yes 0
COVID;Acute RespiratoAny stage of acute kidney injury Yes 0
Cancer;CO Other: No Rate of hospitalization;Duration of hospitali Yes 0
COVID-19 Drug: RemdClinical Status as Assessed by the Investigat Yes 0
COVID-19 IDrug: rhDNSafety of inhaled rhDNase1 in non-ventilatedYes 0
COVID-19 Drug: Meri Number of subjects not hospitalized or, if hoYes 0
COVID-19 Medical Sequelae in COVID- 19 Survivors;Ri Yes 0
COVID-19 Drug: LY38 Number of Participants with One or More SerYes 0

COVID-19 PDrug: CERCProportion of patient alive and free of respir Yes 0
Covid-19;T Drug: Dose 28-days ICU mortality Yes 0
Covid-19 Percentage of children screened with a positYes 0
Covid-19;C Other: ICU Adverse events (safety) Yes 0
SARS-CoV-2Drug: ATYRIncidence of treatment-emergent adverse evYes 0
SARS-CoV 2Other: Pas Myocarditis;Pericarditis Yes 0

CoronavirusOther: File Polymerase Chain Reaction (PCR) test Yes 0
COVID-19;VBiological: Positive for the respiratory questionnaire c Yes 0
COVID;SAROther: SARSARS-CoV-2 hospital mortality;SARS-CoV-2 mor

Yes 0
Quality of Other: CO Health-related quality of life. Yes 0
COVID-19 DDrug: LAU- Health status of the patient on the 7-point Yes 0
Isolation;Anxiety;HealtStress;Anxiety;Depressive symptomology;Pain
Yes 0
COVID-19 Other: sur Measure the students' interest in studying Yes 0
COVID Biological Coagulopathy associated with COVID-19 Yes 0
COVID;COVIDrug: Chlo World Health Organization (WHO) 9-levels scYes 0
Chronic Hem
Biological: The prevalence of SARS-COV2 seroconversionYes 0
COVID-19;RDrug: Ilopr Mechanical ventilation free days Yes 0
COVID-19 Drug: BaricPercentage of Participants who Die or Requ Yes 0
COVID-19; Biological: Severe Hypoxemic Respiratory Failure EndpoYes 0

COVID-19 DOther: Gro Evaluation of the impact of age on mortality Yes 0
CoronaviruOther: Non30-day all-cause mortality Yes 0
COVID Drug: Iver appearance of symptoms ( fever ,cough, soreYes 0
COVID-19 The ratio of individuals living in the provin Yes 0
CoronaviruDiagnostic Number of zones of pulmonary parenchyma Yces 0
COVID-19 Saliva and nasal swab SARSCoV-2 RT-PCR testYes 0

CoronavirusDevice: higshort term mortality;icu stay Yes 0
COVID-19 Number of participants with treatment-TOMYes 0
HypoxemicDrug: OxygDays alive without organ support Yes 0
COVID;Severe Acute ReICU mortality Yes 0
COVID-19 Drug: Breq Safety/tolerability measured by rates of po Yes 0
COVID Device: Lif Monitored versus Non-Monitored in-patient Yes 0

Covid19;CoDiagnostic Antibodies to SARS-CoV2: IgA, IgM, IgG;PCR Yes 0
Contagiou Device: io Reduction in contagion Yes 0
Severe AcuDrug: Iver Illness development;Reduction of need ICU aYes 0
Questionnaire Designssociodemopraphic factors;perceived stress;leYes 0
COVID-19 Drug: Enox To investigate the efficacy of enoxaparin in Yes 0
Bipolar De Device: MaProportion achieving remission on Hamilton Yes 0

Thermal CoOther: Per Skin thermometry;Hygrometry under costumYes 0
COVID-19 Drug: LY38 Change from Baseline to Day 11 in Severe A Yes 0
COVID-19 Radiation: Mortality rate of subjects treated with whol Yes 0
COVID-19 Drug: prophIncidence of SARS-CoV-2 Yes 0
Covid-19 P Procedure:The presence of SARS-CoV2 in adipose tissueYes 0
COVID-19 Drug: ThymReduction in documented infection with COVYes 0

COVID-19 Drug: Chlo Overall mortality Yes 0
COVID19 Drug: nangAdverse Events;Mortality Yes 0
Pneumonia,Drug: IbudiProportion of subjects free from respiratory Yes 0
COVID-19 Drug: Iver Viral clearance at day 6;Viral shedding dur Yes 0
COVID-19 Diagnostic Number of contaminated personnel Yes 0
Smoking BeDiagnostic Percentage of patients with a positive seroloYes 0
Psychologi Other: COVQualitative Interviews with Healthcare Stu Yes 0

COVID-19 Drug: Hydr Impact of hydroxychloroquine in hospitalizedYes 0
Covid-19;FaProcedure:Anxiety;Depression Yes 0
General Su Procedure:Mortality Yes 0
COVID ICU admission Yes 0
Cardiovasc Other: No The impact of COVID-19 on cardiovascular p Yes 0
Diabetes;C Device: D Time In Range (TIR) for blood glucose Yes 0

Feeding anOther: QueComparison of the BMI (kg/mÂ²) evolution bYes 0
Chronic StrOther: MinChange in Perceived Stress Scale Yes 0
Covid-19;HOther: Ser Serology testing for specific COVID-19 Yes 0
SARS-CoV- Other: SamResponse rate of SARS-CoV-2-specific B cells Yes 0
COVID-19 Drug: RemdProportion of Participants Experiencing an Yes 0
CoronaviruDrug: Iver Time to undetectable SARS-CoV-2 viral load Yes 0
Anxiety;DeBehavioral Measure of Anxiety as assessed by the OASI Yes 0

Pregnancy Related;COV
Rates of intestinal atresias and limb abnorm Yes 0
COVID-19 Device: olf sensitivity, specificity and accuracy Yes 0
UltrasonogBehavioral:Change in PO2 values Yes 0
Covid-19 Biological: INCIDENCE OF CRITICAL PNEUMONIA;MORT Yes 0
COVID-19;SBiological Avoidance of intubation at 28 days (group A)Yes 0
COVID-19 Drug: PamrProportion of subjects who never received Yes 0

COVID-19 Biological Percentage of Participants Dying or Requiri Yes 0
COVID-19 Drug: BAT Incidence of adverse events (AEs);Duration ofYes 0
Pregnancy;Other: no Outcome of pregnancy Yes 0
Pregnant Device: Pe Description of the lesions Yes 0
Colon Cancer Interest in colon cancer screening Yes 0
COVID19 Other: HospTo highlight the perceptions, representationsYes 0
Covid-19;MOther: PHQAssociation between Covid-19 pandemic andYes 0

COVID-19 research database of EHR records from COVID
Yes 0
COVID-19 Drug: Pul Response Yes 0
Covid-19 Diagnostic Bland-Altman estimate of bias and Limits of Yes 0
COVID-19 Drug: Lian Proportion of participants who test negativ Yes 0
COVID-19 Diagnostic Measurement of N-terminal pro-B type natriu

Yes 0
COVID COVID19 versus H1N1; radiological comparatYes 0

Cytokine S Drug: DoxyTime Free of Either Hospitalization, Hypoxe Yes 0
Mental HeaOther: QuesPresence of anxiety at baseline;Presence of Yes 0
Physical St Other: QueChange in Burnout before COVID-19 and durYes 0
Satisfactio Other: QueQuality of Life of the patients Yes 0
COVID-19;Intensive C number of death Yes 0
Sars-CoV2; Other: biol Biobank with linkage to registers;Experienc Yes 0
Acute RespDrug: PB10Days alive and free of respiratory failure fro Yes 0
Pancreatiti Other: biocto compare presence of fever in patients witYes 0
Covid-19;C Other: No iOncologic data;COVID-19 diagnosis;Clinical Yes 0
COVID-19 Drug: ConvComposite endpoint of survival and no longerYes 0
Pneumonia;Other: Bes Time to clinical recovery Yes 0
RheumatoidDrug: TradiThe risk of COVID-19 infection among RA patYes 0
COVID-19 Drug: ConvCorrelation between the NAb dose titer in Yes 0
Covid-19 Clinical complications and Mortality;Neutro Yes 0

COVID-19 Drug: FavipRate of viral elimination by Day 10 [pilot sta Yes 0
SARS-CoV-2Diagnostic Incidence of patients with a positive test f Yes 0
COVID Device: 20 Evaluation of the rate of SARS-CoV-2 positiveYes 0
CoagulopatDrug: CamoPercent change in plasma D-Dimer Yes 0
Breast Can Drug: Keto prophylaxis effect of Ketotifen on patient`s No 0
COVID-19 RECAP Early warning score Yes 0
COVID-19;Acute RespirHand grip strength Yes 0

CoronavirusDrug: OpagMeasure the time to weaning from high-flowYes 0
Coronavirus Number of deaths of any cause in nursing-h Yes 0
COVID-19 Drug: Criz Soluble P-selectin level Yes 0
COVID-19 SBiological: Cholesterol concentration Yes 0
COVID-19 Other: Virt performance of healthcare workers;performYes 0
covid19 Drug: Nita The proportion of subjects with laboratory-cYes 0
COVID;Pneumonia, Vira
Reduction of Diffusion of Lung CO (DLCO, si Yes 0
Respirator Device: Vi Recovery respiratory fail Yes 0
Infection, Biological: Number of days with severe respiratory dise Yes 0
SARS-CoV 2;SARS Pneum

Prevalence of Myocarditis Yes 0
Asymptomat
Drug: Iver Adverse event rates;Efficacy for shortening Yes 0
Covid19 Drug: Toci Change in IL-12 values in the 3 study groups Yes 0
COVID 19 Drug: Cicl Improvement in dyspnea at day 7 Yes 0

COVID-19 Drug: Hydr SARS-CoV-2 Infection Yes 0
Healthy Biological Cohorts 1, 2, and 3: Number of Participants wYes 0
COVID Drug: Nicl The primary endpoint is the rate of faecal Yes 0
Preventive Biological Changing ofantibody levels against the SARS Yes 0
COVID-19 Diagnostic Mortality Yes 0
Eating Beh Other: OnliChange in weight (child);Behaviour (child) Yes 0
PostpartumOther: PHQCorrelation between the Covid-19 pandemic Yes 0

COVID 19 Drug: Hydr Prevention of SARS-CoV-2 infection;Presenc Yes 0
COVID-19;SARS-CoV 2 Active Infection;Past Exposure Yes 0
Oncology; Other: ObvCOVID-19 infection's symptoms Yes 0
Corona ViruBiological: Safety and efficacy assessment of infusion Yes 0
Preventive Biological The changing of antibody levels against the Yes 0
COVID;Arrhythmia;Torsa
Arrhythmia Yes 0
COVID;Sar Diagnostic Vaginal fluid Covid-19 PCR test result Yes 0
COVID-19 Biological: Time to Resolution of Symptoms;SAEs withinYes 0
COVID-19 Diagnostic COVID-19 Detection Rate Yes 0
Covid-19 Other: nonenumber of participants with considerable dy Yes 0
Allergy an Drug: COVICOVID-19 associated immune disorder;COVIDYes 0
COVID19 Drug: ConvDuration of hospitalization/Recovery status Yes 0

CoronaviruDrug: Hydr Clinical COVID-19 Yes 0
Covid19 Drug: Iver SADR;Viral load Yes 0
COVID 19 Diagnostic Hospitalization Yes 0
Sars-CoV2 Analysis of the effect of prone position in pa Yes 0
Multiple Sclerosis;Cov Fatigue;Physical activity;Sleep quality;AnxietYes 0
Brain Health Primary endpoint 1;Primary endpoint 2 Yes 0
Covid-19 Drug: MethProportion of patients developing treatmentYes 0

COVID;Coronavirus Cardiac abnormalities in COVID-19 disease i Yes 0
Aplastic A Other: BestProportion of patients who require artificial Yes 0
SARS-CoV-2Biological COVID-19 infection Yes 0
PneumoniaDrug: PTC2Time from Randomization to Respiratory I Yes 0
COVID-19;COther: Pro All-cause mortality;All-cause mortality;Live Yes 0
Covid-19 Drug: AbiveProportion of subjects alive and free of respiYes 0

Loneliness;DepressionLoneliness as evaluated by the UCLA lonelin Yes 0
COVID-19 Drug: MaraProportion of patients developing severe AR Yes 0
covid19 Drug: Nita Change in signs and symptoms scale Yes 0
IMMUNOTH
Biological Death versus survival of treated patients Yes 0
COVID-19;FDG PET/CTPrimary endpoint Yes 0
Covid19;Interstitial Circulating markers for COVID-19 signature Yes 0

Burnout;St Behavioral:Teamwork climate, as measured by selected Yes
it 0
SARS-CoV-2Diagnostic Presence of specific SARS-CoV2 antibodies inYes 0
COVID 19;InflammatorTemporal variations in the frequency and moNo 0
COVID-19; CombinatioCorrelation of adverse events with the inves Yes 0
COVID-19 Biological: Change in Plasma Viscosity Yes 0
Cancer;CovBiological The rate of "flu-like illness" which includes: Yes 0
Gender RelBehavioral Gender division of caregiving/domestic task Yes 0
COVID-19 COVID-19 disease incidence rate (symptomatiYes 0

COVID-19; Drug: CYT1Improvement of the absolute lymphocyte coun
Yes 0
COVID-19 Biological: Oxygen supplementation Yes 0
DepressionOther: ProsPatient Health Questionnaire 9;Generalized Yes 0
Adherence Behavioral:Adherence to WHO-advised hygiene-related;A

Yes 0
CoronaviruBiological Proportion of patients with clinical worseninYes 0
Post Traumatic Stress PTSD Checklist for DSM-5 (PCL-5) Yes 0
Anxiety;Depression;In Patient Health Questionnaire 9 (PHQ-9);The G

Yes 0
Parenting;Anxiety;De Parental stress Yes 0

DepressionBehavioral:Patient Health Questionnaire 9;Generalized Yes 0
Parental B Other: ProsThe Parental Burnout Inventory (PBI) Yes 0
Acute RespOther: ConBlood;Metabolic;Blood;Blood;Metabolic;InfeYes 0
Stress Diso Device: faeGut microbiome composition of exposed groYes 0
Covid-19;P Diagnostic PCR positivity Yes 0
Autism Spectrum DisorNeurodevelopmental Outcomes No 0
COVID-19 Drug: Chlo Negative Polymerase Chain Reaction assay aYes 0

Insomnia;MetacognitivBergen insomnia scale (BIS) Yes 0
COVID-19;SDietary Su Mortality Yes 0
Mental WelBehavioral:The Short Warwick-Edinburgh Mental Well Yes 0
COVID-19 Drug: HydroVirological cure Yes 0
Migrants;Anxiety;Dep Patient Health Questionnaire 9;Generalized Yes 0
COVID-19 Perioperative transmission of SARS-CoV-2 Yes 0
SARS-CoV IDrug: Nitri To Measure the efficacy of NORS compared to

Yes 0
COVID-19 Drug: AnakTreatment success, defined as number of patYes 0
Loneliness During CO UCLA Loneliness Scale-8 (ULS-8);Patient Hea Yes 0
COVID-19 Drug: MeseOverall survival Yes 0
COVID-19 Measure level of Abs in asymptomatic close Yes 0
DepressionBehavioral The Patient Health Questionnaire 9;GeneraliYes 0
Neuroendocrine TumoCorrelation between clinical parameters andYes 0
COVID-19 Pneumonia Time to clinical improvement Yes 0

DepressionOther: Bec Score of Beck Depression Inventory Yes 0
COVID-19; Diagnostic SARS-CoV2 positive conjunctival swabs Yes 0
COVID-19; Other: Blo Anti-viral cytokine levels in blood samples i Yes 0
Osteoporosis;Sarcope SMI Yes 0
CoronaviruBiological Assess the incidence of adverse events (int Yes 0
COVID Diagnostic SARS-COV-2 RNA detection Yes 0

COVID;CoroDrug: Ther Composite main outcome Yes 0
Depressive Symptoms;Patient Health Questionnaire-9 (PHQ-9);Cog Yes 0
CoronaviruBiological The number of adverse events after intramusYes 0
COVID;SarsBiological: Convalescent Plasma Yes 0
COVID-19;ABiological: Safety and tolerability as measured by incid Yes 0
COVID-19 Secondary household infection rate;Secondary

Yes 0
COVID-19;ADrug: Inha change in oxygenation parameters Yes 0
COVID;Acute Kidney InjIncidence of any stage of acute kidney injuryYes 0
COVID-19 Drug: Toci To calulate the time of intubation;To calcul Yes 0
Covid19 Drug: PulmMortality at 28 days;Systemic Therapeutic Yes 0
COVID Drug: Iver time to be symptoms free Yes 0
Psychotic Behavioral Assessment of patients' current status : recoYes 0

COVID 19; Procedure: Evaluate the safety of a new modified stella Yes 0
Covid19 Other: Phys6 minute walk test;Step test Yes 0
SARS-CoV- Drug: GX-1 Safety and tolerability Yes 0
Pediatric Cancer;Imm Number of tristate area pediatric HOT patie Yes 0
COVID-19 Diagnostic diagnostic value of COVID-19 antibodies tes Yes 0
Poliovirus Biological: Mortality or infectious disease causing con Yes 0

Coronavirus Infection Clearance of viral load Yes 0
CoronaviruBiological To evaluate the safety of intravenous infusi Yes 0
COVID Drug: FavipTime to virological cure Yes 0
Stroke, Ac Device: M Prevalence of COVID-19 infection in suspect Yes 0
Corticoste Drug: Dex Effect on transfers to ICU and escalation of Yes 0
SARS-CoV Diagnostic Prevalence of SARS-CoV-2 in the sampled ti Yes 0

Coronavirus (COVID-1 Viral clearance Yes 0
COVID19;T Drug: Pras P/F ratio at day 7 Yes 0
Cancer Other: dat data record Yes 0
Anticoagul Drug: Bival P/F ratio Yes 0
SARS Pneu Diagnostic Optimum positive end-expiratory pressure (PYes 0

COVID-19; Drug: Prev Event of clinical acute respiratory disease Yes 0
Covid-19 Drug: Hydr Incidence of acute respiratory illness in tr Yes 0
SARS-CoV 2Diagnostic SARS-CoV 2 presence in semen;SARS-CoV 2 pr

Yes 0
Covid-19 Description of covid-19 patients receiving Yes 0
History of Diagnostic Seroprevalence Yes 0
COVID-19 DDrug: Apil Viral Load Change Yes 0

COVID-19;SDrug: Duta COVID-19 hospitalization;COVID-19 Ordinal Yes 0
results yes no

Covid 19 Trials

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Covid 19 Trials

Uploaded by

Copyright:

Available Formats

TrialID Last Refre Public title Scientific tiAcronym Primary sp Date registDate regist Export dat Source Reg

NCT04246 3-Feb-20 A Randomize

NCT04252 17-Feb-20 The Efficac A Randomize

NCT04260 17-Feb-20 Clinical S Randomized, Open, Mul

NCT04261 17-Feb-20 The Effica A Randomized, Open-la

ChiCTR200 17-Feb-20 A Medical A Medical Records Based

ChiCTR200 17-Feb-20 A RandomizA Randomized Controlled

ChiCTR200 17-Feb-20 A randomizA randomized controlled

ChiCTR200 17-Feb-20 A Single-b A Single-blind, Randomized

ChiCTR200 17-Feb-20 A Single-a A Single-arm Clinical Trial

ChiCTR200 17-Feb-20 A medical Co-infection of novel corona

ChiCTR200 17-Feb-20 Evaluate t Evaluate the effectiveness

ChiCTR200 17-Feb-20 A comparatA comparative study on Tongji

ChiCTR200 17-Feb-20 A multicentA multicenter, randomiz

ChiCTR200 17-Feb-20 The efficac The efficacy and safetyBeijing

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 Study on c Effecacy and safty of conv

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 Based on DBased on Delphi Method

ChiCTR200 17-Feb-20 Ba-Bao-DanStudy for the pharmacodyn

ChiCTR200 17-Feb-20 PsychologicPsychological survey ofGuangdong

ChiCTR200 17-Feb-20 Clinical T Clinical Trial for Tanreqing

ChiCTR200 17-Feb-20 Clinical S Clinical Study for Anti-agi

ChiCTR200 17-Feb-20 Clinical st Development and applicatio

ChiCTR200 17-Feb-20 Immunomodu

ChiCTR200 17-Feb-20 Analysis of Optimization of treatment

ChiCTR200 17-Feb-20 Clinical Ap Optimization of treatment

ChiCTR200 17-Feb-20 Clinical st Clinical study for the inte

ChiCTR200 17-Feb-20 Randomized

ChiCTR200 17-Feb-20 Traditiona Traditional Chinese medicin

ChiCTR200 17-Feb-20 A multicentA multicenter, randomize

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 A multicentA multicenter, randomized

ChiCTR200 17-Feb-20 Imaging Fe Imaging Features and Mechanis

ChiCTR200 17-Feb-20 The efficac Study on Prevention and

ChiCTR200 17-Feb-20 Clinical st Clinical study of nebulized

ChiCTR200 17-Feb-20 Study for Effect of Novel Coronavirus

ChiCTR200 17-Feb-20 Clinical S Clinical Study for Tradition

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 Efficacy of Efficacy of ChloroquineThe

ChiCTR200 17-Feb-20 A MulticenA Multicenter, Randomized

ChiCTR200 17-Feb-20 Risks of D Risks of Death and Severe

ChiCTR200 17-Feb-20 Early Dete Early Detection of Novel

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 Study for MMental health and psycho

ChiCTR200 17-Feb-20 An observaAn observational studyGuangdong

ChiCTR200 17-Feb-20 Efficacy an Efficacy and safety of aeros

ChiCTR200 17-Feb-20 Immune Rep

ChiCTR200 17-Feb-20 Constructi Construction of Early Warnin

ChiCTR200 17-Feb-20 A real wor A real world study for tradit

ChiCTR200 17-Feb-20 Clinical st Multicenter, randomized,

ChiCTR200 17-Feb-20 A prospectiA prospective, open-label,

ChiCTR200 17-Feb-20 Clinical S Clinical Study for Human

ChiCTR200 17-Feb-20 A RandomizA Randomized, Open-Labe

ChiCTR200 17-Feb-20 Clinical s Clinical study for communi

ChiCTR200 17-Feb-20 CommunityCommunity based prevention

ChiCTR200 17-Feb-20 Clinical st Clinical study on safetyThe

ChiCTR200 17-Feb-20 Safety and Safety and efficacy of um

ChiCTR200 17-Feb-20 Randomized,

ChiCTR200 17-Feb-20 A randomize

ChiCTR200 17-Feb-20 Study for t A prospective cohort study